PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	RUDENKO, G; BLUNDELL, PA; DIRKSMULDER, A; KIEFT, R; BORST, P				RUDENKO, G; BLUNDELL, PA; DIRKSMULDER, A; KIEFT, R; BORST, P			A RIBOSOMAL DNA PROMOTER REPLACING THE PROMOTER OF A TELOMERIC VSG GENE-EXPRESSION SITE CAN BE EFFICIENTLY SWITCHED ON AND OFF IN TRYPANOSOMA-BRUCEI	CELL			English	Article							VARIANT SURFACE GLYCOPROTEIN; RNA POLYMERASE-I; PROTOZOAN TRYPANOSOMA-BRUCEI; BLOOD-STREAM-FORM; ANTIGENIC VARIATION; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION UNITS; INACTIVATION; SEQUENCES; PROTEIN	Trypanosoma brucei survives in the mammalian bloodstream by regularly changing its variant surface glycoprotein (VSG) coat. The active VSG gene is located in a telomeric expression site, and coat switching occurs either by replacing the transcribed VSG gene or by changing the expression site that is active, To determine whether VSG expression site control requires promoter-specific sequences, we replaced the active VSG expression site promoter in bloodstream-form T. brucei with a ribosomal DNA (rDNA) promoter. These transformants were fully infective in laboratory animals, and the rDNA promoter, which is normally constitutively active, was efficiently inactivated and reactivated in the context of the VSG gene expression site. As there is no sequence similarity between the VSG expression site promoter and the rDNA promoter, VSG expression site control does not involve sequences specific to the VSG expression site promoter. We conclude that an epigenetic mechanism, such as telomeric silencing, is involved in VSG expression site control in bloodstream-form T. brucei.			RUDENKO, G (corresponding author), NETHERLANDS CANC INST,DEPT BIOL MOLEC,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.							ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; BERNARDS A, 1984, CELL, V36, P163, DOI 10.1016/0092-8674(84)90085-0; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CARRUTHERS VB, 1993, NUCLEIC ACIDS RES, V21, P2537, DOI 10.1093/nar/21.10.2537; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GOTTESDIENER K, 1990, MOL CELL BIOL, V10, P6079, DOI 10.1128/MCB.10.11.6079; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; JANZ L, 1994, MOL CELL BIOL, V14, P5804, DOI 10.1128/MCB.14.9.5804; JEFFERIES D, 1991, MOL CELL BIOL, V11, P338, DOI 10.1128/MCB.11.1.338; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; LAMONT GS, 1986, PARASITOLOGY, V92, P355, DOI 10.1017/S003118200006412X; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; MICHELS PAM, 1984, EMBO J, V3, P1345, DOI 10.1002/j.1460-2075.1984.tb01975.x; PALLADINO F, 1994, CURR OPIN CELL BIOL, V6, P373, DOI 10.1016/0955-0674(94)90029-9; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; PAYS E, 1989, MOL CELL BIOL, V9, P4018, DOI 10.1128/MCB.9.9.4018; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RICEFICHT AC, 1981, NATURE, V294, P53, DOI 10.1038/294053a0; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; RUDENKO G, 1992, NUCLEIC ACIDS RES, V20, P303, DOI 10.1093/nar/20.2.303; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; VANDERPLOEG LHT, 1991, NEW BIOL, V3, P324; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P1359, DOI 10.1093/nar/19.7.1359	41	125	125	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					547	553		10.1016/0092-8674(95)90094-2	http://dx.doi.org/10.1016/0092-8674(95)90094-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585957	Bronze			2022-12-28	WOS:A1995TF24800007
J	NELSON, MT; CHENG, H; RUBART, M; SANTANA, LF; BONEV, AD; KNOT, HJ; LEDERER, WJ				NELSON, MT; CHENG, H; RUBART, M; SANTANA, LF; BONEV, AD; KNOT, HJ; LEDERER, WJ			RELAXATION OF ARTERIAL SMOOTH-MUSCLE BY CALCIUM SPARKS	SCIENCE			English	Article							TRANSIENT OUTWARD CURRENTS; SIZED CEREBRAL-ARTERIES; RABBIT PORTAL-VEIN; SARCOPLASMIC-RETICULUM; POTASSIUM CHANNELS; K+ CURRENTS; CELLS; RELEASE; THAPSIGARGIN; CONTRACTION	Local increases in intracellular calcium ion concentration ([Ca2+](i)) resulting from activation of the ryanodine-sensitive calcium-release channel in the sarcoplasmic reticulum (SR) of smooth muscle cause arterial dilation. Ryanodine-sensitive, spontaneous local increases in [Ca2+](i) (Ca2+ sparks) from the SR were observed just under the surface membrane of single smooth muscle cells from myogenic cerebral arteries. Ryanodine and thapsigargin inhibited Ca2+ sparks and Ca2+-dependent potassium (K-Ca), currents, suggesting that Ca2+ sparks activate K-Ca channels. Furthermore, K-Ca channels activated by Ca2+ sparks appeared to hyperpolarize and dilate pressurized myogenic arteries because ryanodine and thapsigargin depolarized and constricted these arteries to an extent similar to that produced by blockers of K-Ca channels. Ca2+ sparks indirectly cause vasodilation through activation of K-Ca channels, but have little direct effect on spatially averaged [Ca2+](i), which regulates contraction.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR MED BIOTECHNOL,BALTIMORE,MD 21201; UNIV VERMONT,DEPT PHARMACOL,COLCHESTER,VT 05446; INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,INDIANAPOLIS,IN 46202	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Vermont; Indiana University System; Indiana University-Purdue University Indianapolis			Heping, Cheng/AAE-2680-2019; Santana, Luis/AAF-9298-2019; Lederer, William/B-1285-2010	Heping, Cheng/0000-0002-9604-6702; Santana, Luis/0000-0002-4297-8029; Nelson, Mark/0000-0002-6608-8784	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051728, R01HL025675, R01HL044455] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51728, HL44455, HL25675] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; BENHAM CD, 1986, J PHYSIOL-LONDON, V381, P385, DOI 10.1113/jphysiol.1986.sp016333; BOLTON TB, 1989, J PHYSIOL-LONDON, V409, P385, DOI 10.1113/jphysiol.1989.sp017504; BOND M, 1984, J PHYSIOL-LONDON, V357, P185, DOI 10.1113/jphysiol.1984.sp015496; BRAYDEN JE, 1989, J CEREBR BLOOD F MET, V9, P256, DOI 10.1038/jcbfm.1989.42; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; DEVINE CE, 1972, J CELL BIOL, V52, P690, DOI 10.1083/jcb.52.3.690; FFLEISCHMANN BK, 1994, P NATL ACAD SCI USA, V91, P11914; FLEISCHMANN BK, P NATL ACAD SCI USA, V91, P11914; GANITKEVICH V, 1990, CIRC RES, V67, P525, DOI 10.1161/01.RES.67.2.525; GANITKEVICH VY, 1995, J PHYSIOL-LONDON, V484, P287, DOI 10.1113/jphysiol.1995.sp020665; GELBAND CH, 1993, CIRC RES, V73, P24, DOI 10.1161/01.RES.73.1.24; GLANGIACOMO KM, 1992, BIOCHEMISTRY-US, V31, P6719; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDER DR, 1984, CIRC RES, V55, P197, DOI 10.1161/01.RES.55.2.197; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; HOGG RC, 1993, PFLUG ARCH EUR J PHY, V425, P233, DOI 10.1007/BF00374172; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUME JR, 1989, J PHYSIOL-LONDON, V413, P49, DOI 10.1113/jphysiol.1989.sp017641; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; KAPICKA CL, 1994, AM J PHYSIOL, V266, pC601, DOI 10.1152/ajpcell.1994.266.3.C601; KIRBY MS, 1992, J BIOL CHEM, V267, P12545; KNOT HJ, 1995, AM J PHYSIOL-HEART C, V269, pH348, DOI 10.1152/ajpheart.1995.269.1.H348; LANGTONPD, 1991, AM J PHYSIOL, V260, pH927; LU X, 1994, P NATL ACAD SCI USA, V91, P3294; MATSUYAMA S, 1993, LIFE SCI, V53, P681, DOI 10.1016/0024-3205(93)90244-W; MEININGER GA, 1992, AM J PHYSIOL, V263, pH647, DOI 10.1152/ajpheart.1992.263.3.H647; MEININGERGA, 1991, AM J PHYSL, V261, pH950; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; MORITOKI H, 1994, BRIT J PHARMACOL, V111, P655, DOI 10.1111/j.1476-5381.1994.tb14788.x; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; NILSSON H, 1994, J VASC RES, V31, P314, DOI 10.1159/000159059; QUAYLE JM, 1993, AM J PHYSIOL, V264, pH470, DOI 10.1152/ajpheart.1993.264.2.H470; QUAYLE JM, 1993, AM J PHYSIOL, V265, pC1363, DOI 10.1152/ajpcell.1993.265.5.C1363; QUAYLE JM, 1994, J PHYSIOL-LONDON, V475, P9, DOI 10.1113/jphysiol.1994.sp020045; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STEHNOBITTEL L, 1992, J PHYSIOL-LONDON, V451, P49, DOI 10.1113/jphysiol.1992.sp019153; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRIPATHY A, 1994, BIOPHYS J, V66, pA416; TTHEDFORD SE, 1994, BIOPHYS J, V66, pA20; WATANABE J, 1993, CIRC RES, V73, P465, DOI 10.1161/01.RES.73.3.465; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109	48	1144	1175	1	36	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					633	637		10.1126/science.270.5236.633	http://dx.doi.org/10.1126/science.270.5236.633			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570021				2022-12-28	WOS:A1995TB55700040
J	CARNEY, AS; WEIR, J; BALDWIN, DL				CARNEY, AS; WEIR, J; BALDWIN, DL			CONTAMINATION WITH BLOOD DURING MANAGEMENT OF EPISTAXIS	BRITISH MEDICAL JOURNAL			English	Article									SOUTHMEAD GEN HOSP,DEPT OTOLARYNGOL,BRISTOL BS10 5NB,AVON,ENGLAND	Southmead Hospital			Carney, A/W-8202-2019	Carney, A/0000-0001-7507-7983				BOON D, 1994, J ACCID EMERG MED, V11, P175; BREARLY S, 1989, BRIT MED J, V299, P131; LITTLECHILD P, 1992, BRIT MED J, V305, P156, DOI 10.1136/bmj.305.6846.156; STEEDMAN DJ, 1994, J ACCID EMERG MED, V11, P17; 1990, GUIDANCE CLIN HLTH W	5	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1064	1064		10.1136/bmj.311.7012.1064	http://dx.doi.org/10.1136/bmj.311.7012.1064			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580665	Green Published			2022-12-28	WOS:A1995TB35400024
J	HODGKIN, J; PLASTERK, RHA; WATERSTON, RH				HODGKIN, J; PLASTERK, RHA; WATERSTON, RH			THE NEMATODE CAENORHABDITIS-ELEGANS AND ITS GENOME	SCIENCE			English	Article							GENE; INSERTION; SYSTEM	Over the past two decades, the small soil nematode Caenorhabditis elegans has become established as a major model system for the study of a great variety of problems in biology and medicine. One of its most significant advantages is its simplicity, both in anatomy and in genomic organization. The entire haploid genetic content amounts to 100 million base pairs of DNA, about 1/30 the size of the human value. As a result, C. elegans has also provided a pilot system for the construction of physical maps of larger animal and plant genomes, and subsequently for the complete sequencing of those genomes. By mid-1995, approximately one-fifth of the complete DNA sequence of this animal had been determined. Caenorhabditis elegans provides a test bed not only for the development and application of mapping and sequencing technologies, but also for the interpretation and use of complete sequence information. This article reviews the progress so far toward a realizable goal--the total description of the genome of a simple animal.	NETHERLANDS CANC INST,DIV MOLEC BIOL,1066 CX AMSTERDAM,NETHERLANDS; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,CTR GENOME SEQUENCING,ST LOUIS,MO 63110	Netherlands Cancer Institute; Washington University (WUSTL); Washington University (WUSTL)	HODGKIN, J (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							ANDERSON P, 1992, DYNAMIC GENOME; [Anonymous], UNPUB; BARNES TM, 1995, GENETICS, V141, P159; BRENNER S, 1988, GENETICS, V77, P91; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; DURBIN R, UNPUB; Epstein HF, 1995, METHODS CELL BIOL, V48; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; HODGKIN J, 1993, GENETICS, V133, P543; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; KIMBLE JE, 1977, DEV BIOL, V70, P396; KOHARA Y, UNPUB; KORNFELD K, 1995, GENE DEV, V9, P756, DOI 10.1101/gad.9.6.756; LYNCH AS, IN PRESS NAT GENET; MELTO CC, 1991, EMBO J, V10, P3959; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; RUSHFORTH AM, 1993, MOL CELL BIOL, V13, P902, DOI 10.1128/MCB.13.2.902; SIDOW A, 1994, CURR BIOL, V4, P596, DOI 10.1016/S0960-9822(00)00131-7; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLIAMS BD, 1992, GENETICS, V131, P609; WILLIAMS N, 1995, SCIENCE, V268, P1560, DOI 10.1126/science.7777850; WILSON R, 1964, NATURE, V368, P32; Wood WB, 1988, NEMATODE CAENORHABDI; WU Y, 1995, GENE DEV, V9, P742, DOI 10.1101/gad.9.6.742; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	33	118	121	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					410	414		10.1126/science.270.5235.410	http://dx.doi.org/10.1126/science.270.5235.410			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569995				2022-12-28	WOS:A1995TA37400032
J	HUPP, TR; SPARKS, A; LANE, DP				HUPP, TR; SPARKS, A; LANE, DP			SMALL PEPTIDES ACTIVATE THE LATENT SEQUENCE-SPECIFIC DNA-BINDING FUNCTION OF P53	CELL			English	Article							WILD-TYPE P53; MONOCLONAL-ANTIBODIES; GROWTH ARREST; MOUSE CELLS; PROTEIN; FORMS; UV; IRRADIATION; APOPTOSIS; RADIATION	Normal cells contain p53 protein in a latent state that can be activated for sequence-specific transcription by low levels of UV radiation without an increase in protein levels. Microinjection of cells with an antibody specific to the C-terminal negative regulatory domain can activate the function of p53 as a specific transcription factor in the absence of irradiation damage, suggesting that posttranslational modification of a negative regulatory domain in vivo is a rate-limiting step for p53 activation. Small peptides derived from the negative regulatory domain of p53 have been used as biochemical tools to distinguish between allosteric and steric mechanisms of negative regulation of p53 tetramer activity. Presented is the development of a highly specific peptide activation system that is consistent with an allosteric mechanism of negative regulation and that forms a precedent for the synthesis of novel low molecular mass modifiers of the p53 response.	UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND	University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALL PA, 1993, ONCOGENE, V8, P203; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHLOKA C, 1995, ONCOGENE, V10, P1485; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JUPP TR, 1994, COLD SPRING HARB SYM, V59, P195; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TARUNINA M, 1993, ONCOGENE, V8, P3165; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; YONISH RE, 1991, NATURE, V353, P345; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	38	439	471	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 20	1995	83	2					237	245		10.1016/0092-8674(95)90165-5	http://dx.doi.org/10.1016/0092-8674(95)90165-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585941	Green Submitted, Bronze			2022-12-28	WOS:A1995TA96500010
J	KERREBROCK, AW; MOORE, DP; WU, JS; ORRWEAVER, TL				KERREBROCK, AW; MOORE, DP; WU, JS; ORRWEAVER, TL			MEI-S332, A DROSOPHILA PROTEIN REQUIRED FOR SISTER-CHROMATID COHESION, CAN LOCALIZE TO MEIOTIC CENTROMERE REGIONS	CELL			English	Article							DNA TOPOISOMERASE-II; GCN4 LEUCINE-ZIPPER; CHROMOSOME ORIENTATION; INNER CENTROMERE; CELL-DIVISION; COILED COILS; MELANOGASTER; SEPARATION; ANAPHASE; MITOSIS	Mutations in the Drosophila mei-S332 gene cause premature separation of the sister chromatids in late anaphase of meiosis I. Therefore, the mei-S332 protein was postulated to hold the centromere regions of sister chromatids together until anaphase II. The mei-3332 gene encodes a novel 44 kDa protein. Mutations in mei-S332 that differentially affect function in males or females map to distinct domains of the protein. a fusion of mei-S332 to the green fluorescent protein (GFP) is fully functional and localizes specifically to the centromere region of meiotic chromosomes. When sister chromatids separate at anaphase II, mei-S332-GFP disappears from the chromosomes, suggesting that the destruction or release of this protein is required for sister-chromatid separation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	KERREBROCK, AW (corresponding author), MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.		Wu, JIm S/AAQ-3416-2021					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER BS, 1978, GENETICS, V90, P531; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; CLAYBERG CD, 1959, GENETICS, V44, P1335; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; DAVIS BK, 1971, MOL GEN GENET, V113, P251, DOI 10.1007/BF00339546; DAVIS BK, 1977, DROS INFO SERV, V52, P100; DOBSON MJ, 1994, J CELL SCI, V107, P2749; DOMBRADI V, 1989, EUR J BIOCHEM, V183, P603, DOI 10.1111/j.1432-1033.1989.tb21089.x; EARNSHAW WC, 1991, J CELL SCI, V98, P443; GATTI M, 1991, METHOD CELL BIOL, V35, P543; GERMAN J, 1979, CLIN GENET, V16, P441; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; GOLDSTEIN LSB, 1981, CELL, V25, P591, DOI 10.1016/0092-8674(81)90167-7; GONZALEZ C, 1991, EXP CELL RES, V192, P10, DOI 10.1016/0014-4827(91)90150-S; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KERREBROCK AW, 1992, GENETICS, V130, P827; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACKAY AM, 1993, J CELL BIOL, V123, P373, DOI 10.1083/jcb.123.2.373; MASON JM, 1976, GENETICS, V84, P545; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MIYAZAKI WY, 1992, GENETICS, V132, P1047; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ORRWEAVER TL, 1995, IN PRESS P NATL ACAD; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SANDLER L, 1968, GENETICS, V60, P525; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STEPANOVA NG, 1985, HISTOCHEM J, V17, P131, DOI 10.1007/BF01003213; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0	57	215	220	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 20	1995	83	2					247	256		10.1016/0092-8674(95)90166-3	http://dx.doi.org/10.1016/0092-8674(95)90166-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585942	Bronze			2022-12-28	WOS:A1995TA96500011
J	SHANNON, RV; ZENG, FG; KAMATH, V; WYGONSKI, J; EKELID, M				SHANNON, RV; ZENG, FG; KAMATH, V; WYGONSKI, J; EKELID, M			SPEECH RECOGNITION WITH PRIMARILY TEMPORAL CUES	SCIENCE			English	Article							INERAID COCHLEAR IMPLANT; CONSONANT RECOGNITION; ENVELOPE CUES; STIMULATION; PERCEPTION	Nearly perfect speech recognition was observed under conditions of greatly reduced spectral information. Temporal envelopes of speech were extracted from broad frequency bands and were used to modulate noises of the same bandwidths. This manipulation preserved temporal envelope cues in each band but restricted the listener to severely degraded information on the distribution of spectral energy. The identification of consonants, vowels, and words in simple sentences improved markedly as the number of bands increased; high speech recognition performance was obtained with only three bands of modulated noise. Thus, the presentation of a dynamic temporal pattern in only a few broad spectral regions is sufficient for the recognition of speech.			SHANNON, RV (corresponding author), HOUSE EAR RES INST,2100 W 3RD ST,LOS ANGELES,CA 90057, USA.		Zeng, Fan-Gang/G-4875-2012		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001526] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DCO1526] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Allen JB, 1994, IEEE T SPEECH AUDI P, V2, P567, DOI 10.1109/89.326615; DORMAN M, 1989, EAR HEARING, V10, P288, DOI 10.1097/00003446-198910000-00003; DORMAN M, 1988, J ACOUST SOC AM, V84, P5011; DORMAN MF, 1990, J ACOUST SOC AM, V88, P2074, DOI 10.1121/1.400104; DORMAN MF, 1992, J ACOUST SOC AM, V92, P3428, DOI 10.1121/1.404193; EDDINGTON DK, 1980, J ACOUST SOC AM, V68, P885, DOI 10.1121/1.384827; FREYMAN RL, 1991, J SPEECH HEAR RES, V34, P415, DOI 10.1044/jshr.3402.415; HILL FJ, 1968, J ACOUST SOC AM, V44, P13, DOI 10.1121/1.1911047; Licklider J.C.R., 1951, HDB EXPT PSYCHOL EDI, P1040; LICKLIDER JCR, 1948, J ACOUST SOC AM, V20, P42, DOI 10.1121/1.1906346; MILLER GA, 1955, J ACOUST SOC AM, V27, P338, DOI 10.1121/1.1907526; REMEZ RE, 1981, SCIENCE, V212, P947, DOI 10.1126/science.7233191; ROSEN S, 1989, J SPEECH HEAR RES, V32, P93, DOI 10.1044/jshr.3201.93; ROSEN S, 1992, PHILOS T ROY SOC B, V336, P367, DOI 10.1098/rstb.1992.0070; ROSEN SM, 1981, NATURE, V291, P150, DOI 10.1038/291150a0; SCHROEDE.MR, 1966, PR INST ELECTR ELECT, V54, P720, DOI 10.1109/PROC.1966.4841; SHANNON RV, 1989, J ACOUST SOC AM, V85, P2587, DOI 10.1121/1.397753; SHANNON RV, 1983, HEARING RES, V11, P157, DOI 10.1016/0378-5955(83)90077-1; SHANNON RV, 1992, J ACOUST SOC AM, V91, P1974; SHANNON RV, 1992, AUDITORY PROCESSING, P263; Stevens KN., 1981, PERSPECTIVES STUDY S, P1; TALLAL P, 1993, ANN NY ACAD SCI, V682; VANTASELL DJ, 1987, J ACOUST SOC AM, V82, P1152, DOI 10.1121/1.395251; VANTASSELL DJ, 1992, J ACOUST SOC AM, V92, P1247, DOI 10.1121/1.403920; WILSON B S, 1990, P339; WILSON BS, 1991, NATURE, V352, P236, DOI 10.1038/352236a0	26	2042	2089	8	178	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					303	304		10.1126/science.270.5234.303	http://dx.doi.org/10.1126/science.270.5234.303			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569981				2022-12-28	WOS:A1995RZ34200040
J	BRUGAROLAS, J; CHANDRASEKARAN, C; GORDON, JI; BEACH, D; JACKS, T; HANNON, GJ				BRUGAROLAS, J; CHANDRASEKARAN, C; GORDON, JI; BEACH, D; JACKS, T; HANNON, GJ			RADIATION-INDUCED CELL-CYCLE ARREST COMPROMISED BY P21 DEFICIENCY	NATURE			English	Article							DEPENDENT KINASES; SUBUNIT; MOUSE; P53	THE protein p21 is a dual inhibitor of cyclin-dependent kinases(1-3) and proliferating-cell nuclear antigen (PCNA)(4), both of which are required for passage through the cell cycle. The p21 gene is under the transcriptional control of p53 (ref. 5), suggesting that p21 might promote p53-dependent cell cycle arrest or apoptosis. p21 has also been implicated in cell senescence(6) and in cell-cycle withdrawal upon termination differentiation(7-9). Here we investigate the role of p21 in these processes using chimaeric mice composed partly of p21(-/-) and partly of p21(+/+) cells. Immunohistochemical studies of the p21(+/+) and p21(-/-) components of adult small intestine indicated that deletion of p21 had no detectable effect on the migration-associated differentiation of the four principal intestinal epithelial cell lineages or on p53-dependent apoptosis following irradiation. However, p21(-/-) mouse embryo fibroblasts are impaired in their ability to undergo G1 arrest following DNA damage.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	Washington University (WUSTL); Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	BRUGAROLAS, J (corresponding author), MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.		Hannon, Gregory/AAB-3568-2019					Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CLARKE AR, 1994, ONCOGENE, V9, P1767; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LI YJ, 1994, ONCOGENE, V10, P599; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MERRITT AJ, 1994, CANCER RES, V54, P614; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P710	23	1155	1174	1	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					552	557		10.1038/377552a0	http://dx.doi.org/10.1038/377552a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566157				2022-12-28	WOS:A1995RZ33600069
J	CHEN, RH; MIETTINEN, PJ; MARUOKA, EM; CHOY, L; DERYNCK, R				CHEN, RH; MIETTINEN, PJ; MARUOKA, EM; CHOY, L; DERYNCK, R			A WD-DOMAIN PROTEIN THAT IS ASSOCIATED WITH AND PHOSPHORYLATED BY THE TYPE-II TGF-BETA RECEPTOR	NATURE			English	Article							CLONING; EXPRESSION; BINDING; COMPLEX; KINASES; ACTIVIN; CELLS; ACID	TRANSFORMING growth factor-beta (TGF-beta) is tbe prototype for a family of extracellular polypeptides that affect cell proliferation and differentiation, and tissue morphogenesis(1). TGF-beta signalling is mediated by two types of serine/threonine kinase receptors, the type I and II receptors, which are able to form a heteromeric complex(2). No cytoplasmic proteins that associate with these receptors in vivo, or are their kinase targets, have yet been described. We have now identified a WD-domain-containiag protein, TRIP-1, which specifically associates with the type II TGF-beta receptor in a kinase-dependent way. TRIP-1 does not interact with the type II activin or type I receptors, but associates with the heteromeric TGF-beta receptor complex, TRIP-1 is phosphorylated on serine and threonine by the receptor kinase, strongly suggesting that it has a role in TGF-beta signalling. This is supported by coexpression of TRIP-1 and type II receptor during development. The existence of TRIP-1 homologues in plant and yeast suggests a conserved function in all eukaryotes.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	CHEN, RH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,SAN FRANCISCO,CA 94143, USA.		Chen, Ruey-Hwa/G-6121-2019	Chen, Ruey-Hwa/0000-0001-8124-5832				CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1994, CYTOKINE HDB, P319; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; HARPER JW, 1993, CELL, V75, P805; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P105, DOI 10.1016/0167-4781(92)90472-C; MIETTINEN PJ, 1989, PEDIATR RES, V26, P25, DOI 10.1203/00006450-198907000-00009; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J, 1989, MOL CLONING LABORATO; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	29	174	196	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					548	552		10.1038/377548a0	http://dx.doi.org/10.1038/377548a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566156				2022-12-28	WOS:A1995RZ33600068
J	WEIGEL, D; NILSSON, O				WEIGEL, D; NILSSON, O			A DEVELOPMENTAL SWITCH SUFFICIENT FOR FLOWER INITIATION IN DIVERSE PLANTS	NATURE			English	Article							ARABIDOPSIS FLORAL DEVELOPMENT; INFLORESCENCE DEVELOPMENT; HOMEOTIC GENES; THALIANA; LEAFY; APETALA1; PROMOTER	We have generated transgenic plants in which the flower-meristem-identity gene LEAFY of Arabidopsis is constitutively expressed. LEAFY is sufficient to determine floral fate in lateral shoot meristems of both Arabidopsis and the heterologous species aspen, with the consequence that flower development is induced precociously. Our results also suggest a new level of regulation during flower development, as indicated by the competence of the main shoot to respond to LEAFY activity.	SWEDISH UNIV AGR SCI,S-90183 UMEA,SWEDEN	Swedish University of Agricultural Sciences	WEIGEL, D (corresponding author), SALK INST BIOL STUDIES,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/C-1418-2008; Weigel, Detlef/AAR-3312-2021	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Nilsson, Ove/0000-0002-1033-1909				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; JOHNSON E, 1994, PLANT PHYSIOL, V105, P141, DOI 10.1104/pp.105.1.141; KELLY AJ, 1995, PLANT CELL, V7, P225, DOI 10.1105/tpc.7.2.225; KEMPIN SA, 1994, SCIENCE, V267, P522; LAMB CJ, 1992, BIO-TECHNOL, V10, P1436, DOI 10.1038/nbt1192-1436; LEVIN JZ, 1995, PLANT CELL, V7, P529, DOI 10.1105/tpc.7.5.529; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; MCDANIEL CN, 1992, DEV BIOL, V153, P59, DOI 10.1016/0012-1606(92)90091-T; NILSSON O, 1995, THESIS SWEDISH U AGR; Nilsson Ove, 1992, Transgenic Research, V1, P209, DOI 10.1007/BF02524751; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; Schreiner E. J., 1974, USDA AGR HDB, P645; SCHULTZ EA, 1993, DEVELOPMENT, V119, P745; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SINGER SR, 1992, PLANTA, V188, P546, DOI 10.1007/BF00197047; STRAUSS SH, 1995, MOL BREEDING, V1, P5, DOI 10.1007/BF01682086; TANKSLEY SD, 1989, BIO-TECHNOL, V7, P257, DOI 10.1038/nbt0389-257; Telfer A, 1994, ARABIDOPSIS, P379, DOI DOI 10.1083/JCB.201205114; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL DA, 1995, REV GENET, V29, P19	31	610	758	4	64	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					495	500		10.1038/377495a0	http://dx.doi.org/10.1038/377495a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566146				2022-12-28	WOS:A1995RZ33600051
J	CUNDELL, DR; GERARD, NP; GERARD, C; IDANPAANHEIKKILA, I; TUOMANEN, EI				CUNDELL, DR; GERARD, NP; GERARD, C; IDANPAANHEIKKILA, I; TUOMANEN, EI			STREPTOCOCCUS-PNEUMONIAE ANCHOR TO ACTIVATED HUMAN-CELLS BY THE RECEPTOR FOR PLATELET-ACTIVATING-FACTOR	NATURE			English	Article							HUMAN ENDOTHELIAL-CELLS; INFLAMMATION; LUNG; EXPRESSION; INDUCTION; CLONING; WALL	THE Gram-positive bacterium Streptococcus pneumoniae is a major cause of pneumonia, sepsis and meningitis(1). Although the invasive disease is severe, some 40% of individuals harbour the pneumococcus in the nasopharynx asymptomatically(2). Here we investigate the molecular elements of the encounter between host and pathogen that distinguish these different outcomes. We show that inflammatory activation of human cells shifts the targeting of the pneumococcos to a new receptor, that for the G-protein-coupled platelet-activating factor (PAF). Only virulent pneumococci engage the PAF receptor. Attachment of the bacterial phosphorylcholine to the PAF receptor enhanced adherence, which was coupled to invasion of endothelial, epithelial and PAF-receptor-transfected cells. This progression could be arrested in vitro and in vivo by PAF-receptor-specific antagonists, suggesting a possible approach to therapy.	ROCKEFELLER UNIV,MOLEC INFECT DIS LAB,NEW YORK,NY 10021; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,INA SUE PERLMUTTER CYST FIBROSIS LAB,BOSTON,MA 02115	Rockefeller University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School			Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716; Cundell, Diana/0000-0003-3119-180X				AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35; BKAILY G, 1993, BRIT J PHARMACOL, V110, P519, DOI 10.1111/j.1476-5381.1993.tb13841.x; BUSSOLINO F, 1994, J BIOL CHEM, V269, P2877; CABELLOS C, 1992, J CLIN INVEST, V90, P612, DOI 10.1172/JCI115900; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CUNDELL D, 1934, MICROB PATHOG, V17, P361; ELIAS JA, 1990, AM J RESP CELL MOL, V3, P13, DOI 10.1165/ajrcmb/3.1.13; GARDNER CR, 1993, J LEUKOCYTE BIOL, V53, P190, DOI 10.1002/jlb.53.2.190; GEELEN S, 1993, INFECT IMMUN, V61, P1538, DOI 10.1128/IAI.61.4.1538-1543.1993; GEELEN S, 1992, INFECT IMMUN, V60, P4179, DOI 10.1128/IAI.60.10.4179-4183.1992; GERARD NP, 1994, J IMMUNOL, V152, P793; HELLER R, 1992, J IMMUNOL, V149, P3682; HENSON PM, 1992, AM REV RESPIR DIS, V145, P726, DOI 10.1164/ajrccm/145.3.726; HEUMANN D, 1994, INFECT IMMUN, V62, P2715, DOI 10.1128/IAI.62.7.2715-2721.1994; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LINDER TE, 1994, MICROB PATHOGENESIS, V16, P435, DOI 10.1006/mpat.1994.1043; SHIRASAKI H, 1994, AM J RESP CELL MOL, V10, P533, DOI 10.1165/ajrcmb.10.5.8179916; STOLL LL, 1994, J BIOL CHEM, V269, P4254; SUN DX, 1992, ACTA PHARMACOL SIN, V13, P326; TUOMANEN E, 1985, J INFECT DIS, V151, P859, DOI 10.1093/infdis/151.5.859; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; WEISER JN, 1994, INFECT IMMUN, V62, P2582, DOI 10.1128/IAI.62.6.2582-2589.1994; WINDKELSTEIN J, 1978, J IMMUNOL, V120, P174; WISSNER A, 1986, J MED CHEM, V29, P328, DOI 10.1021/jm00153a005; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	30	557	583	10	54	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					435	438		10.1038/377435a0	http://dx.doi.org/10.1038/377435a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566121				2022-12-28	WOS:A1995RY19000051
J	RAHME, LG; STEVENS, EJ; WOLFORT, SF; SHAO, J; TOMPKINS, RG; AUSUBEL, FM				RAHME, LG; STEVENS, EJ; WOLFORT, SF; SHAO, J; TOMPKINS, RG; AUSUBEL, FM			COMMON VIRULENCE FACTORS FOR BACTERIAL PATHOGENICITY IN PLANTS AND ANIMALS	SCIENCE			English	Article							PSEUDOMONAS-AERUGINOSA; ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; IDENTIFICATION; DETERMINANTS; RESISTANCE; SECRETION; CLONING; REGION; GENES	A Pseudomonas aeruginosa strain (UCBPP-PA14) is infectious both in an Arabidopsis thaliana leaf infiltration model and in a mouse full-thickness skin burn model. UCBPP-PA14 exhibits ecotype specificity for Arabidqosis, causing a range of symptoms from none to severe in four different ecotypes. In the mouse model, UCBPP-PA14 is as lethal as other well-studied P. aeruginosa strains. Mutations in the UCBPP-PA14 toxA, plcS, and gacA genes resulted in a significant reduction in pathogenicity in both hosts, indicating that these genes encode virulence factors required for the full expression of pathogenicity in both plants and animals.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,SHRINERS BURNS INST,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT SURG,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital								BERKA RM, 1982, J BACTERIOL, V152, P239; BODEY GP, 1983, REV INFECT DIS, V5, P279; BURKHOLDER WALTER H., 1950, PHYTOPATH, V40, P115; CHO JJ, 1974, PHYTOPATHOLOGY, V65, P425; Crute I, 1994, ARABIDOPSIS, P705; DAVIS KR, 1991, MOL PLANT MICROBE IN, V4, P477, DOI 10.1094/MPMI-4-477; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; ELROD RP, 1942, J BACTERIOL, V46, P633; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; GAFFNEY TD, 1994, MOL PLANT MICROBE IN, V7, P455, DOI 10.1094/MPMI-7-0455; GOUGH CL, 1992, MOL PLANT MICROBE IN, V5, P384, DOI 10.1094/MPMI-5-384; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; HOLLOWAY BW, 1955, J GEN MICROBIOL, V13, P572, DOI 10.1099/00221287-13-3-572; HUANG HC, 1992, J BACTERIOL, V174, P6878, DOI 10.1128/JB.174.21.6878-6885.1992; HUANG HC, 1993, MOL PLANT MICROBE IN, V6, P515, DOI 10.1094/MPMI-6-515; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; ISHIMOTO KS, 1989, P NATL ACAD SCI USA, V86, P1954, DOI 10.1073/pnas.86.6.1954; KOMINOS SD, 1972, APPL MICROBIOL, V24, P567, DOI 10.1128/AEM.24.4.567-570.1972; LAVILLE J, 1992, P NATL ACAD SCI USA, V89, P1562, DOI 10.1073/pnas.89.5.1562; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; LORY S, 1983, GENE, V22, P95, DOI 10.1016/0378-1119(83)90068-9; LORY S, 1988, J BACTERIOL, V170, P714, DOI 10.1128/jb.170.2.714-719.1988; MEYERS BR, 1972, ANN INTERN MED, V76, P9, DOI 10.7326/0003-4819-76-1-9; OHMAN DE, 1980, INFECT IMMUN, V28, P899; OSTROFF RM, 1987, J BACTERIOL, V169, P4597, DOI 10.1128/jb.169.10.4597-4601.1987; OSTROFF RM, 1989, INFECT IMMUN, V57, P1369, DOI 10.1128/IAI.57.5.1369-1373.1989; RAHME LG, 1991, J BACTERIOL, V170, P575; RICH JJ, 1994, J BACTERIOL, V176, P7468, DOI 10.1128/JB.176.24.7468-7475.1994; ROBERTS RC, 1990, J BACTERIOL, V172, P6204, DOI 10.1128/jb.172.11.6204-6216.1990; RUBIN RA, 1987, PLASMID, V18, P84, DOI 10.1016/0147-619X(87)90081-3; Stevens Emily J., 1994, Journal of Burn Care and Rehabilitation, V15, P232, DOI 10.1097/00004630-199405000-00005; Young, 1977, PSEUDOMONAS AERUGINO, P1	33	961	998	7	140	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1899	1902		10.1126/science.7604262	http://dx.doi.org/10.1126/science.7604262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604262				2022-12-28	WOS:A1995RF99000038
J	GALLAY, P; SWINGLER, S; SONG, JP; BUSHMAN, F; TRONO, D				GALLAY, P; SWINGLER, S; SONG, JP; BUSHMAN, F; TRONO, D			HIV NUCLEAR IMPORT IS GOVERNED BY THE PHOSPHOTYROSINE-MEDIATED BINDING OF MATRIX TO THE CORE DOMAIN OF INTEGRASE	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMA-MEMBRANE; CELL-CYCLE; PROTEIN; INFECTION; DNA; REGION; RNA	The karyophilic properties of the viral matrix (MA) protein govern HIV nuclear import in nondividing cells such as macrophages. A critical regulator of this process is the C-terminal tyrosine phosphorylation of MA during virus maturation. Here, we reveal the mechanism of this phenomenon, by demonstrating that tyrosine phosphorylation induces the binding of MA to integrase (IN). This leads to the incorporation of MA molecules into virus cores, and subsequently into uncoated viral nucleoprotein complexes. A direct interaction between tyrosine-phosphorylated MA and the central domain of IN can be demonstrated in vitro. It is blocked by phosphotyrosine, indicating that IN recognizes the phosphorylated C-terminal residue of MA. These results explain how the karyophilic potential of MA is conferred to the HIV nucleoprotein complex.			GALLAY, P (corresponding author), SALK INST BIOL STUDIES,INFECT DIS LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NIAID NIH HHS [AI34786, AI37510] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037510, R01AI034786] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; FARNET CM, 1991, J VIROL, V65, P1910, DOI 10.1128/JVI.65.4.1910-1915.1991; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HUMPHRIES EH, 1972, J VIROL, V10, P82, DOI 10.1128/JVI.10.1.82-87.1972; HUMPHRIES EH, 1974, J VIROL, V14, P531, DOI 10.1128/JVI.14.3.531-546.1974; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Meltzer M S, 1992, Curr Top Microbiol Immunol, V181, P239; MILLER MD, 1995, J VIROL, V69, P3938, DOI 10.1128/JVI.69.6.3938-3944.1995; MYERS G, 1992, HUMAN RETROVIRUSES A; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SHAROVA N, 1991, AIDS RES HUM RETROV, V7, P303, DOI 10.1089/aid.1991.7.303; SPEARMAN P, 1994, J VIROL, V68, P3232, DOI 10.1128/JVI.68.5.3232-3242.1994; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; YUAN X, 1993, J VIROL, V67, P6387, DOI 10.1128/JVI.67.11.6387-6394.1993; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	33	319	323	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					569	576		10.1016/0092-8674(95)90097-7	http://dx.doi.org/10.1016/0092-8674(95)90097-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585960	Bronze			2022-12-28	WOS:A1995TF24800010
J	LIN, RL; THOMPSON, S; PRIESS, JR				LIN, RL; THOMPSON, S; PRIESS, JR			POP-1 ENCODES AN HMG BOX PROTEIN REQUIRED FOR THE SPECIFICATION OF A MESODERM PRECURSOR IN EARLY C-ELEGANS EMBRYOS	CELL			English	Article							SEX-DETERMINING REGION; DNA-BINDING MOTIF; CAENORHABDITIS-ELEGANS; CELLULAR INTERACTIONS; TRANSCRIPTION FACTOR; ALPHA-ENHANCER; MESSENGER-RNA; GENE; GUT; EXPRESSION	In C. elegans embryogenesis, the MS blastomere produces predominantly mesodermal cell types, while its sister E generates only endodermal tissue. We show that a maternal gene, pop-1, is essential for the specification of MS fate and that a mutation in pop-1 results in MS adopting an E fate. Previous studies have shown that the maternal gene skn-1 is required for both MS and E development and that skn-1 encodes a transcription factor. We show here that the pop-1 gene encodes a protein with an HMG box similar to the HMG boxes in the vertebrate lymphoid-specific transcriptional regulators TCF-1 and LEF-1. We propose that POP-1 and SKN-1 function together in the early embryo to allow MS-specific differentiation.			LIN, RL (corresponding author), HOWARD HUGHES MED INST,FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98109, USA.							AAMODT EJ, 1991, SCIENCE, V252, P579, DOI 10.1126/science.2020855; ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ARTAVANISTSAKON.S, 1995, SCIENCE, V268, P225; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; CHEN BPC, 1994, GENE, V139, P73, DOI 10.1016/0378-1119(94)90525-8; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; EPSTEIN HF, 1982, MUSCLE DEV MOL CELLU, P7; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1227; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GRANATO M, 1994, DEVELOPMENT, V120, P3005; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HO IC, 1990, MOL CELL BIOL, V10, P4720, DOI 10.1128/MCB.10.9.4720; HUTTER H, 1994, DEVELOPMENT, V120, P2051; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JUNKERSDORF B, 1992, ROUX ARCH DEV BIOL, V202, P17, DOI 10.1007/BF00364593; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; MANGO SE, 1994, DEVELOPMENT, V120, P3019; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; ROBINSON PA, 1988, J IMMUNOL METHODS, V108, P115, DOI 10.1016/0022-1759(88)90409-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHNABEL H, 1990, SCIENCE, V250, P686, DOI 10.1126/science.250.4981.686; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WOOD WB, 1994, TRENDS GENET, V10, P49, DOI 10.1016/0168-9525(94)90148-1; XIE W, 1991, BIOTECHNIQUES, V11, P325; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	51	255	261	1	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					599	609		10.1016/0092-8674(95)90100-0	http://dx.doi.org/10.1016/0092-8674(95)90100-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585963	Bronze			2022-12-28	WOS:A1995TF24800013
J	WRIGHT, A; BRADFORD, R				WRIGHT, A; BRADFORD, R			FORTNIGHTLY REVIEW - MANAGEMENT OF ACOUSTIC NEUROMA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	WRIGHT, A (corresponding author), ROYAL NATL THROAT NOSE & EAR HOSP,LONDON WC1X 8EE,ENGLAND.							BROOKES GB, 1994, CLIN OTOLARYNGOL, V19, P204, DOI 10.1111/j.1365-2273.1994.tb01216.x; Hardy M, 1936, ARCH SURG-CHICAGO, V32, P292, DOI 10.1001/archsurg.1936.01180200114005; LEONARD JR, 1970, ARCHIV OTOLARYNGOL, V91, P117; LUNSFORD LD, 1992, OTOLARYNG CLIN N AM, V25, P471; MORRISON AW, 1975, MANAGEMENT SENSORINC, P52; OGUNRINDE OK, 1995, ARCH NEUROL-CHICAGO, V52, P73, DOI 10.1001/archneur.1995.00540250077016; POLLOCK BE, 1995, NEUROSURGERY, V36, P224; RAMSDEN RT, 1994, CLIN OTOLARYNGOL, V19, P1, DOI 10.1111/j.1365-2273.1994.tb01137.x; SILVERSTEIN H, 1986, OTOLARYNG HEAD NECK, V95, P285, DOI 10.1177/01945998860953P104; TOS M, 1992, 1ST P INT C AC NEUR; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G	11	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 28	1995	311	7013					1141	1144		10.1136/bmj.311.7013.1141	http://dx.doi.org/10.1136/bmj.311.7013.1141			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580712	Green Published			2022-12-28	WOS:A1995TC46600022
J	SAKO, D; COMESS, KM; BARONE, KM; CAMPHAUSEN, RT; CUMMING, DA; SHAW, GD				SAKO, D; COMESS, KM; BARONE, KM; CAMPHAUSEN, RT; CUMMING, DA; SHAW, GD			A SULFATED PEPTIDE SEGMENT AT THE AMINO-TERMINUS OF PSGL-1 IS CRITICAL FOR P-SELECTIN BINDING	CELL			English	Article							CELL-ADHESION; GLYCOPROTEIN LIGAND; FACTOR-VIII; IDENTIFICATION; RECOGNITION; EXPRESSION; RESIDUES; PROTEINS; MOLECULE; CD62	P-selectin glycoprotein ligand 1 (PSGL-1) is a mucin-like glycoprotein expressed on the surface of myeloid cells and serves as the high affinity counterreceptor for P-selectin. The PSGL-1-P-selectin interaction is calcium dependent and requires presentation of sialyl-Lewis(x) (sLe(x))-type structures on the O-linked glycans of PSGL-1. We report here the identification of a noncarbohydrate component of the binding determinant that is critical for high affinity binding to P-selectin. Located within the first 19 amino acids, this anionic polypeptide segment contains at least one sulfated tyrosine residue, We propose that this sulfotyrosine-containing segment of PSGL-1, in conjunction with sLe(x) presented on O-linked glycans, constitutes the high affinity P-selectin-binding site.			SAKO, D (corresponding author), GENET INST INC, SMALL MOLEC DRUG DISCOVERY GRP, 85 BOLTON ST, CAMBRIDGE, MA 02140 USA.							ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GIBSON RM, 1995, BLOOD, V85, P151, DOI 10.1182/blood.V85.1.151.bloodjournal851151; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; IMAI Y, 1993, NATURE, V361, P555; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KEOWN WK, 1990, METHODS ENZYMOLOGY G, P527; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEYTE A, 1991, J BIOL CHEM, V266, P740; LIPMANN F, 1958, SCIENCE, V128, P575, DOI 10.1126/science.128.3324.575; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NORGARD KE, 1993, J BIOL CHEM, V268, P22953; PITTMAN DD, 1992, BIOCHEMISTRY-US, V31, P3315, DOI 10.1021/bi00128a003; Rehemtulla Alnawaz, 1992, Current Opinion in Biotechnology, V3, P560, DOI 10.1016/0958-1669(92)90086-X; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VACHINO G, 1995, J BIOL CHEM, V270, P21966, DOI 10.1074/jbc.270.37.21966; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	50	393	404	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					323	331		10.1016/0092-8674(95)90173-6	http://dx.doi.org/10.1016/0092-8674(95)90173-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585949	Bronze			2022-12-28	WOS:A1995TA96500018
J	MUTHUSAMY, N; BARTON, K; LEIDEN, JM				MUTHUSAMY, N; BARTON, K; LEIDEN, JM			DEFECTIVE ACTIVATION AND SURVIVAL OF T-CELLS LACKING THE ETS-1 TRANSCRIPTION FACTOR	NATURE			English	Article							GENE PROMOTER; EXPRESSION; BINDING; PROTOONCOGENE; PROTEINS; ONCOGENE; FAMILY; DOMAIN; MICE	THE Ets-1 proto-oncogene(1) is a member of the Ets family of eukaryotic transcription factors(2-7). Members of this family play important roles in regulating gene expression in response to multiple developmental and mitogenic signals(4,5,8,9) Ets-1 is preferentially expressed at high levels in B and T cells of adult mice(10,11) and is regulated during both thymocyte development(11) and T-cell activation(12,13), To study the role of Ets-1 in T-cell development and function we have used the RAG-2(-/-) complementation system(14) and murine embryonic stem (ES) cells containing homozygous deletions in the Ets-1 gene (Ets-1(-/-)). Ets-1(-/-)-RAG-2(-/-) chimaeric mice displayed markedly decreased numbers of mature thymocytes and peripheral T cells. Ets-1(-/-) T cells expressed normal levels of CD3 and T-cell antigen receptor (TCR)-alpha/beta. However, they displayed a severe proliferative defect in response to multiple activational signals and demonstrated increased rates of spontaneous apoptosis in vitro. These findings demonstrate that Ets-1 is required for the normal survival and activation of murine T cells.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637	University of Chicago; University of Chicago			Muthusamy, Natarajan/A-6915-2009					BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEUNG S, 1993, ONCOGENE, V8, P989; LI X, 1995, CYTOMETRY, V20, P172, DOI 10.1002/cyto.990200210; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOTTON D, 1993, LEUKEMIA, V7, pS55	25	282	286	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					639	642		10.1038/377639a0	http://dx.doi.org/10.1038/377639a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566177				2022-12-28	WOS:A1995TA27500055
J	ZWI, AB				ZWI, AB			LIFE IN THE REAL-WORLD IS MORE COMPLICATED - COMMENTARY	BRITISH MEDICAL JOURNAL			English	Article											ZWI, AB (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH POLICY UNIT,LONDON WC1E 7HT,ENGLAND.		Zwi, Anthony/AAP-8731-2020; Zwi, Anthony/AAP-7026-2021	Zwi, Anthony/0000-0001-6902-6602				[Anonymous], 1994, HUMAN DEV REPORT; Boutros-Ghali B, 1995, AGENDA PEACE REPORTS; Boutros-Ghali Boutros, 1995, AGENDA DEV; GELLERT GA, 1995, BMJ-BRIT MED J, V311, P995; MACRAE J, 1995, POSTCONFLICT REHABIL; 1993, HUMAN DEV REPORT	6	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					1001	1002						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580588				2022-12-28	WOS:A1995TA07900030
J	MARTIN, A; HAXBY, JV; LALONDE, FM; WIGGS, CL; UNGERLEIDER, LG				MARTIN, A; HAXBY, JV; LALONDE, FM; WIGGS, CL; UNGERLEIDER, LG			DISCRETE CORTICAL REGIONS ASSOCIATED WITH KNOWLEDGE OF COLOR AND KNOWLEDGE OF ACTION	SCIENCE			English	Article							VISUAL-CORTEX; PET IMAGES; VERBS; RETRIEVAL; SYSTEMS; NOUNS; BRAIN; COMPREHENSION; ACHROMATOPSIA; ORGANIZATION	The areas of the brain that mediate knowledge about objects were investigated by measuring changes in regional cerebral blood flow (rCBF) using positron emission tomography (PET). Subjects generated words denoting colors and actions associated with static, achromatic line drawings of objects in one experiment, and with the written names of objects in a second experiment. In both studies, generation of color words selectively activated a region in the ventral temporal lobe just anterior to the area involved in the perception of color, whereas generation of action words activated a region in the middle temporal gyrus just anterior to the area involved in the perception of motion. These data suggest that object knowledge is organized as a distributed system in which the attributes of an object are stored close to the regions of the cortex that mediate perception of those attributes.			MARTIN, A (corresponding author), NIMH,PSYCHOL & PSYCHOPATHOL LAB,BLDG 10,ROOM 4C110,10 CTR DR,MSC 1366,BETHESDA,MD 20892, USA.		martin, alex/B-6176-2009					ALBERT ML, 1981, CLIN ASPECTS DYSPHAG, P69; Allport D.A., 1985, CURRENT PERSPECTIVES, P32; BATTIG WF, 1969, J EXPT PSYCHOL MON 2, V80; CARAMAZZA A, 1991, NATURE, V349, P788, DOI 10.1038/349788a0; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DAMASIO A, 1980, NEUROLOGY, V30, P1064, DOI 10.1212/WNL.30.10.1064; DAMASIO AR, 1993, P NATL ACAD SCI USA, V90, P4957, DOI 10.1073/pnas.90.11.4957; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; Desimone R., 1989, HDB NEUROPSYCHOLOGY, P267; FARAH MJ, 1992, J EXP PSYCHOL HUMAN, V18, P241, DOI 10.1037/0096-1523.18.1.241; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; FRISTON KJ, 1991, J COMPUT ASSIST TOMO, V15, P634, DOI 10.1097/00004728-199107000-00020; FRISTON KJ, 1990, BLOOD FLOW METAB, V10, P458; GESCHWIND N, 1966, ARCH NEUROL-CHICAGO, V15, P137, DOI 10.1001/archneur.1966.00470140027004; GLASER WR, 1992, COGNITION, V42, P61, DOI 10.1016/0010-0277(92)90040-O; GOLDBERG E, 1989, J CLIN EXP NEUROPSYC, V11, P489, DOI 10.1080/01688638908400909; HAXBY JV, 1994, J NEUROSCI, V14, P6336; HURTIG RR, 1994, J CEREBR BLOOD F MET, V14, P423, DOI 10.1038/jcbfm.1994.53; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; KOSSLYN SM, 1994, BRAIN, V117, P15; Kucera H., 1967, COMPUTATIONAL ANAL P; LEE KS, 1991, J CEREB BLOOD FLO S2, V11, pS557; LUZZATTI C, 1994, NEUROPSYCHOLOGIA, V32, P933, DOI 10.1016/0028-3932(94)90044-2; MCCARTHY R, 1985, NEUROPSYCHOLOGIA, V23, P709, DOI 10.1016/0028-3932(85)90079-X; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; MICELI G, 1984, CORTEX, V20, P207, DOI 10.1016/S0010-9452(84)80038-6; Milner B., 1964, FRONTAL GRANULAR COR, P313; Neely J. H., 1991, BASIC PROCESSES READ, P264; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Talairach J., 1988, COPLANAR STEREOTAXIC; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; Vaina L., 1994, CEREB CORTEX, V5, P555; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; ZEKI S, 1991, J NEUROSCI, V11, P641; ZEKI S, 1990, BRAIN, V113, P1721, DOI 10.1093/brain/113.6.1721; ZEKI S, 1991, BRAIN, V114, P1721; ZIHL J, 1991, BRAIN, V114, P2235, DOI 10.1093/brain/114.5.2235; ZINGESER LB, 1990, BRAIN LANG, V39, P14, DOI 10.1016/0093-934X(90)90002-X	45	811	828	2	33	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					102	105		10.1126/science.270.5233.102	http://dx.doi.org/10.1126/science.270.5233.102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RY302	7569934				2022-12-28	WOS:A1995RY30200043
J	MENDILLO, M; BAUMGARDNER, J				MENDILLO, M; BAUMGARDNER, J			CONSTRAINTS ON THE ORIGIN OF THE MOONS ATMOSPHERE FROM OBSERVATION DURING A LUNAR ECLIPSE	NATURE			English	Article							EXTENDED SODIUM ATMOSPHERE; POTASSIUM	THE properties of the Moon's rarefied atmosphere, which can be traced through observations of sodium and potassium(1-4), provide important insights into the formation and maintenance of atmospheres on other primitive Solar System bodies(5-7). The lunar atmosphere is believed to be composed of atoms from the surface rocks and soil, which might have been sputtered by micrometeorites(8), by ions in the solar wind(9), or by photons(10,11). It might also form by the evaporation of atoms from the hot, illuminated surface(10,11) Here we report the detection of sodium emission from the Moon's atmosphere during a total lunar eclipse (which occurs when the Moon is full). The sodium atmosphere is considerably more extended at full Moon than expected--it extends to at least nine lunar radii--and its brightness distribution is incompatible with sources involving either solar-wind or micrometeorite sputtering. This leaves photon sputtering or thermal desorption as the preferred explanations for the lunar atmosphere, and suggests that sunlight might also be responsible for the transient atmospheres of other primitive bodies (such as Mercury).	BOSTON UNIV,DEPT ASTRON,BOSTON,MA 02215	Boston University	MENDILLO, M (corresponding author), BOSTON UNIV,CTR SPACE PHYS,BOSTON,MA 02215, USA.		Mendillo, Michael/H-4397-2014					AHEARN MF, 1992, ICARUS, V98, P54, DOI 10.1016/0019-1035(92)90206-M; ELFORD WG, 1964, 9 HARV U RES REP; FLYNN B, 1993, SCIENCE, V261, P184, DOI 10.1126/science.261.5118.184; FLYNN B, IN PRESS J GEOPHYS R; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; IP WH, 1991, GEOPHYS RES LETT, V18, P2093, DOI 10.1029/91GL02549; KOZLOWSKI RWH, 1990, GEOPHYS RES LETT, V17, P2253, DOI 10.1029/GL017i012p02253; MENDILLO M, 1991, GEOPHYS RES LETT, V18, P2097, DOI 10.1029/91GL02622; MENDILLO M, 1993, ADV SPACE RES, V13, P313; MORGAN T, 1991, EOS, V72, P225; MORGAN TH, 1991, J GEOPHYS RES-SPACE, V96, P1351, DOI 10.1029/90JA02127; PAPAGLANNIS MD, 1972, SPACE PHYSICS ASTROP, P94; POTTER AE, 1988, SCIENCE, V241, P675, DOI 10.1126/science.241.4866.675; POTTER AE, 1988, GEOPHYS RES LETT, V15, P1515, DOI 10.1029/GL015i013p01515; POTTER AE, 1994, GEOPHYS RES LETT, V21, P2263, DOI 10.1029/94GL01702; SMYTH WH, 1995, ASTROPHYS J, V441, P839, DOI 10.1086/175407; SMYTH WH, 1995, ASTROPHYS J, V443, P371, DOI 10.1086/175532; SPRAGUE AL, 1990, ICARUS, V84, P93, DOI 10.1016/0019-1035(90)90160-B; SPRAGUE AL, 1992, ICARUS, V96, P27, DOI 10.1016/0019-1035(92)90004-Q; SPRAGUE AL, 1990, THESIS U ARIZONA; STERN SA, 1995, ASTRON J, V109, P835, DOI 10.1086/117327; TYLER AL, 1988, GEOPHYS RES LETT, V15, P1141, DOI 10.1029/GL015i010p01141	22	42	42	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					404	406		10.1038/377404a0	http://dx.doi.org/10.1038/377404a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566115				2022-12-28	WOS:A1995RY19000040
J	ZHENG, LX; FISHER, G; MILLER, RE; PESCHON, J; LYNCH, DH; LENARDO, MJ				ZHENG, LX; FISHER, G; MILLER, RE; PESCHON, J; LYNCH, DH; LENARDO, MJ			INDUCTION OF APOPTOSIS IN MATURE T-CELLS BY TUMOR-NECROSIS-FACTOR	NATURE			English	Article							FACTOR-ALPHA; MICE	T-CELL receptor-induced apoptosis regulates immune responses and can result from interactions between Fas (Apo1/CD95) and Fas ligand (FasL)(1-12). Mutations in the genes for Fas and FasL cause disorders resembling human autoimmune diseases in lpr and gld mice, respectively(13,14). However, peripheral T-cell deletion takes place in lpr mice, acid autoimmune syndromes occur in mouse strains without Fas or FasL defects(15,16). Here we show that tumour necrosis factor (TNF) can mediate mature T-cell receptor-induced apoptosis through the p75 TNF receptor. Blockage of both TNF and Fast is required to abrogate T-cell death and TNF mediates the death of most CD8(+) T cells, whereas FasL mediates the death of most CD4(+) T cells. Our results suggest that autoregulatory apoptosis of the mature T cells can occur by two distinct molecular mechanisms.	NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA; IMMUNEX RES & DEV CORP, DEPT IMMUNOBIOL, SEATTLE, WA 98101 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GILLETTEFERGUSON I, 1994, EUR J IMMUNOL, V24, P1181, DOI 10.1002/eji.1830240526; JACOB CO, 1988, NATURE, V331, P356, DOI 10.1038/331356a0; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARIANI SM, 1994, EUR J IMMUNOL, V24, P3119, DOI 10.1002/eji.1830241231; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; Nagata S, 1994, Semin Immunol, V6, P3, DOI 10.1006/smim.1994.1002; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; RAZVI ES, 1995, AM J PATHOL, V147, P79; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCOTT DE, 1993, J IMMUNOL, V150, P664; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH MR, 1990, J IMMUNOL, V144, P162; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THEOFILOPOULOS AN, 1989, ADV IMMUNOL, V46, P61, DOI 10.1016/S0065-2776(08)60651-3; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J	29	1025	1061	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377	6547					348	351		10.1038/377348a0	http://dx.doi.org/10.1038/377348a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566090				2022-12-28	WOS:A1995RX11100059
J	HILL, MR; JAMES, AL; FAUX, JA; RYAN, G; HOPKIN, JM; LESOUEF, P; MUSK, AW; COOKSON, WOCM				HILL, MR; JAMES, AL; FAUX, JA; RYAN, G; HOPKIN, JM; LESOUEF, P; MUSK, AW; COOKSON, WOCM			FC-EPSILON-RI-BETA POLYMORPHISM AND RISK OF ATOPY IN A GENERAL-POPULATION SAMPLE	BRITISH MEDICAL JOURNAL			English	Article							SINGLE AMINO-ACID; BRONCHIAL HYPERRESPONSIVENESS; SERUM IGE; RESPONSES; ASTHMA; CHROMOSOME-11Q13; LINKAGE; ALLERGY; INFANCY; ADULTS	Objective-To establish the prevalence of Fc epsilon RI-beta polymorphisms Leu181 and Leu181/Leu183 on chromosome 11q13 in the general population and to examine whether when maternally inherited they confer a risk of atopy. Design-A population based survey for measures of atopy (skin prick test reactions, specific IgE titres, total serum IgE concentration), bronchial hyperresponsiveness, and carriage of Fc epsilon RI-beta Leu181 and Leu181/Leu183. Setting-The rural coastal town of Busselton, Western Australia. Subjects-1004 members of 230 two generation families identified through adults aged under 55. Results-Fc epsilon RI-beta Leu181/Leu183 was identified in 45 subjects (4.5%). All 13 children who had inherited the variant maternally were atopic. Six had asthma and nine rhinitis. The odds ratio of a positive Skin prick test reaction to house dust mite or grass pollen in these children compared with the other 523 children was 7.37 (95% confidence interval 1.62 to 33.60). The 95% confidence interval for the odds ratio of a positive specific IgE response (radio-allergosorbent test) was 3.00 to infinity and the odds ratio for bronchial hyperresponsiveness was 3.70 (1.21 to 11.60). By contrast, the eight children mho had derived the variant paternally had negative skin prick and radioallergosorbent test results and did not have increased bronchial responsiveness. Conclusion-Fc epsilon R triple prime beta Leu181/Leu183 when inherited maternally identifies a genetic risk factor for atopy and bronchial hyperresponsiveness.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; QUEEN ELIZABETH II MED CTR,DEPT RESP MED,PERTH,WA 6009,AUSTRALIA; CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND; UNIV WESTERN AUSTRALIA,PRINCESS MARGARET HOSP,DEPT PAEDIAT,PERTH,WA,AUSTRALIA	University of Oxford; University of Western Australia; University of Oxford; University of Western Australia			Hill, Michael/C-4861-2008; Cookson, William/HHC-1790-2022; Le Souef, Peter N/H-5256-2014		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABERG N, 1994, CLIN EXP ALLERGY, V23, P829; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COLLEE JM, 1993, LANCET, V342, P936, DOI 10.1016/0140-6736(93)91988-X; COOKSON WOCM, 1991, CLIN EXP ALLERGY, V21, P473, DOI 10.1111/j.1365-2222.1991.tb01688.x; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; KUEHR J, 1993, CLIN EXP ALLERGY, V23, P600, DOI 10.1111/j.1365-2222.1993.tb00900.x; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MARSH DG, 1992, NAT GENET, V2, P252, DOI 10.1038/ng1292-252; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAKAWA T, 1994, CLIN GENET, V46, P228; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236	25	132	135	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					776	779		10.1136/bmj.311.7008.776	http://dx.doi.org/10.1136/bmj.311.7008.776			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580438	Green Published			2022-12-28	WOS:A1995RX10700019
J	DOWD, P; HERSHLINE, R; HAM, SW; NAGANATHAN, S				DOWD, P; HERSHLINE, R; HAM, SW; NAGANATHAN, S			VITAMIN-K AND ENERGY TRANSDUCTION - A BASE STRENGTH AMPLIFICATION MECHANISM	SCIENCE			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; DEPENDENT CARBOXYLATION REACTION; MATRIX GLA PROTEIN; BINDING-PROPERTIES; BLOOD-COAGULATION; MODEL; INHIBITION; PEPTIDE; BONE; 2,3-EPOXIDE	Energy transfer provides an arrow in the metabolism of living systems. Direct energetic coupling of chemical transformations, such that the free energy generated in one reaction is channeled to another, is the essence of energy transfer, whereas the purpose is the production of high-energy chemical intermediates. Vitamin K provides a particularly instructive example of energy transfer. A key principle at work in the vitamin K system can be termed ''base strength amplification.'' In the base strength amplification sequence, the free energy of oxygenation of vitamin K hydroquinone (vitamin KH2) is used to transform a weak base to a strong base in order to effect proton removal from selected glutamate (Glu) residues in the blood-clotting proteins.			DOWD, P (corresponding author), UNIV PITTSBURGH, DEPT CHEM, PITTSBURGH, PA 15260 USA.							ANTON DL, 1983, J BIOL CHEM, V258, P4084; ARNETT EM, 1992, J AM CHEM SOC, V114, P9209, DOI 10.1021/ja00049a075; CABANISS SE, 1990, INT J PEPT PROT RES, V36, P79; CAIN JD, 1990, INT J PEPT PROT RES, V35, P111; CANFIELD LM, 1987, BIOCHEM BIOPH RES CO, V148, P184, DOI 10.1016/0006-291X(87)91093-X; CANFIELD LM, 1980, ARCH BIOCHEM BIOPHYS, V202, P515, DOI 10.1016/0003-9861(80)90457-9; CARDINALE GJ, 1968, BIOCHEMISTRY-US, V7, P3970, DOI 10.1021/bi00851a026; CHEUNG AY, 1988, CURRENT ADV VITAMIN, P3; Dam H, 1934, NATURE, V133, P909, DOI 10.1038/133909b0; Dam H, 1929, BIOCHEM Z, V215, P475; Dam H, 1935, NATURE, V135, P652, DOI 10.1038/135652b0; Dam H, 1934, BIOCHEM J, V28, P1355, DOI 10.1042/bj0281355; Dam H, 1935, BIOCHEM J, V29, P1273, DOI 10.1042/bj0291273; Dam H, 1930, BIOCHEM Z, V220, P158; DAVIE EW, 1975, ANNU REV BIOCHEM, V44, P729, DOI 10.1146/annurev.bi.44.070175.004055; DEMETZ M, 1982, J BIOL CHEM, V257, P5326; DEMETZ M, 1982, FEBS LETT, V137, P253, DOI 10.1016/0014-5793(82)80361-X; DOWD P, 1992, J AM CHEM SOC, V114, P7613, DOI 10.1021/ja00046a001; DOWD P, 1991, J AM CHEM SOC, V113, P9403, DOI 10.1021/ja00024a075; DOWD P, 1991, J AM CHEM SOC, V113, P7734, DOI 10.1021/ja00020a041; FINLAY TH, 1970, J BIOL CHEM, V245, P5248; FLOWERS RA, 1993, J AM CHEM SOC, V115, P9409, DOI 10.1021/ja00074a006; FRIEDMAN PA, 1976, BIOCHEM BIOPH RES CO, V70, P647, DOI 10.1016/0006-291X(76)91096-2; GALLOP PM, 1980, VITAMIN K METABOLISM, P408; GIRARDOT JM, 1982, J BIOL CHEM, V257, P5008; HALL AL, 1982, ARCH BIOCHEM BIOPHYS, V214, P45, DOI 10.1016/0003-9861(82)90006-6; HAM SW, 1990, J AM CHEM SOC, V112, P1660, DOI 10.1021/ja00160a073; HAUSCHKA PV, 1975, P NATL ACAD SCI USA, V72, P3925, DOI 10.1073/pnas.72.10.3925; HOGG PJ, 1991, J BIOL CHEM, V266, P10953; HOGG PJ, 1991, BIOCHEM BIOPH RES CO, V178, P801, DOI 10.1016/0006-291X(91)90962-7; KING C, 1994, J BIOL CHEM, V258, P25737; KULIOPULOS A, 1992, BIOCHEMISTRY-US, V31, P7722, DOI 10.1021/bi00148a037; LARSON AE, 1981, J BIOL CHEM, V256, P1032; LARSON AE, 1979, FED PROC, V38, P876; LAWSON AE, 1978, P NATL ACAD SCI USA, V75, P5413; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LEWIS MR, 1988, J BIOL CHEM, V263, P1358; LOESER RF, 1992, J BIOL CHEM, V267, P9459; LOWENTHAL J, 1970, Canadian Journal of Chemistry, V48, P3957, DOI 10.1139/v70-662; LUBIN IM, 1994, J BIOL CHEM, V269, P8639; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MANN KG, 1984, PROG HEMOST THROMB, V7, P1; McFarlane WD, 1931, BIOCHEM J, V25, P358, DOI 10.1042/bj0250358; McFarlane WD, 1931, J NUTR, V4, P331, DOI 10.1093/jn/4.3.331; MCTIGUE JJ, 1983, J BIOL CHEM, V258, P2129; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; MOSS RA, 1988, J ORG CHEM, V53, P5860, DOI 10.1021/jo00260a013; NAGANATHAN S, 1994, J AM CHEM SOC, V116, P9831, DOI 10.1021/ja00101a003; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1986, BLOOD COAGULATION, P15; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; OLSON RE, 1984, ANNU REV NUTR, V4, P281, DOI 10.1146/annurev.nu.04.070184.001433; OLSON RE, 1987, CHEM SCRIPTA, V27A, P187; OLSON RE, 1983, POSTTRANSLATIONAL CO, P295; PERSSON E, 1992, FEBS LETT, V314, P5, DOI 10.1016/0014-5793(92)81447-T; POLLOCK JS, 1988, J BIOL CHEM, V263, P14216; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; PRICE PA, 1988, ANNU REV NUTR, V8, P565, DOI 10.1146/annurev.nu.08.070188.003025; PRICE PA, 1983, BIOCHEM BIOPH RES CO, V117, P765, DOI 10.1016/0006-291X(83)91663-7; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; RUF W, 1994, BIOCHEMISTRY-US, V33, P11631, DOI 10.1021/bi00204a026; SADOWSKI JA, 1977, BIOCHEMISTRY-US, V16, P3856, DOI 10.1021/bi00636a022; SLAMA JT, 1990, J MED CHEM, V33, P824, DOI 10.1021/jm00164a056; SORIANOGARCIA M, 1989, BIOCHEMISTRY-US, V28, P6805, DOI 10.1021/bi00443a004; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; SUTTIE J W, 1988, Biofactors, V1, P55; SUTTIE JW, 1978, FED PROC, V37, P2605; SUTTIE JW, 1977, PHYSIOL REV, V57, P1, DOI 10.1152/physrev.1977.57.1.1; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; SUTTIE JW, 1984, HDB VITAMINS NUTRITI, P147; SUTTIE JW, 1988, CURRENT ADV VITAMIN; VANBUSKIRK JJ, 1978, BIOCHEM BIOPH RES CO, V80, P1033, DOI 10.1016/0006-291X(78)91349-9; VERMEER C, 1990, BIOCHEM J, V266, P625, DOI 10.1042/bj2660625; VONKRIES R, 1993, J PEDIATR GASTR NUTR, V16, P231, DOI 10.1097/00005176-199304000-00001; WAGNER AF, 1964, VITAMINS COENZYMES, P407; WHEELAN P, 1989, J ORG CHEM, V54, P4360, DOI 10.1021/jo00279a025; WILSON RM, 1985, J AM CHEM SOC, V107, P4100, DOI 10.1021/ja00299a069; ZHONG DG, 1994, P NATL ACAD SCI USA, V91, P3574, DOI 10.1073/pnas.91.9.3574	78	110	114	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 22	1995	269	5231					1684	1691		10.1126/science.7569894	http://dx.doi.org/10.1126/science.7569894			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569894				2022-12-28	WOS:A1995RV94800027
J	HUNINK, MGM; WONG, JB; DONALDSON, MC; MEYEROVITZ, MF; DEVRIES, J; HARRINGTON, DP				HUNINK, MGM; WONG, JB; DONALDSON, MC; MEYEROVITZ, MF; DEVRIES, J; HARRINGTON, DP			REVASCULARIZATION FOR FEMOROPOPLITEAL DISEASE - A DECISION AND COST-EFFECTIVENESS ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANS-LUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR-DISEASE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; LOWER-EXTREMITY ISCHEMIA; LOWER-LIMB ISCHEMIA; SAPHENOUS-VEIN; POLYTETRAFLUOROETHYLENE GRAFTS; BALLOON ANGIOPLASTY; INTERMITTENT CLAUDICATION; ARTERIAL RECONSTRUCTIONS	Objective.-To evaluate the relative benefits and cost-effectiveness of revascularization for femoropopliteal disease using percutaneous transluminal angioplasty or bypass surgery. Design.-Decision analysis using a multistate transition simulation model (Markov process) and cost-effectiveness analysis from the perspective of the health care system. Setting.-Based on mortality, morbidity, patency, and cost data from a literature review. Patients.-Hypothetical cohort of patients with chronic femoropopliteal disease who desire revascularization. Subgroup analysis for patients defined by age, sex, indication, lesion type, and graft type. Interventions.-Percutaneous transluminal angioplasty, bypass surgery, and a strategies combining the two treatments. Main Outcome Measures.-Five-year patency results, quality-adjusted life expectancy, lifetime costs, and incremental cost-effectiveness ratios. Results.-For 65-year-old men with disabling claudication and a femoropoptiteal stenosis or occlusion and for 65-year-old men with chronic critical ischemia and a femoropopliteal stenosis, initial angioplasty increased quality-adjusted life expectancy by 2 to 13 months and resulted in decreased lifetime expenditures compared with bypass surgery. For patients with chronic critical ischemia and a femoropopliteal occlusion, initial bypass surgery increased quality-adjusted life expectancy by 1 to 4 months and resulted in decreased lifetime expenditures compared with angioplasty. Sensitivity analysis demonstrated that angioplasty would always be the preferred initial treatment if the angioplasty 5-year patency rate exceeds 30%. Conclusion.-Angioplasty is the preferred initial treatment in patients with disabling claudication and a femoropopliteal stenosis or occlusion and in those with chronic critical ischemia and a stenosis. Bypass surgery is the preferred initial treatment in patients with chronic critical ischemia and a femoropopliteal occlusion.	UNIV GRONINGEN HOSP, OFF MED TECHNOL ASSESSMENT, GRONINGEN, NETHERLANDS; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV CLIN DECIS MAKING, BOSTON, MA 02111 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV VASC SURG, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT RADIOL, BOSTON, MA 02115 USA; SUNY STONY BROOK, DEPT RADIOL, STONY BROOK, NY 11794 USA	University of Groningen; Harvard University; Harvard T.H. Chan School of Public Health; Tufts Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	HUNINK, MGM (corresponding author), UNIV GRONINGEN, FAC MED, DEPT HLTH SCI, ANT DEUSINGLAAN 1, 9713 AV GRONINGEN, NETHERLANDS.			Wong, John/0000-0003-4203-9010	AHRQ HHS [HS-06503, HS-06665] Funding Source: Medline; NLM NIH HHS [LM04493] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006665] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM004493] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BECKER GJ, 1989, RADIOLOGY, V170, P921, DOI 10.1148/radiology.170.3.2521745; BELLI AM, 1990, CLIN RADIOL, V41, P380, DOI 10.1016/S0009-9260(05)80595-1; BERGAMINI TM, 1991, J VASC SURG, V13, P137, DOI 10.1016/0741-5214(91)90021-L; CALLOW AD, 1988, INT SURG, V73, P237; CAPEK P, 1991, CIRCULATION, V83, P70; CHESHIRE NJW, 1992, J VASC SURG, V15, P167, DOI 10.1016/0741-5214(92)70025-G; COFFMAN JD, 1991, NEW ENGL J MED, V325, P577, DOI 10.1056/NEJM199108223250810; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; Donaldson M C, 1991, Adv Surg, V24, P69; DONALDSON MC, 1991, ANN SURG, V213, P457, DOI 10.1097/00000658-199105000-00011; DOUBILET P, 1984, NEW ENGL J MED, V310, P95, DOI 10.1056/NEJM198401123100206; DRUMMOND MF, 1987, METHODS EX EVALUATIO; Fowkes F G, 1988, Eur J Vasc Surg, V2, P283, DOI 10.1016/S0950-821X(88)80002-1; GILLUM RF, 1990, AM HEART J, V120, P1414, DOI 10.1016/0002-8703(90)90257-X; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; Gupta S K, 1988, Eur J Vasc Surg, V2, P151, DOI 10.1016/S0950-821X(88)80067-7; GUPTA SK, 1990, J VASC SURG, V11, P348, DOI 10.1067/mva.1990.16967; GUPTA SK, 1991, J VASC SURG, V13, P162; HASSON JE, 1990, SURGERY, V108, P748; HENRIKSEN LO, 1988, ACTA CHIR SCAND, V154, P573; HOBSON RW, 1985, J VASC SURG, V2, P174, DOI 10.1067/mva.1985.avs0020174; Holm J, 1991, Eur J Vasc Surg, V5, P517, DOI 10.1016/S0950-821X(05)80338-X; HOWELL MA, 1989, J VASC SURG, V9, P691, DOI 10.1067/mva.1989.vs0090691; HUNINK MGM, 1994, J VASC SURG, V19, P632, DOI 10.1016/S0741-5214(94)70036-2; HUNINK MGM, 1994, MED DECIS MAKING, V14, P71, DOI 10.1177/0272989X9401400109; HUNINK MGM, 1994, MED DECIS MAKING, V14, P59, DOI 10.1177/0272989X9401400108; HUNINK MGM, 1993, J VASC SURG, V17, P183; JEANS WD, 1990, RADIOLOGY, V177, P559, DOI 10.1148/radiology.177.2.2145608; JOHNSTON KW, 1987, ANN SURG, V206, P403, DOI 10.1097/00000658-198710000-00002; JOHNSTON KW, 1992, RADIOLOGY, V183, P767, DOI 10.1148/radiology.183.3.1294068; JONES BA, 1985, CAN J SURG, V28, P150; JORGENSEN B, 1988, ACTA CHIR SCAND, V154, P647; KENT KC, 1988, ARCH SURG-CHICAGO, V123, P1196; KINNISON ML, 1985, AM J ROENTGENOL, V145, P1241, DOI 10.2214/ajr.145.6.1241; KRAM HB, 1991, J VASC SURG, V14, P386, DOI 10.1016/0741-5214(91)90092-9; LEATHER RP, 1988, ANN SURG, V208, P435, DOI 10.1097/00000658-198810000-00005; MACKEY WC, 1986, SURGERY, V99, P26; MARTIN EC, 1991, CIRCULATION, V83, P1; McDaniel M D, 1989, Ann Vasc Surg, V3, P273, DOI 10.1016/S0890-5096(07)60040-5; MILFORD MA, 1988, J VASC SURG, V8, P292, DOI 10.1067/mva.1988.avs0080292; MILLER N, 1991, J VASC SURG, V13, P705, DOI 10.1016/0741-5214(91)90357-Z; MORSE MH, 1991, BRIT J RADIOL, V64, P5, DOI 10.1259/0007-1285-64-757-5; PENTECOST MJ, 1994, CIRCULATION, V89, P511, DOI 10.1161/01.CIR.89.1.511; PLECHA FR, 1985, J VASC SURG, V2, P769, DOI 10.1067/mva.1985.avs0020769; QUINONESBALDRICH WJ, 1988, J VASC SURG, V8, P219, DOI 10.1067/mva.1988.avs0080219; RAVIOLA CA, 1988, ARCH SURG-CHICAGO, V123, P495; RUTHERFORD RB, 1991, RADIOLOGY, V181, P277, DOI 10.1148/radiology.181.1.1887047; RUTHERFORD RB, 1986, J VASC SURG, V4, P80; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P170; TAYLOR LM, 1990, J VASC SURG, V11, P193, DOI 10.1067/mva.1990.17235; TUNIS SR, 1991, NEW ENGL J MED, V325, P556, DOI 10.1056/NEJM199108223250806; VEITH FJ, 1986, J VASC SURG, V3, P104; WALDEN R, 1986, J VASC SURG, V3, P583, DOI 10.1067/mva.1986.avs0030583; WEIBULL H, 1987, J VASC SURG, V5, P681, DOI 10.1067/mva.1987.avs0050681; Weinstein MC, 1980, CLIN DECISION ANAL; WEISS GN, 1990, J AM GERIATR SOC, V38, P877, DOI 10.1111/j.1532-5415.1990.tb05703.x; WHITTEMORE AD, 1989, J VASC SURG, V10, P299, DOI 10.1067/mva.1989.14116; WITTELS EH, 1990, AM J CARDIOL, V65, P432, DOI 10.1016/0002-9149(90)90806-C; Wolf G L, 1993, J Vasc Interv Radiol, V4, P639, DOI 10.1016/S1051-0443(93)71939-9; WOLF GL, 1984, SEMIN INTERVENT RAD, V1, P237; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; 1991, VITAL STATISTICS U A, V2; 1992, VITAL HLTH STAT 13, V113	65	190	200	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					165	171		10.1001/jama.274.2.165	http://dx.doi.org/10.1001/jama.274.2.165			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596006				2022-12-28	WOS:A1995RH22200031
J	SHALABY, F; ROSSANT, J; YAMAGUCHI, TP; GERTSENSTEIN, M; WU, XF; BREITMAN, ML; SCHUH, AC				SHALABY, F; ROSSANT, J; YAMAGUCHI, TP; GERTSENSTEIN, M; WU, XF; BREITMAN, ML; SCHUH, AC			FAILURE OF BLOOD-ISLAND FORMATION AND VASCULOGENESIS IN FLK-1-DEFICIENT MICE	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; STEM-CELLS; MOUSE; PRECURSORS; EXPRESSION; GENE; DIFFERENTIATION; COMMITMENT; PROTEIN	THE receptor tyrosine kinase Flk-1 (ref. 1) is believed to play a pivotal role in endothelial development. Expression of the Flk-1 receptor is restricted to endothelial cells and their embryonic precursors(2-5), and is complementary to that of its ligand, vascular endothelial growth factor (VEGF)(2,3), which, is aa endothelial-specific mitogen. Highest levels of flk-1 expression are observed during embryonic vasculogenesis and angiogenesis(2-5), and dating pathological processes associated with neovascularization, such its tumour angiogenesis(7,8). Because flk-1 expression can be detected in presumptive mesodermal yolk-sac blood-island progenitors as early as 7.0 days postcoitum, Flk-1 may mark the putative common embryonic endothelial and haematopoietic precursor, the haemangioblast, and thus may also be involved in early haematopoiesis(4). Here rye report the generation of mice deficient in Flk-1 by disruption of the gene using homologous recombination in embryonic stem (ES) cells. Embryos homozygous for this mutation die in utero between 8.5 and 9.5 days post-coitum, as a result of an early defect in the development of haematopoietic and endothelial cells. Yolk-sac blood islands were absent at 7.5 days, organized blood vessels could not be observed in the embryo or yolk sac at any stage, acid haematopoietic progenitors were severely reduced. These results indicate that Flk-1 is essential for yolk-sac Mood-island formation and vasculogenesis in the mouse embryo.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,INST MED SCI,TORONTO,ON M5S 1A8,CANADA; TORONTO HOSP,DIV HAEMATOL ONCOL,TORONTO,ON M5G 2C4,CANADA; CANADIAN RED CROSS SOC,TORONTO BLOOD CTR,TORONTO,ON M5G 2M1,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto								BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; DORHONEN J, 1994, ONCOGENE, V9, P395; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KAIPAINEN A, IN PRESS P NATN ACAD; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; MATHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026; MCCLANAHAN T, 1993, BLOOD, V81, P2903; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILLAUER B, 1993, CELL, V72, P1; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; OELRICHS RB, 1993, ONCOGENE, V8, P11; PLATE KH, 1993, CANCER RES, V53, P5822; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Sambrook J, 1989, MOL CLONING LABORATO; SHIBUYA M, 1990, ONCOGENE, V5, P519; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; Wurst W., 1993, Gene targeting: a practical approach., P33; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YOUNG PE, 1995, BLOOD, V85, P96, DOI 10.1182/blood.V85.1.96.bloodjournal85196; ZIPORI D, 1988, BLOOD, V71, P586	31	3103	3258	3	101	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					62	66		10.1038/376062a0	http://dx.doi.org/10.1038/376062a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596435				2022-12-28	WOS:A1995RH11100062
J	HILL, CS; WYNNE, J; TREISMAN, R				HILL, CS; WYNNE, J; TREISMAN, R			THE RHO-FAMILY GTPASES RHOA, RAC1, AND CDC42HS REGULATE TRANSCRIPTIONAL ACTIVATION BY SRF	CELL			English	Article							SERUM RESPONSE ELEMENT; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITE; YEAST; ACTIN; GTP; IDENTIFICATION; EXPRESSION; PROMOTER	The c-fos serum response element (SRE) forms a ternary complex with the transcription factors SRF (serum response factor) and TCF (ternary complex factor). By itself, SRF can mediate transcriptional activation induced by serum, lysophosphatidic acid, or intracellular activation of heterotrimeric G proteins. Activated forms of the Rho family GTPases RhoA, Rad, and CDC42Hs also activate transcription via SRF and act synergistically at the SRE with signals that activate TCF. Functional Rho is required for signaling to SRF by several stimuli, but not by activated CDC42Hs or Rac1. Activation of the SRF-linked signaling pathway does not correlate with activation of the MAP kinases ERK, SAPK/JNK, or MPK2/p38. Functional Rho is required for regulated activity of the c-fos promoter. These results establish SRF as a nuclear target of a novel Rho-mediated signaling pathway.	IMPERIAL CANC RES FUND,TRANSCRIPT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK				Treisman, Richard/0000-0002-9658-0067; Hill, Caroline/0000-0002-8632-0480				AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRUHN L, 1994, MOL CELL BIOL, V14, P2534, DOI 10.1128/MCB.14.4.2534; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JALINK K, 1994, BBA-REV CANCER, V1198, P185, DOI 10.1016/0304-419X(94)90013-2; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; YUAN YLO, 1993, GENE DEV, V7, P1584, DOI 10.1101/gad.7.8.1584; ZAMBETTI G, 1991, EXP CELL RES, V192, P93, DOI 10.1016/0014-4827(91)90162-N	49	1191	1210	0	28	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1159	1170		10.1016/S0092-8674(05)80020-0	http://dx.doi.org/10.1016/S0092-8674(05)80020-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600583	Bronze			2022-12-28	WOS:A1995RG91000020
J	OGG, SC; WALTER, P				OGG, SC; WALTER, P			SRP SAMPLES NASCENT CHAINS FOR THE PRESENCE OF SIGNAL SEQUENCES BY INTERACTING WITH RIBOSOMES AT A DISCRETE STEP DURING TRANSLATION ELONGATION	CELL			English	Article							PREPRO-ALPHA-FACTOR; RECOGNITION PARTICLE; SACCHAROMYCES-CEREVISIAE; PROTEIN TRANSLOCATION; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; CELL-GROWTH; YEAST; GENE; RNA	The signal recognition particle (SRP) binds to ribosomes that synthesize nascent chains bearing signal sequences and catalyzes their targeting to the endoplasmic reticulum membrane. In S. cerevisiae, a temperature-sensitive mutation in the SEC65 gene, encoding an SRP subunit, results in lowered levels of SRP. Growth and protein translocation defects induced by this mutation can be suppressed specifically by sublethal doses of cycloheximide but not anisomycin, each inhibitors of different steps of translation elongation. Cycloheximide also suppresses protein translocation defects caused by depletion of a different SRP subunit. We propose that reduced elongation rates in the presence of cycloheximide allow otherwise insufficient SRP to interact efficiently with ribosomes. These results are consistent with a sampling model in which SRP cycles on and off of translating ribosomes at specific steps during the elongation cycle to inspect ah nascent chains for the presence of signal sequences.			OGG, SC (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Ogg, Stephen/0000-0003-4157-1654				ARNOLD CE, 1994, J BIOL CHEM, V269, P30412; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; BROWN S, 1989, J MOL BIOL, V209, P79, DOI 10.1016/0022-2836(89)90171-X; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; HANN BC, 1992, NATURE, V356, P532, DOI 10.1038/356532a0; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; JENSEN CG, 1994, J BACTERIOL, V176, P7148, DOI 10.1128/JB.176.23.7148-7154.1994; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; ORRWEAVER TL, 1988, MOL CELL BIOL, V8, P5292, DOI 10.1128/MCB.8.12.5292; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STOCKLEIN W, 1980, CURR GENET, V1, P177, DOI 10.1007/BF00390941; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	30	87	88	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1075	1084		10.1016/S0092-8674(05)80012-1	http://dx.doi.org/10.1016/S0092-8674(05)80012-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600575	Bronze			2022-12-28	WOS:A1995RG91000012
J	KIM, NW; PIATYSZEK, MA; PROWSE, KR; HARLEY, CB; WEST, MD; HO, PLC; COVIELLO, GM; WRIGHT, WE; WEINRICH, SL; SHAY, JW				KIM, NW; PIATYSZEK, MA; PROWSE, KR; HARLEY, CB; WEST, MD; HO, PLC; COVIELLO, GM; WRIGHT, WE; WEINRICH, SL; SHAY, JW			SPECIFIC ASSOCIATION OF HUMAN TELOMERASE ACTIVITY WITH IMMORTAL CELLS AND CANCER	SCIENCE			English	Article							HUMAN FIBROBLASTS; SEQUENCE; REPEATS; DNA; IDENTIFICATION; SENESCENCE; (TTAGGG)N; LENGTH	Synthesis of DNA at chromosome ends by telomerase may be necessary for indefinite proliferation of human cells. A highly sensitive assay for measuring telomerase activity was developed. In cultured cells representing 18 different human tissues, 98 of 100 immortal and none of 22 mortal populations were positive for telomerase. Similarly, 90 of 101 biopsies representing 12 human tumor types and none of 50 normal somatic tissues were positive. Normal ovaries and testes were positive, but benign tumors such as fibroids were negative. Thus, telomerase appears to be stringently repressed in normal human somatic tissues but reactivated in cancer, where immortal cells are likely required to maintain tumor growth.	GERON CORP,MENLO PK,CA 94025; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	Geron Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011; Piatyszek, Mieczyslaw A./F-9365-2015	Piatyszek, Mieczyslaw A./0000-0003-0502-3239; West, Michael/0000-0002-4842-5468	NCI NIH HHS [CA50195, CA65178] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R43CA065178, R01CA050195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; GARNICK MB, 1994, SCI AM, V270, P72, DOI 10.1038/scientificamerican0494-72; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, IN PRESS COLD SPRING, V59; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA E, 1992, JPN J CANCER RES, V83, P159, DOI 10.1111/j.1349-7006.1992.tb00081.x; JONES EC, 1994, AM J CLIN PATHOL, V101, P48, DOI 10.1093/ajcp/101.1.48; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; MEHLE C, 1994, CANCER RES, V54, P236; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; NURNBERG P, 1993, HUM GENET, V91, P190; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165-4608(93)90018-H; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	32	6248	6880	13	575	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2011	2015		10.1126/science.7605428	http://dx.doi.org/10.1126/science.7605428			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7605428				2022-12-28	WOS:A1994PZ26700035
J	ASSCHER, AW; PARR, GD; WHITMARSH, VB				ASSCHER, AW; PARR, GD; WHITMARSH, VB			TOWARDS THE SAFER USE OF MEDICINES	BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG-REACTIONS; GENERAL-PRACTICE; DISEASE; RISKS	In Britain the tools are now available to provide better information on safety of medicines in both hospital and community settings, and this could be done at relatively modest cost. The needs of patients, doctors, and pharmacists are changing; although more research is needed, such information as is presently available must be both better and more widely publicised and understood. Universities, government, the pharmaceutical industry, and educated journalism all have an important part to play in this process.	MED BENEFIT RISK FDN,PHARMACOEPIDEMIOL GRP,LONDON W1M 8AE,ENGLAND									ABRAMSON NS, 1980, JAMA-J AM MED ASSOC, V244, P1582, DOI 10.1001/jama.244.14.1582; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BROWN PJ, PERCEPTION MANAGEMEN, P149; BURKHOLDER DF, 1979, DRUG INTEL CLIN PHAR, V13, P421, DOI 10.1177/106002807901300708; CARTWRIGHT A, 1988, OLDER PEOPLE THEIR M; CONI N, 1988, LECTURE NOTES GERIAT; DEVRIES TPGM, 1993, BRIT J CLIN PHARMACO, V35, P591; DODDSSMITH I, 1995, 2ND P S, P1; DRURY VVM, 1986, DOCTOR MONITORING DR, P651; EVANS JG, 1993, HLTH FUNCTION 3RD AG; FERNER RE, 1992, BRIT J CLIN PHARMACO, V33, P125, DOI 10.1111/j.1365-2125.1992.tb04013.x; FERNER RE, 1994, J ROY SOC MED, V87, P145; GEORGE CF, 1983, BRIT MED J, V287, P1193, DOI 10.1136/bmj.287.6400.1193; GIBBS S, 1987, Pharmaceutical Medicine (London), V2, P23; HAYES A, 1990, PHARM J, V245, pR36; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; JICK H, 1974, NEW ENGL J MED, V291, P824, DOI 10.1056/NEJM197410172911605; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JICK H, 1984, J ALLERGY CLIN IMMUN, V74, P555, DOI 10.1016/0091-6749(84)90106-4; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Keeney R.L., 1976, DECISIONS MULTIPLE O; KNIGHT R, 1987, J ROY COLL GEN PRACT, V37, P19; LAWSON DH, 1978, SCOTTISH MED J, V24, P127; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LIVINGSTONE C, 1993, PHARM J S, V251, pR6; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; MARTYS CR, 1979, BMJ-BRIT MED J, V2, P1194, DOI 10.1136/bmj.2.6199.1194; MILLER RR, 1974, ARCH INTERN MED, V43, P219; MULROY R, 1973, BRIT MED J, V2, P407, DOI 10.1136/bmj.2.5863.407; OBRIEN BJ, 1990, J EPIDEMIOL COMMUN H, V44, P249, DOI 10.1136/jech.44.3.249; OBRIEN BJ, 1990, J RHEUMATOL, V17, P503; OGILVIE RI, 1967, CAN MED ASSOC J, V97, P1450; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; RAWLINS MD, 1988, BRIT J CLIN PHARMACO, V26, P1; RAWLINS MD, 1988, BRIT J CLIN PHARMACO, V26, P7, DOI 10.1111/j.1365-2125.1988.tb03357.x; RAWLINS MD, 1989, RISK AND CONSENT TO RISK IN MEDICINE, P193; RAWLINS MD, 1991, BRIT MED J, V302, P322; RIDOUT S, 1986, BRIT J CLIN PHARMACO, V21, P701, DOI 10.1111/j.1365-2125.1986.tb05236.x; ROBERTS K, 1986, BR J PHARM PRACT, V8, P387; SLOVIC P, 1981, P ROY SOC LOND A MAT, V376, P17, DOI 10.1098/rspa.1981.0073; Slovic P, 1989, PERCEPTION MANAGEMEN; VINCENT C, 1993, MED ACCIDENTS; WILKIE A, 1994, J ROY SOC MED, V87, P594; 1995, WAY HLTH         JUN, P80; 1982, RISK ANAL PERCEPTION; 1994, OBSERVER        0529, P26; 1991, CONSUMER EXPECTATION; 1992, PHARM CARE FUTURE CO; 1993, CHEAPER THAN PRESCRI	49	24	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					1003	1006						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580589				2022-12-28	WOS:A1995TA07900031
J	AUPHAN, N; DIDONATO, JA; ROSETTE, C; HELMBERG, A; KARIN, M				AUPHAN, N; DIDONATO, JA; ROSETTE, C; HELMBERG, A; KARIN, M			IMMUNOSUPPRESSION BY GLUCOCORTICOIDS - INHIBITION OF NF-KAPPA-B ACTIVITY THROUGH INDUCTION OF I-KAPPA-B SYNTHESIS	SCIENCE			English	Article							TRANSCRIPTION FACTOR; NEGATIVE REGULATION; GENE-EXPRESSION; LYMPHOCYTES-T; DNA-BINDING; ACTIVATION; CELLS; ALPHA; PROTEINS; HORMONES	Glucocorticoids are among the most potent anti-inflammatory and immunosuppressive agents. They inhibit synthesis of almost all known cytokines and of several cell surface molecules required for immune function, but the mechanism underlying this activity has been unclear. Here it is shown that glucocorticoids are potent inhibitors of nuclear factor kappa B (NF-kappa B) activation in mice and cultured cells, This inhibition is mediated by induction of the I kappa B alpha inhibitory protein, which traps activated NF-kappa B in inactive cytoplasmic complexes. Because NF-kappa B activates many immunoregulatory genes in response to pro-inflammatory stimuli, the inhibition of its activity can be a major component of the anti-inflammatory activity of glucocorticoids.	UNIV CALIF SAN DIEGO,SCH MED,CTR GENET MOLEC,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	University of California System; University of California San Diego			Hazen, Stanley L/ABD-5845-2021; AUPHAN-ANEZIN, Nathalie/E-7790-2018	AUPHAN-ANEZIN, Nathalie/0000-0002-1967-5206				AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ALLERGE ML, 1991, J IMMUNOL, V146, P1184; ARYA SK, 1984, J IMMUNOL, V133, P273; AUPHAN N, UNPUB; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COHEN JJ, 1989, ANTIINFLAMMATORY STE, P111; COLLART MA, 1987, J IMMUNOL, V139, P949; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; CULPEPPER JA, 1985, J IMMUNOL, V135, P3191; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIDONATO JA, UNPUB; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOEBERITZ MV, 1990, EUR J IMMUNOL, V20, P35, DOI 10.1002/eji.1830200106; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GAUGLER B, 1991, EUR J IMMUNOL, V21, P2581, DOI 10.1002/eji.1830211040; GODOWSKI PJ, 1989, UCLA S MOL CELLULAR, V95; GONZALO JA, 1993, J EXP MED, V177, P1239, DOI 10.1084/jem.177.5.1239; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; Parillo J E, 1979, ANN REV PHARMACOL TO, V19, P179; PARK JH, 1993, J BIOL CHEM, V268, P6299; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROSETTE C, UNPUB; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VACCA A, 1989, MOL ENDOCRINOL, V3, P1659, DOI 10.1210/mend-3-10-1659; WANG Y, 1993, J STEROID BIOCHEM, V44, P203, DOI 10.1016/0960-0760(93)90080-G; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZANKER B, 1990, TRANSPLANTATION, V49, P183, DOI 10.1097/00007890-199001000-00040	57	2009	2092	1	76	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					286	290		10.1126/science.270.5234.286	http://dx.doi.org/10.1126/science.270.5234.286			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569976				2022-12-28	WOS:A1995RZ34200035
J	ALLAART, CF; ROSENDAAL, FR; NOTEBOOM, WMP; VANDENBROUCKE, JP; BRIET, E				ALLAART, CF; ROSENDAAL, FR; NOTEBOOM, WMP; VANDENBROUCKE, JP; BRIET, E			SURVIVAL IN FAMILIES WITH HEREDITARY PROTEIN-C DEFICIENCY, 1820 TO 1993	BRITISH MEDICAL JOURNAL			English	Article							THROMBOTIC DISEASE; VENOUS THROMBOSIS; FACTOR-V; INACTIVATION; MORTALITY; NEWBORN	Objectives-To establish the survival of individuals heterozygous for hereditary protein C deficiency, who have an increased risk of venous thrombotic events, and to compare it with the survival of the general population. Design-Retrospective study in pedigrees of 23 families with hereditary protein C deficiency for period 1820 and 1993. Setting-23 completed family trees of 24 probands from various parts of the Netherlands with symptoms of protein C deficiency. Subjects-All 736 members of the 23 families with a 50% or 100%, probability of being (or having been) heterozygous for the genetic defect on the basis of DNA analysis or their place in the pedigrees, following mendelian rules. Main outcome measures-Observed mortality compared with the mortality of the general Dutch population; the standardised mortality ratio was calculated by dividing the observed mortality by the expected mortality. Results-No excess mortality was found in the 206 proved heterozygous individuals and ''obligatory transmitters'' (those who have definitely passed on the deficiency) (standardised mortality ratio 0.95 (95% confidence interval 0.5 to 1.2)) or in the 530 family members with a 50%, genetic probability of heterozygosity (1.10 (0.9 to 1.3)). Conclusion-Heterozygous individuals with hereditary protein C deficiency type I have normal survival compared with the general population. Prophylactic anticoagulant treatment may prevent thrombotic events in heterozygous individuals but may not be expected to improve their survival.	UNIV LEIDEN HOSP,DEPT CLIN EPIDEMIOL,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	ALLAART, CF (corresponding author), UNIV LEIDEN HOSP,HAEMOSTASIS & THROMBOSIS RES CTR,DEPT HAEMATOL,BLDG 1,C2-R,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BERTINA RM, 1982, THROMB HAEMOSTASIS, V48, P1; BRANSON HE, 1983, LANCET, V2, P1165; BROEKMANS AW, 1983, NEW ENGL J MED, V309, P340, DOI 10.1056/NEJM198308113090604; FULCHER CA, 1984, BLOOD, V63, P486; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; MARLAR RA, 1989, J PEDIATR-US, V114, P528, DOI 10.1016/S0022-3476(89)80688-2; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1157	12	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					910	913						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580547				2022-12-28	WOS:A1995RZ23700018
J	ASPINALL, RL; GOODMAN, NW				ASPINALL, RL; GOODMAN, NW			DENIAL OF EFFECTIVE TREATMENT AND POOR QUALITY OF CLINICAL INFORMATION IN PLACEBO-CONTROLLED TRIALS OF ONDANSETRON FOR POSTOPERATIVE NAUSEA AND VOMITING - A REVIEW OF PUBLISHED TRIALS	BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; INTRAVENOUS ONDANSETRON; PREVENTION; SURGERY; METOCLOPRAMIDE; ANESTHESIA; EFFICACY	Objective-To determine how many patients were deprived of treatment by being given placebo as comparator in trials of ondansetron for postoperative nausea and vomiting. Design-Review of published trials of ondansetron during 1991 to July 1994. Setting-Medline search in a university department of anaesthesia. Subjects-8806 patients who had been included in 18 indexed placebo controlled trials of ondansetron as prophylaxis against or treatment of postoperative nausea and vomiting. Results-Five studies (1236 patients) had been published by July 1992. All were placebo controlled trials. By July 1994, 8806 patients had been included in 18 indexed placebo controlled studies of prophylaxis or treatment. Only 462 patients had been in studies that compared ondansetron with other drugs, and there were no indexed comparative trials of treatment of nausea and vomiting. Roughly 2180 patients had been given placebo as prophylaxis and 440 had been given placebo when already experiencing postoperative nausea or vomiting. Conclusions-Around 2620 patients in the reviewed studies were denied existing drugs, which, though not completely effective or without side effects, do bring some relief from postoperative nausea and vomiting. Drug regulatory bodies should collaborate with drug companies to ensure better comparison of new with established drugs. This would avoid placebos being given to more than the fewest patients necessary to confirm effect and would allow doctors to be informed more quickly about relative efficacies.	SOUTHMEAD GEN HOSP,MED SCH UNIT,UNIV DEPT ANAESTHESIA,BRISTOL BS10 5NB,AVON,ENGLAND	Southmead Hospital								ALON E, 1992, ANESTH ANALG, V75, P561; ALTMAN DG, 1991, PRACTICAL STAT MED R, P450; [Anonymous], 1993, LANCET, V341, P1507; BERO LA, 1994, JAMA-J AM MED ASSOC, V271, P612, DOI 10.1001/jama.271.8.612; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; BODNER M, 1991, ANESTH ANALG, V73, P250; Bohrer H, 1994, Anaesthesiol Reanim, V19, P11; BOULY A, 1992, ANN FR ANESTH, V11, P496, DOI 10.1016/S0750-7658(05)80754-3; CHALMERS J, 1993, DRUG COSTS TREATMENT, P14; CLAYBON L, 1994, ANAESTHESIA, V49, P24, DOI 10.1111/j.1365-2044.1994.tb03579.x; DERSHWITZ M, 1992, CLIN PHARMACOL THER, V52, P96, DOI 10.1038/clpt.1992.107; Du Pen S, 1992, Eur J Anaesthesiol Suppl, V6, P55; DUPEYRON JP, 1993, ANAESTHESIA, V48, P214, DOI 10.1111/j.1365-2044.1993.tb06904.x; GAN TJ, 1994, BRIT J ANAESTH, V72, P544, DOI 10.1093/bja/72.5.544; HELMERS JH, 1992, EUROPEAN J ANAEST S6, V9, P49; HELMERS JHJH, 1993, CAN J ANAESTH, V40, P1155; HERXHEIMER A, 1990, BRIT MED J, V300, P307, DOI 10.1136/bmj.300.6720.307; HERXHEIMER A, 1993, J MED ETHICS, V19, P211, DOI 10.1136/jme.19.4.211; HERXHEIMER A, 1993, J MED ETHICS, V19, P218; ISAL JP, 1992, EUR J ANAESTH     S6, V9, P33; JOSLYN AF, 1994, ANAESTHESIA, V49, P34, DOI 10.1111/j.1365-2044.1994.tb03581.x; KAUFMANN MA, 1994, ANESTH ANALG, V78, P988; KENNY GNC, 1992, BRIT J ANAESTH, V68, P466, DOI 10.1093/bja/68.5.466; Kovac A, 1992, Eur J Anaesthesiol Suppl, V6, P37; LARIJANI GE, 1991, ANESTH ANALG, V73, P246; LEESER J, 1991, ANESTH ANALG, V72, P751; LITMAN RS, 1994, ANESTH ANALG, V78, P478; MALINS AF, 1994, BRIT J ANAESTH, V72, P231, DOI 10.1093/bja/72.2.231; MCKENZIE R, 1993, J CLIN ANESTH, V5, P30, DOI 10.1016/0952-8180(93)90084-R; MCKENZIE R, 1993, ANESTHESIOLOGY, V78, P21, DOI 10.1097/00000542-199301000-00005; PEARMAN MH, 1994, ANAESTHESIA, V49, P11, DOI 10.1111/j.1365-2044.1994.tb03577.x; RAPHAEL JH, 1993, BRIT J ANAESTH, V71, P845, DOI 10.1093/bja/71.6.845; ROCHON PA, 1994, JAMA-J AM MED ASSOC, V272, P108, DOI 10.1001/jama.272.2.108; ROSEN M, 1994, ANAESTHESIA, V49, P1, DOI 10.1111/j.1365-2044.1994.tb03574.x; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; RUSSELL D, 1992, BRIT J ANAESTH, V69, pS63, DOI 10.1093/bja/69.supplement_1.63S; RUST M, 1994, ANAESTHESIA, V49, P16, DOI 10.1111/j.1365-2044.1994.tb03578.x; SCUDERI P, 1993, ANESTHESIOLOGY, V78, P15, DOI 10.1097/00000542-199301000-00004; SUNG YF, 1993, J CLIN ANESTH, V5, P22, DOI 10.1016/0952-8180(93)90083-Q; 1994, 2ND DEP HLTH REP	40	66	67	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					844	846		10.1136/bmj.311.7009.844	http://dx.doi.org/10.1136/bmj.311.7009.844			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580491	Green Published			2022-12-28	WOS:A1995RY19100022
J	MUTHUPILLAI, R; LOMAS, DJ; ROSSMAN, PJ; GREENLEAF, JF; MANDUCA, A; EHMAN, RL				MUTHUPILLAI, R; LOMAS, DJ; ROSSMAN, PJ; GREENLEAF, JF; MANDUCA, A; EHMAN, RL			MAGNETIC-RESONANCE ELASTOGRAPHY BY DIRECT VISUALIZATION OF PROPAGATING ACOUSTIC STRAIN WAVES	SCIENCE			English	Article							BLOOD-FLOW; TISSUES	A nuclear magnetic resonance imaging (MRI) method is presented for quantitatively mapping the physical response of a material to harmonic mechanical excitation. The resulting images allow calculation of regional mechanical properties. Measurements of shear modulus obtained with the MRI technique in gel materials correlate with independent measurements of static shear modulus. The results indicate that displacement patterns corresponding to cyclic displacements smaller than 200 nanometers can be measured. The findings suggest the feasibility of a medical imaging technique for delineating elasticity and other mechanical properties of tissue.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; ADDENBROOKES HOSP, DEPT RADIOL, CAMBRIDGE, ENGLAND	Mayo Clinic; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Muthupillai, Raja/D-6544-2017	Muthupillai, Raja/0000-0001-5041-2562; LOMAS, David/0000-0003-2904-8617	NCI NIH HHS [CA51124] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRYANT DJ, 1984, J COMPUT ASSIST TOMO, V8, P588, DOI 10.1097/00004728-198408000-00002; BURLEW MM, 1980, RADIOLOGY, V134, P517, DOI 10.1148/radiology.134.2.7352242; DUMOULIN CL, 1986, RADIOLOGY, V161, P717, DOI 10.1148/radiology.161.3.3786721; FUNG YC, 1981, BIOMECHANICS MECHANI, P35; HAHN EL, 1960, J GEOPHYS RES, V65, P776, DOI 10.1029/JZ065i002p00776; HUANG SR, 1990, THESIS U ROCHESTER R; KNUTSSON H, 1994, IEEE IMAGE PROC, P36, DOI 10.1109/ICIP.1994.413270; KOLSKY H, 1963, STRESS WAVES SOLIDS, P131; KUMAR A, 1975, J MAGN RESON, V18, P69, DOI 10.1016/0022-2364(75)90224-3; LEWA CJ, 1995, JMRI-J MAGN RESON IM, V5, P242, DOI 10.1002/jmri.1880050221; MADSEN EL, 1983, J ACOUST SOC AM, V74, P1346, DOI 10.1121/1.390158; MORAN P R, 1982, Magnetic Resonance Imaging, V1, P197; OPHIR J, 1991, ULTRASONIC IMAGING, V13, P111, DOI 10.1016/0161-7346(91)90079-W; PARKER KJ, 1990, ULTRASOUND MED BIOL, V16, P241, DOI 10.1016/0301-5629(90)90003-U; PELC LR, 1992, RADIOLOGY, V185, P809, DOI 10.1148/radiology.185.3.1438767; PELC NJ, 1991, JMRI-J MAGN RESON IM, V1, P405, DOI 10.1002/jmri.1880010404; PLEWES DB, 1994, P SOC MAGN RESON, V1, P410; VANDIJK P, 1984, J COMPUT ASSIST TOMO, V8, P429, DOI 10.1097/00004728-198406000-00012	18	1501	1555	1	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 29	1995	269	5232					1854	1857		10.1126/science.7569924	http://dx.doi.org/10.1126/science.7569924			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569924				2022-12-28	WOS:A1995RX19400032
J	TAUBES, G				TAUBES, G			CANCER BIOLOGY - ANOTHER BLOW WEAKENS EMF-CANCER LINK	SCIENCE			English	Editorial Material																			0	9	9	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1816	1817		10.1126/science.269.5232.1816-a	http://dx.doi.org/10.1126/science.269.5232.1816-a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569913				2022-12-28	WOS:A1995RX19400020
J	VOLKMAN, LE				VOLKMAN, LE			BACULOVIRUS BOUNTY	SCIENCE			English	Editorial Material							NUCLEAR POLYHEDROSIS-VIRUS; INSECT CELLS; EXPRESSION; VECTOR; REPLICATION; INTERFERON; GENE				VOLKMAN, LE (corresponding author), UNIV CALIF BERKELEY,DEPT ENVIRONM SCI POLICY & MANAGEMENT,BERKELEY,CA 94720, USA.							AYRES MD, 1994, VIROLOGY, V202, P586, DOI 10.1006/viro.1994.1380; Bonning Bryony C., 1992, V10, P455; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CLEM RJ, 1993, J VIROL, V67, P3730, DOI 10.1128/JVI.67.7.3730-3738.1993; ENGELHARD EK, 1994, P NATL ACAD SCI USA, V91, P3224, DOI 10.1073/pnas.91.8.3224; HAY BA, 1994, DEVELOPMENT, V120, P2121; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; KIRKPATRICK BA, 1994, VIROLOGY, V203, P184, DOI 10.1006/viro.1994.1472; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MAEDA S, 1984, P JPN ACAD B-PHYS, V60, P423, DOI 10.2183/pjab.60.423; PENNOCK GD, 1984, MOL CELL BIOL, V4, P399, DOI 10.1128/MCB.4.3.399; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; SUMMERS MD, 1991, ACS SYM SER, V453, P237; VANIDDEKINGE BJLH, 1983, VIROLOGY, V131, P561, DOI 10.1016/0042-6822(83)90522-6; Vlak J M, 1990, Adv Biotechnol Processes, V14, P91; VOLKMAN LE, 1990, VIROLOGY, V175, P292, DOI 10.1016/0042-6822(90)90211-9; WASHBURN JO, IN PRESS VIROLOGY	19	13	15	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1834	1834		10.1126/science.7569919	http://dx.doi.org/10.1126/science.7569919			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569919				2022-12-28	WOS:A1995RX19400027
J	LEVITAN, D; GREENWALD, I				LEVITAN, D; GREENWALD, I			FACILITATION OF LIN-12-MEDIATED SIGNALING BY SEL-12, A CAENORHABDITIS-ELEGANS S182 ALZHEIMERS-DISEASE GENE	NATURE			English	Article							SPECIFIES CELL FATES; C-ELEGANS; VULVAL INDUCTION; LIN-12; GLP-1; AUTONOMY; DECISION; PROTEIN; LET-60; LOCUS	THE lin-12 and glp-1 genes of Caenorhabditis elegans are members of the lin-12/Notch family of receptors for intercellular signals that specify cell fate(1,2). By screening for suppressors of a lin-12 gain-of-function mutation, we identified a new gene, sel-12, which appears to function in receiving cells to facilitate signalling mediated by lin-12 and glp-1. The sel-12 gene encodes a protein with multiple transmembrane domains, and is similar to S182, which has been implicated in early-onset familial Alzheimer's disease(3). The high degree of sequence conservation suggests that the function of the SEL-12 and S182 proteins may also be conserved.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Columbia University; Howard Hughes Medical Institute; Columbia University; Princeton University								ARTAVANISTSAKON.S, 1995, SCIENCE, V268, P225; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; COULSON A, 1988, NATURE, V235, P184; FERGUSON EL, 1985, NATURE, V110, P259; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KHAN AS, 1992, NAT GENET, V2, P180, DOI 10.1038/ng1192-180; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SUNDARAM M, 1993, GENETICS, V135, P755; TUCK S, 1995, GENE DEV, V9, P341, DOI 10.1101/gad.9.3.341	29	640	676	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					351	354		10.1038/377351a0	http://dx.doi.org/10.1038/377351a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566091				2022-12-28	WOS:A1995RX11100060
J	BARRY, M; RUSSI, M; ARMSTRONG, L; GELLER, D; TESH, R; DEMBRY, L; GONZALEZ, JP; KHAN, AS; PETERS, CJ				BARRY, M; RUSSI, M; ARMSTRONG, L; GELLER, D; TESH, R; DEMBRY, L; GONZALEZ, JP; KHAN, AS; PETERS, CJ			BRIEF REPORT - TREATMENT OF A LABORATORY-ACQUIRED SABIA VIRUS-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							LASSA FEVER; RIBAVIRIN		YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, YALE ARBOVIRUS RES UNIT, NEW HAVEN, CT 06504 USA; CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA USA; INST FRANCAIS RECH SCI DEV COOPERAT, PARIS, FRANCE	Yale University; Centers for Disease Control & Prevention - USA; Institut de Recherche pour le Developpement (IRD)	BARRY, M (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, INT HLTH PROGRAM, 20 YORK ST, NEW HAVEN, CT 06504 USA.		Gonzalez, J-P/C-3077-2013	Gonzalez, J-P/0000-0003-3063-1770				CANONICO PG, 1984, TOXICOL APPL PHARM, V74, P155, DOI 10.1016/0041-008X(84)90138-8; COIMBRA TLM, 1994, LANCET, V343, P391, DOI 10.1016/S0140-6736(94)91226-2; FISHERHOCH SP, 1985, LANCET, V2, P1227; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; PETERS CJ, 1995, MANDELL DOUGLAS BENN, V2, P1572; 1988, MMWR-MORBID M      S, V37, P1	6	86	92	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					294	296		10.1056/NEJM199508033330505	http://dx.doi.org/10.1056/NEJM199508033330505			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL694	7596373				2022-12-28	WOS:A1995RL69400005
J	SALVARANI, C; GABRIEL, SE; OFALLON, WM; HUNDER, GG				SALVARANI, C; GABRIEL, SE; OFALLON, WM; HUNDER, GG			THE INCIDENCE OF GIANT-CELL ARTERITIS IN OLMSTED COUNTY, MINNESOTA - APPARENT FLUCTUATIONS IN A CYCLIC PATTERN	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMYALGIA-RHEUMATICA; TEMPORAL ARTERITIS; INTERMEDIATE FILAMENTS; EPIDEMIOLOGY; ANTIBODIES; 10-YEAR; VIRUS	Objective: To investigate trends in the incidence of giant cell arteritis over Design: Population-based incidence study. Setting: Olmsted County, Minnesota. Methods: All incidence cases of giant cell arteritis first diagnosed between 1950 and 1991 were identified using the unified record system at Mayo Clinic. Age- and sex-specific incidence rates were calculated using the number of incidence cases as the numerator and population estimates as the denominator. Overall rates were age- and sex-adjusted to the 1980 United States. white population. The annual incidence rates were graphically illustrated using a 3-year centered moving average. Results: Between 1950 and 1998, 125 Olmsted County residents (103 women and 22 men) were diagnosed with giant cell arteritis. The age- and sex-adjusted incidence per 100 000 persons 50 years of age or older was 17.8 (95% CI, 14.1 to 21.0); incidence was significantly higher in women (24.2 [CI, 19.5 to 28.9]) than in men (8.2 [CI, 4.8 to 11.6]). Age-specific incidence rates increased with age (P < 0.0001). The annual incidence rates increased significantly over the study period (P = 0.002) and appear to have clustered in five peak periods, which occurred about every 7 years. A significant calendar-time effect was identified; it predicted an increase in incidence of 2.6% (CI, 0.9% to 4.3%) every 5 years. Conclusions: Our observation of a regular cyclic pattern in incidence rates over time supports the hypothesis of an infectious cause for giant cell arteritis. Similar studies in other populations are needed to confirm our findings.	MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV RHEUMATOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic			Salvarani, Carlo/K-2431-2018	Salvarani, Carlo/0000-0001-5426-5133	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 30582] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson DW, 1991, NEUROEPIDEMIOLOGY TR, P239; BARRIER JH, 1988, J RHEUMATOL, V15, P383; BENGTSSON BA, 1982, ACTA MED SCAND, P1; BOESEN P, 1987, ARTHRITIS RHEUM, V30, P294, DOI 10.1002/art.1780300308; CHUANG TY, 1982, ANN INTERN MED, V97, P672, DOI 10.7326/0003-4819-97-5-672; CIMMINO MA, 1993, CLIN EXP RHEUMATOL, V11, P309; DASGUPTA B, 1987, ANN RHEUM DIS, V46, P746, DOI 10.1136/ard.46.10.746; ELLING H, 1980, ANN RHEUM DIS, V39, P511, DOI 10.1136/ard.39.5.511; FESSEL WJ, 1969, LANCET, V2, P1249; FRANZEN P, 1992, J RHEUMATOL, V19, P273; FRIEDMAN G, 1982, ISRAEL J MED SCI, V18, P241; GONZALEZGAY MA, 1992, J RHEUMATOL, V19, P277; HICKSTEIN DD, 1981, ARTHRITIS RHEUM, V24, P1448, DOI 10.1002/art.1780241122; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; HUSTON KA, 1978, ANN INTERN MED, V88, P162, DOI 10.7326/0003-4819-88-2-162; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; MACHADO EBV, 1988, ARTHRITIS RHEUM, V31, P745, DOI 10.1002/art.1780310607; MATHEWSON JA, 1986, J RHEUMATOL, V13, P190; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; NORDBORG E, 1990, J INTERN MED, V227, P233, DOI 10.1111/j.1365-2796.1990.tb00150.x; OBRIEN JP, 1992, ARTHRITIS RHEUM, V35, P794, DOI 10.1002/art.1780350713; SALVARANI C, 1991, ARTHRITIS RHEUM, V34, P351, DOI 10.1002/art.1780340313; SMITH CA, 1983, ARTHRITIS RHEUM, V26, P1214, DOI 10.1002/art.1780261007; TOH BH, 1979, CLIN EXP IMMUNOL, V37, P76	24	246	249	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					192	194		10.7326/0003-4819-123-3-199508010-00006	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598301				2022-12-28	WOS:A1995RL10400006
J	GARNER, P				GARNER, P			TYPE-I DIABETES-MELLITUS AND PREGNANCY	LANCET			English	Review							SPONTANEOUS-ABORTION; INSULIN; MOTHERS; WOMEN; MALFORMATION; GLUCOSE; INFANTS; CARE		UNIV OTTAWA,OTTAWA CIVIC HOSP,DEPT MED,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; Ottawa Hospital Research Institute	GARNER, P (corresponding author), UNIV OTTAWA,OTTAWA CIVIC HOSP,DEPT OBSTET & GYNECOL,OTTAWA,ON K1Y 4E9,CANADA.							[Anonymous], 1994, LANCET, P619; ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; BRADLEY RJ, 1988, BRIT MED J, V297, P1583, DOI 10.1136/bmj.297.6663.1583-a; Campanaro J, 1991, AM J OBSTET GYNECOL, V164, P136; Cousins L, 1987, Obstet Gynecol Surv, V42, P140; DIAMOND MP, 1992, AM J OBSTET GYNECOL, V166, P70, DOI 10.1016/0002-9378(92)91832-U; FREINKEL N, 1985, NEW ENGL J MED, V313, P96, DOI 10.1056/NEJM198507113130206; GARNER PR, 1990, AM J OBSTET GYNECOL, V163, P505, DOI 10.1016/0002-9378(90)91184-E; HANSON U, 1990, DIABETOLOGIA, V33, P100, DOI 10.1007/BF00401047; HARE JW, 1994, SEMIN PERINATOL, V18, P451; HOGAY ZJ, 1994, CLIN OBSTET GYNECOL, V37, P39; JOVANOVICPETERS.L, 1991, AM J OBSTET GYNECOL, V164, P103; KLEIN BEK, 1990, DIABETES CARE, V13, P34, DOI 10.2337/diacare.13.1.34; LAVOIE S, 1988, ADV PERITON DIAL, V8, P90; Matheson D, 1989, Diabetes Educ, V15, P242, DOI 10.1177/014572178901500314; MILLS JL, 1988, NEW ENGL J MED, V319, P1617, DOI 10.1056/NEJM198812223192501; MILLS JL, 1988, NEW ENGL J MED, V318, P671, DOI 10.1056/NEJM198803173181104; MYERS RE, 1981, J PERINAT MED, V9, P78, DOI 10.1515/jpme.1981.9.s1.78; PHELPS RL, 1981, AM J OBSTET GYNECOL, V140, P730, DOI 10.1016/0002-9378(81)90731-6; Reece E A, 1986, Obstet Gynecol Surv, V41, P325, DOI 10.1097/00006254-198606000-00001; REECE EA, 1994, SEMIN PERINATOL, V18, P459; ROSENN B, 1994, OBSTET GYNECOL, V84, P515; SALVESEN DR, 1992, AM J OBSTET GYNECOL, V166, P1287, DOI 10.1016/S0002-9378(11)90623-1; STAMLER EF, 1990, AM J OBSTET GYNECOL, V163, P1217, DOI 10.1016/0002-9378(90)90694-3; STEEL JM, 1990, BRIT MED J, V301, P1070, DOI 10.1136/bmj.301.6760.1070; VEILLE JC, 1992, OBSTET GYNECOL, V79, P51; WARRAM JH, 1988, DIABETES, V37, P1328, DOI 10.2337/diabetes.37.10.1328	27	95	96	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					157	161		10.1016/S0140-6736(95)91213-4	http://dx.doi.org/10.1016/S0140-6736(95)91213-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603233				2022-12-28	WOS:A1995RJ03100013
J	LIU, D; BIENKOWSKA, J; PETOSA, C; COLLIER, RJ; FU, H; LIDDINGTON, R				LIU, D; BIENKOWSKA, J; PETOSA, C; COLLIER, RJ; FU, H; LIDDINGTON, R			CRYSTAL-STRUCTURE OF THE ZETA-ISOFORM OF THE 14-3-3 PROTEIN	NATURE			English	Article								THE 14-3-3 family of proteins have recently been identified as regulatory elements in intracellular signalling pathways(1): 14-3-3 proteins bind to oncogene and proto-oncogene products, including c-Raf-1 (refs 2-5), c-Bcr (ref. 6) and polyomavirus middle-T antigen(7); overexpression of 14-3-3 activates Raf kinase in yeast(2,3) and induces meiotic maturation in Xenopus oocytes(5). Here we report the crystal structure of the major isoform of mammalian 14-3-3 proteins at 2.9 Angstrom resolution. Each subunit of the dimeric protein consists of a bundle of nine antiparallel helices that form a palisade around an amphipathic groove. The groove is large enough to accommodate a tenth helix, and we propose that binding to an amphipathic helix represents a general mechanism for the interaction of 14-3-3 with diverse cellular proteins. The residues in the dimer interface and the putative ligand-binding surface are invariant among vertebrates, yeast and plants, suggesting a conservation of structure and function throughout the 14-3-3 family.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Emory University	LIU, D (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.			Collier, R John/0000-0002-2427-4239; Petosa, Carlo/0000-0002-9975-1167				ADAM R, 1994, J BIOCHEM-TOKYO, V116, P416; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; BOSTON PF, 1982, J NEUROCHEM, V38, P1466, DOI 10.1111/j.1471-4159.1982.tb07927.x; BRUNGER AT, 1992, XPLOR VERSION 31 SYS; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FINN BE, 1995, STRUCTURE, V3, P7, DOI 10.1016/S0969-2126(01)00130-7; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	21	430	449	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					191	194		10.1038/376191a0	http://dx.doi.org/10.1038/376191a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603574				2022-12-28	WOS:A1995RJ02800066
J	EZEH, UO; SHOULDER, VS; MARTIN, JL; BREESON, AJ; LAMB, MD; VELLACOTT, ID				EZEH, UO; SHOULDER, VS; MARTIN, JL; BREESON, AJ; LAMB, MD; VELLACOTT, ID			LOCAL-ANESTHETIC ON FILSHIE CLIPS FOR PAIN RELIEF AFTER TUBAL-STERILIZATION - A RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL	LANCET			English	Article							DAY-CASE LAPAROSCOPY; POSTOPERATIVE PAIN; FALLOPIAN-TUBES; STERILIZATION; MESOSALPINX; LIGATION	Pain during tubal sterilisation is thought to be due to either ischaemia or pressure at the site of impact of sterilising devices on the fallopian tubes. We have evaluated the effectiveness of an application of 2% lignocaine gel to Filshie clips to relieve postoperative pain. In a randomised double-blind placebo-controlled study, 80 healthy women undergoing tubal sterilisation under general anaesthesis at the County Hospital, Lincoln, UK, were allocated to be sterilised by Flishie clips covered with 2% lignocaine gel or K-Y gel as placebo. Pelvic pain was assessed, with a 100 mm visual analogue scale, at 1 hour, at hospital discharge, and time of first analgesia or any other time analgesia was demanded. The lignocaine-treated group had significantly longer time to first analgesia, less pain at 1 hour, less nausea and vomiting, and shorter recovery time. Fewer lignocaine-treated patients needed additional analgesia and they required fewer opioids. There was no case of failed sterilisation or adverse reaction to lignocaine. The application of local anaesthetic gel to Filshie clips is a safe, non-invasive, and effective method of relieving postoperative pain during laparoscopic tubal sterilisation.	CTY HOSP,DEPT OBSTET & GYNAECOL,LINCOLN LN2 5QY,ENGLAND; CTY HOSP,DEPT ANAESTHESIA,LINCOLN LN2 5QY,ENGLAND									ALEXANDER CD, 1987, CAN J ANAESTH, V34, P362, DOI 10.1007/BF03010134; BENHAMOU D, 1994, OBSTET GYNECOL, V84, P877; CHI IC, 1979, AM J OBSTET GYNECOL, V135, P397, DOI 10.1016/0002-9378(79)90713-0; COLLINS KM, 1984, ANAESTHESIA, V39, P819, DOI 10.1111/j.1365-2044.1984.tb06534.x; COOK PT, 1986, ANAESTH INTENS CARE, V14, P148, DOI 10.1177/0310057X8601400209; DAVIS A, 1988, ANAESTHESIA, V43, P796, DOI 10.1111/j.1365-2044.1988.tb05764.x; DEEB RJ, 1985, REGION ANESTH PAIN M, V10, P24; EDWARDS ND, 1991, ANAESTHESIA, V46, P1077, DOI 10.1111/j.1365-2044.1991.tb09930.x; FILSHIE GM, 1981, BRIT J OBSTET GYNAEC, V88, P655, DOI 10.1111/j.1471-0528.1981.tb01226.x; FRASER RA, 1989, PAIN, V30, P189; HELVACIOGLU A, 1992, FERTIL STERIL, V57, P549; KAPLAN P, 1990, OBSTET GYNECOL, V76, P798, DOI 10.1097/00006250-199011000-00014; LEVENSON CJ, 1976, OBSTET GYNECOL, V48, P494; MCKENZIE R, 1986, OBSTET GYNECOL, V67, P447; MILLAR JM, 1988, ANAESTHESIA, V43, P418, DOI 10.1111/j.1365-2044.1988.tb09032.x; NARCHI P, 1991, LANCET, V338, P1569, DOI 10.1016/0140-6736(91)92384-E; PELLAND PC, 1976, OBSTET GYNECOL, V47, P501; SMITH BE, 1991, ANAESTHESIA, V46, P875; SPIELMAN FJ, 1983, AM J OBSTET GYNECOL, V146, P821, DOI 10.1016/0002-9378(83)91085-2; WHEATLEY SA, 1994, BRIT J OBSTET GYNAEC, V101, P443, DOI 10.1111/j.1471-0528.1994.tb11920.x; 1988, STERILIZATION, V113, P1	21	24	25	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					82	85		10.1016/S0140-6736(95)92112-5	http://dx.doi.org/10.1016/S0140-6736(95)92112-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603217	Bronze			2022-12-28	WOS:A1995RH22000010
J	HEDGES, LV; NOWELL, A				HEDGES, LV; NOWELL, A			SEX-DIFFERENCES IN MENTAL TEST-SCORES, VARIABILITY, AND NUMBERS OF HIGH-SCORING INDIVIDUALS	SCIENCE			English	Article							COGNITIVE GENDER DIFFERENCES; META-ANALYSIS; INTELLECTUAL ABILITIES; METAANALYSIS; MATHEMATICS	Sex differences in central tendency, variability, and numbers of high scores on mental tests have been extensively studied. Research has not always seemed to yield consistent results, partly because most studies have not used representative samples of national populations. An analysis of mental test scores from six studies that used national probability samples provided evidence that although average sex differences have been generally small and stable over time, the test scores of males consistently have larger variance. Except in tests of reading comprehension, perceptual speed, and associative memory, males typically outnumber females substantially among high-scoring individuals.			HEDGES, LV (corresponding author), UNIV CHICAGO,DEPT EDUC,5835 S KIMBARK AVE,CHICAGO,IL 60637, USA.			Hedges, Larry/0000-0002-7531-0631				BECKER BJ, 1988, BEHAV BRAIN SCI, V11, P183; BECKER BJ, 1984, J EDUC PSYCHOL, V76, P583, DOI 10.1037/0022-0663.76.4.583; BENBOW CP, 1988, BEHAV BRAIN SCI, V11, P169, DOI 10.1017/S0140525X00049244; BOCK RD, 1986, ADVANTAGE DISADVANTA; COHEN J, 1977, STATISTICAL POWER AN; ELLIS H, 1984, MAN WOMAN STUDY HUMA; FEINGOLD A, 1988, AM PSYCHOL, V43, P95, DOI 10.1037/0003-066X.43.2.95; FEINGOLD A, 1992, REV EDUC RES, V62, P61, DOI 10.3102/00346543062001061; Flanagan J. C., 1962, DESIGN STUDY AM YOUT; FRIEDMAN L, 1989, REV EDUC RES, V59, P185; Hansen M.H., 1953, SAMPLE SURVEY METHOD; HEDGES LV, 1993, REV EDUC RES, V63, P94, DOI 10.3102/00346543063001094; Heinisch O., 1963, PREIS S BIOM J, V1965, P203, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; HOLLINGWORTH LS, 1914, AM J SOCIOL, V22, P19; HYDE JS, 1990, PSYCHOL BULL, V107, P139, DOI 10.1037/0033-2909.107.2.139; HYDE JS, 1988, PSYCHOL BULL, V104, P53, DOI 10.1037/0033-2909.104.1.53; HYDE JS, 1981, AM PSYCHOL, V36, P892, DOI 10.1037/0003-066X.36.8.892; Jensen A, 1971, INTELLIGENCE GENETIC, P107; Kish L, 1965, SURVEY SAMPLING; LAZEAR EP, 1990, J LABOR ECON, V8, pS106, DOI 10.1086/298246; LEWIS C, 1995, ETS RR9513 ED TEST S; Maccoby E.E., 1974, PSYCHOL SEX DIFFEREN; Maccoby E.E., 1966, DEV SEX DIFFERENCES; MICCERI T, 1989, PSYCHOL BULL, V105, P156, DOI 10.1037/0033-2909.105.1.156; MULLIS IVS, 1991, TRENDS ACADEMIC PROG; PAGLIN M, 1990, J LABOR ECON, V8, P123, DOI 10.1086/298239; PEARSON K, 1897, CHANCES DEATH, V1, pCH8; ROCK DA, 1985, PSYCHOMETRIC ANAL NL; ROSEN S, 1981, AM ECON REV, V71, P845; SHAYCROFT MF, 1963, STUDIES COMPLETE AGE; SHIELDS SA, 1975, AM PSYCHOL, V30, P739, DOI 10.1037/h0076948; Stanley J. C., 1992, TALENT DEV, P42; Terman L. M., 1925, GENETIC STUDIES GENI, VI; TERMAN LM, 1954, MANUAL CHILD PSYCHOL, P1064; Thorndike E. L., 1910, ED PSYCHOL; WISE LL, 1979, ORIGINS CAREER CONSE	36	615	624	3	101	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					41	45		10.1126/science.7604277	http://dx.doi.org/10.1126/science.7604277			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RG980	7604277				2022-12-28	WOS:A1995RG98000025
J	BUDRENE, EO; BERG, HC				BUDRENE, EO; BERG, HC			DYNAMICS OF FORMATION OF SYMMETRICAL PATTERNS BY CHEMOTACTIC BACTERIA	NATURE			English	Article							ESCHERICHIA-COLI	MOTILE cells of Escherichia coli aggregate to form stable patterns of remarkable regularity when grown from a single point on certain substrates. Central to this self-organization is chemotaxis, the motion of bacteria along gradients of a chemical attractant that the cells themselves excrete(1). Here we show how these complex patterns develop. The long-range spatial order arises from interactions between two multicellular aggregate structures: a 'swarm ring' that expands radially, and focal aggregates that have lower mobility. Patterning occurs through alternating domination by these two sources of excreted attractant (which we identify here as aspartate). The pattern geometries vary in a systematic way, depending on how long an aggregate remains active; this depends, in turn, on the initial concentration of substrate (here, succinate).	ROWLAND INST SCI INC,CAMBRIDGE,MA 02142		BUDRENE, EO (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Ladoux, Benoit/A-9879-2013					ADLER J, 1967, J GEN MICROBIOL, V46, P175, DOI 10.1099/00221287-46-2-175; ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; BARINAGA M, 1994, SCIENCE, V266, P561, DOI 10.1126/science.7939701; BENJACOB E, 1995, NATURE, V373, P566, DOI 10.1038/373566a0; BLAT Y, 1995, J BACTERIOL, V177, P1683, DOI 10.1128/jb.177.7.1683-1691.1995; BRUNN SD, 1992, ANN ASSOC AM GEOGR, V82, P1; BUDRENE EO, 1991, NATURE, V349, P630, DOI 10.1038/349630a0; GUTNICK D, 1969, J BACTERIOL, V100, P215, DOI 10.1128/JB.100.1.215-219.1969; MARCUS M, 1969, BIOCHIM BIOPHYS ACTA, V177, P314, DOI 10.1016/0304-4165(69)90141-X; Miller J.H., 1972, EXPT MOL GENETICS; NEIDHARDT C, 1990, PHSYL BACTERIAL CELL, P208; NOSSAL R, 1972, EXP CELL RES, V75, P183; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; PARKINSON JS, 1987, GENETICS, V116, P499; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOODWARD DE, 1995, BIOPHYS J, V68, P2181	16	376	376	1	63	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					49	53		10.1038/376049a0	http://dx.doi.org/10.1038/376049a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596432				2022-12-28	WOS:A1995RH11100058
J	ALMEIDA, EAC; HUOVILA, APJ; SUTHERLAND, AE; STEPHENS, LE; CALARCO, PG; SHAW, LM; MERCURIO, AM; SONNENBERG, A; PRIMAKOFF, P; MYLES, DG; WHITE, JM				ALMEIDA, EAC; HUOVILA, APJ; SUTHERLAND, AE; STEPHENS, LE; CALARCO, PG; SHAW, LM; MERCURIO, AM; SONNENBERG, A; PRIMAKOFF, P; MYLES, DG; WHITE, JM			MOUSE EGG INTEGRIN ALPHA-6-BETA-1 FUNCTIONS AS A SPERM RECEPTOR	CELL			English	Article							ACTIVATION-DEPENDENT ADHESION; CELL-ADHESION; CARCINOMA-CELLS; MEMBRANE-FUSION; PROTEIN; LAMININ; EXPRESSION; SUBUNIT; FERTILIZATION; VARIANTS	Binding between sperm and egg plasma membranes is an essential step in fertilization. Whereas fertilin, a mammalian sperm surface protein, is involved in this crucial interaction, sperm receptors on the egg plasma membrane have not been identified. Because fertilin contains a predicted integrin ligand domain, we investigated the expression and function of integrin subunits in unfertilized mouse eggs. Polymerase chain reactions detected mRNAs for alpha 5, alpha 6, alpha v, beta 1, beta 3, and beta 5. Immunofluorescence revealed alpha 6 beta 1 and alpha v beta 3 on the plasma membrane. GoH3, a function-blocking anti-alpha 6 monoclonal antibody, abolished sperm binding, but a nonfunction-blocking anti-alpha 6 monoclonal antibody, a function-blocking anti-alpha v beta 3 polyclonal antibody, and an RGD peptide had no effect. Somatic cells bound sperm avidly, but only if they expressed alpha 6 beta 1. A peptide analog of the fertilin integrin ligand domain inhibited sperm binding to eggs and alpha 6 beta 1(+) cells and diminished GoH3 staining of eggs. Our results indicate a novel role for the integrin alpha 6 beta 1 as a cell-cell adhesion receptor that mediates sperm-egg binding.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; HARVARD UNIV,SCH MED,CANC BIOL LAB,BOSTON,MA 02115; NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS; UNIV CONNECTICUT,DEPT PHYSIOL,FARMINGTON,CT 06030	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Netherlands Cancer Institute; University of Connecticut	ALMEIDA, EAC (corresponding author), UNIV VIRGINIA,DEPT CELL BIOL,CHARLOTTESVILLE,VA 22908, USA.		Huovila, Ari-Pekka/O-1650-2017	Huovila, Ari-Pekka/0000-0002-4853-7160; Sutherland, Ann/0000-0003-1925-2825	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016580, U54HD029125, R01HD016580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048739] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29125, HD16580] Funding Source: Medline; NIGMS NIH HHS [GM48739] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONS D, 1991, MOL REPROD DEV, V30, P258, DOI 10.1002/mrd.1080300314; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRONSON RA, 1990, BIOL REPROD, V43, P1019, DOI 10.1095/biolreprod43.6.1019; BUCK CA, 1987, J CELL SCI S, V8, P231; CALARCO PG, 1991, J ELECTRON MICR TECH, V17, P401, DOI 10.1002/jemt.1060170404; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CONOVER JC, 1988, J REPROD FERTIL, V82, P681, DOI 10.1530/jrf.0.0820681; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; FOLZ KR, 1993, SCIENCE, V259, P1421; FOX JW, 1995, IN PRESS J CELL SC S, V19; FOX JW, 1995, IN PRESS ZINC METALL; FUSI FM, 1993, MOL REPROD DEV, V36, P212, DOI 10.1002/mrd.1080360212; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HEINLEIN UAO, 1994, DEV GROWTH DIFFER, V36, P49; HEMLER ME, 1989, J BIOL CHEM, V264, P6529; HEMLER ME, 1988, J BIOL CHEM, V263, P7660; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HITE LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P182, DOI 10.1006/abbi.1994.1026; HLERCK BP, 1993, CELL ADHES COMMUN, V1, P33; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KINI RM, 1992, TOXICON, V30, P265, DOI 10.1016/0041-0101(92)90869-7; Lallier T, 1994, INTEGRINS MOL BIOL R, P111; MERCURIO AM, 1991, BIOESSAYS, V13, P469, DOI 10.1002/bies.950130907; MYLES DG, 1993, DEV BIOL, V158, P35, DOI 10.1006/dbio.1993.1166; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; NISHIMURA SL, 1994, J BIOL CHEM, V269, P28708; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; RAMARAO CS, 1995, IN PRESS MOL REPROD; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; RUIZ P, 1993, CELL ADHES COMMUN, V1, P67, DOI 10.3109/15419069309095682; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SALANOVA M, 1995, BIOL REPROD, V52, P79, DOI 10.1095/biolreprod52.1.79; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SHAW LM, 1993, J BIOL CHEM, V268, P11401; SHAW LM, 1994, MOL BIOL CELL, V5, P679, DOI 10.1091/mbc.5.6.679; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SONNENBERG A, 1990, J CELL SCI, V96, P207; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SPINDLE A, 1980, IN VITRO CELL DEV B, V16, P669, DOI 10.1007/BF02619196; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TAO J, 1993, MOL REPROD DEV, V36, P183, DOI 10.1002/mrd.1080360209; TARONE G, 1993, DEVELOPMENT, V117, P1369; USAMI Y, 1994, BIOCHEM BIOPH RES CO, V201, P331, DOI 10.1006/bbrc.1994.1706; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Yanagimachi R., 1994, P189	64	454	470	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1095	1104		10.1016/S0092-8674(05)80014-5	http://dx.doi.org/10.1016/S0092-8674(05)80014-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600577	Bronze			2022-12-28	WOS:A1995RG91000014
J	DAS, A; GILBERT, CD				DAS, A; GILBERT, CD			LONG-RANGE HORIZONTAL CONNECTIONS AND THEIR ROLE IN CORTICAL REORGANIZATION REVEALED BY OPTICAL-RECORDING OF CAT PRIMARY VISUAL-CORTEX	NATURE			English	Article							MONKEY STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC SIGNALS; ORGANIZATION; NEURONS; PROJECTIONS; LESIONS; MAPS	THE cortical 'point spread' (PS) is the area of cortex activated by a minimal visual stimulus(1). Here we use the PS to explore the functional role of lateral connectivity in normal cat primary visual cortex (V1) and its involvement in topographic reorganization of cortex following retinal lesions. We compared the distributions of PSs measured with optical recording, which reflects both spiking and subthreshold activity, with those measured with extracellular electrodes, which reveal spiking activity alone. The spiking PS represented only 5% of the area of activation shown in the optical PS, indicating that the remaining 95% was probably generated by subthreshold activation. The orientation dependence of the pattern of the subthreshold activation and its close match with orientation columns suggests that long-range horizontal connections radiating from the locus of spiking activity were responsible for the observed activation. The spike PS showed anisotropies and inhomogeneities that were related to the pattern of orientation columns and indicated distortions in the representation of visual space on the cortical surface. In the reorganized cortex the spike PS expanded, approximating the extent of the optical PS seen in normal cortex, and suggesting that reorganization was mediated by an unmasking of normally subthreshold activation to suprathreshold levels. The orientation map of the reorganized cortex showed a close match to that obtained before placing the lesion, despite the large shift in topography, supporting the idea that intrinsic horizontal connections were responsible for the remapping.			DAS, A (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.							BISHOP PO, 1971, J PHYSIOL-LONDON, V219, P659, DOI 10.1113/jphysiol.1971.sp009682; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; DURBIN R, 1990, NATURE, V343, P644, DOI 10.1038/343644a0; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1990, COLD SPRING HARB SYM, V55, P663; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1994, J NEUROSCI, V14, P2545; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HEINEN SJ, 1991, EXP BRAIN RES, V83, P670; HUBEL DH, 1974, J COMP NEUROL, V158, P295, DOI 10.1002/cne.901580305; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MCILWAIN JT, 1975, J NEUROPHYSIOL, V38, P219, DOI 10.1152/jn.1975.38.2.219; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; TOOTELL RBH, 1982, SCIENCE, V218, P902, DOI 10.1126/science.7134981; TSO DY, 1986, J NEUROSCI, V6, P1160; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630	24	339	344	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					780	784		10.1038/375780a0	http://dx.doi.org/10.1038/375780a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596409				2022-12-28	WOS:A1995RF98900076
J	ZIMMERLY, S; GUO, HT; ESKES, R; YANG, J; PERLMAN, PS; LAMBOWITZ, AM				ZIMMERLY, S; GUO, HT; ESKES, R; YANG, J; PERLMAN, PS; LAMBOWITZ, AM			A GROUP-II INTRON RNA IS A CATALYTIC COMPONENT OF A DNA ENDONUCLEASE INVOLVED IN INTRON MOBILITY	CELL			English	Article							YEAST MITOCHONDRIA; INVITRO; TRANSPOSITION; PROTEINS	The mobility (homing) of the yeast mitochondrial DNA group II intron al2 occurs via target DNA-primed reverse transcription at a double-strand break in the recipient DNA. Here, we show that the site-specific DNA endonuclease that makes the double-strand break is a ribonucleoprotein complex containing the al2-encoded reverse transcriptase protein and excised al2 RNA. Remarkably, the al2 RNA catalyzes cleavage of the sense strand of the recipient DNA, while the al2 protein appears to cleave the antisense strand. The RNA-catalyzed sense strand cleavage occurs via a partial reverse splicing reaction in which the protein component stabilizes the active intron structure and appears to confer preference for DNA substrates. Our results demonstrate a biologically relevant ribozyme reaction with a substrate other than RNA.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ZIMMERLY, S (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.				NIGMS NIH HHS [GM37949, GM31480] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031480, R01GM037949] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELFORT M, 1993, SCIENCE, V262, P1009, DOI 10.1126/science.7694364; GORBALENYA AE, 1994, PROTEIN SCI, V3, P1117, DOI 10.1002/pro.5560030716; HEBBAR SK, 1992, NUCLEIC ACIDS RES, V20, P1747, DOI 10.1093/nar/20.7.1747; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MOHR G, 1993, NUCLEIC ACIDS RES, V21, P4991, DOI 10.1093/nar/21.22.4991; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORL M, 1990, NUCLEIC ACIDS RES, V18, P6545, DOI 10.1093/nar/18.22.6545; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT WM, 1994, J MOL BIOL, V243, P157, DOI 10.1006/jmbi.1994.1642; SELLEM CH, 1993, NATURE, V366, P176, DOI 10.1038/366176a0; SHUB DA, 1994, TRENDS BIOCHEM SCI, V19, P402, DOI 10.1016/0968-0004(94)90086-8; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	23	156	179	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					529	538		10.1016/0092-8674(95)90092-6	http://dx.doi.org/10.1016/0092-8674(95)90092-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585955	Bronze			2022-12-28	WOS:A1995TF24800005
J	POUYANI, T; SEED, B				POUYANI, T; SEED, B			PSGL-1 RECOGNITION OF P-SELECTIN IS CONTROLLED BY A TYROSINE SULFATION CONSENSUS AT THE PSGL-1 AMINO-TERMINUS	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; ENDOTHELIAL VONWILLEBRAND-FACTOR; WEIBEL-PALADE BODIES; ACTIVATED PLATELETS; NEUTROPHIL ADHESION; CELL-ADHESION; CARBOHYDRATE LIGAND; GLYCOPROTEIN LIGAND; MOLECULAR-CLONING; HOMING RECEPTOR	P-selectin binding to neutrophils requires a specific protein, P-selectin glycoprotein ligand 1 (PSGL-1), as well as sialyl-Lewis X (sLe(x)) glycan determinants. We have found that a short segment near the amino terminus nus of PSGL-1 that contains a tyrosine sulfation consensus is essential for P-selectin adhesion and that addition of the amino-terminal segment to some but not all mucin-like molecules confers on those molecules the ability to bind P-selectin. PSGL-1 synthesized in the presence of sulfation inhibitors binds P-selectin weakly, and within the amino-terminal 20 residues, mutation of the tyrosines to phenylalanine abolishes binding. Rolling of HL-60 cells on P-selectin-coated coverslips is strongly attenuated by treatment of cells with an inhibitor of sulfation.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	POUYANI, T (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43031] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; BONFANTI R, 1989, BLOOD, V73, P1109; CECCONI O, 1994, J BIOL CHEM, V269, P15060; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GAMBLE JR, 1990, SCIENCE, V249, P414; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HAMBURGER SA, 1990, BLOOD, V75, P550; HATTORI R, 1989, J BIOL CHEM, V264, P9053; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KUBES P, 1994, J IMMUNOL, V152, P3570; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1990, BLOOD, V75, P227; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MA L, 1994, J BIOL CHEM, V269, P27739; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MURPHY JF, 1994, BIOCHEM J, V303, P619, DOI 10.1042/bj3030619; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NELSON RM, 1993, BLOOD, V82, P3253; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAMMAR M, 1994, INT IMMUNOL, V6, P1027, DOI 10.1093/intimm/6.7.1027; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V164, P1373, DOI 10.1016/0006-291X(89)91821-4; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; THORLACIUS H, 1994, BIOCHEM BIOPH RES CO, V203, P1043, DOI 10.1006/bbrc.1994.2287; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221	60	348	365	1	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					333	343		10.1016/0092-8674(95)90174-4	http://dx.doi.org/10.1016/0092-8674(95)90174-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585950	Bronze			2022-12-28	WOS:A1995TA96500019
J	SEKELSKY, JJ; HAWLEY, RS				SEKELSKY, JJ; HAWLEY, RS			THE BOND BETWEEN SISTERS	CELL			English	Review							SCHIZOSACCHAROMYCES-POMBE; DROSOPHILA-MELANOGASTER; MEIOTIC MUTANTS; CENTROMERE; MEIOSIS; MECHANISMS; YEAST				SEKELSKY, JJ (corresponding author), UNIV CALIF DAVIS,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616, USA.			Hawley, R. Scott/0000-0002-6478-0494; Sekelsky, Jeff/0000-0002-4424-677X				CARPENTER ATC, 1994, CELL, V77, P959, DOI 10.1016/0092-8674(94)90434-0; Darlington C.D., 1932, RECENT ADV CYTOLOGY; DAVIS BK, 1971, MOL GEN GENET, V113, P251, DOI 10.1007/BF00339546; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; HAHNENBERGER KM, 1991, MOL CELL BIOL, V11, P2206, DOI 10.1128/MCB.11.4.2206; HAWLEY RS, 1993, GENETICS, V135, P613; HAWLEY RS, 1992, DEV GENET, V13, P440, DOI 10.1002/dvg.1020130608; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; KERREBROCK AW, 1992, GENETICS, V130, P827; KERREBROCK AW, 1995, CELL, V83; LE MH, 1995, GENETICS, V141, P283; MAGUIRE MP, 1974, J THEOR BIOL, V48, P485, DOI 10.1016/S0022-5193(74)80017-2; MAGUIRE MP, 1990, BIOCHEM CELL BIOL, V68, P1231, DOI 10.1139/o90-183; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MIYAZAKI WY, 1992, GENETICS, V132, P1047; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; SANDLER L, 1968, GENETICS, V60, P525; SEARS DD, 1995, GENETICS, V139, P1159; STEINER NC, 1993, MOL CELL BIOL, V13, P4578, DOI 10.1128/MCB.13.8.4578	20	11	11	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					157	160		10.1016/0092-8674(95)90156-6	http://dx.doi.org/10.1016/0092-8674(95)90156-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585932	Bronze			2022-12-28	WOS:A1995TA96500001
J	CRAIG, NL				CRAIG, NL			UNITY IN TRANSPOSITION REACTIONS	SCIENCE			English	Article							INSERTION SEQUENCES; RIBONUCLEASE-H; MU; RECOMBINATION; INVITRO; COMPLEX; FAMILY				CRAIG, NL (corresponding author), JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.							ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; Berg DE, 1989, MOBILE DNA; CALVI BR, 1991, CELL, V66, P465, DOI 10.1016/0092-8674(81)90010-6; CHALMERS RM, 1994, J BIOL CHEM, V269, P8029; Craig NL, 1996, CURR TOP MICROBIOL, V204, P27; CRAIG NL, 1991, MOL MICROBIOL, V5, P2569, DOI 10.1111/j.1365-2958.1991.tb01964.x; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; Lavoie BD, 1996, CURR TOP MICROBIOL, V204, P83; MAY E, UNPUB; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; RADSTROM P, 1994, J BACTERIOL, V176, P3257, DOI 10.1128/jb.176.11.3257-3268.1994; REZSOHAZY R, 1993, MOL MICROBIOL, V9, P1283, DOI 10.1111/j.1365-2958.1993.tb01258.x; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; SARNOVSKY R, UNPUB; SHERRATT D, 1989, MOBILE DNA, P163; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; VOS JC, 1994, EMBO J, V13, P6125, DOI 10.1002/j.1460-2075.1994.tb06959.x; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	36	147	153	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 13	1995	270	5234					253	254		10.1126/science.270.5234.253	http://dx.doi.org/10.1126/science.270.5234.253			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569973				2022-12-28	WOS:A1995RZ34200026
J	BUMP, NJ; HACKETT, M; HUGUNIN, M; SESHAGIRI, S; BRADY, K; CHEN, P; FERENZ, C; FRANKLIN, S; GHAYUR, T; LI, P; LICARI, P; MANKOVICH, J; SHI, LF; GREENBERG, AH; MILLER, LK; WONG, WW				BUMP, NJ; HACKETT, M; HUGUNIN, M; SESHAGIRI, S; BRADY, K; CHEN, P; FERENZ, C; FRANKLIN, S; GHAYUR, T; LI, P; LICARI, P; MANKOVICH, J; SHI, LF; GREENBERG, AH; MILLER, LK; WONG, WW			INHIBITION OF ICE FAMILY PROTEASES BY BACULOVIRUS ANTIAPOPTOTIC PROTEIN P35	SCIENCE			English	Article							CELL-DEATH; APOPTOSIS; GENE; EXPRESSION; ENZYME	The baculovirus antiapoptotic protein p35 inhibited the proteolytic activity of human interleukin-1 beta converting enzyme (ICD) and three of its homologs in enzymatic assays. Coexpression of p35 prevented the autoproteolytic activation on ICE from its precursor form and blocked ICE-induced apoptosis, Inhibition of enzymatic activity correlated with the cleavage of p35 and the formation of a stable ICE-p35 complex. The ability of p35 to block apoptosis in different pathways and in distantly related organisms suggests a central and conserved role for ICE-like proteases in the induction of apoptosis.	BASF BIORES CORP,WORCESTER,MA 01605; UNIV GEORGIA,DEPT ENTOMOL,ATHENS,GA 30602; UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602; UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG,MB R3E 0V9,CANADA	BASF; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Manitoba				Seshagiri, Somasekar/0000-0003-4272-6443	NIAID NIH HHS [AI 38262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038262] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUMP N, UNPUB; CARTIER JL, 1994, J VIROL, V68, P7728, DOI 10.1128/JVI.68.12.7728-7737.1994; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; HAY BA, 1994, DEVELOPMENT, V120, P2121; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORRIS TD, 1992, J VIROL, V66, P7397, DOI 10.1128/JVI.66.12.7397-7405.1992; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SESHAGIRI S, UNPUB; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	27	584	606	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1885	1888		10.1126/science.7569933	http://dx.doi.org/10.1126/science.7569933			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569933				2022-12-28	WOS:A1995RX19400043
J	KOLB, FC; BRAUN, J				KOLB, FC; BRAUN, J			BLINDSIGHT IN NORMAL OBSERVERS	NATURE			English	Article							UNCONSCIOUS PERCEPTION; TEXTURE-DISCRIMINATION; VISUAL-STIMULI; LOCALIZATION; AWARENESS; VISION	SOME patients with lesions in visual cortex lack conscious visual experience but, when tested, exhibit a significant ability, termed 'blindsight', to discriminate visual stimuli(1-3,27). Here we report two different visual displays that induce blindsight in normal observers. Using an objective measure, we show that conscious experience remains defective at presentation times much longer (1 s) than the onset of visual sensitivity (similar to 60 ms). To obtain this effect, we generate a contrast between visual textures and then conceal the contrast by superimposing 'complementary' textures. Complementarity can involve either opposite motion or binocular rivalry and orthogonal orientation. In both cases, observers locate the texture contrast reliably but do not, by either subjective or objective measures, consciously experience it. Taken together with present knowledge of the visual cortical site(s) at which opposite motion and rivalrous orientation interact(4-7), this observation bears upon the functional anatomy of conscious visual experience.	CALTECH, PASADENA, CA 91125 USA	California Institute of Technology			Braun, Jochen/F-1370-2013	Braun, Jochen/0000-0002-8886-078X				ADAMS JK, 1957, PSYCHOL BULL, V54, P383, DOI 10.1037/h0043350; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; DOBBINS A, 1994, J SOC NEUR ABSTR, V20, P624; FARAH MJ, 1991, NEUROPSYCHOLOGIA, V29, P949, DOI 10.1016/0028-3932(91)90059-H; Fox R, 1991, BINOCULAR VISION, V9, P93; GRAVES RE, 1992, COGN NEUROPSYCHOL, V9, P487, DOI 10.1080/02643299208252069; GREEN DM, 1967, SIGNAL DETECTION THE; GREENWALD AG, 1992, AM PSYCHOL, V47, P766, DOI 10.1037/0003-066X.47.6.766; KARNI A, 1993, SOC NEUR ABSTR, V19, P1503; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LEOPOLD DA, 1995, INVEST OPHTH VIS SCI, V36, pS813; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MALIK J, 1990, J OPT SOC AM A, V7, P923, DOI 10.1364/JOSAA.7.000923; MARCEL AJ, 1983, COGNITIVE PSYCHOL, V15, P197, DOI 10.1016/0010-0285(83)90009-9; MEERES SL, 1990, NEUROPSYCHOLOGIA, V28, P1231, DOI 10.1016/0028-3932(90)90039-Q; MERIKLE PM, 1992, AM PSYCHOL, V47, P792, DOI 10.1037/0003-066X.47.6.792; POPPEL E, 1973, NATURE, V243, P295, DOI 10.1038/243295a0; Press W. A., 1994, Society for Neuroscience Abstracts, V20, P838; QIAN N, 1994, J NEUROSCI, V14, P7367; QIAN N, 1994, J NEUROSCI, V14, P7357; RUBENSTEIN BS, 1990, J OPT SOC AM A, V7, P1632, DOI 10.1364/JOSAA.7.001632; SCHACTER DL, 1992, P NATL ACAD SCI USA, V89, P11113, DOI 10.1073/pnas.89.23.11113; Sidis B., 1898, PSYCHOL SUGGESTION; STOREIG P, 1993, PROGR BRAIN RES, V95, P445; WEISKRANTZ L, 1974, BRAIN, V97, P709, DOI 10.1093/brain/97.1.709; WEISKRANTZ L, 1995, P NATL ACAD SCI USA, V92, P6122, DOI 10.1073/pnas.92.13.6122	27	150	151	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377	6547					336	338		10.1038/377336a0	http://dx.doi.org/10.1038/377336a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RX111	7566086				2022-12-28	WOS:A1995RX11100055
J	FEEHALLY, J				FEEHALLY, J			A PHYSICIAN WITH ENDOCARDITIS	LANCET			English	Editorial Material											FEEHALLY, J (corresponding author), LEICESTER GEN HOSP,DEPT NEPHROL,LEICESTER LE5 4PW,LEICS,ENGLAND.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					166	168		10.1016/S0140-6736(95)91216-9	http://dx.doi.org/10.1016/S0140-6736(95)91216-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603235				2022-12-28	WOS:A1995RJ03100016
J	WANNAMETHEE, SG; SHAPER, AG; WHINCUP, PH; WALKER, M				WANNAMETHEE, SG; SHAPER, AG; WHINCUP, PH; WALKER, M			SMOKING CESSATION AND THE RISK OF STROKE IN MIDDLE-AGED MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ISCHEMIC-HEART-DISEASE; CIGARETTE-SMOKING; BRITISH MEN; WOMEN; INFARCTION; SMOKERS	Objective.-To examine the effects of giving up smoking, years since quitting smoking and the quantity of cigarettes smoked, and primary pipe or cigar smoking on the risk of stroke. Design, Subjects, and Setting.-A prospective study of cardiovascular disease and its risk factors in 7735 men aged 40 through 59 years drawn at random from the age-sex registers of one general practice in each of 24 British towns from 1978 through 1980 (the British Regional Heart Study). Main Outcome Measure.-Incidence of fatal and nonfatal major stroke events (strokes) during an average follow-up period of 12.75 years. Results.-During the 12.75 years of follow-up, there were 167 major stroke events (43 fatal and 124 nonfatal) in the 7264 men with no recall of previous ischemic heart disease or stroke. After full adjustment for other risk factors, current smokers had a nearly fourfold relative risk (RR) of stroke compared with never smokers (RR, 3.7; 95% confidence interval [CI], 2.0 to 6.9). Ex-cigarette smokers showed lower risk than current smokers but showed excess risk compared with never smokers (RR, 1.7, 95% CI, 0.9 to 3.3; P=.11); those who switched to pipe or cigar smoking showed a significantly increased risk (RR, 3.3; 95% CI, 1.6 to 7.1) similar to that of current light smokers. Primary pipe or cigar smokers also showed increased risk (RR, 2.2; 95% CI, 0.6 to 8.0), but the number of subjects involved was small. The benefit of giving up smoking completely was seen within 5 years of quitting, with no further consistent decline in risk thereafter, but this was dependent on the amount of tobacco smoked. Light smokers (<20 cigarettes/d) reverted to the risk level of those who had never smoked. Heavy smokers retained a more than twofold risk compared with never smokers (RR, 2.2; 95% CI, 1.1 to 4.3). The age-adjusted RR of stroke in those who quit smoking during the first 5 years of follow-up (recent quitters) was reduced compared with continuing smokers (RR, 1.8; 95% CI, 0.7 to 4.6 vs RR, 4.3; 95% CI, 2.1 to 8.8). The benefit of quitting smoking was observed in both normotensive and hypertensive men, but the absolute benefit was greater in hypertensive subjects. Conclusion.-Smoking cessation is associated with a considerable and rapid benefit in decreasing the risk of stroke, particularly in light smokers (<20 cigarettes/d); a complete loss of risk is not seen in heavy smokers. Switching to pipe or cigar smoking confers little benefit, emphasizing the need for complete cessation of smoking. The absolute benefit of quitting smoking on risk of stroke is most marked in hypertensive subjects.			WANNAMETHEE, SG (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Whincup, Peter/0000-0002-5589-4107; Wannamethee, Sasiwarang/0000-0001-9484-9977				ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; BONITA R, 1986, BRIT MED J, V293, P6, DOI 10.1136/bmj.293.6538.6; BRUCE NG, 1988, J HYPERTENS, V6, P375; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; COOK DG, 1986, LANCET, V2, P1376; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; COOK DG, 1990, J SMOKING RELATED DI, V1, P45; COX DR, 1972, J R STAT SOC B, V34, P187; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KAUFMAN DW, 1987, BRIT MED J, V294, P1315, DOI 10.1136/bmj.294.6583.1315; KAWACHI I, 1993, JAMA-J AM MED ASSOC, V269, P232, DOI 10.1001/jama.269.2.232; MEADE TW, 1987, LANCET, V2, P986; POCOCK SJ, 1988, HUM TOXICOL, V7, P95, DOI 10.1177/096032718800700201; POCOCK SJ, 1987, LANCET, V2, P197; ROBBINS AS, 1994, ANN INTERN MED, V120, P458, DOI 10.7326/0003-4819-120-6-199403150-00002; ROGERS RL, 1983, JAMA-J AM MED ASSOC, V250, P2796, DOI 10.1001/jama.250.20.2796; ROGERS RL, 1985, JAMA-J AM MED ASSOC, V253, P2970, DOI 10.1001/jama.253.20.2970; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; Tang J, 1992, J SMOKING RELATED DI, V3, P203; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WANNAMETHEE G, 1994, THROMB HAEMOSTASIS, V72, P58; Wannamethee G, 1994, J Cardiovasc Risk, V1, P223; WANNAMETHEE G, 1994, J INTERN MED, V235, P164; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YARNELL JWG, 1987, J CLIN PATHOL, V40, P909, DOI 10.1136/jcp.40.8.909; 1991, SAS R217 SAS I TECHN; [No title captured]; 1990, CDC908416 US DEP HLT	32	192	202	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					155	160						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596004				2022-12-28	WOS:A1995RH22200029
J	SHORT, RV				SHORT, RV			PERCUSSION AS A WAY OF LIFE	LANCET			English	Editorial Material											SHORT, RV (corresponding author), MONASH UNIV,DEPT PHYSIOL,CLAYTON,VIC,AUSTRALIA.							FEISTNER ATC, 1994, FOLIA PRIMATOL, P62	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					67	68		10.1016/S0140-6736(95)92108-7	http://dx.doi.org/10.1016/S0140-6736(95)92108-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603213	Bronze			2022-12-28	WOS:A1995RH22000006
J	BOOKBINDER, LH; CHENG, A; BLEIL, JD				BOOKBINDER, LH; CHENG, A; BLEIL, JD			TISSUE-SPECIFIC AND SPECIES-SPECIFIC EXPRESSION OF SP56, A MOUSE SPERM FERTILIZATION PROTEIN	SCIENCE			English	Article							O-LINKED OLIGOSACCHARIDES; EGG ZONA-PELLUCIDA; RECEPTOR ACTIVITY; TRANSGENIC MICE; BINDING; ZP3; IDENTIFICATION; GLYCOPROTEINS; LOCALIZATION; SUPERFAMILY	Mouse sperm recognize and bind to ZP3, one of three glycoproteins in the egg's zona pellucida. A mouse sperm protein, sp56, was identified that has the characteristics expected of the sperm protein responsible for recognition of ZP3. The complementary DNA encoding sp56 was isolated, and its primary sequence indicates that sp56 is a member of a superfamily of protein receptors. It was shown that sp56 expression is restricted to mouse spermatids and that the presence or absence of sp56 on sperm from different species accounts for species specificity of sperm-egg recognition in mice.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NICHD NIH HHS [R01 HD 27847] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027847] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEDFORD JM, 1977, ANAT RECORD, V188, P477, DOI 10.1002/ar.1091880407; BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1989, J CELL BIOL, V109, P125; CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; HARDUINLEPERS A, 1992, GLYCOBIOLOGY, V2, P361, DOI 10.1093/glycob/2.4.361; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; INOUE M, 1975, BIOL REPROD, V13, P340, DOI 10.1095/biolreprod13.3.340; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; KALAB P, 1994, J BIOL CHEM, V269, P3810; KRISTENSEN T, 1987, FASEB J, V46, P2463; LAMBERT H, 1984, J REPROD FERTIL, V70, P281, DOI 10.1530/jrf.0.0700281; LEE YH, 1993, BIOTECHNIQUES, V14, P191; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; MILLAR MR, 1993, CELL TISSUE RES, V273, P269, DOI 10.1007/BF00312828; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; MILLER DJ, 1993, DEVELOPMENT, V118, P1279; MOLLER CC, 1990, DEV BIOL, V137, P276, DOI 10.1016/0012-1606(90)90254-G; MORI C, 1992, BIOL REPROD, V46, P859, DOI 10.1095/biolreprod46.5.859; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; Sambrook J, 1989, MOL CLONING LABORATO; SCHMELL ED, 1980, BIOL REPROD, V23, P1075, DOI 10.1095/biolreprod23.5.1075; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432	33	135	144	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					86	89		10.1126/science.7604284	http://dx.doi.org/10.1126/science.7604284			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604284				2022-12-28	WOS:A1995RG98000040
J	TRUDEAU, MC; WARMKE, JW; GANETZKY, B; ROBERTSON, GA				TRUDEAU, MC; WARMKE, JW; GANETZKY, B; ROBERTSON, GA			HERG, A HUMAN INWARD RECTIFIER IN THE VOLTAGE-GATED POTASSIUM CHANNEL FAMILY	SCIENCE			English	Article							MAMMALIAN K+ CHANNEL; FUNCTIONAL EXPRESSION; DROSOPHILA; SHAKER; INACTIVATION; RECTIFICATION; BLOCKING; CLONING; REGION; LOCUS	In contrast to other members of the Eag family of voltage-gated, outwardly rectifying potassium channels, the human eag-related gene (HERG) has now been shown to encode an inwardly rectifying potassium channel. The properties of HERG channels are consistent with the gating properties of Eag-related and other outwardly rectifying, S4-containing potassium channels, but with the addition of an inactivation mechanism that attenuates potassium efflux during depolarization. Because mutations in HERG cause a form of long-QT syndrome, these properties of HERG channel function may be critical to the maintenance of normal cardiac rhythmicity.	UNIV WISCONSIN,SCH MED,DEPT PHYSIOL,MADISON,WI 53706; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Robertson, Gail/0000-0003-4694-5790				ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; BUCHANAN LV, 1993, J CARDIOVASC PHARM, V22, P540; CRANEFIELD PF, 1988, CARDIAC ARRHYTHMIAS, P553; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DIFRANCESCO D, 1985, PHILOS T ROY SOC B, V307, P353, DOI 10.1098/rstb.1985.0001; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Ganetzky B, 1983, J NEUROGENET, V1, P17, DOI 10.3109/01677068309107069; HAGIWARA S, 1978, J PHYSIOL-LONDON, V279, P167, DOI 10.1113/jphysiol.1978.sp012338; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P612; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; KAPLAN WD, 1969, GENETICS, V61, P399; KAPLAN WD, 1995, TRENDS GENETICS GUID; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; ROBERTSON GA, 1993, BIOPHYS J, V64, pA340; Robertson Gail A., 1995, Biophysical Journal, V68, pA363; RUDY B, 1992, METHOD ENZYMOL, V207, P225; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Trudeau Matthew C., 1995, Biophysical Journal, V68, pA32; TSENG GN, 1995, CARDIAC ELECTROPHYSI, P260; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zei Paul C., 1995, Biophysical Journal, V68, pA32	41	1050	1082	0	50	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					92	95		10.1126/science.7604285	http://dx.doi.org/10.1126/science.7604285			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604285				2022-12-28	WOS:A1995RG98000042
J	POKORSKI, RJ				POKORSKI, RJ			GENETIC INFORMATION AND LIFE-INSURANCE	NATURE			English	Editorial Material											POKORSKI, RJ (corresponding author), SWISS RE AMER,60 KATONA DR,SUITE 19,FAIRFIELD,CT 06430, USA.							Bernstein T, 1994, RADON RENTAL HOUSING; BLAKESLEE S, 1994, NY TIMES        0913; BREO DL, 1994, JAMA-J AM MED ASSOC, V271, P1452, DOI 10.1001/jama.271.18.1452; HAMMOND JD, 1967, J RISK INSUR, V34, P397, DOI 10.2307/250854; HEATEN RS, 1974, J RISK INSUR, V41, P685; Hoyt R. E., 1990, J INSURANCE REGULATI, V8, P304; HRUBAN RH, 1994, NEW ENGL J MED, V330, P1276, DOI 10.1056/NEJM199405053301805; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KABACK M, 1993, J INSUR MED, V25, P237; KEENEY RL, 1994, NEW ENGL J MED, V331, P193, DOI 10.1056/NEJM199407213310311; KING RA, 1992, GENETIC BASIS COMMON; MANN CC, 1994, SCIENCE, V264, P1686, DOI 10.1126/science.8209246; MARALS D, 1994, CARDIOVAS J S AFR, V4, P7; MILLER HI, 1994, LANCET, V344, P316, DOI 10.1016/S0140-6736(94)91345-5; OLINER JD, 1994, SCI AM SCI MED   SEP, P16; Orleans CT, 1993, NICOTINE ADDICTION P; REA IM, 1994, J AM GERIATR SOC, V42, P978, DOI 10.1111/j.1532-5415.1994.tb06591.x; WILLIAMS GH, 1994, HARRISONS PRINCIPLES, V1, P1116; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; 1993, NIH933686 NAT CTR HU	20	18	18	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					13	14		10.1038/376013a0	http://dx.doi.org/10.1038/376013a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RH111	7596420	Bronze			2022-12-28	WOS:A1995RH11100031
J	GARATTINI, S				GARATTINI, S			CULTURAL SHIFT IN ITALY DRUG POLICY	LANCET			English	Editorial Material											GARATTINI, S (corresponding author), IST RIC FARMACOL MARIO NEGRI,MILAN,ITALY.		Garattini, Silvio/AAA-6390-2020	Garattini, Silvio/0000-0003-0647-9297				GARATTINI L, 1994, PHARMACOECONOMICS, V6, P417, DOI 10.2165/00019053-199406050-00003; GARATTINI S, 1993, LANCET, V342, P1191, DOI 10.1016/0140-6736(93)92181-R	2	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					5	6		10.1016/S0140-6736(95)92647-X	http://dx.doi.org/10.1016/S0140-6736(95)92647-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF985	7603156				2022-12-28	WOS:A1995RF98500005
J	BUTLER, D				BUTLER, D			SCIENCE IN AN ERA OF POLITICAL-CHANGE	NATURE			English	Editorial Material																			0	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					717	717						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596401				2022-12-28	WOS:A1995RF98900020
J	DICKER, A; ARMSTRONG, D				DICKER, A; ARMSTRONG, D			PATIENTS VIEWS OF PRIORITY SETTING IN HEALTH-CARE - AN INTERVIEW SURVEY IN ONE PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To explore the assumptions underlying consumers' responses to questions of resource priorities in the NHS. Design-Qualitative analysis of semi-structured interviews with a heterogeneous sample of 16 patients drawn from a general practice. Results-Interviewees were not persuaded that they had a legitimate role to play in the prioritisation of services, They supported the principle of equity and were reluctant to use their own personal needs as a basis for resource allocation; instead they argued from what they perceived to be the needs of others. Conclusions-Paradoxically, surveys of consumers' views on health care priorities probably do not elicit the personal ideas of respondents but tap into a more general ideological position closer to an earlier collectivist notion of health care.	UNITED MED & DENT SCH,DEPT PUBL HLTH MED,LONDON SE1 9RT,ENGLAND	University of London; King's College London			Armstrong, David/AAI-4476-2021	Armstrong, David/0000-0003-3652-9662				BOWLING A, 1993, SOC SCI MED, V37, P851, DOI 10.1016/0277-9536(93)90138-T; HEGINBOTHAM C, 1993, RATIONING ACTION; Strauss AL., 1987, QUALITATIVE ANAL SOC, Vxv, P319; 1992, LOCAL VOICES VIEWS L	4	42	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 28	1995	311	7013					1137	1139		10.1136/bmj.311.7013.1137	http://dx.doi.org/10.1136/bmj.311.7013.1137			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580710	Green Published			2022-12-28	WOS:A1995TC46600020
J	FAHEY, T; GRIFFITHS, S; PETERS, TJ				FAHEY, T; GRIFFITHS, S; PETERS, TJ			EVIDENCE BASED PURCHASING - UNDERSTANDING RESULTS OF CLINICAL-TRIALS AND SYSTEMATIC REVIEWS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess whether the way in which the results of a randomised controlled trial and a systematic review are presented influences health policy decisions. Design-A postal questionnaire to all members of a health authority within one regional health authority. Setting-Anglia and Oxford regional health authorities. Subjects-182 executive and non-executive members of 13 health authorities, family health services authorities, or health commissions. Main outcome measures-The average score from all health authority members in terms of their willingness to fund a mammography programme or cardiac rehabilitation programme according to four different ways of presenting the same results of research evidence-namely, as a relative risk reduction, absolute risk reduction, proportion of event free patients, or as the number of patients needed to be treated to prevent an adverse event. Results-The willingness to fund either programme was significantly influenced by the way in which data were presented. Results of both programmes when expressed as relative risk reductions produced significantly higher scores when compared with other methods (P<0.05). The difference was more extreme for mammography, for which the outcome condition is rarer. Conclusions-The method of reporting trial results has a considerable influence on the health policy decisions made by health authority members.	OXFORDSHIRE HLTH,DEPT PUBL HLTH MED & HLTH POLICY,OXFORD OX3 9DZ,ENGLAND		FAHEY, T (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND.		Fahey, Tom/C-9367-2012	Fahey, Tom/0000-0002-5896-5783; Peters, Tim/0000-0003-2881-4180				[Anonymous], 1994, CRITICAL APPRAISAL S; BOBBIO M, 1994, LANCET, V343, P1209, DOI 10.1016/S0140-6736(94)92407-4; BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; FARKOUH ME, 1993, CLIN RES, V41, P517; FEINSTEIN AR, 1992, AM J MED, V92, P117, DOI 10.1016/0002-9343(92)90099-W; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; HAYWARD J, 1994, BMJ-BRIT MED J, V309, P823, DOI 10.1136/bmj.309.6958.823; HUX JE, 1994, J GEN INTERN MED, V9, P195, DOI 10.1007/BF02600123; HUX JE, 1994, LANCET, V344, P1223; LAUPACIS A, 1990, CAN MED ASSOC J, V142, P329; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LAUPACIS A, 1992, AM COLLEGE PHYSI MAY, P12; MALENKA DJ, 1993, J GEN INTERN MED, V8, P543, DOI 10.1007/BF02599636; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; SACKETT DL, 1994, BMJ-BRIT MED J, V309, P755, DOI 10.1136/bmj.309.6957.755; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; YUSEF S, 1994, LANCET, V344, P53; 1993, SPSS WINDOWS BASE SY; 1993, EL93115 NHS MAN EX	23	144	147	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1056	1059		10.1136/bmj.311.7012.1056	http://dx.doi.org/10.1136/bmj.311.7012.1056			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580661	Green Published			2022-12-28	WOS:A1995TB35400019
J	RIDLEY, RM; BAKER, HF				RIDLEY, RM; BAKER, HF			THE MYTH OF MATERNAL TRANSMISSION OF SPONGIFORM ENCEPHALOPATHY	BRITISH MEDICAL JOURNAL			English	Article							CREUTZFELDT-JAKOB DISEASE; FIBRIL PROTEIN PRP; EXPERIMENTAL SCRAPIE; NATURAL SCRAPIE; CHEVIOT SHEEP; SUFFOLK SHEEP; SIP GENE; SUSCEPTIBILITY; POLYMORPHISMS; AGENT	It has long been accepted that the pattern of occurrence of scrapie-the form of spongiform encephalopathy associated with sheep-is determined mainly by maternal transmission, and this view has had a profound influence on policy decisions in the control of bovine spongiform encephalopathy and on public concern over the risk to human health from this disease. The occurrence of maternal transmission is, however, not predicted by modern knowledge of the aetiology of spongiform encephalopathy, and even though claims of maternal transmission have been reiterated frequently in the literature, re-examination of the source data reveals that these data are extremely scanty, unreplicated, and probably subject to ascertainment bias. The probability of maternal transmission of spongiform encephalopathy in any species should be viewed with the greatest scepticism.	UNIV CAMBRIDGE, DEPT EXPTL PSYCHOL, CAMBRIDGE CB2 3EB, ENGLAND	University of Cambridge								ALPERS M, 1987, P451; AMYX HL, 1981, P SOC EXP BIOL MED, V166, P469, DOI 10.3181/00379727-166-41092; BAKER HF, 1985, BRIT MED J, V291, P299, DOI 10.1136/bmj.291.6491.299; BARLOW RM, 1990, VET REC, V126, P295; BELT PBGM, 1995, J GEN VIROL, V76, P509, DOI 10.1099/0022-1317-76-3-509; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BROWN P, 1994, NEUROLOGY, V44, P291, DOI 10.1212/WNL.44.2.291; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; CAUGHEY B, 1988, J GEN VIROL, V69, P711, DOI 10.1099/0022-1317-69-3-711; DAVIES DC, 1985, VET REC, V116, P211, DOI 10.1136/vr.116.8.211; DICKINSO.AG, 1974, NATURE, V252, P179, DOI 10.1038/252179b0; DICKINSO.AG, 1965, HEREDITY, V20, P485, DOI 10.1038/hdy.1965.64; DICKINSON AG, 1974, J COMP PATHOL, V84, P19, DOI 10.1016/0021-9975(74)90023-1; DICKINSON AG, 1988, CIBA F SYMP, V135, P63; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; FOOTE WC, 1986, P US ANIM HLTH ASS, V91, P413; FOSTER JD, 1992, VET REC, V130, P341, DOI 10.1136/vr.130.16.341; FOSTER JD, 1988, VET REC, V123, P159, DOI 10.1136/vr.123.6.159; FOSTER JD, 1991, VET REC, V128, P548, DOI 10.1136/vr.128.23.548; FRASER H, 1993, P CONSULTATION BSE S; GADJUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; GOLDMANN W, 1994, J GEN VIROL, V75, P989, DOI 10.1099/0022-1317-75-5-989; HADLOW WJ, 1982, J INFECT DIS, V146, P657, DOI 10.1093/infdis/146.5.657; HADLOW WJ, 1991, CURR T VET, V55, P117; Hadlow WJ, 1979, SLOW TRANSMISSIBLE D, V2, P3; HOINVILLE LJ, 1994, VET REC, V134, P274, DOI 10.1136/vr.134.11.274; Hourrigan J., 1979, Slow transmissible diseases of the nervous system. Volume 1., P331; HOURRIGAN JL, 1990, J AM VET MED ASSOC, V196, P1678; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HUNTER N, 1994, ARCH VIROL, V137, P171, DOI 10.1007/BF01311184; HUNTER N, 1992, VET REC, V130, P389, DOI 10.1136/vr.130.18.389; HUNTER N, 1989, VET REC, V124, P364, DOI 10.1136/vr.124.14.364; KIMBERLIN RH, 1979, J COMP PATHOL, V89, P551, DOI 10.1016/0021-9975(79)90046-X; KIMBERLIN RH, 1990, CAN J VET RES, V54, P30; KIRKWOOD JK, 1994, VET REC, V135, P296, DOI 10.1136/vr.135.13.296; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LACEY RW, 1994, HUM REPROD, V9, P1792, DOI 10.1093/oxfordjournals.humrep.a138334; LACEY RW, 1994, MAD COW DISEASE HIST; LAPLANCHE JL, 1993, GENOMICS, V15, P30, DOI 10.1006/geno.1993.1006; MACIULIS A, 1992, AM J VET RES, V53, P1957; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PARRY HB, 1983, SCRAPIE DISEASE SHEE; PATTISON IH, 1974, BRIT VET J, V130, pR65, DOI 10.1016/S0007-1935(17)35851-7; PATTISON IH, 1972, VET REC, V90, P465, DOI 10.1136/vr.90.17.465; PATTISON IH, 1974, NATURE, V248, P594, DOI 10.1038/248594a0; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; RIDLEY RM, 1986, PSYCHOL MED, V16, P199, DOI 10.1017/S0033291700002634; SCHREUDER BEC, 1994, VET QUART, V16, P174, DOI 10.1080/01652176.1994.9694444; SOUTHWOOD R, 1989, REPORT WORKING PARTY; TAMAI Y, 1992, NEW ENGL J MED, V327, P649; WELLS GAH, 1995, BRAIN PATHOL, V5, P91, DOI 10.1111/j.1750-3639.1995.tb00580.x; WELLS GAH, 1994, VET REC, V135, P40, DOI 10.1136/vr.135.2.40; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WESTAWAY D, 1994, GENE DEV, V8, P959, DOI 10.1101/gad.8.8.959; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; WILESMITH JW, 1988, VET REC, V123, P638; WILESMITH JW, 1993, VET REC, V132, P300, DOI 10.1136/vr.132.12.300; WILESMITH JW, IN PRESS SERONO S; 1990, 5TH HOUS COMM AGR CO; 1995, TRANSMISSIBLE SPONGI	61	43	44	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1071	1075		10.1136/bmj.311.7012.1071	http://dx.doi.org/10.1136/bmj.311.7012.1071			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580668	Green Published			2022-12-28	WOS:A1995TB35400028
J	WHITE, P; ATHERTON, A; HEWETT, G; HOWELLS, K				WHITE, P; ATHERTON, A; HEWETT, G; HOWELLS, K			USING INFORMATION FROM ASTHMA PATIENTS - A TRIAL OF INFORMATION FEEDBACK IN PRIMARY-CARE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE	Objective-To test the effects of feedback of information about patients' asthma to primary care teams. Design-Patients' reports of morbidity, use of health services, and drug use on questionnaire was given to primary care teams. Randomised controlled trial with general practices as the subject of the intervention was used to test effectiveness of supplying information. Setting-Primary care in district health authority, London. Subjects-23 general practices, each of which notified at least 20 asthmatic patients aged 15-60 years for each principal. Practices were randomly allocated to an intervention group (receiving feedback of information on control of asthma) or a control group (no feedback). Intervention-Information on cards inserted in patients' medical records; booklet copies of information for team members; formal presentation to primary care teams; poster displays of data on patients in each practice. Main outcome measures-Type and frequency of asthma symptoms, use of health services, use of asthma drugs. Results-Reported morbidity at entry to the study was substantial: 45% (818) patients reported breathlessness at least once a week. Less than half these patients were using inhaled steroids regularly. Intervention and control groups did not differ in practice or patient characteristics on entry to the study. In spite of the potential for improvement no differences were observed between the two practice groups at the end of the study-for example, breathlessness at least once a week in last six months was experienced by 36% in intervention group v 35% in control group (t=-0.27, P<0.79); surgery attendance in last six months by 48% v 48% (t=-0.05, P<0.96); regular use of inhaled steroids by 60% v 58% (t=0.51, P < 0.62). Conclusion-Feedback to general practitioners of information about patients' asthma does not on its own lead to change in the outcome of clinical care.			WHITE, P (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT GEN PRACTICE & PRIMARY CARE,LONDON SE5 9PJ,ENGLAND.		White, Patrick/AAN-7799-2020	White, Patrick/0000-0002-2047-8787				BARRITT PW, 1991, BRIT J GEN PRACT, V41, P232; GLOVER S, 1992, MAKING MED AUDIT EFF; HEWETT G, 1994, OCCASSIONAL PAPERS S, V1; JONES K, 1991, BRIT J GEN PRACT, V41, P224; KENDRICK AH, 1993, BRIT MED J, V307, P1209, DOI 10.1136/bmj.307.6913.1209-b; LOMAS J, 1993, MILBANK Q, V71, P405, DOI 10.2307/3350408; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; SPIEGAL N, 1992, BRIT MED J, V304, P231, DOI 10.1136/bmj.304.6821.231; SZCZEPURA A, 1994, BR J GEN PRACT, V43, P19; TUCKETT D, 1985, M EXPERTS; WHITE PT, 1989, J ROY COLL GEN PRACT, V39, P182; WINKENS RAG, 1992, BRIT MED J, V304, P1093, DOI 10.1136/bmj.304.6834.1093	12	31	31	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1065	1069		10.1136/bmj.311.7012.1065	http://dx.doi.org/10.1136/bmj.311.7012.1065			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580666	Green Published			2022-12-28	WOS:A1995TB35400025
J	CRYSTAL, RG				CRYSTAL, RG			TRANSFER OF GENES TO HUMANS - EARLY LESSONS AND OBSTACLES TO SUCCESS	SCIENCE			English	Article							ADENOVIRUS-MEDIATED TRANSFER; CYSTIC-FIBROSIS; INVIVO; THERAPY; EPITHELIUM; EXPRESSION; DISEASE; VECTORS; CELLS	Enough information has been gained from clinical trials to allow the conclusion that human gene transfer is feasible, can evoke biologic responses that are relevant to human disease, and can provide important insights into human biology. Adverse events have been uncommon and have been related to the gene delivery strategies, not to the genetic material being transferred. Human gene transfer still faces significant hurdles before it becomes an established therapeutic strategy. However, its accomplishments to date are impressive, and the logic of the potential usefulness of this clinical paradigm continues to be compelling.			CRYSTAL, RG (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,DIV PULM & CRIT CARE MED,520 E 70TH ST,ST505,NEW YORK,NY 10021, USA.							AKPORIAYE ET, 1995, 1995 ANN M AM ASS CA; ALI M, 1994, GENE THER, V1, P367; ANDERSON WF, 1992, SCIENCE, V256, P88; BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BLAESE RM, RAC9007002 REP; BORISLAWRIE K, 1994, ANN NY ACAD SCI, V716, P59, DOI 10.1111/j.1749-6632.1994.tb21703.x; BOUCHER RC, RAC9303042 REP; BRENNER K, RAC9102004 REP; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; BRENNER MK, RAC9105006 REP; BRENNER MK, RAC9303039 REP; BRENNER MK, RAC9105005 REP; BRENNER MK, RAC9206018 REP; BROWN MS, 1994, NAT GENET, V7, P349, DOI 10.1038/ng0794-349; CAI Q, 1995, CANCER GENE THER, V2, P195; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CORNETTA K, 1994, BLOOD, V84, pA401; CORNETTA K, RAC9202014; CRYSTAL RG, 1995, HUM GENE THER, V6, P667, DOI 10.1089/hum.1995.6.5-667; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CRYSTAL RG, RAC9212034 REP; CRYSTAL RG, UNPUB; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; DEISSEROTH AB, RAC9206020 REP; DEISSEROTH AB, RAC9105007 REP; DEISSEROTH AB, RAC9406077 REP; DRANOFF G, RAC9411093 REP; DUNBAR CE, RAC9206023 REP; DUNBAR CE, 1995, BLOOD, V85, P1306; DUNBAR CE, RAC9206024 REP; ECONOMOU JS, RAC9202015 REP; FARHOOD H, 1994, ANN NY ACAD SCI, V716, P23, DOI 10.1111/j.1749-6632.1994.tb21701.x; FELGNER PL, 1993, LIPOSOME RES, V3, P3; GINSBERG H, 1995, JUN CRYST FIBR F GEN; GREENBERG PD, RAC9202017 REP; GROSSMAN M, 1994, NAT GENET, V6, P325; HARRIS D, 1995 ANN M AM ASS CA; HAY JG, IN PRESS HUM GENE TH; HERSH E, RAC9403072 REP; HESLOP HE, RAC9303038 REP; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; KOHN DB, 1994, J CELL BIOCHEM, V18, P38; KOHN DB, 1994, J CELL BIOCHEM, V18, P57; KOHN DB, 1993, BLOOD S, V82, pA1245; KREDICH NM, 1989, METABOLIC BASIS INHE, P1045; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; LOTZE MT, RAC9209033 REP; LOTZE MT, RAC9105009 REP; Lyon Jeff., 1995, ALTERED FATES GENE T; MCELVANEY NG, 1995, NAT MED, V1, P182, DOI 10.1038/nm0395-182b; MIDDLETON PG, 1994, EUR RESPIR J, V7, P2050; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MULLEN CA, 1994, J CELL BIOCHEM, V18, P240; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NABEL EG, 1994, HUM GENE THER, V5, P1089, DOI 10.1089/hum.1994.5.9-1089; NABEL GJ, RAC9306045 REP; NABEL GJ, 1993, P NATL ACAD SCI USA, V93, P11307; NABEL GJ, RAC9202013 REP; OLDFIELD EH, RAC9206019 REP; OLDFIELD EH, RAC9312059 REP; PARKMAN R, 1995, J CELL BIOCHEM, V21, pC6; RAPER SE, IN PRESS ANN SURG; RILL DR, 1992, BLOOD, V79, P2694; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1989, SCIENCE, V245, P1073; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENBERG SA, RAC9007003 REP; ROSENBERG SA, RAC8810001 REP; ROSENBERG SA, RAC9110011 REP; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; ROTH JA, RAC9403031 REP; RUBIN JT, RAC9312064 REP; SCHUENING FG, RAC9209027 REP; SETOGUCHI Y, 1994, AM J RESP CELL MOL, V10, P369, DOI 10.1165/ajrcmb.10.4.8136153; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; TEMIN HM, 1990, HUM GENE THER, V1, P111, DOI 10.1089/hum.1990.1.2-111; VOGELZANG N, RAC9403071 REP; WALKER RE, RAC9209026 REP; WALKER RE, RAC9403069 REP; WELSH MJ, RAC9212036 REP; WELSH MJ, RAC9312067 REP; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WILMOTT RW, RAC9303041 REP; WILSON JM, RAC9110012 REP; WILSON JM, RAC9212035 REP; WIVEL NA, 1993, SCIENCE, V262, P533, DOI 10.1126/science.8211180; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; [No title captured]	95	911	1566	0	49	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					404	410		10.1126/science.270.5235.404	http://dx.doi.org/10.1126/science.270.5235.404			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569994				2022-12-28	WOS:A1995TA37400031
J	LLOYD, DCEF; HARRIS, CM; ROBERTS, DJ				LLOYD, DCEF; HARRIS, CM; ROBERTS, DJ			SPECIFIC THERAPEUTIC GROUP AGE-SEX RELATED PRESCRIBING UNITS (STAR-PUS) - WEIGHTINGS FOR ANALYZING GENERAL PRACTICES PRESCRIBING IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To derive cost comparators for prescribing by English general practitioners in eight specific therapeutic groups, based on age-sex related weightings, and to confirm, from a new dataset, earlier age-sex weightings for overall prescribing (ASTRO-PUs). Design-Calculations based on one year's prescribing data from selected practices using AAH Meditel software, held on MediPlus by Intercontinental Medical Statistics (IMS, UK and Ireland), and research practices using VAMP software, held on the General Practice Research Database. Setting-112 English practices with 739 672 patients and 510 British practices with 3 126 570 patients. Main outcome measures-Cost based weightings for 18 age-sex groups and for temporary residents for eight leading specific therapeutic groups and for prescribing overall. Results-The two datasets were similar in age distribution and in the way that prescription numbers were distributed by age-sex band in each therapeutic group. The cost based weightings for specific therapeutic groups showed great variation in the use of these groups for patients in different age-sex groups. When these weightings were applied to the prescribing of practices in two family health services authorities they differed in their power to predict prescribing costs: for cardiovascular and gastrointestinal drugs predictive power was particularly high; for drugs for infections it was particularly low, since these are widely used at all ages and for both sexes. Cost based weightings for overall prescribing derived from the IMS data were similar to those of the ASTRO-PU system even though they were derived by different methods from different datasets. Conclusions-The weightings (STAR-PUs) offer a sound basis for cost comparisons at the therapeutic group level. Cost-based weightings for overall prescribing derived from the UMS data were reassuringly similar to those of the existing ASTRO-PU system.	UNIV LEEDS,RES SCH MED,PRESCRIBING RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND	University of Leeds								BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; SLEATOR DJD, 1993, BRIT J GEN PRACT, V43, P102	5	53	57	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					991	994						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580642				2022-12-28	WOS:A1995TA07900027
J	JAMES, WH				JAMES, WH			FRAUD AND HOAXES IN SCIENCE	NATURE			English	Editorial Material											JAMES, WH (corresponding author), UNIV LONDON UNIV COLL,DEPT GENET & BIOMETRY,4 STEPHENSON WAY,LONDON NW1 2HE,ENGLAND.							Kuhn T. S., 1996, STRUCTURE SCI REVOLU; SEKAS G, 1995, ANN INTERN MED, V123, P38, DOI 10.7326/0003-4819-123-1-199507010-00006; WATSON JD, 1993, SCIENCE, V261, P1812, DOI 10.1126/science.8378784	3	10	10	1	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					474	474		10.1038/377474a0	http://dx.doi.org/10.1038/377474a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566137	Bronze			2022-12-28	WOS:A1995RZ33600028
J	PETERSEN, JM; SKALICKY, JJ; DONALDSON, LW; MCINTOSH, LP; ALBER, T; GRAVES, BJ				PETERSEN, JM; SKALICKY, JJ; DONALDSON, LW; MCINTOSH, LP; ALBER, T; GRAVES, BJ			MODULATION OF TRANSCRIPTION FACTOR ETS-1 DNA-BINDING - DNA-INDUCED UNFOLDING OF AN ALPHA-HELIX	SCIENCE			English	Article							INDUCED CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; PROTEIN-KINASES; BASIC REGION; DOMAIN; SEQUENCE; FAMILY; GCN4; REPRESSOR; SUBUNITS	Conformational changes, including local protein folding, play important roles in protein-DNA interactions. Here, studies of the transcription factor Ets-1 provided evidence that local protein unfolding also can accompany DNA binding. Circular dichroism and partial proteolysis showed that the secondary structure of the Ets-1 DNA-binding domain is unchanged in the presence of DNA. In contrast, DNA allosterically induced the unfolding of an cr helix that lies within a flanking region involved in the negative regulation of DNA binding. These findings suggest a structural basis for the intramolecular inhibition of DNA binding and a mechanism for the cooperative partnerships that are common features of many eukaryotic transcription factors.	UNIV UTAH,SCH MED,DEPT ONCOL SCI,DIV MOLEC BIOL & GENET,SALT LAKE CITY,UT 84132; UNIV UTAH,SCH MED,HUNTSMAN CANC INST,SALT LAKE CITY,UT 84132; UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER,BC V6T 1Z3,CANADA; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of British Columbia; University of British Columbia; University of California System; University of California Berkeley					NCI NIH HHS [CA 42014] Funding Source: Medline; NIGMS NIH HHS [GM38663, R01 GM038663, GM 48958] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038663, R01GM048958, R29GM038663] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; DONALDSON LW, UNPUB; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FISHER RJ, 1994, PROTEIN SCI, V3, P257; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JONSEN MD, UNPUB; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KUDDUS R, 1993, NUCLEIC ACIDS RES, V21, P1789, DOI 10.1093/nar/21.8.1789; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MUKHERJI S, 1994, J BIOL CHEM, V269, P20733; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PETERSEN JH, UNPUB; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SKALICKY JJ, UNPUB; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; Xu Q., UNPUB; ZHAO D, 1993, J MOL BIOL, V229, P735, DOI 10.1006/jmbi.1993.1076	47	175	175	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1866	1869		10.1126/science.7569926	http://dx.doi.org/10.1126/science.7569926			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569926				2022-12-28	WOS:A1995RX19400036
J	COLLINS, JE; COLE, CG; SMINK, LJ; GARRETT, CL; LEVERSHA, MA; SODERLUND, CA; MASLEN, GL; EVERETT, LA; RICE, KM; COFFEY, AJ; GREGORY, SG; GWILLIAM, R; DUNHAM, A; DAVIES, AF; HASSOCK, S; TODD, CM; LEHRACH, H; HULSEBOS, JM; WEISSENBACH, J; MORROW, B; KUCHERLAPATI, RS; WADEY, R; SCAMBLER, PJ; KIM, UJ; SIMON, MI; PEYRARD, M; XIE, YG; CARTER, NP; DURBIN, R; DUMANSKI, JP; BENTLEY, DR; DUNHAM, I				COLLINS, JE; COLE, CG; SMINK, LJ; GARRETT, CL; LEVERSHA, MA; SODERLUND, CA; MASLEN, GL; EVERETT, LA; RICE, KM; COFFEY, AJ; GREGORY, SG; GWILLIAM, R; DUNHAM, A; DAVIES, AF; HASSOCK, S; TODD, CM; LEHRACH, H; HULSEBOS, JM; WEISSENBACH, J; MORROW, B; KUCHERLAPATI, RS; WADEY, R; SCAMBLER, PJ; KIM, UJ; SIMON, MI; PEYRARD, M; XIE, YG; CARTER, NP; DURBIN, R; DUMANSKI, JP; BENTLEY, DR; DUNHAM, I			A HIGH-DENSITY YAC CONTIG MAP OF HUMAN-CHROMOSOME-22	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; SEQUENCE TAGGED SITES; HUMAN GENOME; HUMAN DNA; CLONES; LIBRARY; REGION; CLONING; GENES; TRANSPEPTIDASE	We have constructed a high-resolution clone map of human chromosome 22 which integrates the available physical and genetic information, establishing a single consensus. The map consists of all classes of DNA landmarks ordered on 705 yeast artificial chromosomes (YACs) at an average landmark density of more than one per 70 kilobases. This map represents the practical limits of currently available YAC resources and provides the basis for determination of the entire gene content and genomic DNA sequence of human chromosome 22.	SANGER CTR,CAMBRIDGE,ENGLAND; UNITED MED & DENT SCH,GUYS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; MAX PLANCK INST MOLEC GENET,D-14195 BERLIN,GERMANY; UNIV AMSTERDAM,ACAD MED CTR,INST HUMAN GENET,1105 AZ AMSTERDAM,NETHERLANDS; GENETHON SA,CNRS,URA 1922,F-91002 EVRY,FRANCE; YESHIVA UNIV ALBERT EINSTEIN COLL MED,BRONX,NY 10461; INST CHILD HLTH,DIV BIOCHEM & GENET,MOLEC MED UNIT,LONDON WC1N 1EH,ENGLAND; CALTECH,DIV BIOL,PASADENA,CA 91125; KAROLINSKA HOSP,DEPT MOLEC GENET,CLIN GENET UNIT,S-17176 STOCKHOLM,SWEDEN	Wellcome Trust Sanger Institute; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Max Planck Society; University of Amsterdam; Academic Medical Center Amsterdam; Centre National de la Recherche Scientifique (CNRS); Yeshiva University; Albert Einstein College of Medicine; University of London; University College London; California Institute of Technology; Karolinska Institutet; Karolinska University Hospital			Kucherlapati, Raju/ABC-8807-2021; Scambler, Peter J/C-4998-2008; Durbin, Richard/AAE-7178-2019; Scambler, Peter/AAZ-6026-2020	Scambler, Peter J/0000-0002-1487-4628; Durbin, Richard/0000-0002-9130-1006; Scambler, Peter/0000-0002-1487-4628; Maslen, Gareth/0000-0001-7318-3678; Dunham, Ian/0000-0003-2525-5598	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; BAUER TR, 1993, IMMUNOGENETICS, V38, P387, DOI 10.1007/BF00184519; BELL CJ, 1995, HUM MOL GENET, V4, P59; BENTLEY DR, 1995, CURR OPIN GENET DEV, V5, P328, DOI 10.1016/0959-437X(95)80047-6; BENTLEY DR, 1992, GENOMICS, V12, P534, DOI 10.1016/0888-7543(92)90445-X; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BUETOW KH, 1993, GENOMICS, V18, P329, DOI 10.1006/geno.1993.1473; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLE CG, 1991, GENOMICS, V10, P816, DOI 10.1016/0888-7543(91)90468-T; COLE CG, 1992, GENOMICS, V14, P931, DOI 10.1016/S0888-7543(05)80114-4; COLLINS JE, 1992, GENOMICS, V14, P1098, DOI 10.1016/S0888-7543(05)80137-5; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; DELATTRE O, 1991, GENOMICS, V9, P721, DOI 10.1016/0888-7543(91)90366-M; DUMANSKI JP, 1990, HUM GENET, V84, P219, DOI 10.1007/BF00200562; DUMANSKI JP, 1991, GENOMICS, V11, P709, DOI 10.1016/0888-7543(91)90079-T; DUNHAM I, 1994, GUIDE HUMAN GENOME C, P111; FIGLEWICZ DA, 1993, GENOMICS, V17, P299, DOI 10.1006/geno.1993.1325; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FRAZER KA, 1992, GENOMICS, V14, P574, DOI 10.1016/S0888-7543(05)80154-5; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALFORD S, 1993, HUM MOL GENET, V2, P191, DOI 10.1093/hmg/2.2.191; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; HUDSON TJ, 1994, GENOMICS, V24, P588, DOI 10.1006/geno.1994.1671; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KOUPRINA N, 1994, GENOMICS, V21, P7, DOI 10.1006/geno.1994.1218; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LORONOV V, 1994, NUCLEIC ACIDS RES, V22, P4154; MACCOLLIN M, 1993, GENOMICS, V15, P680, DOI 10.1006/geno.1993.1125; MCDERMID HE, 1993, GENOMICS, V18, P308, DOI 10.1006/geno.1993.1470; MORROW B, 1995, AM J HUM GENET, V56, P1391; MURAKAWA K, 1994, GENOMICS, V23, P379, DOI 10.1006/geno.1994.1514; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NEIL DL, 1990, NUCLEIC ACIDS RES, V18, P1421, DOI 10.1093/nar/18.6.1421; PAWLAK A, 1988, J BIOL CHEM, V263, P9913; PORTER JC, 1993, GENOMICS, V156, P57; Riley B P, 1994, Eur J Hum Genet, V2, P246; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUTTLEDGE MH, 1994, GENOMICS, V19, P52, DOI 10.1006/geno.1994.1012; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; Sambrook J, 1989, MOL CLONING LABORATO; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; VALLADA HP, 1994, HUM GENET, V93, P688; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; XIE YG, 1994, HUM GENET, V94, P339; XIE YG, 1993, HUM MOL GENET, V2, P1361; 1992, NIH CEPH COLLABORATI, V258, P67	53	95	96	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			367	379						13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566101				2022-12-28	WOS:A1995TA34300007
J	GEMMILL, RM; CHUMAKOV, I; SCOTT, P; WAGGONER, B; RIGAULT, P; CYPSER, J; CHEN, Q; WEISSENBACH, J; GARDINER, K; WANG, H; PEKARSKY, Y; LEGALL, I; LEPASLIER, D; GUILLOU, S; LI, E; ROBINSON, L; HAHNER, L; TODD, S; COHEN, D; DRABKIN, HA				GEMMILL, RM; CHUMAKOV, I; SCOTT, P; WAGGONER, B; RIGAULT, P; CYPSER, J; CHEN, Q; WEISSENBACH, J; GARDINER, K; WANG, H; PEKARSKY, Y; LEGALL, I; LEPASLIER, D; GUILLOU, S; LI, E; ROBINSON, L; HAHNER, L; TODD, S; COHEN, D; DRABKIN, HA			A 2ND-GENERATION YAC CONTIG MAP OF HUMAN-CHROMOSOME-3	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; CYSTIC-FIBROSIS GENE; HUMAN GENOME PROJECT; HUMAN DNA; CLONING; LIBRARY; CLONES; IDENTIFICATION; FRAGMENTS	A map of human chromosome 3 which integrates both physical and genetic data has been developed from the fusion of two large collections of markers and corresponding yeast artificial chromosome (YAC) clones. The map contains 972 megabase-sized YACs identified with 593 primary markers, of which 162 are highly polymorphic sequence-tagged sites (STSs) and form a closely spaced genetic linkage map; the remaining markers are hybridization-based. Chromosome 3 is now represented by 24 large YAC contigs whose order and orientation is largely known. The map generated by fusion of these hybridization- and STS-based datasets covers about 80% (over 160 megabases) of the chromosome and will provide the foundation necessary for vapid development of a detailed genetic understanding for this large autosome.	FDN JEAN DAUSSET,CEPH,F-75010 PARIS,FRANCE; GENETHON SA,F-91002 EVRY,FRANCE; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262	Foundation Jean Dausset-CEPH; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	GEMMILL, RM (corresponding author), ELEANOR ROOSEVELT INST CANC RES,1899 GAYLORD ST,DENVER,CO 80206, USA.			Le Paslier, Denis/0000-0003-4335-9956				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; DAUSSET J, 1992, Behring Institute Mitteilungen, P13; DRABKIN H, 1990, GENOMICS, V8, P435, DOI 10.1016/0888-7543(90)90029-T; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GORDEN J, 1991, CELL, V66, P589; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; ICANNOU PA, 1994, NAT GENET, V6, P84; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAYLOR SL, 1992, SCIENCE, V258, P67; OLSON MV, 1993, P NATL ACAD SCI USA, V90, P4338, DOI 10.1073/pnas.90.10.4338; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	22	71	73	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			299	319						21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566097				2022-12-28	WOS:A1995TA34300004
J	THOMAS, P; LOWITT, NR				THOMAS, P; LOWITT, NR			A TRAUMATIC EXPERIENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DOMESTIC VIOLENCE; BATTERED WOMEN; VICTIMIZATION; EMERGENCY		JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV INTERNAL MED,BALTIMORE,MD	Johns Hopkins University								ABBOTT J, 1995, JAMA-J AM MED ASSOC, V273, P1763, DOI 10.1001/jama.273.22.1763; Bullock L, 1989, Nurse Pract, V14, P53; Bullock L., 1989, NURSE PRACT, V14, p47 50; BULLOCK L, 1989, NURSE PRACT, V14, P53; Campbell J C, 1994, J Emerg Nurs, V20, P280; CAMPBELL JC, 1992, RES NURS HEALTH, V15, P219, DOI 10.1002/nur.4770150308; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; GAYFORD JJ, 1975, BRIT MED J, V1, P194, DOI 10.1136/bmj.1.5951.194; GIN NE, 1991, J GEN INTERN MED, V6, P317, DOI 10.1007/BF02597429; GOLDBERG WG, 1984, JAMA-J AM MED ASSOC, V251, P3259, DOI 10.1001/jama.251.24.3259; Hamberger L K, 1992, Fam Med, V24, P283; Hamberger LK, 1992, FAM MED, V24, P5681; KOSS MP, 1991, ARCH INTERN MED, V151, P342, DOI 10.1001/archinte.151.2.342; MARZUK PM, 1992, JAMA-J AM MED ASSOC, V267, P3179, DOI 10.1001/jama.267.23.3179; McCauley J., 1994, Journal of General Internal Medicine, V9, P33; MCKIBBEN L, 1989, PEDIATRICS, V84, P531; MCLEER SV, 1989, AM J PUBLIC HEALTH, V79, P65, DOI 10.2105/AJPH.79.1.65; MCLEER SV, 1989, ANN EMERG MED, V18, P651, DOI 10.1016/S0196-0644(89)80521-9; PARKER B, 1994, OBSTET GYNECOL, V84, P323; SASSETTI MR, 1993, PRIMARY CARE, V20, P289; SCHULMAN MA, 1980, 792701 DEP JUST HARR; STRAUS MA, 1986, J MARRIAGE FAM, V48, P465, DOI 10.2307/352033; TALLEY NJ, 1994, GASTROENTEROLOGY, V107, P1040, DOI 10.1016/0016-5085(94)90228-3; VANHASSELT VB, 1985, ADDICT BEHAV, V10, P127, DOI 10.1016/0306-4603(85)90018-8; Walker L. E., 1979, BATTERED WOMAN SYNDR; 1981, ICPSR7635 DEP JUST B	26	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					307	310		10.1056/NEJM199508033330509	http://dx.doi.org/10.1056/NEJM199508033330509			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RL694	7596377				2022-12-28	WOS:A1995RL69400009
J	ANTONUCCI, G; GIRARDI, E; RAVIGLIONE, MC; IPPOLITO, G				ANTONUCCI, G; GIRARDI, E; RAVIGLIONE, MC; IPPOLITO, G			RISK-FACTORS FOR TUBERCULOSIS IN HIV-INFECTED PERSONS - A PROSPECTIVE COHORT STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; ACTIVE TUBERCULOSIS; UNITED-STATES; DRUG-USERS; PROGRESSION; AIDS	Objective.-To analyze how demographic, clinical, and laboratory characteristics influence the risk of tuberculosis in human immunodeficiency virus (HIV)infected individuals; to examine the incidence of tuberculosis associated with change in skin test responsiveness in HIV-infected, tuberculin-negative, nonanergic individuals. Design.-Multicenter cohort study. Setting.-Twenty-three infectious disease units in public hospitals in Italy. Subjects.-A consecutive sample of 3397 HIV-infected subjects were considered for entry in the study. Of these, 2695 who were followed up for at least 4 weeks were enrolled in the study; 739 subjects (27.4%) were unavailable for follow-up. The median duration of follow-up was 91 weeks. Main Outcome Measure.-Culture-proven tuberculosis. Results.-Eighty-three episodes of tuberculosis were observed. Incidence rates of tuberculosis were 5.42 per 100 person-years among tuberculin-positive subjects, 3.00 per 100 person-years among anergic subjects, and 0.45 per 100 person-years among tuberculin-negative nonanergic subjects. In multivariate analysis, being tuberculin-positive (hazard ratio [HR], 9.94; 95% confidence interval [CI], 3.84 to 25.72) or anergic (HR, 3.35; 95% CI, 1.40 to 8.00), or having a CD4(+) lymphocyte count less than 0.20x10(9)/L (HR, 4.87; 95% CI, 2.35 to 10.11) or between 0.20 and 0.35x10(9)/L (HR, 2.35; 95% CI, 1.09 to 5.05) were statistically significantly associated with the risk of tuberculosis, Incidence of tuberculosis increased with decreasing levels of CD4(+) lymphocytes in the three groups of subjects with different skin test responsiveness. Skin tests were repeated 1 year after enrollment in 604 tuberculin-negative nonanergic subjects; three cases of tuberculosis were observed among the 13 subjects who converted to tuberculin reactivity. Conclusions.-Risk of tuberculosis in HIV-infected persons can be more precisely quantified by jointly considering skin test reactivity and CD4(+) lymphocyte count. Periodic skin tests in tuberculin-negative nonanergic individuals can be useful in identifying individuals at high risk of active tuberculosis.	WHO, TB PROGRAMME, CH-1211 GENEVA, SWITZERLAND	World Health Organization	ANTONUCCI, G (corresponding author), OSPED L SPALLANZANI, CTR RIFERIMENTO AIDS, VIA PORTUENSE 292, I-00149 ROME, ITALY.		Ippolito, Giuseppe/J-7207-2017	RAVIGLIONE, Mario/0000-0002-9331-2067; Ippolito, Giuseppe/0000-0002-1076-2979; Girardi, Enrico/0000-0001-8182-5896				ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; ANTONUCCI G, 1992, AIDS, V6, P1007, DOI 10.1097/00002030-199209000-00015; AYUELA PD, 1990, REV CLIN ESP, V186, P365; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; BRAUN MM, 1990, ARCH INTERN MED, V150, P1913, DOI 10.1001/archinte.150.9.1913; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; Cox D. R., 1984, ANAL SURVIVAL DATA; DEUTEKOM H, 1990, B INT UNION TUBERC L, V65, P33; DIPERRI G, 1991, NEW ENGL J MED, V325, P1882; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRAZER IH, 1985, CLIN IMMUNOL IMMUNOP, V35, P182, DOI 10.1016/0090-1229(85)90064-9; GIRARDI E, 1994, J INFECTION, V28, P261, DOI 10.1016/S0163-4453(94)91693-4; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORNBLUTH RS, 1993, ANN INTERN MED, V119, P241, DOI 10.7326/0003-4819-119-3-199308010-00011; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; ONORATO IM, 1992, J INFECT DIS, V165, P87, DOI 10.1093/infdis/165.1.87; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PEARCE N, 1989, INT J EPIDEMIOL, V18, P976, DOI 10.1093/ije/18.4.976; PESANTI EL, 1994, AM J RESP CRIT CARE, V149, P1699, DOI 10.1164/ajrccm.149.6.7710481; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1987, AM REV RESPIR DIS, V136, P492; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; 1986, MMWR MROB MORTAL WKL, V35, P334; 1994, AGGIORNAMENTO CASI A; 1987, MMWR MROB MORTAL S1S, V36, P3; 1995, GIORNALE ITALIANO AI, V6, P26; 1991, MMWR MROB MORTAL WKL, V40, P27	34	198	204	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					143	148		10.1001/jama.274.2.143	http://dx.doi.org/10.1001/jama.274.2.143			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596002				2022-12-28	WOS:A1995RH22200027
J	VERSCHUREN, WMM; JACOBS, DR; BLOEMBERG, BPM; KROMHOUT, D; MENOTTI, A; ARAVANIS, C; BLACKBURN, H; BUZINA, R; DONTAS, AS; FIDANZA, F; KARVONEN, MJ; NEDELJKOVIC, S; NISSINEN, A; TOSHIMA, H				VERSCHUREN, WMM; JACOBS, DR; BLOEMBERG, BPM; KROMHOUT, D; MENOTTI, A; ARAVANIS, C; BLACKBURN, H; BUZINA, R; DONTAS, AS; FIDANZA, F; KARVONEN, MJ; NEDELJKOVIC, S; NISSINEN, A; TOSHIMA, H			SERUM TOTAL CHOLESTEROL AND LONG-TERM CORONARY HEART-DISEASE MORTALITY IN DIFFERENT CULTURES - 25-YEAR FOLLOW-UP OF THE 7-COUNTRIES STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-DENSITY-LIPOPROTEIN; 7 COUNTRIES; ZUTPHEN; RISK	Objective.-To compare the relationship between serum total cholesterol and long-term mortality from coronary heart disease (CHD) in different cultures. Design.-Total cholesterol was measured at baseline (1958 through 1964) and at 5- and 10-year follow-up in 12 467 men aged 40 through 59 years in 16 cohorts located in seven countries: five European countries, the United States, and Japan. To increase statistical power six cohorts were formed, based on similarities in culture and cholesterol changes during the first 10 years of follow-up. Main Outcome Measures.-Relative risks (RRs), estimated with Cox proportional hazards (survival) analysis, for 25-year CHD mortality for cholesterol quartiles and per 0.50-mmol/L (20-mg/dL) cholesterol increase. Adjustment was made for age, smoking, and systolic blood pressure. Results.-The age-standardized CHD mortality rates in the six cohorts ranged from 3% to 20%. The RRs for the highest compared with the lowest cholesterol quartile ranged from 1.5 to 2.3, except for Japan's RR of 1.1. For a cholesterol level of around 5.45 mmol/L (210 mg/dL), CHD mortality rates varied from 4% to 5% in Japan and Mediterranean Southern Europe to about 15% in Northern Europe. However, the relative increase in CHD mortality due to a given cholesterol increase was similar in all cultures except Japan. Using a linear approximation, a 0.50-mmol/L (20-mg/dL) increase in total cholesterol corresponded to an increase in GHD mortality risk of 12%, which became an increase in mortality risk of 17% when adjusted for regression dilution bias. Conclusion.-Across cultures, cholesterol is linearly related to CHD mortality, and the relative increase in CHD mortality rates with a given cholesterol increase is the same. The large difference in absolute CHD mortality rates at a given cholesterol level, however, indicates that other factors, such as diet, that are typical for cultures with a low CHD risk are also important with respect to primary prevention.	UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, MINNEAPOLIS, MN USA; MED CTR ATHENS, DEPT CARDIOL, ATHENS, GREECE; WHO, NUTR UNIT, GENEVA, SWITZERLAND; HOME AGED, CTR STUDIES AGE RELATED CHANGES MAN, ATHENS, GREECE; UNIV PERUGIA, IST SCI ALIMENTAT, PERUGIA, ITALY; UNIV KUOPIO, DEPT COMMUNITY HLTH & GEN PRACTICE, SF-70211 KUOPIO, FINLAND; UNIV BELGRADE, CTR CLIN, INST CARDIOVASC DIS, BELGRADE, YUGOSLAVIA; KURUME UNIV, SCH MED, KURUME, FUKUOKA 830, JAPAN	University of Minnesota System; University of Minnesota Twin Cities; World Health Organization; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR); University of Perugia; University of Eastern Finland; University of Belgrade; Kurume University	VERSCHUREN, WMM (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT, DEPT CHRON DIS & ENVIRONM EPIDEMIOL, POB 1, 3720 BA BILTHOVEN, NETHERLANDS.		Kromhout, Daan/A-8566-2014	Jacobs, David/0000-0002-7232-0543				ANDERSON JT, 1956, CLIN CHEM, V2, P145; [Anonymous], 1967, INT CLASSIFICATION D; AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; ESTERBAUER H, 1989, ANN NY ACAD SCI, V570, P254; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Keys A, 1997, Nutrition, V13, P250; Keys A., 1980, 7 COUNTRIES STUDY MU; KEYS A, 1967, ACTA MED SCAND, V460, P1; KLEINBAUM DG, 1988, APPLIED REGRESSION A, P265; KROMHOUT D, 1995, PREV MED, V24, P308, DOI 10.1006/pmed.1995.1049; KROMHOUT D, 1989, AM J CLIN NUTR, V49, P889, DOI 10.1093/ajcn/49.5.889; KROMHOUT D, 1988, ARCH INTERN MED, V148, P1051, DOI 10.1001/archinte.148.5.1051; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MENOTTI A, 1993, EUR J EPIDEMIOL, V9, P527, DOI 10.1007/BF00209531; OCKE MC, 1995, INT J CANCER, V61, P480, DOI 10.1002/ijc.2910610409; REAVEN P, 1993, J CLIN INVEST, V91, P668, DOI 10.1172/JCI116247; Rose G, 1968, CARDIOVASCULAR SURVE; SLYPER AH, 1992, LANCET, V340, P289, DOI 10.1016/0140-6736(92)92368-P; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; 1992, SAS P229 SAS I TECHN	25	564	578	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					131	136						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596000				2022-12-28	WOS:A1995RH22200025
J	SULKE, N; CHAMBERS, J; BLAUTH, C				SULKE, N; CHAMBERS, J; BLAUTH, C			LIFE-THREATENING DEGENERATION OF THE ACCUFIX ACTIVE-FIXATION ATRIAL-PACING ELECTRODE	LANCET			English	Note								More than 47 000 patients world wide have had the Accufix atrial-pacemaker lead implanted. The company has issued warnings because degeneration of the electrode has occurred, with two deaths. We detected a fractured electrode that was Successfully removed with insertion of a new type of electrode. Action is required to prevent further possibly fatal complications occurring.	GUYS HOSP,DEPT CARDIAC SURG,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	SULKE, N (corresponding author), GUYS HOSP,DEPT CARDIOL,LONDON SE1 9RT,ENGLAND.								0	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					25	26		10.1016/S0140-6736(95)92653-4	http://dx.doi.org/10.1016/S0140-6736(95)92653-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603141				2022-12-28	WOS:A1995RF98500011
J	IEZZONI, LI; ASH, AS; SHWARTZ, M; DALEY, J; HUGHES, JS; MACKIERNAN, YD				IEZZONI, LI; ASH, AS; SHWARTZ, M; DALEY, J; HUGHES, JS; MACKIERNAN, YD			PREDICTING WHO DIES DEPENDS ON HOW SEVERITY IS MEASURED - IMPLICATIONS FOR EVALUATING PATIENT OUTCOMES	ANNALS OF INTERNAL MEDICINE			English	Article						SEVERITY OF ILLNESS INDEX; OUTCOME ASSESSMENT (HEALTH CARE); MYOCARDIAL INFARCTION; RISK ASSESSMENT; MORTALITY	ACUTE MYOCARDIAL-INFARCTION; PROSPECTIVE-PAYMENT SYSTEM; IN-HOSPITAL MORTALITY; CORONARY-CARE UNIT; DISEASE; INFORMATION; INSTRUMENT; LENGTH; STAY	Objective: To determine whether assessments of illness severity, defined as risk for in-hospital death, varied across four severity measures. Design: Retrospective cohort study. Setting: 100 hospitals using the MedisGroups severity measure. Patients: 11 880 adults managed medically for acute myocardial infarction; 1574 in-hospital deaths (13.2%). Measurements: For each patient, probability of death was predicted four times, each time by using patient age and sex and one of four common severity measures: 1) admission MedisGroups scores for probability of death scores; 2) scores based on values for 17 physiologic variables at time of admission; 3) Disease Staging's probability-of-mortality model; and 4) All Patient Refined Diagnosis Related Groups (APR-DRGs). Patients were ranked according to probability of death as predicted by each severity measure, and rankings were compared across measures. The presence or absence of each of six clinical findings considered to indicate poor prognosis in patients with myocardial infarction (congestive heart failure, pulmonary edema, coma, low systolic blood pressure, low left ventricular ejection fraction, and high blood urea nitrogen level) was determined for patients ranked differently by different severity measures. Results: MedisGroups and the physiology score gave 94.7% of patients similar rankings. Disease Staging, MedisGroups, and the physiology score gave only 78% of patients similar rankings. MedisGroups and APR-DRGs gave 80% of patients similar rankings. Patients whose illnesses were more severe according to MedisGroups and the physiology score were more likely to have the six clinical findings than were patients whose illnesses were more severe according to Disease Staging and APR-DRGs. Conclusions: Some pairs of severity measures assigned very different severity levels to more than 20% of patients. Evaluations of patient outcomes need to be sensitive to the severity measures used for risk adjustment.	BOSTON UNIV, MED CTR, GEN INTERNAL MED SECT, HLTH CARE RES UNIT, BOSTON, MA 02118 USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, DEPT MED, HLTH SERV RES & DEV, BOSTON, MA 02132 USA; VET AFFAIRS MED CTR, DEPT MED, W HAVEN, CT 06516 USA	Boston University; Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	IEZZONI, LI (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV GEN MED & PRIMARY CARE, ROOM LY-326, BOSTON, MA 02215 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253	AHRQ HHS [R01 HS06742-03] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Ash A, 1994, RISK ADJUSTMENT MEAS, P313; BREWSTER AC, 1985, INQUIRY, V12, P377; CLINTON B, 1993, HLTH SECURITY PRESID, P100; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DALEY J, 1994, RISK ADJUSTMENT MEAS, P254; DONABEDIAN A, 1980, EXPLORATIONS QUALITY, V1, P101; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Iezzoni L I, 1992, QRB Qual Rev Bull, V18, P361; IEZZONI LI, 1992, MED CARE, V30, P347, DOI 10.1097/00005650-199204000-00005; IEZZONI LI, 1993, MED CARE, V31, P277, DOI 10.1097/00005650-199303000-00009; IEZZONI LI, 1991, JAMA-J AM MED ASSOC, V265, P3006, DOI 10.1001/jama.265.22.3006; IEZZONI LI, 1991, INQUIRY-J HEALTH CAR, V28, P117; IEZZONI LI, 1994, JOINT COMM J QUAL IM, V20, P305, DOI 10.1016/S1070-3241(16)30075-X; Iezzoni LI, 2012, RISK ADJUSTMENT MEAS, V4th; IEZZONI LI, 1995, EVALUATING SEVERITY; IEZZONI LI, JAMA-J AM MED ASSOC, V260, P3159; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LOCALIO AR, 1995, ANN INTERN MED, V122, P125, DOI 10.7326/0003-4819-122-2-199501150-00009; MARKSON LE, 1991, EVAL HEALTH PROF, V14, P201, DOI 10.1177/016327879101400205; MCMAHON LF, 1986, ANN INTERN MED, V104, P562, DOI 10.7326/0003-4819-104-4-562; MCMAHON LF, 1988, J GEN INTERN MED, V3, P482, DOI 10.1007/BF02595926; MOREAU R, 1989, CRIT CARE MED, V17, P409, DOI 10.1097/00003246-198905000-00006; NAESSENS JM, 1992, MAYO CLIN PROC, V67, P1140, DOI 10.1016/S0025-6196(12)61143-4; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; SELKER HP, 1991, MED CARE, V29, P1196, DOI 10.1097/00005650-199112000-00003; SHARPIRO MF, 1994, HEALTH SERV RES, V29, P95; SIMBORG DW, 1981, NEW ENGL J MED, V304, P1602, DOI 10.1056/NEJM198106253042611; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; TESKEY RJ, 1991, CHEST, V100, P1637, DOI 10.1378/chest.100.6.1637; VLADECK BC, 1984, ANN INTERN MED, V100, P576, DOI 10.7326/0003-4819-100-4-576; WAGNER DP, 1986, ARCH INTERN MED, V146, P1389, DOI 10.1001/archinte.146.7.1389; 1993, DEFINITION MANUAL; 1994, HLTH CARE REFORM REP; 1994, CORONARY ARTERY BYPA, V2; 1994, US C OFFICE TECHNOLO; 1980, NATIONAL COMMITTE VI; 1989, HOSPITAL ADM GUIDE S; 1989, QUALITY MEASUREMENT; 1994, HLTH CARE EMPLOYERS	51	139	139	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1995	123	10					763	+		10.7326/0003-4819-123-10-199511150-00004	http://dx.doi.org/10.7326/0003-4819-123-10-199511150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TE172	7574194				2022-12-28	WOS:A1995TE17200004
J	THORNTON, JG; HEWISON, J; LILFORD, RJ; VAIL, A				THORNTON, JG; HEWISON, J; LILFORD, RJ; VAIL, A			A RANDOMIZED TRIAL OF 3 METHODS OF GIVING INFORMATION ABOUT PRENATAL TESTING	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTENATAL CARE; DOWNS-SYNDROME; ANXIETY; ULTRASOUND; KNOWLEDGE; PREGNANCY; ETHICS; WOMEN; LAW	Objective-To test the effect of extra nondirective information about prenatal testing, given individually or in a class. Setting-Antenatal clinics in a district general hospital and a university hospital. Design-Randomised controlled trial; participants allocated to control group or offer of extra information individually or in class. Subjects-1691 women booking antenatal care before 15 weeks' gestation. Interventions-All participants received the usual information about prenatal tests from hospital staff. Individual participants were offered a separate session with a research midwife in which prenatal screening was described in detail. Class participants were offered the same extra information in an early prenatal class. Main outcome measures-Attendance at extra information sessions; uptake rates of prenatal tests; levels of anxiety, understanding, and satisfaction with decisions. Results-Attendance at classes was lower than at individual sessions (adjusted odds ratio 0.45; 95% confidence interval 0.35 to 0.58). Ultrasonography was almost universally accepted (99%) and was not affected by either intervention. Uptake of cystic fibrosis testing, high in controls (79%), was lowered in the individual group (0.44; 0.20 to 0.97) and classes (0.39; 0.18 to 0.86). Uptake of screening for Down's syndrome, alreaay low (34%) in controls, was not further depressed by extra information in classes (0.99; 0.70 to 1.39) and was slightly higher in the individual group (1.45; 1.04 to 2.02). Women offered extra information had improved understanding and were more satisfied with information received; satisfaction with decisions about prenatal testing was unchanged. The offer of individual information reduced anxiety later in pregnancy. Conclusions-Ultrasonography is valued for nonmedical reasons and chosen even by fully informed people who eschew prenatal diagnosis. The offer of extra information has no overall adverse effects on anxiety and reduces uptake of blood tests when background uptake rate is high (but not when it is already low). High uptake of prenatal blood tests suggests compliant behaviour and need for more information.	UNIV LEEDS, DEPT PSYCHOL, LEEDS LS2 9LN, W YORKSHIRE, ENGLAND	University of Leeds	THORNTON, JG (corresponding author), UNIV LEEDS, INST EPIDEMIOL & HLTH SERV RES, LEEDS LS2 9LN, W YORKSHIRE, ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876; Vail, Andy/0000-0001-8274-2726				BERWICK DM, 1985, MED CARE, V23, P881, DOI 10.1097/00005650-198507000-00005; CLARKE A, 1993, BRIT MED J, V306, P209, DOI 10.1136/bmj.306.6871.209-a; DALTON ME, 1993, NEW ENGL J MED, V328, P114; FIELD T, 1985, OBSTET GYNECOL, V66, P525; FREEMAN RM, 1986, BMJ-BRIT MED J, V292, P657, DOI 10.1136/bmj.292.6521.657; GREEN JM, 1990, OCCASIONAL PAPERS, V2; GREEN JM, 1992, OBSTETRICS 1990S CUR; HODNETT ED, 1994, SUPPORT CAREGIVERS R; LILFORD RJ, 1992, BMJ-BRIT MED J, V305, P1181, DOI 10.1136/bmj.305.6863.1181; LILFORD RJ, 1989, J REPROD INFANT PSYC, V7, P187; LUMLEY J, 1993, STRATEGIES REDUCING; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; MARTEAU TM, 1989, J PSYCHOSOM RES, V33, P7, DOI 10.1016/0022-3999(89)90101-3; MARTEAU TM, 1988, J PSYCHOSOM RES, V32, P403, DOI 10.1016/0022-3999(88)90023-2; MARTEAU TM, 1992, PUBLIC HEALTH, V106, P131, DOI 10.1016/S0033-3506(05)80390-7; MARTEAU TM, 1992, BRIT MED J, V305, P1433, DOI 10.1136/bmj.305.6866.1433-e; MARTEAU TM, 1993, J PSYCHOSOM OBST GYN, V14, P185, DOI 10.3109/01674829309084441; REID M, 1988, EUR J OBSTET GYN R B, V28, P79; SHAPIRO MC, 1983, SOC SCI MED, V17, P139, DOI 10.1016/0277-9536(83)90247-2; Spielberger C., 1983, STAI MANUAL; STEER P, 1993, BRIT MED J, V307, P697, DOI 10.1136/bmj.307.6906.697; THORNTON JG, 1991, J PERINAT MED, V19, P151, DOI 10.1515/jpme.1991.19.3.151; WALD N, 1992, BRIT MED J, V305, P892, DOI 10.1136/bmj.305.6858.892-b; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1989, CARING FUTURE REPORT; 1989, J R COLL PHYS LOND, V23, P215	27	87	85	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	1995	311	7013					1127	1130		10.1136/bmj.311.7013.1127	http://dx.doi.org/10.1136/bmj.311.7013.1127			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC466	7580707	Green Published			2022-12-28	WOS:A1995TC46600016
J	PEET, SM; CASTLEDEN, CM; MCGROTHER, CW				PEET, SM; CASTLEDEN, CM; MCGROTHER, CW			PREVALENCE OF URINARY AND FECAL INCONTINENCE IN HOSPITALS AND RESIDENTIAL AND NURSING-HOMES FOR OLDER-PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEICESTER,LEICESTER ROYAL INFIRM,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE2 7LX,LEICS,ENGLAND	University of Leicester	PEET, SM (corresponding author), UNIV LEICESTER,LEICESTER GEN HOSP,DIV MED ELEDRLY,LEICESTER LE5 4PW,LEICS,ENGLAND.							Clarke M, 1979, HLTH TRENDS, V11, P17; Donaldson L J, 1983, Health Trends, V15, P58; MCGROTHER CW, 1987, AGE AGEING, V16, P105, DOI 10.1093/ageing/16.2.105; STERN MC, 1993, BRIT MED J, V306, P827, DOI 10.1136/bmj.306.6881.827; TOBIN GW, 1986, AGE AGEING, V15, P292, DOI 10.1093/ageing/15.5.292	5	75	75	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1063	1064		10.1136/bmj.311.7012.1063	http://dx.doi.org/10.1136/bmj.311.7012.1063			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580664	Green Published			2022-12-28	WOS:A1995TB35400023
J	CRAFT, N				CRAFT, N			BEIJING DIARY - 10 DAYS AT THE WOMENS CONFERENCE	BRITISH MEDICAL JOURNAL			English	Article								In the biggest ever United Nations conference, delegates from 180 countries met in Beijing last month for the fourth world conference on women. In the 20 years since the first UN conference on women, the campaign for equality between men and women has witnessed momentous changes and undeniable advances. To date, 139 member states have now signed the Convention on the Elimination of an Forms of Discrimination Against Women adopted by the UN general assembly in 1979. In many countries, women are developing their professional careers and challenging the traditional roles that have been the norm for many years. Progress has been rapid, but inequality remains and the UN recently identified health as one of the areas that needs more attention. The UN conference in Beijing (and the parallel meeting organised by the non-government organisations which was held in Huairou, an hour away from Beijing) aimed to re-examine the issues and to develop a plan of action for the future.											0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					1010	1012						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580591				2022-12-28	WOS:A1995TA07900033
J	MEUNIER, JC; MOLLEREAU, C; TOLL, L; SUAUDEAU, C; MOISAND, C; ALVINERIE, P; BUTOUR, JL; GUILLEMOT, JC; FERRARA, P; MONSARRAT, B; MAZARGUIL, H; VASSART, G; PARMENTIER, M; COSTENTIN, J				MEUNIER, JC; MOLLEREAU, C; TOLL, L; SUAUDEAU, C; MOISAND, C; ALVINERIE, P; BUTOUR, JL; GUILLEMOT, JC; FERRARA, P; MONSARRAT, B; MAZARGUIL, H; VASSART, G; PARMENTIER, M; COSTENTIN, J			ISOLATION AND STRUCTURE OF THE ENDOGENOUS AGONIST OF OPIOID RECEPTOR-LIKE ORL(1) RECEPTOR	NATURE			English	Article							PITUITARY; DYNORPHIN	THE ORL(1) receptor, an orphan receptor whose human(1) and murine(2-8) complementary DNAs have recently been characterized, structurally resembles opioid receptors and is negatively coupled with adenylate cyclase(1). ORL(1) transcripts are particularly abundant in the central nervous system. Here we report the isolation, on the basis of its ability to inhibit the cyclase in a stable recombinant CHO(ORL(1)(+)) cell line, of a neuropeptide that resembles dynorphin A(9) and whose amino acid sequence is Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn- Gln. A rat-brain cDNA encodes the peptide flanked by Lys-Arg proteolytic cleavage motifs. The synthetic heptadecapeptide potently inhibits adenylate cyclase in CHO(ORL(1)(+)) cells in culture and induces hyperalgesia when administered intracerebroventricularly to mice. Taken together, these data indicate that the newly discovered heptadecapeptide is an endogenous agonist of the ORL(1) receptor and that it may be endowed with pro-nociceptive properties.	FAC MED & PHARM ST ETIENNE ROUVRAY, IFRMP,CNRS,UNITE NEUROPSYCHOPHARMACOL EXPTL, URA 1969, F-76803 ST ETIENNE DU ROUVRAY, FRANCE; SANOFI RECH, UNITE BIOCHIM PROT, F-31676 LABEGE, FRANCE; FREE UNIV BRUSSELS, CAMPUS HOSP ERASME, IRIBHN, B-1070 BRUSSELS, BELGIUM; SRI INT, MENLO PK, CA 94025 USA	Centre National de la Recherche Scientifique (CNRS); Sanofi-Aventis; Sanofi France; Universite Libre de Bruxelles; Vrije Universiteit Brussel; SRI International	MEUNIER, JC (corresponding author), CNRS, UPR 8221, PHARMACOL & TOXICOL FONDAMENTALES LAB, 205 ROUTE NARBONNE, F-31077 TOULOUSE, FRANCE.		hu, jenny/AAK-8712-2020	Mollereau, Catherine/0000-0003-1543-5624				ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; CHEN Y, 1994, FEBS LETT, V347, P279, DOI 10.1016/0014-5793(94)00560-5; EDDY NB, 1953, J PHARMACOL EXP THER, V107, P385; EVANS CJ, 1988, OPIATE RECEPTORS, P23; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; GOLDSTEIN A, 1981, P NATL ACAD SCI-BIOL, V78, P7219, DOI 10.1073/pnas.78.11.7219; LACHOWICZ JE, 1995, J NEUROCHEM, V64, P34; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; NISHI M, 1994, BIOCHEM BIOPH RES CO, V205, P1353, DOI 10.1006/bbrc.1994.2814; TESCHEMACHER H, 1975, LIFE SCI, V16, P1771, DOI 10.1016/0024-3205(75)90271-4; WAHLESTEDT C, 1994, TRENDS PHARMACOL SCI, V15, P42, DOI 10.1016/0165-6147(94)90107-4; WANG JB, 1994, J BIOL CHEM, V269, P25966; WANG JB, 1994, FEBS LETT, V348, P75, DOI 10.1016/0014-5793(94)00557-5; WICK MJ, 1994, MOL BRAIN RES, V27, P37, DOI 10.1016/0169-328X(94)90181-3; XUE JC, 1994, J BIOL CHEM, V269, P30195	17	1736	1832	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 12	1995	377	6549					532	535		10.1038/377532a0	http://dx.doi.org/10.1038/377532a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566152				2022-12-28	WOS:A1995RZ33600064
J	CHRYSTIE, IL; WOLFE, CDA; KENNEDY, J; ZANDER, L; TILZEY, A; BANATVALA, JE				CHRYSTIE, IL; WOLFE, CDA; KENNEDY, J; ZANDER, L; TILZEY, A; BANATVALA, JE			VOLUNTARY, NAMED TESTING FOR HIV IN A COMMUNITY-BASED ANTENATAL CLINIC - A PILOT-STUDY	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMISSION; WOMEN; RISK	Despite the increasing advantages of identifying HIV infection in pregnant women, only some 12% of HIV positive women attending antenatal clinics in London have been identified by named testing. As virtually all antenatal care will be community based within the next two to three years, we assessed the problems of introducing named HIV testing during pregnancy into the primary care setting. Planning the service took a considerable time and required the production of educational material for both staff and pregnant women and some reorganisation of procedures. Over a one year period an uptake of 44% was noted. Several problems were encountered including an average of 21 minutes needed to give information on AIDS and HIV, an adverse effect on the midwife-mother relationship, and anxiety (affecting both women and midwives). Possible solutions to this difficult problem are discussed.	UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT VIROL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH,DIRECTORATE OBSTET & GYNAECOL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH,DEPT GEN PRACTICE,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; University of London; King's College London				Wolfe, Charles/0000-0001-8264-0981				ADES AE, 1992, AIDS, V6, P1031, DOI 10.1097/00002030-199209000-00018; BANATVALA JE, 1994, LANCET, V343, P1113, DOI 10.1016/S0140-6736(94)90230-5; BANATVALA JE, 1991, LANCET, V337, P1218, DOI 10.1016/0140-6736(91)92885-6; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; Chrystie I, 1992, Health Trends, V24, P13; CHRYSTIE IL, 1995, AIDS CARE, V7, P135, DOI 10.1080/09540129550126650; CHRYSTIE IL, 1992, LANCET, V339, P364, DOI 10.1016/0140-6736(92)91682-X; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COZEN W, 1993, J ACQ IMMUN DEF SYND, V6, P95; DELAMOTHE T, 1995, BRIT MED J, V310, P213, DOI 10.1136/bmj.310.6974.213; DESMOND N, 1994, BRIT MED J, V309, P877, DOI 10.1136/bmj.309.6958.877a; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Flesch R, 1948, J APPL PSYCHOL, V32, P221, DOI 10.1037/h0057532; Holland F J, 1994, J Med Screen, V1, P176; HOWARD LC, 1989, BRIT J OBSTET GYNAEC, V96, P135, DOI 10.1111/j.1471-0528.1989.tb01651.x; MEADOWS J, 1994, INT J STD AIDS, V5, P400, DOI 10.1177/095646249400500604; MEADOWS J, 1992, LANCET, V339, P622; NICOLL A, 1994, BRIT MED J, V309, P376, DOI 10.1136/bmj.309.6951.376a; 1993, CHANGING CHILDBIRTH; 1994, GUIDELINES OFFERING; 1995, UNLINKED ANONYMOUS H; 1994, LANCET, V343, P1464; 1992, GUIDELINES OFFERING	24	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					928	931						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580555	Green Published			2022-12-28	WOS:A1995RZ23700026
J	JAYARAMAN, V; RODGERS, KR; MUKERJI, I; SPIRO, TG				JAYARAMAN, V; RODGERS, KR; MUKERJI, I; SPIRO, TG			HEMOGLOBIN ALLOSTERY - RESONANCE RAMAN-SPECTROSCOPY OF KINETIC INTERMEDIATES	SCIENCE			English	Article							HISTIDINE LINKAGE; PHOTOLYSIS; DYNAMICS; COOPERATIVITY; RELAXATION; BINDING	The end states, R and T, of the allosteric transition in hemoglobin (Hb) are structurally well characterized, but there is little information on intermediate structures along the allosteric pathway. These intermediates were examined by means of time-resolved resonance Raman spectroscopy in the nanosecond-to-microsecond interval after HbCO photolysis. Complementary spectra of the heme group and of the tyrosine and tryptophan residues were recorded during laser excitation at 436 and 230 nanometers. These spectra reveal a sequence of interleaved tertiary and quaternary motions during the photocycle, motions involving the proximal and distal helices, and the alpha(1) beta(2) subunit interface. This sequence leads to a modified form of the T state, in which the alpha(1) beta(2) interface is deformed as a result of two carbon monoxide molecules binding to the same dimer within the tetramer.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544; N DAKOTA STATE UNIV,DEPT CHEM,FARGO,ND 58105; WESLEYAN UNIV,DEPT BIOCHEM & MOLEC BIOL,MIDDLETOWN,CT 06457	Princeton University; North Dakota State University Fargo; Wesleyan University					NIGMS NIH HHS [GM 25158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025158] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1990, BIOPHYS CHEM, V37, P371, DOI 10.1016/0301-4622(90)88036-R; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BANGCHAROENPAUR.O, 1984, J AM CHEM SOC, V106, P5688; DASGUPTA S, 1986, BIOCHEMISTRY-US, V25, P5941, DOI 10.1021/bi00368a016; FRIEDMAN JM, 1983, J BIOL CHEM, V258, P564; FRIEDMAN JM, 1982, SCIENCE, V218, P1244, DOI 10.1126/science.7146910; FRIEDMAN JM, 1980, NATURE, V284, P570, DOI 10.1038/284570a0; GELLIN BR, 1983, J MOL BIOL, V171, P489; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; JAYARAMAN V, 1995, BIOCHEMISTRY-US, V34, P4511, DOI 10.1021/bi00014a002; JAYARAMAN V, 1993, BIOCHEMISTRY-US, V32, P4547, DOI 10.1021/bi00068a009; KAMINAKA S, 1990, J AM CHEM SOC, V112, P23, DOI 10.1021/ja00157a006; KAMINAKA S, 1992, J AM CHEM SOC, V114, P3256, DOI 10.1021/ja00035a015; KERR EA, 1987, BIOL APPLICATIONS RA, V3, P39; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; LOCKE B, 1991, CHEM PHYS, V158, P409, DOI 10.1016/0301-0104(91)87080-F; MIURA S, 1982, BIOCHEMISTRY-US, V21, P6280, DOI 10.1021/bi00267a037; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MUKERJI I, 1994, BIOCHEMISTRY-US, V33, P13132, DOI 10.1021/bi00248a024; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PERUTZ MF, 1990, MECHANISMS COOPERATI; PIN S, 1986, CHEM PHYS LETT, V128, P79, DOI 10.1016/0009-2614(86)80149-X; RODGERS KR, 1992, J AM CHEM SOC, V114, P3697, DOI 10.1021/ja00036a019; RODGERS KR, 1994, SCIENCE, V265, P1697, DOI 10.1126/science.8085153; ROUSSEAU DL, 1987, BIOL APPLICATIONS RA, V3, P133; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SCHUMACHER MA, 1995, NATURE, V375, P84, DOI 10.1038/375084a0; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701	33	171	172	1	37	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1843	1848		10.1126/science.7569921	http://dx.doi.org/10.1126/science.7569921			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569921				2022-12-28	WOS:A1995RX19400029
J	TSIRKA, SE; GUALANDRIS, A; AMARAL, DG; STRICKLAND, S				TSIRKA, SE; GUALANDRIS, A; AMARAL, DG; STRICKLAND, S			EXCITOTOXIN-INDUCED NEURONAL DEGENERATION AND SEIZURE ARE MEDIATED BY TISSUE-PLASMINOGEN ACTIVATOR	NATURE			English	Article							BRAIN	NEURONAL degeneration in the hippocampus, a region of the brain important for acquisition of memory in humans, occurs in various pathological conditions, including Alzheimer's disease, brain ischaemia and epilepsy. When neuronal activity is stimulated in the adult rat and mouse hippocampus, tissue plasminogen activator (tPA), a serine protease that converts inactive plasminogen to the active protease plasmin, is transcriptionally induced(1,2). The activity of tPA in neural tissue is correlated with neurite outgrowth(3), regeneration(4) and migration(5), suggesting that it might be involved in neuronal plasticity. Here we show that tPA is produced primarily by microglia in the hippocampus. Using excitotoxins to induce neuronal cell loss, we demonstrate that tPA-deficient mice are resistant to neuronal degeneration. These mice are also less susceptible to pharmacologically induced seizures than wild-type mice. These findings identify a role for tPA in neuronal degeneration and seizure.	SUNY STONY BROOK,MED CTR,PROGRAM GENET,STONY BROOK,NY 11794; SUNY STONY BROOK,CTR BEHAV NEUROSCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	TSIRKA, SE (corresponding author), SUNY STONY BROOK,MED CTR,DEPT PHARMACOL,STONY BROOK,NY 11794, USA.		Tsirka, Stella/AAD-4018-2019	Gualandris, anna/0000-0002-2889-4080; Strickland, Sidney/0000-0002-3072-9244				ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARROLL PM, 1994, DEVELOPMENT, V120, P3173; GOLARAI G, 1992, BRAIN RES, V593, P257, DOI 10.1016/0006-8993(92)91316-7; Kandel E.R., 1991, PRINC NEUROSCI, V3rd ed.; KINGSTON IB, 1995, NAT MED, V1, P138; KRYSTOSEK A, 1981, P NATL ACAD SCI-BIOL, V78, P7810, DOI 10.1073/pnas.78.12.7810; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; SALLES FJ, 1990, EMBO J, V9, P2471, DOI 10.1002/j.1460-2075.1990.tb07425.x; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SMEYNE R, 1992, NEURON, V6, P13; STREIT WJ, 1993, J CHEM NEUROANAT, V6, P261, DOI 10.1016/0891-0618(93)90047-8; THANOS S, 1991, EUR J NEUROSCI, V3, P1189, DOI 10.1111/j.1460-9568.1991.tb00054.x	17	574	592	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					340	344		10.1038/377340a0	http://dx.doi.org/10.1038/377340a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566088				2022-12-28	WOS:A1995RX11100057
J	REZZA, G; PEZZOTTI, P; AIUTI, F				REZZA, G; PEZZOTTI, P; AIUTI, F			ACQUIRED IMMUNODEFICIENCY WITHOUT HIV-INFECTION - EPIDEMIOLOGY AND CLINICAL OUTCOME IN ITALY	BRITISH MEDICAL JOURNAL			English	Article							CD4+ T-LYMPHOCYTOPENIA		UNIV ROMA LA SAPIENZA,CATTEDRA ALLERGOL & IMMUNOL CLIN,I-00162 ROME,ITALY	Sapienza University Rome	REZZA, G (corresponding author), IST SUPER SANITA,CTR OPERAT AIDS,I-00161 ROME,ITALY.		PEZZOTTI, PATRIZIO/C-6480-2016; rezza, giovanni/D-4393-2016	PEZZOTTI, PATRIZIO/0000-0002-0805-2927; rezza, giovanni/0000-0003-0268-6790				ABENI DD, 1993, GIORNALE ITALIANO AI, V4, P16; HO DD, 1993, NEW ENGL J MED, V328, P380, DOI 10.1056/NEJM199302113280602; MCNULTY A, 1994, BRIT MED J, V308, P825, DOI 10.1136/bmj.308.6932.825; MONTELLA F, 1994, AIDS, V8, P390, DOI 10.1097/00002030-199403000-00018; SMITH DK, 1993, NEW ENGL J MED, V328, P373, DOI 10.1056/NEJM199302113280601	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					785	786		10.1136/bmj.311.7008.785	http://dx.doi.org/10.1136/bmj.311.7008.785			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580441	Green Published			2022-12-28	WOS:A1995RX10700022
J	BIASI, D; CARAMASCHI, P				BIASI, D; CARAMASCHI, P			PSORIATIC-ARTHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									IST CLIN MED,I-37134 VERONA,ITALY		BIASI, D (corresponding author), IST PATOL SPECIALE MED,I-37134 VERONA,ITALY.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					297	297		10.1056/NEJM199508033330506	http://dx.doi.org/10.1056/NEJM199508033330506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL694	7596374				2022-12-28	WOS:A1995RL69400006
J	SHEN, XT; YU, LL; WEIR, JW; GOROVSKY, MA				SHEN, XT; YU, LL; WEIR, JW; GOROVSKY, MA			LINKER HISTONES ARE NOT ESSENTIAL AND AFFECT CHROMATIN CONDENSATION IN-VIVO	CELL			English	Article							TETRAHYMENA-THERMOPHILA; CELL-CYCLE; SEQUENCE; PHOSPHORYLATION; TRANSFORMATION; GENE; H1; HYBRIDIZATION; MICRONUCLEI; MACRONUCLEI	We have (separately) disrupted all of the expressed macronuclear copies of the HHO gene encoding macronuclear histone H1 and of the micronuclear linker histone (MLH) gene encoding the protein MicLH in Tetrahymena thermophila. These disruptions are shown to eliminate completely the expression of each protein. Strains without either linker histone grow at normal rates and reach near-normal cell densities, demonstrating that linker histones are not essential for cell survival. Histone H1 knockout (Delta H1) cells have enlarged DAPI-stained macronuclei and normal-sized micronuclei, while MicLH knockout (Delta MicLH) cells have enlarged micronuclei and normal-sized macronuclei. Delta MicLH cells undergo mitosis normally. However, the micronuclear mitotic chromosome structure is less condensed. These studies provide evidence that linker histones are nonessential and are involved in chromatin packaging and condensation in vivo.			SHEN, XT (corresponding author), UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627, USA.			Shen, Xuetong/0000-0002-4267-5298	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026973] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26973] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1981, J CELL BIOL, V90, P279, DOI 10.1083/jcb.90.2.279; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALLIS CD, 1984, J CELL BIOL, V99, P1669, DOI 10.1083/jcb.99.5.1669; ALLIS CD, 1982, DEV BIOL, V93, P519, DOI 10.1016/0012-1606(82)90139-7; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BANNON GA, 1983, NUCLEIC ACIDS RES, V11, P3903, DOI 10.1093/nar/11.12.3903; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CHICOINE LG, 1985, DEV BIOL, V109, P1, DOI 10.1016/0012-1606(85)90339-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; DASSO M, 1994, P NATL ACAD SCI USA, V91, P12477, DOI 10.1073/pnas.91.26.12477; ELLIOTT AM, 1963, CELL MITOSIS, P107; GAERTIG J, 1994, P NATL ACAD SCI USA, V91, P4549, DOI 10.1073/pnas.91.10.4549; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG J, 1992, P NATL ACAD SCI USA, V89, P9196, DOI 10.1073/pnas.89.19.9196; GARRARD WT, 1991, BIOESSAYS, V13, P87, DOI 10.1002/bies.950130208; GLOVER CVC, 1981, CELL, V23, P73, DOI 10.1016/0092-8674(81)90271-3; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; Gorovsky M.A., 1986, P227; GOROVSKY MA, 1974, J CELL BIOL, V61, P134, DOI 10.1083/jcb.61.1.134; GOROVSKY MA, 1973, J PROTOZOOL, V20, P19, DOI 10.1111/j.1550-7408.1973.tb05995.x; GOROVSKY MA, 1980, ANNU REV GENET, V14, P203, DOI 10.1146/annurev.ge.14.120180.001223; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAYASHI T, 1987, J BIOCHEM-TOKYO, V102, P369, DOI 10.1093/oxfordjournals.jbchem.a122063; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOHMANN P, 1983, MOL CELL BIOCHEM, V57, P81; IWAMURA Y, 1979, BIOCHEMISTRY-US, V18, P5289, DOI 10.1021/bi00591a004; JOHMANN CA, 1976, J CELL BIOL, V71, P89, DOI 10.1083/jcb.71.1.89; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KAHN RW, 1993, P NATL ACAD SCI USA, V90, P9295, DOI 10.1073/pnas.90.20.9295; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; Maniatis T., 1982, MOL CLONING; Nanney D.L., 1980, EXPT CILIATOLOGY; NER S S, 1992, Current Biology, V2, P208, DOI 10.1016/0960-9822(92)90541-H; NER SS, 1994, EMBO J, V13, P1817, DOI 10.1002/j.1460-2075.1994.tb06450.x; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; Orias E., 1986, P45; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROTH SY, 1991, EMBO J, V10, P2069, DOI 10.1002/j.1460-2075.1991.tb07738.x; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; SWEET MT, 1993, CHROMOSOMA, V102, P637, DOI 10.1007/BF00352312; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P180, DOI 10.1093/nar/22.2.180; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P174, DOI 10.1093/nar/22.2.174; THOMA F, 1979, J CELL BIOL, V83, P407; TONDRAVI MM, 1986, P NATL ACAD SCI USA, V83, P4369, DOI 10.1073/pnas.83.12.4369; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; van Holde KE., 1989, SPRINGER SERIES MOL; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WHITE EM, 1988, NUCLEIC ACIDS RES, V16, P179, DOI 10.1093/nar/16.1.179; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; WU M, 1988, P NATL ACAD SCI USA, V85, P2205, DOI 10.1073/pnas.85.7.2205; WU M, 1994, MOL CELL BIOL, V14, P10, DOI 10.1128/MCB.14.1.10; WU M, 1986, P NATL ACAD SCI USA, V83, P8674, DOI 10.1073/pnas.83.22.8674; WU M, 1989, THESIS U ROCHESTER R; YAO MC, 1991, P NATL ACAD SCI USA, V88, P9493, DOI 10.1073/pnas.88.21.9493; ZLATANOVA J, 1992, J CELL SCI, V103, P889	63	247	256	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					47	56		10.1016/0092-8674(95)90051-9	http://dx.doi.org/10.1016/0092-8674(95)90051-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606784	Bronze			2022-12-28	WOS:A1995RK42400008
J	MASTERS, GA; GOLOMB, HM				MASTERS, GA; GOLOMB, HM			MANAGEMENT OF PULMONARY METASTASES	LANCET			English	Editorial Material							SARCOMA; LUNG				MASTERS, GA (corresponding author), UNIV CHICAGO,MED CTR,CHEST ONCOL PROGRAM,CHICAGO,IL 60637, USA.							CASSON AG, 1992, CANCER, V69, P662, DOI 10.1002/1097-0142(19920201)69:3<662::AID-CNCR2820690311>3.0.CO;2-I; CROW J, 1981, CANCER, V47, P2595, DOI 10.1002/1097-0142(19810601)47:11<2595::AID-CNCR2820471114>3.0.CO;2-Q; GIRARD P, 1994, AM J RESP CRIT CARE, V149, P469, DOI 10.1164/ajrccm.149.2.8306048; GIRARD P, 1994, CANCER, V74, P2791, DOI 10.1002/1097-0142(19941115)74:10<2791::AID-CNCR2820741008>3.0.CO;2-Q; HARPOLE DH, 1992, J THORAC CARDIOV SUR, V103, P743; HELLMAN S, 1995, J CLIN ONCOL, V113, P8; MATTHAY RA, 1993, AM REV RESPIR DIS, V148, P1691, DOI 10.1164/ajrccm/148.6_Pt_1.1691; MENTZER SJ, 1993, J SURG ONCOL, V53, P54, DOI 10.1002/jso.2930530114; MOUNTAIN CF, 1984, ANN THORAC SURG, V38, P323, DOI 10.1016/S0003-4975(10)62280-1; TODD TR, 1993, CHEST, V103, pS401, DOI 10.1378/chest.103.4_Supplement.401S	10	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					68	68		10.1016/S0140-6736(95)92109-5	http://dx.doi.org/10.1016/S0140-6736(95)92109-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603214				2022-12-28	WOS:A1995RH22000007
J	DENT, P; JELINEK, T; MORRISON, DK; WEBER, MJ; STURGILL, TW				DENT, P; JELINEK, T; MORRISON, DK; WEBER, MJ; STURGILL, TW			REVERSAL OF RAF-1 ACTIVATION BY PURIFIED AND MEMBRANE-ASSOCIATED PROTEIN PHOSPHATASES	SCIENCE			English	Article							KINASE-ACTIVITY; PHOSPHORYLATION; CELLS; MECHANISM	The Raf-1 protein kinase participates in transduction of mitogenic signals, but its mechanisms of activation are incompletely understood. Treatment of human Raf-1 purified from insect Sf9 cells co-expressing c-H-Ras and Src(Y527F) (in which phenylalanine replaces tyrosine at residue 527) with either serine-threonine or tyrosine phosphatases resulted in enzymatic inactivation of Raf-1. Inactivation of purified Raf-1 was blocked by addition of either the 14-3-3 zeta protein or heat shock protein 90, Loading of plasma membranes from transformed cells with guanosine triphosphate (GTP) resulted in inactivation of endogenous or exogenous Raf-1; inactivation was blocked by inclusion of protein phosphatase inhibitors. These results suggest the existence of protein phosphatases in the cell membrane that are regulated by GTP and are responsible for Raf-1 inactivation.	UNIV VIRGINIA,HOWARD HUGHES MED INST,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,MARKEY CTR CELL SIGNALING,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,MARKEY CTR CELL SIGNALING,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS INC,BASIC RES PROGRAM,FREDERICK,MD 21702	Howard Hughes Medical Institute; University of Virginia; University of Virginia; University of Virginia; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-46000] Funding Source: Medline; NIDDK NIH HHS [DK41077] Funding Source: Medline; NIGMS NIH HHS [GM47322] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALLOU LM, 1986, ENZYMES, V27, P311; BARFORD D, 1994, J MOL BIOL, V239, P726, DOI 10.1006/jmbi.1994.1409; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRAUTIGAN DL, 1989, ARCH BIOCHEM BIOPHYS, V275, P44, DOI 10.1016/0003-9861(89)90348-2; CHEN FS, 1994, FEBS LETT, V347, P128, DOI 10.1016/0014-5793(94)00520-6; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; DENT P, UNPUB; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; HALL A, 1986, J BIOL CHEM, V261, P963; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JELINEK T, UNPUB; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MORRISON D, UNPUB; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; USUI H, 1983, J BIOL CHEM, V258, P455; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421	39	187	190	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1902	1906		10.1126/science.7604263	http://dx.doi.org/10.1126/science.7604263			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604263				2022-12-28	WOS:A1995RF99000039
J	DAVIS, AP; WITTE, DP; HSIEHLI, HM; POTTER, SS; CAPECCHI, MR				DAVIS, AP; WITTE, DP; HSIEHLI, HM; POTTER, SS; CAPECCHI, MR			ABSENCE OF RADIUS AND ULNA IN MICE LACKING HOXA-11 AND HOXD-11	NATURE			English	Article							VERTEBRATE LIMB; HOMEOTIC TRANSFORMATIONS; PATTERN-FORMATION; HOX-4 GENES; EXPRESSION; EVOLUTION	MICE with targeted disruptions(1) in Hox genes have been generated to evaluate the role of the Hox complex in determining the mammalian body plan. This complex of 38 genes encodes transcription factors that specify regional information along the embryonic axes. Early in vertebrate evolution an ancestral complex shared with invertebrates was duplicated twice to give rise to the four linkage groups (Hox A, B, C and D)(2,3). As a consequence, corresponding genes on the separate linkage groups, called paralogues, are most closely related to each other. Based on sequence similarities, the Hox genes have been subdivided into 13 paralogous groups. The five most 5' groups (Hox 9-13) pattern the posterior region of the vertebrate embryo and the appendicular skeleton(4-18). Mice with individual mutations in the paralogous genes hoxa-11 and hoxd-11 have been described(15-18). By breeding these two strains together we have generated double mutants which have dramatic phenotypes not apparent in mice homozygous for the individual mutations. The radius and the ulna of the forelimb are almost entirely eliminated, the axial skeleton shows homeotic transformations, and there are severe kidney defects not present in either single mutant. The limb and axial phenotypes are quantitative: as more mutant alleles are added to the genotype, the phenotype becomes progressively more severe. The appendicular skeleton defects suggest that paralogous Hox genes function together to specify limb outgrowth and patterning along the proximodistal axis.	UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,CHILDRENS HOSP RES FDN,DIV BASIC SCI RES & PATHOL,CINCINNATI,OH 45229	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati								CAPECCHI MR, 1994, SCI AM, V270, P54; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; CONDIE BG, 1994, NATURE, V370, P304, DOI 10.1038/370304a0; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; DUBOULE D, 1994, SCIENCE, V268, P575; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FAVIER B, 1994, P NATL ACAD SCI USA, V92, P310; HAACK H, 1993, DEV BIOL, V157, P410, DOI 10.1006/dbio.1993.1145; HOLLAND PWH, 1994, DEVELOPMENT, P125; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; LI HMH, 1995, DEVELOPMENT, V121, P1373; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OSTER GF, 1988, EVOLUTION, V42, P862, DOI 10.1111/j.1558-5646.1988.tb02508.x; PETERSON RL, 1994, MECH DEVELOP, V47, P253, DOI 10.1016/0925-4773(94)90043-4; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; RUDDLE FH, 1994, ANNU REV GENET, V28, P423, DOI 10.1146/annurev.ge.28.120194.002231; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	29	478	490	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					791	795		10.1038/375791a0	http://dx.doi.org/10.1038/375791a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596412				2022-12-28	WOS:A1995RF98900079
J	WEISSMAN, JS; HOHL, CM; KOVALENKO, O; KASHI, Y; CHEN, SX; BRAIG, K; SAIBIL, HR; FENTON, WA; HORWICH, AL				WEISSMAN, JS; HOHL, CM; KOVALENKO, O; KASHI, Y; CHEN, SX; BRAIG, K; SAIBIL, HR; FENTON, WA; HORWICH, AL			MECHANISM OF GROEL ACTION - PRODUCTIVE RELEASE OF POLYPEPTIDE FROM A SEQUESTERED POSITION UNDER GROES	CELL			English	Article							ESCHERICHIA-COLI; ORNITHINE TRANSCARBAMYLASE; MOLECULAR CHAPERONE; CENTRAL CAVITY; COOPERATIVITY; HYDROLYSIS; SURFACE; BINDING; CYCLE	The chaperonin GroEL is a large, double-ring structure that, together with ATP and the cochaperonin GroES, assists protein folding in vivo. GroES forms an asymmetric complex with GroEL in which a single GroES ring binds one end of the GroEL cylinder. Cross-linking studies reveal that polypeptide binding occurs exclusively to the GroEL ring not occupied by GroES (trans). During the folding reaction, however, released GroES can rebind to the GroEL ring containing polypeptide (cis). The polypeptide is held tightly in a proteolytically protected environment in cis complexes, in the presence of ADP. Single turnover experiments with ornithine transcarbamylase reveal that polypeptide is productively released from the cis but not the trans complex. These observations suggest a two-step mechanism for GroEL-mediated folding. First, GroES displaces the polypeptide from its initial binding sites, sequestering it in the GroEL central cavity. Second, ATP hydrolysis induces release of GroES and productive release of polypeptide.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,LONDON WC1E 7HX,ENGLAND	Howard Hughes Medical Institute; Yale University; University of London; Birkbeck University London	WEISSMAN, JS (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510, USA.		Kashi, Yechezkel/D-5433-2013					AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRIMM R, 1993, J BIOL CHEM, V268, P5220; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SCHMIDT M, 1994, J BIOL CHEM, V14, P10304; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	43	372	376	0	19	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					577	587		10.1016/0092-8674(95)90098-5	http://dx.doi.org/10.1016/0092-8674(95)90098-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585961	hybrid			2022-12-28	WOS:A1995TF24800011
J	NORCINI, JJ; BLANK, LL; ARNOLD, GK; KIMBALL, HR				NORCINI, JJ; BLANK, LL; ARNOLD, GK; KIMBALL, HR			THE MINI-CEX (CLINICAL-EVALUATION EXERCISE) - A PRELIMINARY INVESTIGATION	ANNALS OF INTERNAL MEDICINE			English	Article							RESIDENTS; CERTIFICATION; COMPETENCE	Objective: To gather preliminary data on the mini-CEX (clinical evaluation exercise), a device for assessing the clinical skills of residents. Design: Evaluation of residents by faculty members using the mini-CEX. Setting: 5 internal medicine training programs in Pennsylvania. Participants: 388 mini-CEX encounters involving 88 residents and 97 evaluators. Measurements: A mini-CEX encounter consists of a single faculty member observing a resident while that resident conducts a focused history and physical examination in any of several settings. After asking the resident for a diagnosis and treatment plan, the faculty member rates the resident and provides educational feedback. The encounters are intended to be short (about 20 minutes) and to occur as a routine part of training so that each resident can be evaluated on several occasions by different faculty members. Results: The encounters occurred in both inpatient and ambulatory settings and were longer than anticipated (median duration, 25 minutes). Residents saw either new or follow-up patients who collectively presented with a broad range of clinical problems. The median evaluator assessed two residents and was generally satisfied with the mini-CEX format; residents were even more satisfied with the format. The reproducibility of the mini-CEX is higher than that of the traditional CEX, and its measurement characteristics are similar to those of other test formats, such as standardized patients and standardized oral examinations. Conclusions: The mini-CEX assesses residents in a much broader range of clinical situations than the traditional CEX, has better reproducibility, and offers residents greater opportunity for observation and feedback by more than one faculty member and with more than one patient. On the other hand, the mini-CEX may be more difficult to administer because multiple encounters must be scheduled for each resident. Exclusive use of the mini-CEX also prevents residents from being observed while doing a complete history and physical examination. Given the promising results and measurement characteristics of the mini-CEX, however, the American Board of Internal Medicine encourages the use of this method in conjunction with or as an alternative to the traditional CEX.			NORCINI, JJ (corresponding author), AMER BOARD INTERNAL MED, 3624 MARKET ST, 2ND FLOOR, PHILADELPHIA, PA 19104 USA.			Norcini, John/0000-0002-8464-4115				BRENNAN RL, 1983, ELEMENTS GENERALIZAB; Crocker L, 1986, INTRO CLASSICAL MODE; DAY SC, 1990, J GEN INTERN MED, V5, P421, DOI 10.1007/BF02599432; Elstein AS, 1978, MED PROBLEM SOLVING; KROBOTH FJ, 1992, J GEN INTERN MED, V7, P174, DOI 10.1007/BF02598008; MAATSCH JL, 1986, NEWER DEV ASSESSING; NOEL GL, 1992, ANN INTERN MED, V117, P757, DOI 10.7326/0003-4819-117-9-757; NORCINI JJ, 1987, J MED EDUC, V62, P457; Shavelson, 1994, APPL MEAS EDUC, V7, P323, DOI [10.1207/s15324818ame0704_4, DOI 10.1207/S15324818AME0704_4]; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; WOOLLISCROFT JO, 1984, J MED EDUC, V59, P799; 1994, GUIDE EVALUATION RES	12	309	333	4	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1995	123	10					795	799		10.7326/0003-4819-123-10-199511150-00008	http://dx.doi.org/10.7326/0003-4819-123-10-199511150-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE172	7574198				2022-12-28	WOS:A1995TE17200008
J	DROSSMAN, DA				DROSSMAN, DA			DIAGNOSING AND TREATING PATIENTS WITH REFRACTORY FUNCTIONAL GASTROINTESTINAL DISORDERS	ANNALS OF INTERNAL MEDICINE			English	Article							IRRITABLE-BOWEL-SYNDROME; PSYCHOLOGICAL TREATMENT; CONTROLLED TRIAL; PERSONALITY-DISORDER; DYSPEPSIA SUBGROUPS; CHRONIC PAIN; HYPNOTHERAPY; MANAGEMENT; PSYCHOTHERAPY; PREVALENCE	One of the clinician's most difficult tasks is to successfully care for patients with painful and refractory functional gastrointestinal disorders. Because the diagnosis of these disorders is never assured and symptomatic treatments are not always successful, these patients are susceptible to receiving unnecessary, costly, and sometimes risky studies and treatments. This article offers an approach to the diagnosis and care of these patients that emphasizes 1) using a diagnostic strategy that incorporates symptom-based criteria, a screening evaluation, early symptomatic treatment, symptom monitoring, and reassessment; 2) asking several questions during the first visit to assess the psychosocial contributions to the illness; 3) developing an effective patient-physician relationship through empathy, reassurance, education, and a negotiated and realistic treatment plan; and 4) providing the option for psychological consultation and treatment as a way to help the patient better control symptoms. This approach is likely to improve patient and physician satisfaction, adherence to treatment, and clinical outcome.			DROSSMAN, DA (corresponding author), UNIV N CAROLINA, SCH MED, DIV DIGEST DIS, CB 7080, 420 BURNETT WOMACK BLDG, CHAPEL HILL, NC 27599 USA.							[Anonymous], 1992, GASTROENTEROL INT; BECKMAN LF, 1979, AM J EPIDEMIOL, V109, P186; BENNETT P, 1985, BRIT J CLIN PSYCHOL, V24, P215, DOI 10.1111/j.2044-8260.1985.tb01340.x; Benson H., 1975, RELAXATION RESPONSE; Bernstein D.A., 1973, PROGR RELAXATION TRA; BLACKWELL B, 1986, ILLNESS BEHAVIOUR MU, P401; BLANCHARD EB, 1992, BEHAV RES THER, V30, P175, DOI 10.1016/0005-7967(92)90141-3; BLANCHARD EB, 1993, BIOFEEDBACK SELF-REG, V18, P125, DOI 10.1007/BF00999789; CAMILLERI M, 1992, ANN INTERN MED, V116, P1001, DOI 10.7326/0003-4819-116-12-1001; Cohen S., 1985, SOCIAL SUPPORT HLTH, P3; COONS PM, 1988, J NERV MENT DIS, V176, P519, DOI 10.1097/00005053-198809000-00001; CORAZZIARI F, 1993, GASTROENTEROLOGY INT, V6, P129; DEVAUL RA, 1978, AM J SURG, V135, P828, DOI 10.1016/0002-9610(78)90176-9; Drossman D., 1990, GASTR INT, V3, P159; DROSSMAN DA, 1982, AM J PSYCHIAT, V139, P1549; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DROSSMAN DA, 1994, AM J MED, V97, P105, DOI 10.1016/0002-9343(94)90019-1; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; DROSSMAN DA, 1978, ANN INTERN MED, V88, P366, DOI 10.7326/0003-4819-88-3-366; DROSSMAN DA, 1992, ANN INTERN MED, V116, P1009, DOI 10.7326/0003-4819-116-12-1009; DROSSMAN DA, 1994, AM J GASTROENTEROL, V89, P1441; DROSSMAN DA, 1995, TXB GASTROENTEROLOGY, P620; DROSSMAN DA, 1995, IN PRESS ANN INTERN, P123; Drossman DA, 1994, FUNCTIONAL GASTROINT; DROSSMAN DA, 1994, DIFFICULT DECISIONS, P405; Drossman DA, 1994, FUNCTIONAL GASTROINT, P1; DROSSMAN DA, 1993, BASIC CLIN ASPECTS C, P271; DROSSMAN DA, 1993, GASTROINTESTINAL DIS, P3; ENGEL GL, 1959, AM J MED, V26, P899, DOI 10.1016/0002-9343(59)90212-8; GREENE B, 1994, J CONSULT CLIN PSYCH, V62, P576, DOI 10.1037/0022-006X.62.3.576; GRICHNIK KP, 1991, MT SINAI J MED, V58, P217; GUTHRIE E, 1993, BRIT J PSYCHIAT, V163, P315, DOI 10.1192/bjp.163.3.315; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; GUTHRIE EA, 1992, GUT, V33, P361, DOI 10.1136/gut.33.3.361; HARVEY RF, 1989, LANCET, V1, P424; HARVEY RF, 1987, LANCET, V1, P963; HOLMES KM, 1982, BRIT MED J, V285, P1533, DOI 10.1136/bmj.285.6354.1533; Jacobsen E., 1938, PROGR RELAXATION; KELLNER R, 1994, PSYCHOTHER PSYCHOSOM, V61, P4, DOI 10.1159/000288868; KLEIN KB, 1991, TXB GASTROENTEROLOGY, P660; Lazarus RS., 1984, STRESS APPRAISAL COP; LONGSTRETH GF, 1993, DIGEST DIS SCI, V38, P1581, DOI 10.1007/BF01303163; LOWMAN BC, 1987, J CLIN GASTROENTEROL, V9, P324, DOI 10.1097/00004836-198706000-00017; LYDIARD RB, 1994, AM J PSYCHIAT, V151, P64; LYNCH PM, 1989, BEHAV THER, V20, P509, DOI 10.1016/S0005-7894(89)80130-3; LYNN RB, 1993, NEW ENGL J MED, V329, P1940, DOI 10.1056/NEJM199312233292608; MALONE MD, 1988, PAIN, V34, P231, DOI 10.1016/0304-3959(88)90118-2; MECHANIC D, 1962, J CHRON DIS, V15, P189, DOI 10.1016/0021-9681(62)90068-1; MILHOLLAND AV, 1973, NEW ENGL J MED, V288, P1272, DOI 10.1056/NEJM197306142882405; Minuchin S., 1978, PSYCHOSOMATIC FAMILI; MITCHELL CM, 1987, GASTROENTEROLOGY, V92, P1282, DOI 10.1016/S0016-5085(87)91099-7; NEFF DF, 1987, BEHAV THER, V18, P70, DOI 10.1016/S0005-7894(87)80052-7; NELSON JB, 1989, GASTROENTEROL CLIN N, V18, P195; PAYNE A, 1995, IN PRESS J CONSULT C; POYNARD T, 1994, ALIMENT PHARM THERAP, V8, P499; PRIOR A, 1990, GUT, V31, P896, DOI 10.1136/gut.31.8.896; Richter J E, 1991, Gastroenterology, V101, P866; RICHTER JE, 1989, ANN INTERN MED, V110, P66, DOI 10.7326/0003-4819-110-1-66; RICHTER JE, 1992, GASTROENTEROL INT, V5, P3; RUMSEY N, 1991, CURRENT APPROACHES C; SALKOVSKIS P, 1992, ANONYMOUS MED SYMPTO, P70; SANSONE RA, 1991, AM FAM PHYSICIAN, V44, P194; SCARINCI IC, 1994, AM J MED, V97, P108, DOI 10.1016/0002-9343(94)90020-5; SCHLESINGER RD, 1989, SOUTHERN MED J, V82, P210, DOI 10.1097/00007611-198902000-00016; Schultz J. H., 1969, AUTOGENIC THERAPY; SCHUMAKER HRJ, 1988, PRIMER RHEUMATIC DIS; SHARPE M, 1992, J PSYCHOSOM RES, V36, P515, DOI 10.1016/0022-3999(92)90037-3; SHIMBERG EF, 1988, RELIEF IBS IRRITABLE, P1; SVEDLUND J, 1983, LANCET, V2, P589; SVENDSEN JH, 1985, SCAND J GASTROENTERO, V20, P415, DOI 10.3109/00365528509089673; Talley N, 1991, GASTROENTEROL INT, V4, P145; TALLEY NJ, 1992, GASTROENTEROLOGY, V102, P1259; TALLEY NJ, 1993, GASTROENTEROLOGY, V105, P1378, DOI 10.1016/0016-5085(93)90142-Y; TALLEY NJ, 1995, AM J GASTROENTEROL, V90, P366; TALLEY NJ, 1994, FUNCTIONAL GASTROINT, P71; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; Thomson WG, 1994, FUNCTIONAL GASTROINT, P115; TONER BB, 1992, INT J PSYCHIAT MED, V22, P99, DOI 10.2190/ENP4-2PDW-A83P-PPA3; TONER BB, 1990, PSYCHOSOM MED, V52, P149, DOI 10.1097/00006842-199003000-00003; TONER BB, 1990, CAN J PSYCHIAT, V35, P158, DOI 10.1177/070674379003500210; VANOUTRYVE M, 1991, J CLIN GASTROENTEROL, V13, P49; VOIROL MW, 1987, SCHWEIZ MED WSCHR, V117, P1117; WALD A, 1991, TXB GASTROENTEROLOGY, P779; WALKER EA, 1990, AM J PSYCHIAT, V147, P565; Whitehead W. E., 1991, GASTROENTEROLOGY INT, V4, P99; WHITEHEAD WE, 1994, PSYCHOSOM MED, V56, P541, DOI 10.1097/00006842-199411000-00010; WHITEHEAD WE, 1982, DIGEST DIS SCI, V27, P202, DOI 10.1007/BF01296915; WHITEHEAD WE, 1990, SEMIN GASTROINTEST D, V1, P74; Whitehead WE, 1992, GASTROENTEROL INT, V5, P92; WHITEHEAD WE, 1994, AM J GASTROENTEROL, V89, P1700; WHORWELL PJ, 1987, GUT, V28, P423, DOI 10.1136/gut.28.4.423; WHORWELL PJ, 1984, LANCET, V2, P1232, DOI 10.1016/S0140-6736(84)92793-4; WHORWELL PJ, 1992, LANCET, V340, P69, DOI 10.1016/0140-6736(92)90394-I; WILKIE A, 1994, BRIT J HOSP MED, V51, P421; WOOD SF, 1993, SCAND J GASTROENTERO, V28, P5, DOI 10.3109/00365529309098322; ZINN W, 1993, ARCH INTERN MED, V153, P306, DOI 10.1001/archinte.153.3.306; 1994, DIAGNOSTIC STATISTIC	98	71	79	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					688	697		10.7326/0003-4819-123-9-199511010-00008	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TA696	7574225				2022-12-28	WOS:A1995TA69600008
J	GORE, SM; BIRD, AG; ROSS, AJ				GORE, SM; BIRD, AG; ROSS, AJ			PRISON RITES - STARTING TO INJECT INSIDE	BRITISH MEDICAL JOURNAL			English	Article									CHURCHILL HOSP,DEPT IMMUNOL,OXFORD OX3 7LJ,ENGLAND; BIAS,MRC,CTR HIV RES,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND	University of Oxford; University of Edinburgh	GORE, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							BIRD AG, 1994, AIDS, V8, P1345, DOI 10.1097/00002030-199409000-00021; BIRD AG, 1995, IN PRESS AIDS; GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293; STRANG J, 1989, BRIT MED J, V298, P1310, DOI 10.1136/bmj.298.6683.1310; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289	5	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 28	1995	311	7013					1135	1136		10.1136/bmj.311.7013.1135	http://dx.doi.org/10.1136/bmj.311.7013.1135			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580709	Green Published			2022-12-28	WOS:A1995TC46600018
J	SALONEN, JT; NYYSSONEN, K; TUOMAINEN, TP; MAENPAA, PH; KORPELA, H; KAPLAN, GA; LYNCH, J; HELMRICH, SP; SALONEN, R				SALONEN, JT; NYYSSONEN, K; TUOMAINEN, TP; MAENPAA, PH; KORPELA, H; KAPLAN, GA; LYNCH, J; HELMRICH, SP; SALONEN, R			INCREASED RISK OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS AT LOW PLASMA VITAMIN-E CONCENTRATIONS - A 4 YEAR FOLLOW-UP-STUDY IN MEN	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; EASTERN FINNISH MEN; RADICAL SCAVENGERS; SERUM; POPULATION; PREVALENCE	Objective-To investigate whether low vitamin E status is a risk factor for incident non-insulin dependent diabetes mellitus. Design-Population based follow up study with diabetes assessed at baseline and at four years. Setting-Eastern Finland. Subjects-Random sample of 944 men aged 42-60 who had no diabetes at the baseline examination. Intervention-Oral glucose tolerance test at four year follow up. Main outcome measures-A man was defined diabetic if he had either (a) a fasting blood glucose concentration greater than or equal to 6.7 mmol/l, or (b) a blood glucose concentration greater than or equal to 10.0 mmol/l two hours after a glucose load, or (c) a clinical diagnosis of diabetes with either dietary, oral, or insulin treatment. Results-45 men developed diabetes during the follow up period. In a multivariate logistic regression model including the strongest predictors of diabetes, a low lipid standardised plasma vitamin E (below median) concentration was associated with a 3.9-fold (95% confidence interval 1.8-fold to 8.6-fold) risk of incident diabetes. A decrement of 1 mu mol/l of uncategorised unstandardised vitamin E concentration was associated with an increment of 22% in the risk of diabetes when allowing for the strongest other risk factors as well as serum low density lipoprotein cholesterol and triglyceride concentrations. Conclusions-There was a strong independent association between low vitamin E status before follow up and an excess risk of diabetes at four years. This supports the theory that free radical stress has a role in the causation of non-insulin dependent diabetes mellitus.	UNIV KUOPIO,DEPT BIOCHEM & BIOTECHNOL,SF-70211 KUOPIO,FINLAND; UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,SF-70211 KUOPIO,FINLAND; CALIF DEPT HLTH SERV,HUMAN POPULAT LAB,BERKELEY,CA 94704	University of Eastern Finland; University of Eastern Finland; California Department of Health Care Services	SALONEN, JT (corresponding author), UNIV KUOPIO,PUBL HLTH RES INST,POB 1627,SF-70211 KUOPIO,FINLAND.		Kaplan, George/AAJ-2398-2020; Lynch, John W/A-4797-2008	Lynch, John W/0000-0003-2781-7902	NHLBI NIH HHS [HL44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CABALLERO B, 1993, NUTR REV, V51, P339, DOI 10.1111/j.1753-4887.1993.tb03761.x; COHEN G, 1983, AGING SERIES, V27, P307; DELEENHEER AP, 1979, J CHROMATOGR, V162, P408, DOI 10.1016/S0378-4347(00)81528-5; FLECHNER I, 1990, DIABETES RES CLIN EX, V13, P67; GALLOU G, 1993, CLIN CHIM ACTA, V214, P227, DOI 10.1016/0009-8981(93)90114-J; GEY KF, 1993, BRIT MED BULL, V49, P679, DOI 10.1093/oxfordjournals.bmb.a072640; GOLAY A, 1994, DIABETES METAB, V20, P3; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAYWARD AR, 1992, J LAB CLIN MED, V119, P503; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; KAUHANEN J, 1992, BEHAV MED, V18, P121, DOI 10.1080/08964289.1992.9936962; LAAKSO M, 1991, AM J EPIDEMIOL, V133, P850, DOI 10.1093/oxfordjournals.aje.a115965; LAKKA TA, 1992, INT J EPIDEMIOL, V21, P467, DOI 10.1093/ije/21.3.467; LOVEN DP, 1985, SUPEROXIDE DISMUTASE, V3; MURTHY VK, 1992, DIABETES RES CLIN PR, V18, P11, DOI 10.1016/0168-8227(92)90049-W; NISHIGAKI I, 1981, BIOCHEM MED METAB B, V25, P373, DOI 10.1016/0006-2944(81)90096-X; Norusis M.J., 1993, SPSS WINDOWS ADV STA, P1; OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; PACKER L, 1993, DIABETOLOGIA, V36, P1212, DOI 10.1007/BF00401070; PAOLISSO G, 1993, AM J CLIN NUTR, V57, P650, DOI 10.1093/ajcn/57.5.650; SALONEN JT, 1988, ATHEROSCLEROSIS, V70, P155, DOI 10.1016/0021-9150(88)90109-8; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SATO Y, 1979, BIOCHEM MED METAB B, V21, P104, DOI 10.1016/0006-2944(79)90061-9; SINCLAIR AJ, 1992, FREE RADICALS AGING, P342; TSAI EC, 1994, DIABETES, V43, P1010, DOI 10.2337/diabetes.43.8.1010; TUOMILEHTO J, 1991, INT J EPIDEMIOL, V20, P1010, DOI 10.1093/ije/20.4.1010; WOLFF SP, 1993, BRIT MED BULL, V49, P642, DOI 10.1093/oxfordjournals.bmb.a072637; 1989, RECOMMENDED DIETARY, P103; 1985, WHO TECH REP SER, V727	30	181	195	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 28	1995	311	7013					1124	1127		10.1136/bmj.311.7013.1124	http://dx.doi.org/10.1136/bmj.311.7013.1124			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580706	Green Published, Green Submitted			2022-12-28	WOS:A1995TC46600015
J	HWANG, J; TAMM, LK; BOHM, C; RAMALINGAM, TS; BETZIG, E; EDIDIN, M				HWANG, J; TAMM, LK; BOHM, C; RAMALINGAM, TS; BETZIG, E; EDIDIN, M			NANOSCALE COMPLEXITY OF PHOSPHOLIPID MONOLAYERS INVESTIGATED BY NEAR-FIELD SCANNING OPTICAL MICROSCOPY	SCIENCE			English	Article							LANGMUIR-BLODGETT-FILMS; ATOMIC-FORCE MICROSCOPY; DIMYRISTOYLPHOSPHATIDIC ACID; LIPID MONOLAYERS; INTERFACE; TRANSITIONS; RESOLUTION; DIFFUSION; BILAYERS; SYSTEM	Near-field scanning optical microscopy of phospholipid monolayers doped with fluorescent lipid analogs reveals previously undescribed features in various phases, including a concentration gradient at the liquid-expanded/liquid-condensed domain boundary and weblike structures in the solid-condensed phase. Presumably, the web structures are grain boundaries between crystalline solid lipid. These structures are strongly modulated by the addition of low concentrations of cholesterol and ganglioside G(M1) in the monolayer.	UNIV VIRGINIA,DEPT MOLEC PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908; AT&T BELL LABS,MURRAY HILL,NJ 07974	University of Virginia; AT&T; Nokia Corporation; Nokia Bell Labs	HWANG, J (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.				NIAID NIH HHS [AI14584, R37 AI030557, AI30557] Funding Source: Medline; NIDDK NIH HHS [DK44375] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030557, R01AI014584, R37AI030557, R37AI014584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044375] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BETZIG E, 1992, SCIENCE, V257, P189, DOI 10.1126/science.257.5067.189; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; BOHM C, 1993, BIOPHYS J, V64, P553, DOI 10.1016/S0006-3495(93)81386-9; CHI LF, 1993, SCIENCE, V259, P213, DOI 10.1126/science.259.5092.213; Fischer A., 1984, Journal de Physique Lettres, V45, P785, DOI 10.1051/jphyslet:019840045016078500; FISHER A, 1984, J PHYSIQUE, V45, P517; GARNAES J, 1992, NATURE, V357, P54, DOI 10.1038/357054a0; HECKL WM, 1988, LANGMUIR, V4, P1352, DOI 10.1021/la00084a026; HICKEL W, 1990, J APPL PHYS, V67, P3572, DOI 10.1063/1.345307; HINTERDORFER P, 1994, J BIOL CHEM, V269, P20360; HWANG JS, 1994, BIOPHYS J, V66, pA277; LEE KYC, 1994, SCIENCE, V263, P655, DOI 10.1126/science.8303272; LOSCHE M, 1983, BER BUNSEN PHYS CHEM, V87, P848, DOI 10.1002/bbpc.19830871004; MCCONNELL HM, 1991, ANNU REV PHYS CHEM, V42, P171, DOI 10.1146/annurev.physchem.42.1.171; MCCONNELL HM, 1984, P NATL ACAD SCI USA, V81, P3249, DOI 10.1073/pnas.81.10.3249; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; MIKRUT JM, 1993, PHYS REV B, V48, P14479, DOI 10.1103/PhysRevB.48.14479; MOERS MHP, 1994, LANGMUIR, V10, P2774, DOI 10.1021/la00020a044; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P441, DOI 10.1146/annurev.pc.41.100190.002301; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PETERS R, 1983, P NATL ACAD SCI-BIOL, V80, P7183, DOI 10.1073/pnas.80.23.7183; SEUL M, 1985, J PHYS CHEM-US, V89, P3592, DOI 10.1021/j100263a003; TAMM LK, 1988, BIOCHEMISTRY-US, V27, P1450, DOI 10.1021/bi00405a009; WEIS RM, 1984, NATURE, V310, P47, DOI 10.1038/310047a0; WEIS RM, 1985, J PHYS CHEM-US, V89, P4453, DOI 10.1021/j100267a011; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003; YANG J, 1993, J MICROSC-OXFORD, V171, P183, DOI 10.1111/j.1365-2818.1993.tb03375.x	27	135	135	0	27	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					610	614		10.1126/science.270.5236.610	http://dx.doi.org/10.1126/science.270.5236.610			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570018				2022-12-28	WOS:A1995TB55700032
J	TANAKA, E; SABRY, J				TANAKA, E; SABRY, J			MAKING THE CONNECTION - CYTOSKELETAL REARRANGEMENTS DURING GROWTH CONE GUIDANCE	CELL			English	Review							DYNAMIC INSTABILITY; ACTIN-FILAMENTS; MYOSIN-I; MICROTUBULES; ORGANIZATION; AXONS; ELONGATION; FILOPODIA; POLARITY; NEURONS		STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University	TANAKA, E (corresponding author), LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND.		Tanaka, Elly M/F-8572-2010					BAIER H, 1990, SCIENCE, V255, P472; BRAY D, 1985, J NEUROSCI, V5, P3204; BRAY D, 1978, P NATL ACAD SCI USA, V75, P5226, DOI 10.1073/pnas.75.10.5226; BURMEISTER DW, 1988, J NEUROSCI, V8, P3151; CHIEN CB, 1993, NEURON, V11, P237, DOI 10.1016/0896-6273(93)90181-P; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; DODD J, 1995, CELL, V81, P471, DOI 10.1016/0092-8674(95)90066-7; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GOLDBERG DJ, 1986, J CELL BIOL, V103, P1921, DOI 10.1083/jcb.103.5.1921; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; Grenningloh G, 1992, Curr Opin Neurobiol, V2, P42, DOI 10.1016/0959-4388(92)90160-M; HEIDEMANN SR, 1981, J CELL BIOL, V91, P661, DOI 10.1083/jcb.91.3.661; HILL TL, 1982, P NATL ACAD SCI-BIOL, V79, P490, DOI 10.1073/pnas.79.2.490; HOLT CE, 1989, J NEUROSCI, V9, P3123; HOLY TE, 1994, P NATL ACAD SCI USA, V91, P5682, DOI 10.1073/pnas.91.12.5682; Keynes Roger J., 1995, Current Opinion in Neurobiology, V5, P75, DOI 10.1016/0959-4388(95)80090-5; LAMOUREUX P, 1989, Nature (London), V340, P159, DOI 10.1038/340159a0; LETOURNEAU PC, 1975, DEV BIOL, V44, P92, DOI 10.1016/0012-1606(75)90379-6; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; LIN CH, 1993, J CELL BIOL, V121, P1369, DOI 10.1083/jcb.121.6.1369; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MARTENSON C, 1993, NATURE, V366, P66, DOI 10.1038/366066a0; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MYERS PZ, 1993, J NEUROSCI, V13, P127; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OCONNOR TP, 1993, J CELL BIOL, V123, P935, DOI 10.1083/jcb.123.4.935; OCONNOR TP, 1990, J NEUROSCI, V10, P3935, DOI 10.1523/JNEUROSCI.10-12-03935.1990; OLEARY DDM, 1988, NEURON, V1, P901, DOI 10.1016/0896-6273(88)90147-X; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; SABRY JH, 1991, J CELL BIOL, V115, P1381; SCHNAPP BJ, 1982, J CELL BIOL, V94, P667, DOI 10.1083/jcb.94.3.667; TANAKA E, 1995, J CELL BIOL, V128, P127, DOI 10.1083/jcb.128.1.127; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; VASILIEV JM, 1970, J EMBRYOL EXP MORPH, V24, P625; YAMADA KM, 1970, P NATL ACAD SCI USA, V66, P1206, DOI 10.1073/pnas.66.4.1206	45	299	302	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					171	176		10.1016/0092-8674(95)90158-2	http://dx.doi.org/10.1016/0092-8674(95)90158-2			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585934	Bronze			2022-12-28	WOS:A1995TA96500003
J	SMITH, J; CHANNER, KS				SMITH, J; CHANNER, KS			INCREASING PRESCRIPTION OF DRUGS FOR SECONDARY PREVENTION AFTER MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							TRIALS		ROYAL HALLAMSHIRE HOSP,DEPT CARDIOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield								ECCLES M, 1991, BMJ-BRIT MED J, V302, P91, DOI 10.1136/bmj.302.6768.91; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LAWSONMATTHEW PJ, 1994, J ROY COLL PHYS LOND, V28, P49; 1990, DRUG THER B, V28, P47	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					917	918						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580549				2022-12-28	WOS:A1995RZ23700020
J	DEMENOCAL, PB				DEMENOCAL, PB			PLIOPLEISTOCENE AFRICAN CLIMATE	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; EQUATORIAL ATLANTIC; TROPICAL ATLANTIC; LAST GLACIATION; NORTH-ATLANTIC; 2.4 MYR; DROUGHT; CIRCULATION; ETHIOPIA; SAHEL	Marine records of African climate variability document a shift toward more arid conditions after 2.8 million years ago (Ma), evidently resulting from remote forcing by cold North Atlantic sea-surface temperatures associated with the onset of Northern Hemisphere glacial cycles. African climate before 2.8 Ma was regulated by low-latitude insolation forcing of monsoonal climate due to Earth orbital precession. Major steps in the evolution of African hominids and other vertebrates are coincident with shifts to more arid, open conditions near 2.8 Ma, 1.7 Ma, and 1.0 Ma, suggesting that some Pliocene (Plio)-Pleistocene speciation events may have been climatically mediated.			DEMENOCAL, PB (corresponding author), LAMONT DOHERTY EARTH OBSERV,PALISADES,NY 10964, USA.		demenocal, peter/B-1386-2013	demenocal, peter/0000-0002-7191-717X				ASFAW B, 1992, NATURE, V362, P732; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; Blackman R.B., 1958, MEASUREMENT POWER SP, P1; BLOEMENDAL J, 1989, NATURE, V342, P897, DOI 10.1038/342897a0; BONNEFILLE R, 1983, NATURE, V303, P487, DOI 10.1038/303487a0; BONNEFILLE R, 1987, PALAEOGEOGR PALAEOCL, V60, P249, DOI 10.1016/0031-0182(87)90035-6; BONNEFILLE R, 1990, NATURE, V345, P347; BRAIN CK, 1981, ANN GEOL SOC S AFR, V84, P1; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; Brown F.H., 1992, QUATERN INT, V13-14, P55, DOI DOI 10.1016/1040-6182(92)90010-Y; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; CERLING TE, 1992, NATURE, V97, P241; Clark J.D., 1980, HUMAN ECOLOGY SAVANN, P41; CLEMENS SC, 1991, P OCEAN DRILLING PRO, V0117; DAVIES TD, 1985, J CLIMATOL, V5, P17, DOI 10.1002/joc.3370050103; DEMENOCAL PB, 1993, J GEOPHYS RES-ATMOS, V98, P7265, DOI 10.1029/92JD02924; DEMENOCAL PB, 1993, PALEOCEANOGRAPHY, V8, P209, DOI 10.1029/93PA02688; DEMENOCAL PB, IN PRESS PALEOCLIMAT; DRUYAN LM, 1989, INT J CLIMATOL, V9, P77, DOI 10.1002/joc.3370090107; DUPONT LM, 1989, ACTA BOT NEERL, V38, P405, DOI 10.1111/j.1438-8677.1989.tb01372.x; FEIBEL CS, 1989, AM J PHYS ANTHROPOL, V78, P595, DOI 10.1002/ajpa.1330780412; FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602a0; GASSE F, 1994, EARTH PLANET SC LETT, V126, P435, DOI 10.1016/0012-821X(94)90123-6; GASSE F, 1990, NATURE, V346, P141, DOI 10.1038/346141a0; GASSE F, 1989, NATURE, V342, P57, DOI 10.1038/342057a0; GRINE FE, 1986, S AFR J SCI, V82, P87; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; Hamilton A. C., 1982, ENV HIST E AFRICA; HARRIS JWK, 1983, AFRICAN ACHAEOLOGICA, P3; HASTENRATH S, 1985, CLIMATE CIRCULATION; Hilgen FJ, 1989, TERRA NOVA, V1, P409, DOI 10.1111/j.1365-3121.1989.tb00401.x; HILL A, 1992, NATURE, V355, P719, DOI 10.1038/355719a0; IMBRIE J, 1993, PALEOCEANOGRAPHY, V8, P699, DOI 10.1029/93PA02751; JANSEN E, 1991, NATURE, V349, P600, DOI 10.1038/349600a0; KIMBEL W, IN PRESS PALEOCLIMAT; KLEIN RG, 1988, EVOLUTION HIST ROBUS; LAMB PJ, 1978, MON WEATHER REV, V106, P482, DOI 10.1175/1520-0493(1978)106<0482:CSOTAS>2.0.CO;2; LEROY S, 1994, NATURE, V109, P295; McIntyre A, 1989, PALEOCEANOGRAPHY, V4, P19, DOI 10.1029/PA004i001p00019; MIDDLETON NJ, 1985, NATURE, V316, P431, DOI 10.1038/316431a0; MOLFINO B, 1990, SCIENCE, V249, P766, DOI 10.1126/science.249.4970.766; NAIR RR, 1989, NATURE, V338, P749, DOI 10.1038/338749a0; NEWELL RE, 1984, J CLIMATOL, V4, P27, DOI 10.1002/joc.3370040103; NICHOLSON SE, LIMNOLOGY CLIMATOLOG; POKRAS EM, 1985, QUATERNARY RES, V24, P137, DOI 10.1016/0033-5894(85)90001-8; PRELL WL, 1987, J GEOPHYS RES-ATMOS, V92, P8411, DOI 10.1029/JD092iD07p08411; PROSPERO JM, 1986, NATURE, V320, P735, DOI 10.1038/320735a0; PROSPERO JM, 1977, SCIENCE, V196, P1196, DOI 10.1126/science.196.4295.1196; Pye K., 1987, AEOLIAN DUST DUST DE; RAYMO ME, 1990, EARTH PLANET SC LETT, V97, P353, DOI 10.1016/0012-821X(90)90051-X; REA DK, 1994, REV GEOPHYS, V32, P159, DOI 10.1029/93RG03257; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; Rossignol-Strick M., 1983, NATURE, V303, P46; Ruddiman WF, 1989, PALEOCEANOGRAPHY, V4, P353, DOI 10.1029/PA004i004p00353; RUDDIMAN WF, 1989, P OCEAN DRILLING PRO, V0108; Sama-Wojcicki A. M., 1985, NATURE, V313, P306; SARNTHEIN M, 1981, NATURE, V293, P193, DOI 10.1038/293193a0; SCHRENK F, 1993, NATURE, V365, P833, DOI 10.1038/365833a0; SHACKLETON NJ, 1984, NATURE, V307, P620, DOI 10.1038/307620a0; SHACKLETON NJ, 1990, T ROY SOC EDIN-EARTH, V81, P251, DOI 10.1017/S0263593300020782; SHACKLETON NJ, IN PRESS P OCEAN DRI; SIROCKO F, 1991, QUATERNARY RES, V36, P72, DOI 10.1016/0033-5894(91)90018-Z; SIROCKO F, 1989, NATO ASI SER C-MATH, P401; STREETPERROTT FA, 1990, NATURE, V343, P607, DOI 10.1038/343607a0; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; VRBA ES, 1989, OSSA, V14, P127; VRBA ES, IN PRESS PALEOCLIMAT; WEBB R, 1994, EOS, V75, P381; WEBSTER PJ, 1978, QUATERNARY RES, V10, P279, DOI 10.1016/0033-5894(78)90024-8; WESSELMAN HB, 1985, S AFR J SCI, V81, P260; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; YEMANE K, 1985, NATURE, V318, P653, DOI 10.1038/318653a0; 1981, GEOL SOC AM MAP CHAR, V36; [No title captured]	76	841	877	7	142	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					53	59		10.1126/science.270.5233.53	http://dx.doi.org/10.1126/science.270.5233.53			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569951				2022-12-28	WOS:A1995RY30200030
J	HOLDEN, C				HOLDEN, C			CAREERS-95 - THE FUTURE OF THE PHD	SCIENCE			English	Article																			0	13	13	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					121	122		10.1126/science.270.5233.121	http://dx.doi.org/10.1126/science.270.5233.121			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569936				2022-12-28	WOS:A1995RY30200047
J	JOHNSON, CH; KNIGHT, MR; KONDO, T; MASSON, P; SEDBROOK, J; HALEY, A; TREWAVAS, A				JOHNSON, CH; KNIGHT, MR; KONDO, T; MASSON, P; SEDBROOK, J; HALEY, A; TREWAVAS, A			CIRCADIAN OSCILLATIONS OF CYTOSOLIC AND CHLOROPLASTIC FREE CALCIUM IN PLANTS	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; CYTOPLASMIC CALCIUM; GENE-EXPRESSION; PROTEIN-KINASE; TRANSFORMATION; PHYTOCHROME; ARABIDOPSIS; CHANNELS; CELLS; PROTOPLASTS	Tobacco and Arabidopsis plants, expressing a transgene for the calcium-sensitive luminescent protein apoaequorin, revealed circadian oscillations in free cytosolic calcium that can be phase-shifted by light-dark signals. When apoaequorin was targeted to the chloroplast, circadian chloroplast calcium rhythms were likewise observed after transfer of the seedlings to constant darkness. Circadian oscillations in free calcium concentrations can be expected to control many calcium-dependent enzymes and processes accounting for circadian outputs. Regulation of calcium flux is therefore fundamental to the organization of circadian systems.	UNIV OXFORD,DEPT PLANT SCI,OXFORD OX1 3RB,ENGLAND; NAGOYA UNIV,FAC SCI,DEPT BIOL,NAGOYA,AICHI 46401,JAPAN; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; UNIV EDINBURGH,INST CELL & MOLEC BIOL,EDINBURGH EH9 3JH,MIDLOTHIAN,SCOTLAND	University of Oxford; Nagoya University; University of Wisconsin System; University of Wisconsin Madison; University of Edinburgh	JOHNSON, CH (corresponding author), VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235, USA.		Johnson, Carl H/I-4655-2014	Knight, Marc/0000-0002-4830-8608	NIGMS NIH HHS [GM48053] Funding Source: Medline; NIMH NIH HHS [MH43836, MH01179] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043836, K02MH001179, R29MH043836] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMON DI, 1949, PLANT PHYSIOL, V24, P1; ANDERSON S, 1986, BIOCHEM J, V240, P709, DOI 10.1042/bj2400709; BRUSSLAN JA, 1992, P NATL ACAD SCI USA, V89, P7791, DOI 10.1073/pnas.89.16.7791; Campbell A.K, 1983, INTRACELLULAR CALCIU; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; Edmunds LN, 1988, CELLULAR MOL BASES B; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; GOMEZ LA, 1995, PHOTOCHEM PHOTOBIOL, V61, P210, DOI 10.1111/j.1751-1097.1995.tb03963.x; GOTO K, 1985, SCIENCE, V228, P1284, DOI 10.1126/science.2988128; GUESZ ME, 1994, NEUROSCI BIOBEHAV RE, V18, P555; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HETHERINGTON A, 1982, FEBS LETT, V145, P67, DOI 10.1016/0014-5793(82)81208-8; HORWITZ BA, 1978, PLANT SCI LETT, V13, P9, DOI 10.1016/0304-4211(78)90058-5; JOHANNES E, 1991, BIOESSAYS, V13, P331, DOI 10.1002/bies.950130704; Johnson Carl Hirschie, 1994, Seminars in Cell Biology, V5, P355, DOI 10.1006/scel.1994.1042; KIM HY, 1993, SCIENCE, V260, P960, DOI 10.1126/science.260.5110.960; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; KNIGHT MR, 1993, J CELL BIOL, V121, P83, DOI 10.1083/jcb.121.1.83; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; LI HM, 1991, PLANT PHYSIOL, V96, P720, DOI 10.1104/pp.96.3.720; LUMSDEN PJ, 1991, ANNU REV PLANT PHYS, V42, P351, DOI 10.1146/annurev.pp.42.060191.002031; MALHO R, 1993, PLANT J, V5, P331; MELKONIAN B, 1990, CURR T PL B, V9, P38; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1994, ANNU REV GENET, V28, P325, DOI 10.1146/annurev.ge.28.120194.001545; MILLER AJ, 1987, NATURE, V326, P397, DOI 10.1038/326397a0; MOURIOUX G, 1981, PLANT PHYSIOL, V67, P470, DOI 10.1104/pp.67.3.470; NAKASHIMA H, 1984, PLANT PHYSIOL, V74, P268, DOI 10.1104/pp.74.2.268; NEGRUTIU I, 1987, PLANT MOL BIOL, V8, P363, DOI 10.1007/BF00015814; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; OKAZAKI Y, 1990, J MEMBRANE BIOL, V114, P189, DOI 10.1007/BF01869213; PIERSON ES, 1994, PLANT CELL, V6, P1815, DOI 10.1105/tpc.6.12.1815; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; ROENNEBERG T, 1993, NATURE, V362, P362, DOI 10.1038/362362a0; Roux Stanley J., 1994, P187; SATTER RL, 1981, ANNU REV PLANT PHYS, V32, P83, DOI 10.1146/annurev.pp.32.060181.000503; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; SHACKLOCK PS, 1992, NATURE, V358, P753, DOI 10.1038/358753a0; SHEEN J, 1990, PLANT CELL, V2, P1027, DOI 10.1105/tpc.2.10.1027; SHIMOMURA O, 1993, BIOCHEM J, V296, P549, DOI 10.1042/bj2960549; Sweeney BM., 1987, RHYTHMIC PHENOMENA P; TSUKAYA H, 1991, PLANT PHYSIOL, V97, P1414, DOI 10.1104/pp.97.4.1414; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536	46	271	289	0	33	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1863	1865		10.1126/science.7569925	http://dx.doi.org/10.1126/science.7569925			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569925				2022-12-28	WOS:A1995RX19400035
J	MASON, JW; OCONNELL, JB; HERSKOWITZ, A; ROSE, NR; MCMANUS, BM; BILLINGHAM, ME; MOON, TE; COSTANZO, MR; GRADY, K; KANTROWITZ, NE; ZELDIS, SM; KANE, S; COGLIANESE, ME; TOMEO, C; BACON, K; MCLAUGHLIN, PR; LIU, P; ROSS, B; PALACIOS, IF; DEC, W; BLOCK, B; COCCASPOFFARD, D; YOUNG, JB; LEON, C; CASTA, R; KINGRY, C; STRICKMAN, NE; HARLAN, M; FOWLER, N; ENGEL, P; NUNN, N; DAS, SK; SUHY, P; KLINE, E; GILLES, AJ; FRENCH, WJ; SKINNER, A; UNVERFERTH, DV; SARLING, R; NEWTON, P; WOODINGSCOTT, M; UNTEREKER, WJ; POLL, D; HOFFMAN, K; FRANK, J; FOWLES, R; MILLAR, K; FREEDMAN, L; LYVER, S; LATHAM, R; PEEPLES, R; GOLDENBERG, IF; HUNN, D; ANDERSON, P; WEISS, MB; TRUELIEB, N; HOSENPUD, J; CONNER, R; BROWN, LJ; RAMANATHAN, KB; POUNDERS, C; MILLS, M; KANTOR, K; ABELMANN, WH; FLAHERTY, A; THORP, K; STRAIN, J; VIRZI, P; GRAYESKI, A; KELLY, A; HOBBS, RE; PELEGRIN, D; COHEN, M; HAWKINS, L; KOSTUK, WJ; KENNEDY, R; HAGER, WD; DOUGHERTY, J; RIBA, A; LARKIN, S; KEARNY, L; DAVIES, RA; DROUIN, K; MATSUMORI, A; GROSE, RM; LEVINE, B; URETSKY, BF; MURALI, S; BETSCHART, A; WILLIAMS, GA; MILLER, L; WITTRY, S; HAGAN, AD; DURHAM, J; SHABETAI, R; CREMO, R; MCMANUS, BM; SEARS, T; ARTEAGA, W				MASON, JW; OCONNELL, JB; HERSKOWITZ, A; ROSE, NR; MCMANUS, BM; BILLINGHAM, ME; MOON, TE; COSTANZO, MR; GRADY, K; KANTROWITZ, NE; ZELDIS, SM; KANE, S; COGLIANESE, ME; TOMEO, C; BACON, K; MCLAUGHLIN, PR; LIU, P; ROSS, B; PALACIOS, IF; DEC, W; BLOCK, B; COCCASPOFFARD, D; YOUNG, JB; LEON, C; CASTA, R; KINGRY, C; STRICKMAN, NE; HARLAN, M; FOWLER, N; ENGEL, P; NUNN, N; DAS, SK; SUHY, P; KLINE, E; GILLES, AJ; FRENCH, WJ; SKINNER, A; UNVERFERTH, DV; SARLING, R; NEWTON, P; WOODINGSCOTT, M; UNTEREKER, WJ; POLL, D; HOFFMAN, K; FRANK, J; FOWLES, R; MILLAR, K; FREEDMAN, L; LYVER, S; LATHAM, R; PEEPLES, R; GOLDENBERG, IF; HUNN, D; ANDERSON, P; WEISS, MB; TRUELIEB, N; HOSENPUD, J; CONNER, R; BROWN, LJ; RAMANATHAN, KB; POUNDERS, C; MILLS, M; KANTOR, K; ABELMANN, WH; FLAHERTY, A; THORP, K; STRAIN, J; VIRZI, P; GRAYESKI, A; KELLY, A; HOBBS, RE; PELEGRIN, D; COHEN, M; HAWKINS, L; KOSTUK, WJ; KENNEDY, R; HAGER, WD; DOUGHERTY, J; RIBA, A; LARKIN, S; KEARNY, L; DAVIES, RA; DROUIN, K; MATSUMORI, A; GROSE, RM; LEVINE, B; URETSKY, BF; MURALI, S; BETSCHART, A; WILLIAMS, GA; MILLER, L; WITTRY, S; HAGAN, AD; DURHAM, J; SHABETAI, R; CREMO, R; MCMANUS, BM; SEARS, T; ARTEAGA, W			A CLINICAL-TRIAL OF IMMUNOSUPPRESSIVE THERAPY FOR MYOCARDITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOMYOCARDIAL BIOPSY; ACTIVE MYOCARDITIS; HEART; CARDIOMYOPATHY	Background. Myocarditis is a serious disorder, and treatment options are limited, This trial was designed to determine whether immunosuppressive therapy improves left ventricular function in patients with myocarditis. Methods. We randomly assigned 111 patients with a histopathological diagnosis of myocarditis and a left ventricular ejection fraction of less than 0.45 to receive conventional therapy alone or combined with a 24-week regimen of immunosuppressive therapy, Immunosuppressive therapy consisted of prednisone with either cyclosporine or azathioprine, The primary outcome measure was a change in the left ventricular ejection fraction at 28 weeks. Results. In the group as a whole, the mean (+/-SE) left ventricular ejection fraction improved from 0.25+/-0.01 at base line to 0.34+/-0.02 at 28 weeks (P<0.001), The mean change in the left ventricular ejection fraction at 28 weeks did not differ significantly between the group of patients who received immunosuppressive therapy (a gain of 0.10; 95 percent confidence interval, 0.07 to 0.12) and the control group (a gain of 0.07; 95 percent confidence interval, 0.03 to 0.12), A higher left ventricular ejection fraction at base line, less intensive conventional drug therapy at base line, and a shorter duration df disease, but not the treatment assignment, were positive independent predictors of the left ventricular ejection fraction at week 28, There was no significant difference in survival between the two groups (P=0.96), The mortality rate for the entire group was 20 percent at 1 year and 56 percent at 4.3 years, features suggesting an effective inflammatory response were associated with less severe initial disease. Conclusions. Our results do not support routine treatment of myocarditis with immunosuppressive drugs. Ventricular function improved regardless of whether patients received immunosuppressive therapy, but long-term mortality was high.	UNIV MISSISSIPPI,DEPT MED,JACKSON,MS; JOHNS HOPKINS UNIV,DIV CARDIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,DEPT MOLEC MICROBIOL & IMMUNOL,BALTIMORE,MD; UNIV BRITISH COLUMBIA,DEPT PATHOL,VANCOUVER,BC,CANADA; STANFORD UNIV,DEPT PATHOL,STANFORD,CA; UNIV ARIZONA,DEPT FAMILY & COMMUNITY MED,TUCSON,AZ	University of Mississippi; Johns Hopkins University; Johns Hopkins University; University of British Columbia; Stanford University; University of Arizona	MASON, JW (corresponding author), UNIV UTAH,MED CTR,DIV CARDIOL,50 N MED DR,SALT LAKE CITY,UT 84132, USA.		Strickman, Neil/AFS-7515-2022		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034744] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NHLBI NIH HHS [R0-1-HL34744] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; ARETZ HT, 1993, CIRCULATION, V88, P552; Burek C. Lynne, 1995, P207; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; DEC GW, 1985, NEW ENGL J MED, V312, P885, DOI 10.1056/NEJM198504043121404; ENSLEY RD, 1994, J AM COLL CARDIOL, V24, P1769, DOI 10.1016/0735-1097(94)90186-4; HAHN EA, IN PRESS EUR HEART J; JONES SR, 1991, AM J CARDIOL, V68, P370, DOI 10.1016/0002-9149(91)90834-8; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; KISHIMOTO C, 1994, CIRCULATION, V89, P2836, DOI 10.1161/01.CIR.89.6.2836; LODGE PA, 1987, AM J PATHOL, V128, P455; MASON JW, 1980, AM J CARDIOL, V45, P1037, DOI 10.1016/0002-9149(80)90174-5; MASON JW, 1989, CIRCULATION, V79, P971, DOI 10.1161/01.CIR.79.5.971; MASON JW, 1978, AM J CARDIOL, V41, P887, DOI 10.1016/0002-9149(78)90729-4; MATSUMORI A, 1982, CIRCULATION, V66, P355, DOI 10.1161/01.CIR.66.2.355; MCMANUS BM, 1993, CLIN IMMUNOL IMMUNOP, V68, P159, DOI 10.1006/clin.1993.1113; MORTENSEN SA, 1985, INT J IMMUNOTHER, V1, P35; NEUMANN DA, 1994, J IMMUNOL, V152, P343; NEUMANN DA, 1990, J AM COLL CARDIOL, V16, P839; OCONNELL JB, 1990, STAT MED, V9, P193, DOI 10.1002/sim.4780090126; OCONNELL JB, 1989, WESTERN J MED, V150, P431; ROSE NR, 1992, ADV INTERNAL MED, V37, P411; WOODRUFF JF, 1980, AM J PATHOL, V101, P425; YAMADA T, 1994, CIRCULATION, V89, P846, DOI 10.1161/01.CIR.89.2.846; 1991, CIRCULATION S2, V84, P2; 1990, SAS STAT USERS GUIDE	26	817	848	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					269	275		10.1056/NEJM199508033330501	http://dx.doi.org/10.1056/NEJM199508033330501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL694	7596370	Bronze			2022-12-28	WOS:A1995RL69400001
J	NYLENNA, M				NYLENNA, M			NORWAY DECENTRALIZED, SINGLE-PAYER HEALTH SYSTEM FACES GREAT CHALLENGES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											NYLENNA, M (corresponding author), JOURNAL NORWEGIAN MED ASSOC,FJELLVEIEN 5,N-1324 LYSAKER,NORWAY.							BERG O, 1994, MED SOM PEDAGOGIKK S; BRODY BA, 1993, J MED PHILOS, V18, P437, DOI 10.1093/jmp/18.5.437; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P324, DOI 10.1001/jama.272.4.324; FUGELLI P, 1980, FAM MED, V21, P88; Fugelli P, 1989, FAM MED, V21, P150; GONZALEZ ML, 1994, SOCIOECONOMIC CHARAC; HOLM HA, 1993, J CONTIN EDUC HEALTH, V13, P77; NEW B, 1994, 18 KINGS FUND I RES; ROEMER M, 1991, NATIONAL HLTH SYSTEM, V1, P181; Saetnan A R, 1988, Int J Technol Assess Health Care, V4, P359; 1994, FRA MED KUNNSKAP BED; 1995, Q REPRT WAITING LIST; 1994, NATIONAL ACCOUNTS MA; 1993, FORHOLDET MELLOM PAS; 1994, STORTINGSMELDING, V50; 1988, RULES PROVISIONAL SY; 1994, STATISTICAL YB 1994; 1990, I4390 SOS DEP RUND S; 1994, INNSTILLING ARBEIDSG; 1994, 42 NORD MED COMM REP; 1993, OECD HLTH DATA VERSI	21	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					120	124		10.1001/jama.274.2.120	http://dx.doi.org/10.1001/jama.274.2.120			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7595992				2022-12-28	WOS:A1995RH22200009
J	BERTHOZ, A; ISRAEL, I; GEORGESFRANCOIS, P; GRASSO, R; TSUZUKU, T				BERTHOZ, A; ISRAEL, I; GEORGESFRANCOIS, P; GRASSO, R; TSUZUKU, T			SPATIAL MEMORY OF BODY LINEAR DISPLACEMENT - WHAT IS BEING STORED	SCIENCE			English	Article							GUIDED SACCADES; HUMANS; NAVIGATION; ROTATION; OTOLITHS	The ability to evaluate traveled distance is common to most animal species. Head trajectory in space is measured on the basis of the converging signals of the visual, vestibular, and somatosensory systems, together with efferent copies of motor commands. Recent evidence from human studies has shown that head trajectory in space can be stored in spatial memory. A fundamental question, however, remains unanswered: How is movement stored? In this study, humans who were asked to reproduce passive linear whole-body displacement distances while blindfolded were also able to reproduce velocity profiles. This finding suggests that a spatiotemporal dynamic pattern of motion is stored and can be retrieved with the use of vestibular and somesthetic cues.	COLL FRANCE, PHYSIOL PERCEPT & ACT LAB, CNRS, F-75006 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France								BERITOFF JS, 1965, NEURAL MECHANISMS HI, P107; BERTHOZ A, 1987, NEUROSCI LETT, V82, P285, DOI 10.1016/0304-3940(87)90270-9; Berthoz A, 1988, Adv Otorhinolaryngol, V41, P76; BLOOMBERG J, 1991, EXP BRAIN RES, V84, P47; BLOOMBERG J, 1988, ADV OTORHINOLARYNGOL, V40, P71; ETIENNE AS, 1986, ANIM BEHAV, V34, P696, DOI 10.1016/S0003-3472(86)80054-9; ETIENNE AS, 1988, BEHAVIOUR, V106, P81, DOI 10.1163/156853988X00106; GLASAUER S, 1994, EXP BRAIN RES, V98, P323; GUEDRY FE, 1963, LABYRINTHINE FUNCTIO; GUILFORD T, 1993, NATURE, V363, P112, DOI 10.1038/363112a0; ISRAEL I, 1993, J NEUROPHYSIOL, V70, P1270, DOI 10.1152/jn.1993.70.3.1270; ISRAEL I, 1989, J NEUROPHYSIOL, V62, P247, DOI 10.1152/jn.1989.62.1.247; ISRAEL I, 1992, ANN NY ACAD SCI, V656, P472, DOI 10.1111/j.1749-6632.1992.tb25229.x; ISRAEL I, 1995, ACTA OTO-LARYNGOL, V115, P3, DOI 10.3109/00016489509133338; ISRAEL I, 1991, NATO ADV SCI I D-BEH, V62, P599; ISRAEL I, 1993, EXP BRAIN RES, V96, P335; ISRAEL I, IN PRESS BRAIN; ISRAEL I, 1992, TUTORIALS MOTOR BEHA, V2, P195; LICHTENBERG BK, 1982, EXP BRAIN RES, V48, P127; MATTHEWS GVT, 1951, J EXP BIOL, V28, P508; MCCLOSKEY DI, 1981, HDB PHYSL NERVOUS SY, V2, P1391; MCNAUGHTON BL, 1991, J COGNITIVE NEUROSCI, V3, P192, DOI 10.1162/jocn.1991.3.2.190; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; METCALFE T, 1992, ANN NY ACAD SCI, V656, P695; MILLER S, 1983, PHYSIOL PSYCHOL, V11, P1; Mittelstaedt H., 1982, P290; MITTELSTAEDT ML, 1991, ZOOL JAHRB ALLG ZOOL, V95, P427; MITTELSTAEDT ML, 1980, NATURWISSENSCHAFTEN, V67, P566, DOI 10.1007/BF00450672; OMARA SM, 1994, J NEUROSCI, V14, P6511; PIERROTDESEILLIGNY C, 1993, EXP BRAIN RES, V95, P166; Potegal M, 1982, SPATIAL ABILITIES DE, P361; Poulton E.C., 1981, HDB PHYSL SECTION 1, V2, P1337; SHARP PE, 1995, J NEUROSCI, V15, P173; Shelhamer M, 1994, J Vestib Res, V4, P1; STEVENS SS, 1960, AM SCI, V48, P226; WIENER SI, 1989, J NEUROSCI, V9, P2737; Wiener SI, 1993, MULTISENSORY CONTROL, P427, DOI [10.1093/acprof:oso/9780198547853.003.0208, DOI 10.1093/ACPROF:OSO/9780198547853.003.0208]; Young L.R, 1984, HDB PHYSL NERVOUS SY, P978; YOUNG LR, 1968, AEROSPACE MED, V39, P606	39	179	181	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 7	1995	269	5220					95	98		10.1126/science.7604286	http://dx.doi.org/10.1126/science.7604286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604286				2022-12-28	WOS:A1995RG98000043
J	[Anonymous]				[Anonymous]			QUALITY-OF-LIFE AND CLINICAL-TRIALS	LANCET			English	Editorial Material							OF-LIFE; CANCER; ISSUES											[Anonymous], 1991, LANCET, V338, P350; BJORDAL K, 1994, INT J RADIAT ONCOL, V28, P847, DOI 10.1016/0360-3016(94)90104-X; BUCCHERI GF, 1989, CANCER, V63, P428, DOI 10.1002/1097-0142(19890201)63:3<428::AID-CNCR2820630305>3.0.CO;2-V; COATES A, 1993, EUR J CANCER, V29A, P1731, DOI 10.1016/0959-8049(93)90115-V; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GOODARE H, 1995, BMJ-BRIT MED J, V310, P1277, DOI 10.1136/bmj.310.6990.1277; GOTAY CC, 1992, J NATL CANCER I, V84, P575, DOI 10.1093/jnci/84.8.575; JOHNSON JR, 1985, CANCER TREAT REP, V69, P1155; KOOPMANS PP, 1995, BRIT MED J, V310, P1305, DOI 10.1136/bmj.310.6990.1305; Osoba D, 1992, Qual Life Res, V1, P211, DOI 10.1007/BF00635620; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; SLEVIN ML, 1992, BRIT MED J, V305, P466, DOI 10.1136/bmj.305.6851.466; VANDENBOS GAM, 1995, EUR J PUBLIC HEALTH, V5, P1; 1994, LANCET, V343, P1049; 1993, ADVICE APPLICANTS CL	16	94	95	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					1	2						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603136				2022-12-28	WOS:A1995RF98500001
J	SLOAN, VS; CAMERON, P; PORTER, G; GAMMON, M; AMAYA, M; MELLINS, E; ZALLER, DM				SLOAN, VS; CAMERON, P; PORTER, G; GAMMON, M; AMAYA, M; MELLINS, E; ZALLER, DM			MEDIATION BY HLA-DM OF DISSOCIATION OF PEPTIDES FROM HLA-DR	NATURE			English	Article							ANTIGEN-PROCESSING MUTANT; MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN PEPTIDES; CLASS-II MOLECULES; GENES; CELLS	HUMAN leukocyte antigen (HLA)-DM is an unconventional major histocompatibility complex (MHC) class II heterodimer that is important for B-cell-mediated antigen processing and presentation to MHC class II-restricted T cells(1-12). HLA-DM is encoded by two genes, DMA and DMB, which map to the MHC class II region(1), and shares some homology with MHC class I and class II proteins(2,3). Here we define the biochemical role of HLA-DM. Recombinant soluble HLA-DM heterodimers have been purified from culture supernatants of insect cell transformants. At pH 5.0, they induce the dissociation of a subset of peptides bound to HLA-DR, including a nested set of class-II-associated invariant chain peptides (CLIP). This process liberates HLA-DR and leads to the enhanced binding of exogenous peptides.	MERCK & CO INC,RES LABS,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065; MERCK & CO INC,RES LABS,DEPT AUTOIMMUNE DIS RES,RAHWAY,NJ 07065; MERCK & CO INC,RES LABS,DEPT MOLEC DESIGN & DIVERS,RAHWAY,NJ 07065; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104	Merck & Company; Merck & Company; Merck & Company; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia				Mellins, Elizabeth/0000-0003-2577-139X				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CEMAN S, 1992, J IMMUNOL, V149, P754; DENZIN LK, 1994, IMMUNITY, V2, P595; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MONJI T, 1994, J IMMUNOL, V153, P4468; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QUI Y, 1994, J CELL BIOL, V125, P595, DOI DOI 10.1083/JCB.125.3.595; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	30	497	501	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					802	806		10.1038/375802a0	http://dx.doi.org/10.1038/375802a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596415				2022-12-28	WOS:A1995RF98900082
J	WEINTRAUB, SJ; CHOW, KNB; LUO, RX; ZHANG, SH; HE, S; DEAN, DC				WEINTRAUB, SJ; CHOW, KNB; LUO, RX; ZHANG, SH; HE, S; DEAN, DC			MECHANISM OF ACTIVE TRANSCRIPTIONAL REPRESSION BY THE RETINOBLASTOMA PROTEIN	NATURE			English	Article							LARGE T-ANTIGEN; GENE-PRODUCT; BINDING PROTEIN; CELL-CYCLE; C-MYC; DOMAIN; TRANSACTIVATION; PHOSPHORYLATION; EXPRESSION; PROMOTER	THE retinoblastoma tumour-suppressor protein (Rb) belongs to a family that share a motif known as the pocket. The pocket was originally identified as the region of Rb required for binding to oncoproteins from DNA tumour viruses(1,2), which disrupt the binding of Rb to the E2F family of cell-cycle transcription factors (referred to collectively here as E2F)(3). Rb switches E2F sites from positive to negative elements(4), suggesting that Rb-E2F is an active complex that blocks transcription. Here we report that Rb is selectively recruited to promoters through E2F, where it in turn inactivates surrounding transcription factors by blocking their interaction with the basal transcription complex. We suggest that this repressor activity is essential for inhibiting promoters that contain enhancers in addition to E2F sites.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	29	451	456	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					812	815		10.1038/375812a0	http://dx.doi.org/10.1038/375812a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596417				2022-12-28	WOS:A1995RF98900085
J	FERMO, I; DANGELO, SV; PARONI, R; MAZZOLA, G; CALORI, G; DANGELO, A				FERMO, I; DANGELO, SV; PARONI, R; MAZZOLA, G; CALORI, G; DANGELO, A			PREVALENCE OF MODERATE HYPERHOMOCYSTEINEMIA IN PATIENTS WITH EARLY-ONSET VENOUS AND ARTERIAL OCCLUSIVE DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERHOMOCYSTEINEMIA; HOMOCYSTEINE; ARTERIAL OCCLUSIVE DISEASES; THROMBOPHLEBITIS; THROMBOEMBOLISM	POOR ANTICOAGULANT RESPONSE; PROTEIN-C ACTIVATION; PLASMA HOMOCYSTEINE; ENDOTHELIAL-CELLS; VASCULAR-DISEASE; ORAL ANTICOAGULATION; THROMBOGENIC AGENT; RISK FACTOR; THROMBOSIS; HOMOCYST(E)INE	Objective: To evaluate the prevalence of moderate hyperhomocysteinemia and inherited thrombophilia disorders (congenital defects of the natural anticoagulant or fibrinolytic mechanisms) in patients with early-onset venous or arterial thromboembolic disease. Design: Cross-sectional e-year evaluation of consecutive unrelated patients with a history of venous or arterial occlusive disease occurring before the age of 45 years or at unusual sites, in the absence of local predisposing factors. Setting: Thrombosis research unit of a community hospital. Patients: 107 patients with venous thromboembolism (mean age at event, 32.9 +/- 11.9 years) and 50 patients with arterial occlusive disease (mean age at event, 31.1 +/- 10 years) who did not have acquired coagulation defects, overt cancer, or acquired conditions affecting methionine metabolism. Measurements: Total plasma homocysteine (fasting levels), antithrombin III, protein C, protein S, activated protein C resistance, plasminogen, and heparin cofactor II were measured at least 3 months after the event. In 87 patients, total plasma homocysteine levels were also measured 8 hours after an oral methionine load was administered (L-methionine, 0.1 g/kg body weight). Ninety-fifth percentiles of the distribution of these variables were established in 60 apparently healthy persons; sex-specific ranges were used for protein S and total plasma homocysteine. Relatives of patients with laboratory abnormalities were studied to confirm inheritance of the defects. Results: Moderate hyperhomocysteinemia was detected in 13.1% (95% Cl, 7.6% to 21.3%) and in 19.2% (CI, 9.0% to 31.9%) of patients with venous or arterial occlusive disease. The prevalence of hyperhomocysteinemia was almost twice as high when based on homocysteine measurements done after oral methionine load as when based on fasting levels. The remaining defects were detected only in patients with venous occlusive disease (activated protein C resistance in 11.2% of patients, protein S or C deficiency in 6.6%, and plasminogen deficiency in 0.9%), with an overall prevalence of 18.7% (Cl, 12.1% to 27.6%). Inheritance of hyperhomocysteinemia and of the other defects was confirmed in 26 of the 30 families studied. Event-free survival analysis showed that the relative risk for occlusive disease in patients with moderate hyperhomocysteinemia and other defects was 1.70 times (Cl, 1.19 to 2.42; P < 0.01) greater than in patients without defects. After adjustment for the presence of predisposing factors (for example, use of contraceptive drugs, pregnancy, surgery, prolonged bedrest, smoking, mild hypertension or dyslipidemia) and a family history of thrombosis, the age at first event of patients with moderate hyperhomocysteinemia was similar to that of patients with the other defects (26.4 +/- 11.2 years compared with 25.2 +/- 10.6 years), and the 43 patients with defects were significantly younger at first event than the 114 patients without defects (25.5 +/- 11.1 years compared with 31.0 +/- 12.3; P < 0.005). Patients with mild hyperhomocysteineria had a higher rate of recurrence than those without defects (52% compared with 25%; P = 0.01); among the 56 patients who had their first event more than 1 year before observation, the recurrence rate was higher (80% [Cl, 51% to 95%]) in patients with defects than in patients without defects (41% [Cl, 26% to 57%] P = 0.01). Conclusions: Moderate hyperhomocysteinemia may have pathogenic significance in premature venous and arterial occlusive disease and should be included among the (inherited) disorders of venous and arterial thrombophilia.			FERMO, I (corresponding author), IRCCS, IST SCI HS RAFFAELE, ANAL LAB, VIA OLGETTINA 60, I-20132 MILAN, ITALY.		D'Angelo, Armando/K-2583-2018; fermo, isabella/AAN-3999-2020; PARONI, RITA/C-2955-2012; PARONI, RITA/AAC-6265-2020	D'Angelo, Armando/0000-0002-9857-4509; fermo, isabella/0000-0003-2947-1933; PARONI, RITA/0000-0002-3186-8860; PARONI, RITA/0000-0002-3186-8860				BANDELLO F, 1994, THROMB HAEMOSTASIS, V72, P39; BERTINA RM, 1994, NATURE, V64, P369; BLANN AD, 1992, ATHEROSCLEROSIS, V94, P89, DOI 10.1016/0021-9150(92)90192-J; BRATTSTROM L, 1991, HAEMOSTASIS, V21, P51; CADROY Y, 1994, BLOOD, V83, P2008; CHRISTENSEN E, 1987, HEPATOLOGY, V7, P1346, DOI 10.1002/hep.1840070628; CUSHMAN M, 1994, THROMB HAEMOSTASIS, V72, P647; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; DANGELO A, 1988, J CLIN INVEST, V81, P1445, DOI 10.1172/JCI113475; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DANGELO SV, 1992, THROMB HAEMOSTASIS, V67, P631; DANGELO SV, 1995, THROMB RES, V77, P375; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; FERMO I, 1992, J CHROMATOGR, V593, P171, DOI 10.1016/0021-9673(92)80283-Z; FERMO I, 1993, AMINO ACIDS, V5, P17, DOI 10.1007/BF00806188; FRANKEN DG, 1994, ARTERIOSCLER THROMB, V14, P465, DOI 10.1161/01.ATV.14.3.465; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; GRIFFIN JH, 1993, BLOOD, V82, P1989; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HIRSH J, 1994, HEMOSTASIS THROMBOSI, P1543; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1994, J INTERN MED, V236, P603, DOI 10.1111/j.1365-2796.1994.tb00854.x; MANSOOR MA, 1992, CLIN CHEM, V38, P1316; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1983, METABOLIC BASIS INHE, P522; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; OLSZEWSKI AJ, 1988, ATHEROSCLEROSIS, V69, P109, DOI 10.1016/0021-9150(88)90003-2; PATHASARATHY S, 1987, BIOCHIM BIOPHYS ACTA, V917, P337; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TAYLOR LM, 1991, J VASC SURG, V13, P128, DOI 10.1016/0741-5214(91)90020-U; UELAND PM, 1989, J LAB CLIN MED, V114, P473; WANG J, 1993, THROMB HAEMOSTASIS, V70, P1047	46	217	222	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1995	123	10					747	+		10.7326/0003-4819-123-10-199511150-00002	http://dx.doi.org/10.7326/0003-4819-123-10-199511150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE172	7574192				2022-12-28	WOS:A1995TE17200002
J	PETERSON, JC; ADLER, S; BURKART, JM; GREENE, T; HEBERT, LA; HUNSICKER, LG; KING, AJ; KLAHR, S; MASSRY, SG; SEIFTER, JL				PETERSON, JC; ADLER, S; BURKART, JM; GREENE, T; HEBERT, LA; HUNSICKER, LG; KING, AJ; KLAHR, S; MASSRY, SG; SEIFTER, JL			BLOOD-PRESSURE CONTROL, PROTEINURIA, AND THE PROGRESSION OF RENAL-DISEASE - THE MODIFICATION OF DIET IN RENAL-DISEASE STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						PROTEINURIA; BLOOD PRESSURE; GLOMERULAR FILTRATION RATE; DIET; KIDNEY DISEASES	ANTIHYPERTENSIVE TREATMENT; DIABETIC NEPHROPATHY; LONGITUDINAL DATA; KIDNEY-FUNCTION; FAILURE; INSUFFICIENCY	Objective: To examine the relations among proteinuria, prescribed and achieved blood pressure, and decline in glomerular filtration rate in the Modification of Diet in Renal Disease Study. Design: 2 randomized trials in patients with chronic renal diseases of diverse cause. Setting 15 outpatient nephrology practices at university hospitals. Patients: 840 patients, of whom 585 were in study A (glomerular filtration rate, 25 to 55 mL/min 1.73 m(2)) and 255 were in study B (glomerular filtration rate, 13 to 24 mL/min . 1.73 m(2)). Diabetic patients who required insulin were excluded. Interventions : Patients were randomly assigned to a usual blood pressure goal (target mean arterial pressure, less than or equal to 107 mm Hg for patients less than or equal to 60 years of age and less than or equal to 113 mm Hg for patients less than or equal to 61 years of age) or a low blood pressure goal (target mean arterial pressure, less than or equal to 92 mm Hg for patients less than or equal to 60 years of age and less than or equal to 98 mm Hg for patients less than or equal to 61 years of age). Main Outcome Measures: Rate of decline in glomerular filtration rate and change in proteinuria during follow-up. Results: The low brood pressure goal had a greater beneficial effect in persons with higher baseline proteinuria in both study A (P = 0.02) and study B (P = 0.01). Glomerular filtration rate declined faster in patients with higher achieved blood pressure during follow-up in both study A (r = -0.20; P < 0.001) and study B (r = -0.34; Pt 0.001), and these correlations were stronger in persons with higher baseline proteinuria (P < 0.001 in study A; P < 0.01 in study B). In study A, the association between decline in glomerular filtration rate and achieved follow-up blood pressure was nonlinear (P = 0.011) and was stronger at higher mean arterial pressure. in both studies, the low blood pressure goal significantly reduced proteinuria during the first 4 months after randomization. This, in turn, correlated with a slower subsequent decline in glomerular filtration rate. Conclusions: Our study supports the concept that proteinuria is an independent risk factor for the progression of renal disease. For patients with proteinuria of more than 1 g/d, we suggest a target blood pressure of less then 92 mm Hg (125/75 mm Hg). For patients with proteinuria of 0.25 to 1.0 g/d, a target mean arterial pressure of less than 98 mm Hg (about 130/80 mm Hg) may be advisable. The extent to which lowering blood pressure reduces proteinuria may be a measure of the effectiveness of this therapy in slowing the progression of renal disease.			PETERSON, JC (corresponding author), CLEVELAND CLIN FDN, DEPT BIOSTAT & EPIDEMIOL,MDRD, CTR STUDY DATA COORDINATING,STUDY GRP, P88, CLEVELAND, OH 44195 USA.							ALVESTRAND A, 1988, NEPHROL DIAL TRANSPL, V3, P624, DOI 10.1093/oxfordjournals.ndt.a091717; APPERLOO A J, 1992, Journal of the American Society of Nephrology, V3, P279; BECK GJ, 1991, CONTROL CLIN TRIALS, V12, P566, DOI 10.1016/0197-2456(91)90069-X; BRAZY PC, 1989, KIDNEY INT, V35, P670, DOI 10.1038/ki.1989.37; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; FRISANCHO AR, 1990, ANTHR STANDARDS ASSE; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GORDGE MP, 1991, NEPHROL DIAL TRANSPL, V6, P21, DOI 10.1093/ndt/6.1.21; GREENE T, 1993, J AM SOC NEPHROL, V4, P1221; Hunsicker L. G., 1993, Journal of the American Society of Nephrology, V4, P254; HUNT LP, 1988, KIDNEY INT, V34, P382, DOI 10.1038/ki.1988.192; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; KLAHR S, 1989, NEW ENGL J MED, V320, P731, DOI 10.1056/NEJM198903163201110; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; KUSEK JW, 1993, CONTROL CLIN TRIALS, V14, P538, DOI 10.1016/0197-2456(93)90033-A; LAZARUS J, 1994, 3RD P ANN SPR CLIN N, pA4; LEVEY AS, 1993, J AM SOC NEPHROL, V4, P1159; LEVEY AS, 1994, 3RD P ANN SPR CLIN N, pA14; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; PARVING HH, 1985, HYPERTENSION, V7, P114; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PERRONE RD, 1990, AM J KIDNEY DIS, V16, P224, DOI 10.1016/S0272-6386(12)81022-5; PERRONE RD, 1992, KIDNEY INT, V41, pS26; PESCE MA, 1973, CLIN CHEM, V19, P1265; PRAGA M, 1992, AM J KIDNEY DIS, V20, P240, DOI 10.1016/S0272-6386(12)80696-2; REMUZZI G, 1990, KIDNEY INT, V38, P384, DOI 10.1038/ki.1990.217; SCHLUCHTER MD, 1992, STAT MED, V11, P1861, DOI 10.1002/sim.4780111408; STENVINKEL P, 1989, J INTERN MED, V226, P183, DOI 10.1111/j.1365-2796.1989.tb01377.x; WILLIAMS JD, 1994, KIDNEY INT, V45, P443, DOI 10.1038/ki.1994.58; WILLIAMS PS, 1988, Q J MED, V67, P343	31	1091	1127	0	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1995	123	10					754	+		10.7326/0003-4819-123-10-199511150-00003	http://dx.doi.org/10.7326/0003-4819-123-10-199511150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE172	7574193				2022-12-28	WOS:A1995TE17200003
J	ROBERTS, I; PLESS, B				ROBERTS, I; PLESS, B			FOR DEBATE - SOCIAL-POLICY AS A CAUSE OF CHILDHOOD ACCIDENTS - THE CHILDREN OF LONE MOTHERS	BRITISH MEDICAL JOURNAL			English	Article							PRESCHOOL-CHILDREN; HOME CARE; RISK; INJURY; TRIAL	Almost one in five British mothers is a lone mother. Their children have injury rates that are twice those of children in two parent families. In this article the link between lone parenthood and childhood injury is examined. The increased injury rates for the children of lone mothers can be explained by the poverty, poor housing conditions, and social isolation of lone mothers in Britain. The problem of reconciling the demands of paid work with the demands of the unpaid work of childrearing is particularly difficult for lone mothers, who find themselves in a benefit dependent poverty trap. Many such mothers would seek paid work if affordable day care were available. Day care would also provide a safe environment for their children, who are otherwise exposed to the environmental hazards of poor housing. Provision of day care is a social polic;i that would have important effects on the health and welfare oflone mothers and their children. These effects deserve to be properly evaluated.	MCGILL UNIV,MONTREAL CHILDRENS HOSP C 538,DEPT COMMUNITY PAEDIAT RES,MONTREAL,PQ H3H 1P3,CANADA	McGill University								AVERY JG, 1993, CHILDREN THEIR ACCID; BERRUETACLEMENT J, 1984, CHANGED LIVES EFFECT; BRADSHAW J, 1991, 6 DEP SOC SEC RES RE; BROOKSGUNN J, 1994, AM J PUBLIC HEALTH, V84, P924, DOI 10.2105/AJPH.84.6.924; BROWN GW, 1978, LANCET, V1, P378; COBB S, 1976, PSYCHOSOM MED, V38, P18; Cohen S, 1985, SOCIAL SUPPORT HLTH; CONSTANTINIDES P, 1988, RADICAL COMMUNITY ME, P31; GUNN WJ, 1991, AM J DIS CHILD, V145, P779; HALL LA, 1985, AM J PUBLIC HEALTH, V75, P518, DOI 10.2105/AJPH.75.5.518; HARDEY M, 1991, LONE PARENTHOOD; JOHNSON Z, 1993, BRIT MED J, V306, P1449, DOI 10.1136/bmj.306.6890.1449; JUDGE K, 1993, BRIT MED J, V306, P677, DOI 10.1136/bmj.306.6879.677; LARSON CP, 1988, AM J DIS CHILD, V142, P1052, DOI 10.1001/archpedi.1988.02150100046023; MACKENBACH JP, 1995, BRIT MED J, V310, P1152, DOI 10.1136/bmj.310.6988.1152; MCCORMICK MC, 1981, AM J DIS CHILD, V135, P159, DOI 10.1001/archpedi.1981.02130260051015; MILLAR J, 1989, POVERTY LONE PARENT; MUELLER BA, 1990, AM J EPIDEMIOL, V132, P550, DOI 10.1093/oxfordjournals.aje.a115691; Oakley A, 1994, EUROPEAN J PUBLIC HL, V4, P81; OAKLEY A, 1994, EUR J PUBLIC HEALTH, V4, P265; OLDS DL, 1986, PEDIATRICS, V78, P65; PovertyUSA, 2021, POV FACTS; RIVARA FP, 1989, PEDIATRICS, V84, P1011; ROBERTS I, 1995, BRIT MED J, V310, P91, DOI 10.1136/bmj.310.6972.91; ROBERTS I, 1994, J PAEDIATR CHILD H, V30, P530, DOI 10.1111/j.1440-1754.1994.tb00727.x; ROBERTS I, 1995, PEDIATRICS, V95, P213; ROBERTS IG, 1994, J PAEDIATR CHILD H, V30, P220, DOI 10.1111/j.1440-1754.1994.tb00622.x; RUNYAN CW, 1992, NEW ENGL J MED, V327, P859, DOI 10.1056/NEJM199209173271207; SCHWEINHART LJ, 1993, SIGNIFICANT EFFECTS; SELLSTROM E, 1994, 1992 P INT C CHILD D, P1033; SIBERT R, 1975, BRIT MED J, V3, P87, DOI 10.1136/bmj.3.5975.87; TOWNER E, 1993, REDUCING CHILDHOOD A; Townsend P., 1979, POVERTY UK SURVEY HO; WADSWORTH J, 1983, J EPIDEMIOL COMMUN H, V37, P100, DOI 10.1136/jech.37.2.100; WILLIAMS H, 1985, J CHILD PSYCHOL PSYC, V26, P277, DOI 10.1111/j.1469-7610.1985.tb02266.x; WOODROFFE C, 1993, CHILDREN TEENAGERS H; 1974, REPORT COMMITTEE ONE; 1995, SOCIAL TRENDS, V25	38	40	43	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					925	928						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580554				2022-12-28	WOS:A1995RZ23700025
J	FISHERHOCH, SP; TOMORI, O; NASIDI, A; PEREZORONOZ, GI; FAKILE, Y; HUTWAGNER, L; MCCORMICK, JB				FISHERHOCH, SP; TOMORI, O; NASIDI, A; PEREZORONOZ, GI; FAKILE, Y; HUTWAGNER, L; MCCORMICK, JB			REVIEW OF CASES OF NOSOCOMIAL LASSA FEVER IN NIGERIA - THE HIGH PRICE OF POOR MEDICAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate two hospital outbreaks of Lassa fever in southern central Nigeria. Setting-Hospitals and clinics in urban and rural areas of Imo State, Nigeria. Design-Medical records were reviewed in hospitals and clinics in both areas. Patients with presumed and laboratory confirmed Lassa fever were identified and contracts traced. Hospital staff, patients, and local residents were questioned, records were carefully reviewed, and serum samples were taken. Serum samples were assayed for antibody specific to Lassa virus, and isolates of Lassa virus were obtained. Results-Among 34 patients with Lassa fever, including 20 patients, six nurses, two surgeons, one physician, and the son of a patient, there were 22 deaths (65% fatality rate). Eleven cases were laboratory confirmed, five by isolation of virus. Most patients had been exposed in hospitals (attack rate in patients in one hospital 55%). Both outbreak hospitals were inadequately equipped and staffed, with poor medical practice. Compelling, indirect evidence revealed that parenteral drug rounds with sharing of syringes, conducted by minimally educated and supervised staff, fuelled the epidemic among patients. Staff were subsequently infected during emergency surgery and while caring for nosocomially infected patients. Conclusion-This outbreak illustrates the high price exacted by the practice of modern medicine, particularly use of parenteral injections and surgery, without due attention to good medical practice. High priority must be given to education of medical staff in developing countries and to guidelines for safe operation of clinics and hospitals. Failure to do so will have far reaching, costly, and ultimately devastating consequences.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,BIOSTAT BRANCH,ATLANTA,GA 30333; UNIV IBADAN,COLL MED,DEPT VIROL,IBADAN,NIGERIA; FED MINIST HLTH,FED EPIDEMIOL DIV,LAGOS,NIGERIA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Ibadan			TOMORI, OYEWALE/GWQ-4419-2022; TOMORI, OYEWALE/X-3021-2019; Fakile, Yetunde F/AAL-7938-2020	TOMORI, OYEWALE/0000-0002-6959-5749; Fakile, Yetunde F/0000-0002-6439-8981; McCormick, Joseph/0000-0002-5844-8102				ALTER MJ, 1991, HEPATOLOGY, V14, P389, DOI 10.1016/0270-9139(91)91431-Y; [Anonymous], 1978, Bull World Health Organ, V56, P271; BOWEN GS, 1975, B WORLD HEALTH ORGAN, V52, P599; CAREY DE, 1972, T ROY SOC TROP MED H, V66, P402, DOI 10.1016/0035-9203(72)90271-4; FABIYI A, 1979, NIGERIAN MED J, V9, P23; FRAME JD, 1970, AM J TROP MED HYG, V19, P670, DOI 10.4269/ajtmh.1970.19.670; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; JOHNSON KM, 1987, J INFECT DIS, V155, P456, DOI 10.1093/infdis/155.3.456; MCCORMICK JB, 1987, J INFECT DIS, V155, P437, DOI 10.1093/infdis/155.3.437; MCCORMICK JB, 1987, J INFECT DIS, V155, P445, DOI 10.1093/infdis/155.3.445; TOMORI O, 1988, AM J TROP MED HYG, V38, P407, DOI 10.4269/ajtmh.1988.38.407	11	225	235	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					857	859		10.1136/bmj.311.7009.857	http://dx.doi.org/10.1136/bmj.311.7009.857			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580496	Green Published			2022-12-28	WOS:A1995RY19100029
J	STEMMLER, M; USHER, M; NIEBUR, E				STEMMLER, M; USHER, M; NIEBUR, E			LATERAL INTERACTIONS IN PRIMARY VISUAL-CORTEX - A MODEL BRIDGING PHYSIOLOGY AND PSYCHOPHYSICS	SCIENCE			English	Article							EXCITATORY POSTSYNAPTIC POTENTIALS; INTRINSIC CONNECTIONS; MACAQUE MONKEY; STRIATE CORTEX; FACILITATION; SUPPRESSION; NEOCORTEX; PATTERNS	Recent physiological studies show that the spatial context of visual stimuli enhances the response of cells in primary visual cortex to weak stimuli and suppresses the response to strong stimuli. A model of orientation-tuned neurons was constructed to explore the role of lateral cortical connections in this dual effect. The differential effect of excitatory and inhibitory current and noise conveyed by the lateral connections explains the physiological results as well as the psychophysics of pop-out and contour completion. Exploiting the model's property of stochastic resonance, the visual context changes the model's intrinsic input variability to enhance the detection of weak signals.	UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15260; CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University	STEMMLER, M (corresponding author), CALTECH,COMPUTAT & NEURAL SYST PROGRAM,139-74,PASADENA,CA 91125, USA.				NIMH NIH HHS [MH47566, MH45156] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH047566, P50MH045156] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERGEN JR, 1983, IEEE T SYST MAN CYB, V13, P857, DOI 10.1109/TSMC.1983.6313080; BERNANDER O, 1994, J NEUROPHYSIOL, V72, P2743, DOI 10.1152/jn.1994.72.6.2743; BLASDEL GG, 1992, J NEUROSCI, V12, P3139, DOI 10.1523/JNEUROSCI.12-08-03139.1992; CANNON MW, 1993, VISION RES, V33, P1685, DOI 10.1016/0042-6989(93)90034-T; CAULLER LJ, 1992, SINGLE NEURON COMPUT, P19; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; GILBERT CD, 1992, NEURON, V9, P1, DOI 10.1016/0896-6273(92)90215-Y; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1994, J NEUROSCI, V14, P2545; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; HUBEL DH, 1959, J PHYSIOL-LONDON, V148, P574, DOI 10.1113/jphysiol.1959.sp006308; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; POLAT U, 1993, VISION RES, V33, P993, DOI 10.1016/0042-6989(93)90081-7; POLAT U, UNPUB VISION RES; Somers D., 1994, Society for Neuroscience Abstracts, V20, P1577; SOMERS DC, 1995, J NEUROSCI, V15, P5448; SOMERS DC, IN PRESS LATERAL INT; THOMSON AM, 1993, NEUROSCIENCE, V54, P347, DOI 10.1016/0306-4522(93)90257-G; THOMSON AM, 1993, NEUROSCIENCE, V54, P329, DOI 10.1016/0306-4522(93)90256-F; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; WORGOTTER F, 1991, J NEUROPHYSIOL, V66, P444, DOI 10.1152/jn.1991.66.2.444	27	174	175	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1877	1880		10.1126/science.7569930	http://dx.doi.org/10.1126/science.7569930			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569930				2022-12-28	WOS:A1995RX19400040
J	GONG, XH; DUBOIS, DH; MILLER, DJ; SHUR, BD				GONG, XH; DUBOIS, DH; MILLER, DJ; SHUR, BD			ACTIVATION OF A G-PROTEIN COMPLEX BY AGGREGATION OF BETA-1,4-GALACTOSYLTRANSFERASE ON THE SURFACE OF SPERM	SCIENCE			English	Article							NUCLEOTIDE REGULATORY PROTEIN; PERTUSSIS TOXIN; MOUSE SPERM; ACROSOME REACTION; ZONA-PELLUCIDA; RAT HEPATOCYTES; BINDING; RECEPTOR; ZP3; MEMBRANES	Fertilization is initialed by the species-specific binding of sperm to the extracellular coat of the egg. One sperm receptor for the mouse egg is beta-1,4-galactosyltransferase (GalTase), which binds O-linked oligosaccharides on the egg coat glycoprotein ZP3. ZP3 binding induces acrosomal exocytosis through the activation of a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein (G protein). The cytoplasmic domain of sperm surface GalTase bound to and activated a heterotrimeric G protein complex that contained the G(i alpha) subunit. Aggregation of GalTase by multivalent ligands elicited G protein activation. Sperm from transgenic mice that overexpressed GalTase had higher rates of G protein activation than did wild-type sperm, which rendered transgenic sperm hypersensitive to their ZP3 ligand. Thus, the cytoplasmic domain of cell surface GalTase appears to enable it to function as a signal-transducing receptor for extracellular oligosaccharide ligands.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NICHD NIH HHS [T32 HD07324, R01 HD23479, R01 HD22590] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007324, R01HD022590, R01HD023479] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; ENDO Y, 1988, DEV BIOL, V129, P12, DOI 10.1016/0012-1606(88)90157-1; EVANS SC, 1995, BIOESSAYS, V17, P261, DOI 10.1002/bies.950170313; FLORMAN HM, 1994, DEV BIOL, V165, P152, DOI 10.1006/dbio.1994.1242; GONG X, UNPUB; HUANG CL, 1989, J BIOL CHEM, V264, P4391; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; KALAB P, 1994, J BIOL CHEM, V269, P3810; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LIANG M, 1991, J BIOL CHEM, V266, P13342; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; MACEK MB, 1991, DEV BIOL, V147, P440, DOI 10.1016/0012-1606(91)90301-I; Miller David J., 1994, Seminars in Developmental Biology, V5, P255, DOI 10.1006/sedb.1994.1033; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; NGUYEN TTM, 1994, J BIOL CHEM, V269, P28000; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1991, BIOCHEM BIOPH RES CO, V179, P10, DOI 10.1016/0006-291X(91)91326-8; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; PRATT SA, 1993, DEV BIOL, V156, P80, DOI 10.1006/dbio.1993.1060; ROLDAN ERS, 1994, SCIENCE, V266, P1578, DOI 10.1126/science.7985030; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; STROUS GJ, 1987, EUR J BIOCHEM, V169, P307, DOI 10.1111/j.1432-1033.1987.tb13613.x; SUN H, 1995, P NATL ACAD SCI USA, V92, P2229, DOI 10.1073/pnas.92.6.2229; WARD CR, 1992, J BIOL CHEM, V267, P14061; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YOUAKIM A, 1994, J CELL BIOL, V126, P1573, DOI 10.1083/jcb.126.6.1573	32	152	157	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1718	1721		10.1126/science.7569899	http://dx.doi.org/10.1126/science.7569899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569899				2022-12-28	WOS:A1995RV94800037
J	KRONTIRIS, TG				KRONTIRIS, TG			MINISATELLITES AND HUMAN-DISEASE	SCIENCE			English	Editorial Material							HUMAN INSULIN GENE; HRAS1 MINISATELLITE; DNA-SEQUENCE; LOCUS; MUTATION; ALLELES; ACTIVATION; REGION; CANCER		TUFTS UNIV,SCH MED,GENET PROGRAM,BOSTON,MA 02111; TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111	Tufts University; Tufts Medical Center	KRONTIRIS, TG (corresponding author), TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111, USA.							BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BUARD J, 1994, EMBO J, V13, P3203, DOI 10.1002/j.1460-2075.1994.tb06619.x; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; GREEN M, 1993, GENOMICS, V17, P429, DOI 10.1006/geno.1993.1343; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; KASPERCZYK A, 1990, AM J HUM GENET, V47, P854; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; OWERBACH D, 1994, AM J HUM GENET, V54, P909; OWERBACH D, 1993, DIABETES, V42, P1708, DOI 10.2337/diabetes.42.12.1708; Phelan C., 1994, American Journal of Human Genetics, V55, pA67; TREPICCHIO WL, 1992, NUCLEIC ACIDS RES, V20, P2427, DOI 10.1093/nar/20.10.2427; TREPICCHIO WL, 1993, NUCLEIC ACIDS RES, V21, P977, DOI 10.1093/nar/21.4.977; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; WOLFF RK, 1989, GENOMICS, V5, P382, DOI 10.1016/0888-7543(89)90076-1; WOLFF RK, 1988, GENOMICS, V3, P347, DOI 10.1016/0888-7543(88)90126-7	27	64	64	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1682	1683		10.1126/science.7569893	http://dx.doi.org/10.1126/science.7569893			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569893				2022-12-28	WOS:A1995RV94800026
J	BOORE, JL; COLLINS, TM; STANTON, D; DAEHLER, LL; BROWN, WM				BOORE, JL; COLLINS, TM; STANTON, D; DAEHLER, LL; BROWN, WM			DEDUCING THE PATTERN OF ARTHROPOD PHYLOGENY FROM MITOCHONDRIAL-DNA REARRANGEMENTS	NATURE			English	Article							RIBOSOMAL-RNA; GENE; EVOLUTION; SEQUENCE; ORIGIN; GENOME	THE origins of arthropods and the phylogenetic relationships among their three major living groups (atdocerates, crustaceans and chelicerates) are vigorously contended. To help resolve this, we determined mitochondrial gene arrangements for a chelicerate, a myriapod, two crustaceans, an onychophoran, a mollusc and an annelid, and compared them with published gene orders of other species. The result strongly supports the monophyly of Arthropoda and of Mandibulata (atelocerates plus crustaceans) and refutes the Uniramia (atelocerates plus onychophorans). Gene arrangement comparisons are emerging as a powerful new tool for resolving ancient phylogenetic relationships.	UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			Brown, William/GXN-2777-2022					Adoutte Andre, 1993, Experientia Supplementum (Basel), V63, P1; BALLARD JWO, 1992, SCIENCE, V258, P1345, DOI 10.1126/science.1455227; BOORE JL, 1994, GENETICS, V138, P423; BOORE JL, 1994, NAUTILUS, V108, P61; Boudreaux H. B., 1979, ARTHROPOD PHYLOGENY; Brusca R.C., 1990, INVERTEBRATES; CISNE JL, 1974, SCIENCE, V186, P13, DOI 10.1126/science.186.4158.13; CROZIER RH, 1993, GENETICS, V133, P97; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; HAUCKE HR, 1988, CURR GENET, V14, P471, DOI 10.1007/BF00521271; HENDRIKS L, 1988, EUR J BIOCHEM, V177, P15, DOI 10.1111/j.1432-1033.1988.tb14339.x; HESSLER R R, 1975, Fossils and Strata, V4, P437; KUKALOVAPECK J, 1992, CAN J ZOOL, V70, P236, DOI 10.1139/z92-037; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; Liu H, 1992, MOL PHYLOGENET EVOL, V1, P41, DOI 10.1016/1055-7903(92)90034-E; Maddison W.P., 1992, ANAL PHYLOGENY CHARA; Manton S. M., 1979, ORIGIN MAJOR INVERTE, P269; MITCHELL SE, 1993, GENOME, V36, P1058, DOI 10.1139/g93-141; PASHLEY DP, 1992, MOL BIOL EVOL, V9, P1061; PATTERSON C, 1993, ANNU REV ECOL SYST, V24, P153; PREUSS K, 1992, J MED ENTOMOL, V29, P644; SANKOFF D, 1992, P NATL ACAD SCI USA, V89, P6575, DOI 10.1073/pnas.89.14.6575; SMITH MJ, 1993, J MOL EVOL, V36, P545, DOI 10.1007/BF00556359; TIEGS OWQ, 1947, J MICROSC SCI, V82, P165; VALENTINE JW, 1989, P NATL ACAD SCI USA, V86, P2272, DOI 10.1073/pnas.86.7.2272; VALVERDE JR, 1994, J MOL EVOL, V39, P400, DOI 10.1007/BF00160272; VAWTER L, 1993, GENETICS, V134, P597; WHEELER WC, 1993, CLADISTICS, V9, P11; WOLSTENHOLME DR, 1992, INT REV CYTOL, V141, P173, DOI 10.1016/S0074-7696(08)62066-5	30	336	350	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					163	165		10.1038/376163a0	http://dx.doi.org/10.1038/376163a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603565	Green Submitted			2022-12-28	WOS:A1995RJ02800057
J	BIZEBARD, T; GIGANT, B; RIGOLET, P; RASMUSSEN, B; DIAT, O; BOSECKE, P; WHARTON, SA; SKEHEL, JJ; KNOSSOW, M				BIZEBARD, T; GIGANT, B; RIGOLET, P; RASMUSSEN, B; DIAT, O; BOSECKE, P; WHARTON, SA; SKEHEL, JJ; KNOSSOW, M			STRUCTURE OF INFLUENZA-VIRUS HEMAGGLUTININ COMPLEXED WITH A NEUTRALIZING ANTIBODY	NATURE			English	Article							HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; FUSION; RECOGNITION; MECHANISM; RECEPTOR; MUTANT; ACID	HAEMAGGLUTININ (HA) is the influenza surface glycoprotein that interacts with infectivity-neutralizing antibodies. As a consequence of this immune pressure it is the variable virus component, which is important in antigenic drift, that results in recurrent epidemics of influenza. We have determined the crystallographic structure of a complex formed between the antigen-binding fragment (Fab) of a neutralizing antibody tend the membrane-distal domain ((HA top') of a HA subunit prepared from HA in its membrane-fusion-active conformation. A dramatic change is seen in the structure of the Fab-combining site on complex formation. Our results indicate that neutralization of infectivity by this antibody involves the inhibition of receptor binding, and demonstrate how influenza virus can maintain its conserved receptor-binding site despite the immune selective pressure for change in this region of the molecule; they also contribute to a complete description of the endosomal pH-induced fusion-active HA structure.	EUROPEAN SYNCHROTRON RADIAT FACIL,F-38043 GRENOBLE,FRANCE; ILL GRENOBLE,EUROPEAN MOLEC BIOL LAB,GRENOBLE OUTSTN,F-38042 GRENOBLE,FRANCE; NATL INST MED RES,MRC,DIV VIROL,LONDON NW7 1AA,ENGLAND	European Synchrotron Radiation Facility (ESRF); European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL); MRC National Institute for Medical Research	BIZEBARD, T (corresponding author), UNIV PARIS SUD,BIOL STRUCT LAB,CNRS,UMR 9920,BAT 34,F-91198 GIF SUR YVETTE,FRANCE.		diat, olivier PC/B-5985-2016; Rigolet, Pascal/S-8602-2018	diat, olivier PC/0000-0003-3011-8168; Rigolet, Pascal/0000-0001-6868-4953; Gigant, Benoit/0000-0002-5946-6759				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BIZEBARD T, 1994, ACTA CRYSTALLOGR D, V50, P768, DOI 10.1107/S0907444994001903; BIZEBARD T, 1990, J MOL BIOL, V216, P513, DOI 10.1016/0022-2836(90)90378-Y; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHERFILS J, 1994, PROTEINS, V18, P8, DOI 10.1002/prot.340180104; DANIELS RS, 1983, J GEN VIROL, V64, P1657, DOI 10.1099/0022-1317-64-8-1657; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DANIELS RS, 1987, EMBO J, V6, P1459, DOI 10.1002/j.1460-2075.1987.tb02387.x; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; GRUNGER AT, 1992, XPLOR VERSION 3 1; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KNOSSOW M, 1984, NATURE, V311, P678, DOI 10.1038/311678a0; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P924; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, CCP4; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PARRY N, 1990, NATURE, V347, P569, DOI 10.1038/347569a0; RUIGROK RW, 1988, J GEN VIROL, P2785; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; SKEHEL JJ, 1971, VIROLOGY, V44, P396, DOI 10.1016/0042-6822(71)90270-4; WARD CW, 1981, CURR TOP MICROBIOL, V94-5, P1; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WHARTON SA, 1988, J BIOL CHEM, V263, P4474; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.iy.08.040190.003513; WRIGLEY NG, 1983, VIROLOGY, P308	30	208	220	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					92	94		10.1038/376092a0	http://dx.doi.org/10.1038/376092a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596443				2022-12-28	WOS:A1995RH11100069
J	HOPFIELD, JJ				HOPFIELD, JJ			PATTERN-RECOGNITION COMPUTATION USING ACTION-POTENTIAL TIMING FOR STIMULUS REPRESENTATION	NATURE			English	Article							INFERIOR COLLICULUS; INTERAURAL TIME; VISUAL-CORTEX; DELAY-LINES; BRAIN-STEM; INFORMATION; OSCILLATIONS; CIRCUIT; CELLS; BAT	A computational model is described in which the sizes of variables are represented by the explicit times at which action potentials occur, rather than by the more usual 'firing rate' of neurons. The comparison of patterns over sets of analogue variables is done by a network using different delays for different information paths. This mode of computation explains how one scheme of neuroarchitecture can be used for very different sensory modalities and seemingly different computations. The oscillations and anatomy of the mammalian olfactory systems have a simple interpretation in terms of this representation, and relate to processing in the auditory system. Single-electrode recording would plot detect such neural computing. Recognition 'units' in this style respond more like radial basis function units than elementary sigmoid un its.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology	HOPFIELD, JJ (corresponding author), CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125, USA.							ADRIAN ED, 1941, J PHYSIOL-LONDON, V100, P459; ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; Aticky JJ, 2011, NETWORK-COMP NEURAL, V22, P4, DOI [10.1088/0954-898X/3/2/009, 10.3109/0954898X.2011.638888]; BIALEK W, 1992, TRENDS NEUROSCI, V15, P428, DOI 10.1016/0166-2236(92)90005-S; BULLOCK TH, 1993, ANNU REV NEUROSCI, V16, P1, DOI 10.1146/annurev.ne.16.030193.000245; Burgess N, 1993, ADV NEURAL INFORMATI, V5, P929; CARR CE, 1988, P NATL ACAD SCI USA, V85, P8311, DOI 10.1073/pnas.85.21.8311; CARR CE, 1990, J NEUROSCI, V10, P3227; DELANEY KR, 1994, P NATL ACAD SCI USA, V91, P669, DOI 10.1073/pnas.91.2.669; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; GIROSI F, 1990, BIOL CYBERN, V63, P169, DOI 10.1007/BF00195855; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; HABERLY LB, 1985, CHEM SENSES, V10, P219, DOI 10.1093/chemse/10.2.219; HARNISCHFEGER G, 1985, J NEUROPHYSIOL, V53, P89, DOI 10.1152/jn.1985.53.1.89; HEILIGENBERG WF, 1991, NEURAL NETS ELECTRIC, P51; Herz J., 1991, INTRO THEORY NEURAL; HOSSAM O, 1994, NEURAL COMPUTAT, V6, P927; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; KUWABARA N, 1993, J NEUROPHYSIOL, V69, P1713, DOI 10.1152/jn.1993.69.5.1713; LAURENT G, 1994, J NEUROSCI, V14, P2993; MCCLURKIN JW, 1991, SCIENCE, V253, P675, DOI 10.1126/science.1908118; Nickell W.T., 1992, SCIENCE OLFACTION, P172; Perkel D.H., 1968, NEUROSCI RES PROGRAM, V6, P221; REICHARDT W, 1957, Z NATURFORSCH PT B, V12, P448, DOI 10.1515/znb-1957-0707; REVIAL MF, 1982, CHEM SENSES, V7, P175, DOI 10.1093/chemse/7.2.175; RODIECK RW, 1973, VERTEBRATE RETINA; Shepherd G, 1979, SYNAPTIC ORG BRAIN, P289; SHEPHERD GM, 1979, BRAIN RES, V175, P377, DOI 10.1016/0006-8993(79)91020-5; SHEPHERD GM, 1979, SYNAPTIC ORG BRAIN, P152; SILVA LR, 1991, SCIENCE, V252, P432; TANK DW, 1987, P NATL ACAD SCI USA, V84, P1896, DOI 10.1073/pnas.84.7.1896; TANK DW, 1994, SCIENCE, V265, P1819, DOI 10.1126/science.265.5180.1819; UNNIKRISHNAN KP, 1991, IEEE T SIGNAL PROCES, V39, P698, DOI 10.1109/78.80888	33	812	846	1	66	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					33	36		10.1038/376033a0	http://dx.doi.org/10.1038/376033a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596429				2022-12-28	WOS:A1995RH11100054
J	PARK, HW; KIM, ST; SANCAR, A; DEISENHOFER, J				PARK, HW; KIM, ST; SANCAR, A; DEISENHOFER, J			CRYSTAL-STRUCTURE OF DNA PHOTOLYASE FROM ESCHERICHIA-COLI	SCIENCE			English	Article							T4 ENDONUCLEASE-V; X-RAY-DIFFRACTION; THYMINE PHOTODIMER; ANACYSTIS-NIDULANS; ELECTRON-TRANSFER; MACROMOLECULAR CRYSTALLOGRAPHY; PYRIMIDINE DIMERS; ENERGY-TRANSFER; ACTIVE FORM; BINDING	Photolyase repairs ultraviolet (UV) damage to DNA by splitting the cyclobutane ring of the major UV photoproduct, the cis,syn-cyclobutane pyrimidine dimer (Pyr >$($) over bar Pyr). The reaction is initiated by blue light and proceeds through long-range energy transfer, single electron transfer, and enzyme catalysis by a radical mechanism. The three-dimensional crystallographic structure of DNA photolyase from Escherichia coli is presented and the atomic model was refined to an R value of 0.172 at 2.3 Angstrom resolution. The polypeptide chain of 471 amino acids is folded into an amino-terminal alpha/beta domain resembling dinucleotide binding domains and a carboxyl-terminal helical domain; a loop of 72 residues connects the domains. The light-harvesting cofactor 5,10-methenyltetrahydrofolylpolyglutamate (MTHF) binds in a cleft between the two domains. Energy transfer from MTHF to the catalytic cofactor flavin adenine dinucleotide (FAD) occurs over a distance of 16.8 Angstrom. The FAD adopts a U-shaped conformation between two helix clusters in the center of the helical domain and is accessible through a hole in the surface of this domain. Dimensions and polarity of the hole match those of a Pyr >$($) over bar Pyr dinucleotide, suggesting that the Pyr >$($) over bar Pyr ''flips out'' of the helix to fit into this hole, and that electron transfer between the flavin and the Pyr >$($) over bar Pyr occurs over van der Waals contact distance.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	PARK, HW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM31082] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031082, R37GM031082] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BAER ME, 1993, J BIOL CHEM, V268, P16717; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHEN P, 1992, J MOL BIOL, V227, P283, DOI 10.1016/0022-2836(92)90698-J; COLONNACESARI F, 1986, J BIOL CHEM, V261, P5273; DEISENHOFER J, 1991, ANNU REV CELL BIOL, V7, P1; Forster T., 1959, DISCUSS FARADAY SOC, V27, P7, DOI DOI 10.1039/DF9592700007; FOX ME, 1994, MOL CELL BIOL, V14, P8071, DOI 10.1128/MCB.14.12.8071; HAMMALVAREZ S, 1989, J BIOL CHEM, V264, P9649; HAMMALVAREZ S, 1990, J BIOL CHEM, V265, P18656; Harm W, 1980, BIOL EFFECTS ULTRAVI; HAYES FN, 1971, J AM CHEM SOC, V93, P4940, DOI 10.1021/ja00748a065; HEELIS PF, 1990, BIOCHEMISTRY-US, V29, P5694, DOI 10.1021/bi00476a008; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; HUSAIN I, 1987, NUCLEIC ACIDS RES, V15, P1109; HUSAIN I, 1988, P NATL ACAD SCI USA, V85, P2558, DOI 10.1073/pnas.85.8.2558; INAOKA T, 1989, J BIOL CHEM, V264, P2609; ISHIDA M, 1990, BIOCHEMISTRY-US, V29, P3817, DOI 10.1021/bi00468a002; JANIN J, 1990, J BIOL CHEM, V265, P16027; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; JORNS MS, 1985, BIOCHEMISTRY-US, V24, P1856, DOI 10.1021/bi00329a008; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KATO T, 1994, NUCLEIC ACIDS RES, V22, P4119, DOI 10.1093/nar/22.20.4119; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; Kim S.O., UNPUB; KIM ST, 1991, BIOCHEMISTRY-US, V30, P11262, DOI 10.1021/bi00111a011; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; KIM ST, 1992, P NATL ACAD SCI USA, V89, P900, DOI 10.1073/pnas.89.3.900; KIM ST, 1993, P NATL ACAD SCI USA, V90, P8023, DOI 10.1073/pnas.90.17.8023; KIM ST, 1993, PHOTOCHEM PHOTOBIOL, V57, P895, DOI 10.1111/j.1751-1097.1993.tb09232.x; KIM ST, 1992, BIOCHEMISTRY-US, V31, P11244, DOI 10.1021/bi00160a040; KIM ST, 1994, J AM CHEM SOC, V116, P3115, DOI 10.1021/ja00086a048; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Kleywegt G. J., UNPUB; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE BJ, 1994, BIOCHEMISTRY-US, V33, P57, DOI 10.1021/bi00167a008; LI YF, 1990, BIOCHEMISTRY-US, V29, P5698, DOI 10.1021/bi00476a009; LI YF, 1990, BIOCHEMISTRY-US, V30, P6322; MALHOTRA K, 1992, J BIOL CHEM, V267, P15406; MALHOTRA K, 1994, BIOCHEMISTRY-US, V33, P8712, DOI 10.1021/bi00195a012; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MALHOTRA K, UNPUB; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; MIKI K, 1993, J MOL BIOL, V233, P167, DOI 10.1006/jmbi.1993.1492; MOFFAT K, 1989, ANNU REV BIOPHYS BIO, V18, P309, DOI 10.1146/annurev.biophys.18.1.309; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; Nicholls A., 1992, GRASP GRAPHICAL REPR; OKAMURA T, 1991, J AM CHEM SOC, V113, P3143, DOI 10.1021/ja00008a050; OKAMURA T, 1994, J AM CHEM SOC, V116, P3115; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PARK HW, 1993, J MOL BIOL, V231, P1122, DOI 10.1006/jmbi.1993.1356; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P5706, DOI 10.1021/bi00476a010; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; RAO SN, 1984, NUCLEIC ACIDS RES, V12, P4789, DOI 10.1093/nar/12.11.4789; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REARDON JT, UNPUB; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; RUPERT CS, 1958, J GEN PHYSIOL, V41, P451, DOI 10.1085/jgp.41.3.451; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR GB, 1985, BIOCHEMISTRY-US, V24, P1849, DOI 10.1021/bi00329a007; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SEAWELL PC, 1980, BIOCHEMISTRY-US, V19, P1685, DOI 10.1021/bi00549a026; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; STELGEMANN W, 1992, PROGRAM SYSTEM CRYST; STOLARSKI R, 1992, SCIENCE, V256, P342, DOI 10.1126/science.256.5055.342; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TODO T, 1994, MUTAT RES-DNA REPAIR, V315, P213, DOI 10.1016/0921-8777(94)90033-7; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; VRIEND G, 1991, PROTEINS, V11, P52, DOI 10.1002/prot.340110107; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; YAJIMA H, 1991, NUCLEIC ACIDS RES, V19, P5359, DOI 10.1093/nar/19.19.5359; YASUHIRA S, 1992, J BIOL CHEM, V267, P25644	88	473	487	2	67	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1866	1872		10.1126/science.7604260	http://dx.doi.org/10.1126/science.7604260			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604260				2022-12-28	WOS:A1995RF99000029
J	HOHFELD, J; MINAMI, Y; HARTL, FU				HOHFELD, J; MINAMI, Y; HARTL, FU			HIP, A NOVEL COCHAPERONE INVOLVED IN THE EUKARYOTIC HSC70/HSP40 REACTION CYCLE	CELL			English	Article							HEAT-SHOCK PROTEINS; BINDING-SPECIFICITY; ATPASE; CLONING; HSP90; HSP70; DNAK; IDENTIFICATION; EXPRESSION; FRAGMENT	The Hsc70-interacting protein Hip, a tetratricopeptide repeat protein, participates in the regulation of the eukaryotic 70 kDa heat shock cognate Hsc70. One Hip oligomer binds the ATPase domains of at least two Hsc70 molecules dependent on activation of the Hsc70 ATPase by Hsp40. While hydrolysis remains the rate-limiting step in the ATPase cycle, Hip stabilizes the ADP state of Hsc70 that has a high affinity for substrate protein. Through its own chaperone activity, Hip may contribute to the interaction of Hsc70 with various target proteins. We propose a mechanism for the regulation of eukaryotic Hsc70 that is distinct from that of bacterial Hsp70. The Hsc70/Hsp40/Hip system is apparently independent of a GrpE-like nucleotide exchange factor.	HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048742] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48742] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1988, MOL REPROD DEV; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CHAPPEL TG, 1987, J BIOL CHEM, V252, P746; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HARLOW W, 1988, ANTIBODIES LABORATOR; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOHFELD J, 1994, CURR OPIN CELL BIOL, V6, P499, DOI 10.1016/0955-0674(94)90068-X; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEWIN B, 1990, GENES, V4, P120; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9407; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; UPARANUKRAW P, 1993, MOL BIOCHEM PARASIT, V33, P101; WANG TF, 1993, J BIOL CHEM, V268, P26049; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412; [No title captured]	46	352	365	0	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 17	1995	83	4					589	598						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585962				2022-12-28	WOS:A1995TF24800012
J	KINOSHITA, N; MINSHULL, J; KIRSCHNER, MW				KINOSHITA, N; MINSHULL, J; KIRSCHNER, MW			THE IDENTIFICATION OF 2 NOVEL LIGANDS OF THE FGF RECEPTOR BY A YEAST SCREENING METHOD AND THEIR ACTIVITY IN XENOPUS DEVELOPMENT	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; AMINO-ACID SEQUENCE; SACCHAROMYCES-CEREVISIAE; PANCREATIC RIBONUCLEASE; MIDBLASTULA TRANSITION; MESODERM INDUCTION; BINDING-PROTEIN; FACTOR-II; GENE; EXPRESSION	We have developed a functional screen in yeast to identify ligands for receptor tyrosine kinases, Using this method, we cloned two Xenopus genes that activate the fibroblast growth factor (FGF) receptor. These encode novel secreted proteins, designated FRL1 and FRL2, distantly related to the epidermal growth factor and angiogenin/ribonuclease families, respectively. Both genes activate the FGF receptor in Xenopus oocytes as well as in yeast. Overexpression induces mesoderm and neural-specific genes in Xenopus explants; induction Is blocked by a dominant negative inhibitor of the FGF receptor. FRL1 is broadly expressed during gastrulation and neurulation, while FRL2 is expressed principally in the axial mesoderm and brain at later stages. Our results indicate that despite their lack of similarity with FGF, FRL1 and FRL2 are ligands for the FGF receptor that play distinct roles in development.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	KINOSHITA, N (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.			Kinoshita, Noriyuki/0000-0002-1362-4045				AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BASSEZ T, 1990, DEVELOPMENT, V110, P955; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BOND MD, 1993, BIOCHIM BIOPHYS ACTA, V1162, P177, DOI 10.1016/0167-4838(93)90145-H; BOND MD, 1990, BIOCHEM BIOPH RES CO, V171, P988, DOI 10.1016/0006-291X(90)90781-H; BRANDLI AW, 1995, DEV DYNAM, V203, P119; BYERS S, 1992, DEV BIOL, V152, P411, DOI 10.1016/0012-1606(92)90149-B; CARLSON M, 1983, MOL CELL BIOL, V3, P439, DOI 10.1128/MCB.3.3.439; CARSANA A, 1988, NUCLEIC ACIDS RES, V16, P5491, DOI 10.1093/nar/16.12.5491; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; CORNELL RA, 1994, DEVELOPMENT, V120, P453; DONO R, 1993, DEVELOPMENT, V118, P1157; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; Faber J., 1994, NORMAL TABLE XENOPUS, P2; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GALLWITZ D, 1981, NUCLEIC ACIDS RES, V9, P6339, DOI 10.1093/nar/9.23.6339; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATI-BRIVANLOUA, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HOPP TP, 1986, BIOTECHNOLOGY, V6, P1205; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KAY BK, 1990, P NATL ACAD SCI USA, V87, P1367, DOI 10.1073/pnas.87.4.1367; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABONNE C, 1994, DEVELOPMENT, V120, P463; LUSTIG KD, 1995, P NATL ACAD SCI USA, V92, P6234, DOI 10.1073/pnas.92.14.6234; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; LYONS S, 1984, P NATL ACAD SCI-BIOL, V81, P7426, DOI 10.1073/pnas.81.23.7426; MAES P, 1988, FEBS LETT, V241, P41, DOI 10.1016/0014-5793(88)81027-5; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; RECHLER MM, 1980, ENDOCRINOLOGY, V107, P1451, DOI 10.1210/endo-107-5-1451; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SCHULLER C, 1990, MOL BIOL EVOL, V7, P29; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMYTH DG, 1963, J BIOL CHEM, V238, P227; TITANI K, 1987, BIOCHEMISTRY-US, V26, P2189, DOI 10.1021/bi00382a018; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WESTERMARK B, 1991, CANCER RES, V51, P2087; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	56	131	133	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					621	630		10.1016/0092-8674(95)90102-7	http://dx.doi.org/10.1016/0092-8674(95)90102-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585965	Bronze			2022-12-28	WOS:A1995TF24800015
J	FERRELL, BA				FERRELL, BA			PAIN EVALUATION AND MANAGEMENT IN THE NURSING-HOME	ANNALS OF INTERNAL MEDICINE			English	Article							PATIENT-CONTROLLED ANALGESIA; LOW-BACK-PAIN; DIABETIC NEUROPATHY; CANCER-PATIENTS; TOPICAL CAPSAICIN; AGE; NARCOTICS; NEURALGIA; THERAPY; PROGRAM	As many as 45% to 80% of nursing home residents have pain that contributes materially to functional impairment and decreased quality of life. Substantial barriers, including a high frequency of dementia, multiple pain problems, and increased sensitivity to drug side effects often make pain assessment and management more difficult in the nursing home setting. Logistic problems in carrying out diagnostic procedures and management interventions are also common. Pain can be alleviated in nursing homes through the careful use of analgesic drugs combined with nonpharmacologic strategies, including exercise programs and other physical therapies. Elderly nursing home residents are more sensitive to the side effects associated with many analgesic drugs, but this does not justify the failure to treat pain, especially in those who are terminally ill or near the end of life. Structured programs for routine pain assessment and treatment are needed. Physician involvement in pain assessment and management is necessary if pain control is to be improved for nursing home patients.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	FERRELL, BA (corresponding author), VET AFFAIRS MED CTR, 16111 PLUMMER ST, SEPULVEDA, CA 91343 USA.							[Anonymous], 1992, ACUTE PAIN MANAGEMEN; BARRIER G, 1989, INTENS CARE MED, V15, pS37, DOI 10.1007/BF00260882; BARSKY AJ, 1990, JAMA-J AM MED ASSOC, V264, P1132, DOI 10.1001/jama.264.9.1132; BAYER AJ, 1986, J AM GERIATR SOC, V34, P263, DOI 10.1111/j.1532-5415.1986.tb04221.x; BEAVER WT, 1988, AM J MED, V84, P3, DOI 10.1016/0002-9343(88)90471-8; BELLVILL.JW, 1971, J AMER MED ASSOC, V217, P1835, DOI 10.1001/jama.217.13.1835; BENDER JS, 1989, MED CLIN N AM, V73, P1413, DOI 10.1016/S0025-7125(16)30606-X; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; Branch L G, 1987, Clin Geriatr Med, V3, P29; CROOK J, 1986, ARCH PHYS MED REHAB, V67, P451; Davis M A, 1988, Clin Geriatr Med, V4, P241; DEYO RA, 1990, NEW ENGL J MED, V322, P1627, DOI 10.1056/NEJM199006073222303; EGBERT AM, 1990, ARCH INTERN MED, V150, P1897, DOI 10.1001/archinte.150.9.1897; Ferrell B R, 1991, Oncol Nurs Forum, V18, P1303; Ferrell B R, 1991, J Clin Ethics, V2, P108; FERRELL BA, 1990, J AM GERIATR SOC, V38, P409, DOI 10.1111/j.1532-5415.1990.tb03538.x; FERRELL BA, 1991, J AM GERIATR SOC, V39, P64, DOI 10.1111/j.1532-5415.1991.tb05908.x; FERRELL BA, 1995, IN PRESS J PAIN SYMP; FERRELL BR, 1994, J PAIN SYMPTOM MANAG, V9, P221, DOI 10.1016/0885-3924(94)90099-X; FERRELL BR, 1993, CANCER-AM CANCER SOC, V72, P3426, DOI 10.1002/1097-0142(19931201)72:11+<3426::AID-CNCR2820721608>3.0.CO;2-D; FOLEY KM, 1987, MED CLIN N AM, V71, P207, DOI 10.1016/S0025-7125(16)30866-5; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; HANKS GW, 1987, DRUG ALCOHOL DEPEN, V20, P339, DOI 10.1016/0376-8716(87)90007-X; HARKINS SW, 1984, RECENT ADV MANAGEMEN, V7; HARKINS SW, 1992, HDB PAIN ASSESSMENT; Herr K A, 1993, Appl Nurs Res, V6, P39; HURLEY AC, 1992, RES NURS HEALTH, V15, P369, DOI 10.1002/nur.4770150506; JACOX A, 1994, AHCPR940592 PUBL; KAIKO RF, 1982, MED CLIN N AM, V66, P1079, DOI 10.1016/S0025-7125(16)31383-9; KAIKO RF, 1980, CLIN PHARMACOL THER, V28, P823, DOI 10.1038/clpt.1980.241; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; KANE RL, 1989, ESSENTIALS CLIN GERI; KANTOR TG, 1984, ANALGESICS NEUROCHEM; KERR IG, 1988, ANN INTERN MED, V108, P554, DOI 10.7326/0003-4819-108-4-554; LAU-TING C, 1988, SMJ Singapore Medical Journal, V29, P164; LAVSKYSHULAN M, 1985, J AM GERIATR SOC, V33, P23, DOI 10.1111/j.1532-5415.1985.tb02855.x; LEE CR, 1993, DRUGS, V46, P313, DOI 10.2165/00003495-199346020-00008; LINDSTROM P, 1987, PAIN, V28, P45, DOI 10.1016/0304-3959(87)91058-X; MAX MB, 1994, PROG PAIN RES MANAG, V1, P229; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; MELDING PS, 1991, PAIN, V46, P119, DOI 10.1016/0304-3959(91)90064-5; MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27; NISHIKAWA ST, 1993, CLIN GERIATR ISSUES, V1, P15; NORMAN DC, 1983, J AM GERIATR SOC, V31, P677, DOI 10.1111/j.1532-5415.1983.tb04154.x; OUSLANDER J, 1991, MED CARE NURSING HOM; OUSLANDER JG, 1989, JAMA-J AM MED ASSOC, V262, P2582, DOI 10.1001/jama.262.18.2582; PARMELEE PA, 1991, J GERONTOL, V46, pP15, DOI 10.1093/geronj/46.1.P15; PARMELEE PA, 1993, J AM GERIATR SOC, V41, P517, DOI 10.1111/j.1532-5415.1993.tb01888.x; PAYNE R, 1992, J PAIN SYMPTOM MANAG, V7, pS40, DOI 10.1016/0885-3924(92)90052-J; PERNEGER TV, 1994, NEW ENGL J MED, V331, P1675, DOI 10.1056/NEJM199412223312502; PORTENOY RK, 1987, SEMIN NEUROL, V7, P139, DOI 10.1055/s-2008-1041414; PORTENOY RK, 1991, APS B, V1, P4; RAUCK RL, 1994, CURR THER RES CLIN E, V55, P1417, DOI 10.1016/S0011-393X(05)80748-9; Rhiner M, 1993, Cancer Pract, V1, P137; ROCHON PA, 1993, ARCH INTERN MED, V153, P243, DOI 10.1001/archinte.153.2.243; ROTH SH, 1989, RHEUM DIS CLIN N AM, V15, P479; ROY R, 1986, CAN FAM PHYSICIAN, V32, P513; SHAPIRO RS, 1994, J PAIN SYMPTOM MANAG, V9, P1; SJOGREN P, 1989, PAIN, V39, P5, DOI 10.1016/0304-3959(89)90168-1; SORKIN BA, 1990, J GERONTOL, V45, pP64, DOI 10.1093/geronj/45.2.P64; STEINBERG RB, 1992, ANESTH ANALG, V75, P1014; STRACKE H, 1992, DIABETES CARE, V15, P1550, DOI 10.2337/diacare.15.11.1550; SWERDLOW M, 1988, PAIN CLINIC, V2, P3; TANDAN R, 1992, DIABETES CARE, V15, P15, DOI 10.2337/diacare.15.1.15; THORSTEINSSON G, 1987, GERIATRICS, V42, P75; WALL PD, 1990, TXB PAIN; Wall R T 3rd, 1990, Clin Geriatr Med, V6, P345; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WATSON CPN, 1988, PAIN, V33, P333, DOI 10.1016/0304-3959(88)90292-8; Whedon M, 1991, Oncol Nurs Forum, V18, P1135; ZULLICH SG, 1992, ANN PHARMACOTHER, V26, P539; 1992, AMA DRUG EVALUATIONS	74	214	222	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					681	687		10.7326/0003-4819-123-9-199511010-00007	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TA696	7574224				2022-12-28	WOS:A1995TA69600007
J	MAKADON, HJ; SILIN, JG				MAKADON, HJ; SILIN, JG			PREVENTION OF HIV-INFECTION IN PRIMARY-CARE - CURRENT PRACTICES, FUTURE POSSIBILITIES	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMPROVING PHYSICIAN COMPLIANCE; MEDICAL-PRACTICE; RISK ASSESSMENT; AIDS; ATTITUDES; PRACTITIONERS; GUIDELINES; EDUCATION; KNOWLEDGE	More than a decade has passed since the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome (AIDS) epidemic began; our failure to develop an effective vaccine and adequate medical treatments indicates that future research and practice must work to prevent the spread of HIV. We review the literature on the current HIV-prevention practices of primary care physicians and highlight opportunities for clinical prevention. Prevention is hindered in four ways: 1) by narrow conceptions of medical care and of the role of the physician; 2) by physicians' discomfort with discussing human sexuality and illicit drug use and their attitudes toward persons with HIV or AIDS; 3) by constraints on time and resources; and 4) by the ambiguity of HIV prevention messages. We suggest strategies to overcome these barriers, including modifications in public policy, health care delivery systems, and medical education. These strategies support a nonhierarchical physician-patient relationship, with attention to culture and values, that will help physicians to identify and work with persons at increased risk for HIV infection.	HARVARD UNIV, SCH MED, BOSTON, MA USA; UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, SAN FRANCISCO, CA USA; BANK ST COLL EDUC, NEW YORK, NY 10025 USA	Harvard University; Harvard Medical School; University of California System; University of California San Francisco	MAKADON, HJ (corresponding author), BETH ISRAEL HOSP, DIV GEN MED & PRIMARY CARE, LY 330, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							ADAMS PF, 1991, VITAL HLTH STAT, V181, P1; ALDERMAN M, 1994, NY TIMES        0624, P17; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BAILEY WA, 1992, 8 INT C AIDS AMST; BELCHER D W, 1988, American Journal of Preventive Medicine, V4, P27; BELL NK, 1991, AIDS ETHICS, P128; BOEKELOO BO, 1991, AM J PUBLIC HEALTH, V81, P1645, DOI 10.2105/AJPH.81.12.1645; CATES W, 1992, NEW ENGL J MED, V327, P492, DOI 10.1056/NEJM199208133270711; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V42, P988; CHOI KH, 1994, AIDS, V8, P1371, DOI 10.1097/00002030-199410000-00003; COHEN DI, 1982, MED CARE, V20, P1040, DOI 10.1097/00005650-198210000-00006; COOKE M, 1989, NEW ENGL J MED, V321, P1334, DOI 10.1056/NEJM198911093211911; DARDICK L, 1980, ANN INTERN MED, V93, P115, DOI 10.7326/0003-4819-93-1-115; DAVID AK, 1980, J FAM PRACTICE, V11, P77; EICKHOFF TC, 1994, ANN INTERN MED, V120, P310; ENDE J, 1984, ARCH INTERN MED, V144, P558, DOI 10.1001/archinte.144.3.558; FRAME PS, 1984, J FAM PRACTICE, V19, P341; FRANCIS DP, 1992, JAMA-J AM MED ASSOC, V268, P1444, DOI 10.1001/jama.268.11.1444; FRIEDMAN H, 1990, HDB HLTH BEHAVIOR; GEMSON DH, 1991, ARCH INTERN MED, V151, P1102, DOI 10.1001/archinte.151.6.1102; GEMSON DH, 1986, AM J PREV MED, V2, P226; GERBERT B, 1990, AM J PUBLIC HEALTH, V80, P467, DOI 10.2105/AJPH.80.4.467; GERBERT B, 1989, JAMA-J AM MED ASSOC, V262, P1969; GERBERT B, 1988, J AM DENT ASSOC, V116, P851, DOI 10.14219/jada.archive.1988.0273; GIFFORD AL, 1994, AM J PREV MED, V10, P5, DOI 10.1016/S0749-3797(18)30639-1; GIMMETT PP, 1992, REV RES EDUC, P385; GONZALEZWILLIS A, 1990, ACAD MED, V65, pS7, DOI 10.1097/00001888-199009000-00018; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUINAN ME, 1994, AM J PREV MED, V10, P1; HAMADEH G, 1987, J FAM PRACTICE, V25, P561; HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428; Hearst N, 1994, J Am Board Fam Pract, V7, P44; KASS NE, 1991, AIDS WOMEN NEXT GENE, P308; KELLY JA, 1994, AM J PUBLIC HEALTH, V84, P1918, DOI 10.2105/AJPH.84.12.1918; KELLY JA, 1987, AM J PUBLIC HEALTH, V77, P789, DOI 10.2105/AJPH.77.7.789; King E., 1993, SAFETY NUMBERS SAFER; KOTTKE TE, 1992, J FAM PRACTICE, V34, P701; KOTTKE TE, 1993, MAYO CLIN PROC, V68, P785, DOI 10.1016/S0025-6196(12)60638-7; LEVINE RJ, 1991, AIDS ETHICS, P188; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; Like R C, 1986, Fam Med, V18, P87; MANNING DT, 1989, J FAM PRACTICE, V29, P173; ODONNELL L, 1994, AIDS EDUC PREV, V6, P140; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; RABIN DL, 1994, ANN INTERN MED, V121, P513, DOI 10.7326/0003-4819-121-7-199410010-00007; ROTELLO G, 1994, OUT, V6, P148; SCHAPPERT SM, 1992, NATIONAL AMBULATORY; SHAPIRO JA, 1989, BRIT MED J, V298, P1563, DOI 10.1136/bmj.298.6687.1563; SHAPIRO MF, 1992, JAMA-J AM MED ASSOC, V268, P510, DOI 10.1001/jama.268.4.510; Silin JG., 1995, SEX DEATH ED CHILDRE; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P3157, DOI 10.1001/jama.267.23.3157; TAYLOR WC, 1994, MED EDUC, V28, P481, DOI 10.1111/j.1365-2923.1994.tb02723.x; TOSTESON DC, 1991, JAMA-J AM MED ASSOC, V265, P1022, DOI 10.1001/jama.265.8.1022; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; VALENTE C M, 1986, American Journal of Preventive Medicine, V2, P82; WALSH JME, 1992, HEALTH EDUC QUART, V19, P157, DOI 10.1177/109019819201900202; Weaver F J, 1978, Health Values, V2, P249; WECHSLER H, 1983, NEW ENGL J MED, V308, P97, DOI 10.1056/NEJM198301133080211; WHEAT ME, 1993, AM J PREV MED, V9, P307, DOI 10.1016/S0749-3797(18)30707-4; WINETT RA, 1993, HEALTH EDUC QUART, V20, P555, DOI 10.1177/109019819302000413; Witherell C., 1991, STORIES LIVES TELL N; 1978, NATIONWIDE SURVEY BA; 1994, MMWR-MORBID MORTAL W, V43, P285; 1988, INFORMATIONAL REPORT; 1991, HLTH PEOPLE 2000	65	40	40	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					715	719		10.7326/0003-4819-123-9-199511010-00010	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TA696	7574227				2022-12-28	WOS:A1995TA69600010
J	BOWIE, C; RICHARDSON, A; SYKES, W				BOWIE, C; RICHARDSON, A; SYKES, W			CONSULTING THE PUBLIC ABOUT HEALTH-SERVICE PRIORITIES	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Consulting the public is an important component of commissioning health services. Somerset Health Authority has devised a method of consultation using eight focus groups meeting three times a year. Each group consists of 12 people, and together the groups are demographically representative of Somerset's population. The groups are asked about issues that are concerning the health authority, and their views have influenced health authority decisions. Each group is given some background information before the meeting, together with more information at the meeting. The discussions are tape recorded and analysed for qualitative information, but the groups are also asked to score certain priorities, The groups have been found to be representative, valid, and focused on community rather than individual values. Health authorities wanting to know the values people attach to health services should adopt this qualitative approach to consultation.	SOMERSET HLTH AUTHOR, DEPT PUBL HLTH, TAUNTON TA2 7PQ, SOMERSET, ENGLAND					Bowie, Cam/0000-0002-6956-3691				HAM C, 1993, BMJ-BRIT MED J, V307, P435, DOI 10.1136/bmj.307.6901.435; KITZHABER JA, 1993, BRIT MED J, V307, P373, DOI 10.1136/bmj.307.6900.373; MOSTYN B, 1978, HDB MOTIVATIONAL ATT; MURRAY SA, 1994, BRIT MED J, V308, P698, DOI 10.1136/bmj.308.6930.698; PATTON MQ, 1986, UTILIZATION FOCUSED; POLLOCK AM, 1992, BRIT MED J, V305, P535, DOI 10.1136/bmj.305.6853.535; 1992, LOCAL VOICES VIEWS L	7	67	67	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	1995	311	7013					1155	1158		10.1136/bmj.311.7013.1155	http://dx.doi.org/10.1136/bmj.311.7013.1155			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580716	Green Published			2022-12-28	WOS:A1995TC46600027
J	HIRATA, J; NAKAGOSHI, H; NABESHIMA, Y; MATSUZAKI, F				HIRATA, J; NAKAGOSHI, H; NABESHIMA, Y; MATSUZAKI, F			ASYMMETRIC SEGREGATION OF THE HOMEODOMAIN PROTEIN PROSPERO DURING DROSOPHILA DEVELOPMENT	NATURE			English	Article							GENE; TRANSFORMATION; EMBRYOS; CELLS	ASYMMETRIC divisions that produce two distinct cells play fundamental roles in generating different cell types during development(1,2). In the Drosophila central nervous system, neural stem cells called neuroblasts divide unequally into another neuroblast and a ganglion mother cell which is Subsequently cleaved into neurons. Correct gene expression of ganglion mother tells requires the transcription factor Prospero(3-5). Here we demonstrate the asymmetric segregation of Prospero on neuroblast division, Prospero synthesized in neuroblasts is retained in the cytoplasm and at mitosis is exclusively partitioned to ganglion mother cells, in which it is translocated to the nucleus, Differential segregation of Prospero was also found in the endoderm. We have identified a region in Prospero that is responsible for this event, The region shares a common motif with Numb(6), which also shows unequal segregation(7). We propose that asymmetric segregation of transcription factors is an intrinsic mechanism for establishing asymmetry in gene expression between sibling cells.	UNIV TOKYO,FAC MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	HIRATA, J (corresponding author), NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DEPT MOLEC GENET,4-1-1 OGAWAHIGASHI,KODAIRA,TOKYO 187,JAPAN.		NAKAGOSHI, Hideki/B-2145-2011	NAKAGOSHI, Hideki/0000-0003-0850-1814				BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; PRATT WB, 1989, CANCER RES, V49, pS2222; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Skaer Helen, 1993, P941; SPANA EP, IN PRESS DEVELOPMENT; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; TEPASS U, 1995, DEVELOPMENT, V121, P393; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WARTON RP, 1991, CELL, V67, P955; ZINMAN M, 1993, MOL BIOL CELL, V4, P1307	27	300	300	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					627	630		10.1038/377627a0	http://dx.doi.org/10.1038/377627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566173				2022-12-28	WOS:A1995TA27500051
J	IHLE, JN				IHLE, JN			CYTOKINE RECEPTOR SIGNALING	NATURE			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; MOTH-EATEN; GENE; PHOSPHORYLATION; TRANSDUCTION; ASSOCIATION; MUTATIONS; KINASE; RAS	Many cell functions are regulated by members of the cytokine receptor superfamily. Signalling by these receptors depends upon their association with Janus kinases (JAKs), which couple ligand binding to tyrosine phosphorylation of signalling proteins recruited to the receptor complex. Among these are the signal transducers and activators of transcription (STATs), a family of transcription factors that contribute to the diversity of cytokine responses.			IHLE, JN (corresponding author), ST JUDE CHILDRENS RES HOSP, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COLAMONICI O, IN PRESS MOL CELL BI; CYSTER JG, 1995, IMMUNITY, V2, P1; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LI S, 1995, MOL CELL BIOL, V15, P2063; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYOUSSOUFIAN H, 1993, BLOOD, V9, P2223; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NOSAKA T, IN PRESS SCIENCE; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PAXTON WG, 1994, BIOCHEM BIOPH RES CO, V200, P260, DOI 10.1006/bbrc.1994.1443; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; QUELLE FW, IN PRESS J BIOL CHEM; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5561; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; RUSSELL SM, IN PRESS SCIENCE; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; THORNIS DC, IN PRESS SCIENCE; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YIN TG, 1994, J BIOL CHEM, V269, P26614; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZHANG Z, 1995, SCIENCE, V267, P1990; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	93	1100	1140	3	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					591	594		10.1038/377591a0	http://dx.doi.org/10.1038/377591a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566171				2022-12-28	WOS:A1995TA27500040
J	COLETURNER, R				COLETURNER, R			RELIGION AND GENE PATENTING	SCIENCE			English	Editorial Material											COLETURNER, R (corresponding author), MEMPHIS THEOL SEMINARY,168 E PKWY S,MEMPHIS,TN 38104, USA.							Cole-Turner Ronald, 1993, NEW GENESIS THEOLOGY; Holifield EB, 1986, HLTH MED METHODIST T; STONE R, 1995, SCIENCE, V268, P1126, DOI 10.1126/science.7761825; 1995, MAY F EC TRENDS GEN; 1995, US TODAY        0519, pA12	5	12	12	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					52	52		10.1126/science.270.5233.52	http://dx.doi.org/10.1126/science.270.5233.52			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	RY302	7569950				2022-12-28	WOS:A1995RY30200029
J	POON, RYC; HUNTER, T				POON, RYC; HUNTER, T			DEPHOSPHORYLATION OF CDK2 THR(160) BY THE CYCLIN-DEPENDENT KINASE-INTERACTING PHOSPHATASE KAP IN THE ABSENCE OF CYCLIN	SCIENCE			English	Article							GENE	The activation of cyclin-dependent kinases (CDKs) requires the phosphorylation of a conserved threonine (Thr(160) in Cdk2) by CDK-activating kinase (CAK). Human KAP (also called Cdl1), a CDK-associated phosphatase, was shown to dephosphorylate Thr(160) in human Cdk2. KAP was unable to dephosphorylate Tyr(15) and only dephosphorylated Thr(160) in native monomeric Cdk2. The binding of cyclin A to Cdk2 inhibited the dephosphorylation of Thr(160) by KAP but did not preclude the binding of KAP to the cyclin A-Cdk2 complex. Moreover, the dephosphorylation of Thr(160) bit KAP prevented Cdk2 kinase activity upon subsequent association with cyclin A. These results suggest that KAP binds to Cdk2 and dephosphorylates Thr(160) when the associated cyclin subunit is degraded or dissociates.			POON, RYC (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,10100 N TORREY PINES RD,LA JOLLA,CA 92037, USA.			Poon, Randy/0000-0001-5571-6231	NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, CA14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; POON RYC, 1994, ANAL BIOCHEM, V218, P26, DOI 10.1006/abio.1994.1137; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, UNPUB; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x	24	149	154	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					90	93		10.1126/science.270.5233.90	http://dx.doi.org/10.1126/science.270.5233.90			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569954				2022-12-28	WOS:A1995RY30200039
J	JOUAVILLE, LS; ICHAS, F; HOLMUHAMEDOV, EL; CAMACHO, P; LECHLEITER, JD				JOUAVILLE, LS; ICHAS, F; HOLMUHAMEDOV, EL; CAMACHO, P; LECHLEITER, JD			SYNCHRONIZATION OF CALCIUM WAVES BY MITOCHONDRIAL SUBSTRATES IN XENOPUS-LAEVIS OOCYTES	NATURE			English	Article							INOSITOL TRISPHOSPHATE; ACINAR-CELLS; PROPAGATION; MECHANISMS; CHANNELS; RECEPTOR; PROTEIN	IN Xenopus oocytes, as well as other cells, inositol-1,4,5-trisphosphate (Ins(1,4,5)P-3)-induced Ca2+ release(1-4) is an excitable process that generates propagating Ca2+ waves(5-7) that annihilate upon collision(8-12). The fundamental property responsible for excitability appears to be the Ca2+ dependency of the Ins(1,4,5)P-3 receptor(9). Here we report that Ins(1,4,5)P-3-induced Ca2+ were activity is strengthened by oxidizable substrates that energize mitochrondria, increasing Ca2+ wave amplitude, velocity and interwave period. The effects of pyruvate/malate are blocked by ruthenium red at the Ca2+ uniporter, by rotenone at complex I, and by antimycin A at complex III, and are subsequently rescued at complex IV by ascorbate tetramethylphenylenediamine (TMPD)(14). Our data reveal that potential-driven mitochondrial Ca2+ uptake is a major factor in the regulation of Ins(1,4,5)P-3-induced Ca2+ release and clearly demonstrate a physiological role of mitrochondria in intracellular Ca2+ signalling.			JOUAVILLE, LS (corresponding author), UNIV VIRGINIA,DEPT NEUROSCI,CHARLOTTESVILLE,VA 22908, USA.		Holmuhamedov, Ekhson L/P-5228-2016; Ichas, François/ABD-8277-2020	Holmuhamedov, Ekhson L/0000-0002-0809-350X; Ichas, François/0000-0001-8184-5248				BEMENT WM, 1989, CELL TISSUE RES, V255, P183; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BIRD GS, 1992, J BIOL CHEM, V267, P18382; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; CAHCON E, 1994, BIOPHYS J, V66, P942; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DELISLE S, 1992, J BIOL CHEM, V267, P7963; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GOLDSTONE TP, 1987, BIOCHEMISTRY-US, V26, P246, DOI 10.1021/bi00375a034; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PETERSEN OH, 1994, REV PHYSL, V56, P297; POZAN T, 1994, PHYSIOL REV, V74, P595; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SPEKSNIJDER JE, 1993, J CELL BIOL, V120, P1337, DOI 10.1083/jcb.120.6.1337; TOESCU EC, 1993, BIOCHEM BIOPH RES CO, V192, P854, DOI 10.1006/bbrc.1993.1493; WERTH JL, 1994, J NEUROSCI, V14, P348; WINFREE AT, 1980, GEOMETRY BIOL TIME, P246	30	356	362	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					438	441		10.1038/377438a0	http://dx.doi.org/10.1038/377438a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566122				2022-12-28	WOS:A1995RY19000052
J	SULLIVAN, F; MITCHELL, E				SULLIVAN, F; MITCHELL, E			HAS GENERAL-PRACTITIONER COMPUTING MADE A DIFFERENCE TO PATIENT-CARE - A SYSTEMATIC REVIEW OF PUBLISHED REPORTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-RECORD; COMPUTERIZED REMINDERS; CLINICAL-PRACTICE; CONTROLLED TRIAL; FAMILY-PRACTICE; MANAGEMENT; CONSULTATION; HYPERTENSION; INFORMATION; VACCINATION	Objective-To review findings from studies of the influence of desktop computers on primary care consultations. Design-Systematic review of world reports from 1984 to 1994. Setting-The computerised catalogues of Medline, BIDS, and GPlit were searched, as well as conference proceedings, books, bibliographies, and references in books and journal articles. Subjects-30 papers met the inclusion criteria and were included for detailed review. Interventions-A validated scheme for assessing methodological adequacy was used to score each paper. Main outcome measures-Papers were rated on sample formation, baseline differences, unit of allocation, outcome measures, and follow up. Differences in outcomes were also recorded. Results-Four of the six papers dealing with the consultation process showed that consultations took longer. Doctor initiated and ''medical'' content of consultations increased at the expense of a reduction in patient initiated and ''social'' content. Each of the 21 studies which looked at clinician performance showed an improvement when a computer was used (from 8% to 50%, with better results for single preventive measures). Only one of the three studies looking at patient outcomes showed an improvement (diastolic blood pressure control 5 mm Hg better after one year, with fewer doctor-patient consultations). Conclusions-Using a computer in the consultation may help improve clinician performance but may increase the length of the consultation. More studies are needed to assess the effects on patient outcomes of using a computer in consultations.			SULLIVAN, F (corresponding author), UNIV GLASGOW, WOODSIDE HLTH CTR, DEPT GEN PRACTICE, GLASGOW G20 7LR, LANARK, SCOTLAND.		Sullivan, Frank/L-8286-2019; Sullivan, Frank m/A-7767-2009	Sullivan, Frank/0000-0002-6623-4964; Mitchell, Elizabeth/0000-0002-2833-1632				BARNETT GO, 1984, NEW ENGL J MED, V310, P1643, DOI 10.1056/NEJM198406213102506; BLEICH HL, 1985, NEW ENGL J MED, V312, P756, DOI 10.1056/NEJM198503213121205; BRADLEY P, 1993, COMPUTING B, V49, P151; BROWNBRIDGE G, 1986, J ROY COLL GEN PRACT, V36, P198; BROWNBRIDGE G, 1985, BRIT MED J, V291, P639, DOI 10.1136/bmj.291.6496.639; Chalmers I, 1995, SYSTEMATIC REV; CHAMBERS CV, 1989, J FAM PRACTICE, V29, P273; Dick R.S., 1991, COMPUTER BASED PATIE; DONALD JB, 1986, BRIT MED J, V292, P937, DOI 10.1136/bmj.292.6525.937; DONALD JB, 1989, BRIT MED J, V299, P28, DOI 10.1136/bmj.299.6690.28; Essex B., 1994, DOCTORS DILEMMAS DEC; FEINSTEIN AR, 1972, LANCET, V2, P421; GARR DR, 1993, AM J PREV MED, V9, P55, DOI 10.1016/S0749-3797(18)30769-4; GEHLBACH SH, 1984, MED CARE, V22, P193, DOI 10.1097/00005650-198403000-00002; GILLILAND AEW, 1992, FAM PRACT, V9, P441, DOI 10.1093/fampra/9.4.441; Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HARRISS C, 1994, FAM PRACT, V11, P51, DOI 10.1093/fampra/11.1.51; HART JT, 1991, BMJ-BRIT MED J, V302, P1509, DOI 10.1136/bmj.302.6791.1509; HAYNES RB, 1987, ARCH INTERN MED, V147, P1297, DOI 10.1001/archinte.147.7.1297; HERZMARK G, 1984, J ROY COLL GEN PRACT, V34, P649; JOHNSON P, 1991, PRACTICE COMPUTING, V6, P47; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kinn S., 1994, British Journal of Healthcare Computing & Information Management, V11, P21; LEANING MS, 1993, BRIT MED J, V307, P217, DOI 10.1136/bmj.307.6898.217; LLEWELYN H, 1993, ANAL WE REACH CLIN D; MAZZUCA SA, 1990, AM EDUC RES J, V27, P473, DOI 10.3102/00028312027003473; MCALISTER NH, 1986, BRIT MED J, V293, P670, DOI 10.1136/bmj.293.6548.670; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDONALD CJ, 1992, MD COMPUT, V7, P532; MCDOWELL I, 1989, J FAM PRACTICE, V28, P420; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; MCDOWELL I, 1986, CAN MED ASSOC J, V135, P991; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; ORNSTEIN SM, 1991, J FAM PRACTICE, V32, P82; PRINGLE M, 1990, BRIT MED J, V301, P827, DOI 10.1136/bmj.301.6756.827; PRINGLE M, 1985, BRIT MED J, V290, P1789, DOI 10.1136/bmj.290.6484.1789; PRINGLE M, 1986, BRIT MED J, V293, P20, DOI 10.1136/bmj.293.6538.20; PRINGLE M, 1985, BRIT MED J, V290, P1709, DOI 10.1136/bmj.290.6483.1709; RECTOR AL, 1991, METHOD INFORM MED, V30, P179; RETHANS JJ, 1988, BRIT MED J, V296, P1446, DOI 10.1136/bmj.296.6634.1446; ROLAND MO, 1985, BRIT MED J, V291, P456, DOI 10.1136/bmj.291.6493.456; ROSSER WW, 1992, CAN MED ASSOC J, V146, P911; SHELDON M, 1994, DECISION MAKING GENE; SHORTLIFFE EH, 1990, MED INFORMATICS; SPENCE J, 1953, LANCET, V1, P275; SULLIVAN FM, 1992, THEORETICAL SURGERY, V7, P454; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; WEINGARTEN MA, 1989, FAM PRACT, V6, P120, DOI 10.1093/fampra/6.2.120; WYATT J, 1991, 15TH P ANN S COMP AP, P3; WYATT JC, 1994, LANCET, V344, P1682, DOI 10.1016/S0140-6736(94)90463-4; WYATT JC, 1994, LANCET, V344, P1543, DOI 10.1016/S0140-6736(94)90353-0; 1994, IMPLEMENTING CLIN PR; 1993, COMPUTERISATIONS GP	56	132	133	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 30	1995	311	7009					848	852		10.1136/bmj.311.7009.848	http://dx.doi.org/10.1136/bmj.311.7009.848			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580494	Green Published			2022-12-28	WOS:A1995RY19100025
J	NIELSEN, FC; OSTERGAARD, L; NIELSEN, J; CHRISTIANSEN, J				NIELSEN, FC; OSTERGAARD, L; NIELSEN, J; CHRISTIANSEN, J			GROWTH-DEPENDENT TRANSLATION OF IGF-II MESSENGER-RNA BY A RAPAMYCIN-SENSITIVE PATHWAY	NATURE			English	Article							RIBOSOMAL PROTEIN-S6; INSULIN; KINASE; CELLS; DNA	INSULIN-LIKE growth factor (IGF)-II is important for fetal growth and development(1). The human IGF-II gene generates multiple mature transcripts with different 5' untranslated regions (5'UTRs) but identical coding regions and 3'UTRs(2). We have previously shown that a minor 4.8-kilobase messenger RNA was engaged in the synthesis of preproIGF-II, and a major 6.0-kb mRNA was untranslated and stored in a 100S ribonucleoprotein particle(3). Here we demonstrate that the 6.0-kb mRNA is selectively mobilized and translated in dispersed exponentially growing cells. Translational activation is prevented by rapamycin and mimicked by anisomycin, which suggests that translation of the 6.0-kb mRNA is regulated by the p70(S6k)/85(S6k) kinase signalling pathway. Therefore, the minor 4.8-kb mRNA generates a constitutive production of preproIGF-II, whereas the major 6.0-kb mRNA provides a post-transcriptionally regulated species.	UNIV COPENHAGEN,INST MOLEC BIOL,DK-1307 COPENHAGEN K,DENMARK; RIGSHOSP,DEPT CLIN BIOCHEM,DK-2100 COPENHAGEN 0,DENMARK	University of Copenhagen; Rigshospitalet; University of Copenhagen			Ostergaard, Lars/AAA-3020-2020; Christiansen, Jan/L-3312-2014; Nielsen, Finn Cilius/AAA-4926-2020	Ostergaard, Lars/0000-0003-2459-0511; Christiansen, Jan/0000-0001-8624-4601; Ostergaard, Lars/0000-0002-7619-605X; Nielsen, Jacob/0000-0001-9842-2276				AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEMOOR CH, 1995, BIOCHEM J, V307, P225, DOI 10.1042/bj3070225; DILLING MB, 1994, CANCER RES, V54, P903; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JENO P, 1989, J BIOL CHEM, V264, P1293; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NEWELL S, 1994, MOL REPROD DEV, V39, P249, DOI 10.1002/mrd.1080390302; NIELSEN FC, 1992, J BIOL CHEM, V267, P19404; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; Nielsen Finn Cilius, 1992, Progress in Growth Factor Research, V4, P257, DOI 10.1016/0955-2235(92)90023-B; OHLSSON R, 1989, EMBO J, V8, P1993, DOI 10.1002/j.1460-2075.1989.tb03606.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0	29	155	156	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					358	362		10.1038/377358a0	http://dx.doi.org/10.1038/377358a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566093				2022-12-28	WOS:A1995RX11100062
J	SHORT, N				SHORT, N			ON FIRST LOOKING INTO THE HUMAN GENOME - FOREWORD	NATURE			English	Editorial Material																			0	2	2	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			1	1						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566095				2022-12-28	WOS:A1995TA34300001
J	PAUL, REL; PACKER, MJ; WALMSLEY, M; LAGOG, M; RANFORDCARTWRIGHT, LC; PARU, R; DAY, KP				PAUL, REL; PACKER, MJ; WALMSLEY, M; LAGOG, M; RANFORDCARTWRIGHT, LC; PARU, R; DAY, KP			MATING PATTERNS IN MALARIA PARASITE POPULATIONS OF PAPUA-NEW-GUINEA	SCIENCE			English	Article							ANOPHELES-PUNCTULATUS COMPLEX; PLASMODIUM-FALCIPARUM; GENETIC DIVERSITY; SPOROZOITE RATES; TRANSMISSION; EPIDEMIOLOGY; RESISTANCE; MADANG; AREA	Description of the genetic structure of malaria parasite populations is central to an understanding of the spread of multiple-locus drug and vaccine resistance. The Plasmodium falciparum mating patterns from Madang, Papua New Guinea, where intense transmission of malaria occurs, are described here. A high degree of inbreeding occurs in the absence of detectable linkage disequilibrium. This contrasts with other studies, indicating that the genetic structure of malaria parasite populations is neither clonal nor panmictic but will vary according to the transmission characteristics of the region.	UNIV OXFORD, DEPT ZOOL, WELLCOME CTR EPIDEMIOL INFECT DIS, OXFORD OX1 3PS, ENGLAND; PAPUA NEW GUINEA INST MED RES, MADANG, PAPUA N GUINEA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, LONDON SW7 2BB, ENGLAND; UNIV EDINBURGH, INST CELL ANIM & POPULAT BIOL, DIV BIOL SCI, EDINBURGH EH9 3JT, MIDLOTHIAN, SCOTLAND	University of Oxford; PNG Institute Of Medical Research; Imperial College London; University of Edinburgh			Day, Karen/F-3697-2015; Ranford-Cartwright, Lisa C/H-4701-2013	Day, Karen/0000-0002-6115-6135; Ranford-Cartwright, Lisa C/0000-0003-1992-3940	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AITKIN M, 1989, STATISTICAL MODELLIN; BABIKER H, 1994, T ROY SOC TROP MED H, V88, P328, DOI 10.1016/0035-9203(94)90103-1; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BORRE MB, 1991, MOL BIOCHEM PARASIT, V49, P119, DOI 10.1016/0166-6851(91)90135-S; BURKOT TR, 1989, AM J TROP MED HYG, V40, P229, DOI 10.4269/ajtmh.1989.40.229; BURKOT TR, 1988, AM J TROP MED HYG, V39, P135, DOI 10.4269/ajtmh.1988.39.135; CARTER R, 1975, T ROY SOC TROP MED H, V69, P371, DOI 10.1016/0035-9203(75)90191-1; CATTANI JA, 1986, AM J TROP MED HYG, V35, P3, DOI 10.4269/ajtmh.1986.35.3; CATTANI JA, 1986, PAPUA NEW GUINEA MED, V29, P11; CAUGANT DA, 1981, GENETICS, V98, P467; CONWAY DJ, 1991, T ROY SOC TROP MED H, V85, P454, DOI 10.1016/0035-9203(91)90217-M; CONWAY DJ, 1991, PARASITOLOGY, V103, P7, DOI 10.1017/S0031182000059229; Crawley M.J., 1993, GLIM ECOLOGISTS; CURTIS CF, 1986, T ROY SOC TROP MED H, V80, P889, DOI 10.1016/0035-9203(86)90248-8; DAY KP, 1992, PARASITOLOGY, V104, pS35, DOI 10.1017/S0031182000075235; DYE C, 1992, MODELLING VECTOR BOR, P165; GUPTA S, 1994, PARASITOL TODAY, V10, P476, DOI 10.1016/0169-4758(94)90160-0; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; Hartl D., 1989, PRINCIPLES POPULATIO; Hartl DL, 1992, CURR OPIN GENET DEV, V2, P937, DOI 10.1016/S0959-437X(05)80119-4; HILL WG, 1995, GENET RES, V65, P53, DOI 10.1017/S0016672300033000; KEMP DJ, 1990, ADV PARASIT, V29, P75; KOELLA JC, 1990, T ROY SOC TROP MED H, V84, P662, DOI 10.1016/0035-9203(90)90135-2; LENSKI RE, 1993, P NATL ACAD SCI USA, V90, P4334, DOI 10.1073/pnas.90.10.4334; MARSHALL VM, 1993, PROTOCOLS MOL PARASI, V21, P223; MAYNARDSMITH J, 1993, P NATIONAL ACADEMY S, V90, P4384; RANFORDCARTWRIGHT LC, 1991, MOL BIOCHEM PARASIT, V49, P239, DOI 10.1016/0166-6851(91)90067-G; RANFORDCARTWRIGHT LC, 1993, PARASITOLOGY, V107, P11, DOI 10.1017/S003118200007935X; READ AF, 1992, PARASITOLOGY, V104, P387, DOI 10.1017/S0031182000063630; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; TIBAYRENC M, 1991, P NATL ACAD SCI USA, V88, P5129, DOI 10.1073/pnas.88.12.5129; TIBAYRENC M, 1991, PARASITOL TODAY, V7, P228, DOI 10.1016/0169-4758(91)90234-F; TRIGLIA T, 1992, PARASITOL TODAY, V8, P225, DOI 10.1016/0169-4758(92)90118-L; VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85; WALLIKER D, 1991, PARASITOL TODAY, V7, P232, DOI 10.1016/0169-4758(91)90235-G; WALLIKER D, 1989, EXP PARASITOL, V69, P303, DOI 10.1016/0014-4894(89)90078-7; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI [10.2307/2408641, 10.1111/j.1558-5646.1984.tb05657.x]; Wright S., 1969, THEORY GENE FREQUENC, V2, P520	38	267	274	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 22	1995	269	5231					1709	1711		10.1126/science.7569897	http://dx.doi.org/10.1126/science.7569897			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569897				2022-12-28	WOS:A1995RV94800034
J	SIVILOTTI, L; COLQUHOUN, D				SIVILOTTI, L; COLQUHOUN, D			ACETYLCHOLINE-RECEPTORS - TOO MANY CHANNELS, TOO FEW FUNCTIONS	SCIENCE			English	Editorial Material							RAT HIPPOCAMPAL-NEURONS; CURRENTS; PERMEABILITY; SUBTYPES; SUBUNIT; CORTEX; BRAIN		UCL, WELLCOME LAB MOLEC PHARMACOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London	SIVILOTTI, L (corresponding author), UCL, DEPT PHARMACOL, LONDON WC1E 6BT, ENGLAND.		Colquhoun, David/C-1664-2008; Sivilotti, Lucia/D-8919-2011	Colquhoun, David/0000-0002-4263-017X; Sivilotti, Lucia/0000-0003-2510-8424				ALKONDON M, 1993, J PHARMACOL EXP THER, V265, P1455; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; CLARKE PBS, 1992, TRENDS PHARMACOL SCI, V13, P407, DOI 10.1016/0165-6147(92)90125-P; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; CONNOLLY JG, 1995, J PHYSIOL-LONDON, V484, P87, DOI 10.1113/jphysiol.1995.sp020650; FLORES CM, 1992, MOL PHARMACOL, V41, P31; GALZI JL, 1995, NEUROPHARMACOLOGY, V34, P563, DOI 10.1016/0028-3908(95)00034-4; Hill AV, 1909, J PHYSIOL-LONDON, V39, P361; Hille B., 1992, IONIC CHANNELS EXCIT; LENA C, 1993, J NEUROSCI, V13, P2680, DOI 10.1523/JNEUROSCI.13-06-02680.1993; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; LESTER RAJ, 1995, J NEUROPHYSIOL, V74, P195, DOI 10.1152/jn.1995.74.1.195; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MCMAHON LL, 1994, J NEUROPHYSIOL, V71, P826, DOI 10.1152/jn.1994.71.2.826; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; PATON WDM, 1951, BRIT J PHARM CHEMOTH, V6, P155, DOI 10.1111/j.1476-5381.1951.tb00631.x; PERRY EK, 1995, NEUROSCIENCE, V64, P385, DOI 10.1016/0306-4522(94)00410-7; SANDS SB, 1993, BIOPHYS J, V65, P2614, DOI 10.1016/S0006-3495(93)81296-7; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHOEPFER R, 1988, NEURON, V1, P241, DOI 10.1016/0896-6273(88)90145-6; SUGAYA K, 1990, J NEUROSCI RES, V27, P349, DOI 10.1002/jnr.490270314; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VIDAL C, 1993, NEUROSCIENCE, V56, P23, DOI 10.1016/0306-4522(93)90558-W; Wonnacott S, 1990, BIOL NICOTINE DEPEND; ZORUMSKI CF, 1992, MOL PHARMACOL, V41, P931	29	49	51	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 22	1995	269	5231					1681	1682		10.1126/science.7569892	http://dx.doi.org/10.1126/science.7569892			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569892				2022-12-28	WOS:A1995RV94800025
J	BORST, P; BITTER, W; MCCULLOCH, R; VANLEEUWEN, F; RUDENKO, G				BORST, P; BITTER, W; MCCULLOCH, R; VANLEEUWEN, F; RUDENKO, G			ANTIGENIC VARIATION IN MALARIA	CELL			English	Review											BORST, P (corresponding author), NETHERLANDS CANC INST, DIV MOLEC BIOL, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS.		Bitter, Wilbert/AAA-6872-2019; Bitter, Wilbert/ABG-3726-2020; Bitter, W/CAJ-5778-2022; van Leeuwen, Fred/A-7698-2010	Bitter, Wilbert/0000-0001-8347-6511; van Leeuwen, Fred/0000-0002-7267-7251				BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BERENDT AR, 1994, PARASITOLOGY, V108, pS19, DOI 10.1017/S0031182000075685; BORST P, 1994, SCIENCE, V264, P1872, DOI 10.1126/science.7516579; BORST P, 1991, IMMUNOPARASITOL TOD, pA29, DOI 10.1016/S0167-5699(05)80009-X; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; DYBRIG K, 1993, MOL MICROBIOL, V10, P465; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; PASLOSKE BL, 1994, ANNU REV MED, V45, P283; PETERSON DS, 1995, IN PRESS P NATL ACAD, V92; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; [No title captured]	13	114	118	2	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					1	4		10.1016/0092-8674(95)90044-6	http://dx.doi.org/10.1016/0092-8674(95)90044-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606774	Bronze			2022-12-28	WOS:A1995RK42400001
J	GAUS, CR				GAUS, CR			HEALTH-SERVICES RESEARCH - NOW MORE THAN EVER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GAUS, CR (corresponding author), AGCY HLTH CARE POLICY & RES,ROCKVILLE,MD, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					108	108						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RH222	7595988				2022-12-28	WOS:A1995RH22200005
J	MIGONE, TS; LIN, JX; CERESETO, A; MULLOY, JC; O'SHEA, JJ; FRANCHINI, G; LEONARD, WJ				MIGONE, TS; LIN, JX; CERESETO, A; MULLOY, JC; O'SHEA, JJ; FRANCHINI, G; LEONARD, WJ			CONSTITUTIVELY ACTIVATED JAK-STAT PATHWAY IN T-CELLS TRANSFORMED WITH HTLV-I	SCIENCE			English	Article							VIRUS TYPE-I; RECEPTOR GAMMA-CHAIN; LEUKEMIA-LYMPHOMA; FUNCTIONAL COMPONENT; INFECTED-CELLS; IL-2 RECEPTOR; PROTEINS; LEUKOCYTES; EXPRESSION; GROWTH	Human T cell lymphotropic virus I (HTLV-I) is the etiological agent for adult T cell leukemia and tropical spastic paraparesis (also termed HTLV-I-associated myelopathy). HTLV-I-infected peripheral blood T cells exhibit an initial phase of interleukin-2 (IL-2)-dependent growth; over time, by an un known mechanism, the cells become IL-2-independent. Whereas the Jak kinases Jak1 and Jak3 and the signal transducer and activator of transcription proteins Stat3 and Stat5 are activated in normal T cells in response to IL-2, this signaling pathway was constitutively activated in HTLV-I-transformed cells. In HTLV-I-infected cord blood lymphocytes, the transition from IL-2-dependent to IL-2-independent growth correlated with the acquisition of a constitutively activated Jak-STAT pathway, which suggests that this pathway participates in HTLV-I-mediated T cell transformation.	NHLBI, MOLEC IMMUNOL LAB, BETHESDA, MD 20892 USA; NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA; NIAMSD, ARTHRITIS & RHEUMATISM BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)			Leonard, Warren/AAA-1397-2022	Cereseto, Anna/0000-0003-4453-2597				ARYA SK, 1984, SCIENCE, V223, P1086, DOI 10.1126/science.6320374; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; DANIAL PB, IN PRESS SCIENCE; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FRIEDMANN M, UNPUB; GALLO RC, 1986, SCI AM, V255, P88, DOI 10.1038/scientificamerican1286-88; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MAEDA M, 1987, BLOOD, V70, P1407; MIGONE TS, UNPUB; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MULLOY JC, UNPUB; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; ROHWER F, 1994, INT J ONCOL, V5, P1163; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; YODOI J, 1992, IMMUNOL TODAY, V13, P4; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; YSSEL H, 1989, J IMMUNOL, V142, P2279	43	501	518	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					79	81		10.1126/science.7604283	http://dx.doi.org/10.1126/science.7604283			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604283				2022-12-28	WOS:A1995RG98000037
J	HORTON, R				HORTON, R			THE INTERPRETIVE TURN	LANCET			English	Editorial Material																		CORNFIELD J, 1976, AM J EPIDEMIOL, V104, P408, DOI 10.1093/oxfordjournals.aje.a112313; DYSON F, 1995, NEW YORK REV BO 0525, P31; Housman A.E., 1988, COLLECTED POEMS SELE, P325	3	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					3	3		10.1016/S0140-6736(95)92644-5	http://dx.doi.org/10.1016/S0140-6736(95)92644-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603144				2022-12-28	WOS:A1995RF98500002
J	PEARCE, MC; SHERIDAN, JW; JONES, DM; LAWRENCE, GW; MURPHY, DM; MASUTTI, B; MCCOSKER, C; DOUGLAS, V; GEORGE, D; OKEEFE, A; YOUNG, F; THOMSON, M; GORMAN, B; HANSMAN, D; HILL, PS				PEARCE, MC; SHERIDAN, JW; JONES, DM; LAWRENCE, GW; MURPHY, DM; MASUTTI, B; MCCOSKER, C; DOUGLAS, V; GEORGE, D; OKEEFE, A; YOUNG, F; THOMSON, M; GORMAN, B; HANSMAN, D; HILL, PS			CONTROL OF GROUP-C MENINGOCOCCAL DISEASE IN AUSTRALIAN ABORIGINAL CHILDREN BY MASS RIFAMPICIN CHEMOPROPHYLAXIS AND VACCINATION	LANCET			English	Article							POPULATION; CARRIAGE; VACCINES; INFANTS	An outbreak of 12 cases of meningitis, 11 caused by Neisseria meningitidis serogroup C, occurred at Doomadgee from September, 1990, to April, 1991. The incidence of meningitis was 17.55/10(3) person-years. Only children aged 1-10 years were affected. In October, 1990, or shortly thereafter, 473/509 children aged between 1 and 15 years inclusive had one dose of Mencevax AC. From the time of vaccination until April, 1991, a further eight cases occurred, six in vaccinated children. Vaccine efficacy in 1-15 year olds was calculated as 77%. Despite this, in April, 1991, the prevalence of antibody to group C polysaccharide in vaccinated children (78%) was not significantly different from that in unvaccinated children and adults. 45 nonresponders were revaccinated, and, in February, 1992, 78% had antibodies to group C polysaccharide. In April, 1991, an estimated 3.0% of the population had group C organisms, carriage being directly related to household crowding. In June, 1991, 2 months after mass prophylaxis with rifampicin, none of these individuals were carriers. In October, 1991, the carriage rate of group C organisms was 0.64%. There have been no further cases caused by the epidemic strain. Although uncrowded housing is a basic need, mass chemoprophylaxis and two doses of vaccine for children should be used in similar outbreaks.	QUEENSLAND HLTH,COMMUNICABLE DIS BRANCH,BRISBANE,QLD 4001,AUSTRALIA; AUSTRALIAN NATL UNIV,NATL CTR EPIDEMIOL & POPULAT HLTH,CANBERRA,ACT,AUSTRALIA; WITHINGTON HOSP,PUBL HLTH LAB,MANCHESTER M20 8LR,LANCS,ENGLAND; QUEENSLAND INST MED RES,HERSTON,QLD,AUSTRALIA; STATE HLTH LAB SERV,BRISBANE,QLD,AUSTRALIA; DOOMADGEE HOSP,ABORIGINAL HLTH PROGRAMME,DOOMADGEE,QLD,AUSTRALIA; MT ISA HOSP,MT ISA,QLD,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,DEPT MICROBIOL,ADELAIDE,SA,AUSTRALIA; UNIV QUEENSLAND,SCH MED,TROP HLTH PROGRAM,HERSTON,QLD,AUSTRALIA	Queensland Health; Australian National University; QIMR Berghofer Medical Research Institute; University of Queensland			Hill, Peter/F-2768-2010; Hill, Peter Stewart/AAL-8053-2020	Hill, Peter/0000-0001-7091-5108; Hill, Peter Stewart/0000-0001-7091-5108				ARTENSTEIN MS, 1969, NEW ENGL J MED, V281, P678, DOI 10.1056/NEJM196909182811210; BLAKEBROUGH IS, 1983, ANN TROP MED PARASIT, V77, P175, DOI 10.1080/00034983.1983.11811694; BUTCHER R, 1986, SAMPLING ERRORS MANU; GOLD R, 1979, J INFECT DIS, V140, P690, DOI 10.1093/infdis/140.5.690; GREENFIELD S, 1971, J INFECT DIS, V123, P67, DOI 10.1093/infdis/123.1.67; GREENWOOD BM, 1980, T ROY SOC TROP MED H, V74, P340, DOI 10.1016/0035-9203(80)90095-4; HOGUE CJR, 1983, AM J EPIDEMIOL, V118, P396, DOI 10.1093/oxfordjournals.aje.a113646; JONES DM, 1989, BRIT MED J, V298, P542, DOI 10.1136/bmj.298.6673.542; KAISER AB, 1974, J INFECT DIS, V130, P217, DOI 10.1093/infdis/130.3.217; Levy P, 1980, SAMPLING HLTH PROFES; MUMFORD RS, 1974, LANCET, V1, P1275; PELTOLA H, 1985, PEDIATRICS, V76, P91; Pizzi M, 1944, AM J PUBLIC HEALTH N, V34, P231, DOI 10.2105/AJPH.34.3.231; RAKE G, 1934, J EXP MED, V59, P533; STUART JM, 1989, BRIT MED J, V298, P569, DOI 10.1136/bmj.298.6673.569; WEIDMER CE, 1971, J INFECT DIS, V124, P172, DOI 10.1093/infdis/124.2.172	16	18	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					20	23		10.1016/S0140-6736(95)92651-8	http://dx.doi.org/10.1016/S0140-6736(95)92651-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603139				2022-12-28	WOS:A1995RF98500009
J	COSO, OA; CHIARIELLO, M; YU, JC; TERAMOTO, H; CRESPO, P; XU, NG; MIKI, T; GUTKIND, JS				COSO, OA; CHIARIELLO, M; YU, JC; TERAMOTO, H; CRESPO, P; XU, NG; MIKI, T; GUTKIND, JS			THE SMALL GTP-BINDING PROTEINS RAC1 AND CDC42 REGULATE THE ACTIVITY OF THE JNK/SAPK SIGNALING PATHWAY	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SERINE THREONINE KINASE; DBL-ONCOGENE PRODUCT; MOLECULAR-CLONING; ACTIVATING PROTEINS; CELL-PROLIFERATION; PROTO-ONCOGENE; RAS; RHO; PHOSPHORYLATES	c-Jun amino-terminal kinases (JNKs) and mitogen-activated protein kinases (MAPKs) are closely related; however, they are independently regulated by a variety of environmental stimuli. Although molecules linking growth factor receptors to MAPKs have been recently identified, little is known about pathways controlling JNK activation. Here, we show that in COS-7 cells, activated Rac1 effectively stimulates MAPK but poorly induces JNK activity. In contrast, mutationally activated Rac1. and Cdc42 GTPases potently activate JNK without affecting MAPK, and oncogenic guanine nucleotide exchange factors for these Rho-like proteins selectively stimulate JNK activity. Furthermore, expression of inhibitory molecules for Rho-related GTPases and dominant negative mutants of Rac1 and Cdc42 block JNK activation by oncogenic exchange factors or after induction by inflammatory cytokines and growth factors. Taken together, these findings strongly support a critical role for Rac1 and Cdc42 in controlling the JNK signaling pathway.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	COSO, OA (corresponding author), NIDR,CELLULAR DEV & ONCOL LAB,MOLEC SIGNALING UNIT,BETHESDA,MD 20892, USA.		Gutkind, J. Silvio/A-1053-2009; Chiariello, Mario/O-3642-2014; Gutkind, J. Silvio/J-1201-2016; Crespo, Piero/M-3273-2014	Chiariello, Mario/0000-0001-8434-5177; Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1991, COLD SH Q B, V56, P237; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; UEDA T, 1990, J BIOL CHEM, V265, P9373; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAN MH, 1994, NATURE, V372, P798	52	1560	1576	2	36	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1137	1146		10.1016/S0092-8674(05)80018-2	http://dx.doi.org/10.1016/S0092-8674(05)80018-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600581	Bronze			2022-12-28	WOS:A1995RG91000018
J	BANFIELD, DK; LEWIS, MJ; PELHAM, HRB				BANFIELD, DK; LEWIS, MJ; PELHAM, HRB			A SNARE-LIKE PROTEIN REQUIRED FOR TRAFFIC THROUGH THE GOLGI-COMPLEX	NATURE			English	Article							INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; YEAST GENES; APPARATUS; ER; GLYCOPROTEIN; RECEPTORS; RETRIEVAL	THE secretory pathway of eukaryotic cells comprises several distinct membrane-bound compartments which are interconnected by transport vesicles that pinch off from one membrane and fuse with the next. Targeting of these vesicles is mediated in part by interactions between integral membrane proteins on the vesicles and target organelles (soluble NSF attachment protein receptors (SNAREs)), termed v-SNAREs and t-SNAREs, respectively(1-4). SNAREs required for endoplasmic reticulum (ER)-Golgi transport and for fusion of vesicles with the plasma membrane are already known. Here we identify two yeast membrane proteins that show genetic interactions with Sed5p, which is the t-SNARE for ER-Golgi traffic(3,4). One of these membrane proteins, Sft1p, is structurally similar to the known v-SNAREs and is required for transport from an early to a later Golgi compartment. Our results indicate that a single t-SNARE can control more than one transport step, and provide the first candidate for a SNARE involved in intra-Golgi traffic.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology								BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x	20	130	133	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	1995	375	6534					806	809		10.1038/375806a0	http://dx.doi.org/10.1038/375806a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596416				2022-12-28	WOS:A1995RF98900083
J	MCQUAY, H; CARROLL, D; JADAD, AR; WIFFEN, P; MOORE, A				MCQUAY, H; CARROLL, D; JADAD, AR; WIFFEN, P; MOORE, A			ANTICONVULSANT DRUGS FOR MANAGEMENT OF PAIN - A SYSTEMATIC REVIEW	BRITISH MEDICAL JOURNAL			English	Article							POST-HERPETIC NEURALGIA; TRIGEMINAL NEURALGIA; RHEUMATOID-ARTHRITIS; PHENYTOIN; CARBAMAZEPINE; VALPROATE; THERAPY	Objective-To determine effectiveness and adverse effects of anticonvulsant drugs in management of pain. Design-Systematic review of randomised controlled trials of anticonvulsants for acute, chronic, or cancer pain identified by using Medline, by hand searching, by searching reference lists, and by contacting investigators. Subjects-Between 1966 and February 1994, 37 reports were found; 20 reports, of four anticonvulsants, were eligible. Main outcome measures-Numbers needed to treat were calculated for effectiveness, adverse effects, and drug related withdrawal from study. Results-The only placebo controlled study in acute pain found no analgesic effect of sodium valproate. For treating trigeminal neuralgia, carbamazepine had a combined number needed to heat of 2.6 for effectiveness, 3.4 for adverse effects, and 24 for severe effects (withdrawal from study). For treating diabetic neuropathy, anticonvulsants had a combined number needed to treat of 2.5 for effectiveness, 3.1 for adverse effects, and 20 for severe effects. For migraine prophylaxis, anticonvulsants had a combined number needed to treat of 1.6 for effectiveness, 2.4 for adverse effects, and 39 for severe effects. Phenytoin had no effect an the irritable bowel syndrome, and carbamazepine had little effect on pain after stroke. Clonazepam was effective in one study for temporomandibular joint dysfunction. No study compared one anticonvulsant with another. Conclusions-Anticonvulsants were effective for trigeminal neuralgia and diabetic neuropathy and for migraine prophylaxis. Minor adverse effects occurred as often as benefit.	CHURCHILL HOSP,DEPT PHARM,OXFORD OX3 7LJ,ENGLAND	University of Oxford	MCQUAY, H (corresponding author), CHURCHILL HOSP,OXFORD PAIN RELIEF UNIT,OXFORD OX3 7LJ,ENGLAND.		Wiffen, Philip/GNP-1768-2022					ARIEFF AJ, 1967, DIS NERV SYST, V28, P820; CAMPBELL FG, 1966, J NEUROL NEUROSUR PS, V29, P265, DOI 10.1136/jnnp.29.3.265; Chadda V S, 1978, J Assoc Physicians India, V26, P403; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; EDDY DM, 1993, JAMA-J AM MED ASSOC, V270, P520; FARAGO F, 1987, EUR NEUROL, V26, P73, DOI 10.1159/000116315; FROMM GH, 1984, ANN NEUROL, V15, P240, DOI 10.1002/ana.410150306; GERSON GR, 1977, POSTGRAD MED J, V53, P104; Goncikowska M, 1984, Wiad Lek, V37, P1093; GRAHAMESMITH DG, 1992, OXFORD TXB CLIN PHAR, P433; GREENBAUM DS, 1973, NEW ENGL J MED, V288, P13, DOI 10.1056/NEJM197301042880103; HARKINS S, 1991, Journal of Craniomandibular Disorders, V5, P179; HATTA V, 1992, ANAESTHESIA, V47, P664, DOI 10.1111/j.1365-2044.1992.tb02386.x; HERING R, 1992, CEPHALALGIA, V12, P81, DOI 10.1046/j.1468-2982.1992.1202081.x; HOLMES B, 1984, DRUGS, V27, P6, DOI 10.2165/00003495-198427010-00002; HOPKINS S, 1991, AM J MED S3A, V91, P40; JACOX A, 1994, AHCPR PUBLICATION, P41; JADAD AR, 1994, THESIS U OXFORD OXFO; JADAD AR, 1993, ONLINE J CURRENT CLI, V2; KECZKES K, 1980, BRIT J DERMATOL, V102, P551, DOI 10.1111/j.1365-2133.1980.tb07654.x; Kienast H W, 1968, Headache, V8, P1, DOI 10.1111/j.1526-4610.1968.hed0801001.x; KIENAST H W, 1968, Proceedings of the Institute of Medicine of Chicago, V27, P50; KILLIAN JM, 1968, ARCH NEUROL-CHICAGO, V19, P129, DOI 10.1001/archneur.1968.00480020015001; LECHIN F, 1989, ARCH NEUROL-CHICAGO, V46, P960, DOI 10.1001/archneur.1989.00520450030015; LEIJON G, 1989, PAIN, V36, P27, DOI 10.1016/0304-3959(89)90108-5; LINDSTROM P, 1987, PAIN, V28, P45, DOI 10.1016/0304-3959(87)91058-X; Loeser J, 1994, TXB PAIN, P699; MARTIN C, 1988, Annales Francaises d'Anesthesie et de Reanimation, V7, P387, DOI 10.1016/S0750-7658(88)80055-8; MATHEW NT, 1991, HEADACHE, V31, P71, DOI 10.1111/j.1526-4610.1991.hed3102071.x; MONKS R, 1994, TXB PAIN, P963; NAIDU MUR, 1991, DRUG EXP CLIN RES, V17, P271; NICOL C F, 1969, Headache, V9, P54, DOI 10.1111/j.1526-4610.1969.hed0901054.x; Rall TW, 1992, PHARMACOL BASIS THER, P436; RAPPAPORT ZH, 1994, PAIN, V56, P127, DOI 10.1016/0304-3959(94)90086-8; RASMUSSEN P, 1970, ACTA NEUROL SCAND, V46, P385, DOI 10.1111/j.1600-0404.1970.tb05803.x; REYNOLDS JEF, 1993, MARTINDALE EXTRA PHA, P292; RICHARDS IM, 1987, ANN RHEUM DIS, V46, P667, DOI 10.1136/ard.46.9.667; ROMPEL H, 1970, South African Medical Journal, V44, P75; RULL JA, 1969, DIABETOLOGIA, V5, P215, DOI 10.1007/BF01212087; SAUDEK CD, 1977, CLIN PHARMACOL THER, V22, P196; SCHAFFLER K, 1991, ARZNEIMITTELFORSCH, V41-1, P427; Schulz KF, 1994, CONTROL CLIN TRIALS, V15, P63; SHARAV Y, 1991, PAIN, V44, P171, DOI 10.1016/0304-3959(91)90133-I; SHIBASAKI H, 1973, J NEUROL SCI, V18, P47, DOI 10.1016/0022-510X(73)90019-1; STENSRUD P, 1979, HEADACHE, V19, P333, DOI 10.1111/j.1526-4610.1979.hed1906333.x; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; TWYCROSS R, 1994, ANAESTHESIA, P1635; VILMING ST, 1986, CEPHALALGIA, V6, P181, DOI 10.1046/j.1468-2982.1986.0603181.x; Westerholm N, 1970, Scand J Dent Res, V78, P144; YAJNIK S, 1992, J PAIN SYMPTOM MANAG, V7, P209, DOI 10.1016/0885-3924(92)90077-U; Young R J, 1985, Diabet Med, V2, P363; 1992, ASSESSING EFFECTS HL	53	471	486	2	23	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1047	1052		10.1136/bmj.311.7012.1047	http://dx.doi.org/10.1136/bmj.311.7012.1047			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580659	Green Published			2022-12-28	WOS:A1995TB35400017
J	YAGAMIHIROMASA, T; SATO, T; KURISAKI, T; KAMIJO, K; NABESHIMA, Y; FUJISAWASEHARA, A				YAGAMIHIROMASA, T; SATO, T; KURISAKI, T; KAMIJO, K; NABESHIMA, Y; FUJISAWASEHARA, A			A METALLOPROTEASE-DISINTEGRIN PARTICIPATING IN MYOBLAST FUSION	NATURE			English	Article							PLATELET-AGGREGATION INHIBITOR; CELL-ADHESION MOLECULE; SPERM-EGG FUSION; HEMORRHAGIC PROTEIN; N-CADHERIN; MYOGENESIS; INTEGRIN; SEQUENCE; VENOM; PURIFICATION	SKELETAL muscle development involves the formation of multinucleated myotubes. This is thought to proceed by the induction of differentiation (acquisition of fusion competence) of myoblast cells, their aggregation, and union of their plasma membranes(1-3) Various membrane proteins including N-(4,5) and M-cadherins(6), N-(5,7-9) and V-CAMs(10) and integrins(10,11) participate in myotube formation, but the molecular mechanisms of muscle cell fusion are poorly understood. Here we report the identification of three new, myoblast-expressed gene products, mcltrin-alpha, beta and gamma, with homology to both viper haemorrhagic factors(12,13) and fertilin (PH-30)(14,15), a membrane protein involved in egg-sperm fusion. Meltrin-alpha, a member of the metalloproteinase/disintegrin protein family, appears to be required for myotube formation. Involvement of a fertilin-related protein in myogenesis suggests that there are common mechanisms in gamete and myoblast fusion.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV MOLEC GENET,KODAIRA,TOKYO 187,JAPAN; CHIBA UNIV,FAC SCI,DEPT BIOL,CHIBA 260,JAPAN	National Center for Neurology & Psychiatry - Japan; Chiba University								AU LC, 1991, BIOCHEM BIOPH RES CO, V181, P585, DOI 10.1016/0006-291X(91)91230-A; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DONALIES M, 1991, P NATL ACAD SCI USA, V88, P8024, DOI 10.1073/pnas.88.18.8024; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; KNUDSEN KA, 1990, DEV BIOL, V138, P159, DOI 10.1016/0012-1606(90)90185-L; KNUDSEN KA, 1990, EXP CELL RES, V188, P175, DOI 10.1016/0014-4827(90)90157-6; KNUDSEN KA, 1992, MEMBRANE FUSION, P601; LAMB RA, 1993, VIROLOGY, V197, P1, DOI 10.1006/viro.1993.1561; MEGE RM, 1992, J CELL SCI, V103, P897; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MINTZ B, 1967, P NATL ACAD SCI USA, V58, P592, DOI 10.1073/pnas.58.2.592; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORRISON TG, 1988, VIRUS RES, V10, P113, DOI 10.1016/0168-1702(88)90010-X; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; NEEPER MP, 1990, NUCLEIC ACIDS RES, V18, P4255, DOI 10.1093/nar/18.14.4255; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PECK D, 1993, J CELL BIOL, V123, P1587, DOI 10.1083/jcb.123.6.1587; PERRY ACF, 1992, BIOCHEM J, V286, P671, DOI 10.1042/bj2860671; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEYA H, 1990, J BIOL CHEM, V265, P16068; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1965, DEV BIOL, V11, P300, DOI 10.1016/0012-1606(65)90062-X; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585	30	418	439	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					652	656		10.1038/377652a0	http://dx.doi.org/10.1038/377652a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566181				2022-12-28	WOS:A1995TA27500059
J	RYLANCE, G; BOWEN, C; RYLANCE, J				RYLANCE, G; BOWEN, C; RYLANCE, J			MEASLES AND RUBELLA IMMUNIZATION - INFORMATION AND CONSENT IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article									KING EDWARD VI CAMP HILL SCH GIRLS,BIRMINGHAM B14 7QJ,W MIDLANDS,ENGLAND; KING EDWARD VI CAMP HILL SCH BOYS,BIRMINGHAM B14 7QJ,W MIDLANDS,ENGLAND		RYLANCE, G (corresponding author), CHILDRENS HOSP,LADYWOOD MIDDLEWAY,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND.		Rylance, Jamie/ABD-9314-2021	Rylance, Jamie/0000-0002-2323-3611				Alderson P., 1993, CHILDRENS CONSENT SU; 1994, DOH PL CNO9412 DEP H; 1994, DOH1525 95M994 DEP H; 1994, 9000M894 DEP HLTH HL	4	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					923	924						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580552	Green Published			2022-12-28	WOS:A1995RZ23700023
J	CRANE, BR; SIEGEL, LM; GETZOFF, ED				CRANE, BR; SIEGEL, LM; GETZOFF, ED			SULFITE REDUCTASE STRUCTURE AT 1.6 ANGSTROM - EVOLUTION AND CATALYSIS FOR REDUCTION OF INORGANIC ANIONS	SCIENCE			English	Article							ESCHERICHIA-COLI HEMOFLAVOPROTEIN; ELECTRON-PARAMAGNETIC-RES; SPINACH NITRITE REDUCTASE; PROSTHETIC GROUPS; HEMOPROTEIN SUBUNIT; MACROMOLECULAR CRYSTALLOGRAPHY; DESULFOVIBRIO-VULGARIS; SALMONELLA-TYPHIMURIUM; ANOMALOUS DIFFRACTION; SYNCHROTRON RADIATION	Fundamental chemical transformations for biogeochemical cycling of sulfur and nitrogen are catalyzed by sulfite and nitrite reductases. The crystallographic structure of Escherichia coli sulfite reductase hemoprotein (SiRHP), which catalyzes the concerted six-electron reductions of sulfite to sulfide and nitrite to ammonia, was solved with multiwavelength anomalous diffraction (MAD) of the native siroheme and Fe4S4 cluster cofactors, multiple isomorphous replacement, and selenomethionine sequence markers. Twofold symmetry within the 84-kilodalton polypeptide generates a distinctive three-domain alpha/beta fold that controls cofactor assembly and reactivity. Homology regions conserved between the symmetry-related halves of SiRHP and among other sulfite and nitrite reductases revealed key residues for stability and function, and identified a sulfite or nitrite reductase repeat (SNiRR) common to a redox-enzyme superfamily. The saddle-shaped siroheme shares a cysteine thiolate ligand with the Fe4S4 cluster and ligates an unexpected phosphate anion. In the substrate complex, sulfite displaces phosphate and binds to siroheme iron through sulfur. An extensive hydrogen-bonding network of positive side chains, water molecules, and siroheme carboxylates activates S-O bonds for reductive cleavage.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Scripps Research Institute; Duke University					NIGMS NIH HHS [GM37684, GM212226] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; BACK E, 1988, MOL GEN GENET, V212, P20, DOI 10.1007/BF00322440; BOMINAAR EL, 1995, J AM CHEM SOC, V117, P6976, DOI 10.1021/ja00131a021; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CAMERON EM, 1982, NATURE, V296, P145, DOI 10.1038/296145a0; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHANG CK, 1981, P NATL ACAD SCI USA, V78, P2652, DOI 10.1073/pnas.78.5.2652; CHRISTNER JA, 1983, J BIOL CHEM, V258, P1147; CLINE JF, 1985, BIOCHEMISTRY-US, V25, P7942; COLE JA, 1988, 42ND S SOC GEN MICR; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; CRANE BR, UNPUB; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; DAHL C, 1993, J GEN MICROBIOL, V139, P1817, DOI 10.1099/00221287-139-8-1817; DAY EP, 1988, BIOCHEMISTRY-US, V27, P2126, DOI 10.1021/bi00406a046; FUREY W, 1990, P AM CRYSTALLOGRAPHI, P73; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GILSON MK, 1985, J MOL BIOL, V183, P503; GISSELMANN G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P102, DOI 10.1016/0005-2728(93)90037-G; HAN SW, 1989, BIOCHEMISTRY-US, V28, P5461, DOI 10.1021/bi00439a022; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUYNH BH, 1984, J BIOL CHEM, V259, P5373; JANICK PA, 1982, BIOCHEMISTRY-US, V21, P3538, DOI 10.1021/bi00258a003; JANICK PA, 1983, BIOCHEMISTRY-US, V22, P396, DOI 10.1021/bi00271a025; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAUFMAN J, 1993, BIOCHEMISTRY-US, V32, P2853, DOI 10.1021/bi00062a017; Kinghorn J. R., 1989, Molecular and genetic aspects of nitrate assimilation., P385; KRUEGER RJ, 1982, BIOCHEMISTRY-US, V21, P2892, DOI 10.1021/bi00541a014; LEE J, 1973, J BACTERIOL, V259, P15373; LESLIE AGW, 1986, CCP4 NEWSLETTER, V18, P33; LIDE DR, 1990, HDB CHEM PHYSICS; LUQUE I, 1993, PLANT MOL BIOL, V21, P1201, DOI 10.1007/BF00023618; MADDEN JF, 1989, BIOCHEMISTRY-US, V28, P5471, DOI 10.1021/bi00439a023; MCREE DE, 1986, J BIOL CHEM, V261, P277; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MOURA I, 1988, J AM CHEM SOC, V110, P1075, DOI 10.1021/ja00212a013; MOURA I, 1986, BIOCHEM BIOPH RES CO, V141, P1032, DOI 10.1016/S0006-291X(86)80148-6; MURPHY MJ, 1973, J BIOL CHEM, V248, P6911; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15726; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PECK HD, 1988, S SOC GEN MICROBIOL, V42, P99; Postgate J.R, 1979, SULPHATE REDUCING BA; Price C. C., 1962, SULFUR BONDING; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUTTEN M, 1972, ORIGIN LIFE NATURAL; SCHEIDT WR, 1981, CHEM REV, V81, P543, DOI 10.1021/cr00046a002; Schidlowski M., 1983, P149; SEKI Y, 1979, J BIOCHEM-TOKYO, V86, P273; SEKI Y, 1981, J BIOCHEM-TOKYO, V90, P1487, DOI 10.1093/oxfordjournals.jbchem.a133615; SIEGEL LM, 1982, J BIOL CHEM, V257, P6343; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; SIEGEL LM, 1974, J BIOL CHEM, V249, P1572; SIEGEL LM, 1975, METABOLIC PATHWAYS, V7, P217; Singleton Jr R., 1993, SULFATE REDUCING BAC; SORIANO A, 1995, J AM CHEM SOC, V117, P4724, DOI 10.1021/ja00121a038; TAN J, 1991, BIOCHEMISTRY-US, V30, P9900, DOI 10.1021/bi00105a013; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; Wray J.L., 1989, MOL GENETIC ASPECTS; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YOUNG LJ, 1988, BIOCHEMISTRY-US, V27, P2790, DOI 10.1021/bi00408a020	74	281	287	0	49	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					59	67		10.1126/science.270.5233.59	http://dx.doi.org/10.1126/science.270.5233.59			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569952				2022-12-28	WOS:A1995RY30200031
J	ADAMS, MD; KERLAVAGE, AR; FLEISCHMANN, RD; FULDNER, RA; BULT, CJ; LEE, NH; KIRKNESS, EF; WEINSTOCK, KG; GOCAYNE, JD; WHITE, O; SUTTON, G; BLAKE, JA; BRANDON, RG; CHIU, MW; CLAYTON, RA; CLINE, RT; COTTON, MD; EARLEHUGHES, J; FINE, LD; FITZGERALD, LM; FITZHUGH, WM; FRITCHMAN, JL; GEOGHAGEN, NSM; GLODEK, A; GNEHM, CL; HANNA, MC; HEDBLOM, E; HINKLE, PS; KELLEY, JM; KLIMEK, KM; KELLEY, JC; LIU, LI; MARMAROS, SM; MERRICK, JM; MORENOPALANQUES, RF; MCDONALD, LA; NGUYEN, DT; PELLEGRINO, SM; PHILLIPS, CA; RYDER, SE; SCOTT, JL; SAUDEK, DM; SHIRLEY, R; SMALL, KV; SPRIGGS, TA; UTTERBACK, TR; WELDMAN, JF; LI, Y; BARTHLOW, R; BEDNARIK, DP; CAO, LA; CEPEDA, MA; COLEMAN, TA; COLLINS, EJ; DIMKE, D; FENG, P; FERRIE, A; FISCHER, C; HASTINGS, GA; HE, WW; HU, JS; HUDDLESTON, KA; GREENE, JM; GRUBER, J; HUDSON, P; KIM, A; KOZAK, DL; KUNSCH, C; JI, HJ; LI, HD; MEISSNER, PS; OLSEN, H; RAYMOND, L; WEI, YF; WING, J; XU, C; YU, GL; RUBEN, SM; DILLON, PJ; FANNON, MR; ROSEN, CA; HASELTINE, WA; FIELDS, C; FRASER, CM; VENTER, JC				ADAMS, MD; KERLAVAGE, AR; FLEISCHMANN, RD; FULDNER, RA; BULT, CJ; LEE, NH; KIRKNESS, EF; WEINSTOCK, KG; GOCAYNE, JD; WHITE, O; SUTTON, G; BLAKE, JA; BRANDON, RG; CHIU, MW; CLAYTON, RA; CLINE, RT; COTTON, MD; EARLEHUGHES, J; FINE, LD; FITZGERALD, LM; FITZHUGH, WM; FRITCHMAN, JL; GEOGHAGEN, NSM; GLODEK, A; GNEHM, CL; HANNA, MC; HEDBLOM, E; HINKLE, PS; KELLEY, JM; KLIMEK, KM; KELLEY, JC; LIU, LI; MARMAROS, SM; MERRICK, JM; MORENOPALANQUES, RF; MCDONALD, LA; NGUYEN, DT; PELLEGRINO, SM; PHILLIPS, CA; RYDER, SE; SCOTT, JL; SAUDEK, DM; SHIRLEY, R; SMALL, KV; SPRIGGS, TA; UTTERBACK, TR; WELDMAN, JF; LI, Y; BARTHLOW, R; BEDNARIK, DP; CAO, LA; CEPEDA, MA; COLEMAN, TA; COLLINS, EJ; DIMKE, D; FENG, P; FERRIE, A; FISCHER, C; HASTINGS, GA; HE, WW; HU, JS; HUDDLESTON, KA; GREENE, JM; GRUBER, J; HUDSON, P; KIM, A; KOZAK, DL; KUNSCH, C; JI, HJ; LI, HD; MEISSNER, PS; OLSEN, H; RAYMOND, L; WEI, YF; WING, J; XU, C; YU, GL; RUBEN, SM; DILLON, PJ; FANNON, MR; ROSEN, CA; HASELTINE, WA; FIELDS, C; FRASER, CM; VENTER, JC			INITIAL ASSESSMENT OF HUMAN GENE DIVERSITY AND EXPRESSION PATTERNS BASED UPON 83-MILLION NUCLEOTIDES OF CDNA SEQUENCE	NATURE			English	Article							CAENORHABDITIS-ELEGANS; HUMAN BRAIN; TAGS; DNA; LIBRARY; IDENTIFICATION; CLONES; EFFICIENT; INVENTORY; ALGORITHM	In an effort to identify new genes and analyse their expression patterns, 174,472 partial complementary DNA sequences (expressed sequence tags (ESTs)), totalling more than 52 million nucleotides of human DNA sequence, have been generated from 300 cDNA libraries constructed from 37 distinct organs and tissues. These ESTs have been combined with an additional 118,406 ESTs from the database dbEST, for a total of 83 million nucleotides, and treated as a shotgun sequence assembly project. The assembly process yielded 29,599 distinct tentative human consensus (THC) sequences and 58,384 non-overlapping ESTs. Of these 87,983 distinct sequences, 10,214 further characterize previously known genes based on statistically significant similarity to sequences in the available databases; the remainder identify previously unknown genes. Thirty tissues were sampled by over 1,000 ESTs each; only eight genes were matched by ESTs from all 30 tissues, and 227 genes were represented in 20 or more of the tissues sampled with more than 1,000 ESTs. Approximately 40% of identified human genes appear to be associated with basic energy metabolism, cell structure, homeostasis and cell division, 22% with RNA and protein synthesis and processing, and 12% with cell signalling and communication.	INST GENOM RES, ROCKVILLE, MD 20850 USA; HUMAN GENOME SCI INC, ROCKVILLE, MD 20850 USA	J. Craig Venter Institute; GlaxoSmithKline; Human Genome Sciences Inc			Bednarik, Daniel/GRN-7985-2022	Fredrikson, Karin/0000-0001-7360-4276; Fraser, Claire/0000-0003-1462-2428; Blake, Judith/0000-0001-8522-334X; Fields, Chris/0000-0002-4812-0744; Kerlavage, Anthony/0000-0002-3954-9653				ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1994, NATURE, V368, P474, DOI 10.1038/368474a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AFFARA NA, 1994, GENOMICS, V22, P205, DOI 10.1006/geno.1994.1363; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUFFRAY C, 1995, CR ACAD SCI III-VIE, V318, P263; BENSON D, 1993, NUCLEIC ACIDS RES, V21, P2963, DOI 10.1093/nar/21.13.2963; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BRUTLAG DL, 1993, COMPUT CHEM, V17, P203, DOI 10.1016/0097-8485(93)85011-Z; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAVERIE JM, 1992, GENOMICS, V12, P838, DOI 10.1016/0888-7543(92)90321-I; CLAVERIE JM, 1994, AUTOMATED DNA SEQUEN; COHEN D, 1995, NATURE, V377, P321; COLLET C, 1994, BIOCHEM GENET, V32, P181, DOI 10.1007/BF00554621; CUTICCHIA AJ, 1993, NUCLEIC ACIDS RES, V21, P3003, DOI 10.1093/nar/21.13.3003; DUBNICK M, 1992, COMPUT APPL BIOSCI, V8, P601; DURKIN AS, 1994, CYTOGENET CELL GENET, V65, P86, DOI 10.1159/000133606; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; FIELDS C, 1994, BIOCHEM BIOPH RES CO, V198, P288, DOI 10.1006/bbrc.1994.1040; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GIESER L, 1992, GENOMICS, V13, P873, DOI 10.1016/0888-7543(92)90173-P; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAY B, 1992, STRATEGIES, V5, P16; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; HORNES E, 1990, GENET ANAL-BIOMOL E, V7, P145, DOI 10.1016/0735-0651(90)90028-E; KEITH CS, 1993, PLANT PHYSIOL, V101, P329, DOI 10.1104/pp.101.1.329; KERLAVAGE AR, IN PRESS ENG MED BIO, V14; KHAN AS, 1992, NAT GENET, V2, P180, DOI 10.1038/ng1192-180; KHAN WN, 1992, GENOMICS, V12, P780, DOI 10.1016/0888-7543(92)90309-G; KIM CW, 1993, J MOL BIOL, V231, P960, DOI 10.1006/jmbi.1993.1345; KRAUSE M, 1989, J MOL BIOL, V208, P381, DOI 10.1016/0022-2836(89)90503-2; LEE NH, INPRESS P NATN ACAD; LIEW CC, 1993, J MOL CELL CARDIOL, V25, P891, DOI 10.1006/jmcc.1993.1101; LIEW CC, 1994, P NATL ACAD SCI USA, V91, P10645, DOI 10.1073/pnas.91.22.10645; MATSUBARA K, 1993, GENE, V135, P265, DOI 10.1016/0378-1119(93)90076-F; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; MCCOMBIE WR, 1993, DNA SEQ DNA SEQ MAP, V2, P289; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Okubo K, 1994, DNA Res, V1, P37, DOI 10.1093/dnares/1.1.37; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARK YS, 1993, PLANT PHYSIOL, V103, P359, DOI 10.1104/pp.103.2.359; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLYMEROPOULOS MH, 1993, NAT GENET, V4, P381, DOI 10.1038/ng0893-381; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; SUTTON GG, IN PRESS GENOME SCI; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; TSAI JY, 1994, NAT GENET, V8, P321, DOI 10.1038/ng1294-321; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; UCHIMIYA H, 1992, PLANT J, V2, P1005, DOI 10.1111/j.1365-313X.1992.01005.x; UTTERBACK T, IN PRESS GENOME SCI; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WARD CJ, 1994, CELL, V77, P881; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Watson J. D., 1987, MOL BIOL GENE; WHITE O, 1993, NUCLEIC ACIDS RES, V21, P3829, DOI 10.1093/nar/21.16.3829; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85	68	727	868	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377			S			3	+						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566098				2022-12-28	WOS:A1995TA34300002
J	WODARZ, A; HINZ, U; ENGELBERT, M; KNUST, E				WODARZ, A; HINZ, U; ENGELBERT, M; KNUST, E			EXPRESSION OF CRUMBS CONFERS APICAL CHARACTER ON PLASMA-MEMBRANE DOMAINS OF ECTODERMAL EPITHELIA OF DROSOPHILA	CELL			English	Article							ADHESION MOLECULE UVOMORULIN; CELL-SURFACE POLARITY; FASCICLIN-III; ORGANIZATION; MELANOGASTER; PROTEIN; PATHWAYS; RECEPTOR; PRODUCT; ENCODES	The crumbs protein of Drosophila is an integral membrane protein, with 30 EGF-like and 4 laminin A G domain-like repeats in its extracellular segment, which is expressed on the apical plasma membrane of all ectodermally derived epithelia. Here, we present evidence to show that the insertion of crumbs into the plasma membrane is necessary and sufficient to confer apical character on a membrane domain. Overexpression of crumbs results in an enormous expansion of the apical plasma membrane and the concomitant reduction of the basolateral domain. This is followed by the redistribution of beta(Heavy)-spectrin, a component of the membrane cytoskeleton, and by the ectopic deposition of cuticle and other apical components into these areas. Strikingly, overexpression of the membrane-bound cytoplasmic portion of crumbs alone is sufficient to produce this dominant phenotype. Our results suggest that crumbs plays a key role in specifying the apical plasma membrane domain of ectodermal epithelial cells of Drosophila.	UNIV COLOGNE,INST ENTWICKLUNGSBIOL,D-50923 COLOGNE,GERMANY	University of Cologne			Wodarz, Andreas/D-4642-2013; Knust, Elisabeth/B-4338-2017	Wodarz, Andreas/0000-0002-0007-6289; 				BRAND AH, 1993, DEVELOPMENT, V118, P401; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; DUBREUIL RR, 1990, J CELL BIOL, V111, P1849, DOI 10.1083/jcb.111.5.1849; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fleming Tom P., 1992, P111; Foe Victoria E., 1993, P149; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KNUST E, 1994, TRENDS GENET, V10, P275, DOI 10.1016/0168-9525(90)90010-4; KNUST E, 1993, DEVELOPMENT S, V119, P261; KORNEZOS A, 1992, MOL GEN GENET, V235, P397, DOI 10.1007/BF00279386; LAFONT F, 1994, NATURE, V372, P801; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; McNeill Helen, 1992, P53; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PATTHY L, 1991, FEBS LETT, V289, P99, DOI 10.1016/0014-5793(91)80917-R; Poodry C.A., 1980, Genetics and Biology of Drosophila, V2d, P443; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SCHONBAUM CP, 1992, DEV BIOL, V151, P431, DOI 10.1016/0012-1606(92)90183-H; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TEPASS U, 1994, DEV BIOL, V161, P563, DOI 10.1006/dbio.1994.1054; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; TEPASS U, 1990, ROUX ARCH DEV BIOL, V199, P189, DOI 10.1007/BF01682078; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; WARN RM, 1992, EPITHELIAL ORG DEV, P136; Wieschaus E., 1986, P199; WILEY LM, 1990, BIOESSAYS, V12, P67, DOI 10.1002/bies.950120204; WODARZ A, 1993, MECH DEVELOP, V44, P175, DOI 10.1016/0925-4773(93)90066-7	41	548	551	0	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					67	76		10.1016/0092-8674(95)90053-5	http://dx.doi.org/10.1016/0092-8674(95)90053-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606787	Bronze			2022-12-28	WOS:A1995RK42400010
J	VANSCHAYCK, CP; VANDENBROEK, PJJA; DENOTTER, JJ; VANHERWAARDEN, CLA; MOLEMA, J; VANWEEL, C				VANSCHAYCK, CP; VANDENBROEK, PJJA; DENOTTER, JJ; VANHERWAARDEN, CLA; MOLEMA, J; VANWEEL, C			PERIODIC TREATMENT REGIMENS WITH INHALED STEROIDS IN ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY-DISEASE - IS IT POSSIBLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIR-FLOW OBSTRUCTION; BRONCHODILATOR THERAPY; CHRONIC-BRONCHITIS; CLINICAL ASTHMA; BUDESONIDE; CORTICOSTEROIDS; HYPERRESPONSIVENESS; RESPONSIVENESS; INFLAMMATION; TERBUTALINE	Objective.-To determine whether inhaled corticosteroids can be discontinued in the stable phase of asthma or chronic obstructive pulmonary disease (COPD) or if this therapy should be continued. Design.-Nonrandomized open uncontrolled 5-year trial. Setting.-Prospective study in general practice. Patients.-Forty-eight patients with steroid-dependent asthma or COPD who had shown a decline in forced expiratory volume in 1 second (FEV(1)) of at least 80 mt per year and at least one exacerbation per year during the first 2 years of bronchodilator treatment. Subjects were treated additionally with inhaled steroids for another 2 years and were finally given the option to stop using steroids. Sixteen patients were willing to stop using beclomethasone and were studied for another year. No recruitment bias took place in this consecutive sample in the fifth year of follow-up. Two of 16 patients developed carcinomas and dropped out. Interventions.-Two years of bronchodilator treatment alone (400 mu g of salbutamol or 40 mu g of ipratropium bromide four times daily), followed by 2 years of additional inhaled corticosteroid treatment (400 mu g of beclomethasone two times daily), and finally 1 year of bronchodilator treatment alone. Main Outcome Measures.-Decline in lung function (FEV(1)), change in bronchial hyperresponsiveness, indicated by a provocative concentration of histamine causing a 20% fall in FEV(1) (PC20), morning peak expiratory flow rate (PEFR), diurnal PEFR, week-to-week variation of PEFR, bronchial symptoms, and exacerbations. Results.-The course of FEV(1) during the year in which beclomethasone was discontinued was not significantly different when compared with the 2-year period of beclomethasone treatment. Neither did the course of PC20, morning PEFR, diurnal PEFR, symptom score, and exacerbation rate change. Only the week-to-week variation of the PEFR increased after discontinuing steroids. Conclusions.-Discontinuing inhaled steroids is possible in some patients with asthma or COPD after 2 years of regular treatment. This might indicate that for certain groups of patients with mild asthma or COPD, periodic treatment schedules with inhaled steroids is the treatment policy for the future.	UNIV NIJMEGEN,LUNG CTR DEKKERSWALD,NIJMEGEN,NETHERLANDS	Radboud University Nijmegen	VANSCHAYCK, CP (corresponding author), UNIV NIJMEGEN,DEPT GEN PRACTICE FAMILY PRACTICE,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				BEL EH, 1991, AM REV RESPIR DIS, V143, P109, DOI 10.1164/ajrccm/143.1.109; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; DSOUZA W, 1994, EUR RESPIR J, V7, P1260, DOI 10.1183/09031936.94.07071260; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; JENKINS CR, 1988, THORAX, V43, P378, DOI 10.1136/thx.43.5.378; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; MAGNUSSEN H, 1992, American Review of Respiratory Disease, V145, pA498; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; POSTMA DS, 1988, EUR RESPIR J, V1, P22; SILVERMAN BA, 1987, ANN ALLERGY, V59, P350; TAGGART VS, 1987, ANN ALLERGY, V58, P173; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527, DOI 10.1164/ajrccm/140.6.1527; VANDENBROEK PJJ, 1993, EUR RESPIR J, V607, pS257; VANESSENZANDVLI.EE, 1993, THESIS ERASMUS U NET; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; WHYTE MKB, 1993, RESP MED, V87, P29, DOI 10.1016/S0954-6111(05)80310-5; 1994, BRIT MED J, V308, P564; 1990, BRIT MED J, V301, P651; 1992, EUR RESPIR J, V5, P601	27	14	14	15	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					161	164		10.1001/jama.274.2.161	http://dx.doi.org/10.1001/jama.274.2.161			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596005				2022-12-28	WOS:A1995RH22200030
J	OREOPOULOS, DG				OREOPOULOS, DG			WITHDRAWAL FROM DIALYSIS - WHEN LETTING DIE IS BETTER THAN HELPING TO LIVE	LANCET			English	Editorial Material							ATTITUDES; DECISIONS				OREOPOULOS, DG (corresponding author), TORONTO HOSP, DIV NEPHROL, WESTERN DIV, TORONTO, ON, CANADA.							AGODOA LY, 1995, AM J KIDNEY DIS, V25, P119, DOI 10.1016/0272-6386(95)90638-X; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; COHEN LM, 1993, PSYCHOSOMATICS, V34, P395, DOI 10.1016/S0033-3182(93)71842-3; DISNEY APS, 1994, ANZDATA REPORT; KJELLSTRAND C, 1993, DEV NEPHROL, V34, P563; MOSS AH, 1993, J AM SOC NEPHROL, V4, P229; NELSON CB, 1994, J AM SOC NEPHROL, V4, P1608; OREOPOULOS DG, 1994, PERITON DIALYSIS INT, V14, P205; SCHNEIDERMAN LJ, 1994, AM J MED, V96, P110, DOI 10.1016/0002-9343(94)90130-9; SINGER PA, 1992, J AM SOC NEPHROL, V2, P1235; 1993, CANADIAN ORGAN REPLA; 1995, USRDS 1995 ANN DATA, P87	12	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 1	1995	346	8966					3	4		10.1016/S0140-6736(95)92645-3	http://dx.doi.org/10.1016/S0140-6736(95)92645-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603145				2022-12-28	WOS:A1995RF98500003
J	HEARST, JE				HEARST, JE			THE STRUCTURE OF PHOTOLYASE - USING PHOTON ENERGY FOR DNA-REPAIR	SCIENCE			English	Editorial Material											HEARST, JE (corresponding author), UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720, USA.							AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BEUKERS R, 1960, RECL TRAV CHIM PAY B, V79, P101; DULBECCO R, 1949, NATURE, V163, P949, DOI 10.1038/163949b0; EKER APM, 1990, J BIOL CHEM, V265, P8009; HARM H, 1976, PHOTOCHEM PHOTOBIOL, V2, P219; HERSHEY AD, 1952, J GEN PHYSIOL, V36, P39, DOI 10.1085/jgp.36.1.39; HOLLAENDER A, 1937, B NATL RES COUNC NAT, V100, P75; KELNER A, 1949, P NATL ACAD SCI USA, V35, P73, DOI 10.1073/pnas.35.2.73; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; RUPERT CS, 1958, J GEN PHYSIOL, V41, P451, DOI 10.1085/jgp.41.3.451; SANCAR A, 1978, GENE, V4, P294; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SETLOW JK, 1963, NATURE, V197, P560, DOI 10.1038/197560a0; SETLOW RB, 1962, P NATL ACAD SCI USA, V48, P1250, DOI 10.1073/pnas.48.7.1250; WOLF D, 1962, BIOCHEM BIOPH RES CO, V7, P237	20	80	80	1	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1858	1859		10.1126/science.7604259	http://dx.doi.org/10.1126/science.7604259			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604259				2022-12-28	WOS:A1995RF99000027
J	KAUFMAN, PD; KOBAYASHI, R; KESSLER, N; STILLMAN, B				KAUFMAN, PD; KOBAYASHI, R; KESSLER, N; STILLMAN, B			THE P150 AND P60 SUBUNITS OF CHROMATIN ASSEMBLY FACTOR-I - A MOLECULAR LINK BETWEEN NEWLY SYNTHESIZED HISTONES AND DNA-REPLICATION	CELL			English	Article							CELL-FREE SYSTEM; ACETYLATION; INVITRO; TRANSCRIPTION; TETRAHYMENA; PURIFICATION; COMPLEXES; MECHANISM; EXISTENCE; EXTRACTS	Chromatin assembly factor I (CAF-I) from human cell nuclei is a three-subunit protein complex that assembles histone octamers onto replicating DNA in a cell-free system. Sequences of cDNAs encoding the two largest CAF-I subunits reveal that the p150 protein contains large clusters of charged residues, whereas p60 contains WD repeats. p150 and p60 directly interact and are both required for DNA replication-dependent assembly of nucleosomes. Deletion of the p60-binding domain from the p150 protein prevents chromatin assembly. p150 and p60 form complexes with newly synthesized histones H3 and acetylated H4 in human cell extracts, suggesting that such complexes are intermediates between histone synthesis and assembly onto replicating DNA.			KAUFMAN, PD (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091; Kaufman, Paul/0000-0003-3089-313X	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLIS CD, 1985, P NATL ACAD SCI USA, V82, P8048, DOI 10.1073/pnas.82.23.8048; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HARLOW E, 1988, ANTIBODIES LABORATOR; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KRUDE T, 1993, J BIOL CHEM, V268, P14432; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEVY A, 1978, CELL, V14, P259, DOI 10.1016/0092-8674(78)90112-5; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Sambrook J, 1989, MOL CLONING; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SMITH PA, 1984, BIOCHEMISTRY-US, V23, P1576, DOI 10.1021/bi00302a036; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SMITH S, 1991, J BIOL CHEM, V266, P12041; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; THOMAS JO, 1989, METHOD ENZYMOL, V170, P549; TURNER BM, 1991, J CELL SCI, V99, P13; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; van Holde KE., 1989, SPRINGER SERIES MOL; WOLFFE A, 1992, CHROMATIN STRUCTURE; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3	42	325	329	2	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1105	1114		10.1016/S0092-8674(05)80015-7	http://dx.doi.org/10.1016/S0092-8674(05)80015-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600578	Bronze			2022-12-28	WOS:A1995RG91000015
J	POEHLMAN, ET; TOTH, MJ; GARDNER, AW				POEHLMAN, ET; TOTH, MJ; GARDNER, AW			CHANGES IN ENERGY-BALANCE AND BODY-COMPOSITION AT MENOPAUSE - A CONTROLLED LONGITUDINAL-STUDY	ANNALS OF INTERNAL MEDICINE			English	Note							CORONARY HEART-DISEASE; FAT DISTRIBUTION; FRAMINGHAM; TIME	Objective: To describe the effects of menopause on resting metabolic rate, body composition, fat distribution, physical activity during leisure time, and fasting insulin levels. Design: A longitudinal comparison of metabolic changes in women who experienced menopause with changes in age-matched women who did not experience menopause. Setting: General clinical research center. Patients: An initial cohort of 35 sedentary healthy premenopausal women (age range, 44 to 48 years). After 6 years of follow-up, 18 women had spontaneously stopped menstruating for at least 12 months and 17 women remained premenopausal. No women received hormone replacement therapy. Results: Women who experienced menopause lost more fat-free mass than women who remained premenopausal (-3.0 +/- 1.1 kg and -0.5 +/- 0.5 kg, respectively), had greater decreases in resting metabolic rate (-103 +/- 55 kcal/d and -8 +/- 17 kcal/d) and physical activity during leisure time (-127 +/- 79 kcal/d and 64 +/- 60 kcal/d), and had greater increases in fat mass (2.5 +/- 2 kg and 1.0 +/- 1.5 kg), fasting insulin levels (11 +/- 9 pmol/L and -2 +/- 5 pmol/L), and waist-to-hip ratios (0.04 +/- 0.01 and 0.01 +/- 0.01) (P less than or equal to 0.01 for all comparisons). Menopause did not affect energy intake, fasting glucose levels, or peak oxygen consumption. Conclusions: Natural menopause is associated with reduced energy expenditure during rest and physical activity, an accelerated loss of fat-free mass, and increased central adiposity and fasting insulin levels. These changes may indicate a worsening cardiovascular and metabolic risk profile.	UNIV MARYLAND, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	POEHLMAN, ET (corresponding author), VET AFFAIRS MED CTR, GERIATR SERV 18, 10 N GREENE ST, BALTIMORE, MD 21201 USA.				NATIONAL INSTITUTE ON AGING [K04AG000564, R01AG007857, R29AG007857, T32AG000219] Funding Source: NIH RePORTER; NIA NIH HHS [KO4-AG00564, T32-AG00219, AG-07857] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALOIA JF, 1991, AM J CLIN NUTR, V53, P1378, DOI 10.1093/ajcn/53.6.1378; ARCIERO PJ, 1993, J APPL PHYSIOL, V75, P2514, DOI 10.1152/jappl.1993.75.6.2514; Barrett-Connor E, 1993, Int J Fertil Menopausal Stud, V38 Suppl 1, P6; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; GARDNER AW, 1994, J CLIN EPIDEMIOL, V47, P283, DOI 10.1016/0895-4356(94)90009-4; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; HAARBO J, 1991, METABOLISM, V40, P1323, DOI 10.1016/0026-0495(91)90037-W; HJORTLAND MC, 1976, AM J EPIDEMIOL, V103, P304, DOI 10.1093/oxfordjournals.aje.a112228; LEY CJ, 1992, AM J CLIN NUTR, V55, P950, DOI 10.1093/ajcn/55.5.950; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; PASQUALI R, 1994, INT J OBESITY, V18, P614; POEHLMAN ET, 1993, AM J PHYSIOL, V264, pE450, DOI 10.1152/ajpendo.1993.264.3.E450; POEHLMAN ET, 1993, J AM GERIATR SOC, V41, P552, DOI 10.1111/j.1532-5415.1993.tb01895.x; SCHWARTZ RS, 1991, METABOLISM, V40, P545, DOI 10.1016/0026-0495(91)90239-S; Siri W., 1961, TECHNIQUES MEASURING, P223; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; WANG QL, 1994, AM J CLIN NUTR, V60, P843, DOI 10.1093/ajcn/60.6.843; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; WING RR, 1991, ARCH INTERN MED, V151, P97, DOI 10.1001/archinte.151.1.97; 1987, DHHS PHS871120 MONTH, V35	20	399	427	0	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					673	675		10.7326/0003-4819-123-9-199511010-00005	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574222				2022-12-28	WOS:A1995TA69600005
J	PHILLIPS, VL				PHILLIPS, VL			COMMUNITY CARE FOR SEVERELY DISABLED PEOPLE ON LOW INCOMES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the volume and distribution of formal and informal care received by severely disabled adults living at home in the community on low incomes according to type of disease. Design-Analysis of computerised reports from social workers which include information on disabling conditions and on the weekly hours of care at home from formal and informal sources. Subjects-1298 severely disabled people aged 16 to 98 who received financial assistance from the Independent Living Fund in 1991-2. Results-Over half (733; 56.6% (53.8 to 59.2)) of the sample were completely unable to perform five or more of the basic activities of daily living. On average the whole sample received 6.8 (6.1 to 7.6) hours of care at home a week from formal sources and 64.2 (62.4 to 65.9) hours from informal sources. In seven out of 14 disease groups, less than half in each group received any formal help at home. There were large differences in the volume of formal care within groups. In most cases no significant differences were found within diagnostic groups between those receiving care at home from district health authorities or local authorities, or both, and those who received no help at home with regard to age, dependency score, and duration of disability. Weekly hours of informal care were an important determinant of who received formal help in nine out of 14 groups. Conclusions-The amount of care received at home by low income, severely disabled people from formal sources differs across and within diagnostic groups. The fact that the variation was not systematically related to age, dependency, or duration suggests that the existing distribution of community care resources needs to be examined. Weekly hours of informal care and diagnosis seem to affect the volume and type of care received. The methods by which people in need of assistance receive help merit further investigation.			PHILLIPS, VL (corresponding author), EMORY UNIV,ROLLINS SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,ATLANTA,GA 30322, USA.							CHALLIS L, 1994, BRIT MED J, V308, P1496, DOI 10.1136/bmj.308.6942.1496; GLENDINNING C, 1992, COSTS INFORMAL CARE; GROVES T, 1994, BRIT MED J, V308, P708, DOI 10.1136/bmj.308.6930.708; KESTENBAUM A, 1993, MAKING COMMUNITY CAR; Kestenbaum A., 1992, CASH CARE REPORT EXP; KINGMAN S, 1994, BRIT MED J, V308, P966, DOI 10.1136/bmj.308.6934.966; Martin J., 1988, PREVALENCE DISABILIT; PHILLIPS VL, 1993, CARING SEVERELY DISA; ROBINSON R, 1994, BRIT MED J, V308, P778, DOI 10.1136/bmj.308.6931.778; TONKS A, 1994, BRIT MED J, V308, P839, DOI 10.1136/bmj.308.6932.839; 1992, HLTH SERVICE INDICAT; 1990, CARING PEOPLE COMMUN; 1992, LOCAL AUTHORITY SOCI; 1991, SOCIAL SECURITY STAT	14	11	11	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 28	1995	311	7013					1121	1123		10.1136/bmj.311.7013.1121	http://dx.doi.org/10.1136/bmj.311.7013.1121			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC466	7580705	Green Published			2022-12-28	WOS:A1995TC46600014
J	KOVACS, JA; SHONER, SC; ELLISON, JJ				KOVACS, JA; SHONER, SC; ELLISON, JJ			METAL-CARBON BONDS IN NATURE	SCIENCE			English	Editorial Material							IRON-SULFUR CLUSTERS; MONOXIDE DEHYDROGENASE; CLOSTRIDIUM-THERMOACETICUM; CO DEHYDROGENASE; CHEMISTRY				KOVACS, JA (corresponding author), UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195, USA.		Kovacs, Julie A./G-5792-2015	Kovacs, Julie A./0000-0003-2358-1269				ALANI FT, 1988, J CHEM SOC DALTON, P2329, DOI 10.1039/dt9880002329; AVERILL BA, 1978, J AM CHEM SOC, V100, P5234, DOI 10.1021/ja00484a067; Berg J. M., 1982, IRON SULFUR PROTEINS; CAI LS, 1994, J AM CHEM SOC, V116, P7177, DOI 10.1021/ja00095a021; CIURLI S, 1992, J AM CHEM SOC, V114, P5415, DOI 10.1021/ja00039a063; Crabtree R. H., 1994, ORGANOMETALLIC CHEM; CRANE BR, 1995, SCIENCE, V270, P59, DOI 10.1126/science.270.5233.59; Dolphin D., 1982, B12, V1; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HOLM RH, 1992, ADV INORG CHEM, V38, P1, DOI 10.1016/S0898-8838(08)60061-6; KOVACS JA, ADV INORGANIC BIOCH, V9, pCH5; KUMAR M, 1995, SCIENCE, V270, P628, DOI 10.1126/science.270.5236.628; LINDAHL PA, 1990, J BIOL CHEM, V265, P3880; LINDAHL PA, 1900, J CLUSTER SCI, V1, P29; MATSUNAGA PT, 1994, ANGEW CHEM INT EDIT, V33, P1748, DOI 10.1002/anie.199417481; MCREE DE, 1986, J BIOL CHEM, V261, P277; QIU D, 1994, SCIENCE, V264, P817, DOI 10.1126/science.8171334; QIU D, 1995, J AM CHEM SOC, V117, P2653, DOI 10.1021/ja00114a032; Ragsdale S.W., 1988, BIOINORGANIC CHEM NI; RAGSDALE SW, 1985, J BIOL CHEM, V260, P3970; RAGSDALE SW, 1985, P NATL ACAD SCI USA, V82, P6811, DOI 10.1073/pnas.82.20.6811; SELLMANN D, 1992, INORG CHIM ACTA, V198, P351, DOI 10.1016/S0020-1693(00)92377-6; STAVROPOULOS P, 1991, J AM CHEM SOC, V113, P8485, DOI 10.1021/ja00022a041; TAN GO, 1992, P NATL ACAD SCI USA, V89, P4427, DOI 10.1073/pnas.89.10.4427; TESLER J, 1986, J BIOL CHEM, V261, P4840; TUCCI GC, 1995, J AM CHEM SOC, V117, P6489, DOI 10.1021/ja00129a011; YAMAMURA T, 1993, J CHEM SOC CHEM COMM, P1656, DOI 10.1039/c39930001656	27	9	9	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					587	588		10.1126/science.270.5236.587	http://dx.doi.org/10.1126/science.270.5236.587			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570015				2022-12-28	WOS:A1995TB55700025
J	COUCOUVANIS, E; MARTIN, GR				COUCOUVANIS, E; MARTIN, GR			SIGNALS FOR DEATH AND SURVIVAL - A 2-STEP MECHANISM FOR CAVITATION IN THE VERTEBRATE EMBRYO	CELL			English	Article							PROGRAMMED CELL-DEATH; MOUSE EMBRYOS; NERVOUS-SYSTEM; CARCINOMA-CELLS; APOPTOSIS; DIFFERENTIATION; TERATOCARCINOMA; FIBROBLASTS; BLASTOCYST; INDUCTION	Conversion of a solid primordium to a hollow tube of cells is a morphogenetic process used frequently during vertebrate embryogenesis. In the early mouse embryo, this process of cavitation transforms the solid embryonic ectoderm into a columnar epithelium surrounding a cavity. Using both established cell lines and normal embryos, we provide evidence that cavitation in the early mouse embryo is the result of the interplay of two signals, one from an outer layer of endoderm cells that acts over short distances to create a cavity by inducing apoptosis of the inner ectodermal cells, and the other a rescue signal mediated by contact with the basement membrane that is required for the survival of the columnar cells that line the cavity. This simple model provides a paradigm for investigating tube morphogenesis in diverse developmental settings.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	COUCOUVANIS, E (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022731] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD22731] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BORGHESE E, 1955, J ANAT, V84, P287; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROKS PC, 1994, CELL, V79, P1157; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CROSBY WM, 1962, OBSTET GYNECOL, V20, P507; ELLIOTT B, 1992, J CELL PHYSIOL, V152, P292, DOI 10.1002/jcp.1041520210; ELSHERSH.AM, 1974, J EMBRYOL EXP MORPH, V31, P643; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GARCIAMARTINEZ V, 1993, J CELL SCI, V106, P201; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HAMBURGER V, 1949, J EXP ZOOL, V111, P451; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HINCHLIFFE JR, 1981, CELL DEATH BIOL PATH, P35; Hogan B., 1986, MANIPULATING MOUSE E, P17; HOGAN BLM, 1981, J EMBRYOL EXP MORPH, V62, P379; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOFF ARTHUR K., 1933, CARNEGIE INST WASHINGTON [PUBL 443] CONTR TO EMBR, V24, P61; LANG RA, 1993, CELL, V74, P453, DOI 10.1016/0092-8674(93)80047-I; LEHMAN JM, 1974, J CELL PHYSIOL, V84, P13, DOI 10.1002/jcp.1040840103; MARTIN GR, 1977, DEV BIOL, V61, P230, DOI 10.1016/0012-1606(77)90294-9; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MUMMERY CL, 1991, DIFFERENTIATION, V46, P51, DOI 10.1111/j.1432-0436.1991.tb00865.x; MUMMERY CL, 1985, DEV BIOL, V108, P402; Nagy A., 1993, Gene targeting: a practical approach., P147; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PRATT RM, 1976, DEV BIOL, V54, P135, DOI 10.1016/0012-1606(76)90292-X; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Snow M.H.L., 1987, P202; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SOLTER D, 1975, P NATL ACAD SCI USA, V72, P5099, DOI 10.1073/pnas.72.12.5099; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wyllie A H, 1980, Int Rev Cytol, V68, P251	48	485	499	0	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					279	287		10.1016/0092-8674(95)90169-8	http://dx.doi.org/10.1016/0092-8674(95)90169-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585945	Bronze			2022-12-28	WOS:A1995TA96500014
J	ELIEZER, D; JENNINGS, PA; WRIGHT, PE; DONIACH, S; HODGSON, KO; TSURUTA, H				ELIEZER, D; JENNINGS, PA; WRIGHT, PE; DONIACH, S; HODGSON, KO; TSURUTA, H			THE RADIUS OF GYRATION OF AN APOMYOGLOBIN FOLDING INTERMEDIATE	SCIENCE			English	Article							PATHWAY		STANFORD UNIV, DEPT APPL PHYS, STANFORD, CA 94305 USA; STANFORD UNIV, STANFORD SYNCHROTRON RADIAT LAB, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA	Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Stanford University	ELIEZER, D (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.		Eliezer, David/GRS-5702-2022	Wright, Peter/0000-0002-1368-0223	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034909, R37DK034909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014541] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01209] Funding Source: Medline; NIDDK NIH HHS [DK34909] Funding Source: Medline; NIGMS NIH HHS [GM14541] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ELIEZER D, 1993, BIOPHYS J, V65, P912, DOI 10.1016/S0006-3495(93)81124-X; ELIEZER D, 1994, EUR BIOPHYS J, V23, P297; GRIKO YV, 1988, J MOL BIOL, V202, P127, DOI 10.1016/0022-2836(88)90525-6; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; JENNINGS PA, 1994, STATISTICAL MECHANIC; NISHII I, 1994, BIOCHEMISTRY-US, V33, P4903, DOI 10.1021/bi00182a019	7	131	131	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					487	488		10.1126/science.270.5235.487	http://dx.doi.org/10.1126/science.270.5235.487			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7570004				2022-12-28	WOS:A1995TA37400046
J	WINANDY, S; WU, P; GEORGOPOULOS, K				WINANDY, S; WU, P; GEORGOPOULOS, K			A DOMINANT MUTATION IN THE IKAROS GENE LEADS TO RAPID DEVELOPMENT OF LEUKEMIA AND LYMPHOMA	CELL			English	Article							MATURE T-CELLS; RETINOBLASTOMA; MICE; LYMPHOCYTES; SELECTION; GLD; REARRANGEMENT; AUTOIMMUNITY; COMMITMENT; SUICIDE	The Ikaros gene is essential for lymphoid lineage specification. As previously reported, mice homozygous fora mutation in the Ikaros DNA-binding domain fail to generate mature lymphocytes as well as their earliest described progenitors. In addition, our studies with mice heterozygous for this mutation establish the Ikaros gene as an essential regulator of T cell proliferation. Thymocytes display augmented TCR-mediated proliferative responses, and peripheral T cells are autoproliferative. A general lymphoproliferation precedes the T cell leukemia and lymphoma that rapidly develop in all heterozygotes. The first step toward leukemic transformation occurs within the maturing thymocyte population and is demarcated by clonal expansions and loss of the single Ikaros wild-type allele. From these studies, we propose that within developing and mature T lymphocytes, distinct thresholds of Ikaros activity are required to regulate proliferation. A decrease in Ikaros activity below the first threshold causes the rapid accumulation of T lymphoblasts, whereas a further decrease leads to neoplastic transformation.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129	Harvard University; Harvard Medical School; Massachusetts General Hospital					NIAID NIH HHS [R01-AI33062-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033062] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON SJ, 1995, IMMUNOL TODAY, V16, P99, DOI 10.1016/0167-5699(95)80096-4; ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GEORGOPOULOS K, 1994, CELL, V78, P143; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JANEWAY CA, 1994, IMMUNITY, V1, P3, DOI 10.1016/1074-7613(94)90003-5; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MOLNAR A, 1995, IN PRESS J IMMUNOL; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; RODEWALD HR, 1994, EMBO J, V13, P7229; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; TAKAHAMA Y, 1994, NATURE, V371, P67, DOI 10.1038/371067a0; VASQUEZ NJ, 1994, IMMUNITY, V1, P45, DOI 10.1016/1074-7613(94)90008-6; VONBOEHMER H, 1993, CELL, V73, P207, DOI 10.1016/0092-8674(93)90220-K; WAYNE J, 1994, IMMUNITY, V1, P95, DOI 10.1016/1074-7613(94)90103-1	35	349	364	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					289	299		10.1016/0092-8674(95)90170-1	http://dx.doi.org/10.1016/0092-8674(95)90170-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585946	Bronze			2022-12-28	WOS:A1995TA96500015
J	KNOBLICH, JA; JAN, LY; JAN, YN				KNOBLICH, JA; JAN, LY; JAN, YN			ASYMMETRIC SEGREGATION OF NUMB AND PROSPERO DURING CELL-DIVISION	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; C-ELEGANS EMBRYOS; CAENORHABDITIS-ELEGANS; DROSOPHILA EMBRYOS; GENE; EMBRYOGENESIS; VISUALIZATION; CYTOKINESIS; PATTERNS; GRANULES	A CELL can divide asymmetrically by specifically segregating a determinant into one of its daughter cells(1). The Numb protein is a candidate for such a determinant in the asymmetric cell divisions of the developing Drosophila nervous system(2,3). Numb is a membrane-associated protein that localizes asymmetrically during cell division and segregates into one daughter cell, where it is required for the specification of the correct cell fate(3-5). Here we show that a nuclear protein, Prospero(6,7), translocates to the membrane at the beginning of cell division and colocalizes with Numb throughout mitosis, suggesting a common mechanism for asymmetric segregation. Numb and Prospero localization is coupled to mitosis and tightly correlated with the position of one of the two centrosomes. In contrast to centrosome positioning, however, Numb and Prospero localization is independent of microtubules. Cytochalasin D treatment suggests that the process is also independent of actin, We propose that there is an organizer of asymmetric cell division which provides positional information for both the orientation of the mitotic spindle and asymmetric localization of Numb and Prospero.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	KNOBLICH, JA (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		Knoblich, Juergen A/C-2974-2015	Knoblich, Juergen A/0000-0002-6751-3404; Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1992, DEVELOPMENT, V116, P855; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HARTENSTEIN V, 1994, DEV BIOL, V165, P480, DOI 10.1006/dbio.1994.1269; HIME G, 1992, DEVELOPMENT, V114, P165; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; JARMAN AP, 1995, DEVELOPMENT, V121, P2019; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; LEHNER CF, 1992, J CELL SCI, V103, P1021; ORSULIC S, 1994, BIOTECHNIQUES, V16, P441; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; SPANA EP, IN PRESS DEVELOPMENT; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1986, J CELL BIOL, V103, P2241, DOI 10.1083/jcb.103.6.2241; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; TEPASS U, 1995, DEVELOPMENT, V121, P393; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8	26	409	417	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					624	627		10.1038/377624a0	http://dx.doi.org/10.1038/377624a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566172				2022-12-28	WOS:A1995TA27500050
J	TAKAHARA, PM; ROSENZWEIG, AC; FREDERICK, CA; LIPPARD, SJ				TAKAHARA, PM; ROSENZWEIG, AC; FREDERICK, CA; LIPPARD, SJ			CRYSTAL-STRUCTURE OF DOUBLE-STRANDED DNA CONTAINING THE MAJOR ADDUCT OF THE ANTICANCER DRUG CISPLATIN	NATURE			English	Article							MOLECULAR-STRUCTURE; A-DNA; CIS-DIAMMINEDICHLOROPLATINUM(II); PLATINUM; CIS-<PT(NH3)2(D(PGPG))>; PROTEIN; SINGLE; DUPLEX; GROOVE	THE success of cisplatin in cancer chemotherapy derives from its ability to crosslink DNA and alter the structure, Most cisplatin-DNA adducts are intrastrand d(GpG) and d(ApG) crosslinks(1), which unwind and bend the duplex to facilitate the binding of proteins that contain one or more high-mobility-group (HMG) domains(2). When HMG-domain proteins such as HMG1, IXR (intrastrand-crosslink recognition) protein from yeast, or human upstream-binding factor (hUBF) bind cisplatin intrastrand crosslinks, they can be diverted from their natural binding sites on the genome and shield the adducts from excision repair(3-5). These activities sensitize cells to cisplatin and contribute to its cytotoxic properties, Crystallographic information about the structure of cisplatin-DNA adducts has been limited to short single-stranded deoxyoligonucleotides such as Cis-[Pt(NH3)(2){d(pGpG)}](6-8). Here we describe the X-ray structure at 2.6 Angstrom resolution of a double-stranded DNA dodecamer containing this adduct. Our information provides, to our knowledge, the first crystallographic look at a platinated DNA duplex and should help the design of new platinum and other metal crosslinking antitumour drug candidates. Moreover, the structure reveals a unique fusion of A- and B-type DNA segments that could be of more general importance.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	TAKAHARA, PM (corresponding author), MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA.							ADMIRAAL G, 1987, J AM CHEM SOC, V109, P592, DOI 10.1021/ja00236a053; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHOW CS, 1994, BIOCHEMISTRY-US, V33, P15124, DOI 10.1021/bi00254a023; DENHARTOG JHJ, 1985, J BIOMOL STRUCT DYN, V2, P1137, DOI 10.1080/07391102.1985.10507629; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; FREDERICK CA, 1989, EUR J BIOCHEM, V181, P295, DOI 10.1111/j.1432-1033.1989.tb14724.x; HERMAN F, 1990, EUR J BIOCHEM, V194, P119, DOI 10.1111/j.1432-1033.1990.tb19435.x; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P226; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SHERMAN SE, 1988, J AM CHEM SOC, V110, P7368, DOI 10.1021/ja00230a017; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; WANG AHJ, 1982, P NATL ACAD SCI-BIOL, V79, P3968, DOI 10.1073/pnas.79.13.3968; WANG AHJ, 1988, J CRYST GROWTH, V90, P295, DOI 10.1016/0022-0248(88)90325-9; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WHITEHEAD JP, METAL IONS BIOL SYST	27	699	717	1	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 19	1995	377	6550					649	652		10.1038/377649a0	http://dx.doi.org/10.1038/377649a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566180				2022-12-28	WOS:A1995TA27500058
J	DARMON, AJ; NICHOLSON, DW; BLEACKLEY, RC				DARMON, AJ; NICHOLSON, DW; BLEACKLEY, RC			ACTIVATION OF THE APOPTOTIC PROTEASE CPP32 BY CYTOTOXIC T-CELL-DERIVED GRANZYME-B	NATURE			English	Article							SERINE PROTEASES; LYMPHOCYTES-T; PURIFICATION; INHIBITION; POLYMERASE	CYTOTOXIC T lymphocyte (CTL)-mediated cytotoxicity represents the body's major defence against virus-infected and tumorigenic cells, and contributes to transplant rejection and autoimmune disease. During killing, CTL granules are exocytosed, releasing their contents into the intercellular space between the target cell and the effector. Perforin facilitates the entry of cytotoxic cell serine proteases, the granzymes, into the target cell, where they induce apoptotic death by an unknown pathway(1). Granzyme B is essential for the induction of DNA fragmentation and apoptosis in target cells(2-5), yet its substrate is unknown. Identification of the intracellular substrate far granzyme B is therefore the key to understanding the mechanism of CTL-mediated killing. Here we show that granzyme B cleaves and activates CPP32, the precursor of the protease responsible for cleavage of poly(ADP-ribose) polymerase.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA	University of Alberta; Merck & Company								BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DING RC, 1994, CANCER RES, V54, P4627; GARNER R, 1994, J IMMUNOL, V153, P5413; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; NICHOLSON DW, 1994, NATURE, V376, P37; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; REDEGELD FA, 1992, J IMMUNOL, V149, P3509; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; SU B, 1994, EUR J IMMUNOL, V24, P2073, DOI 10.1002/eji.1830240921; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509	23	616	633	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					446	448		10.1038/377446a0	http://dx.doi.org/10.1038/377446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566124				2022-12-28	WOS:A1995RY19000054
J	BRITTO, J; NADEL, S; MACONOCHIE, I; LEVIN, M; HABIBI, P				BRITTO, J; NADEL, S; MACONOCHIE, I; LEVIN, M; HABIBI, P			MORBIDITY AND SEVERITY OF ILLNESS DURING INTERHOSPITAL TRANSFER - IMPACT OF A SPECIALIZED PEDIATRIC RETRIEVAL TEAM	BRITISH MEDICAL JOURNAL			English	Article							AIRWAY MANAGEMENT; TRANSPORT; STABILIZATION	Objective-To evaluate the morbidity and severity of illness during interhospital transfer of critically ill children by a specialised paediatric retrieval team. Design-Prospective, descriptive study. Setting-Hospitals without paediatric intensive care facilities in and around the London area, and a paediatric intensive care unit at a tertiary centre. Subjects-51 critically ill children transferred to the paediatric intensive care unit. Main outcome measures-Adverse events related to equipment and physiological deterioration during transfer. Paediatric risk of mortality score before and after retrieval. Therapeutic intervention score before and after arrival of retrieval team. Results-Two (4%) patients had preventable physiological deterioration during transport. There were no adverse events related to equipment. Severity of illness decreased during stabilisation and transport by the retrieval team, suggested by the difference between risk of mortality scores before and after retrieval (P < 0.001). The median (range) difference between the two scores was 3.0 (-6 to 17). Interventions during stabilisation by the retrieval team increased, demonstrated by the difference between intervention scores before and after retrieval, median (range) difference between the two scores being 6 (-8 to 38) (P < 0.001). Conclusions-Our study indicates that a specialised paediatric retrieval team can rapidly deliver intensive care to critically iu children awaiting transfer. Such children can be transferred to a paediatric intensive care unit with minimal morbidity and mortality related to transport. There was no deterioration in the clinical condition of most patients during transfer.			BRITTO, J (corresponding author), ST MARYS HOSP,DEPT PAEDIAT,PRAED ST,LONDON W2 1NY,ENGLAND.			Levin, Michael/0000-0003-2767-6919; Maconochie, Ian/0000-0001-6319-8550				BARRY PW, 1994, ARCH DIS CHILD, V71, P8, DOI 10.1136/adc.71.1.8; BLACK RE, 1982, NEW ENGL J MED, V307, P1465, DOI 10.1056/NEJM198212023072342; EDGE WE, 1994, CRIT CARE MED, V22, P1186, DOI 10.1097/00003246-199407000-00023; FULLER J, 1991, CAN J ANAESTH, V38, P252, DOI 10.1007/BF03008156; HENNING R, 1992, MED J AUSTRALIA, V156, P117; KANTER RK, 1989, PEDIATRICS, V84, P43; KANTER RK, 1993, CRIT CARE MED, V21, pS265; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; MACNAB AJ, 1991, J TRAUMA, V31, P205, DOI 10.1097/00005373-199131020-00009; MCCLOSKEY K A, 1991, Emergency Medicine Clinics of North America, V9, P475; MCDONALD TB, 1993, PEDIATR CLIN N AM, V40, P381; ORR RA, 1994, CRIT CARE MED, V22, P101, DOI 10.1097/00003246-199401000-00020; ORR RA, 1992, TXB PEDIATRIC INTENS, P1571; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; ROBB HM, 1992, BRIT J INTENSIVE CAR, V2, P371; WETZEL RC, 1992, TXB PEDIATRIC INTENS, P563; WHITFIELD JM, 1993, PEDIATR EMERG CARE, V9, P69, DOI 10.1097/00006565-199304000-00002; 1995, CRD1 NHS CTR REV DIS; 1993, CARE CRITICALLY ILL	20	96	98	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					836	839		10.1136/bmj.311.7009.836	http://dx.doi.org/10.1136/bmj.311.7009.836			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580489	Green Published			2022-12-28	WOS:A1995RY19100019
J	JARRIAULT, S; BROU, C; LOGEAT, F; SCHROETER, EH; KOPAN, R; ISRAEL, A				JARRIAULT, S; BROU, C; LOGEAT, F; SCHROETER, EH; KOPAN, R; ISRAEL, A			SIGNALING DOWNSTREAM OF ACTIVATED MAMMALIAN NOTCH	NATURE			English	Article							BINDING-PROTEIN; CELL-FATE; DROSOPHILA; EXPRESSION; GENE; DIFFERENTIATION; ENHANCER; SEQUENCE; RECEPTOR; HOMOLOG	NOTCH belongs to a family of transmembrane proteins that are widely conserved from flies to vertebrates and are thought to be involved in cell-fate decisions. In Drosophila, the Suppressor of hairless (Su(H)) gene(1,2) and genes of the Enhancer of split (E(Spl)) complex, which encode proteins of the basic helix-loop-helix type(3,4) have been implicated in the Notch signalling pathway. Mammalian homologues of E(Spl), such as the mouse Hairy enhancer of split (HES-1)(5), have been isolated. Both HES-1 and the intracellular domain of murine Notch (mNotch) are able to block MyoD-induced myogenesis(5-7). Here we show that activated forms of mNotch associate with the human analogue of Su(H), KBF2/RBP-J kappa (refs 8,9) and act as transcriptional activators through the KBF2-binding sites of the HES-1 promoter.	WASHINGTON UNIV, DIV DERMATOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	JARRIAULT, S (corresponding author), INST PASTEUR, CNRS, URA 1149, UNITE BIOL MOLEC EXPRESS GENET, 28 RUE DR ROUX, F-75724 PARIS 15, FRANCE.		Kopan, Raphael/AFG-3275-2022; Kopan, Raphael/AAF-1357-2022	Kopan, Raphael/0000-0002-0350-2730				BROU C, 1994, GENE DEV, V8, P2491, DOI 10.1101/gad.8.20.2491; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPAN R, 1994, DEVELOPMENT, V120, P2385; NYE JS, 1994, DEVELOPMENT, V120, P2421; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHWEISGUTH F, 1995, DEVELOPMENT, V121, P1875; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; TATA F, 1993, DEVELOPMENT, P139; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WALTZER L, 1994, EMBO J, V13, P5633, DOI 10.1002/j.1460-2075.1994.tb06901.x; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	24	1197	1246	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377	6547					355	358		10.1038/377355a0	http://dx.doi.org/10.1038/377355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566092				2022-12-28	WOS:A1995RX11100061
J	MILLMAN, A; LEE, N; BROOKE, A				MILLMAN, A; LEE, N; BROOKE, A			ABC OF MEDICAL COMPUTING - COMPUTERS IN GENERAL-PRACTICE .1.	BRITISH MEDICAL JOURNAL			English	Article									WESTERN EYE HOSP,LONDON,ENGLAND; HILLINGDON HOSP,HILLINGDON,ENGLAND		MILLMAN, A (corresponding author), GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND.								0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					800	802		10.1136/bmj.311.7008.800	http://dx.doi.org/10.1136/bmj.311.7008.800			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580446	Green Published			2022-12-28	WOS:A1995RX10700029
J	BACON, KB; PREMACK, BA; GARDNER, P; SCHALL, TJ				BACON, KB; PREMACK, BA; GARDNER, P; SCHALL, TJ			ACTIVATION OF DUAL T-CELL SIGNALING PATHWAYS BY THE CHEMOKINE RANTES	SCIENCE			English	Article							LYMPHOCYTES-T; TYROSINE PHOSPHORYLATION; COUPLED RECEPTORS; CALCIUM CURRENT; G-PROTEIN; INTERLEUKIN-8; FLUORESCENCE; DEPLETION; STORES	The chemokine RANTES induced biphasic mobilization of Ca2+ in T cells. The initial peak, a transient increase in cytosolic Ca2+ mediated by a heterotrimeric guanine nucleotide-binding protein (G protein)-coupled pathway, was associated predominantly with chemotaxis. The second peak, Ca2+ release and sustained influx dependent on protein tyrosine kinases, was associated with a spectrum of cellular responses--Ca2+ channel opening, interleukin-2 receptor expression, cytokine release, and T cell proliferation-characteristic of T cell receptor activation. Other chemokines did not produce these responses. Thus, in addition to inducing chemotaxis, RANTES can act as an antigenin-dependent activator of T cells in vitro.	STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305	Stanford University	BACON, KB (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,901 CALIF AVE,PALO ALTO,CA 94304, USA.				NIGMS NIH HHS [GM07065] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON KB, 1995, J IMMUNOL, V154, P3654; BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; BACON KB, 1993, BLOOD, V81, P430; BACON KB, 1990, BIOCHEM BIOPH RES CO, V169, P1099, DOI 10.1016/0006-291X(90)92008-N; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; GRAHAM GJ, 1994, J BIOL CHEM, V269, P4974; GRAY LS, 1989, J IMMUNOL, V142, P1631; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JUNE CH, 1990, J IMMUNOL, V144, P1591; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; MODESTO J, 1991, CELL SIGNAL, V3, P25, DOI 10.1016/0898-6568(91)90004-E; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PREMACK BA, 1994, ADV EXP MED BIOL, V365, P91; PREMACK BA, 1994, J IMMUNOL, V152, P5226; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1115; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RONCAROLO MG, 1989, J EXP MED, V168, P2139; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1994, CYTOKINE HDB, P419; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; SOZZANI S, 1994, J IMMUNOL, V152, P3615; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	35	396	409	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1727	1730		10.1126/science.7569902	http://dx.doi.org/10.1126/science.7569902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569902				2022-12-28	WOS:A1995RV94800040
J	BERTHELEMY, P; BOUISSON, M; ESCOURROU, J; VAYSSE, N; RUMEAU, JL; PRADAYROL, L				BERTHELEMY, P; BOUISSON, M; ESCOURROU, J; VAYSSE, N; RUMEAU, JL; PRADAYROL, L			IDENTIFICATION OF K-RAS MUTATIONS IN PANCREATIC-JUICE IN THE EARLY DIAGNOSIS OF PANCREATIC-CANCER	ANNALS OF INTERNAL MEDICINE			English	Note							ONCOGENE ACTIVATION; GENE-MUTATIONS; CARCINOMAS; ADENOCARCINOMAS	Objective: To develop an early diagnostic test for pancreatic cancer based on the identification of K-ras mutations in pure pancreatic juice collected during endoscopic retrograde pancreatography. Design: Prospective study with masked comparison. The standard criteria for the diagnosis of pancreatic cancer were pancreatography or surgery (or both) and histopathology, with follow-up ranging from 6 to 40 months. Setting: Referral center. Patients: 24 patients with no pancreatic disease (group 1); 29 patients with nontumoral pancreatic disease (group 2); and 22 patients with pancreatic tumor (group 3). Endoscopic ductal aspiration of cells or brush cytology was done on patients having endoscopic retrograde pancreatography for diagnostic or therapeutic reasons. Main Outcome Measure: Confirmation of mutation rates in patients with pancreatic cancer. Results: K-ras gene analysis was done by polymerase chain reaction-mediated restriction fragment length polymorphism analysis and direct sequencing. AH patients from groups 1 and 2 (n = 53) had a normal sequence for the K-ras 12th codon (group 1, 0% [95% CI, 0% to 14%]; group 2, 0% [CI, 0% to 12%]). Mutations were seen in 17 of the 22 patients in group 3 (77% [CI, 55% to 92%]). Two of the 17 had no evidence of pancreatic cancer when K-ras was first studied. One had chronic abdominal pain and the other presented with acute pancreatitis. Both were initially free of any pancreatic mass, but they developed tumors 18 and 40 months, respectively, after the K-ras mutations were identified. Conclusion: Identification of K-ras mutations in samples of pancreatic juice may be useful in differentiating between pancreatic cancer and noncancerous pancreatic diseases. K-ras mutation can precede clinical evidence of pancreatic cancer, hut the clinical implications of this finding need further study.			BERTHELEMY, P (corresponding author), CHU RANGUEIL, INST LOUIS BUGNARD,INSERM,U151,BT L3, 1 AVE J POULHES, F-31054 TOULOUSE, FRANCE.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; CALDAS C, 1994, CANCER RES, V54, P3568; GONZALEZCADAVID NF, 1989, ONCOGENE, V4, P1137; GULLO L, 1994, NEW ENGL J MED, V331, P81, DOI 10.1056/NEJM199407143310203; HRUBAN RH, 1993, AM J PATHOL, V143, P545; JIANG W, 1989, ONCOGENE, V4, P923; KONDO H, 1994, CANCER, V73, P1589, DOI 10.1002/1097-0142(19940315)73:6<1589::AID-CNCR2820730609>3.0.CO;2-7; LEMOINE NR, 1992, GASTROENTEROLOGY, V102, P230, DOI 10.1016/0016-5085(92)91805-E; LI ZH, 1994, AM J PATHOL, V144, P303; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; LYON JL, 1989, INT J EPIDEMIOL, V18, P305, DOI 10.1093/ije/18.2.305; SAIKI RK, 1990, AMPLIFICATION GENOMI, P13; SHIBATA D, 1990, CANCER RES, V50, P1279; TADA M, 1991, CANCER, V67, P634, DOI 10.1002/1097-0142(19910201)67:3<634::AID-CNCR2820670318>3.0.CO;2-7; TADA M, 1993, CANCER RES, V53, P2472; TOBI M, 1994, J NATL CANCER I, V86, P1007; TSUCHIYA R, 1986, ANN SURG, V203, P77, DOI 10.1097/00000658-198601000-00013; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706	18	152	155	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					188	191		10.7326/0003-4819-123-3-199508010-00005	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598300				2022-12-28	WOS:A1995RL10400005
J	PODZAMCZER, D; MIRO, JM; BOLAO, F; GATELL, JM; COSIN, J; SIRERA, G; DOMINGO, P; LAGUNA, F; SANTAMARIA, J; VERDEJO, J; GUDIOL, F; GUELAR, A; BARRIO, JL; CLOTET, B; GONZALEZLAHOZ, J				PODZAMCZER, D; MIRO, JM; BOLAO, F; GATELL, JM; COSIN, J; SIRERA, G; DOMINGO, P; LAGUNA, F; SANTAMARIA, J; VERDEJO, J; GUDIOL, F; GUELAR, A; BARRIO, JL; CLOTET, B; GONZALEZLAHOZ, J			TWICE-WEEKLY MAINTENANCE THERAPY WITH SULFADIAZINE-PYRIMETHAMINE TO PREVENT RECURRENT TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						ACQUIRED IMMUNODEFICIENCY SYNDROME; TOXOPLASMOSIS CEREBRAL; SULFADIAZINE; PYRIMETHAMINE; ENCEPHALITIS	PNEUMOCYSTIS-CARINII PNEUMONIA; HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE TOXOPLASMOSIS; PROPHYLAXIS; COMBINATION; COTRIMOXAZOLE; EFFICACY; SERUM	Objective: To evaluate the efficacy of twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent toxoplasmic encephalitis relapse in patients with the acquired immunodeficiency syndrome (AIDS). Design: Randomized, open, multicenter trial. Patients were randomly assigned to receive sulfadiazine (500 mg) four times per day plus pyrimethamine (25 mg) plus folinic acid (15 mg) either daily (n = 60) or twice weekly (n = 45). Setting: 8 university teaching hospitals. Patients: Between February 1990 and June 1993, 105 patients with HIV infection were enrolled after each had had resolution of an acute episode of toxoplasmic encephalitis treated with sulfadiazine (1 g four times per day) plus pyrimethamine (50 mg/d) plus folinic acid (15 mg/d) for 4 to 8 weeks. Measurements: Clinical and biological evaluations done every 30 to 60 days. End points were toxoplasmic encephalitis relapse, death, and interruption of therapy due to adverse reactions. ttl Results: After a median follow-up period of 11 months (range, 1 to 39 months), patients receiving the twice-weekly regimen had a higher rate of relapse than patients receiving the daily regimen (19.5 compared with 4.4 per 100 patient-years; incidence rate ratio, 4.36 [95% CI, 1.05 to 25.5]; P = 0.024). The estimated cumulative percentages of relapse at 12 months were 30% and 6%, respectively (P = 0.029), with an adjusted risk ratio (adjusted for age, sex, risk behavior, previous diagnosis of AIDS, Pneumocystis carinii pneumonia prophylaxis before initial episode of toxoplasmosis, CD4 cell count, baseline number of brain lesions, radiologic sequelae, and antiretroviral therapy during follow-up) of 5.6 (CI, 1.2 to 25.6; P = 0.028). Patients receiving the twice-weekly regimen had 1.6 times (CI, 0.9 to 2.9 times; P = 0.11) the adjusted risk for death of patients receiving the daily regimen. No statistical differences were found in the patients who stopped receiving the regimens due to adverse effects. No patient developed P. carinii pneumonia during the study period, even though 17 patients (10 receiving the daily regimen and 7 receiving the twice-weekly regimen) had had an episode of P carinii pneumonia before study entry. Conclusions: At the given doses, a combination of sulfadiazine, pyrimethamine, and folinic acid was less effective when administered twice weekly than when administered daily, although the twice-weekly regimen was much more effective than historic controls.	HOSP GEN GREGORIO MARANON, INFECT DIS HIV SERV, E-28027 MADRID, SPAIN; HOSP GERMANS TRIAS & PUJOL, CTR HIV DAY CARE, E-08015 BARCELONA, SPAIN; HOSP SANTA CRUZ & SAN PABLO, INTERNAL MED SERV, E-08028 BARCELONA, SPAIN; INST CARLOS III, CTR INFECT CLIN, INFECT DIS SERV, E-28029 MADRID, SPAIN; HOSP CRUCES, INFECT DIS SERV, E-48013 BILBAO, SPAIN; HOSP PRINCESSA, INST CARLOS III, MADRID, SPAIN	General University Gregorio Maranon Hospital; Hospital Germans Trias i Pujol; Hospital Universitario Cruces; Hospital de La Princesa	PODZAMCZER, D (corresponding author), HOSP CLIN, CIUTAT SANITARIA BELLVITGE, INFECT DIS SERV, C-FEIXA LLARGA S-N, E-08907 LHOSPITALET DE LLOBREGAT, SPAIN.		Domingo, Pere/CAF-3577-2022; Domingo, Pere/AAP-7571-2021	Domingo, Pere/0000-0003-1138-5770				ARAUJO FG, 1993, J INFECT DIS, V167, P494, DOI 10.1093/infdis/167.2.494; ARAUJO FG, 1992, ANTIMICROB AGENTS CH, V36, P2454, DOI 10.1128/AAC.36.11.2454; BEAMAN MH, 1992, ANN INTERN MED, V117, P163, DOI 10.7326/0003-4819-117-2-163; DEROUIN F, 1992, ANTIMICROB AGENTS CH, V36, P997, DOI 10.1128/AAC.36.5.997; GIRARD PM, 1989, LANCET, V1, P1459; HALL AJH, 1991, SCAND J INFECT DIS, V23, P43, DOI 10.3109/00365549109023373; HAVERKOS HW, 1987, AM J MED, V82, P907, DOI 10.1016/0002-9343(87)90151-3; HEALD A, 1991, ANN INTERN MED, V115, P760, DOI 10.7326/0003-4819-115-10-760; KATLAMA C, 1992, INTERSCIENCE C ANTIM, P313; KATLAMA C, 1994, 4TH EUR C CLIN ASP T, P191; KOVACS JA, 1992, LANCET, V340, P637, DOI 10.1016/0140-6736(92)92172-C; KOVACS JA, 1992, CLIN INFECT DIS, V14, P1005, DOI 10.1093/clinids/14.5.1005; LEPORT C, 1992, AIDS, V6, P1040, DOI 10.1097/00002030-199209000-00021; LEVY RM, 1985, J NEUROSURG, V62, P475, DOI 10.3171/jns.1985.62.4.0475; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; PEDROL E, 1990, AIDS, V4, P511, DOI 10.1097/00002030-199006000-00003; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PODZAMCZER D, 1995, ANN INTERN MED, V122, P755, DOI 10.7326/0003-4819-122-10-199505150-00004; PODZAMCZER D, 1993, AIDS, V7, P501, DOI 10.1097/00002030-199304000-00008; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; WEISS LM, 1988, J INFECT DIS, V157, P580, DOI 10.1093/infdis/157.3.580	22	34	36	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					175	180		10.7326/0003-4819-123-3-199508010-00003	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598298				2022-12-28	WOS:A1995RL10400003
J	BROOK, RH				BROOK, RH			IMPLEMENTING MEDICAL GUIDELINES	LANCET			English	Editorial Material									UNIV CALIF LOS ANGELES,CTR HLTH SCI,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	BROOK, RH (corresponding author), RAND CORP,HLTH SCI PROGRAM,SANTA MONICA,CA 90406, USA.							CLINE DM, 1995, ANN EMERG MED, V25, P52, DOI 10.1016/S0196-0644(95)70355-1; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Kanouse DE, 1989, CHANGING MED PRACTIC; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KONSTAM M, 1994, CLIN PRACTICE GUIDEL, V11; KOSECOFF J, 1990, JAMA-J AM MED ASSOC, V264, P1980, DOI 10.1001/jama.264.15.1980; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LENNOX EL, 1979, BRIT MED J, V2, P567, DOI 10.1136/bmj.2.6190.567; LEWIS LM, 1995, EMERGEN MED, V25, P9; LOHR K, 1986, MED CARE S9, V24; MEADOWS AT, 1983, CANCER INVEST, V1, P49, DOI 10.3109/07357908309040932; WELLS KB, 1994, AM J PSYCHIAT, V151, P694	12	30	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					132	132		10.1016/S0140-6736(95)91202-9	http://dx.doi.org/10.1016/S0140-6736(95)91202-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603223				2022-12-28	WOS:A1995RJ03100003
J	ASHAR, HR; FEJZO, MS; TKACHENKO, A; ZHOU, X; FLETCHER, JA; WEREMOWICZ, S; MORTON, CC; CHADA, K				ASHAR, HR; FEJZO, MS; TKACHENKO, A; ZHOU, X; FLETCHER, JA; WEREMOWICZ, S; MORTON, CC; CHADA, K			DISRUPTION OF THE ARCHITECTURAL FACTOR HMGI-C - DNA-BINDING AT HOOK MOTIFS FUSED IN LIPOMAS TO DISTINCT TRANSCRIPTIONAL REGULATORY DOMAINS	CELL			English	Article							PULMONARY CHONDROID HAMARTOMA; NF-KAPPA-B; DIAGNOSTIC RELEVANCE; DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; INSULIN GENE; ALL-1 GENE; PROTEINS; TRANSLOCATION; TUMORS	Lipomas are one of the most common mesenchymal neoplasms in humans. They are characterized by consistent cytogenetic aberrations involving chromosome 12 in bands q14-15. Interestingly, this region is also the site of rearrangement for other mesenchymally derived tumors. This study demonstrates that HMGI-C, an architectural factor that functions in transcriptional regulation, has been disrupted by rearrangement at the 12q14-15 chromosomal breakpoint in lipomas. Chimeric transcripts were isolated from two lipomas in which HMGI-C DNA-binding domains (AT hook motifs) are fused to either a LIM or an acidic transactivation domain. These results, identifying a gene rearranged in a benign neoplastic process that does not proceed to a malignancy, suggest a role for HMGI-C in adipogenesis and mesenchyme differentiation.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	ASHAR, HR (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.			Fejzo, Marlena/0000-0001-6800-687X	NCI NIH HHS [1K11 CA 01498] Funding Source: Medline; NICHD NIH HHS [HD30498] Funding Source: Medline; NIGMS NIH HHS [GM38731] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030498] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K11CA001498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BENSON KF, 1994, GENET RES, V64, P27, DOI 10.1017/S0016672300032511; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BRIDGE JA, 1995, GENE CHROMOSOME CANC, V12, P70, DOI 10.1002/gcc.2870120113; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DALCIN P, 1993, GENE CHROMOSOME CANC, V8, P131; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FEJZO MS, 1995, GENOMICS, V26, P265, DOI 10.1016/0888-7543(95)80210-D; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FLETCHER JA, 1993, GENE CHROMOSOME CANC, V6, P24, DOI 10.1002/gcc.2870060106; FLETCHER JA, 1992, CANCER RES, V52, P6224; FLETCHER JA, 1990, CANCER RES, V50, P4092; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P218; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; JENKINS RB, 1989, CYTOGENET CELL GENET, V51, P1019; JUSTICE MJ, 1990, GENETICS, V125, P855; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MacArthur JW, 1944, AM NAT, V78, P142, DOI 10.1086/281181; MANDAHL N, 1993, CANCER, V71, P3009, DOI 10.1002/1097-0142(19930515)71:10<3009::AID-CNCR2820711020>3.0.CO;2-Y; MANDAHL N, 1988, HUM GENET, V79, P203, DOI 10.1007/BF00366238; MANDAHL N, 1989, CANCER, V65, P242; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NILBERT M, 1990, GENE CHROMOSOME CANC, V2, P3, DOI 10.1002/gcc.2870020103; NOGUERA R, 1989, VIRCHOWS ARCH A, V415, P377, DOI 10.1007/BF00718640; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REEVES R, 1990, J BIOL CHEM, V265, P8573; ROGERS P, 1980, BRIT J NUTR, V43, P83, DOI 10.1079/BJN19800066; ROHEN C, 1993, CANCER GENET CYTOGEN, V69, P68, DOI 10.1016/0165-4608(93)90117-5; ROTHER RP, 1992, BIOTECHNIQUES, V13, P524; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAITOH Y, 1994, CELL, V75, P609; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SREEKANTAIAH C, 1991, CANCER RES, V51, P422; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VANNI R, 1993, CANCER GENET CYTOGEN, V68, P32, DOI 10.1016/0165-4608(93)90070-3; VARTIAINEN E, 1988, FEBS LETT, V228, P45, DOI 10.1016/0014-5793(88)80581-7; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; XIANG X, 1990, SCIENCE, V247, P967, DOI 10.1126/science.2305264; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YUSPA SH, 1989, GENETIC MECHANISMS C, P115	69	395	408	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					57	65						9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606786				2022-12-28	WOS:A1995RK42400009
J	ROBERTS, RJ				ROBERTS, RJ			ON BASE FLIPPING	CELL			English	Review							DNA				ROBERTS, RJ (corresponding author), NEW ENGLAND BIOLABS INC,32 TOZER RD,BEVERLY,MA 01915, USA.			Roberts, Richard/0000-0002-4348-0169				BORMAN S, 1995, CHEM ENG NEWS, V27, P9; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KLIMASAUSKAS S, 1989, NUCLEIC ACIDS RES, V17, P9823, DOI 10.1093/nar/17.23.9823; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; MI S, 1995, NUCLEIC ACIDS RES, V23, P620, DOI 10.1093/nar/23.4.620; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MOORE MH, 1994, EMBO J, V13, P1495, DOI 10.1002/j.1460-2075.1994.tb06410.x; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARKER HW, 1995, IN PRESS SCIENCE; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	18	165	166	0	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					9	12		10.1016/0092-8674(95)90046-2	http://dx.doi.org/10.1016/0092-8674(95)90046-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606789	Bronze			2022-12-28	WOS:A1995RK42400003
J	STANFORD, JL; WEISS, NS; VOIGT, LF; DALING, JR; HABEL, LA; ROSSING, MA				STANFORD, JL; WEISS, NS; VOIGT, LF; DALING, JR; HABEL, LA; ROSSING, MA			COMBINED ESTROGEN AND PROGESTIN HORMONE REPLACEMENT THERAPY IN RELATION TO RISK OF BREAST-CANCER IN MIDDLE-AGED WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROLIFERATION; SURVEILLANCE; PREVENTION; MODELS	Objective.-To determine the risk of breast cancer in relation to the use of combined estrogen and progestin hormone replacement therapy (HRT). Design.-A population-based case-control study. Setting.-The general female population of King County in western Washington State. Participants.-Middle-aged (50 to 64 years) women, including 537 patients with incident primary breast cancer diagnosed between January 1, 1988, and June 30, 1990, who were ascertained through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry and 492 randomly selected control women without a history of breast cancer. Main Outcome Measure,-Breast cancer risk in relation to use of menopausal hormones. Results.-Menopausal hormones of some type had been used by 57.6% of breast cancer cases and 61.0% of comparison women. The women who had ever taken combined estrogen-progestin HRT, representing 21.5% of cases and 21.3% of controls, were not at increased risk of breast cancer (relative odds [RO]=0.9; 95% confidence interval [CI], 0.7 to 1.3). Compared with nonusers of menopausal hormones, those who used estrogen-progestin HRT for 8 or more years had, if anything, a reduced risk of breast cancer (RO=0.4; 95% CI, 0.2 to 1.0). Conclusions.-On the whole, the use of estrogen with progestin HRT does not appear to be associated with an increased risk of breast cancer in middle-aged women. Nonetheless, since the use of combined estrogen-progestin HRT has only recently become prevalent, future investigations must assess whether breast cancer incidence is altered many years after estrogen-progestin HRT has been initiated, particularly among long-term users.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	STANFORD, JL (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,1124 COLUMBIA ST,MP-474,SEATTLE,WA 98104, USA.			Habel, Laurel/0000-0002-7230-587X	NCI NIH HHS [N01-CN-05230, R35-CA39779, K07-CA01364] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K07CA001364, R35CA039779] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON TJ, 1989, HUM PATHOL, V20, P1139, DOI 10.1016/S0046-8177(89)80003-6; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BERGKVIST L, 1990, NEW ENGL J MED, V322, P204; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; Breslow NE, 1980, ANAL CASE CONTROL ST; Breslow NE Day NE, 1987, DESIGN ANAL COHORT S; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER WB, 1990, NEW ENGL J MED, V322, P202; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; GAMBRELL RD, 1986, MATURITAS, V8, P169, DOI 10.1016/0378-5122(86)90023-X; GENALO MA, 1988, P SECTION SURVEY RES; GINSBURG KA, 1988, FERTIL STERIL, V49, pS16; GOING JJ, 1988, AM J PATHOL, V130, P193; HARLOW BL, 1988, AM J EPIDEMIOL, V127, P857, DOI 10.1093/oxfordjournals.aje.a114869; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; HEMMINKI E, 1988, American Journal of Public Health, V78, P1479, DOI 10.2105/AJPH.78.11.1479; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JORDAN VC, 1993, CANCER, V71, P1501, DOI 10.1002/cncr.2820710415; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; POTTEN CS, 1988, BRIT J CANCER, V58, P163, DOI 10.1038/bjc.1988.185; PRENTICE RL, 1978, BIOMETRIKA, V65, P153, DOI 10.2307/2335290; RISCH HA, 1994, AM J EPIDEMIOL, V139, P670, DOI 10.1093/oxfordjournals.aje.a117057; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; SEBOLD J, 1988, TELEPHONE SURVEY MET; STANFORD JL, 1993, EPIDEMIOL REV, V15, P98, DOI 10.1093/oxfordjournals.epirev.a036120; VOIGT LF, 1992, AM J EPIDEMIOL, V136, P1393, DOI 10.1093/oxfordjournals.aje.a116452; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360	35	310	314	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					137	142		10.1001/jama.274.2.137	http://dx.doi.org/10.1001/jama.274.2.137			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596001				2022-12-28	WOS:A1995RH22200026
J	STACHELHAUS, T; SCHNEIDER, A; MARAHIEL, MA				STACHELHAUS, T; SCHNEIDER, A; MARAHIEL, MA			RATIONAL DESIGN OF PEPTIDE ANTIBIOTICS BY TARGETED REPLACEMENT OF BACTERIAL AND FUNGAL DOMAINS	SCIENCE			English	Article							OPEN READING FRAME; BACILLUS-SUBTILIS; GENE; BIOSYNTHESIS; SURFACTIN; SEQUENCE; ENZYMES; BREVIS; GRSB	Peptide synthetases involved in the nonribosomal synthesis of peptide secondary metabolites possess a highly conserved domain structure. The arrangement of these domains within the multifunctional enzymes determines the number and order of the amino acid constituents of the peptide product. A general approach has been developed for targeted substitution of amino acid-activating domains within the srfA operon, which encodes the protein templates for the synthesis of the lipopeptide antibiotic surfactin in Bacillus subtilis. Exchange of domain-coding regions of bacterial and fungal origin led to the construction of hybrid genes that encoded peptide synthetases with altered amino acid specificities and the production of peptides with modified amino acid sequences.	UNIV MARBURG,FACHBEREICH CHEM,D-35032 MARBURG,GERMANY	Philipps University Marburg								ANTONIEWSKI C, 1990, J BACTERIOL, V172, P86, DOI 10.1128/JB.172.1.86-93.1990; BORCHERT S, 1994, J BACTERIOL, V176, P2458, DOI 10.1128/JB.176.8.2458-2462.1994; COOPER DG, 1986, MICROBIOL SCI, V3, P145; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; CUTTING SM, 1990, MOL BIOL METHODS BAC; DSOUZA C, 1994, P NATL ACAD SCI USA, V91, P9397, DOI 10.1073/pnas.91.20.9397; FUMA S, 1993, NUCLEIC ACIDS RES, V21, P93, DOI 10.1093/nar/21.1.93; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; HAMOEN LW, 1994, MOL MICROBIOL, V15, P55; ITAYA M, 1990, MOL GEN GENET, V223, P268, DOI 10.1007/BF00265063; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; KRAUSE M, 1985, J BACTERIOL, V162, P1120, DOI 10.1128/JB.162.3.1120-1125.1985; LAEMMLI UK, 1970, NATURE, V227, P491; Lipmann F, 1980, Adv Microb Physiol, V21, P227; MARAHIEL MA, 1992, FEBS LETT, V307, P40, DOI 10.1016/0014-5793(92)80898-Q; NAKANO MM, 1992, MOL GEN GENET, V232, P313, DOI 10.1007/BF00280011; NAKANO MM, 1988, J BACTERIOL, V170, P5662, DOI 10.1128/jb.170.12.5662-5668.1988; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTTCRAIG JS, 1992, J BIOL CHEM, V267, P26044; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1111/j.1574-6968.1995.tb07328.x; STACHELHAUS T, UNPUB; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURGAY K, 1994, PEPTIDE RES, V7, P238; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; Zuber Peter, 1993, P897	29	243	264	1	41	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					69	72		10.1126/science.7604280	http://dx.doi.org/10.1126/science.7604280			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604280				2022-12-28	WOS:A1995RG98000034
J	SIMONS, EL				SIMONS, EL			SKULLS AND ANTERIOR TEETH OF CATOPITHECUS (PRIMATES, ANTHROPOIDEA) FROM THE EOCENE AND ANTHROPOID ORIGINS	SCIENCE			English	Article							CRANIAL MORPHOLOGY; SEXUAL DIMORPHISM; EGYPT; AEGYPTOPITHECUS; OLIGOCENE	Recent finds of Catopithecus browni at an upper Eocene fossil site in the Fayum depression, Egypt, reveal features of the earliest higher primates. This basal anthropoidean shows a set of derived cranial and dental features that first occur in combination in this fossil. Old World Anthropoidea or Catarrhini can now be traced back to Catopithecus in Egypt. Size, shape, orientation of incisors and canines, and other features of the teeth and skull relate Catopithecus both to later Anthropoidea and to the early and middle Eocene cercamoniine adapoids. Most defining characteristics of higher primates cannot be documented earlier than the late Eocene of Africa.			SIMONS, EL (corresponding author), DUKE UNIV,DEPT BIOL ANTHROPOL & ANAT,DURHAM,NC 27705, USA.							BEARD KC, 1994, NATURE, V368, P604, DOI 10.1038/368604a0; Ciochon Russell L., 1994, P143; Franzen Jens Lorenz, 1994, P99; Gingerich P. D., 1977, Geobios Lyon Memoire Special, VNo. 1, P165; GINGERICH PD, 1990, NATURE, V346, P411, DOI 10.1038/346411a0; GINGERICH PD, 1981, J HUM EVOL, V10, P345, DOI 10.1016/S0047-2484(81)80057-7; GINGERICH PD, 1981, AM J PHYS ANTHROPOL, V56, P217, DOI 10.1002/ajpa.1330560303; GODINOT M, 1992, NATURE, V357, P324, DOI 10.1038/357324a0; Godinot Marc, 1994, P235; Hartenberger J.-L., 1992, Human Evolution, V7, P9, DOI 10.1007/BF02437474; KALIN J., 1961, ANN PALEONTOL, V47, P1; KAY RF, 1981, AM J PHYS ANTHROPOL, V55, P293, DOI 10.1002/ajpa.1330550305; KRISHTALKA L, 1990, P NATL ACAD SCI USA, V87, P5223, DOI 10.1073/pnas.87.13.5223; MAW B, 1979, NATURE, V282, P65, DOI 10.1038/282065a0; Osborn HF, 1908, B AM MUS NAT HIST, V24, P265; RASMUSSEN DT, 1992, INT J PRIMATOL, V13, P477, DOI 10.1007/BF02547829; Rosenberger A.L., 1980, P139; ROSENBERGER AL, 1985, FOLIA PRIMATOL, V44, P15, DOI 10.1159/000156195; Schlosser M., 1911, Beitreage zur Palaeontologie u Geologie Oesterreich-Ungarns u des Orients Wien u Leipzig, V24; SIGE B, 1990, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V214, P31; SIMONS EL, 1990, SCIENCE, V247, P1567, DOI 10.1126/science.2108499; SIMONS EL, 1994, P NATL ACAD SCI USA, V91, P9946, DOI 10.1073/pnas.91.21.9946; SIMONS EL, 1992, P NATL ACAD SCI USA, V89, P10743, DOI 10.1073/pnas.89.22.10743; SIMONS EL, 1989, AM J PHYS ANTHROPOL, V79, P1, DOI 10.1002/ajpa.1330790103; SIMONS EL, 1965, NATURE, V205, P135, DOI 10.1038/205135a0; SIMONS EL, 1989, P NATL ACAD SCI USA, V86, P9956, DOI 10.1073/pnas.86.24.9956; SIMONS EL, 1987, J HUM EVOL, V16, P273, DOI 10.1016/0047-2484(87)90003-0; SIMONS EL, IN PRESS J HUM EVOL; Simons Elwyn L., 1994, P179; SPATZ WB, 1968, FOLIA PRIMATOL, V9, P22, DOI 10.1159/000155166; Walker A., 1972, CALIBRATION HOMINOID, P195	31	34	35	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1885	1888		10.1126/science.7604261	http://dx.doi.org/10.1126/science.7604261			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RF990	7604261				2022-12-28	WOS:A1995RF99000033
J	CHITNIS, A; HENRIQUE, D; LEWIS, J; ISHHOROWICZ, D; KINTNER, C				CHITNIS, A; HENRIQUE, D; LEWIS, J; ISHHOROWICZ, D; KINTNER, C			PRIMARY NEUROGENESIS IN XENOPUS EMBRYOS REGULATED BY A HOMOLOG OF THE DROSOPHILA NEUROGENIC GENE-DELTA	NATURE			English	Article							CELL FATE; NERVOUS-SYSTEM; MOUSE NOTCH; SPINAL-CORD; EXPRESSION; PATTERN; MELANOGASTER; SERRATE; PROTEIN; XOTCH	X-Delta-1, a Xenopus homologue of the Drosophila Delta gene, is expressed in the early embryonic nervous system in scattered cells that appear to be the prospective primary neurons. Ectopic X-Delta-1 activity inhibits production of primary neurons and interference with endogenous X-Delta-1 activity results in overproduction of primary neurons. These results indicate that the X-Delta-1 protein mediates lateral inhibition delivered by prospective neurons to adjacent cells, and that commitment to a neural fate in vertebrates is regulated by Delta-Notch signalling as in Drosophila.	UNIV OXFORD, DEPT ZOOL,IMPERIAL CANC RES FUND, DEV GENET & ORGANOGENESIS LABS,DEV BIOL UNIT, OXFORD OX1 3PS, ENGLAND	University of Oxford	CHITNIS, A (corresponding author), SALK INST BIOL STUDIES, POB 85800, SAN DIEGO, CA 92186 USA.		Lewis, Julian H/E-8733-2010; Henrique, Domingos M/E-5460-2010	Henrique, Domingos M/0000-0001-8869-1894; Ish-Horowicz, David/0000-0001-5684-7129				ALRDELLI M, 1994, MECH DEVELOP, V46, P123; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; BIERKAMP C, 1993, MECH DEVELOP, V43, P87, DOI 10.1016/0925-4773(93)90027-U; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1993, J NEUROBIOL, V24, P1305, DOI 10.1002/neu.480241005; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CONLON RA, 1995, DEVELOPMENT, V121, P1533; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; DOE CQ, 1992, DEVELOPMENT, V116, P855; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; GORIELY A, 1991, DEVELOPMENT, V113, P1395; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARTENSTEIN V, 1989, NEURON, V3, P399, DOI 10.1016/0896-6273(89)90200-6; HARTENSTEIN V, 1993, J COMP NEUROL, V328, P213, DOI 10.1002/cne.903280205; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; KOPAN R, 1994, DEVELOPMENT, V120, P2385; KORZH V, 1993, DEVELOPMENT, V118, P417; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LEHMANN R, 1981, ROUX ARCH DEV BIOL, V190, P226, DOI 10.1007/BF00848307; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; NYE JS, 1994, DEVELOPMENT, V120, P2421; OSCHWALD R, 1991, International Journal of Developmental Biology, V35, P399; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; ROBERTS A, 1982, PHILOS T R SOC B, V296, P195, DOI 10.1098/rstb.1982.0002; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SIMPSON P, 1992, COLD SPRING HARB SYM, V57, P391, DOI 10.1101/SQB.1992.057.01.044; SKEATH JB, 1994, FASEB J, V8, P714, DOI 10.1096/fasebj.8.10.8050670; STERNBERG PW, 1993, CURR BIOL, V3, P763, DOI 10.1016/0960-9822(93)90025-J; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; THOMAS U, 1991, DEVELOPMENT, V111, P749; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8	46	622	636	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	1995	375	6534					761	766		10.1038/375761a0	http://dx.doi.org/10.1038/375761a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596407				2022-12-28	WOS:A1995RF98900070
J	HENRIQUE, D; ADAM, J; MYAT, A; CHITNIS, A; LEWIS, J; ISHHOROWICZ, D				HENRIQUE, D; ADAM, J; MYAT, A; CHITNIS, A; LEWIS, J; ISHHOROWICZ, D			EXPRESSION OF A DELTA-HOMOLOG IN PROSPECTIVE NEURONS IN THE CHICK	NATURE			English	Article							NEUROGENIC GENE-DELTA; DROSOPHILA-MELANOGASTER; TRANSMEMBRANE PROTEIN; CELL-INTERACTIONS; SERRATE ENCODES; NOTCH; COMPLEX; PATTERN; FATE; RNA	THE product of the Delta gene, acting as ligand, and that of the Notch gene, acting as receptor, are key components in a lateral-inhibition signalling pathway that regulates the detailed patterning of many different tissues in Drosophila(1-8). During neurogenesis in particular, neural precursors, by expressing Delta, inhibit neighbouring Notch-expressing cells from becoming committed to a neural fate(5,9,10). Vertebrates are known to have several Notch genes(11-14), but their functions are unclear and their ligands hitherto unidentified. Here we identify and describe a chick Delta homologue, C-Delta-1. We show that C-Delta-1 is expressed in prospective neurons during neurogenesis, as new cells are being born and their fates decided. Our data from the chick, combined with parallel evidence from Xenopus(15), suggest that both the Delta/Notch signalling mechanism and its role in neurogenesis have been conserved in vertebrates.	UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,ORGANOGENESIS LAB,BIOL UNIT,OXFORD OX1 3PS,ENGLAND; SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	University of Oxford; Salk Institute	HENRIQUE, D (corresponding author), UNIV OXFORD,DEV GENET LAB,S PARKS RD,OXFORD OX1 3PS,ENGLAND.		Lewis, Julian H/E-8733-2010; Henrique, Domingos M/E-5460-2010	Henrique, Domingos M/0000-0001-8869-1894; Ish-Horowicz, David/0000-0001-5684-7129; Adam, Julie/0000-0002-7980-7151				ARTAVANISTSAKON.S, 1991, TRENDS GENET, V7, P403; BIFFO S, 1992, J HISTOCHEM CYTOCHEM, V40, P535, DOI 10.1177/40.4.1552187; Campos-Ortega Jose A., 1993, P1091; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FUJITA S, 1963, J COMP NEUROL, V120, P37, DOI 10.1002/cne.901200104; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAENLIN M, 1990, DEVELOPMENT, V110, P905; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MARTIN AH, 1965, J EMBRYOL EXP MORPH, V14, P23; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; SECHRIST J, 1991, NEURON, V7, P947, DOI 10.1016/0896-6273(91)90340-6; STRAHLE U, 1994, TRENDS GENET, V10, P75, DOI 10.1016/0168-9525(94)90221-6; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; THOMAS U, 1991, DEVELOPMENT, V111, P749; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931	29	928	946	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					787	790		10.1038/375787a0	http://dx.doi.org/10.1038/375787a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596411				2022-12-28	WOS:A1995RF98900078
J	IMPERIALE, TF; SPEROFF, T; CEBUL, RD; MCCULLOUGH, AJ				IMPERIALE, TF; SPEROFF, T; CEBUL, RD; MCCULLOUGH, AJ			A COST-ANALYSIS OF ALTERNATIVE TREATMENTS FOR DUODENAL-ULCER	ANNALS OF INTERNAL MEDICINE			English	Article						DUODENAL ULCER; HELICOBACTER PYLORI; HISTAMINE H-2 ANTAGONISTS; COST-BENEFIT ANALYSIS; ANTIBIOTICS	HELICOBACTER-PYLORI INFECTION; RANDOMIZED CONTROLLED TRIAL; TRIPLE THERAPY; RECURRENCE; ERADICATION; RANITIDINE; DISEASE; CIMETIDINE	Objective: To compare the costs of alternative strategies for the treatment of Design: A cost comparison using decision analysis. Methods: A decision model was used to compare the costs per cure of an endoscopically documented duodenal ulcer for three initial treatment strategies: 1) H-2-receptor antagonist therapy for 8 weeks, 2) antibiotic therapy for Helicobacter pylori infection plus H-2-receptor antagonist therapy, and 3) urease test-based treatment. For symptomatic recurrences, secondary treatment strategies included empiric retreatment with the same or other regimen, and treatment based on repeat endoscopy-guided urease test or biopsy, with an assumption of subsequent cure. The cohort modeled for this analysis consisted of patients at low risk for a malignant ulcer. probability estimates were derived from published clinical trials, cohort studies, and expert opinion. Side effects from combination therapy with antibiotics and H-2-receptor antagonists and resulting costs were included from the perspective of a group practice model health maintenance organization. Results: For all secondary treatment strategies, initial therapy with antibiotics for H. pylori infection plus an H-2-receptor antagonist resulted in the lowest average costs per symptomatic cure when the prevalence or likelihood of H. pylori infection exceeded 66% to 76%; the costs ranged from $284 for secondary (re)treatment with empiric antibiotic and H-2-receptor antagonist therapy to $398 for endoscopy-guided secondary treatment. Initial treatment with an H-2-receptor antagonist resulted in the highest costs, ranging from $372 for secondary treatment with empiric antibiotic and H-2-receptor antagonist therapy to $679 for endoscopy-guided secondary treatment. The results were not sensitive to the rates of duodenal ulcer recurrence after either treatment, to the cost of either treatment, or to prevalence of H. pylori. Conclusions: This cost analysis indicates that, regardless of the secondary treatment used for ulcer recurrence, initial therapy with antibiotics for H. pylori infection plus an H-2-receptor antagonist provides the lowest costs per symptomatic cure. These cost savings and the lower recurrence rates associated with this treatment favor eradication of H. pylori as part of the initial treatment of duodenal ulcer.			IMPERIALE, TF (corresponding author), METROHLTH MED CTR, CASE WESTERN RESERVE UNIV, 2500 METROHEALTH DR, CLEVELAND, OH 44109 USA.			Imperiale, Thomas/0000-0001-7586-1073				BARTHEL JS, 1990, REV INFECT DIS, V12, pS107; BAYERDORFFER E, 1987, DEUT MED WOCHENSCHR, V112, P1407, DOI 10.1055/s-2008-1068260; Black M, 1987, Am J Med, V83, P68, DOI 10.1016/0002-9343(87)90814-X; BLASER MJ, 1991, REV INFECT DIS, V13, pS704; BORODY TJ, 1991, AM J GASTROENTEROL, V86, P1154; BROWN KE, 1993, GASTROENTEROL CLIN N, V22, P105; BURLAND WL, 1980, POSTGRAD MED J, V56, P173, DOI 10.1136/pgmj.56.653.173; CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716; CUTLER AF, 1993, AM J GASTROENTEROL, V88, P1359; DALY MJ, 1990, GUT, V31, P653; DEBOER WA, 1994, AM J GASTROENTEROL, V89, P1993; DOOLEY CP, 1993, CURR OPIN GASTROEN, V9, P112, DOI 10.1097/00001574-199301000-00018; ELASHOFF JD, 1983, J CLIN GASTROENTEROL, V5, P509, DOI 10.1097/00004836-198312000-00008; FORBES GM, 1994, LANCET, V343, P258, DOI 10.1016/S0140-6736(94)91111-8; GARCIAPAREDES J, 1991, AM J MED, V91, pS64, DOI 10.1016/0002-9343(91)90453-5; GRAHAM DY, 1991, ANN INTERN MED, V115, P266, DOI 10.7326/0003-4819-115-4-266; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; GRAHAM DY, 1992, GASTROENTEROLOGY, V102, P493, DOI 10.1016/0016-5085(92)90095-G; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HOLLENBERG J, 1985, SMLTREE ALL PURPOSE; HOSKING SW, 1992, BRIT MED J, V305, P502, DOI 10.1136/bmj.305.6852.502; HUI WM, 1992, AM J MED, V92, P265, DOI 10.1016/0002-9343(92)90076-N; Isenberg JI, 1991, TXB GASTROENTEROLOGY, P1241; KURATA JH, 1989, GASTROENTEROLOGY, V96, P569, DOI 10.1016/S0016-5085(89)80052-6; LEWIS JH, 1987, AM J GASTROENTEROL, V82, P987; MANTZARIS GJ, 1993, DIGEST DIS SCI, V38, P1132, DOI 10.1007/BF01295732; MOHAMED AH, 1994, GASTROENTEROLOGY, V106, pA142; PAULKER SG, 1980, NEW ENGL J MED, V302, P1109; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; Sax MJ, 1987, PHARMACOTHERAPY, V7, P110, DOI 10.1002/j.1875-9114.1987.tb03534.x; SONTAG S, 1984, NEW ENGL J MED, V311, P689, DOI 10.1056/NEJM198409133111101; THILLAINAYAGAM AV, 1991, GUT, V32, P467, DOI 10.1136/gut.32.5.467; TYTGAT GNJ, 1993, GASTROENTEROL CLIN N, V22, P127; VONHAUNALTER G, 1977, COST ULCER DISEASE U; WANG CY, 1992, J GASTROEN HEPATOL, V7, P572, DOI 10.1111/j.1440-1746.1992.tb01488.x; WARREN JR, 1983, LANCET, V1, P1273; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65; NIH CONSENSUS C; 1994, RED BOOK	39	72	72	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					665	+		10.7326/0003-4819-123-9-199511010-00004	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574221				2022-12-28	WOS:A1995TA69600004
J	SU, CY; BRANDT, LJ				SU, CY; BRANDT, LJ			ESCHERICHIA-COLI O157-H7 INFECTION IN HUMANS	ANNALS OF INTERNAL MEDICINE			English	Review							HEMOLYTIC-UREMIC SYNDROME; SHIGA-LIKE-TOXIN; THROMBOTIC THROMBOCYTOPENIC PURPURA; POLYMERASE CHAIN-REACTION; NUCLEOTIDE-SEQUENCE ANALYSIS; CYTOTOXIN-PRODUCING STRAINS; LINKED IMMUNOSORBENT-ASSAY; TRANSFER RNA-BINDING; PHAGE-TYPING SCHEME; CELL CYTO-TOXIN	Objective: To review the clinical relevance of Escherichia coli O157:H7 infection, including the epidemiology of the infection and its clinical presentations, pathogenesis, microbiology, diagnosis, treatment, and prevention. Data Sources: Articles on E. coli O157:H7 were identified through MEDLINE and the bibliographies of relevant articles. Study Selection: All articles and case reports describing E. coli O157:H7 and its infection were selected. Data Extraction: The data were abstracted without judgments about study design. Data quality and validity were assessed by independent author reviews. Data Synthesis: Infection with E. coli O157:H7 presents with a wide spectrum of clinical manifestations, including asymptomatic carriage, nonbloody diarrhea, hemorrhagic colitis, the hemolytic-uremic syndrome, and thrombotic thrombocytopenic purpura. Not only is E. coli O157:H7 an important agent for hemorrhagic colitis, it is also one of the leading causes of bacterial diarrhea. Patients at extremes of age have an increased risk for infection and associated complications. Transmission of E. coli O157:H7 is primarily food-borne. Undercooked meat is the most common culprit, and secondary person-to-person spread is also important. The organism produces at least two Shiga-like toxins that differ antigenically, physicochemically, immunologically, and in their biological effects. These toxins are thought to have direct pathogenic significance in E. coli O157:H7 infection. This infection is usually diagnosed from a positive stool culture, from the presence of Shiga-like toxins, or both. Timely collection (within 7 days of illness onset) of a stool sample for culture is imperative for a high recovery rate. Treatment is primarily supportive and includes the management of complications as necessary. Antibiotic therapy has not been proved beneficial. Important public health measures include educating the public on the danger of eating undercooked meat, increasing physician awareness of E. coli O157:H7 infection, and mandating case reporting. Conclusions: Infection with E. coli O157:H7 presents with many clinical manifestations and should be included in the differential diagnosis for any patient with new-onset bloody diarrhea. Development of the hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura should raise strong suspicion of E. coli O157:H7 infection and should lead to prompt evaluation. If infection is confirmed, it should be reported to public health officials.	MONTEFIORE MED CTR, BRONX, NY 10467 USA; ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine								ACHESON DWK, 1990, J INFECT DIS, V161, P134, DOI 10.1093/infdis/161.1.134; AHMED R, 1987, J INFECT DIS, V155, P806, DOI 10.1093/infdis/155.4.806; ALBERT M J, 1989, Journal of Diarrhoeal Diseases Research, V7, P96; ASHKENAZI S, 1990, J MED MICROBIOL, V32, P255, DOI 10.1099/00222615-32-4-255; ASHKENAZI S, 1988, J PEDIATR-US, V113, P1008, DOI 10.1016/S0022-3476(88)80572-9; ASHKENAZI S, 1989, J CLIN MICROBIOL, V27, P1145, DOI 10.1128/JCM.27.6.1145-1150.1989; BALE JF, 1980, AM J DIS CHILD, V134, P869, DOI 10.1001/archpedi.1980.02130210053014; BARZIV J, 1974, PEDIATR RADIOL, V2, P203, DOI 10.1007/BF00972734; BEERY JT, 1984, CURR MICROBIOL, V11, P335, DOI 10.1007/BF01567702; BEERY JT, 1985, APPL ENVIRON MICROB, V49, P310, DOI 10.1128/AEM.49.2.310-315.1985; BELL BP, 1994, JAMA-J AM MED ASSOC, V272, P1349, DOI 10.1001/jama.272.17.1349; BELONGIA EA, 1991, J INFECT DIS, V164, P338, DOI 10.1093/infdis/164.2.338; BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BERMAN W, 1972, J PEDIATR-US, V81, P275, DOI 10.1016/S0022-3476(72)80295-6; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; BITZAN M, 1991, J PEDIATR-US, V119, P380, DOI 10.1016/S0022-3476(05)82049-9; BOHM H, 1992, J CLIN MICROBIOL, V30, P2169; BOYD B, 1989, NEPHRON, V51, P207, DOI 10.1159/000185286; BRANDT LJ, 1995, GASTROENTEROLOGY, V108, pA787; BRIAN MJ, 1992, J CLIN MICROBIOL, V30, P1801, DOI 10.1128/JCM.30.7.1801-1806.1992; BROWN JE, 1989, INFECT IMMUN, V57, P2811, DOI 10.1128/IAI.57.9.2811-2814.1989; BROWNING NG, 1990, S AFR J SURG, V28, P28; CAHOON FE, 1987, CAN J MICROBIOL, V33, P914, DOI 10.1139/m87-158; CALDERWOOD SB, 1987, P NATL ACAD SCI USA, V84, P4364, DOI 10.1073/pnas.84.13.4364; CAPRIOLI A, 1992, J INFECT DIS, V166, P154, DOI 10.1093/infdis/166.1.154; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; CHAPMAN PA, 1989, J CLIN PATHOL, V42, P1109, DOI 10.1136/jcp.42.10.1109; CHART H, 1991, LANCET, V337, P138, DOI 10.1016/0140-6736(91)90801-U; CHART H, 1989, J CLIN PATHOL, V42, P973, DOI 10.1136/jcp.42.9.973; CIMOLAI N, 1990, J PEDIATR-US, V117, P676, DOI 10.1016/S0022-3476(05)80721-8; CIMOLAI N, 1992, PEDIATRICS, V90, P616; CIMOLAI N, 1990, J PEDIATR-US, V116, P589, DOI 10.1016/S0022-3476(05)81609-9; COHEN A, 1987, J BIOL CHEM, V262, P17088; CORDOVEZ A, 1992, J CLIN MICROBIOL, V30, P2153; DALAL BI, 1987, CAN J SURG, V30, P207; DEV VJ, 1991, LANCET, V337, P1412, DOI 10.1016/0140-6736(91)93092-N; DOWNES FP, 1989, J CLIN MICROBIOL, V27, P1292, DOI 10.1128/JCM.27.6.1292-1297.1989; DOWNES FP, 1988, INFECT IMMUN, V56, P1926, DOI 10.1128/IAI.56.8.1926-1933.1988; DOYLE MP, 1984, APPL ENVIRON MICROB, V48, P855, DOI 10.1128/AEM.48.4.855-856.1984; DOYLE MP, 1987, APPL ENVIRON MICROB, V53, P2394, DOI 10.1128/AEM.53.10.2394-2396.1987; Duncan L., 1986, ONTARIO DIS SURVEILL, V7, P604; DYKSTRA SA, 1993, VET PATHOL, V30, P410, DOI 10.1177/030098589303000502; DYTOC M, 1993, INFECT IMMUN, V61, P3382, DOI 10.1128/IAI.61.8.3382-3391.1993; EDELMAN R, 1988, J INFECT DIS, V157, P1102, DOI 10.1093/infdis/157.5.1102; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; FARMER JJ, 1985, J CLIN MICROBIOL, V22, P620, DOI 10.1128/JCM.22.4.620-625.1985; FARMER JJ, 1983, LANCET, V1, P702; FITZPATRICK MM, 1991, POSTGRAD MED J, V67, P707, DOI 10.1136/pgmj.67.790.707; FONG JSC, 1982, PEDIATR CLIN N AM, V29, P835; FRANCIS DH, 1986, INFECT IMMUN, V51, P953, DOI 10.1128/IAI.51.3.953-956.1986; FURUTANI M, 1990, MICROBIOL IMMUNOL, V34, P387, DOI 10.1111/j.1348-0421.1990.tb01019.x; GARCH H, 1992, INFECT IMMUN, V60, P3464; GIANANTONIO CA, 1973, NEPHRON, V11, P174; GRANSDEN WR, 1986, J INFECT DIS, V154, P522, DOI 10.1093/infdis/154.3.522; GRIFFIN PM, 1990, GASTROENTEROLOGY, V99, P142, DOI 10.1016/0016-5085(90)91241-W; GRIFFIN PM, 1988, ANN INTERN MED, V109, P705, DOI 10.7326/0003-4819-109-9-705; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; GUNZER F, 1992, J CLIN MICROBIOL, V30, P1807, DOI 10.1128/JCM.30.7.1807-1810.1992; GYLES CL, 1992, CAN J MICROBIOL, V38, P734, DOI 10.1139/m92-120; HALDANE DJM, 1986, J CLIN MICROBIOL, V24, P652, DOI 10.1128/JCM.24.4.652-653.1986; HAMANO S, 1993, ACTA PAEDIATR, V82, P454, DOI 10.1111/j.1651-2227.1993.tb12721.x; HAVENS PL, 1992, MICROBIOL IMMUNOL, V36, P1077, DOI 10.1111/j.1348-0421.1992.tb02111.x; IGARASHI K, 1987, FEMS MICROBIOL LETT, V44, P91; ISHSHALOM N, 1986, PEDIATR RES, V20, pA228; ITO H, 1990, MICROB PATHOGENESIS, V8, P47, DOI 10.1016/0882-4010(90)90007-D; JACKSON MP, 1987, MICROB PATHOGENESIS, V2, P147, DOI 10.1016/0882-4010(87)90106-9; JACKSON MP, 1987, FEMS MICROBIOL LETT, V44, P109, DOI 10.1016/0378-1097(87)90210-2; JOHNSON WM, 1983, LANCET, V1, P76; KAPLAN BS, 1987, SEMIN HEMATOL, V24, P148; KARCH H, 1986, FEMS MICROBIOL LETT, V35, P141, DOI 10.1016/0378-1097(86)90080-7; KARCH H, 1989, J CLIN MICROBIOL, V27, P1180, DOI 10.1128/JCM.27.6.1180-1186.1989; KARCH H, 1987, INFECT IMMUN, V55, P455, DOI 10.1128/IAI.55.2.455-461.1987; KARCH H, 1989, J CLIN MICROBIOL, V27, P2751, DOI 10.1128/JCM.27.12.2751-2757.1989; KARCH H, 1988, MICROB PATHOGENESIS, V5, P215, DOI 10.1016/0882-4010(88)90024-1; KARMALI MA, 1983, LANCET, V2, P1299; KARMALI MA, 1988, LANCET, V1, P526; KARMALI MA, 1985, J CLIN MICROBIOL, V22, P614, DOI 10.1128/JCM.22.4.614-619.1985; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15, DOI 10.1128/CMR.2.1.15-38.1989; KARMALI MA, 1983, LANCET, V1, P619, DOI 10.1016/s0140-6736(83)91795-6; KEENAN KP, 1986, AM J PATHOL, V125, P69; KEENE WE, 1994, NEW ENGL J MED, V331, P579, DOI 10.1056/NEJM199409013310904; KELLY J, 1990, AM J SURG PATHOL, V14, P87, DOI 10.1097/00000478-199001000-00010; KHAKHRIA R, 1990, EPIDEMIOL INFECT, V105, P511, DOI 10.1017/S0950268800048135; KIM HH, 1994, J INFECT DIS, V170, P1606, DOI 10.1093/infdis/170.6.1606; KLEANTHOUS H, 1990, ARCH DIS CHILD, V65, P722, DOI 10.1136/adc.65.7.722; KONOWALCHUK J, 1977, INFECT IMMUN, V18, P775, DOI 10.1128/IAI.18.3.775-779.1977; KOVACS MJ, 1990, AM J MED, V88, P177, DOI 10.1016/0002-9343(90)90470-X; KRISHNAN C, 1987, J CLIN MICROBIOL, V25, P1043, DOI 10.1128/JCM.25.6.1043-1047.1987; KWAAN HC, 1987, SEMIN HEMATOL, V24, P71; Levin M, 1989, Adv Pediatr Infect Dis, V4, P51; LEVINE MM, 1987, J INFECT DIS, V155, P377, DOI 10.1093/infdis/155.3.377; LINE JE, 1991, J FOOD PROTECT, V54, P762, DOI 10.4315/0362-028X-54.10.762; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; LIOR H, 1988, CAN MED ASSOC J, V139, P1073; LOIRAT C, 1988, PEDIATR NEPHROL, V2, P279, DOI 10.1007/BF00858677; LOPEZ EL, 1989, J INFECT DIS, V160, P469, DOI 10.1093/infdis/160.3.469; LOUIE M, 1993, INFECT IMMUN, V61, P4085, DOI 10.1128/IAI.61.10.4085-4092.1993; MACDONALD KL, 1988, JAMA-J AM MED ASSOC, V259, P3567, DOI 10.1001/jama.259.24.3567; MACDONALD KL, 1993, JAMA-J AM MED ASSOC, V269, P2264, DOI 10.1001/jama.269.17.2264; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; MARCH SB, 1989, J CLIN MICROBIOL, V27, P1675, DOI 10.1128/JCM.27.7.1675-1677.1989; MARQUES LRM, 1986, J INFECT DIS, V154, P338, DOI 10.1093/infdis/154.2.338; MARTIN DL, 1990, NEW ENGL J MED, V323, P1161, DOI 10.1056/NEJM199010253231703; MARTIN ML, 1986, LANCET, V2, P1043; MILFORD DV, 1989, J PEDIATR-US, V115, P502, DOI 10.1016/S0022-3476(89)80872-8; MILFORD DV, 1990, ARCH DIS CHILD, V65, P716, DOI 10.1136/adc.65.7.716; MILLER WT, 1971, RADIOLOGY, V100, P71, DOI 10.1148/100.1.71; MORGAN GM, 1988, EPIDEMIOL INFECT, V101, P83, DOI 10.1017/S0950268800029241; MORRISON DM, 1986, AM J CLIN PATHOL, V86, P108, DOI 10.1093/ajcp/86.1.108; NEILL MA, 1987, GASTROENTEROLOGY, V92, P1551; NEILL MA, 1987, PEDIATRICS, V80, P37; NEILL MA, 1985, ARCH INTERN MED, V145, P2215, DOI 10.1001/archinte.145.12.2215; NEWLAND JW, 1988, J CLIN MICROBIOL, V26, P1292, DOI 10.1128/JCM.26.7.1292-1297.1988; NODA M, 1987, MICROB PATHOGENESIS, V2, P339, DOI 10.1016/0882-4010(87)90076-3; OBRIEN AD, 1984, SCIENCE, V226, P694, DOI 10.1126/science.6387911; OBRIEN AD, 1987, MICROBIOL REV, V51, P206, DOI 10.1128/MMBR.51.2.206-220.1987; OBRIEN AD, 1983, INFECT IMMUN, V40, P675, DOI 10.1128/IAI.40.2.675-683.1983; OBRIEN AD, 1982, J INFECT DIS, V146, P763, DOI 10.1093/infdis/146.6.763; OBRIEN AD, 1983, LANCET, V1, P702; OBRIEN AD, 1983, LANCET, V2, P573; OBRIG TG, 1987, LANCET, V2, P687; OGASAWARA T, 1988, MICROB PATHOGENESIS, V4, P127, DOI 10.1016/0882-4010(88)90054-X; OGBORN MR, 1990, CAN MED ASSOC J, V143, P1323; Ostroff S M, 1991, MMWR CDC Surveill Summ, V40, P1; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; OSTROFF SM, 1989, J INFECT DIS, V160, P994, DOI 10.1093/infdis/160.6.994; OSTROFF SM, 1989, JAMA-J AM MED ASSOC, V262, P355, DOI 10.1001/jama.262.3.355; PADHYE NV, 1991, J CLIN MICROBIOL, V29, P99, DOI 10.1128/JCM.29.1.99-103.1991; PADHYE VV, 1986, BIOCHEM BIOPH RES CO, V139, P424, DOI 10.1016/S0006-291X(86)80008-0; PADHYE VV, 1987, J INFECT DIS, V155, P1249, DOI 10.1093/infdis/155.6.1249; PAI CH, 1984, ANN INTERN MED, V101, P738, DOI 10.7326/0003-4819-101-6-738; PAI CH, 1986, INFECT IMMUN, V51, P16, DOI 10.1128/IAI.51.1.16-23.1986; PAI CH, 1988, J INFECT DIS, V157, P1054, DOI 10.1093/infdis/157.5.1054; PAROS M, 1993, J INFECT DIS, V168, P1300, DOI 10.1093/infdis/168.5.1300; PATON AW, 1993, J CLIN MICROBIOL, V31, P3063, DOI 10.1128/JCM.31.11.3063-3067.1993; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; PERERA LP, 1988, J CLIN MICROBIOL, V26, P2127, DOI 10.1128/JCM.26.10.2127-2131.1988; PETERSON RB, 1976, RADIOLOGY, V118, P667, DOI 10.1148/118.3.667; PICHLER HET, 1987, AM J MED, V82, P329; PICKERING LK, 1994, PEDIATR INFECT DIS J, V13, P459, DOI 10.1097/00006454-199406000-00001; POLLARD DR, 1990, J CLIN MICROBIOL, V28, P540, DOI 10.1128/JCM.28.3.540-545.1990; POTTER ME, 1985, J INFECT DIS, V152, P1341, DOI 10.1093/infdis/152.6.1341; PROULX F, 1992, J PEDIATR-US, V121, P299, DOI 10.1016/S0022-3476(05)81209-0; RATNAM S, 1986, CAN MED ASSOC J, V134, P43; RATNAM S, 1988, J CLIN MICROBIOL, V26, P2006, DOI 10.1128/JCM.26.10.2006-2012.1988; RATNAM S, 1986, NEW ENGL J MED, V315, P1612, DOI 10.1056/NEJM198612183152513; REMIS RS, 1984, ANN INTERN MED, V101, P624, DOI 10.7326/0003-4819-101-5-624; RICHARDSON SE, 1988, HUM PATHOL, V19, P1102, DOI 10.1016/S0046-8177(88)80093-5; RICHARDSON SE, 1992, INFECT IMMUN, V60, P4154, DOI 10.1128/IAI.60.10.4154-4167.1992; RIDOLFI RL, 1981, MEDICINE, V60, P413, DOI 10.1097/00005792-198111000-00003; RILEY LW, 1987, ANNU REV MICROBIOL, V41, P383, DOI 10.1146/annurev.micro.41.1.383; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; RIZZONI G, 1988, J PEDIATR-US, V112, P284, DOI 10.1016/S0022-3476(88)80071-4; ROBSON WLM, 1991, PEDIATR NEPHROL, V5, P289, DOI 10.1007/BF00867478; ROSE PE, 1985, J CLIN PATHOL, V38, P438, DOI 10.1136/jcp.38.4.438; ROWE PC, 1991, J PEDIATR-US, V119, P218, DOI 10.1016/S0022-3476(05)80730-9; ROWE PC, 1991, EPIDEMIOL INFECT, V106, P523, DOI 10.1017/S0950268800067583; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SAMADPOUR M, 1993, J CLIN MICROBIOL, V31, P3179, DOI 10.1128/JCM.31.12.3179-3183.1993; SANDVIG K, 1987, INFECT IMMUN, V55, P298, DOI 10.1128/IAI.55.2.298-303.1987; SAWAF H, 1978, PEDIATRICS, V61, P315; SCHLIEPER A, 1992, ARCH DIS CHILD, V67, P930, DOI 10.1136/adc.67.7.930; SCHMIDT H, 1993, INFECT IMMUN, V61, P4894, DOI 10.1128/IAI.61.11.4894-4898.1993; SCHWARTZ DL, 1978, PEDIATRICS, V62, P54; SCOTLAND SM, 1987, EPIDEMIOL INFECT, V99, P613, DOI 10.1017/S0950268800066462; SCOTLAND SM, 1983, LANCET, V2, P216; SCOTLAND SM, 1985, LANCET, V2, P885; SCOTLAND SM, 1988, J MED MICROBIOL, V25, P237, DOI 10.1099/00222615-25-4-237; SERIWATANA J, 1988, J CLIN MICROBIOL, V26, P1614, DOI 10.1128/JCM.26.8.1614-1615.1988; SHERMAN P, 1987, INFECT IMMUN, V55, P1824, DOI 10.1128/IAI.55.8.1824-1829.1987; SHERMAN P, 1991, INFECT IMMUN, V59, P890, DOI 10.1128/IAI.59.3.890-899.1991; SHERMAN PM, 1988, J MED MICROBIOL, V26, P11, DOI 10.1099/00222615-26-1-11; SIEGLER RL, 1988, J PEDIATR-US, V112, P1014, DOI 10.1016/S0022-3476(88)80239-7; SMITH HR, 1987, LANCET, V1, P1062; SMITH HR, 1984, LANCET, V1, P1242; SMITH HW, 1983, J GEN MICROBIOL, V129, P3121; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; SRAMKOVA L, 1990, INFECTION, V18, P204, DOI 10.1007/BF01643386; STOCKBINE NA, 1988, J BACTERIOL, V160, P1116; STROCKBINE NA, 1985, INFECT IMMUN, V50, P695, DOI 10.1128/IAI.50.3.695-700.1985; STROCKBINE NA, 1986, INFECT IMMUN, V53, P135, DOI 10.1128/IAI.53.1.135-140.1986; SWERDLOW DL, 1992, ANN INTERN MED, V117, P812, DOI 10.7326/0003-4819-117-10-812; TAKAO T, 1988, MICROB PATHOGENESIS, V5, P357, DOI 10.1016/0882-4010(88)90036-8; TARR PI, 1989, J INFECT DIS, V159, P344, DOI 10.1093/infdis/159.2.344; TARR PI, 1989, AM J EPIDEMIOL, V129, P582, DOI 10.1093/oxfordjournals.aje.a115170; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; TARR PI, 1988, NEW ENGL J MED, V318, P1697; THOMAS A, 1993, J CLIN MICROBIOL, V31, P1700, DOI 10.1128/JCM.31.7.1700-1703.1993; THOMPSON JS, 1990, J CLIN MICROBIOL, V28, P2165, DOI 10.1128/JCM.28.10.2165-2168.1990; TISON DL, 1990, J CLIN MICROBIOL, V28, P612, DOI 10.1128/JCM.28.3.612-613.1990; TOTH I, 1990, INFECT IMMUN, V58, P1223, DOI 10.1128/IAI.58.5.1223-1231.1990; TZIPORI S, 1987, INFECT IMMUN, V55, P3117, DOI 10.1128/IAI.55.12.3117-3125.1987; TZIPORI S, 1986, J INFECT DIS, V154, P712, DOI 10.1093/infdis/154.4.712; VOELKER R, 1994, JAMA-J AM MED ASSOC, V272, P503; VONWULFFEN H, 1989, LANCET, V1, P1449; WADDELL T, 1988, BIOCHEM BIOPH RES CO, V152, P674, DOI 10.1016/S0006-291X(88)80091-3; WADE WG, 1979, LANCET, V2, P1235; WALTERSPIEL JN, 1992, INFECTION, V20, P25, DOI 10.1007/BF01704889; WELLS JG, 1991, J CLIN MICROBIOL, V29, P985, DOI 10.1128/JCM.29.5.985-989.1991; WELLS JG, 1983, J CLIN MICROBIOL, V18, P512, DOI 10.1128/JCM.18.3.512-520.1983; WHITINGTON PF, 1979, GASTROENTEROLOGY, V76, P728; WHITTAM TS, 1988, J INFECT DIS, V157, P1124, DOI 10.1093/infdis/157.6.1124; WILLSHAW GA, 1987, J GEN MICROBIOL, V133, P1309; YAMADA S, 1993, MICROBIOL IMMUNOL, V37, P111, DOI 10.1111/j.1348-0421.1993.tb03187.x; YANNELLI B, 1990, AM J INFECT CONTROL, V18, P341, DOI 10.1016/0196-6553(90)90236-L; YU J, 1992, MOL MICROBIOL, V6, P411, DOI 10.1111/j.1365-2958.1992.tb01484.x; 1987, BRIT MED J, V295, P1545; 1988, WISCONSIN EPIDEMIOLO, V10, P1; 1991, MMWR-MORBID MORTAL W, V40, P265; 1983, CANADA DISEASES WEEK, V9, P29; 1989, CANADA DISEASES WEEK, V15, P9; 1987, CANADA DISEASES WEEK, V13, P5; 1993, JAMA-J AM MED ASSOC, V269, P2194; 1982, MMWR-MORBID MORTAL W, V31, P580; 1987, CANADA DISEASES WEEK, V13, P203; 1986, MMWR-MORBID MORTAL W, V35, P549	217	256	262	0	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					698	714		10.7326/0003-4819-123-9-199511010-00009	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00009			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574226				2022-12-28	WOS:A1995TA69600009
J	ALBERTI, W; ANDERSON, G; BARTOLUCCI, A; BELL, D; VILLALBA, JB; BRODIN, O; CARDIELLO, C; CARTEI, F; CARTEI, G; CELLERINO, R; CHASTANG, C; CORMIER, Y; COX, JD; CRINO, L; CROWLEY, J; DAUTZENBERG, B; DEPIERRE, A; DIETEMANN, A; DILLMAN, RO; DOI, O; FELD, R; FIGLIN, R; GANZ, PA; GREEN, MR; GREGOR, A; HELLE, PA; HERNDON, JE; HITOMI, S; HOST, H; IMAIZUMI, M; JETT, JR; JOHNSON, D; KAASA, S; KIMURA, H; KLASTERSKY, J; KONDO, H; KREISMAN, H; KRIS, MG; KUNISHIMA, K; KUWAHARA, O; LAD, TE; LAING, AH; MACBETH, F; MASAOKA, A; MATTSON, K; MINATEL, E; MIRA, JG; MORI, T; MOUNTAIN, CF; NIEDERLE, N; NIIRANEN, A; NOU, E; PAGE, W; PATER, J; PIANTADOSI, S; PISTERS, KMW; PYRHONEN, S; QUOIX, E; RAPP, E; ROWELL, NP; SAHMOUD, T; SAWAMURA, K; SCHALLIER, DCC; SCOTT, C; SIMPSON, J; STAGG, M; TERAMATSU, T; TROVO, MG; TSUCHIYA, R; TUMMARELLO, D; VANHOUTTE, P; VANZANDWIJK, N; VINCENT, RG; WADA, H; WHITE, JE; WILLIAMS, CJ; WOODS, RL; YAMAGUCHI, Y; ARRIAGADA, R; CARTMELLDAVIES, J; GIRLING, DJ; LECHEVALIER, T; MARSONI, S; PARMAR, MKB; PIGNON, JP; REKACEWICZ, C; SOUHAMI, RL; STEWART, LA; TARAYRE, M; TINAZZI, A; TONI, V				ALBERTI, W; ANDERSON, G; BARTOLUCCI, A; BELL, D; VILLALBA, JB; BRODIN, O; CARDIELLO, C; CARTEI, F; CARTEI, G; CELLERINO, R; CHASTANG, C; CORMIER, Y; COX, JD; CRINO, L; CROWLEY, J; DAUTZENBERG, B; DEPIERRE, A; DIETEMANN, A; DILLMAN, RO; DOI, O; FELD, R; FIGLIN, R; GANZ, PA; GREEN, MR; GREGOR, A; HELLE, PA; HERNDON, JE; HITOMI, S; HOST, H; IMAIZUMI, M; JETT, JR; JOHNSON, D; KAASA, S; KIMURA, H; KLASTERSKY, J; KONDO, H; KREISMAN, H; KRIS, MG; KUNISHIMA, K; KUWAHARA, O; LAD, TE; LAING, AH; MACBETH, F; MASAOKA, A; MATTSON, K; MINATEL, E; MIRA, JG; MORI, T; MOUNTAIN, CF; NIEDERLE, N; NIIRANEN, A; NOU, E; PAGE, W; PATER, J; PIANTADOSI, S; PISTERS, KMW; PYRHONEN, S; QUOIX, E; RAPP, E; ROWELL, NP; SAHMOUD, T; SAWAMURA, K; SCHALLIER, DCC; SCOTT, C; SIMPSON, J; STAGG, M; TERAMATSU, T; TROVO, MG; TSUCHIYA, R; TUMMARELLO, D; VANHOUTTE, P; VANZANDWIJK, N; VINCENT, RG; WADA, H; WHITE, JE; WILLIAMS, CJ; WOODS, RL; YAMAGUCHI, Y; ARRIAGADA, R; CARTMELLDAVIES, J; GIRLING, DJ; LECHEVALIER, T; MARSONI, S; PARMAR, MKB; PIGNON, JP; REKACEWICZ, C; SOUHAMI, RL; STEWART, LA; TARAYRE, M; TINAZZI, A; TONI, V			CHEMOTHERAPY IN NON-SMALL-CELL LUNG-CANCER - A METAANALYSIS USING UPDATED DATA ON INDIVIDUAL PATIENTS FROM 52 RANDOMIZED CLINICAL-TRIALS	BRITISH MEDICAL JOURNAL			English	Article							ADJUVANT CHEMOTHERAPY; SUPPORTIVE CARE; COMBINATION CHEMOTHERAPY; BRONCHOGENIC-CARCINOMA; PROLONG SURVIVAL; FINAL REPORT; RADIOTHERAPY; RADIATION; CYCLOPHOSPHAMIDE; CISPLATIN	Objective-To evaluate the effect of cytotoxic chemotherapy on survival in patients with non-small cell lung cancer. Design-Meta-analysis using updated data on individual patients from all available randomised trials, both published and unpublished. Subjects-9387 patients (7151 deaths) from 52 randomised clinical trials. Main outcome measure-Survival. Results-The results for modern regimens containing cisplatin favoured chemotherapy in all comparisons and reached conventional levels of significance when used with radical radiotherapy and with supportive care. Trials comparing surgery with surgery plus chemotherapy gave a hazard ratio of 0.87 (13% reduction in the risk of death, equivalent to an absolute benefit of 5% at five years). Trials comparing radical radiotherapy with radical radiotherapy plus chemotherapy gave a hazard ratio of 0.87 (13% reduction in the risk of death; absolute benefit of 4% at two years), and trials comparing supportive care with supportive care plus chemotherapy 0.73 (27% reduction in the risk of death; 10% improvement in survival at one year). The essential drugs needed to achieve these effects were not identified. No difference in the size of effect was seen in any subgroup of patients. In all but the radical radiotherapy setting, older trials using long term alkylating agents tended to show a detrimental effect of chemotherapy. This effect reached conventional significance in the adjuvant surgical comparison. Conclusion-At the outset of this meta-analysis there was considerable pessimism about the role of chemotherapy in non-small cell lung cancer. These results offer hope of progress and suggest that chemotherapy may have a role in treating this disease.	MRC,CANC TRIALS OFF,CAMBRIDGE CB2 2BW,ENGLAND				Rowell, Nick/AAA-3308-2020	Rowell, Nick/0000-0002-7836-9567; Stewart, Lesley/0000-0003-0287-4724; PIGNON, Jean-Pierre/0000-0003-2047-1582				ALBERTI W, 1990, Journal of Cancer Research and Clinical Oncology, V116, P503; ANDERSON G, 1985, SEMIN ONCOL, V12, P21; ANDERSON G, 1981, THORAX, V36, P190, DOI 10.1136/thx.36.3.190; ASOLA R, 1991, EUR J CANCER       S, V2, pA529; ASOLA R, 1991, EUR J CANCER       S, V2, pS91; BERGSAGEL DE, 1972, CANCER-AM CANCER SOC, V30, P621, DOI 10.1002/1097-0142(197209)30:3<621::AID-CNCR2820300305>3.0.CO;2-0; BRODEN O, 1991, LUNG CANCER S, V7, P165; BRUNNER KW, 1971, EUR J CANCER, V7, P285, DOI 10.1016/0014-2964(71)90071-5; CARDIELLO C, 1985, P AN M AM SOC CLIN, V4, pC692; CARTEI G, 1993, JNCI-J NATL CANCER I, V85, P794, DOI 10.1093/jnci/85.10.794; CELLERINO R, 1991, J CLIN ONCOL, V9, P1453, DOI 10.1200/JCO.1991.9.8.1453; CHASTANG CL, 1991, EUR J CANCER S2, V27, pA1017; CORMIER Y, 1982, CANCER, V50, P845, DOI 10.1002/1097-0142(19820901)50:5<845::AID-CNCR2820500507>3.0.CO;2-S; CRINO L, 1993, ANN ONCOL, V4, P847, DOI 10.1093/oxfordjournals.annonc.a058391; DERSIMONIAN R, 1980, CONTROL CLIN TRIALS, V7, P177; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; FELD R, 1993, JNCI-J NATL CANCER I, V85, P299, DOI 10.1093/jnci/85.4.299; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GANZ PA, 1989, CANCER, V63, P1271, DOI 10.1002/1097-0142(19890401)63:7<1271::AID-CNCR2820630707>3.0.CO;2-6; GIRLING DJ, 1985, BRIT J CANCER, V52, P867, DOI 10.1038/bjc.1985.271; GREGOR A, 1993, J NATL CANCER I, V85, P997, DOI 10.1093/jnci/85.12.997; Holmes EC, 1991, LUNG CANCER, V7, P11; HOST H, 1973, CANCER CHEMOTH REP 3, V4, P161; ISRAEL L, 1982, RECENT RES CANCER, V80, P214; ISRAEL L, 1979, LUNG CANC PROGR THER, P443; JOHNSON DH, 1990, ANN INTERN MED, V113, P33, DOI 10.7326/0003-4819-113-1-33; KAASA S, 1991, CANCER, V67, P2443, DOI 10.1002/1097-0142(19910515)67:10<2443::AID-CNCR2820671008>3.0.CO;2-K; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARRER K, 1978, CANCER CHEMOTH PHARM, V1, P145; KAUNG DT, 1974, CANCER CHEMOTH REP 1, V58, P359; KIMURA H, 1991, LUNG CANCER S, V7, pA498; LAD T, 1988, J CLIN ONCOL, V6, P9; LAING AH, 1975, LANCET, V1, P1161; LECHEVALIER T, 1991, JNCI-J NATL CANCER I, V83, P417, DOI 10.1093/jnci/83.6.417; MATTSON K, 1988, EUR J CANCER CLIN ON, V24, P477, DOI 10.1016/S0277-5379(98)90020-7; MINET P, 1987, RADIOTHER ONCOL, V8, P217, DOI 10.1016/S0167-8140(87)80245-1; MORTON RF, 1991, ANN INTERN MED, V115, P681, DOI 10.7326/0003-4819-115-9-681; MOUNTAIN CF, 1979, LUNG CANCER PROGR TH, P421; NIIRANEN A, 1992, J CLIN ONCOL, V10, P1927, DOI 10.1200/JCO.1992.10.12.1927; OHTA M, 1993, J THORAC CARDIOV SUR, V106, P703, DOI 10.1016/S0022-5223(19)33714-6; Parkin DM, 1993, LUNG CANCER, V9, P1; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PETROVICH Z, 1978, CANCER, V42, P1129, DOI 10.1002/1097-0142(197809)42:3<1129::AID-CNCR2820420315>3.0.CO;2-F; PISTERS KMW, 1994, J SURG ONCOL, V56, P236, DOI 10.1002/jso.2930560407; QUOIX E, 1991, B CANCER, V78, P341; Rankin EM, 1986, RANDOMISED TRIALS CA, P447; RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633; Rudd R, 1991, RESP DIS PRACTICE, V7, P12; Sawamura K, 1988, LUNG CANCER, V4, pA166; SCHALLIER DC, 1988, CLIN EXP METASTAS, V6, P39, DOI 10.1007/BF01580405; SHIELDS TW, 1982, CANCER, V50, P1713, DOI 10.1002/1097-0142(19821101)50:9<1713::AID-CNCR2820500910>3.0.CO;2-B; SHIELDS TW, 1972, CANCER, V40, P2057; SIDOROWITZ E, 1985, 4TH P WORLD C LUNG C, pA277; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SIMPSON JR, 1985, INT J RADIAT ONCOL, V11, P751, DOI 10.1016/0360-3016(85)90307-4; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; SQUIRES TS, 1993, CA CANC J CLIN, V43, P7; STEWART THM, 1992, CELLULAR IMMUNE MECHANISMS AND TUMOR DORMANCY, P213; STOTT H, 1977, BRIT MED J, V2, P1513, DOI 10.1136/bmj.2.6101.1513; TERAMATSU T, 1991, LUNG CANCER, V7, pA462; Till J E, 1992, Qual Life Res, V1, P31, DOI 10.1007/BF00435433; TROVO MG, 1990, CANCER, V65, P400, DOI 10.1002/1097-0142(19900201)65:3<400::AID-CNCR2820650304>3.0.CO;2-H; Van Houtte P, 1988, Antibiot Chemother (1971), V41, P131; WHITE JE, 1982, CANCER TREAT REP, V66, P1113; WOODS RL, 1990, BRIT J CANCER, V61, P608, DOI 10.1038/bjc.1990.135; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1992, HAI GAN, V32, P481	68	2843	2898	0	93	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					899	909						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580546				2022-12-28	WOS:A1995RZ23700017
J	VEEKEN, H				VEEKEN, H			LETTER FROM CUBA - CUBA - PLENTY OF CARE, FEW CONDOMS, NO CORRUPTION	BRITISH MEDICAL JOURNAL			English	Article								The health system in Cuba guarantees accessibility to the entire population, is free of charge, and covers the spectrum from vaccinations to sophisticated interventions. The results are impressive: Cuba's health figures are on a par with developed countries that have 20 times the budget. The country is experiencing a difficult period because of the collapse and loss of support from the Soviet Union; over 30 years' trade embargo by the United States; and the gradual change from a centrally planned economy towards more of a free market system. Shortages are experienced in every sector, and maintaining health care services at the current level is too expensive. Doctors and nurses continue to work towards the goal of health for all Cubans, even though their salaries are minimal. Signs of negligence or corruption, often seen in other socialist countries where incentives for output are lacking, are unknown. Topics such as family planning and AIDS deserve immediate attention.			VEEKEN, H (corresponding author), MED SANS FRONTIERES,POB 1001,1001 EA AMSTERDAM,NETHERLANDS.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X					0	12	12	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					935	937						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580557				2022-12-28	WOS:A1995RZ23700028
J	CHEN, CC; AKOPIAN, AN; SIVILOTTI, L; COLQUHOUN, D; BURNSTOCK, G; WOOD, JN				CHEN, CC; AKOPIAN, AN; SIVILOTTI, L; COLQUHOUN, D; BURNSTOCK, G; WOOD, JN			A P2X PURINOCEPTOR EXPRESSED BY A SUBSET OF SENSORY NEURONS	NATURE			English	Article							ATP-ACTIVATED CHANNELS; RAT; TRANSCRIPTION; RECEPTORS; INVITRO	ATP is known to depolarize sensory neurons, and may play a role in nociceptor activation when released from damaged tissue(1-10). Here we report the molecular cloning and characterization of a new member of the P2X receptor family(3,11,12), P2X(3), expressed by these cells, The channel transcript was present in a subset of rat dorsal-root-ganglion sensory neurons, some of which express nociceptor-associated markers; it was absent in other tissues that were tested, including sympathetic, enteric and central nervous system neurons. Moreover, when expressed in Xenopus oocytes, the channel showed an ATP-dependent cation flux, P2X(3) is the only ligand-gated channel known to be expressed exclusively by a subset of sensory neurons. The remarkable selectivity of expression of the channel coupled with its sensory neuron-like pharmacology suggests that this channel may transduce ATP-evoked nociceptor activation.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London	CHEN, CC (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Sivilotti, Lucia/D-8919-2011; Chen, Chih-Cheng/S-7015-2018; Colquhoun, David/C-1664-2008; Chen, Chih-Cheng/AAT-1062-2021	Sivilotti, Lucia/0000-0003-2510-8424; Chen, Chih-Cheng/0000-0003-4768-5660; Colquhoun, David/0000-0002-4263-017X; Chen, Chih-Cheng/0000-0003-4768-5660	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; AKOPIAN A, IN PRESS J BIOL CHEM; ANDREWS PW, 1984, LAB INVEST, V50, P147; BEAN BP, 1990, J NEUROSCI, V10, P11; BEAN BP, 1990, J NEUROSCI, V10, P1; BEAN BP, 1990, ION CHANNELS, V2, P163; BLEEHEN T, 1977, PAIN, V3, P367, DOI 10.1016/0304-3959(77)90066-5; BOUVIER MM, 1991, EUR J NEUROSCI, V3, P285, DOI 10.1111/j.1460-9568.1991.tb00090.x; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BURNSTOCK G, 1993, DRUG DEVELOP RES, V28, P195, DOI 10.1002/ddr.430280303; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; COLQUHOUN D, 1971, LECTURES BIOSTATISTI; ESCURAT M, 1990, J NEUROSCI, V10, P764; HO BT, 1992, ANTI-CANCER DRUG, V2, P91; HOONG K, 1994, NATURE, V367, P470; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; KHAKH BS, 1995, J PHYSIOL-LONDON, V484, P385, DOI 10.1113/jphysiol.1995.sp020672; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRISHTAL OA, 1988, BRIT J PHARMACOL, V95, P1057, DOI 10.1111/j.1476-5381.1988.tb11739.x; KRISHTAL OA, 1986, BIOMED RES-TOKYO, V7, P79; Lawson SN., 1992, SENSORY NEURONS DIVE, P27; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; ROBERTSON SJ, IN PRESS BR J PHARM; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WOOD JN, 1988, J NEUROSCI, V8, P3208; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084	29	883	947	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					428	431		10.1038/377428a0	http://dx.doi.org/10.1038/377428a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566119				2022-12-28	WOS:A1995RY19000049
J	DIEPPE, P				DIEPPE, P			FORTNIGHTLY REVIEW - MANAGEMENT OF HIP OSTEOARTHRITIS	BRITISH MEDICAL JOURNAL			English	Article							KNEE; JOINT; DRUGS				DIEPPE, P (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,RHEUMATOL UNIT,BRISTOL BS2 8HW,AVON,ENGLAND.							AMSTRUTZ HC, 1992, OSTEOARTHRITIS, P314; BATEMAN DN, 1995, BRIT MED J, V310, P817, DOI 10.1136/bmj.310.6983.817; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; CROFT P, 1990, AM J EPIDEMIOL, V132, P514, DOI 10.1093/oxfordjournals.aje.a115687; CROFT P, 1992, BRIT MED J, V304, P1269, DOI 10.1136/bmj.304.6837.1269; CURREY HLF, 1970, ANN RHEUM DIS, V29, P488, DOI 10.1136/ard.29.5.488; Dieppe P, 1993, Curr Opin Rheumatol, V5, P487; DIEPPE P, 1994, RHEUMATOLOGY, P781; DIEPPE PA, 1993, LANCET, V341, P353, DOI 10.1016/0140-6736(93)90147-9; FELSON DT, 1988, EPIDEMIOL REV, V10, P1; Jobanputra Paresh, 1994, Current Opinion in Rheumatology, V6, P433, DOI 10.1097/00002281-199407000-00014; JONES A, 1995, BRIT MED J, V310, P457, DOI 10.1136/bmj.310.6977.457; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; LEDINGHAM J, 1993, ANN RHEUM DIS, V52, P263, DOI 10.1136/ard.52.4.263; LIANG MH, 1991, NEW ENGL J MED, V325, P125, DOI 10.1056/NEJM199107113250210; MARCH L, 1994, BRIT MED J, V309, P1041, DOI 10.1136/bmj.309.6961.1041; NEWMAN NM, 1985, LANCET, V2, P11; RADIN EL, 1984, SEMIN ARTHRITIS RHEU, V13, P293, DOI 10.1016/0049-0172(84)90031-3; RASHAD S, 1989, LANCET, V2, P111; SCHAPIRA D, 1986, ARCH PHYS MED REHAB, V67, P815; SCOTT DL, 1993, J ROY COLL PHYS LOND, V27, P391; UETT DW, 1994, ANN INTERN MED, V121, P133; 1994, MANAGEMENT OSTEOARTH	23	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					853	857		10.1136/bmj.311.7009.853	http://dx.doi.org/10.1136/bmj.311.7009.853			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580495	Green Published			2022-12-28	WOS:A1995RY19100028
J	LAND, M; HORWOOD, J				LAND, M; HORWOOD, J			WHICH PARTS OF THE ROAD GUIDE STEERING	NATURE			English	Article								A DRIVER Steering a car on a twisting road has two distinct tasks: to match the road curvature, and to keep a proper distance from the lane edges. Both are achieved by turning the steering wheel, but it is not dear which part or parts of the road ahead supply the visual information needed, or how it is used. Current models of the behaviour of real drivers(1,2) or 'co-driver' simulators(3-5) vary greatly in their implementation of these tasks, but all agree that successful steering requires the driver to monitor the angular deviation of the road from the vehicle's present heading at some 'preview' distance ahead, typically about Is into the future. Eye movement recordings generally support this view(6-9). Here we have used a simple road simulator, in which only certain parts of the road are displayed, to show that at moderate to high speeds accurate driving requires that both a distant and a near region of the road are visible. The former is used to estimate road curvature and the latter to provide position-in-lane feedback. At lower speeds only the near region is necessary, These results support a two-stage model(1) of driver behaviour.			LAND, M (corresponding author), UNIV SUSSEX,SCH BIOL SCI,SUSSEX CTR NEUROSCI,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND.							DICKMANNS E, 1992, ACTIVE VISION, P303; DONGES E, 1978, HUM FACTORS, V29, P691; JURGENSOHN T, 1991, VISION VEHICLES, V3, P171; LAND MF, 1994, NATURE, V369, P742, DOI 10.1038/369742a0; LAND MF, 1993, P IEEE SYST MAN CYB, V3, P490; LEE DN, 1977, SCAND J PSYCHOL, V18, P224, DOI 10.1111/j.1467-9450.1977.tb00281.x; MACADAM CC, 1981, IEEE T SYST MAN CYBE, V11; OKUNO A, 1992, VISION BASED VEHICLE, P222; SERAFIN C, 1993, UMTRI9329, P1; SHINAR D, 1977, HUM FACTORS, V19, P63, DOI 10.1177/001872087701900107; WARREN WH, 1991, J EXP PSYCHOL HUMAN, V17, P28, DOI 10.1037/0096-1523.17.1.28; [No title captured]	12	262	271	0	47	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					339	340		10.1038/377339a0	http://dx.doi.org/10.1038/377339a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RX111	7566087				2022-12-28	WOS:A1995RX11100056
J	MOSS, SJ; GORRIE, GH; AMATO, A; SMART, TG				MOSS, SJ; GORRIE, GH; AMATO, A; SMART, TG			MODULATION OF GABA(A) RECEPTORS BY TYROSINE PHOSPHORYLATION	NATURE			English	Article							A RECEPTOR; MOLECULAR-BIOLOGY; TRANSFECTED CELLS; BETA-1-SUBUNIT; PHARMACOLOGY; POTENTIATION; SUBUNIT; KINASE	gamma-AMINOBUTYRIC acid type-A (GABA(A)) receptors are the major sites of fast synaptic inhibition in the brain, They are presumed to be pentameric heteroligomers assembled from four classes of subunits with multiple members: alpha (1-6), beta (1-3), gamma (1-3) and delta (1)(1-5). Here, GABA(A) receptors consisting of alpha 1, beta 1 and gamma 2L subunits, coexpressed in mammalian cells with the tyrosine kinase vSRC (the transforming gene product of the Rous sarcoma virus), were phosphorylated on tyrosine residues within the gamma 2L and beta 1 subunits. Tyrosine phosphorylation enhanced the whole-cell current induced by GABA. Site-specific mutagenesis of two tyrosine residues within the predicted intracellular domain of the gamma 2L subunit abolished tyrosine phosphorylation of this subunit and eliminated receptor modulation. A similar modulation of GABA(A) receptor function was observed in primary neuronal cultures. As GABA(A) receptors are critical in mediating fast synaptic inhibition, such a regulation by tyrosine kinases may therefore have profound effects on the control of neuronal excitation.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND; UNIV LONDON,SCH PHARM,DEPT PHARMACOL,LONDON WC1N 1AX,ENGLAND	University of London; University College London; University of London; University College London; University of London School of Pharmacy	MOSS, SJ (corresponding author), UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,GORDON ST,LONDON WC1E 6BT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; EVANS GI, 1985, MOL CELL BIOL, V353, P769; HERB A, 1992, P NATL ACAD SCI USA, V89, P1433, DOI 10.1073/pnas.89.4.1433; HERBST R, 1991, J BIOL CHEM, V266, P19908; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; MOSS SJ, 1993, NEUROCHEM RES, V18, P105, DOI 10.1007/BF00966929; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; MOSS SJ, 1991, NEUROSCI LETT, V123, P265, DOI 10.1016/0304-3940(91)90947-R; NAYEEM N, 1994, J NEUROCHEM, V62, P815; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SCHOFIELD PR, 1987, NATURE, V326, P221; SMART TG, 1992, J PHYSIOL-LONDON, V447, P587, DOI 10.1113/jphysiol.1992.sp019020; SONGYANG Z, 1994, NATURE, V373, P536; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U	23	203	212	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					344	348		10.1038/377344a0	http://dx.doi.org/10.1038/377344a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566089				2022-12-28	WOS:A1995RX11100058
J	CRAYFORD, T; SHANKS, J; BAJEKAL, M; LANGFORD, S				CRAYFORD, T; SHANKS, J; BAJEKAL, M; LANGFORD, S			ANALYSIS FROM INNER LONDON OF DEPRIVATION PAYMENTS BASED ON ENUMERATION DISTRICTS RATHER THAN WARDS	BRITISH MEDICAL JOURNAL			English	Article							UNDERPRIVILEGED AREAS	Objective-To estimate the effect of calculating the Jarman index using the smaller geographical unit of the census enumeration district on the changes in deprivation payments made to general practitioners. The Jarman index, or underprivileged area score, is used to calculate the allowance that general practices in the United Kingdom receive for each patient registered with them who lives in an area of relative social deprivation. Current values of the Jarman score are derived from the 1981 census and are based on electoral wards. The change in payments to some practices brought about by using data from the 1991 census may cause severe financial hardship. Design-Jarman indices for wards and enumeration districts from the 1981 and 1991 censuses were used to calculate the payments made to 169 practices in Lambeth, Southwark, and Lewisham; the changes in payments under ward and enumeration district based schemes were then compared. Main outcome measures-Standard deviations of the changes in payments to practices. Extreme values of changes in payments. Results-The standard deviation of the change in payment between the two censuses was pound 6365 with the enumeration district Jarman index, whereas it was pound 9452 under the ward based scheme. If the ward based scheme is used 10 practices would find their payments changed by over pound 20000, whereas only two practices would have changed by more than this amount under the scheme based on enumeration districts. Conclusion-The Jarman index could be more sensitively and appropriately applied to calculate the deprivation payments that practices receive using the census enumeration district as its unit for calculation. This would result in fewer precipitate changes in payments when census data change every 10 years.	ST MARYS HOSP,SCH MED,DEPT PRIMARY CARE & GEN PRACTICE,LONDON W2 1PG,ENGLAND; LAMBETH SOUTHWARK & LEWISHAM HLTH COMMISS,LONDON SE1 7NT,ENGLAND	Imperial College London	CRAYFORD, T (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT PUBL HLTH,LONDON SE5 9RS,ENGLAND.							BENSHLOMO Y, 1992, J EPIDEMIOL COMMUN H, V46, P532, DOI 10.1136/jech.46.5.532; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; LLOYD CEF, 1995, BRIT MED J, V310, P165; SMITH GD, 1991, BRIT MED J, V302, P359, DOI 10.1136/bmj.302.6773.359; TALBOT RJ, 1991, BRIT MED J, V302, P383, DOI 10.1136/bmj.302.6773.383; 1991, SASPAC 1991	7	19	19	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					787	788		10.1136/bmj.311.7008.787	http://dx.doi.org/10.1136/bmj.311.7008.787			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580442	Green Published			2022-12-28	WOS:A1995RX10700023
J	AVORN, J; GURWITZ, JH				AVORN, J; GURWITZ, JH			DRUG-USE IN THE NURSING-HOME	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; POSTMENOPAUSAL ESTROGEN THERAPY; HIP FRACTURE; H-2-RECEPTOR ANTAGONISTS; THIAZIDE DIURETICS; RANDOMIZED TRIAL; ELDERLY PATIENTS; CLINICAL-TRIAL; MEDICATION USE; HEART-FAILURE	Some of the most intensive pharmacotherapy today occurs in nursing homes in very complex and vulnerable patients. The nursing home provides an opportunity for highly effective drug use, but it also presents risks for polypharmacy and adverse events. Nursing homes are complex social institutions, in which physicians, nurses, consultant pharmacists, other health care professionals, aides, and administrators must interact to make decisions about drug use for patients who generally are frail and have numerous comorbid conditions. Federal regulations have recently been implemented to direct the ways in which specific drugs are to be used in this setting. The nursing home environment can present an ideal opportunity for comprehensive drug regimen review, an exercise too often neglected in the care of elderly patients in all clinical settings. Psychoactive medications, analgesics, and laxatives are examples of drugs that should receive such review. The possible underuse of drug therapies that may be beneficial to nursing home residents, including antidepressant, antihypertensive, and antithrombotic agents; calcium supplements; and vaccines, must be further quantified and must receive increased attention. Morbidity and functional incapacity can be substantially reduced by applying currently established principles of geriatric pharmacology in the nursing home setting, but enormous gaps still exist in the knowledge base necessary to guide this aspect of geriatric medical practice. Data on the efficacy, toxicity, and cost-effectiveness of pharmacotherapeutic choices in nursing home patients are in short supply; considerably more clinical and epidemiologic research is needed to define the relations between the benefits and risks of drugs for this unique population.	HARVARD UNIV, SCH MED, BOSTON, MA USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, BOSTON, MA USA	Harvard University; Harvard Medical School; Harvard University	AVORN, J (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV GERONTOL, PROGRAM ANAL CLIN STRATEGIES, 221 LONGWOOD AVE, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER; NIA NIH HHS [K08 AG00510] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1991, JAMA, V265, P3255; AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; AVORN J, 1990, JAMA-J AM MED ASSOC, V263, P1823, DOI 10.1001/jama.263.13.1823; AVORN J, 1994, ARCH INTERN MED, V154, P1113, DOI 10.1001/archinte.154.10.1113; AVORN J, 1995, IN PRESS AM J MED; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; BEERS MH, 1992, ANN INTERN MED, V117, P684, DOI 10.7326/0003-4819-117-8-684; BEERS MH, 1989, J AM GERIATR SOC, V37, P679, DOI 10.1111/j.1532-5415.1989.tb02227.x; BOLLINI P, 1992, ARCH INTERN MED, V152, P1289, DOI 10.1001/archinte.152.6.1289; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BRYMER C, 1992, J AM GERIATR SOC, V40, P902, DOI 10.1111/j.1532-5415.1992.tb01987.x; BUSTO U, 1986, NEW ENGL J MED, V315, P854, DOI 10.1056/NEJM198610023151403; CASTLE SC, 1991, GERIATRICS, V46, P84; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHRISCHILLES EA, 1992, J GERONTOL, V47, pM137, DOI 10.1093/geronj/47.5.M137; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; ELON R, 1992, J AM GERIATR SOC, V40, P958, DOI 10.1111/j.1532-5415.1992.tb01996.x; ETTINGER B, 1993, NEW ENGL J MED, V329, P1192, DOI 10.1056/NEJM199310143291610; EVERITT DE, 1991, J AM GERIATR SOC, V39, P792, DOI 10.1111/j.1532-5415.1991.tb02702.x; FELDMAN M, 1990, NEW ENGL J MED, V323, P1672; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; FORMAN DE, 1991, ARCH INTERN MED, V151, P2194, DOI 10.1001/archinte.151.11.2194; GARRARD J, 1991, JAMA-J AM MED ASSOC, V265, P463, DOI 10.1001/jama.265.4.463; GERSON SC, 1988, J CLIN PSYCHOPHARM, V8, P311; GLASSMAN AH, 1993, JAMA-J AM MED ASSOC, V269, P2673, DOI 10.1001/jama.269.20.2673; GREENBLATT DJ, 1991, J CLIN PSYCHIAT, V52, P4; GREENBLATT DJ, 1991, NEW ENGL J MED, V324, P1691, DOI 10.1056/NEJM199106133242403; GREENBLATT DJ, 1977, CLIN PHARMACOL THER, V21, P355; GREENBLATT DJ, 1987, NEW ENGL J MED, V317, P722, DOI 10.1056/NEJM198709173171202; GURWITZ JH, 1992, J AM GERIATR SOC, V40, P359, DOI 10.1111/j.1532-5415.1992.tb02135.x; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P781, DOI 10.1001/jama.272.10.781; GURWITZ JH, 1990, JAMA-J AM MED ASSOC, V264, P471, DOI 10.1001/jama.264.4.471; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P316, DOI 10.1001/jama.272.4.316; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; GURWITZ JH, 1990, J AM GERIATR SOC, V38, P542, DOI 10.1111/j.1532-5415.1990.tb02406.x; HARARI D, 1994, J AM GERIATR SOC, V42, P947, DOI 10.1111/j.1532-5415.1994.tb06585.x; HARARI D, 1993, J AM GERIATR SOC, V41, P1130, DOI 10.1111/j.1532-5415.1993.tb06463.x; HEANEY RP, 1993, NEW ENGL J MED, V328, P503, DOI 10.1056/NEJM199302183280710; HEIDRICH FE, 1991, ANN INTERN MED, V115, P1, DOI 10.7326/0003-4819-115-1-1; HESTON LL, 1992, J AM GERIATR SOC, V40, P1117, DOI 10.1111/j.1532-5415.1992.tb01800.x; Hing E, 1990, Vital Health Stat 13, P1; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; JACOBY R, 1993, BRIT J PSYCHIAT, V162, P175; KATZ J, 1992, J AM GERIATR SOC, V40, P425, DOI 10.1111/j.1532-5415.1992.tb02149.x; KOENIG HG, 1989, J GEN INTERN MED, V4, P498, DOI 10.1007/BF02599548; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LEDERLE FA, 1990, AM J MED, V89, P597, DOI 10.1016/0002-9343(90)90177-F; LOHR JB, 1992, CLIN GERIATRIC PSYCH, P79; MCBEAN AM, 1991, ARCH INTERN MED, V151, P2009, DOI 10.1001/archinte.151.10.2009; MONANE M, 1993, ARCH INTERN MED, V153, P633, DOI 10.1001/archinte.153.5.633; OSTROM JR, 1985, MED CARE, V23, P157, DOI 10.1097/00005650-198502000-00006; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PARMELEE PA, 1992, J GERONTOL, V47, pM189, DOI 10.1093/geronj/47.6.M189; PARMELEE PA, 1989, J GERONTOL, V44, pM22, DOI 10.1093/geronj/44.1.M22; POPE JE, 1993, ARCH INTERN MED, V153, P477, DOI 10.1001/archinte.153.4.477; PSATY BM, 1990, JAMA-J AM MED ASSOC, V263, P1653, DOI 10.1001/jama.263.12.1653; RAY WA, 1993, ARCH INTERN MED, V153, P713, DOI 10.1001/archinte.153.6.713; RAY WA, 1991, ANN INTERN MED, V115, P64, DOI 10.7326/0003-4819-115-1-64; RAY WA, 1989, LANCET, V1, P687; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; RICHTER JM, 1989, AM J MED, V87, P278; ROVNER BW, 1992, AM J PSYCHIAT, V149, P1390; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; SACKETT DL, 1979, COMPLIANCE HLTH CARE; SCHNEIDER LS, 1990, J AM GERIATR SOC, V38, P553, DOI 10.1111/j.1532-5415.1990.tb02407.x; SHERMAN DS, 1987, J AM GERIATR SOC, V35, P1023, DOI 10.1111/j.1532-5415.1987.tb04008.x; SHORR RI, 1994, JAMA-J AM MED ASSOC, V271, P358; SMITH B, 1968, GUT, V9, P139, DOI 10.1136/gut.9.2.139; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; STEAD WW, 1985, NEW ENGL J MED, V312, P1483, DOI 10.1056/NEJM198506063122304; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; STEAD WW, 1994, PRINCIPLES GERIATRIC, P575; SVARSTAD BL, 1991, J AM GERIATR SOC, V39, P869, DOI 10.1111/j.1532-5415.1991.tb04453.x; TALLIS R, 1993, LANCET, V341, P1444, DOI 10.1016/0140-6736(93)90887-M; WHITCOMB DC, 1994, JAMA-J AM MED ASSOC, V272, P1845, DOI 10.1001/jama.272.23.1845; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; WINOGRAD CH, 1991, J AM GERIATR SOC, V39, P724, DOI 10.1111/j.1532-5415.1991.tb03629.x; YUSUF S, 1992, AM J CARDIOL, V69, pG64, DOI 10.1016/0002-9149(92)91255-3; 1991, DHHS PHS9150212 US D; 1974, FED REGISTER, V39, P12; 1992, J AM GERIATR SOC, V40, P946	85	136	136	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					195	204		10.7326/0003-4819-123-3-199508010-00007	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RL104	7598302				2022-12-28	WOS:A1995RL10400007
J	NAURATH, HJ; JOOSTEN, E; RIEZLER, R; STABLER, SP; ALLEN, RH; LINDENBAUM, J				NAURATH, HJ; JOOSTEN, E; RIEZLER, R; STABLER, SP; ALLEN, RH; LINDENBAUM, J			EFFECTS OF VITAMIN-B12, FOLATE, AND VITAMIN-B6 SUPPLEMENTS IN ELDERLY PEOPLE WITH NORMAL SERUM VITAMIN CONCENTRATIONS	LANCET			English	Article							OCCLUSIVE ARTERIAL-DISEASE; COBALAMIN DEFICIENCY; METHYLMALONIC ACID; TOTAL HOMOCYSTEINE; PLASMA HOMOCYSTEINE; VASCULAR-DISEASE; RISK FACTOR; ELEVATION; HYPERHOMOCYSTEINEMIA; HETEROZYGOSITY	In a prospective, multicentre, double-blind controlled study, the effect of an intramuscular vitamin supplement containing 1 mg vitamin B12, 1.1 mg folate, and 5 mg vitamin B6 an serum concentrations of methylmalonic acid (MMA), homocysteine (HCYS), 2-methylcitric acid (2-MCA), and cystathionine (CYSTA) was compared with that of placebo in 175 elderly subjects living at home and 110 in hospital. Vitamin supplement and placebo were administered eight times over a 3-week period. Vitamin supplement but not placebo significantly reduced all four metabolite concentrations at the end of the study in both study groups. The maximum effects of treatment were usually seen within 5-12 days. Initially elevated metabolite concentrations returned to normal in a higher proportion of the vitamin than of the placebo group: 92% vs 20% for HYCS; 82% vs 20% for MMA; 62% vs 25% for 2-MCA; and 42% vs 25% for CYSTA. The response rate to vitamin supplements supports the notion that metabolic evidence of vitamin deficiency is common in the elderly, even in the presence of normal serum Vitamin levels. Metabolite assays permit identification of elderly subjects who may benefit from vitamin supplements.	KATHOLIEKE UNIV LEUVEN HOSP,DEPT INTERNAL MED,DIV GERIATR MED,B-3000 LOUVAIN,BELGIUM; UNIV WITTEN HERDECKE,DEPT GERIATR MED,VELBERT,GERMANY; SEVERI MED GMBH,MUNSTER,GERMANY; UNIV COLORADO,HLTH SCI CTR,DIV HEMATOL,DENVER,CO; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY	Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; Witten Herdecke University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Columbia University								ALLEN RH, 1993, METABOLISM, V42, P978, DOI 10.1016/0026-0495(93)90010-L; ALLEN RH, 1993, FASEB J, V7, P1344, DOI 10.1096/fasebj.7.14.7901104; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; JOOSTEN E, 1993, EUR J HAEMATOL, V51, P25; JOOSTEN E, 1993, AM J CLIN NUTR, V58, P468, DOI 10.1093/ajcn/58.4.468; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; LINDENBAUM J, 1994, AM J CLIN NUTR, V60, P2, DOI 10.1093/ajcn/60.1.2; LINDENBAUM J, 1990, AM J HEMATOL, V34, P99, DOI 10.1002/ajh.2830340205; MOELBY L, 1992, SCAND J CLIN LAB INV, V52, P351, DOI 10.3109/00365519209088369; MOELBY L, 1990, J INTERN MED, V228, P373, DOI 10.1111/j.1365-2796.1990.tb00248.x; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; PENNYPACKER LC, 1992, J AM GERIATR SOC, V40, P1197, DOI 10.1111/j.1532-5415.1992.tb03641.x; ROSENBERG LE, 1989, METABOLIC BASIS INHE, P821; SAVAGE DG, 1994, AM J MED, V96, P239, DOI 10.1016/0002-9343(94)90149-X; STABLER SP, 1988, J CLIN INVEST, V81, P466, DOI 10.1172/JCI113343; STABLER SP, 1993, BLOOD, V81, P3404; STABLER SP, 1994, BLOOD, V84, pA118; STABLER SP, 1986, J CLIN INVEST, V7, P1606; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; UELAND PM, 1989, J LAB CLIN MED, V114, P473; UELAND PM, 1993, CLIN CHEM, V39, P1764; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; 1989, RECOMMENDED DIETARY	28	243	254	1	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					85	89		10.1016/S0140-6736(95)92113-3	http://dx.doi.org/10.1016/S0140-6736(95)92113-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603218	hybrid			2022-12-28	WOS:A1995RH22000011
J	AITKEN, RJ				AITKEN, RJ			THE COMPLEXITIES OF CONCEPTION	SCIENCE			English	Editorial Material							RECEPTOR ACTIVITY; HUMAN SPERM; ZP3; BINDING; SURFACE				AITKEN, RJ (corresponding author), MRC,REPROD BIOL UNIT,37 CHALMERS ST,EDINBURGH EH3 9EW,MIDLOTHIAN,SCOTLAND.		Aitken, Robert John/AAY-8238-2020	Aitken, Robert John/0000-0002-9152-156X				AITKEN RJ, IN PRESS J CELL SCI; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BENOFF S, 1994, AM FERT SOC ANN M S, V1; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; BURKS DJ, 1995, SCIENCE, V269, P83, DOI 10.1126/science.7541556; CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; GONG X, UNPUB; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LUCONI M, 1995, MOL CELL ENDOCRINOL, V108, P35, DOI 10.1016/0303-7207(95)92576-A; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; MORI K, 1989, AM J OBSTET GYNECOL, V161, P207, DOI 10.1016/0002-9378(89)90267-6; RICHARDSON RT, 1994, DEV BIOL, V165, P688, DOI 10.1006/dbio.1994.1285; TESARIK J, 1993, ENDOCRINOLOGY, V133, P328, DOI 10.1210/en.133.1.328; TULSIANI DRP, 1990, BIOL REPROD, V42, P843, DOI 10.1095/biolreprod42.5.843	16	21	22	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					39	40		10.1126/science.7604276	http://dx.doi.org/10.1126/science.7604276			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604276				2022-12-28	WOS:A1995RG98000024
J	MOCROFT, AJ; JOHNSON, MA; SABIN, CA; LIPMAN, M; ELFORD, J; EMERY, V; MORCINEK, J; YOULE, M; JANOSSY, G; LEE, CA; PHILLIPS, AN				MOCROFT, AJ; JOHNSON, MA; SABIN, CA; LIPMAN, M; ELFORD, J; EMERY, V; MORCINEK, J; YOULE, M; JANOSSY, G; LEE, CA; PHILLIPS, AN			STAGING SYSTEM FOR CLINICAL AIDS PATIENTS	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NATURAL-HISTORY; SURVIVAL; LYMPHOCYTES; ZIDOVUDINE; DIAGNOSIS; MORTALITY; INFECTION; TRIALS; COHORT	Although there are wide differences in prognosis between patients with AIDS they are often thought of as a single homogeneous group. We think a simple staging system that accounts for important prognostic factors including type and number of AIDS diseases and the CD4 lymphocyte count is required. We followed 363 AIDS patients at the Royal Free Hospital and reported the occurrence of 680 AIDS-defining diseases (ADDs). We measured CD4 counts at approximately monthly intervals. Severity of AIDS diseases was defined a priori on the basis of survival in the AIDS in Europe study of 6578 AIDS patients: mild-oesophageal candidiasis, Kaposis sarcoma (cutaneous), Pneumocystis carinii pneumonia, extrapulmonary tuberculosis; severe-all other ADDs except lymphoma; very severe-lymphoma, The risk of death increased by 15% (p=0.08) for each mild condition experienced, by 89% (p<0.001) for each new severe condition and by 535% (p<0.0001) when a lymphoma developed. Estimates from the Cox model were used to derive a score reflecting the risk of death. Patient experience was divided into three categories. Patients in AIDS Grade I had an average death rate of one per 10.1 years, compared with one per 2.8 years in AIDS Grade II and one per 1.1 years in AIDS Grade III. Similar rates were seen in an independent validation study on 1230 AIDS patients at different hospital. Our grading system should be useful for patient management, clinical trial design, surveillance, and resource management.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT THORAC MED,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT VIROL,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,CTR HAEMOPHILIA,DEPT HAEMATOL & IMMUNOL,LONDON,ENGLAND; CHELSEA & WESTMINSTER HEALTHCARE NHS TRUST,ST STEPHENS CLIN,HIV GUM RES UNIT,LONDON,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Mocroft, Amanda/G-8748-2011; Sabin, Caroline/C-2464-2008; Phillips, Andrew N/B-4427-2008; Mocroft, Amanda/C-1527-2008; Emery, Vincent/G-8928-2013	Mocroft, Amanda/0000-0001-8316-1122; Sabin, Caroline/0000-0001-5173-2760; Phillips, Andrew N/0000-0003-2384-4807; Emery, Vincent/0000-0001-5893-9756; Lipman, Marc/0000-0001-7501-4448				BACHETTI P, 1988, J INFECT DIS, V157, P1044; BLUM S, 1994, AM J EPIDEMIOL, V139, P351, DOI 10.1093/oxfordjournals.aje.a117007; BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; CHANG HGH, 1993, AM J EPIDEMIOL, V138, P341, DOI 10.1093/oxfordjournals.aje.a116864; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; COLFORD JM, 1994, AM J EPIDEMIOL, V139, P206, DOI 10.1093/oxfordjournals.aje.a116982; Darbyshire J, 1991, AIDS, V5 Suppl 2, pS167, DOI 10.1097/00002030-199101001-00024; ELLENBERG SS, 1992, J AM STAT ASSOC, V87, P562, DOI 10.2307/2290291; GONELLA JD, 1994, JAMA-J AM MED ASSOC, V251, P637; HANSON DL, 1993, J ACQ IMMUN DEF SYND, V6, P624; HUGHES MD, 1994, J INFECT DIS, V169, P28, DOI 10.1093/infdis/169.1.28; JUSTICE AC, 1989, NEW ENGL J MED, V320, P1388, DOI 10.1056/NEJM198905253202106; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LIN DY, 1993, STAT MED, V12, P835, DOI 10.1002/sim.4780120904; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; MARASCA G, 1986, BRIT MED J, V292, P1727, DOI 10.1136/bmj.292.6537.1727; MILLS GD, 1993, AIDS, V7, P1383, DOI 10.1097/00002030-199310000-00013; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; NEATON J, 1993, 9 INT C AIDS BERL; RABENECK L, 1993, ARCH INTERN MED, V153, P2749, DOI 10.1001/archinte.153.24.2749; TURNER BJ, 1991, J ACQ IMMUN DEF SYND, V4, P1059; 1990, SAS USERS GUIDE STAT; 1994, LANCET, V343, P871; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1992, MMWR-MORBID MORTAL W, V41, P1	26	50	51	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					12	17		10.1016/S0140-6736(95)92649-6	http://dx.doi.org/10.1016/S0140-6736(95)92649-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603137				2022-12-28	WOS:A1995RF98500007
J	ALPERT, EJ				ALPERT, EJ			VIOLENCE IN INTIMATE-RELATIONSHIPS AND THE PRACTICING INTERNIST - NEW DISEASE OR NEW AGENDA	ANNALS OF INTERNAL MEDICINE			English	Article							DOMESTIC VIOLENCE; BATTERED WOMEN; ABUSE; PREGNANCY; EMERGENCY; VICTIMS; CARE	Domestic Violence is endemic in U.S. society and is seen in nearly every venue of medical care. A history of abuse should be considered and routinely queried in all women who present for emergency care, should be suspected in any woman who presents with an injury, and should be routinely screened for in primary care settings. Clinical manifestations, suggested diagnostic strategies, obstacles to leaving the abusive relationship, and the barriers that patients face in obtaining and that physicians face in providing optimal care in situations of domestic violence are discussed. Physicians can play a pivotal role in primary prevention, early intervention, and follow-up care during and after an episode of intimate partner violence. Clinical competence in the treatment and prevention of family violence is an important component of the new agenda for hearth care, particularly in generalist fields such as general internal medicine.			ALPERT, EJ (corresponding author), BOSTON UNIV, SCH MED, 80 E CONCORD ST, BOSTON, MA 02118 USA.							ABBOTT J, 1995, JAMA-J AM MED ASSOC, V273, P1763, DOI 10.1001/jama.273.22.1763; ALPERT EJ, 1992, PARTNER VIOLENCE HOW; ALPERT EJ, 1995, REPORT COMMITTEE VIO; AMARO H, 1990, AM J PUBLIC HEALTH, V80, P575, DOI 10.2105/AJPH.80.5.575; BACHMAN R, 1994, VIOLENCE WOMEN NATIO; BOGRAD M, 1984, AM J ORTHOPSYCHIAT, V54, P558, DOI 10.1111/j.1939-0025.1984.tb01526.x; CALIFIA P, 1986, ADVOCATE         MAR, P42; DOMINO JV, 1987, HEADACHE, V27, P310, DOI 10.1111/j.1526-4610.1987.hed2706310.x; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; Flitcraft A.H., 1992, DIAGNOSTIC TREATMENT; Geffner R., 1995, INTEGRATING FAMILY T, P501; GOLDBERG WG, 1984, JAMA-J AM MED ASSOC, V251, P3259, DOI 10.1001/jama.251.24.3259; GROVES BM, 1993, JAMA-J AM MED ASSOC, V269, P262, DOI 10.1001/jama.269.2.262; HABER JD, 1985, WESTERN J NURS RES, V7, P1; HARROPGRIFFITHS J, 1988, OBSTET GYNECOL, V71, P589; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; Hendricks-Matthews M K, 1991, Fam Med, V23, P194; Herman Judith, 2001, TRAUMA RECOVERY; King M C, 1989, Nurse Pract, V14, P47; LOBEL K, 1986, NAMING VIOLENCE; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; MCLEER SV, 1989, AM J PUBLIC HEALTH, V79, P65, DOI 10.2105/AJPH.79.1.65; MCLEER SV, 1989, ANN EMERG MED, V18, P651, DOI 10.1016/S0196-0644(89)80521-9; PARKER B, 1993, NURS RES, V42, P173; Rath G D, 1990, S D J Med, V43, P19; REITER RC, 1990, OBSTET GYNECOL, V75, P428; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P3157, DOI 10.1001/jama.267.23.3157; Walker L., 1984, BATTERED WOMAN SYNDR; 1994, WHAT SOULD KNOW DOME; 1989, CURRENT OPINIONS COU; 1989, MMWR-MORBID MORTAL W, V38, P17; 1992, JAMA-J AM MED ASSOC, V267, P3190	33	73	73	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1995	123	10					774	781		10.7326/0003-4819-123-10-199511150-00006	http://dx.doi.org/10.7326/0003-4819-123-10-199511150-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TE172	7574196				2022-12-28	WOS:A1995TE17200006
J	ARIGONI, F; POGLIANO, K; WEBB, CD; STRAGIER, P; LOSICK, R				ARIGONI, F; POGLIANO, K; WEBB, CD; STRAGIER, P; LOSICK, R			LOCALIZATION OF PROTEIN IMPLICATED IN ESTABLISHMENT OF CELL-TYPE TO SITES OF ASYMMETRIC DIVISION	SCIENCE			English	Article							ANTI-SIGMA FACTOR; BACILLUS-SUBTILIS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; SPORULATION; MORPHOGENESIS	Asymmetric division in Bacillus subtilis generates progeny cells with dissimilar fates. SpoIIE, a membrane protein required for the establishment of cell type, was shown to localize near sites of potential polar division. SpoIIE initially localizes in a bipolar pattern, coalescing at marks in the cell envelope at which asymmetric division can take place. Then, during division, SpoIIE becomes restricted to the polar septum and is lost from the distal pole. Thus, when division is complete, SpoIIE sits at the boundary between the progeny from which it dictates cell fate by the activation of a cell-specific transcription factor.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,BIOL LABS,CAMBRIDGE,MA 02138; INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE	Harvard University				Pogliano, Kit/0000-0002-7868-3345; STRAGIER, Patrick/0000-0003-0849-3025	NIGMS NIH HHS [GM18568] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018568, R37GM018568] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; ARIGONI F, UNPUB; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; DNCAN L, 1995, SCIENCE, V270, P641; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; GUZMAN P, 1988, J BACTERIOL, V170, P1598, DOI 10.1128/jb.170.4.1598-1609.1988; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; ILLING N, 1991, J BACTERIOL, V173, P3159, DOI 10.1128/JB.173.10.3159-3169.1991; LEWIS PJ, 1994, P NATL ACAD SCI USA, V91, P3849, DOI 10.1073/pnas.91.9.3849; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; Ogasawara N, 1994, DNA Res, V1, P1, DOI 10.1093/dnares/1.1.1; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; POGLIANO K, IN PRESS MOL MICROBI; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SALAMITOU S, 1994, J BACTERIOL, V176, P2828, DOI 10.1128/JB.176.10.2828-2834.1994; SETLOW B, 1991, J BACTERIOL, V173, P6270, DOI 10.1128/jb.173.19.6270-6278.1991; SPRINGER M, 1986, P NATL ACAD SCI USA, V83, P4384, DOI 10.1073/pnas.83.12.4384; STERLINI JM, 1969, BIOCHEM J, V113, P29, DOI 10.1042/bj1130029; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STUDIER FW, 1986, J MOL BIOL, V189, P116; SUN DX, 1991, J BACTERIOL, V173, P7867, DOI 10.1128/jb.173.24.7867-7874.1991; WEBB CD, IN PRESS J BACTERIOL; WU LJ, 1995, GENE DEV, V9, P1316, DOI 10.1101/gad.9.11.1316; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014	29	153	153	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					637	640		10.1126/science.270.5236.637	http://dx.doi.org/10.1126/science.270.5236.637			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570022				2022-12-28	WOS:A1995TB55700041
J	DUNCAN, L; ALPER, S; ARIGONI, F; LOSICK, R; STRAGIER, P				DUNCAN, L; ALPER, S; ARIGONI, F; LOSICK, R; STRAGIER, P			ACTIVATION OF CELL-SPECIFIC TRANSCRIPTION BY A SERINE PHOSPHATASE AT THE SITE OF ASYMMETRIC DIVISION	SCIENCE			English	Article							ANTI-SIGMA FACTOR; BACILLUS-SUBTILIS; EXPRESSION; SPOIIAB	Cell fate is determined by cell-specific activation of transcription factor sigma(F) after asym metric division during sporulation by Bacillus subtilis. The activity of sigma(F) is governed by SpoIIAA, SpoIIAB, and SpoIIE, a membrane protein localized at the polar septum. SpoIIAB binds to and inhibits of, and SpoIIAA inhibits SpoIIAB, which prevents SpoIIAB from binding to sigma(F). SpoIIAB is also a serine kinase that inactivates SpoIIAA. Here, it is demonstrated that SpoIIE dephosphorylates SpoIIAA-P and overcomes SpoIIAB-mediated inhibition of sigma(F). The finding that SpoIIE is a serine phosphatase links asymmetric division to the pathway governing cell-specific gene transcription.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,BIOL LABS,CAMBRIDGE,MA 02138; INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE	Harvard University				STRAGIER, Patrick/0000-0003-0849-3025	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018568, R01GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; ARIGONI F, UNPUB; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BENSON AK, 1993, P NATL ACAD SCI USA, V90, P2330, DOI 10.1073/pnas.90.6.2330; BENSON AK, 1992, J BACTERIOL, V174, P749, DOI 10.1128/jb.174.3.749-757.1992; BOYLAN SA, 1992, J BACTERIOL, V174, P3695, DOI 10.1128/JB.174.11.3695-3706.1992; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; DUFOUR A, 1994, J BACTERIOL, V176, P1813, DOI 10.1128/jb.176.7.1813-1820.1994; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; DUNCAN LL, UNPUB; ERINGTON J, 1993, MICROBIOL REV, V57, P1; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; KAIMAN S, 1990, J BACTERIOL, V172, P5575; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; NAJAFI SMA, 1995, J BACTERIOL, V177, P2912, DOI 10.1128/jb.177.10.2912-2913.1995; Ogasawara N, 1994, DNA Res, V1, P1, DOI 10.1093/dnares/1.1.1; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SUN DX, 1991, J BACTERIOL, V173, P7867, DOI 10.1128/jb.173.24.7867-7874.1991; VOELKER U, 1995, J BACTERIOL, V177, P114, DOI 10.1128/jb.177.1.114-122.1995; WISE AA, 1995, J BACTERIOL, V177, P123, DOI 10.1128/jb.177.1.123-133.1995	24	204	209	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					641	644		10.1126/science.270.5236.641	http://dx.doi.org/10.1126/science.270.5236.641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570023				2022-12-28	WOS:A1995TB55700042
J	MATHER, HM; ELKELES, RS				MATHER, HM; ELKELES, RS			ATTITUDES OF CONSULTANT PHYSICIANS TO THE CALMAN PROPOSALS - A QUESTIONNAIRE SURVEY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the views of a large and representative group of consultant physicians on the Calman proposals, in which acute general medical services will change from being primarily consultant led to consultant provided. Design-Postal questionnaires. Subjects-All 236 consultant physicians in acute hospitals in North West and South West Thames regions. Results-Replies were received from 179 (76%). One hundred and thirty seven (77%) indicated that they would not resume emergency residential duties, and 126 (71%) indicated that they would probably withdraw from general medical duties under these circumstances. One hundred and twenty six (70%) and 137 (77%) had not inserted a central venous line or temporary pacemaker, respectively, within the previous five years. Of 157 answering a question on the impact of the Calman proposals on the quality of patient services, 125 considered that it would be detrimental, and only 18 (11%) thought that it would be beneficial. Conclusion-Most consultant physicians are not prepared to resume emergency duties and could not do so without retraining in practical procedures. There is widespread antagonism to the Calman proposals, and most physicians consider that their impact on the quality of patient services will be detrimental.	ST MARYS HOSP,LONDON W2 1NY,ENGLAND	Imperial College London	MATHER, HM (corresponding author), EALING GEN HOSP,SOUTHALL UB1 3HW,MIDDX,ENGLAND.							CALMAN K, 1993, HOSPITAL DOCTORS TRA; CALMAN K, 1994, HOSPITAL DOCTORS TRA; CHARLTON BG, 1993, BRIT MED J, V307, P339; 1995, SHO TRAINING TACKLIN	4	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1060	1062		10.1136/bmj.311.7012.1060	http://dx.doi.org/10.1136/bmj.311.7012.1060			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580662	Green Published			2022-12-28	WOS:A1995TB35400021
J	MCDONALD, CC; ALEXANDER, FE; WHYTE, BW; FORREST, AP; STEWART, HJ				MCDONALD, CC; ALEXANDER, FE; WHYTE, BW; FORREST, AP; STEWART, HJ			CARDIAC AND VASCULAR MORBIDITY IN WOMEN RECEIVING ADJUVANT TAMOXIFEN FOR BREAST-CANCER IN A RANDOMIZED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							THERAPY	Objective-To determine any cardiac or vascular morbidity associated with long term treatment with tamoxifen given after mastectomy for primary breast cancer. Design-Cohort study using linkage between database of a randomised trial and statistics of Scottish hospital inpatients to identify episodes of cardiac and vascular morbidity. Setting-NHS hospitals in Scotland. Subjects-1312 women who had undergone mastectomy for breast cancer and who were randomised either to a treatment group to receive adjuvant tamoxifen or to a control group to be given tamoxifen only on first relapse of disease. Maximum duration of tamoxifen treatment was 14 years. Total woman years of follow up were 9943. Main outcome measures-Randomised and observational comparisons of risk (expressed as hazard ratios) of myocardial infarction, other cardiac event, cerebrovascular disease, or thromboembolic event according to treatment allocated and between nonusers, former users, and current users of tamoxifen. Results-Use of tamoxifen was associated with lower rates of myocardial infarction. Hazard ratio for women in control group was 1.92 (95% confidence interval 0.99 to 3.73) compared with women allocated to adjuvant treatment. The association was stronger for current use: hazard ratio for nonusers was 3.49 (1.52 to 8.03) compared with current users. Current users of tamoxifen, however, had higher rates of thromboembolic events: hazard ratio for non-users was 0.40 (0.18 to 0.90) compared with current users. Conclusions-Our results provide further evidence that tamoxifen reduces the risk of myocardial infarction. Thromboembolic events should be carefully monitored in trials of tamoxifen, particularly those of prophylactic treatment, in which tamoxifen is given to healthy women.	UNIV EDINBURGH,DEPT PUBL HLTH SCI,EDINBURGH,MIDLOTHIAN,SCOTLAND; ARGYLL & CLYDE HLTH BOARD,PAISLEY,RENFREW,SCOTLAND; INT MED COLL,KUALA LUMPUR,MALAYSIA	University of Edinburgh; International Medical University Malaysia	MCDONALD, CC (corresponding author), UNIV EDINBURGH,SCH MED,SCOTTISH CANC TRIALS OFF,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							ALTMAN DG, 1994, STAT MED, V13, P301, DOI 10.1002/sim.4780130402; [Anonymous], 1978, INT CLASSIFICATION D; BRUNING PF, 1988, BRIT J CANCER, V58, P497, DOI 10.1038/bjc.1988.248; CUZICK J, 1993, EUR J CANCER, V29A, P15, DOI 10.1016/0959-8049(93)90568-Z; DEWAR JA, 1992, BRIT MED J, V305, P225, DOI 10.1136/bmj.305.6847.225; JORDAN VC, 1987, CANCER RES, V47, P4517; LOVE RR, 1990, J NATL CANCER I, V16, P1327; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; RUTQVIST LE, 1993, J NATL CANCER I, V85, P1398, DOI 10.1093/jnci/85.17.1398; SAPHNER T, 1991, J CLIN ONCOL, V9, P286, DOI 10.1200/JCO.1991.9.2.286; 1987, LANCET, V2, P171; 1988, ARCH INTERN MED, V148, P36	12	228	232	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					977	980						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580638				2022-12-28	WOS:A1995TA07900020
J	MELE, A; STROFFOLINI, T; CATAPANO, R; PALUMBO, F; MOIRAGHI, A; NOVACO, F				MELE, A; STROFFOLINI, T; CATAPANO, R; PALUMBO, F; MOIRAGHI, A; NOVACO, F			INCIDENCE OF TRANSFUSION-ASSOCIATED BHEPATITIS AND NON-AHEPATITIS, NON-B-HEPATITIS IN ITALY	BRITISH MEDICAL JOURNAL			English	Article									IST SUPER SANITA,EPIDEMIOL & BIOSTAT LAB,I-00161 ROME,ITALY; UNIV ROMA TOR VERGATA,DIPARTIMENTO SANITA PUBBL,ROME,ITALY; ASSESSORATO SANITA REG CAMPANIA,NAPLES,ITALY; UNIV TURIN,DIPARTIMENTO SANITA PUBBL,TURIN,ITALY; REG EMILIA ROMAGNA,ASSESSORATO SANITA,BOLOGNA,ITALY	Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; University of Turin								CAMPS J, 1994, HEPATOLOGY, V20, pA200; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; MELE A, 1986, European Journal of Epidemiology, V2, P300, DOI 10.1007/BF00419494; THIERS V, 1988, LANCET, V2, P1273; 1991, LANCET, V338, P1040	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					846	847		10.1136/bmj.311.7009.846	http://dx.doi.org/10.1136/bmj.311.7009.846			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580492	Green Published			2022-12-28	WOS:A1995RY19100023
J	WOLPERT, DM; GHAHRAMANI, Z; JORDAN, MI				WOLPERT, DM; GHAHRAMANI, Z; JORDAN, MI			AN INTERNAL MODEL FOR SENSORIMOTOR INTEGRATION	SCIENCE			English	Article								On the basis of computational studies it has been proposed that the central nervous system internally simulates the dynamic behavior of the motor system in planning, control, acid learning; the existence and use of such an internal model is still under debate. A sensorimotor integration task was investigated in which participants estimated the location of one of their hands at the end of movements made in the dark and under externally imposed forces. The temporal propagation of errors in this task was analyzed within the theoretical framework of optimal state estimation. These results provide direct support for the existence of an internal model.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Jordan, Michael I/C-5253-2013	Wolpert, Daniel/0000-0003-2011-2790				Craig J. J, 1986, INTRO ROBOTICS; GALLISTEL C, 1990, ORG LEARNING, pCH4; Gallistel C.R., 1980, ORG ACTION; Goodwin G, 1984, ADAPTIVE FILTERING P; Hastie T.J., 1990, GEN ADDITIVE MODELS; Ito M, 1984, CEREBELLUM NEURAL CO; JORDAN MI, 1992, COGNITIVE SCI, V16, P307, DOI 10.1207/s15516709cog1603_1; JORDAN MI, 1995, HDB PERCEPTION ACTIO; Kalman R. E., 1961, J BASIC ENG-T ASME, V83, P95, DOI [10.1115/1.3658902, DOI 10.1115/1.3658902]; Kawato M., 1987, BIOL CYBERN, V56, P1; MIALL RC, 1993, J MOTOR BEHAV, V25, P203, DOI 10.1080/00222895.1993.9942050; ROBINSON DA, 1986, BIOL CYBERN, V55, P43, DOI 10.1007/BF00363977; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P582, DOI 10.1152/jn.1989.62.2.582; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; WOLPERT DM, 1995, EXP BRAIN RES, V103, P460	15	2154	2164	7	155	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1880	1882		10.1126/science.7569931	http://dx.doi.org/10.1126/science.7569931			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RX194	7569931				2022-12-28	WOS:A1995RX19400041
J	VAUGHAN, PS; AZIZ, F; VANWIJNEN, AJ; WU, SJ; HARADA, H; TANIGUCHI, T; SOPRANO, KJ; STEIN, JL; STEIN, GS				VAUGHAN, PS; AZIZ, F; VANWIJNEN, AJ; WU, SJ; HARADA, H; TANIGUCHI, T; SOPRANO, KJ; STEIN, JL; STEIN, GS			ACTIVATION OF A CELL-CYCLE-REGULATED HISTONE GENE BY THE ONCOGENIC TRANSCRIPTION FACTOR IRF-2	NATURE			English	Article							PROTEIN-DNA INTERACTIONS; FACTOR-I; MESSENGER-RNAS; EXPRESSION; PURIFICATION; PROMOTERS; INDUCTION; COMPLEX; GROWTH; BINDS	THE human histone H4 gene FO108 is regulated during the cell cycle with a peak in transcription during early S phase(1,2). The cell-cycle element (CCE) required for H4 histone activation is a sequence of 11 base pairs that binds a protein factor in electrophoretic mobility shift assays that has been designated histone nuclear factor M (HiNF-M)(2,3). Here we report the purification of HiNF-M, and show it to be a protein of relative molecular mass (M(r)) 48K that is identical to interferon (IFN) regulatory factor 2 (IRF-2), a negative transcriptional regulator of the IFN response(4). Recombinant IRF-2 (as well as the related protein IRF-1 (ref. 5)) binds the CCE specifically and activates transcription of this H4 histone gene, IRF-2 has been shown to have oncogenic potential(6), and our results demonstrate a link between IRF-2 and a gene that is functionally coupled to DNA replication and cell-cycle progression at the G1/S phase transition.	TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Tokyo	VAUGHAN, PS (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT CELL BIOL,CTR CANC,55 LAKE AVE N,WORCESTER,MA 01655, USA.		van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Ausubel FM, 1994, CURRENT PROTOCOLS MO; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V56, P729; ITOH S, 1989, NUCLEIC ACIDS RES, V17, P8372, DOI 10.1093/nar/17.20.8372; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PENA A, 1993, J BIOL CHEM, V268, P27277; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; RAMSEYEWING A, 1994, P NATL ACAD SCI USA, V91, P4475, DOI 10.1073/pnas.91.10.4475; SHAKOORI R, IN PRESS J CELL BIOC; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VANWIJNEN AJ, 1992, MOL CELL BIOL, V12, P3273, DOI 10.1128/MCB.12.7.3273; VANWIJNEN AJ, 1994, P NATL ACAD SCI USA, V91, P12882, DOI 10.1073/pnas.91.26.12882; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; YAMAMOTO H, 1994, ONCOGENE, V9, P1423	29	167	170	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					362	365		10.1038/377362a0	http://dx.doi.org/10.1038/377362a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566094				2022-12-28	WOS:A1995RX11100063
J	BAUER, TM; RITZ, R; HABERTHUR, C; HA, HR; HUNKELER, W; SLEIGHT, AJ; SCOLLOLAVIZZARI, G; HAEFELI, WE				BAUER, TM; RITZ, R; HABERTHUR, C; HA, HR; HUNKELER, W; SLEIGHT, AJ; SCOLLOLAVIZZARI, G; HAEFELI, WE			PROLONGED SEDATION DUE TO ACCUMULATION OF CONJUGATED METABOLITES OF MIDAZOLAM	LANCET			English	Article							MORPHINE-6-GLUCURONIDE; PLASMA	Midazolam is a short-acting benzodiazepine routinely used in intensive-care medicine. Conjugates of its main metabolite, alpha-hydroxymidazolam, have been shown to accumulate in renal failure but have not previously been related to the prolonged sedative effects commonly observed in critically ill patients. We report five patients with severe renal failure who had prolonged sedation after administration of midazolam. In all five patients, the comatose state was immediately reversed by the benzodiazepine-receptor antagonist flumazenil. Serum concentration monitoring showed high concentrations of conjugated alpha-hydroxymidazolam when concentrations of the unconjugated metabolite and the parent drug were below the therapeutic range. In-vitro binding studies showed that the affinity of binding to the cerebral benzodiazepine receptor of glucuronidated alpha-hydroxymidazolam was only about ten times weaker (affinity constant 16 nmol/L) than that of midazolam (1 . 4 nmol/L) or unconjugated alpha-hydroxymidazolam (2 . 2 nmol/L). Conjugated metabolites of midazolam have substantial pharmacological activity. Physicians should be aware that these metabolites can accumulate in patients with renal failure.	UNIV BASEL HOSP,DEPT INTERNAL MED,DIV CLIN PHARMACOL,CH-4031 BASEL,SWITZERLAND; UNIV BASEL HOSP,DEPT INTERNAL MED,DIV INTENS CARE,CH-4031 BASEL,SWITZERLAND; UNIV BASEL HOSP,DEPT NEUROL,CH-4031 BASEL,SWITZERLAND; UNIV ZURICH HOSP,CARDIOVASC THERAPY RES UNIT,CH-8091 ZURICH,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,CH-4002 BASEL,SWITZERLAND	University of Basel; University of Basel; University of Basel; University of Zurich; University Zurich Hospital; Roche Holding			Haefeli, Walter Emil/AAJ-3024-2020	Haefeli, Walter Emil/0000-0003-0672-6876				BYATT CM, 1984, BRIT MED J, V289, P799, DOI 10.1136/bmj.289.6448.799; DREISSEN JJ, 1991, ACTA ANAESTH BELG, V42, P149; HA HR, 1993, THER DRUG MONIT, V15, P338, DOI 10.1097/00007691-199308000-00013; HAND CW, 1987, LANCET, V2, P1207; HEISMANN P, 1983, BR J CLIN PHARM, V16, pS43; KROEMER HK, 1992, CLIN PHARMACOKINET, V23, P292, DOI 10.2165/00003088-199223040-00005; MOHLER H, 1981, NATURE, V294, P763, DOI 10.1038/294763a0; MOHLER H, 1981, J NEUROCHEM, V37, P714; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLDENHOF H, 1988, CLIN PHARMACOL THER, V43, P263, DOI 10.1038/clpt.1988.31; OSBORNE R, 1988, LANCET, V1, P828; PERSSON MP, 1988, CLIN PHARMACOL THER, V43, P324; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; SCOLLOLAVIZZARI G, 1987, EUR NEUROL, V26, P161, DOI 10.1159/000116329	14	208	225	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					145	147		10.1016/S0140-6736(95)91209-6	http://dx.doi.org/10.1016/S0140-6736(95)91209-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603229				2022-12-28	WOS:A1995RJ03100009
J	URBANOMARQUEZ, A; ESTRUCH, R; FERNANDEZSOLA, J; NICOLAS, JM; PARE, JC; RUBIN, E				URBANOMARQUEZ, A; ESTRUCH, R; FERNANDEZSOLA, J; NICOLAS, JM; PARE, JC; RUBIN, E			THE GREATER RISK OF ALCOHOLIC CARDIOMYOPATHY AND MYOPATHY IN WOMEN COMPARED WITH MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; LIVER-DISEASE; ETHANOL; SEX; CONSUMPTION; CIRRHOSIS; DRINKING; MUSCLE; METABOLISM; SKELETAL	Objective.-To compare the cardiac and muscular status of male and female alcoholics to determine if the response of women to alcohol is different from that of men. Design.-Cross-sectional study. Setting.-An ambulatory alcoholism treatment unit in the Hospital Clinic of Barcelona. Patients.-Fifty asymptomatic alcoholic women, 100 asymptomatic alcoholic men, and 50 female nonalcoholic controls. Main Outcome Measures.-Studies included clinical assessment of muscle strength, muscle biopsy, echocardiography, radionuclide cardiac angiography, and treadmill exercise electrocardiographic recording test. Results.-The mean strength of the deltoid muscle in alcoholic women was significantly lower than that in controls (P<.001) and half suffered clinical weakness (muscle strength greater than or equal to SD below controls). Muscle biopsy specimens from half of all asymptomatic women showed histologic evidence of myopathy. Left ventricular ejection fractions tended to be depressed, and a third of the alcoholic women had evidence of cardiomyopathy. Muscular strength and ejection fractions in women were inversely correlated with the total lifetime dose of ethanol, whereas the left ventricular mass showed a direct correlation. Of the alcoholic men, 39% suffered clinical weakness, and 45% had histologic evidence of myopathy. Evidence of cardiomyopathy was found in almost a third of the men, and their ejection fractions also correlated inversely with the total lifetime dose of ethanol. However, the threshold dose for the development of cardiomyopathy was considerably less in women than in men, and the decline in the ejection fraction with increasing alcohol dose was significantly steeper (P<.001). Conclusions.-Despite the fact that the mean lifetime dose of alcohol in female alcoholics was only 60% that in male alcoholics, cardiomyopathy and myopathy were as common in female alcoholics as in male alcoholics. This finding, together with a more pronounced response of the ejection fraction to the dose of ethanol, indicates that women are more sensitive than men to the toxic effects of alcohol on striated muscle.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; UNIV BARCELONA,HOSP CLIN,DEPT INTERNAL MED & CARDIOL,BARCELONA,SPAIN	Jefferson University; University of Barcelona; Hospital Clinic de Barcelona			SOLA, JOAQUIM FERNANDEZ/K-3991-2019	SOLA, JOAQUIM FERNANDEZ/0000-0002-3218-0582				ACKER C, 1985, ALCOHOL ALCOHOLISM, V20, P379; ARTHUR MJP, 1984, CLIN SCI, V67, P397, DOI 10.1042/cs0670397; BATEY RG, 1992, MED J AUSTRALIA, V156, P413, DOI 10.5694/j.1326-5377.1992.tb139846.x; BISHOP CW, 1981, AM J CLIN NUTR, V34, P2530, DOI 10.1093/ajcn/34.11.2530; Blackburn G L, 1977, JPEN J Parenter Enteral Nutr, V1, P11, DOI 10.1177/014860717700100111; BURRITT MF, 1984, HUM PATHOL, V15, P130, DOI 10.1016/S0046-8177(84)80052-0; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DORIA J, 1990, ALCOHOL HLTH RES, V14, P349; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; ECKHARDT MJ, 1981, JAMA-J AM MED ASSOC, V246, P648; ERICKSON CJP, 1993, ALCOHOL ALCOHOLISM, V28, P230; FERNANDEZSOLA J, 1994, ANN INTERN MED, V120, P529, DOI 10.7326/0003-4819-120-7-199404010-00001; FOX J, 1994, LINEAR REGRESSION MO; FOY A, 1988, ALCOHOL CLIN EXP RES, V12, P360, DOI 10.1111/j.1530-0277.1988.tb00208.x; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; JACOBSON R, 1986, PSYCHOL MED, V16, P547, DOI 10.1017/S003329170001031X; Jelliffe DB, 1966, WHO MONOGRAPH SERIES, V53; JOHNSON RA, 1982, NEW ENGL J MED, V307, P1051, DOI 10.1056/NEJM198210213071704; KALEBER C, 1981, CIRCULATION S3, V64, P1; KELBAEK H, 1988, ALCOHOL ALCOHOLISM, V23, P211; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KUPARI M, 1991, AM J CARDIOL, V67, P274, DOI 10.1016/0002-9149(91)90559-4; KUPARI M, 1992, AM J CARDIOL, V70, P645, DOI 10.1016/0002-9149(92)90206-E; MANN K, 1992, ALCOHOL CLIN EXP RES, V16, P1052, DOI 10.1111/j.1530-0277.1992.tb00698.x; MARSHALL AW, 1983, HEPATOLOGY, V3, P701; MASTAGLIA FL, 1982, SKELETAL MUSCLE PATH; MEZEY E, 1988, AM J CLIN NUTR, V48, P148, DOI 10.1093/ajcn/48.1.148; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MORGAN MY, 1977, BRIT MED J, V1, P939, DOI 10.1136/bmj.1.6066.939; NORTON R, 1987, BMJ-BRIT MED J, V295, P80, DOI 10.1136/bmj.295.6590.80; Pequignot G, 1974, REV ALCOHOLISM, V20, p191 ; PERKOFF GT, 1966, NEW ENGL J MED, V274, P1277, DOI 10.1056/NEJM196606092742301; ROBIN E, 1970, AM HEART J, V80, P103, DOI 10.1016/0002-8703(70)90043-8; RUBIN E, 1979, NEW ENGL J MED, V301, P28; SLAVIN G, 1983, J CLIN PATHOL, V36, P772, DOI 10.1136/jcp.36.7.772; SOBELL LC, 1979, BEHAV RES THER, V17, P157, DOI 10.1016/0005-7967(79)90025-1; THOMAS AP, 1989, J MOL CELL CARDIOL, V21, P555, DOI 10.1016/0022-2828(89)90821-3; TUYNS AJ, 1984, INT J EPIDEMIOL, V13, P53, DOI 10.1093/ije/13.1.53; URBANOMARQUEZ A, 1985, ANN NEUROL, V17, P418, DOI 10.1002/ana.410170423; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; WU CF, 1976, AM HEART J, V91, P281, DOI 10.1016/S0002-8703(76)80209-8	42	205	207	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					149	154		10.1001/jama.274.2.149	http://dx.doi.org/10.1001/jama.274.2.149			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596003				2022-12-28	WOS:A1995RH22200028
J	PEISACH, E; CASEBIER, D; GALLION, SL; FURTH, P; PETSKO, GA; HOGAN, JC; RINGE, D				PEISACH, E; CASEBIER, D; GALLION, SL; FURTH, P; PETSKO, GA; HOGAN, JC; RINGE, D			INTERACTION OF A PEPTIDOMIMETIC AMINIMIDE INHIBITOR WITH ELASTASE	SCIENCE			English	Article							LIBRARY; LIGANDS; BINDING	The crystal structure of an aminimide analog of a dipeptide inhibitor of porcine pancreatic elastase bound to its target serine protease has been solved. The peptidomimetic molecule binds in the same fashion as the class of dipeptides from which it was derived, making similar interactions with the subsites on the elastase surface. Because aminimides are readily synthesized from a wide variety of starting materials, they form the basis for a combinatorial chemistry approach to rational drug design.	BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT CHEM,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,PROGRAM BIOPHYS,WALTHAM,MA 02254	Brandeis University; Brandeis University; Brandeis University; Brandeis University			Petsko, Gregory/AAO-7962-2020	Peisach, Ezra/0000-0002-7905-6327	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007596] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GMO7596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUR A, 1994, INT J PEPT PROT RES, V43, P297; AUBURY A, 1994, INT J PEPT PROT RES, V43, P305; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DELASIERRA IL, 1990, J MOL RECOG, V0003; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GEYSEN HM, 1986, CIBA F S, V119; HUGHES DL, 1982, J MOL BIOL, V162, P645, DOI 10.1016/0022-2836(82)90393-X; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVIE A, COMMUNICATION; MATTOS C, 1994, NAT STRUCT BIOL, V1, P55, DOI 10.1038/nsb0194-55; MATTOS C, 1995, BIOCHEMISTRY-US, V34, P3193, DOI 10.1021/bi00010a008; MATTOS C, 1993, QSAR DRUG DESIGN THE, P226; RENAUD A, 1983, J BIOL CHEM, V258, P8312; RINGE D, 1995, NEW PERSPECTIVES IN DRUG DESIGN, P89; RINGE D, UNPUB; SAWYER L, 1978, J MOL BIOL, V118, P137, DOI 10.1016/0022-2836(78)90412-6; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHOTTON D M, 1970, Nature (London), V225, P811, DOI 10.1038/225811a0	23	43	47	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					66	69		10.1126/science.7604279	http://dx.doi.org/10.1126/science.7604279			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604279				2022-12-28	WOS:A1995RG98000033
J	STARGELL, LA; STRUHL, K				STARGELL, LA; STRUHL, K			THE TBP-TFIIA INTERACTION IN THE RESPONSE TO ACIDIC ACTIVATORS IN-VIVO	SCIENCE			English	Article							TATA-BINDING PROTEIN; RNA POLYMERASE-II; GENERAL TRANSCRIPTION FACTOR; YEAST; INITIATION; PROMOTERS; CLONING; MUTANTS; DOMAIN; VP16	A yeast TBP mutant (N2-1) is described here that is defective specifically in responding to acidic activators in vivo. N2-1 does not support activation by Gal4, Ace1, and Gcn4, but appears unaffected for constitutive transcription, repression by the Cyc8-Tup1 and Not complexes, and transcription by polymerase I (Pol) and Pol III. In vitro, N2-1 fails to interact with TFIIA, but it associates normally with a TATA element, an acidic activation domain, and TFIIB. Fusion of the small subunit of TFIIA to N2-1 restores activation function in vivo. Thus, an efficient interaction between TBP and TFIIA is required for transcriptional activation in vivo.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Stargell, Laurie/GWC-7423-2022		NIGMS NIH HHS [GM30186] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030186, R01GM030186] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BUTLER G, 1991, MOL CELL BIOL, V11, P476, DOI 10.1128/MCB.11.1.476; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIM K, 1994, J BIOL CHEM, V269, P4891; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; STARGELL LA, 1994, MOL CELL BIOL, V14, P723, DOI 10.1128/MCB.14.1.723; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; YOKOMORI K, 1994, GENE DEV, V8, P2336; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	50	103	103	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					75	78		10.1126/science.7604282	http://dx.doi.org/10.1126/science.7604282			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604282				2022-12-28	WOS:A1995RG98000036
J	RICHARDS, FM				RICHARDS, FM			ANFINSEN,CHRISTIAN,B. (1916-95) - OBITUARY	NATURE			English	Item About an Individual											RICHARDS, FM (corresponding author), YALE UNIV,260 WHITNEY AVE,NEW HAVEN,CT 06520, USA.							ANFINSEN CB, PUBLICATION LIST	1	2	2	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					19	19		10.1038/376019a0	http://dx.doi.org/10.1038/376019a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596423				2022-12-28	WOS:A1995RH11100036
J	BERTHOLD, J; BAUER, MF; SCHNEIDER, HC; KLAUS, C; DIETMEIER, K; NEUPERT, W; BRUNNER, M				BERTHOLD, J; BAUER, MF; SCHNEIDER, HC; KLAUS, C; DIETMEIER, K; NEUPERT, W; BRUNNER, M			THE MIM COMPLEX MEDIATES PREPROTEIN TRANSLOCATION ACROSS THE MITOCHONDRIAL INNER MEMBRANE AND COUPLES IT TO THE MT-HSP70/ATP DRIVING SYSTEM	CELL			English	Article							PROTEIN IMPORT MACHINERY; YEAST MITOCHONDRIA; OUTER-MEMBRANE; CONTACT SITES; IDENTIFICATION; PRECURSOR; CROSS; COMPONENT; LINKING; MPI1	We have identified a complex in mitochondria that functions as a part of the preprotein import machinery of the inner membrane (MIM complex). Two known components, MIM23 and MIM17, and two novel components, MIM33 and MIM14, were found as constituents of this complex. In the presence of a translocating chain, the outer membrane import machinery (MOM complex) and the MINI complex form translocation contact sites. On the matrix side, the MIM complex is associated with the mt-Hsp70-MIM44 system. We propose a structure of the import machinery in which the MIM complex constitutes a proteinaceous channel that accepts preproteins from the MOM complex, facilitates their reversible transmembrane movement, and mediates unidirectional transport by linkage to the ATP-dependent mt-Hsp70-MIM44 system.			BERTHOLD, J (corresponding author), UNIV MUNICH, INST PHYSIOL CHEM, GOETHESTR 33, D-80336 MUNICH, GERMANY.			Brunner, Michael/0000-0001-9798-3047				ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; BROACH JR, 1983, EXPT MANIPULATION GE, P85; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DAUM G, 1982, J BIOL CHEM, V257, P3075; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; HARLOW E, 1988, LABORATORY MANUAL; HIGH S, 1993, J BIOL CHEM, V268, P26745; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HOCHULI E, 1989, CHEM IND, V12, P69; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; PFANNER N, 1995, CURR BIOL, V5, P132; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; Sherman F., 1986, METHODS YEAST GENETI; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VALE RD, 1994, CELL, V78, P733, DOI 10.1016/S0092-8674(94)90402-2	41	153	153	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1085	1093		10.1016/S0092-8674(05)80013-3	http://dx.doi.org/10.1016/S0092-8674(05)80013-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600576	Bronze			2022-12-28	WOS:A1995RG91000013
J	WISELY, J; HAINES, A				WISELY, J; HAINES, A			COMMISSIONING A NATIONAL PROGRAM OF RESEARCH-AND-DEVELOPMENT ON THE INTERFACE BETWEEN PRIMARY AND SECONDARY CARE	BRITISH MEDICAL JOURNAL			English	Article								The first call for applications to the NHS research and development programme on the interface between primary and secondary care was advertised in February 1994. A total of 674 outline proposals were submitted and 54 (8%) secured funding. Projects have been commissioned in 16 of the 21 priority areas and around pound 6m has been committed. Analysis shows that multidisciplinary applications are more likely to be funded and that the odds for a successful application are on average nearly doubled for each discipline represented up to five. A survey of applicants and peer reviewers found satisfaction with much of the commissioning process, but peer review and feedback were subject to criticism, particularly by unsuccessful applicants. The programme shows that it is possible to commission a large number of projects in an innovative area of research and development and has identified refinements that will further increase the efficiency and acceptability of the process.	NATL HLTH SERV EXECUT,LONDON W2 3QR,ENGLAND					Haines, Andy/0000-0002-8053-4605				JONES R, 1995, BRIT MED J, V311, P1076, DOI 10.1136/bmj.311.7012.1076; 1995, NHS RES DEV PROGRAMM; 1994, RES DEV PRIORITIES R	3	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1080	1082		10.1136/bmj.311.7012.1080	http://dx.doi.org/10.1136/bmj.311.7012.1080			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580670	Green Published			2022-12-28	WOS:A1995TB35400031
J	MUELLER, PR; COLEMAN, TR; KUMAGAI, A; DUNPHY, WG				MUELLER, PR; COLEMAN, TR; KUMAGAI, A; DUNPHY, WG			MYT1 - A MEMBRANE-ASSOCIATED INHIBITORY KINASE THAT PHOSPHORYLATES CDC2 ON BOTH THREONINE-14 AND TYROSINE-15	SCIENCE			English	Article							PROTEIN-KINASE; NEGATIVE REGULATION; WEE1; ACTIVATION; MITOSIS; XENOPUS; GENE	Cdc2 is the cyclin-depefident kinase that controls entry of cells into mitosis. Phosphorylation of Cdc2 on threonine-14 and tyrosine-15 inhibits the activity of the enzyme and prevents premature initiation of mitosis. Although Wee1 has been identified as the kinase that phosphorylates tyrosine-15 in various organisms, the threonine-14-specific kinase has not been isolated. A complementary DNA was cloned from Xenopus that encodes Myt1, a member of the Wee1 family that was discovered io phosphorylate Cdc2 efficiently on both threonine-14 and tyrosine-15. Myt1 is a membrane-associated protein that contains a putative transmembrane segment. Immunodepletion studies suggested that Myt1 is the predominant threonine-14-specific kinase in Xenopus egg extracts, Myt1 activity is highly regulated during the cell cycle, suggesting that this relative of Wee1 plays a role in mitotic control.	CALTECH, HOWARD HUGHES MED INST, DIV BIOL 21676, PASADENA, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute			Mueller, Paul/B-6699-2012	Coleman, Thomas/0000-0002-1665-4768				ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LEE MS, 1994, J BIOL CHEM, V269, P30530; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, UNPUB; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x	26	533	546	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 6	1995	270	5233					86	90		10.1126/science.270.5233.86	http://dx.doi.org/10.1126/science.270.5233.86			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569953				2022-12-28	WOS:A1995RY30200038
J	DECOCK, KM; LUCAS, SB; MABEY, D; PARRY, E				DECOCK, KM; LUCAS, SB; MABEY, D; PARRY, E			TROPICAL MEDICINE FOR THE 21ST-CENTURY	BRITISH MEDICAL JOURNAL			English	Article								The specialty of tropical medicine originated from the needs of the colonial era and is removed from many of the health care requirements of tropical countries today. Tropical medicine concentrates on parasitic diseases of warm climates, although other infections and diseases related to poverty rather than climate dominate medicine in developing countries challenged by population pressure, civil strife, and migration. In the new century, tropical medicine would best be absorbed into the specialty of infectious diseases, which should incorporate parasitic diseases, travel medicine, and sexually transmitted diseases. Pressing questions for health care and research in developing countries concern the provision of appropriate services for problems such as HIV/AIDS, tuberculosis, sexually transmitted diseases, and injuries. The question of how to provide appropriate clinical care in resource poor settings for the major causes of morbidity and premature mortality has been neglected by donors, academic institutions, and traditional tropical medicine.	UNITED MED & DENT SCH,DEPT HISTOPATHOL,LONDON SE1 7EH,ENGLAND	University of London; King's College London	DECOCK, KM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.			Mabey, David/0000-0002-0031-8276				[Anonymous], 1994, TB GLOBAL EMERGENCY; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; COOK GC, 1994, T ROY SOC TROP MED H, V88, P4, DOI 10.1016/0035-9203(94)90481-2; DECOCK KM, 1983, BRIT MED J, V287, P1139; DENNIS DT, 1994, BRIT MED J, V309, P893, DOI 10.1136/bmj.309.6959.893; DOUCET I, 1994, LANDMINES COMPREHENS; HARDY RI, 1994, 43RD ANN EP INT SERV; KENNEDY P, 1993, PREPARING 21ST CENTU; LAGA M, 1994, AIDS S1, V8, pS119; MCCORD C, 1990, NEW ENGL J MED, V322, P173, DOI 10.1056/NEJM199001183220306; MCGREGOR IA, 1995, T ROY SOC TROP MED H, V89, P1, DOI 10.1016/0035-9203(95)90636-3; PACQUET C, 1994, LANCET, V344, P823; STANLEY K, 1993, DIS CONTROL PRIORITI, P703; STANSFIELD SK, 1993, DISEASE CONTROL PRIO, P609; Walsh JA, 1993, DIS CONTROL PRIORITI, P363; WARREN KS, 1990, REV INFECT DIS, V12, P142; WAUGH MA, 1990, SEXUALLY TRANSMITTED, P3; 1994, 1994 TROP HLTH ED TR; 1993, MMWR-MORBID MORTAL W, V42, P89; 1993, 1993 WHO WORLD DEV R; 1993, TROPICAL DISEASE RES; 1993, STATE WORLDS REFUGEE	22	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					860	862		10.1136/bmj.311.7009.860	http://dx.doi.org/10.1136/bmj.311.7009.860			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580497	Green Published			2022-12-28	WOS:A1995RY19100030
J	WHINCUP, P; COOK, D; PAPACOSTA, O; WALKER, M				WHINCUP, P; COOK, D; PAPACOSTA, O; WALKER, M			BIRTH-WEIGHT AND BLOOD-PRESSURE - CROSS-SECTIONAL AND LONGITUDINAL RELATIONS IN CHILDHOOD	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION INUTERO; ADULT LIFE; CHILDREN; INITIATION; MORTALITY; FETAL; SIZE; RISK	Objective-To examine cross sectional and longitudinal relations between birth weight and blood pressure in childhood. Design-Cross sectional study of primary school children aged 9-11 years, with analysis in relation to previous measurements at 5-7 years in a subgroup. Setting-20 primary schools in Guildford and Carlisle. Subjects-1511 children measured at 9-11 years (response rate 79%), including 549 who had been measured at 5-7 years. Main outcome measures-Blood pressure at 9-11 years, change in blood pressure between 5-7 and 9-11 years, birth weight (based on maternal recall), and placental weight (based on birth records). Results-At 9-11 years birth weight was inversely related both to systolic blood pressure (regression coefficient -2.80 mm Hg/kg; 95% confidence interval -3.84 to -1.76) and to diastolic blood pressure (regression coefficient -1.42 mm Hg/kg; -2.14 to -0.70) once current height and body mass index were taken into account. Placental weight was inversely related to blood pressure after adjustment for current height and body mass index but placental ratio (placental weight to birth weight) was unrelated to blood pressure. Between 5-7 and 9-11 years systolic blood pressure rose more rapidly in children of lower birth weight (regression coefficient -1.71 mm Hg/kg; -3.35 to -0.07). This effect seemed to be stronger in girls. Conclusions-Birth weight rather than placental ratio is the early Life factor most importantly related to blood pressure in childhood. The results support the possibility of ''amplification'' of the relation between birth weight and blood pressure, particularly in girls.	UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND; UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND	St Georges University London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School				Papacosta, Olia/0000-0001-8781-6747; Whincup, Peter/0000-0002-5589-4107				BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; CARTER J, 1984, LOW BIRTHWEIGHT MED, P191; FROHLICH ED, 1988, CIRCULATION, V77, P502; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; LAUNER LJ, 1993, BMJ-BRIT MED J, V307, P1451, DOI 10.1136/bmj.307.6917.1451; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LUCAS A, 1991, CIBA F SYMP, V156, P38; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MATTHES JWA, 1994, BMJ-BRIT MED J, V308, P1074, DOI 10.1136/bmj.308.6936.1074; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; WHINCUP P, 1994, J HUM HYPERTENS, V8, P337; WHINCUP PH, 1988, LANCET, V2, P890; WHINCUP PH, 1992, J EPIDEMIOL COMMUN H, V46, P164, DOI 10.1136/jech.46.2.164; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WHINCUP PH, 1989, J HYPERTENS, V7, P845, DOI 10.1097/00004872-198910000-00010; WHINCUP PH, 1993, BRIT MED J, V306, P584, DOI 10.1136/bmj.306.6877.584; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; 1985, SAS USERS GUIDE BASI	22	141	147	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					773	776		10.1136/bmj.311.7008.773	http://dx.doi.org/10.1136/bmj.311.7008.773			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580437	Green Published			2022-12-28	WOS:A1995RX10700018
J	MACLEOD, RJ; BENNETT, HPJ; HAMILTON, JR				MACLEOD, RJ; BENNETT, HPJ; HAMILTON, JR			INHIBITION OF INTESTINAL SECRETION BY RICE	LANCET			English	Note							LIQUID-CHROMATOGRAPHY	Rates of stool output are reduced when cooked rice is incorporated into oral rehydration solutions. We found that a fraction extracted from rice inhibited the response of intestinal epithelial crypt cells to adenosine 3'5'-cyclic monophosphate, a major intracellular mediator of secretion. This response to rice was seen as an inhibition of cell shrinkage and of chloride efflux in fresh suspended guineapig crypt cells. The active fraction was of low molecular weight (<1.5 kDa), hydrophobic, and not a peptide or glycoprotein. It may be chloride-channel blocker.	MCGILL UNIV,MONTREAL CHILDRENS HOSP,RES INST,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,DEPT PEDIAT,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,MONTREAL,PQ H3A 1A1,CANADA	McGill University; McGill University; McGill University; Royal Victoria Hospital								BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BROWNE CA, 1982, ANAL BIOCHEM, V124, P201, DOI 10.1016/0003-2697(82)90238-X; FIELD M, 1993, ANNU REV PHYSIOL, V55, P631, DOI 10.1146/annurev.ph.55.030193.003215; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; MACLEOD RJ, 1994, AM J PHYSIOL, V267, pG387, DOI 10.1152/ajpgi.1994.267.3.G387; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358	6	27	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					90	92		10.1016/S0140-6736(95)92115-X	http://dx.doi.org/10.1016/S0140-6736(95)92115-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603220				2022-12-28	WOS:A1995RH22000013
J	VINCENT, A; NEWLAND, C; BRUETON, L; BEESON, D; RIEMERSMA, S; HUSON, SM; NEWSOMDAVIS, J				VINCENT, A; NEWLAND, C; BRUETON, L; BEESON, D; RIEMERSMA, S; HUSON, SM; NEWSOMDAVIS, J			ARTHROGRYPOSIS MULTIPLEX CONGENITA WITH MATERNAL AUTOANTIBODIES SPECIFIC FOR A FETAL ANTIGEN	LANCET			English	Note							ACETYLCHOLINE-RECEPTOR	Fetal arthrogryposis multiplex congenita (AMC) is characterised by non-progressive multiple joint contractures, which may result in fetal death, and is heterogeneous in origin. It can associate with maternal myasthenia gravis and autoantibodies to acetylcholine receptor (AChR). We found antibodies that selectively inhibit the fetal form of the AChR in a mother who herself had no features of myasthenia gravis. Maternal autoantibodies specific for fetal antigens could be an unrecognised cause of other congenital disorders.	NORTHWICK PK HOSP & CLIN RES CTR,KENNEDY GALTON CTR,HARROW,MIDDX,ENGLAND; OXFORD RADCLIFFE HOSP,DEPT CLIN GENET,OXFORD,ENGLAND	Imperial College London; University of Oxford	VINCENT, A (corresponding author), UNIV OXFORD,OXFORD RADCLIFFE HOSP,INST MOLEC MED,DEPT CLIN NEUROL,NEUROSCI GRP,OXFORD OX3 9DU,ENGLAND.		Vincent, Angela/AAE-7310-2019					BARNES PRJ, 1995, NEUROMUSCULAR DISORD, V5, P59, DOI 10.1016/0960-8966(94)E0029-8; BEESON D, 1993, EUR J BIOCHEM, V215, P229, DOI 10.1111/j.1432-1033.1993.tb18027.x; DRACHMAN DB, 1961, LANCET, V2, P523; GARABEDIAN BV, 1994, J CLIN INVEST, V94, P555; HALL JG, 1990, PRINCIPLES PRACTICE; HENNEKAM RCM, 1992, AM J MED GENET, V43, P1047, DOI 10.1002/ajmg.1320430630; HESSELMANS KFG, 1991, ANAT REC, V236, P553; STIRRAT GM, 1992, BAILLIERE CLIN OB GY, V6, P195; VINCENT A, 1995, J PHYSIOL-PARIS, V89, P129, DOI 10.1016/0928-4257(96)80110-0; YAMAMOTO T, 1991, ANN NEUROL, V30, P550, DOI 10.1002/ana.410300407	10	115	116	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					24	25		10.1016/S0140-6736(95)92652-6	http://dx.doi.org/10.1016/S0140-6736(95)92652-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603140				2022-12-28	WOS:A1995RF98500010
J	MINDEN, A; LIN, AN; CLARET, FX; ABO, A; KARIN, M				MINDEN, A; LIN, AN; CLARET, FX; ABO, A; KARIN, M			SELECTIVE ACTIVATION OF THE JNK SIGNALING CASCADE AND C-JUN TRANSCRIPTIONAL ACTIVITY BY THE SMALL GTPASES RAC AND CDC42HS	CELL			English	Article							GTP-BINDING PROTEINS; GUANINE-NUCLEOTIDE EXCHANGE; MAP KINASE; YEAST; ONCOGENE; GENE; PHOSPHORYLATION; SUPERFAMILY; RECEPTOR; PRODUCT	The Rho subfamily of GTPases is involved in control of cell morphology In mammals and yeast. The mammalian Rac and Cdc42 proteins control formation of lamellipodia and filopodia, respectively. These proteins also activate MAP kinase (MAPK) cascades that regulate gene expression. Constitutively activated forms of Rac and Cdc42Hs are efficient activators of a cascade leading to JNK and p38/Mpk2 activation. RhoA did not exhibit this activity, and none of the proteins activated the ERK subgroup of MAPKs. JNK, but not ERK, activation was also observed in response to Dbl, an oncoprotein that acts as a nucleotide exchange factor for Cdc42Hs. Results with dominant interfering alleles place Rac1 as an intermediate between Ha-Ras and MEKK in the signaling cascade leading from growth factor receptors and v-Src to JNK activation. JNK and p38 activation are likely to contribute to the biological effects of Rac, Cdc42Hs, and Dbl on cell growth and proliferation.	ONYX PHARMACEUT,RICHMOND,CA 94806		MINDEN, A (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093, USA.		Claret, Francois X/R-2104-2016	Claret, Francois X/0000-0003-4629-6495				ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS JM, 1992, ONCOGENE, V7, P611; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; COBB M, 1995, IN PRESS J BIOL CHEM; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CVRCKOVA F, 1995, IN PRESS GENES DEV; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAEDA T, 1995, IN PRESS SCIENCE; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RPOTHMAN JE, 1994, NATURE, V372, P55; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU XM, 1994, J BIOL CHEM, V269, P23569; YAN MH, 1994, NATURE, V372, P798	66	1471	1487	2	26	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1147	1157		10.1016/S0092-8674(05)80019-4	http://dx.doi.org/10.1016/S0092-8674(05)80019-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600582	Bronze			2022-12-28	WOS:A1995RG91000019
J	ANDERSON, SL; BERMAN, J; KUSCHNER, R; WESCHE, D; MAGILL, A; WELLDE, B; SCHNEIDER, I; DUNNE, M; SCHUSTER, BG				ANDERSON, SL; BERMAN, J; KUSCHNER, R; WESCHE, D; MAGILL, A; WELLDE, B; SCHNEIDER, I; DUNNE, M; SCHUSTER, BG			PROPHYLAXIS OF PLASMODIUM-FALCIPARUM MALARIA WITH AZITHROMYCIN ADMINISTERED TO VOLUNTEERS	ANNALS OF INTERNAL MEDICINE			English	Note							MEFLOQUINE	Objective: To determine whether azithromycin, 250 mg/d, is effective prophylaxis for liver infection or for both liver and subsequent blood infection with Plasmodium falciparum. Design: Controlled phase II trial with two cohorts entered sequentially. Setting: Clinical trials center of Waiter Reed Army Institute of Research, Washington, D.C. Patients: Each of the two cohorts consisted of 12 normal adult volunteers who had not had malaria during the previous 2 years: 10 who received azithromycin prophylaxis and 2 controls who did not receive treatment. Intervention: For cohort 1, prophylactic efficacy against liver infection alone during the initial 7 days of the infection was determined by loading participants with azithromycin before challenge with P falciparum-infected mosquitoes on day 0 and by then giving the drug for 7 days after the challenge. The regimen was 500 mg on day 14 before the challenge, followed by 250 mg/d from day 13 before the challenge through day 7 after the challenge. For cohort 2, prophylactic efficacy against both the liver infection and the subsequent blood infection was determined by continuing drug administration for 28 days after the challenge. Measurements: Plasmodium falciparum infection was diagnosed through peripheral blood smears obtained up to 70 days after challenge. Malarial symptoms and adverse drug reactions were also monitored. Results: In cohort 1,4 of 10 volunteers who received azithromycin prophylaxis (40%) did not develop parasitemia. In cohort 2, none of the 10 volunteers receiving azithromycin prophylaxis (100%) developed parasitemia. For each cohort, both control volunteers became parasitemic on days 9 through 13 after the challenge. Adverse drug reactions were few and mild. Conclusions: In this model, prophylaxis with azithro-mycin (250 mg/d) was partially effective against liver parasites and completely successful against the combination of liver and blood parasites. These data suggest that azithromycin has the potential to be an effective, well-tolerated clinical prophylactic agent for P. falciparum malaria.	PFIZER INC, CENT RES, GROTON, CT 06340 USA	Pfizer	ANDERSON, SL (corresponding author), WALTER REED ARMY INST RES, DIV EXPTL THERAPEUT, WASHINGTON, DC 20307 USA.		Dunne, Michael W/AAD-7418-2020	Dunne, Michael W/0000-0001-6186-5196				ANDERSEN SL, 1994, ANTIMICROB AGENTS CH, V38, P1862, DOI 10.1128/AAC.38.8.1862; CHULAY JD, 1986, AM J TROP MED HYG, V35, P66, DOI 10.4269/ajtmh.1986.35.66; FONTANET AL, 1993, B WORLD HEALTH ORGAN, V71, P377; FOULDS G, 1993, 33RD INT C ANT AG CH; KEYSTONE JS, 1993, HLTH HINTS TROPICS, P21; KUSCHNER RA, 1994, LANCET, V343, P1396, DOI 10.1016/S0140-6736(94)92526-7; PANG L, 1988, J INFECT DIS, V158, P1124, DOI 10.1093/infdis/158.5.1124; SHMUKLARSKY MJ, 1994, ANN INTERN MED, V120, P294, DOI 10.7326/0003-4819-120-4-199402150-00006; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W	9	62	70	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1995	123	10					771	773		10.7326/0003-4819-123-10-199511150-00005	http://dx.doi.org/10.7326/0003-4819-123-10-199511150-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE172	7574195				2022-12-28	WOS:A1995TE17200005
J	ROUSH, W				ROUSH, W			PHYSIOLOGY/MEDICINE - FLY DEVELOPMENT WORK BEARS PRIZE-WINNING FRUIT	SCIENCE			English	Editorial Material																		PEIFER, 1994, SCIENCE         0513, P904; 1978, NATURE          1207, P565; 1980, NATURE          1030, P795; 1995, CELL, V82, P803	4	13	13	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					380	381		10.1126/science.270.5235.380	http://dx.doi.org/10.1126/science.270.5235.380			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569990				2022-12-28	WOS:A1995TA37400024
J	LABEIT, S; KOLMERER, B				LABEIT, S; KOLMERER, B			TITINS - GIANT PROTEINS IN CHARGE OF MUSCLE ULTRASTRUCTURE AND ELASTICITY	SCIENCE			English	Article							RABBIT SKELETAL-MUSCLE; MONOCLONAL-ANTIBODIES; IMMUNOELECTRON MICROSCOPY; SELECTIVE REMOVAL; STRIATED-MUSCLE; RESTING TENSION; FILAMENTS; CONNECTIN; DOMAIN; BAND	In addition to thick and thin filaments, vertebrate striated muscle contains a third filament system formed by the giant protein titin. Single titin molecules extend from Z discs to M lines and are longer than 1 micrometer. The titin filament contributes to muscle assembly and resting tension, but more details are not known because of the large size of the protein. The complete complementary DNA sequence of human cardiac titin was determined. The 82-kilobase complementary DNA predicts a 3-megadalton protein composed of 244 copies of immunoglobulin and fibronectin type III (FN3) domains. The architecture of sequences in the A band region of titin suggests why thick filament structure is conserved among vertebrates. In the I band region, comparison of titin sequences from muscles of different passive tension identifies two elements that correlate with tissue stiffness. This suggests that titin may act as two springs in series. The differential expression of the springs provides a molecular explanation for the diversity of sarcomere length and resting tension in vertebrate striated muscles.			LABEIT, S (corresponding author), EUROPEAN MOLEC BIOL LAB,POB 102209,D-69012 HEIDELBERG,GERMANY.							AARLI JA, 1990, CLIN EXP IMMUNOL, V82, P284; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRAIG R, 1977, J MOL BIOL, V109, P69, DOI 10.1016/S0022-2836(77)80046-6; CRAIG R, 1976, PROC R SOC SER B-BIO, V192, P451, DOI 10.1098/rspb.1976.0023; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FEINBERG AP, 1983, ANAL BIOCHEM, V13, P6; FUNATSU T, 1993, J CELL BIOL, V120, P711, DOI 10.1083/jcb.120.3.711; FUNATSU T, 1990, J CELL BIOL, V110, P53, DOI 10.1083/jcb.110.1.53; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; FURST DO, UNPUB; GAUTEL M, 1993, EMBO J, V12, P3827, DOI 10.1002/j.1460-2075.1993.tb06061.x; GRANZIER HL, 1995, BIOPHYS J, V68, P1027, DOI 10.1016/S0006-3495(95)80278-X; HILL C, 1986, J CELL BIOL, V102, P1099, DOI 10.1083/jcb.102.3.1099; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOROWITS R, 1986, NATURE, V323, P160, DOI 10.1038/323160a0; HOROWITZ R, 1993, BIOPHYS J, V61, P392; ITOH Y, 1988, J BIOCHEM-TOKYO, V104, P504, DOI 10.1093/oxfordjournals.jbchem.a122499; KOLMERER B, UNPUB; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1995, J MOL BIOL, V248, P308, DOI 10.1016/S0022-2836(95)80052-2; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAGID A, 1985, SCIENCE, V230, P1280, DOI 10.1126/science.4071053; MARUYAMA K, 1993, BIOCHEM BIOPH RES CO, V194, P1288, DOI 10.1006/bbrc.1993.1963; MARUYAMA K, 1977, J BIOCHEM, V82, P317; MARUYAMA K, 1994, BIOPHYS CHEM, V50, P73, DOI 10.1016/0301-4622(94)85021-6; NAVE R, 1989, J CELL BIOL, V109, P2177, DOI 10.1083/jcb.109.5.2177; PFUHL M, 1995, STRUCTURE, V3, P391, DOI 10.1016/S0969-2126(01)00170-8; POLITOU AS, IN PRESS BIOPHYS J; SAKI RK, 1985, SCIENCE, V230, P1350; SALVIATI G, 1990, AM J PHYSIOL, V259, pC144, DOI 10.1152/ajpcell.1990.259.1.C144; SJOSTROM M, 1977, J MOL BIOL, V109, P49, DOI 10.1016/S0022-2836(77)80045-4; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; SOTERIOU A, 1993, J CELL SCI, V104, P119; SUZUKI J, 1994, J BIOCHEM-TOKYO, V116, P406, DOI 10.1093/oxfordjournals.jbchem.a124539; TRINICK J, 1994, TRENDS BIOCHEM SCI, V19, P405, DOI 10.1016/0968-0004(94)90088-4; TROMBITAS K, 1993, J MUSCLE RES CELL M, V14, P416, DOI 10.1007/BF00121293; WANG K, 1993, BIOPHYS J, V64, P1161, DOI 10.1016/S0006-3495(93)81482-6; WANG K, 1979, P NATL ACAD SCI USA, V76, P3698, DOI 10.1073/pnas.76.8.3698; WANG K, 1991, P NATL ACAD SCI USA, V88, P7101, DOI 10.1073/pnas.88.16.7101; WITT C, UNPUB	40	951	976	1	95	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					293	296		10.1126/science.270.5234.293	http://dx.doi.org/10.1126/science.270.5234.293			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569978				2022-12-28	WOS:A1995RZ34200037
J	HOCHMAN, DW; BARABAN, SC; OWENS, JWM; SCHWARTZKROIN, PA				HOCHMAN, DW; BARABAN, SC; OWENS, JWM; SCHWARTZKROIN, PA			DISSOCIATION OF SYNCHRONIZATION AND EXCITABILITY IN FUROSEMIDE BLOCKADE OF EPILEPTIFORM ACTIVITY	SCIENCE			English	Article							RAT HIPPOCAMPAL SLICE; EXTRACELLULAR POTASSIUM; WATER-INTOXICATION; CHEMICAL SYNAPSES; TRANSPORT; SEIZURES; NEURONS; CELLS; BRAIN; POTENTIALS	Furosemide, a chloride cotransport inhibitor, reversibly blocked synchronized burst discharges in hippocampal slices without reducing the pyramidal cell response to single electrical stimuli. Images of the intrinsic optical signal acquired during these slice experiments indicated that furosemide coincidentally blocked changes in extracellular space. In urethane-anesthetized rats, systemically injected furosemide blocked kainic acid-induced electrical discharges recorded from cortex. These results suggest that (i) neuronal synchronization involved in epileptiform activity can be dissociated from synaptic excitability; (ii) nonsynaptic mechanisms, possibly associated with furosemide-sensitive cell volume regulation, may be critical for synchronization of neuronal activity; and (iii) agents that affect extracellular volume may have clinical utility as antiepileptic drugs.	UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Baraban, Scott/0000-0003-1975-9781	NINDS NIH HHS [NS07144, NS15317] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015317] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGHAJANIAN AK, 1989, SYNAPSE, V31, P331; ANDERSON WW, 1986, BRAIN RES, V398, P215, DOI 10.1016/0006-8993(86)91274-6; BARAN H, 1987, NEUROSCIENCE, V21, P679, DOI 10.1016/0306-4522(87)90029-7; BUCKMASTER PS, 1993, J NEUROPHYSIOL, V70, P1281, DOI 10.1152/jn.1993.70.4.1281; CARTER CH, 1962, EPILEPSIA, V3, P198; DELVA NJ, 1988, BRIT J PSYCHIAT, V152, P242, DOI 10.1192/bjp.152.2.242; DIETZEL I, 1980, EXP BRAIN RES, V40, P432; Dudek F E, 1986, Adv Neurol, V44, P593; DUDEK FE, 1990, NEUROSCI LETT, V120, P267, DOI 10.1016/0304-3940(90)90056-F; FERRIER IN, 1985, BRIT MED J, V291, P1594, DOI 10.1136/bmj.291.6509.1594; FORSYTHE WI, 1981, DEV MED CHILD NEUROL, V23, P761; GALVAN M, 1982, BRAIN RES, V241, P75, DOI 10.1016/0006-8993(82)91230-6; Garland HG, 1943, LANCET, V2, P566; GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0; GUILLAUME D, 1991, EPILEPSIA, V32, P10, DOI 10.1111/j.1528-1157.1991.tb05603.x; HAMMARLUND MM, 1982, BIOPHARM DRUG DISPOS, V3, P345, DOI 10.1002/bdd.2510030408; JEFFERYS JGR, 1982, NATURE, V200, P448; KIMELBERG HK, 1985, BRAIN RES, V361, P125, DOI 10.1016/0006-8993(85)91282-X; KIMELBERG HK, 1986, ASTROCYTES, V3, P129; KONNERTH A, 1984, EXP BRAIN RES, V51, P153; LANGTON PD, 1993, J PHYSIOL-LONDON, V471, P1; LIPTON P, 1973, J PHYSIOL-LONDON, V231, P365, DOI 10.1113/jphysiol.1973.sp010238; LOTHMAN EW, 1981, NEUROLOGY, V31, P806, DOI 10.1212/WNL.31.7.806; MACVICAR BA, 1991, J NEUROSCI, V11, P1458; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MCBAIN CJ, 1990, SCIENCE, V249, P674, DOI 10.1126/science.2382142; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; MEDANI CR, 1987, SOUTHERN MED J, V80, P421, DOI 10.1097/00007611-198704000-00003; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PEARCE RA, 1993, NEURON, V10, P189, DOI 10.1016/0896-6273(93)90310-N; READ DJ, 1964, J PHARM, V146, P154; RICHARDSON TL, 1984, BRAIN RES, V294, P255, DOI 10.1016/0006-8993(84)91037-0; ROPER SN, 1992, ANN NEUROL, V31, P81, DOI 10.1002/ana.410310115; ROSEN AS, 1990, NEUROSCIENCE, V38, P579, DOI 10.1016/0306-4522(90)90052-6; SCHWARTZKROIN PA, 1980, BRAIN RES, V183, P61, DOI 10.1016/0006-8993(80)90119-5; Schwartzkroin Philip A., 1993, P83; STASHEFF SF, 1985, BRAIN RES, V344, P296, DOI 10.1016/0006-8993(85)90807-8; TANIMUKAI H, 1965, BIOCHEM PHARMACOL, V14, P961; TAYLOR CP, 1982, SCIENCE, V218, P810, DOI 10.1126/science.7134978; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P512, DOI 10.1152/jn.1989.61.3.512; THOMPSON SM, 1988, J NEUROPHYSIOL, V60, P105, DOI 10.1152/jn.1988.60.1.105; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259, DOI 10.1152/jn.1988.59.1.259; Van Harreveld A., 1967, Journal of Neurophysiology, V30, P911; VANHARREVELD A, 1971, EXP MOL PATHOL, V15, P61, DOI 10.1016/0014-4800(71)90019-0; WALZ W, 1984, J CEREBR BLOOD F MET, V4, P301, DOI 10.1038/jcbfm.1984.42; White H S, 1986, Adv Neurol, V44, P695; ZHANG CL, 1995, EPILEPSY RES, V20, P105	49	161	173	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					99	102		10.1126/science.270.5233.99	http://dx.doi.org/10.1126/science.270.5233.99			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569957				2022-12-28	WOS:A1995RY30200042
J	BAIK, JH; PICETTI, R; SAIARDI, A; THIRIET, G; DIERICH, A; DEPAULIS, A; LEMEUR, M; BORRELLI, E				BAIK, JH; PICETTI, R; SAIARDI, A; THIRIET, G; DIERICH, A; DEPAULIS, A; LEMEUR, M; BORRELLI, E			PARKINSONIAN-LIKE LOCOMOTOR IMPAIRMENT IN MICE LACKING DOPAMINE D2 RECEPTORS	NATURE			English	Article							BASAL GANGLIA; MESSENGER-RNA; EXPRESSION; NEURONS; GENE; SEQUENCE; ANTAGONISTS; CATALEPSY; SCH-23390; PROTEINS	DOPAMINERGIC neuronal pathways arise from mesencephalic nuclei and project axons to the striatum, cortex, limbic system and hypothalamus(1,2). Through these pathways dopamine affects many physiological functions, such as the control of coordinated movement and hormone secretion(3). Here we have studied the physiological involvement of the dopamine D2 receptors in dopaminergic transmission, using homologous recombination to generate D2-receptor-deficient mice. Absence of D2 receptors leads to animals that are akinetic and bradykinetic in behavioural tests, and which show significantly reduced spontaneous movements. This phenotype presents analogies with symptoms characteristic of Parkinson's disease(4,5). Our study shows that D2 receptors have a key role in the dopaminergic control of nervous function. These mice have therapeutic potential as a model for investigating and correcting dysfunctions of the dopaminergic system.	INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; FAC MED STRASBOURG,INSERM,U398,F-67085 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Depaulis, Antoine/B-6098-2012; Picetti, Roberto/B-9944-2011; Borrelli, Emiliana/M-8994-2018	Depaulis, Antoine/0000-0001-6543-6700; Picetti, Roberto/0000-0003-4756-5271; 				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; BANNON MJ, 1986, J BIOL CHEM, V261, P6640; CASEY DE, 1992, PSYCHOPHARMACOLOGY, V107, P18, DOI 10.1007/BF02244960; CIVELLI O, 1985, P NATL ACAD SCI USA, V82, P4291, DOI 10.1073/pnas.82.12.4291; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; FUXE K, 1987, NEUROENDOCRINOLOGY, V5, P5; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GUIRAMAND J, 1995, J BIOL CHEM, V270, P7354, DOI 10.1074/jbc.270.13.7354; HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; JANSSEN PAJ, 1960, PSYCHOPHARMACOLOGIA, V1, P389, DOI 10.1007/BF00441186; KAUFMAN DL, 1986, SCIENCE, V232, P1138, DOI 10.1126/science.3518061; KITA H, 1988, BRAIN RES, V447, P346, DOI 10.1016/0006-8993(88)91138-9; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; MEYER ME, 1992, PHARMACOL BIOCHEM BE, V41, P507, DOI 10.1016/0091-3057(92)90365-M; MONTMAYEUR JP, 1991, FEBS LETT, V278, P239, DOI 10.1016/0014-5793(91)80125-M; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MORELLI M, 1985, EUR J PHARMACOL, V117, P179, DOI 10.1016/0014-2999(85)90602-8; OGREN SO, 1988, NEUROSCI LETT, V85, P333, DOI 10.1016/0304-3940(88)90588-5; PERTWEE RG, 1972, BRIT J PHARMACOL, V46, P753, DOI 10.1111/j.1476-5381.1972.tb06900.x; SEEMAN P, 1990, FASEB J, V4, P2737, DOI 10.1096/fasebj.4.10.2197154; WOLFFGRAMM J, 1990, PHARM BIOCH BEHAV, V36, P9007; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZURAWSKI G, 1986, SCIENCE, V232, P772, DOI 10.1126/science.2938259	30	456	467	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					424	428		10.1038/377424a0	http://dx.doi.org/10.1038/377424a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566118				2022-12-28	WOS:A1995RY19000048
J	KRAUTER, K; MONTGOMERY, K; YOON, SJ; LEBLANCSTRACESKI, J; RENAULT, B; MARONDEL, I; HERDMAN, V; CUPELLI, L; BANKS, A; LIEMAN, J; MENNINGER, J; BRAYWARD, P; NADKARNI, P; WEISSENBACH, J; LEPASLIER, D; RIGAULT, P; CHUMAKOV, I; COHEN, D; MILLER, P; WARD, D; KUCHERLAPATI, R				KRAUTER, K; MONTGOMERY, K; YOON, SJ; LEBLANCSTRACESKI, J; RENAULT, B; MARONDEL, I; HERDMAN, V; CUPELLI, L; BANKS, A; LIEMAN, J; MENNINGER, J; BRAYWARD, P; NADKARNI, P; WEISSENBACH, J; LEPASLIER, D; RIGAULT, P; CHUMAKOV, I; COHEN, D; MILLER, P; WARD, D; KUCHERLAPATI, R			A 2ND-GENERATION YAC CONTIG MAP OF HUMAN-CHROMOSOME-12	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; HUMAN GENOME; LINKAGE MAP; CLONES; SEQUENCES	Human chromosome 12 constitutes approximately 4.5% of the human genome and has an estimated size of 135 million base pairs (Mb). We have started to construct a high-resolution physical map of chromosome 12 as overlapping yeast artificial chromosomes (YACs), using as a foundation the first-generation physical map which contained overlapping clones corresponding to 56 markers. Our second-generation map of this chromosome covers nearly 102 Mb of DNA and includes 426 highly polymorphic, monomorphic and gene-based markers. We also mapped 119 of the YACs, most of which are part of the physical map, by cytogenetic methods. Thus the map integrates genetic, physical and cytogenetic data and provides information about the organization of this chromosome and will help in the localization and cloning of disease-related genes. The strategy used here to generate the chromosome-12 map could be applied for the vapid construction of physical and expression maps for other human chromosomes.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,CTR MED INFORMAT,NEW HAVEN,CT 06510; GENETHON SA,F-91002 EVRY,FRANCE; JEAN DAUSSET FDN,F-75010 PARIS,FRANCE	Yale University; Yale University	KRAUTER, K (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Kucherlapati, Raju/ABC-8807-2021	Le Paslier, Denis/0000-0003-4335-9956				BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BONNET D, 1994, NAT GENET, V6, P405, DOI 10.1038/ng0494-405; CARTER SA, 1994, GENOMICS, V24, P378, DOI 10.1006/geno.1994.1632; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DAWSON E, 1993, GENOMICS, V17, P245, DOI 10.1006/geno.1993.1314; ENGLE EC, 1994, NAT GENET, V7, P69, DOI 10.1038/ng0594-69; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HOLT M, 1992, SCIENCE, V258, P67; KOBAYASHI H, IN PRESS GENES CHROM; LEBIANCSTRACESK.JM, 1994, GENOMICS, V19, P341; LICHTER JB, 1993, GENOMICS, V16, P320, DOI 10.1006/geno.1993.1192; LUKUO JM, 1994, HUM MOL GENET, V3, P99, DOI 10.1093/hmg/3.1.99; MONTGOMERY KT, 1993, GENOMICS, V17, P682, DOI 10.1006/geno.1993.1390; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; MURRAY JC, 1994, SCIENCE, V263, P2049; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; RAIMONDI SC, 1986, BLOOD, V68, P69; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROUYER F, 1990, EMBO J, V9, P505, DOI 10.1002/j.1460-2075.1990.tb08137.x; STEPHENS JC, 1990, SCIENCE, V250, P237, DOI 10.1126/science.2218527; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; TERRETT JA, 1994, NAT GENET, V6, P401, DOI 10.1038/ng0494-401; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEISSENBACH J, 1993, GENE, V135, P275, DOI 10.1016/0378-1119(93)90077-G	30	118	119	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			321	333						13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566099				2022-12-28	WOS:A1995TA34300005
J	MANT, J; HICKS, N				MANT, J; HICKS, N			DETECTING DIFFERENCES IN QUALITY OF CARE - THE SENSITIVITY OF MEASURES OF PROCESS AND OUTCOME IN TREATING ACUTE MYOCARDIAL-INFARCTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; UNITS	The merits or otherwise of publishing hospital specific death rates are much debated. This article compares the relative sensitivity of measures of process and outcome to differences in quality of care for the hospital treatment of myocardial infarction. Aspects of hospital care that have a proved impact on mortality from myocardial infarction are identified, and the results from meta-analysis and large randomised controlled trials are used to estimate the impact that optimal use of these interventions would have on mortality in a typical district general hospital. Sample size calculations are then performed to determine how many years of data would be needed to detect significant differences between hospitals. A comparison is then made with the amount of data that would be needed to detect significant differences if information about process of care was being collected. Process measures based on the results of randomised controlled trials were found to be able to detect relevant differences between hospitals that would not be identified by comparing hospital specific mortality, which is an insensitive indicator of the quality of care.	OXFORDSHIRE HLTH, HEADINGTON, OXON, ENGLAND		MANT, J (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX2 6HE, ENGLAND.			Hicks, Nicholas/0000-0002-7214-9678				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V2, P57; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; CLARKE A, 1993, BRIT MED J, V307, P1436, DOI 10.1136/bmj.307.6917.1436; COLLINS R, 1995, LANCET, V345, P669; DEVITA C, 1994, LANCET, V343, P1115; DILLNER L, 1994, BRIT MED J, V309, P1599, DOI 10.1136/bmj.309.6969.1599a; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MCMURRAY J, 1994, BMJ-BRIT MED J, V309, P1343, DOI 10.1136/bmj.309.6965.1343; Moher M., 1995, EVIDENCE EFFECTIVENE; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; ROBINSON R, 1995, BRIT MED J, V310, P755, DOI 10.1136/bmj.310.6982.755; ROWAN KM, 1993, BRIT MED J, V307, P977, DOI 10.1136/bmj.307.6910.977; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; Sheldon T A, 1993, Qual Health Care, V2, P149, DOI 10.1136/qshc.2.3.149; 1995, ASSESSING OPTIONS CO; 1992, LANCET, V239, P753; 1993, LANCET, V341, P1183	21	221	222	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	1995	311	7008					793	796		10.1136/bmj.311.7008.793	http://dx.doi.org/10.1136/bmj.311.7008.793			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580444	Green Published			2022-12-28	WOS:A1995RX10700026
J	KORNAU, HC; SCHENKER, LT; KENNEDY, MB; SEEBURG, PH				KORNAU, HC; SCHENKER, LT; KENNEDY, MB; SEEBURG, PH			DOMAIN INTERACTION BETWEEN NMDA RECEPTOR SUBUNITS AND THE POSTSYNAPTIC DENSITY PROTEIN PSD-95	SCIENCE			English	Article							AMINO-ACID RECEPTORS; TUMOR SUPPRESSOR GENE; SPINAL-CORD NEURONS; HIPPOCAMPAL-NEURONS; MOLECULAR-CLONING; DROSOPHILA; SYSTEM; ANTAGONISTS; EXPRESSION; AGONISTS	The N-methyl-D-aspartate (NMDA) receptor subserves synaptic glutamate-induced transmission and plasticity in central neurons. The yeast two-hybrid system was used to show that the cytoplasmic tails of NMDA receptor subunits interact with a prominent postsynaptic density protein PSD-95. The second PDZ domain in PSD-95 binds to the seven-amino acid, COOH-terminal domain containing the terminal tSXV motif (where S is serine, X is any amino acid, and V is valine) common to NR2 subunits and certain NR1 splice forms. Transcripts encoding PSD-95 are expressed in a pattern similar to that of NMDA receptors, and the NR2B subunit co-localizes with PSD-95 in cultured rat hippocampal neurons. The interaction of these proteins may affect the plasticity of excitatory synapses.	UNIV HEIDELBERG,CTR MOLEC BIOL,D-69120 HEIDELBERG,GERMANY; CALTECH,DIV BIOL,PASADENA,CA 91125	Ruprecht Karls University Heidelberg; California Institute of Technology				Kennedy, Mary/0000-0003-1369-0525	NINDS NIH HHS [NS-28710] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028710] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BOURNE HR, 1993, NEURON S, V10, P65; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; ISHII T, 1992, J BIOL CHEM, V268, P2836; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KENNEDY MB, 1994, ANNU REV BIOCHEM, V63, P571, DOI 10.1146/annurev.biochem.63.1.571; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUTSUWADA T, 1993, NATURE, V358, P36; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LAURIE DJ, UNPUB; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MULLER M, 1994, J NEUROSCI, V15, P2354; NOVAK L, 1984, NATURE, V307, P462; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	45	1538	1587	1	79	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1737	1740		10.1126/science.7569905	http://dx.doi.org/10.1126/science.7569905			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569905				2022-12-28	WOS:A1995RV94800043
J	GODFRAY, HCJ				GODFRAY, HCJ			EVOLUTIONARY-THEORY OF PARENT-OFFSPRING CONFLICT	NATURE			English	Review							EGRET SIBLING AGGRESSION; BROOD REDUCTION; CLUTCH SIZE; HANDICAP PRINCIPLE; OBLIGATE SIBLICIDE; ALTRICIAL BIRDS; MODELS; INVESTMENT; FOOD; COMPETITION	Natural selection can act in different ways on genes expressed in parents and their young, giving rise to parent-offspring conflict. The way ire which this genetic conflict manifests itself at the behavioural level is unclear, and there has been widespread dissatisfaction that the theory has provided few testable predictions. A recent shift in emphasis from models that define the possible extent of conflict to those that predict its resolution offers greater hope of a testable theory of parent-offspring conflict.	UNIV LONDON IMPERIAL COLL SCI & TECHNOL,NERC,CTR POPULAT BIOL,ASCOT SL5 7PY,BERKS,ENGLAND	Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	GODFRAY, HCJ (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL,DEPT BIOL,SILWOOD PK,ASCOT SL5 7PY,BERKS,ENGLAND.							Alexander R.D., 1974, Annual Rev Ecol Syst, V5, P325, DOI 10.1146/annurev.es.05.110174.001545; ANDERSON DJ, 1990, EVOLUTION, V44, P2069, DOI 10.1111/j.1558-5646.1990.tb04312.x; ANDERSON DJ, 1990, AM NAT, V135, P334, DOI 10.1086/285049; BATESON P, 1994, TRENDS ECOL EVOL, V9, P399, DOI 10.1016/0169-5347(94)90066-3; BOOMSMA JJ, 1989, AM NAT, V133, P517, DOI 10.1086/284933; BOURKE AFG, 1988, Q REV BIOL, V83, P291; CLARK CW, 1990, EVOL ECOL, V4, P312, DOI 10.1007/BF02270930; Clutton-Brock T. H., 1991, EVOLUTION PARENTAL C; CLUTTONBROCK TH, 1995, NATURE, V373, P209, DOI 10.1038/373209a0; Dawkins Richard, 1976, SELFISH GENE; DICKINS DW, 1987, J THEOR BIOL, V125, P301, DOI 10.1016/S0022-5193(87)80061-9; Dorward D.F., 1962, IBIS LOND 1859, V103 B, P174, DOI [10.1111/j.1474-919X.1962.tb07244.x, DOI 10.1111/J.1474-919X.1962.TB07244.X]; DRUMMOND H, 1986, BEHAV ECOL SOCIOBIOL, V19, P365, DOI 10.1007/BF00295710; EMLEN ST, 1992, NATURE, V356, P331, DOI 10.1038/356331a0; ESHEL I, 1991, AM NAT, V137, P167, DOI 10.1086/285152; ESHEL I, 1991, AM NAT, V138, P954, DOI 10.1086/285262; ESHEL I, 1994, AM NAT, V143, P987, DOI 10.1086/285645; FELDMAN MW, 1982, AM NAT, V119, P285, DOI 10.1086/283909; FORBES LS, 1991, OIKOS, V62, P325, DOI 10.2307/3545497; FORBES LS, 1993, AM NAT, V142, P82, DOI 10.1086/285530; FORBES LS, 1990, J THEOR BIOL, V147, P345, DOI 10.1016/S0022-5193(05)80492-8; GODFRAY H C J, 1991, Philosophical Transactions of the Royal Society of London B Biological Sciences, V332, P67, DOI 10.1098/rstb.1991.0034; GODFRAY HC, IN PRESS J AM NAT; GODFRAY HCJ, 1987, AM NAT, V129, P221, DOI 10.1086/284632; GODFRAY HCJ, 1990, J THEOR BIOL, V145, P163, DOI 10.1016/S0022-5193(05)80122-5; GODFRAY HCJ, 1992, ANIM BEHAV, V43, P473, DOI 10.1016/S0003-3472(05)80106-X; GODFRAY HCJ, 1991, NATURE, V352, P328, DOI 10.1038/352328a0; GRAFEN A, 1990, J THEOR BIOL, V144, P473, DOI 10.1016/S0022-5193(05)80087-6; GRAFEN A, 1990, J THEOR BIOL, V144, P517, DOI 10.1016/S0022-5193(05)80088-8; HAIG D, 1993, Q REV BIOL, V68, P495, DOI 10.1086/418300; HAIG D, 1992, SEMIN DEV BIOL, V3, P153; HAIG D, 1995, CELL, V64, P1045; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HARPER AB, 1986, AM NAT, V128, P99, DOI 10.1086/284542; HASKELL D, 1994, P ROY SOC B-BIOL SCI, V257, P161, DOI 10.1098/rspb.1994.0110; JOHNSTONE RA, 1993, ANIM BEHAV, V46, P759, DOI 10.1006/anbe.1993.1253; JOHNSTONE RA, 1994, NATURE, V372, P172, DOI 10.1038/372172a0; KOSLOWSKI J, 1989, EVOLUTION, V43, P1369; LACK D, 1947, IBIS, V89, P302, DOI 10.1111/j.1474-919X.1947.tb04155.x; LACK D, 1954, NATURAL REGULATION A; LAZERUS J, 1986, ANIM BEHAV, V34, P1791; LUNDBERG S, 1994, J THEOR BIOL; MACNAIR MR, 1978, ANIM BEHAV, V26, P111, DOI 10.1016/0003-3472(78)90010-6; MACNAIR MR, 1979, ANIM BEHAV, V27, P1202, DOI 10.1016/0003-3472(79)90067-8; MAGRATH RD, 1990, BIOL REV, V65, P587, DOI 10.1111/j.1469-185X.1990.tb01239.x; Mangel M., 1988, DYNAMIC MODELING BEH; MOCK DW, 1987, BEHAV ECOL SOCIOBIOL, V20, P247, DOI 10.1007/BF00292177; MOCK DW, 1986, EVOLUTION, V40, P459, DOI 10.1111/j.1558-5646.1986.tb00499.x; MOCK DW, 1992, TRENDS ECOL EVOL, V7, P409, DOI 10.1016/0169-5347(92)90022-4; MOCK DW, 1987, ECOLOGY, V68, P1760, DOI 10.2307/1939867; MOCK DW, 1990, AM SCI, V78, P438; MOCK DW, 1991, AM NAT, V138, P1015, DOI 10.1086/285265; MOCK DW, IN PRESS EVOLUTION S; Mock DW, 1984, INFANTICIDE COMP EVO, P3; NONACS P, 1986, Q REV BIOL, V61, P1, DOI 10.1086/414723; OCONNOR RJ, 1978, ANIM BEHAV, V26, P79, DOI 10.1016/0003-3472(78)90008-8; Parker GA, 1987, EVOL ECOL, V1, P161, DOI 10.1007/BF02067398; PARKER GA, 1985, ANIM BEHAV, V33, P519, DOI 10.1016/S0003-3472(85)80075-0; PARKER GA, 1978, ANIM BEHAV, V26, P97, DOI 10.1016/0003-3472(78)90009-X; PARKER GA, 1989, AM NAT, V133, P846, DOI 10.1086/284956; PARKER GA, 1979, ANIM BEHAV, V27, P1210, DOI 10.1016/0003-3472(79)90068-X; PIJANOWSKI BC, 1992, AM NAT, V139, P1270, DOI 10.1086/285386; POLIS GA, 1981, ANNU REV ECOL SYST, V12, P225, DOI 10.1146/annurev.es.12.110181.001301; Queller D. C., 1989, Oxford Surveys in Evolutionary Biology, V6, P73; REDONDO T, 1992, IBIS, V134, P180, DOI 10.1111/j.1474-919X.1992.tb08395.x; ROITBERG BD, 1993, AM NAT, V142, P443, DOI 10.1086/285548; ROSENHEIM JA, 1993, AM NAT, V141, P90, DOI 10.1086/285462; RYDEN O, 1980, Z TIERPSYCHOL, V53, P209; SHAANKER RU, 1988, ANNU REV ECOL SYST, V19, P177, DOI 10.1146/annurev.es.19.110188.001141; SIMMONS R, 1988, IBIS, V130, P339, DOI 10.1111/j.1474-919X.1988.tb00992.x; SJERPS M, 1994, EVOL ECOL, V8, P269, DOI 10.1007/BF01238278; SMITH HG, 1991, BEHAV ECOL SOCIOBIOL, V29, P307, DOI 10.1007/BF00163989; Stamps J. A., 1980, SOCIOBIOLOGY NATURE, P589; STAMPS JA, 1978, BEHAV ECOL SOCIOBIOL, V3, P367; STINSON CH, 1979, EVOLUTION, V33, P1219, DOI 10.1111/j.1558-5646.1979.tb04775.x; TEMME DH, 1987, J THEOR BIOL, V126, P137, DOI 10.1016/S0022-5193(87)80225-4; TOKUDA H, 1994, J THEOR BIOL, V170, P145, DOI 10.1006/jtbi.1994.1174; TRIVERS RL, 1976, SCIENCE, V191, P249, DOI 10.1126/science.1108197; TRIVERS RL, 1974, AM ZOOL, V14, P249; YAMAMURA N, 1992, EVOLUTION, V46, P1236, DOI 10.1111/j.1558-5646.1992.tb00633.x; Zahavi A., 1977, P253; ZAHAVI A, 1975, J THEOR BIOL, V67, P603; [No title captured]	83	334	339	1	159	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					133	138		10.1038/376133a0	http://dx.doi.org/10.1038/376133a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603563				2022-12-28	WOS:A1995RJ02800050
J	GU, XN; SPITZER, NC				GU, XN; SPITZER, NC			DISTINCT ASPECTS OF NEURONAL DIFFERENTIATION ENCODED BY FREQUENCY OF SPONTANEOUS CA2+ TRANSIENTS	NATURE			English	Article							C-FOS TRANSCRIPTION; PROTEIN-KINASE-C; SPINAL NEURONS; ELECTRICAL-ACTIVITY; SIGNALING PATHWAYS; SENSORY NEURONS; CALCIUM; MIGRATION; CHANNELS; CULTURE	STIMULATION of transient increases in intracellular calcium (Ca-i(2+)) activates protein kinases(1-3), regulates transcription(4-9) and influences motility and morphology Developing neurons generate spontaneous Ca-i(2+) transients, but their role in directing neuronal differentiation and the way in which they encode information are unknown. Acre we image Ca2+ in spinal neurons throughout an extended period of early development, and find that two types of spontaneous events, spikes and waves, are expressed at distinct frequencies. Neuronal differentiation is altered when they are eliminated by preventing Ca2+ influx. Reimposing different frequency patterns of Ca2+ elevation demonstrates that natural spike activity is sufficient to promote normal neurotransmitter expression and channel maturation, whereas wave activity is sufficient to regulate neurite extension. Suppression of spontaneous Ca2+ elevations by BAPTA loaded intracellularly indicates that they are also necessary for differentiation. Ca2+ transients appear to encode information in their frequency, like action potentials, although they are 10(4) times longer in duration and less frequent, and implement an intrinsic development programme.	UNIV CALIF SAN DIEGO, CTR GENET MOLEC, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	GU, XN (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.			Spitzer, Nicholas/0000-0002-3523-1103				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BIXBY JL, 1984, DEV BIOL, V106, P89, DOI 10.1016/0012-1606(84)90065-4; BRAHA O, 1993, J NEUROSCI, V13, P1839; CLINE HT, 1991, NEURON, V6, P259, DOI 10.1016/0896-6273(91)90361-3; COHAN CS, 1986, SCIENCE, V232, P1638, DOI 10.1126/science.3715470; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DESARMENIEN MG, 1991, NEURON, V7, P797, DOI 10.1016/0896-6273(91)90282-5; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FATATIS A, 1992, GLIA, V5, P95, DOI 10.1002/glia.440050203; FIELDS RD, 1990, J NEUROSCI, V10, P2950; FLUCHER BE, 1993, CELL MOTIL CYTOSKEL, V25, P143, DOI 10.1002/cm.970250204; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GU XN, 1994, J NEUROSCI, V14, P6325; HOLLIDAY J, 1991, NEURON, V7, P787, DOI 10.1016/0896-6273(91)90281-4; HOLLIDAY J, 1990, DEV BIOL, V141, P13, DOI 10.1016/0012-1606(90)90098-4; KOCSIS JD, 1994, J NEUROBIOL, V25, P252, DOI 10.1002/neu.480250306; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; LEREA LS, 1993, NEURON, V10, P31, DOI 10.1016/0896-6273(93)90239-N; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RINK TJ, 1989, TRENDS NEUROSCI, V12, P43, DOI 10.1016/0166-2236(89)90133-1; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHENG HZ, 1993, J NEUROSCI RES, V35, P459, DOI 10.1002/jnr.490350502; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SPITZER NC, 1993, J COMP NEUROL, V337, P168, DOI 10.1002/cne.903370111; TURRIGIANO G, 1994, SCIENCE, V264, P974, DOI 10.1126/science.8178157; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379	30	462	469	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	1995	375	6534					784	787		10.1038/375784a0	http://dx.doi.org/10.1038/375784a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596410				2022-12-28	WOS:A1995RF98900077
J	CAMPBELL, MJ; JULIOUS, SA; ALTMAN, DG				CAMPBELL, MJ; JULIOUS, SA; ALTMAN, DG			ESTIMATING SAMPLE SIZES FOR BINARY, ORDERED CATEGORICAL, AND CONTINUOUS OUTCOMES IN 2 GROUP COMPARISONS	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; CONFIDENCE-INTERVALS; POWER; DESIGN	Sample size calculations are now mandatory for many research protocols, but the ones useful in common situations are not all easily accessible. This paper outlines the ways of calculating sample sizes in two group studies for binary, ordered categorical, and continuous outcomes. Formulas and worked examples are given. Maximum power is usually achieved by having equal numbers in the two groups. However, this is not always possible and calculations for unequal group sizes are given.	IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	CAMPBELL, MJ (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHALL SO16 6YD,MIDDX,ENGLAND.							BORENSTEIN M, 1994, J CLIN EPIDEMIOL, V47, P1277, DOI 10.1016/0895-4356(94)90133-3; BURNAND B, 1990, J CLIN EPIDEMIOL, V43, P1273, DOI 10.1016/0895-4356(90)90093-5; CONOVER W. J, 1980, PRACTICAL NONPARAMET; DALY LE, 1991, BRIT MED J, V302, P333, DOI 10.1136/bmj.302.6772.333; DAY SJ, 1991, STAT MED, V10, P33, DOI 10.1002/sim.4780100109; DILETTI E, 1991, INT J CLIN PHARM TH, V29, P1; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; Drummond M, 1993, Health Econ, V2, P205, DOI 10.1002/hec.4730020303; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; FAYERS PM, 1995, BRIT J CANCER, V72, P1, DOI 10.1038/bjc.1995.268; FLOREY CD, 1993, BRIT MED J, V306, P1181, DOI 10.1136/bmj.306.6886.1181; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GARDNER MJ, 1986, BRIT MED J, V292, P810, DOI 10.1136/bmj.292.6523.810; GODFREY KM, 1993, BRIT MED J, V307, P405, DOI 10.1136/bmj.307.6901.405; GOLDSTEIN R, 1989, AM STAT, V43, P253, DOI 10.2307/2685373; GORE SM, 1982, STATISTICS PRACTICE; KINMONTH AL, 1992, BRIT MED J, V305, P1134, DOI 10.1136/bmj.305.6862.1134; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; LEHR R, 1992, STAT MED, V11, P1099, DOI 10.1002/sim.4780110811; MACHIN D, 1987, STATISTICAL TABLES D; MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122; NAYLOR CD, 1994, J CLIN EPIDEMIOL, V47, P787, DOI 10.1016/0895-4356(94)90176-7; PINOL A, 1995, SAMPLE; RAHLFS V, 1987, N HDB; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527; TOVEY SJ, 1993, BRIT MED J, V307, P987, DOI 10.1136/bmj.307.6910.987; WHITEHEAD J, 1993, STAT MED, V12, P2257, DOI 10.1002/sim.4780122404; Woodward M., 1992, STATISTICIAN, V41, P185	28	339	343	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 28	1995	311	7013					1145	1148		10.1136/bmj.311.7013.1145	http://dx.doi.org/10.1136/bmj.311.7013.1145			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580713	Green Published			2022-12-28	WOS:A1995TC46600023
J	TAFURI, A; ALFERINK, J; MOLLER, P; HAMMERLING, GJ; ARNOLD, B				TAFURI, A; ALFERINK, J; MOLLER, P; HAMMERLING, GJ; ARNOLD, B			T-CELL AWARENESS OF PATERNAL ALLOANTIGENS DURING PREGNANCY	SCIENCE			English	Article							DIFFERENTIAL EXPRESSION; ALPHA-CHAINS; MICE; TOLERANCE; RECEPTOR; PLACENTA; ANTIGEN; IMMUNE; GRAFT	During pregnancy a semiallogeneic fetus survives despite the presence of maternal T cells specific for paternally inherited histocompatibility antigens. A mouse transgenic for a T cell receptor recognizing the major histocompatibility (MHC) antigen H-2K(b) was used to follow the fate of T cells reactive to paternal alloantigens. In contrast to syngeneic and third-party allogeneic pregnancies, mice bearing a Kb-positive conceptus had reduced numbers of Kb-reactive T cells and accepted K-b-positive tumor grafts. T cell phenotype and responsiveness were restored after delivery. Thus, during pregnancy maternal T cells acquire a transient state of tolerance specific for paternal alloantigens.	DEUTSCH KREBSFORSCHUNGSZENTRUM,TUMOR IMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,INST PATHOL,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Tafuri, Agostino/AAC-2186-2019	Tafuri, Agostino/0000-0001-7911-9263; alferink, judith/0000-0002-3251-6584				ABRAMSKY O, 1984, PROG CLIN BIOL RES, V12, P695; ALFERIINK B, 1995, INT IMMUNOL, V7, P331; CHAOUAT G, 1993, IMMUNOLOGY PREGNANCY, P1; CLARK DA, 1991, CRIT REV IMMUNOL, V11, P215; CLARK DA, 1990, J IMMUNOL, V144, P3008; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DELASSUS S, 1994, J IMMUNOL, V152, P2411; FABRIS N, 1977, CLIN EXP IMMUNOL, V28, P306; GILL TJI, 1984, CRIT REV IMMUNOL, V5, P201; GUIMEZANES A, COMMUNICATION; HEATH WR, 1993, J EXP MED, V178, P1807, DOI 10.1084/jem.178.5.1807; HEDLEY ML, 1989, J IMMUNOL, V142, P4046; HERRERAGONZALEZ NE, 1993, DEV COMP IMMUNOL, V17, P1, DOI 10.1016/0145-305X(93)90011-E; HETHERINGTON CM, 1990, IMMUNOLOGY, V71, P449; LIMMER A, UNPUB; NICKLIN S, 1982, CLIN EXP IMMUNOL, V49, P135; OHEARN M, 1981, TRANSPLANTATION, V32, P389, DOI 10.1097/00007890-198111000-00009; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; PARVIN M, 1992, MICROBIOL IMMUNOL, V36, P77; PAVIA CS, 1979, J IMMUNOL, V123, P2194; PHILIP PJM, 1982, IMMUNOL LETT, V4, P175, DOI 10.1016/0165-2478(82)90032-3; PRIBYL TM, 1993, P NATL ACAD SCI USA, V90, P10695, DOI 10.1073/pnas.90.22.10695; RAGHUPATHY R, 1981, J IMMUNOL, V127, P2074; RAMSDELL F, 1992, SCIENCE, V257, P1130, DOI 10.1126/science.257.5073.1130; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SIMMONS RL, 1962, ANN NY ACAD SCI, V99, P717, DOI 10.1111/j.1749-6632.1962.tb45356.x; VARNER MW, 1991, SEMIN PERINATOL, V15, P238; VOISIN GA, 1994, FOLIA BIOL-PRAGUE, V40, P505; WAITES GT, 1987, CLIN EXP IMMUNOL, V67, P467; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	33	444	474	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					630	633		10.1126/science.270.5236.630	http://dx.doi.org/10.1126/science.270.5236.630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570020				2022-12-28	WOS:A1995TB55700039
J	FRASER, CM; GOCAYNE, JD; WHITE, O; ADAMS, MD; CLAYTON, RA; FLEISCHMANN, RD; BULT, CJ; KERLAVAGE, AR; SUTTON, G; KELLEY, JM; FRITCHMAN, JL; WEIDMAN, JF; SMALL, KV; SANDUSKY, M; FUHRMANN, J; NGUYEN, D; UTTERBACK, TR; SAUDEK, DM; PHILLIPS, CA; MERRICK, JM; TOMB, JF; DOUGHERTY, BA; BOTT, KF; HU, PC; LUCIER, TS; PETERSON, SN; SMITH, HO; HUTCHISON, CA; VENTER, JC				FRASER, CM; GOCAYNE, JD; WHITE, O; ADAMS, MD; CLAYTON, RA; FLEISCHMANN, RD; BULT, CJ; KERLAVAGE, AR; SUTTON, G; KELLEY, JM; FRITCHMAN, JL; WEIDMAN, JF; SMALL, KV; SANDUSKY, M; FUHRMANN, J; NGUYEN, D; UTTERBACK, TR; SAUDEK, DM; PHILLIPS, CA; MERRICK, JM; TOMB, JF; DOUGHERTY, BA; BOTT, KF; HU, PC; LUCIER, TS; PETERSON, SN; SMITH, HO; HUTCHISON, CA; VENTER, JC			THE MINIMAL GENE COMPLEMENT OF MYCOPLASMA-GENITALIUM	SCIENCE			English	Article							TRANSFER RNA-SYNTHETASE; DNA POLYMERASE-III; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; AMINO-ACIDS; PROTEIN; GENOME; PNEUMONIAE; CAPRICOLUM; SEQUENCE	The complete nucleotide sequence (580,070 base pairs) of the Mycoplasma genitalium genome, the smallest known genome of any free-living organism, has been determined by whole-genome random sequencing and assembly. A total of only 470 predicted coding regions were identified that include genes required for DNA replication, transcription and translation, DNA repair, cellular transport, and energy metabolism. Comparison of this genome to that of Haemophilus influenzae suggests that differences in genome content are reflected as profound differences in physiology and metabolic capacity between these two organisms.	SUNY BUFFALO, DEPT MICROBIOL, BUFFALO, NY 14214 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA; UNIV N CAROLINA, SCH MED, CHAPEL HILL, NC 27599 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	FRASER, CM (corresponding author), INST GENOM RES, 9712 MED CTR DR, ROCKVILLE, MD 20850 USA.			Kerlavage, Anthony/0000-0002-3954-9653; Fraser, Claire/0000-0003-1462-2428	NHLBI NIH HHS [HL19171] Funding Source: Medline; NIAID NIH HHS [AIO8998, AI33161] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL019171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI008998, R01AI033161, R37AI008998, R01AI008998] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY CC, 1994, J BACTERIOL, V176, P5814, DOI 10.1128/JB.176.18.5814-5819.1994; BASEMAN JB, 1988, J CLIN MICROBIOL, V26, P2266, DOI 10.1128/JCM.26.11.2266-2269.1988; BORK P, 1995, MOL MICROBIOL, V16, P955, DOI 10.1111/j.1365-2958.1995.tb02321.x; BORODOVSKY M, 1988, METHOD ENZYMOL, V164, P123; BRUTLAG DL, 1993, COMPUT CHEM, V17, P203, DOI 10.1016/0097-8485(93)85011-Z; COLLIER AM, 1992, ZENTRALBL BAKTERIO S, V20, P73; COLLIER DN, 1994, J BACTERIOL, V176, P4937, DOI 10.1128/jb.176.16.4937-4940.1994; COLMAN SD, 1990, MOL MICROBIOL, V4, P683, DOI 10.1111/j.1365-2958.1990.tb00638.x; DALLO SF, 1990, MICROB PATHOGENESIS, V8, P371, DOI 10.1016/0882-4010(90)90096-9; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GILSON E, 1988, EMBO J, V7, P3971, DOI 10.1002/j.1460-2075.1988.tb03284.x; GUTHRIE B, 1990, J BACTERIOL, V172, P5555, DOI 10.1128/jb.172.10.5555-5562.1990; HAYFLICK L, 1965, TEX REP BIOL MED, VS 23, P285; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HU PC, 1987, INFECT IMMUN, V55, P1126, DOI 10.1128/IAI.55.5.1126-1131.1987; INAMINE JM, 1989, GENE, V82, P259, DOI 10.1016/0378-1119(89)90051-6; JENSEN JS, 1993, GENITOURIN MED, V69, P265; KOMBERG A, 1992, DNA REPLICATION; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAPOINTE J, 1986, J BACTERIOL, V165, P88, DOI 10.1128/jb.165.1.88-93.1986; LUCIER TS, 1994, GENE, V150, P27, DOI 10.1016/0378-1119(94)90853-2; LUCIER TS, UNPUB; MAIDAK BL, 1994, NUCLEIC ACIDS RES, V22, P3485, DOI 10.1093/nar/22.17.3485; Maniloff Jack, 1992, P549; MARTIN N, 1976, J MOL BIOL, V101, P285, DOI 10.1016/0022-2836(76)90148-0; MARTIN NC, 1977, BIOCHEMISTRY-US, V16, P4672, DOI 10.1021/bi00640a022; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; MIYATA M, 1993, NUCLEIC ACIDS RES, V21, P4816, DOI 10.1093/nar/21.20.4816; OGASAWARA N, 1990, BACTERIAL CHROMOSOME, P287; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; PATERSON SN, 1995, IN PRESS P NATL ACAD; PETERSON SN, 1995, J BACTERIOL, V177, P3199, DOI 10.1128/jb.177.11.3199-3204.1995; PETERSON SN, 1993, J BACTERIOL, V175, P7918, DOI 10.1128/JB.175.24.7918-7930.1993; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PROULX M, 1983, J BIOL CHEM, V258, P753; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAZIN S, 1985, MICROBIOL REV, V49, P419, DOI 10.1128/MMBR.49.4.419-455.1985; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; ROGERS MJ, 1985, P NATL ACAD SCI USA, V82, P1160, DOI 10.1073/pnas.82.4.1160; ROGERS MJ, 1984, ISRAEL J MED SCI, V20, P768; SANJANWALA B, 1989, P NATL ACAD SCI USA, V86, P4421, DOI 10.1073/pnas.86.12.4421; SANJANWALA B, 1991, MOL GEN GENET, V226, P467, DOI 10.1007/BF00260660; SAWADA M, 1981, MOL GEN GENET, V182, P502, DOI 10.1007/BF00293942; SCHON A, 1988, BIOCHIMIE, V70, P391, DOI 10.1016/0300-9084(88)90212-X; SIMONEAU P, 1993, NUCLEIC ACIDS RES, V21, P4967, DOI 10.1093/nar/21.21.4967; STRAUCH MA, 1988, J BACTERIOL, V170, P916, DOI 10.1128/jb.170.2.916-920.1988; SU CJ, 1990, J BACTERIOL, V172, P4705, DOI 10.1128/jb.172.8.4705-4707.1990; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; TAYLORROBINSON D, 1994, LANCET, V13, P1066; TULLY JG, 1983, INT J SYST BACTERIOL, V33, P387, DOI 10.1099/00207713-33-2-387; UTTERBACK TR, 1995, GENOME SCI TECHNOL, V1, P1; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATERMAN MS, 1988, METHOD ENZYMOL, V164, P765; WEISBURG WG, 1989, J BACTERIOL, V171, P6455, DOI 10.1128/jb.171.12.6455-6467.1989; WILCOX M, 1969, EUR J BIOCHEM, V11, P405, DOI 10.1111/j.1432-1033.1969.tb00788.x; ZHU PP, 1994, PROTEIN SCI, V3, P2115, DOI 10.1002/pro.5560031125; ZHU PP, 1993, J BIOL CHEM, V268, P26531	59	2001	2615	3	165	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 20	1995	270	5235					397	403		10.1126/science.270.5235.397	http://dx.doi.org/10.1126/science.270.5235.397			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569993				2022-12-28	WOS:A1995TA37400030
J	HIBBS, ML; TARLINTON, DM; ARMES, J; GRAIL, D; HODGSON, G; MAGLITTO, R; STACKER, SA; DUNN, ARR				HIBBS, ML; TARLINTON, DM; ARMES, J; GRAIL, D; HODGSON, G; MAGLITTO, R; STACKER, SA; DUNN, ARR			MULTIPLE DEFECTS IN THE IMMUNE-SYSTEM OF LYN-DEFICIENT MICE, CULMINATING IN AUTOIMMUNE-DISEASE	CELL			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; AFFINITY IGE RECEPTOR; CELL ANTIGEN RECEPTOR; LYMPHOCYTES-B; SRC FAMILY; KINASES; IMMUNOGLOBULIN; STIMULATION; ASSOCIATION; ALPHA	Mice homozygous for a disruption at the Lyn locus display abnormalities associated with the B lymphocyte lineage and in mast cell function, Despite reduced numbers of recirculating B lymphocytes, Lyn(-/-) mice are immunoglobulin M (IgM) hyperglobulinemic. Immune responses to T-independent and T-dependent antigens are affected. Lyn(-/-) mice fail to mediate an allergic response to IgE cross-linking, indicating that activation of LYN plays an indispensable role in Fc epsilon RI signaling. Lyn(-/-) mice have circulating autoreactive antibodies, and many show severe glomerulonephritis caused by the deposition of IgG immune complexes in the kidney, a pathology reminiscent of systemic lupus erythematosus. Collectively, these results implicate LYN as having an indispensable role in immunoglobulin-mediated signaling, particularly in establishing B cell tolerance.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; AUSTIN HOSP,DEPT ANAT PATHOL,HEIDELBERG,VIC 3084,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	HIBBS, ML (corresponding author), ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA.		Hibbs, Margaret L/D-7013-2011; Armes, Jane/D-6396-2012	Hibbs, Margaret L/0000-0002-3751-6751; Armes, Jane/0000-0002-2215-0347; Stacker, Steven/0000-0003-4096-9273; Tarlinton, David/0000-0001-9928-686X	PHS HHS [A1-03958] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BELMONT JW, 1995, TRENDS GENET, V11, P112, DOI 10.1016/S0168-9525(00)89012-5; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CORCORAN LM, 1994, IMMUNITY, V1, P635, DOI 10.1016/1074-7613(94)90035-3; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DRAKE CG, 1992, CURR OPIN IMMUNOL, V4, P733, DOI 10.1016/0952-7915(92)90054-I; EISEMAN E, 1992, NATURE, V355, P78; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HANDYSIDE AH, 1989, ROUX ARCH DEV BIOL, V198, P8; HAYAKAWA K, 1983, J EXP MED, V157, P202, DOI 10.1084/jem.157.1.202; HIBBS ML, 1995, GENE, V156, P175, DOI 10.1016/0378-1119(95)00022-X; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; LALOR PA, 1992, EUR J IMMUNOL, V22, P3001, DOI 10.1002/eji.1830221136; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MOUNTZ J D, 1991, Current Opinion in Rheumatology, V3, P738, DOI 10.1097/00002281-199110000-00004; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; SMITH KGC, 1994, IMMUNITY, V1, P803, DOI 10.1016/S1074-7613(94)80022-7; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VARMUS HE, 1994, BLOOD, V83, P5; WECHSLER RJ, 1995, J IMMUNOL, V154, P3234; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	47	598	616	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					301	311		10.1016/0092-8674(95)90171-X	http://dx.doi.org/10.1016/0092-8674(95)90171-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585947	Bronze			2022-12-28	WOS:A1995TA96500016
J	SCHMIDT, R; WEST, J; LOVE, K; LENEHAN, Z; LISTER, C; THOMPSON, H; BOUCHEZ, D; DEAN, C				SCHMIDT, R; WEST, J; LOVE, K; LENEHAN, Z; LISTER, C; THOMPSON, H; BOUCHEZ, D; DEAN, C			PHYSICAL MAP AND ORGANIZATION OF ARABIDOPSIS-THALIANA CHROMOSOME-4	SCIENCE			English	Article							POLYMORPHISM LINKAGE MAP; REPEATED DNA-SEQUENCES; DISEASE RESISTANCE; YEAST; GENOME; GENES; LIBRARY; PROTEIN; CONSTRUCTION; CHROMATIN	A physical map of Arabidopsis thaliana chromosome 4 was constructed in yeast artificial chromosome clones and used to analyze the organization of the chromosome. Mapping of the nucleolar organizing region and the centromere integrated the physical and cytogenetic maps. Detailed comparison of physical with genetic distances showed that the frequency of recombination varied substantially, with relative hot and cold spots occurring along the whole chromosome. Eight repeated DNA sequence families were found in a complex arrangement across the centromeric region and nowhere else on the chromosome.	JOHN INNES CTR PLANT SCI RES, BIOTECHNOL & BIOL SCI RES COUNCIL, DEPT MOLEC GENET, NORWICH NR4 7UH, NORFOLK, ENGLAND; INRA, BIOL CELLULAIRE LAB, F-78026 VERSAILLES, FRANCE	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; INRAE; UDICE-French Research Universities; Universite Paris Saclay			Thompson, Helen L/E-7726-2017; Thompson, Henry J/K-7242-2012; Bouchez, David/B-7463-2019	Thompson, Helen L/0000-0003-4414-8018; Thompson, Henry J/0000-0002-3730-9322; Bouchez, David/0000-0003-3545-4339; Schmidt, Renate/0000-0002-8037-3581				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ALBINI SM, 1994, PLANT J, V5, P665, DOI 10.1111/j.1365-313X.1994.00665.x; BAUWENS S, 1991, CHROMOSOMA, V101, P41, DOI 10.1007/BF00360685; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; CAMPELL BR, 1992, GENE, V112, P225, DOI 10.1016/0378-1119(92)90380-8; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; COPENHAVER G, COMMUNICATION; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COUPLAND G, 1994, PLANT CELL, V6, P75; CREUSOT F, IN PRESS PLANT J; DEAN C, 1995, ANNU REV PLANT PHYS, V46, P395, DOI 10.1146/annurev.pp.46.060195.002143; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; GANAL MW, 1988, MOL GEN GENET, V213, P262, DOI 10.1007/BF00339590; GOODMAN H, GT148 DEP MOL BIOL; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HAAF T, 1992, CELL, V70, P681, DOI 10.1016/0092-8674(92)90436-G; HESLOPHARRISON JS, 1991, J CELL SCI, V100, P15; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; HUBEL A, 1994, PLANT MOL BIOL, V26, P353, DOI 10.1007/BF00039545; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KEITH B, 1991, P NATL ACAD SCI USA, V88, P8821, DOI 10.1073/pnas.88.19.8821; KIEDROWSKI S, 1992, EMBO J, V11, P4677, DOI 10.1002/j.1460-2075.1992.tb05572.x; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KORFHAGE U, 1994, PLANT CELL, V6, P695, DOI 10.1105/tpc.6.5.695; Kosambi D. D., 1944, ANN EUGENICS, V12, P172; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LAST RL, 1991, PLANT CELL, V3, P345, DOI 10.1105/tpc.3.4.345; LEPINIEC L, 1995, FEBS LETT, V364, P103, DOI 10.1016/0014-5793(95)00335-7; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LISTER C, UNPUB; Lui Y., UNPUB; MALUSZYNSKA J, 1991, PLANT J, V1, P159, DOI 10.1111/j.1365-313X.1991.00159.x; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; MCGRATH JM, 1993, THEOR APPL GENET, V86, P880, DOI 10.1007/BF00212616; Meyerowitz E. M., 1992, Methods in Arabidopsis research., P100; MEYEROWITZ EM, 1994, ARABIDOPSIS; MOORE G, 1991, GENOMICS, V10, P461, DOI 10.1016/0888-7543(91)90333-A; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PALME K, 1992, PLANT CELL, V4, P193, DOI 10.1105/tpc.4.2.193; PARKER JE, 1993, PLANT J, V4, P821, DOI 10.1046/j.1365-313X.1993.04050821.x; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; QUAEDVLIEG N, 1995, PLANT CELL, V7, P117, DOI 10.1105/tpc.7.1.117; SCHMIDT R, 1992, AUST J PLANT PHYSIOL, V19, P341, DOI 10.1071/PP9920341; SCHMIDT R, 1994, PLANT J, V5, P735, DOI 10.1111/j.1365-313X.1994.00735.x; SCHMIDT R, UNPUB; Schweizer D, 1987, ARABID INF SERV, V25, P27; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; TANKSLEY SD, 1992, GENETICS, V132, P1141; THOMPSON H, UNPUB; TOURMENTE S, 1994, NUCLEIC ACIDS RES, V22, P3317, DOI 10.1093/nar/22.16.3317; VANLIJSEBETTENS M, 1994, EMBO J, V13, P3378, DOI 10.1002/j.1460-2075.1994.tb06640.x; VONSCHAEWEN A, 1990, EMBO J, V9, P3033, DOI 10.1002/j.1460-2075.1990.tb07499.x; WALKER M, PLM117 U CAMBR DEP P; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9	60	175	188	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 20	1995	270	5235					480	483		10.1126/science.270.5235.480	http://dx.doi.org/10.1126/science.270.5235.480			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7570002				2022-12-28	WOS:A1995TA37400044
J	LAWRENCE, K; MCWHINNIE, D; GOODWIN, A; DOLL, H; GORDON, A; GRAY, A; BRITTON, J; COLLIN, J				LAWRENCE, K; MCWHINNIE, D; GOODWIN, A; DOLL, H; GORDON, A; GRAY, A; BRITTON, J; COLLIN, J			RANDOMIZED CONTROLLED TRIAL OF LAPAROSCOPIC VERSUS OPEN REPAIR OF INGUINAL-HERNIA - EARLY RESULTS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To establish the safety, short term outcome, and theatre costs of transabdominal laparoscopic repair of inguinal hernia performed as day surgery. Design-Randomised controlled trial. The control operation was the two layer modified Maloney dam. Setting-Teaching hospital and district general hospital. Subjects-125 men randomised to laparoscopic or open repair of inguinal hernia. Outcome measures-Morbidity postoperative pain and use of analgesics, quality of life, and theatre costs. Outcome was assessed by questionnaires administered to patients daily for 10 days and at six weeks postoperatively and by outpatient review at six weeks. Return to normal activity was assessed by questionnaire at three months. Results-One vascular complication (2%) occurred in the group that had open repair. Seven complications (12%) including vessel injury and early recurrence arose in the group that had laparoscopic repair (difference in complication rate 10% (95% confidence interval 4% to 18%; P=0.02). Pain scores and quality of life assessed by the short form 36 showed a significant benefit to the group that had laparoscopic repair in the early postoperative period. Return to normal activity was not significantly different between the two groups. Total theatre costs were higher in the group that had laparoscopic repair (mean cost for laparoscopic repair pound 850 (pound 622 to pound 1078); mean cost for open repair pound 268 (pound 245 to pound 292)). Conclusions-Because of the greater complication rate and higher theatre costs for laparoscopic repair and the patient outcome preferences expressed, the results of larger trials of clinical and cost effectiveness using recurrence as the primary outcome measure should be known before laparoscopic herniorrhaphy is widely adopted.	UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND; UNIV OXFORD,NUFFIELD DEPT SURG,OXFORD,ENGLAND; UNIV OXFORD,WOLFSON COLL,CTR SOCIOLEGAL STUDIES,OXFORD,ENGLAND; UNIV OXFORD,NUFFIELD DEPT ANAESTHET,OXFORD,ENGLAND	University of Oxford; University of Oxford; University of Oxford; University of Oxford								[Anonymous], 1980, CLASSIFICATION OCCUP; CAPOZZI JA, 1988, SURG GYNECOL OBSTET, V167, P124; KAVIC MS, 1993, SURG ENDOSC-ULTRAS, V7, P163, DOI 10.1007/BF00594099; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MALONEY GE, 1948, LANCET, V2, P45; MCMAHON AJ, 1994, LANCET, V343, P135, DOI 10.1016/S0140-6736(94)90932-6; MILROY SJ, 1994, BRIT MED J, V308, P199, DOI 10.1136/bmj.308.6922.199c; MORGAN M, 1991, ANN ROY COLL SURG, V73, P341; PHILIPP M, 1993, INT CLIN PSYCHOPHARM, V7, P149, DOI 10.1097/00004850-199300730-00005; RALPHS DNL, 1984, ANN R COLL SURG ENGL, V66, P382; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SHULMAN AG, 1992, AM SURGEON, V58, P255; STOKER D, 1994, LANCET, V343, P1243, DOI 10.1016/S0140-6736(94)92148-2; VITALE GC, 1991, AM J SURG, V161, P396, DOI 10.1016/0002-9610(91)90606-E; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WINCHESTER DJ, 1993, ARCH SURG-CHICAGO, V128, P781; 1990, HLTH POLICY, V16, P199; 1992, GUIDELINES DAY CASE	18	139	142	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					981	985						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580639				2022-12-28	WOS:A1995TA07900021
J	ERDELYI, M; MICHON, AM; GUICHET, A; GLOTZER, JB; EPHRUSSI, A				ERDELYI, M; MICHON, AM; GUICHET, A; GLOTZER, JB; EPHRUSSI, A			REQUIREMENT FOR DROSOPHILA CYTOPLASMIC TROPOMYOSIN IN OSKAR MESSENGER-RNA LOCALIZATION	NATURE			English	Article							MATERNAL MESSENGER-RNA; XENOPUS OOCYTES; CELL-FORMATION; GENE; MELANOGASTER; MICROTUBULES; ENCODES; DIFFERENTIATION; MICROFILAMENTS; PATTERN	THE localization of oskar (osk) RNA to the posterior pole of the developing fruit fly (Drosophila) oocyte induces the assembly of pole plasm, causing development of tbe abdomen and germ line(1,2). Failure to localize oskar RNA results in embryos that lack abdomen and germ cells. Conversely, mis-targeting of oskar RNA to the anterior of the oocyte causes formation of ectopic abdomen and germ cells at the anterior pole(3). Maternal mutants that have reduced pole plasm activity produce sterile adults with normal abdominal development, suggesting that germ cells are more sensitive than abdomen to defects in pole plasm assembly(4). Thus mutations in genes that reduce oskar RNA localization or activity can be recovered as viable sterile adults. In a screen for mutants defective in germ cell formation, we isolated nine alleles of the tropomyosin II gene(5). Here we show that mutations in tropomyosin II (TmII) virtually abolish oskar RNA localization to the posterior pole, suggesting an involvement of the actin network in oskar RNA localization.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Ephrussi, Anne/AAG-4075-2020; Ephrussi, Anne/ABD-4393-2021	Ephrussi, Anne/0000-0002-5061-4620				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; GUTZEIT H, 1986, ROUX ARCH DEV BIOL, V195, P173, DOI 10.1007/BF02439435; HALES KH, 1994, DEV BIOL, V165, P639, DOI 10.1006/dbio.1994.1282; HANKE PD, 1987, J BIOL CHEM, V262, P17370; HANKE PD, 1988, MOL CELL BIOL, V8, P3591, DOI 10.1128/MCB.8.9.3591; KARLIK CC, 1986, MOL CELL BIOL, V6, P1965, DOI 10.1128/MCB.6.6.1965; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; LANGFORD GM, 1995, CURR OPIN CELL BIOL, V7, P82, DOI 10.1016/0955-0674(95)80048-4; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; POKRYWKA NJ, 1994, DEV BIOL, V166, P210, DOI 10.1006/dbio.1994.1308; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; PONDEL MD, 1988, P NATL ACAD SCI USA, V85, P7612, DOI 10.1073/pnas.85.20.7612; SQUIRE JM, 1983, TRENDS NEUROL SCI, V66, P409; STELZER EHK, 1989, SCANNING IMAGINGS, V1028, P146; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; WIESCHAUS E, 1979, DEV BIOL, V68, P29, DOI 10.1016/0012-1606(79)90241-0; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	31	183	184	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					524	527		10.1038/377524a0	http://dx.doi.org/10.1038/377524a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566149				2022-12-28	WOS:A1995RZ33600061
J	STEPHENS, TW; BASINSKI, M; BRISTOW, PK; BUEVALLESKEY, JM; BURGETT, SG; CRAFT, L; HALE, J; HOFFMANN, J; HSIUNG, HM; KRIAUCIUNAS, A; MACKELLAR, W; ROSTECK, PR; SCHONER, B; SMITH, D; TINSLEY, FC; ZHANG, XY; HEIMAN, M				STEPHENS, TW; BASINSKI, M; BRISTOW, PK; BUEVALLESKEY, JM; BURGETT, SG; CRAFT, L; HALE, J; HOFFMANN, J; HSIUNG, HM; KRIAUCIUNAS, A; MACKELLAR, W; ROSTECK, PR; SCHONER, B; SMITH, D; TINSLEY, FC; ZHANG, XY; HEIMAN, M			THE ROLE OF NEUROPEPTIDE-Y IN THE ANTIOBESITY ACTION OF THE OBESE GENE-PRODUCT	NATURE			English	Article							AGENT; RATS	RECENTLY Zhang et al.(1) cloned a gene that is expressed only in adipose tissue of tbe mouse. The obese phenotype of the ob/ob mouse is linked to a mutation in the obese gene that results in expression of a truncated inactive protein. Human and rat homologues for this gene are known(1,2). Previous experiments(3,4) predict such a hormone to have a hypothalamic target. Hypothalamic neuropeptide Y stimulates food intake, decreases thermogenesis, and increases plasma insulin and corticosterone levels making it a potential target(5). Here we express the obese protein in Escherichia coli and find that it suppresses food intake and decreases body weight dramatically when administered to normal and ob/ob mice but not db/db (diabetic) mice, which are thought to lack the appropriate receptor. High-affinity binding was detected in the rat hypothalamus. One mechanism by which this protein regulated food intake and metabolism was inhibition of neuropeptide-Y synthesis and release.	ELI LILLY & CO,LILLY RES LABS,DIV TECHNOL CORE,INDIANAPOLIS,IN 46285	Eli Lilly	STEPHENS, TW (corresponding author), ELI LILLY & CO,LILLY RES LABS,DIV ENDOCRINE RES,INDIANAPOLIS,IN 46285, USA.							BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; CORDER R, 1988, LIFE SCI, V43, P1879, DOI 10.1016/S0024-3205(88)80005-5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HULSEY MG, 1992, PHYSIOL BEHAV, V52, P1141, DOI 10.1016/0031-9384(92)90473-F; KARAKASH C, 1977, AM J PHYSIOL, V232, pE286, DOI 10.1152/ajpendo.1977.232.3.E286; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/en.132.5.1939; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; [No title captured]	12	1419	1468	2	58	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					530	532		10.1038/377530a0	http://dx.doi.org/10.1038/377530a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566151				2022-12-28	WOS:A1995RZ33600063
J	GRIFFITH, LL; SHOCK, EL				GRIFFITH, LL; SHOCK, EL			A GEOCHEMICAL MODEL FOR THE FORMATION OF HYDROTHERMAL CARBONATES ON MARS	NATURE			English	Article							ICELAND; ORIGIN; REYKJANES; DEPOSITS; SYSTEMS	IT IS often argued(1-3) that substantially more carbon dioxide and water were degassed from the martian interior that can be found at present in the atmosphere, polar caps and regolith. Calculations have shown that atmospheric escape cannot account for all of the missing volatiles(4). Suggestions that carbon dioxide is stored as marine or lacustrine deposits(5), are challenged by Earth-based and spacecraft remote-sensing data(6,7). Moreover, recent modelling of the martian atmosphere suggests that rainfall or open bodies of water are in any case unlikely to have persisted for extended periods of time(8,9). Hydrothermal carbonates therefore provide a possible solution to this dilemma. Using an accessible terrestrial system (Iceland) as a guide to the underlying processes, and a host rock composition inferred from the least-altered martian meteorite(10), we present a geochemical model for the formation of carbonates in possible martian hydrothermal systems. Our results suggest that an extensive reservoir of carbonate minerals--equivalent to an atmospheric pressure of carbon dioxide of at least one bar--could have been sequestered beneath the surface by widespread hydrothermal activity in the martian past.			GRIFFITH, LL (corresponding author), WASHINGTON UNIV,MCDONNELL CTR SPACE SCI,DEPT EARTH & PLANETARY SCI,CAMPUS BOX 1169,ST LOUIS,MO 63130, USA.			Shock, Everett/0000-0002-4283-0163				ARNORSSON S, 1983, GEOCHIM COSMOCHIM AC, V47, P547, DOI 10.1016/0016-7037(83)90277-6; BLANEY DL, 1990, J GEOPHYS RES, V94, P10159; CARMICHAEL ISE, 1964, J PETROL, V5, P435, DOI 10.1093/petrology/5.3.435; CARR MH, 1986, ICARUS, V68, P187, DOI 10.1016/0019-1035(86)90019-9; EXLEY RA, 1982, J GEOPHYS RES, V87, P6547, DOI 10.1029/JB087iB08p06547; Fanale F.P., 1992, MARS, P1135; HABERLE RM, 1994, ICARUS, V109, P102, DOI 10.1006/icar.1994.1079; Helgeson HC, 1979, GEOCHEMISTRY HYDROTH, P568; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; LONKER SW, 1993, AM J SCI, V293, P605, DOI 10.2475/ajs.293.7.605; MEHEGAN JM, 1982, J GEOPHYS RES, V87, P6511, DOI 10.1029/JB087iB08p06511; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; NEDELL SS, 1987, ICARUS, V70, P409, DOI 10.1016/0019-1035(87)90086-8; NEWSOM HE, 1980, ICARUS, V44, P207, DOI 10.1016/0019-1035(80)90066-4; PALMASON G, 1974, ANNU REV EARTH PL SC, V2, P25, DOI 10.1146/annurev.ea.02.050174.000325; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P14595, DOI 10.1029/JB095iB09p14595; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; SHOCK EL, 1992, ORIGINS LIFE EVOL B, V22, P67, DOI 10.1007/BF01808019; Squyres S. W., 1992, MARS, P523; STOLPER E, 1979, GEOCHIM COSMOCHIM AC, V43, P1475, DOI 10.1016/0016-7037(79)90142-X; SVEINBJORNSDOTT.AE, 1986, CONTRIB MINERAL PET, V94, P99; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; VIERECK LG, 1982, J GEOPHYS RES, V87, P6459, DOI 10.1029/JB087iB08p06459; WALTER MR, 1993, ICARUS, V101, P129, DOI 10.1006/icar.1993.1011; WOLERY TJ, 1986, UCRLMA110662 LAWR LI	27	59	60	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					406	408		10.1038/377406a0	http://dx.doi.org/10.1038/377406a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566116				2022-12-28	WOS:A1995RY19000041
J	HUA, J; CHANG, C; SUN, Q; MEYEROWITZ, EM				HUA, J; CHANG, C; SUN, Q; MEYEROWITZ, EM			ETHYLENE INSENSITIVITY CONFERRED BY ARABIDOPSIS ERS GENE	SCIENCE			English	Article							2-COMPONENT REGULATORS; PLANT TRANSFORMATION; SIGNAL-TRANSDUCTION; THALIANA; PATHWAY	ERS (ethylene response sensor), a gene in the Arabidopsis thaliana ethylene hormone-response pathway, was uncovered by cross-hybridization with the Arabidopsis ETR1 gene. The deduced ERS protein has sequence similarity with the amino-terminal domain and putative histidine protein kinase domain of ETR1, but it does not have a receiver domain as found in ETR1. A missense mutation identical to the dominant etr1-4 mutation was introduced into the ERS gene. The altered ERS gene conferred dominant ethylene insensitivity to wild-type Arabidopsis. Double-mutant analysis indicates that ERS acts upstream of the CTR1 protein kinase gene in the ethylene-response pathway.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Meyerowitz, Elliot M/A-7118-2009					Abeles F, 1992, ETHYLENE PLANT BIOL; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; FRALEY RT, 1985, BIO-TECHNOL, V3, P629, DOI 10.1038/nbt0785-629; FUNKE G. L., 1938, BIOLOGISCH JAARBOEK, V5, P335; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HARPHAM NVJ, 1991, ANN BOT-LONDON, V68, P55, DOI 10.1093/oxfordjournals.aob.a088218; HUA J, UNPUB; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MARTON L, 1991, PLANT CELL REP, V10, P235, DOI 10.1007/BF00232565; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; ROMAN G, 1995, GENETICS, V139, P1393; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; VANANDEL OM, 1978, J EXP BOT, V29, P638; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N	22	457	496	1	54	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1712	1714		10.1126/science.7569898	http://dx.doi.org/10.1126/science.7569898			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569898				2022-12-28	WOS:A1995RV94800035
J	REINISCH, KM; CHEN, L; VERDINE, GL; LIPSCOMB, WN				REINISCH, KM; CHEN, L; VERDINE, GL; LIPSCOMB, WN			THE CRYSTAL-STRUCTURE OF HAEIII METHYLTRANSFERASE COVALENTLY COMPLEXED TO DNA - AN EXTRAHELICAL CYTOSINE AND REARRANGED BASE-PAIRING	CELL			English	Article							TARGET-RECOGNIZING DOMAINS; MACROMOLECULAR CRYSTALLOGRAPHY; CPG ISLAND; FRAGILE-X; PROTEIN; REFINEMENT; MECHANISM; METHYLATION; BINDING; SITE	Many organisms expand the information content of their genome through enzymatic methylation of cytosine residues. Here we report the 2.8 Angstrom crystal structure of a bacterial DNA (cytosine-5)-methyltransferase (DCMtase), M. HaeIII, bound covalently to DNA. In this complex, the substrate cytosine is extruded from the DNA helix and inserted into the active site of the enzyme, as has been observed for another DCMtase, M. HhaI. The DNA is bound in a cleft between the two domains of the protein and is distorted from the characteristic B-form conformation at its recognition sequence. A comparison of structures shows a variation in the mode of DNA recognition: M. HaeIII differs from M. HhaI in that the remaining bases in its recognition sequence undergo an extensive rearrangement in their pairing. In this process, the bases are unstacked, and a gap 8 Angstrom long opens in the DNA.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University	REINISCH, KM (corresponding author), HARVARD UNIV,GIBBS CHEM LAB,CAMBRIDGE,MA 02138, USA.		chen, Lin/A-3392-2008	chen, Lin/0000-0003-4798-6199	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044853, R01GM006920, R37GM006920] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 44853, GM06920] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams R. L. P., 1985, MOL BIOL DNA METHYLA; BALGANESH TS, 1987, EMBO J, V6, P3543, DOI 10.1002/j.1460-2075.1987.tb02681.x; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BEHRENS B, 1987, EMBO J, V6, P1137, DOI 10.1002/j.1460-2075.1987.tb04869.x; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CHEN L, 1993, J AM CHEM SOC, V115, P5318, DOI 10.1021/ja00065a063; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; CUNIASSE P, 1989, BIOCHEMISTRY-US, V28, P2018, DOI 10.1021/bi00431a009; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1985, METHOD ENZYMOL, V115, P359; JOSHUATOR L, 1992, J MOL BIOL, V225, P397, DOI 10.1016/0022-2836(92)90929-E; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1991, NUCLEIC ACIDS RES, V19, P6183, DOI 10.1093/nar/19.22.6183; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KURIYAN J, 1986, J MOL BIOL, V190, P227, DOI 10.1016/0022-2836(86)90295-0; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P801; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MI S, 1992, NUCLEIC ACIDS RES, V20, P4811, DOI 10.1093/nar/20.18.4811; MILLER M, 1988, NATURE, V334, P85, DOI 10.1038/334085a0; MOE JG, 1992, BIOCHEMISTRY-US, V31, P8421, DOI 10.1021/bi00151a005; NICHOLIS RD, 1995, SEMIN DEV BIOL, V3, P139; NOLLING J, 1992, J BACTERIOL, V174, P5719; OSTERMAN DG, 1988, BIOCHEMISTRY-US, V27, P5204, DOI 10.1021/bi00414a039; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REINISCH K, 1995, THESIS HARVARD U CAM; REINISCH KM, 1994, J MOL BIOL, V238, P626, DOI 10.1006/jmbi.1994.1319; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RODGERS DW, 1994, STRUCTURE, V2, P1135, DOI 10.1016/S0969-2126(94)00116-2; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SCHHUMACHER MA, 1994, SCIENCE, V266, P763; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TIMSIT Y, 1991, NATURE, V354, P167, DOI 10.1038/354167a0; TRAUTNER TA, 1988, NUCLEIC ACIDS RES, V16, P6649, DOI 10.1093/nar/16.14.6649; VERDINE GL, 1994, CELL, V76, P197, DOI 10.1016/0092-8674(94)90326-3; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x; WINKLER FK, 1994, STRUCTURE, V2, P79, DOI 10.1016/S0969-2126(00)00009-5; WU JC, 1987, J BIOL CHEM, V262, P4778; YANG W, 1995, IN PRESS CELL, V82	64	366	370	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					143	153		10.1016/0092-8674(95)90060-8	http://dx.doi.org/10.1016/0092-8674(95)90060-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606780	Bronze			2022-12-28	WOS:A1995RK42400017
J	CHEN, YH; INOBE, J; MARKS, R; GONNELLA, P; KUCHROO, VK; WEINER, HL				CHEN, YH; INOBE, J; MARKS, R; GONNELLA, P; KUCHROO, VK; WEINER, HL			PERIPHERAL DELETION OF ANTIGEN-REACTIVE T-CELLS IN ORAL TOLERANCE	NATURE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; COLLAGEN-INDUCED ARTHRITIS; MYELIN BASIC-PROTEIN; II COLLAGEN; SUPPRESSION; INDUCTION; MICE	ORAL administration of antigen is used to induce antigen-specific peripheral immune tolerance(1,2). As well as preventing systemic immune responses to ingested proteins(3), oral tolerance to autoantigens has also been used to suppress autoimmune diseases in animals(4-10) and humans(11,12). Both active suppression and clonal anergy are suggested to be mechanisms of oral tolerance, depending on the dose of antigen fed(13,14). Here we report that oral antigen can delete antigen-reactive T cells in Peyer's patches, in mice transgenic for the ovalbumin-specific T-cell receptor genes, The deletion was mediated by apoptosis, and was dependent on dosage and frequency of feeding. At lower doses deletion was not observed; instead there was induction of antigen-specific cells that produced transforming growth factor (TGF)beta and interleukin (IL)-4 and IL-10 cytokines. At higher doses, both Th1 and Th2 cells were deleted following their initial activation, whereas cells which secrete TGF-beta were resistant to deletion. These findings demonstrate that orally administered antigen can induce tolerance not only by active suppression and clonal anergy	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Chen, Youhai/AAJ-4031-2021					BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COFFMAN R, 1989, J EXP MED, V144, P3411; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; HARDIN JA, 1992, J IMMUNOL METHODS, V154, P99, DOI 10.1016/0022-1759(92)90217-H; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; HUANG L, 1994, INT IMMUNOL, V6, P533, DOI 10.1093/intimm/6.4.533; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAGLERANDERSON C, 1986, P NATL ACAD SCI USA, V83, P7443, DOI 10.1073/pnas.83.19.7443; NOGUCHI PD, 1994, CURRENT PROTOCOLS IM; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; ROCHA B, 1992, SCIENCE, V251, P1225; SANTOS LMB, 1994, CELL IMMUNOL, V157, P439, DOI 10.1006/cimm.1994.1240; THOMPSON HSG, 1986, CLIN EXP IMMUNOL, V64, P581; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Wells HG, 1911, J INFECT DIS, V8, P147; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; XUAMANO JC, 1992, INT IMMUNOL, V4, P433, DOI 10.1093/intimm/4.4.433; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	25	698	722	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					177	180		10.1038/376177a0	http://dx.doi.org/10.1038/376177a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603570				2022-12-28	WOS:A1995RJ02800062
J	RATHMELL, JC; COOKE, MP; HO, WY; GREIN, J; TOWNSEND, SE; DAVIS, MM; GOODNOW, CC				RATHMELL, JC; COOKE, MP; HO, WY; GREIN, J; TOWNSEND, SE; DAVIS, MM; GOODNOW, CC			CD95 (FAS) DEPENDENT ELIMINATION OF SELF-REACTIVE B-CELLS UPON INTERACTION WITH CD4(+) T-CELLS	NATURE			English	Article							LYMPHOCYTES-B; LPR/LPR MICE; SYSTEMIC AUTOIMMUNITY; LPR; APOPTOSIS; ANTIGEN; DEFECT; MOUSE; INDUCTION; TOLERANCE	THE recessive mouse mutations lpr and gld create deficiencies in an interacting pair of cell surface molecules, CD95 (Fas/APO-1) and Fas-ligand (FasL), respectively(1-3), resulting in autoantibody production resembling human systemic lupus erythematosus(4). The mechanisms of self-tolerance affected by deficiency in either molecule are not established, but CD95 deficiency both in B cells and in CD4(+) T cells recognizing major histocompatibility complex (MHC) class II molecules is required for autoimmunity in lpr mice(5-8). Here we track the outcome of in vivo interactions between B cells and CD4(+) T cells that recognize a transgene-encoded autoantigen, hen egg lysozyme (HEL), using cells from mice transgenic for immunoglobulin and T-cell receptor (TCR) genes. B cells that had not previously encountered HEL autoantigen (naive cells) were triggered into proliferation and antibody-production upon interaction with antigen and HEL-specific CD4(+) T cells. By contrast, B cells that had been chronically exposed to HEL during their development and carried desensitized surface immunoglobulin (sIg) antigen receptors(9) (anergic cells) did not produce antibody but instead were eliminated in the presence of HEL-specific CD4(+) T cells. CD95-deficient anergic B cells, however, were not eliminated by CD4(+) T cells and were triggered to proliferate. These findings identify a novel regulatory step for eliminating autoreactive B cells that seems unique in its dependence on CD95.	STANFORD UNIV,SCH MED,PROGRAM IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University; Stanford University	RATHMELL, JC (corresponding author), STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305, USA.		Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155; Davis, Mark/0000-0001-6868-657X				BOSSU P, 1993, J IMMUNOL, V151, P7233; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; FULCHER DA, 1994, J EXP MED, V179, P125, DOI 10.1084/jem.179.1.125; GILLETTEFERGUSO.I, 1994, EUR J IMMUNOL, V4, P1181; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HO WY, 1994, J EXP MED, V179, P1539, DOI 10.1084/jem.179.5.1539; JEVNIKAR AM, 1994, J EXP MED, V179, P1137, DOI 10.1084/jem.179.4.1137; KANOST D, 1994, EUR J IMMUNOL, V24, P1186, DOI 10.1002/eji.1830240527; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MATSUZAWA A, 1990, J EXP MED, V171, P519, DOI 10.1084/jem.171.2.519; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEMAZEE D, 1991, J IMMUNOL, V147, P2536; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; RATHMELL JC, 1994, J IMMUNOL, V153, P2831; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SOBEL ES, 1991, J EXP MED, V173, P1441, DOI 10.1084/jem.173.6.1441; SOBEL ES, 1993, J IMMUNOL, V150, P4160; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WESTON KM, 1988, J IMMUNOL, V141, P1941; ZHOU T, 1991, J IMMUNOL, V147, P466; ZHOU T, 1992, J EXP MED, V176, P1063, DOI 10.1084/jem.176.4.1063	29	411	415	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					181	184		10.1038/376181a0	http://dx.doi.org/10.1038/376181a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603571				2022-12-28	WOS:A1995RJ02800063
J	PAPADOPOULOS, N; NICOLAIDES, NC; LIU, B; PARSONS, R; LENGAUER, C; PALOMBO, F; DARRIGO, A; MARKOWITZ, S; WILLSON, JKV; KINZLER, KW; JIRICNY, J; VOGELSTEIN, B				PAPADOPOULOS, N; NICOLAIDES, NC; LIU, B; PARSONS, R; LENGAUER, C; PALOMBO, F; DARRIGO, A; MARKOWITZ, S; WILLSON, JKV; KINZLER, KW; JIRICNY, J; VOGELSTEIN, B			MUTATIONS OF GTBP IN GENETICALLY UNSTABLE CELLS	SCIENCE			English	Article							ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; CLONES	The molecular defects responsible for tumor cell hypermutability in humans have not yet been fully identified. Here the gene encoding a G/T mismatch-binding protein (GTBP) was localized to within 1 megabase of the related hMSH2 gene on chromosome 2 and was found to be inactivated in three hypermutable cell lines. Unlike cells defective in other mismatch repair genes, which display widespread alterations in mononucleotide, dinucleotide, and other simple repeated sequences, the GTBP-deficient cells showed alterations primarily in mononucleotide tracts. These results suggest that GTBP is important for maintaining the integrity of the human genome and document molecular defects accounting for variation in mutator phenotype.	HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; IST RIC BIOL MOLEC P ANGELETTI,I-00040 POMEZIA,ITALY; UNIV HOSP CLEVELAND,IRELAND CANC CTR,DEPT MED,CLEVELAND,OH; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; University Hospitals of Cleveland; Case Western Reserve University			Papadopoulos, Nickolas/K-7272-2012	Parsons, Ramon/0000-0002-6656-3514; Palombo, Fabio/0000-0003-0473-4901	NCI NIH HHS [CA62924, CA47527, CA35494] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924, R01CA047527, R37CA035494, R01CA035494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BREUKEL C, 1991, NUCLEIC ACIDS RES, V19, P5804, DOI 10.1093/nar/19.20.5804; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GYAPAY G, 1995, NAT GENET, V7, P246; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LENGAUER C, 1992, CANCER RES, V52, P2590; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; MARRO G, IN PRESS J NAT CANCE; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, UNPUB; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	27	477	497	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1915	1917		10.1126/science.7604266	http://dx.doi.org/10.1126/science.7604266			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604266				2022-12-28	WOS:A1995RF99000043
J	ROBERTSON, MP; MILLER, SL				ROBERTSON, MP; MILLER, SL			AN EFFICIENT PREBIOTIC SYNTHESIS OF CYTOSINE AND URACIL	NATURE			English	Article							CHEMICAL EVOLUTION; PYRIMIDINES; ACIDS	In contrast to the purines(1-3), the routes that have been proposed for the prebiotic synthesis of pyrimidines from simple precursors give only low yields. Cytosine can be synthesized from cyanoacetylene and cyanate(4,5); the former precursor is produced from a spark discharge in a CH4/N-2 mixture(4,5) and is an abundant interstellar molecule(6). But this reaction requires relatively high concentrations of cyanate (>0.1 M), which are unlikely to occur in aqueous media as cyanate is hydrolysed rapidly to CO2 and NH3. An alternative route that has been explored(7) is the reaction of cyanoacetaldehyde (formed by hydrolysis of cyanoacetylene(8)) with urea. But at low concentrations of urea, this reaction produces no detectable quantities of cytosine(7). Here we show that in concentrated urea solution-such as might have been found in an evaporating lagoon or in pools on drying beaches on the early Earth-cyanoacetaldehyde reacts to form cytosine in yields of 30-50%, from which uracil can be formed by hydrolysis. These reactions provide a plausible route to the pyrimidine bases required in the RNA world(9).			ROBERTSON, MP (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093, USA.							CHITTENDEN GJF, 1976, NATURE, V263, P350, DOI 10.1038/263350a0; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; FERRIS JP, 1974, J MOL EVOL, V3, P301, DOI 10.1007/BF01796045; FERRIS JP, 1968, J MOL BIOL, V33, P693, DOI 10.1016/0022-2836(68)90314-8; FERRIS JP, 1978, J MOL EVOL, V11, P293, DOI 10.1007/BF01733839; FERRIS JP, 1970, J AM CHEM SOC, V92, P6598, DOI 10.1021/ja00725a036; GARRETT ER, 1972, J PHARM SCI, V61, P1052, DOI 10.1002/jps.2600610703; KOLB VM, 1994, J MOL EVOL, V38, P549; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; LOHRMANN R, 1972, J MOL EVOL, V1, P263, DOI 10.1007/BF01660246; LOWE CU, 1963, NATURE, V199, P219, DOI 10.1038/199219a0; Miller S. L., 1974, ORIGINS LIFE EARTH; MILLER SL, 1955, J AM CHEM SOC, V77, P2351, DOI 10.1021/ja01614a001; ORO J, 1960, BIOCHEM BIOPH RES CO, V2, P407, DOI 10.1016/0006-291X(60)90138-8; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; SANCHEZ R, 1966, SCIENCE, V153, P72, DOI 10.1126/science.153.3731.72; SANCHEZ RA, 1966, SCIENCE, V154, P784, DOI 10.1126/science.154.3750.784; SANCHEZ RA, 1968, J MOL BIOL, V38, P121, DOI 10.1016/0022-2836(68)90132-0; SHAPIRO R, 1966, BIOCHEMISTRY-US, V5, P2358, DOI 10.1021/bi00871a026; Shnidman L, 1932, J PHYS CHEM-US, V36, P1232, DOI 10.1021/j150334a013; STOKS PG, 1981, GEOCHIM COSMOCHIM AC, V45, P563, DOI 10.1016/0016-7037(81)90189-7; STOKS PG, 1979, NATURE, V282, P709, DOI 10.1038/282709a0; TESTELAND RF, 1993, RNA WORLD; TURNER BE, 1971, ASTROPHYS J, V163, pL35, DOI 10.1086/180662; WACHTERSHAUSER G, 1988, P NATL ACAD SCI USA, V85, P1134, DOI 10.1073/pnas.85.4.1134	25	186	190	1	59	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					772	774		10.1038/375772a0	http://dx.doi.org/10.1038/375772a0			3	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596408				2022-12-28	WOS:A1995RF98900073
J	COTE, R; BATTISTA, RN; ABRAHAMOWICZ, M; LANGLOIS, Y; BOURQUE, F; MACKEY, A; LECLERC, J; MCILRAITH, D; WADUP, L; BERGER, L; GODIN, M; LEBRUN, LH; MARCHAND, L; LEWIS, R; BOGOUSSLAVSKY, J; BUCHAN, A; SHUAIB, A; ESDAILE, J; GROVER, S; BRET, P; JOSEPH, S; DUBERGER, R; HU, XP; WANG, SS; BLACK, D; LAJOIE, V; LAMARRE, M; LECOURS, B; DELEON, AP; ROEDERER, G; ROY, S; BOURQUE, L; DESROCHERS, MP; DANEAULT, N; FONTAINE, S; CARLTON, J; MILLER, N; LAJEUNESSE, A; SIMARD, D; ROBERGE, C				COTE, R; BATTISTA, RN; ABRAHAMOWICZ, M; LANGLOIS, Y; BOURQUE, F; MACKEY, A; LECLERC, J; MCILRAITH, D; WADUP, L; BERGER, L; GODIN, M; LEBRUN, LH; MARCHAND, L; LEWIS, R; BOGOUSSLAVSKY, J; BUCHAN, A; SHUAIB, A; ESDAILE, J; GROVER, S; BRET, P; JOSEPH, S; DUBERGER, R; HU, XP; WANG, SS; BLACK, D; LAJOIE, V; LAMARRE, M; LECOURS, B; DELEON, AP; ROEDERER, G; ROY, S; BOURQUE, L; DESROCHERS, MP; DANEAULT, N; FONTAINE, S; CARLTON, J; MILLER, N; LAJEUNESSE, A; SIMARD, D; ROBERGE, C			LACK OF EFFECT OF ASPIRIN IN ASYMPTOMATIC PATIENTS WITH CAROTID BRUITS AND SUBSTANTIAL CAROTID NARROWING	ANNALS OF INTERNAL MEDICINE			English	Article						ASPIRIN; CAROTID ARTERY DISEASES; CAROTID STENOSIS; ISCHEMIA; ULTRASONOGRAPHY	NATURAL-HISTORY; ARTERY DISEASE; CEREBROVASCULAR-DISEASE; STENOSIS; STROKE; ENDARTERECTOMY; PREVALENCE; POPULATION	Objective: To determine the effectiveness of aspirin in preventing ischemic ev Design: Double-blind, placebo-controlled trial. Setting: University-affiliate hospitals. Patients: 372 neurologically asymptomatic patients with carotid stenosis of 50% or more in at least one artery as determined by luminal diameter reduction on duplex ultrasonography. Intervention: Patients were randomly assigned to receive either enteric coated aspirin, 325 mg/d, or identically appearing placebo. Duration of therapy was 2.0 years for the aspirin recipients and 1.9 years for the placebo recipients. Outcome Measures: Patients were scheduled for a clinical examination every 6 months for assessment of the occurrence of any clinical event in the composite end point, which consisted of transient ischemic attack, stroke, myocardial infarction, unstable angina, or death. Results: At baseline, the 188 patients receiving aspirin and the 184 patients receiving placebo had similar demographic, ultrasonographic, and laboratory characteristics. The median duration of follow-up was 2.3 years. The annual rate of all ischemic events and death from any cause was 12.3% for the placebo group and 11.0% for the aspirin group (P = 0.61). The Cox proportional hazards analysis yielded an adjusted hazard ratio (aspirin-placebo) of 0.99 (95% CI, 0.67 to 1.46; P = 0.95). The annual rates for vascular events only were 11% for the placebo group and 10.7% for the aspirin group (P = 0.99). The multivariate analysis yielded a hazard ratio of 1.08 (CI, 0.72 to 1.62; P = 0.71). Conclusion: Aspirin did not have a significant longterm protective effect in asymptomatic patients with high-grade (greater than or equal to 50%) carotid stenosis.	HOP HOTEL DIEU, MONTREAL, PQ H2W 1T8, CANADA; HOP ST LUC, MONTREAL, PQ H2X 1P1, CANADA; CHARLES LEMOYNE HOSP, GREENFIELD PK, PQ, CANADA; MONTREAL GEN HOSP, DIV CLIN EPIDEMIOL, MONTREAL, PQ H3G 1A4, CANADA; JEWISH GEN HOSP, DIV VASC SURG, MONTREAL, PQ H3T 1E2, CANADA; HOP ENFANTS JESUS, DIV NEUROL, QUEBEC CITY, PQ G1J 1Z4, CANADA	Universite de Montreal; Universite de Montreal; University of Sherbrooke; McGill University; McGill University; Laval University	COTE, R (corresponding author), MONTREAL GEN HOSP, DIV NEUROL, 1650 CEDAR AVE, MONTREAL, PQ H3G 1A4, CANADA.		Buchan, Alastair M/B-9095-2009	Buchan, Alastair M/0000-0002-2918-5200; Abrahamowicz, Michal/0000-0002-3172-3952				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AUTRET A, 1987, LANCET, V1, P888; BARNETT HJM, 1993, NEW ENGL J MED, V328, P276, DOI 10.1056/NEJM199301283280410; BOCK RW, 1993, J VASC SURG, V17, P160, DOI 10.1016/0741-5214(93)90020-M; BOGOUSSLAVSKY J, 1986, NEUROLOGY, V36, P861, DOI 10.1212/WNL.36.6.861; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; COX DR, 1972, J R STAT SOC B, V34, P187; DYKEN ML, 1992, STROKE, V23, P1395, DOI 10.1161/01.STR.23.10.1395; ESDAILE JM, 1994, ARTHRITIS RHEUM, V37, P359, DOI 10.1002/art.1780370309; GENT M, 1988, STROKE, V19, P1203, DOI 10.1161/01.STR.19.10.1203; HELGASON CM, 1994, STROKE, V25, P2331, DOI 10.1161/01.STR.25.12.2331; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HENNERICI M, 1987, BRAIN, V110, P777, DOI 10.1093/brain/110.3.777; HENNERICI M, 1981, STROKE, V12, P750, DOI 10.1161/01.STR.12.6.750; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; HOBSON RW, 1993, J VASC SURG, V17, P257, DOI 10.1016/0741-5214(93)90411-E; JONAS S, 1990, ARCH NEUROL-CHICAGO, V47, P1352, DOI 10.1001/archneur.1990.00530120098017; KIEFFER G, 1989, THROMB HAEMOSTASIS, V62, P411; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lefkowitz D, 1991, Clin Geriatr Med, V7, P417; LOVE BB, 1992, STROKE, V23, P939, DOI 10.1161/01.STR.23.7.939; MACKEY A, 1993, NEUROLOGY, V43, pA351; MAHONEY F I, 1965, Md State Med J, V14, P61; MEISSNER I, 1987, JAMA-J AM MED ASSOC, V258, P2704; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PRATI P, 1992, STROKE, V23, P1705, DOI 10.1161/01.STR.23.12.1705; PUJIA A, 1992, STROKE, V23, P818, DOI 10.1161/01.STR.23.6.818; SLUD E, 1982, J AM STAT ASSOC, V77, P862, DOI 10.2307/2287319; SOLOMON DH, 1994, CURR OPIN NEUROL, V7, P48, DOI 10.1097/00019052-199402000-00009; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707; WILTERDINK JL, 1992, ARCH NEUROL-CHICAGO, V49, P857, DOI 10.1001/archneur.1992.00530320089016; ZUCKER DM, 1990, ANN STAT, V18, P329, DOI 10.1214/aos/1176347503; 1990, STROKE, V21, P169; 1991, ARCH NEUROL-CHICAGO, V48, P683	39	105	108	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					649	+		10.7326/0003-4819-123-9-199511010-00002	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574219				2022-12-28	WOS:A1995TA69600002
J	HARDING, SP; BROADBENT, DM; NEOH, C; WHITE, MC; VORA, J				HARDING, SP; BROADBENT, DM; NEOH, C; WHITE, MC; VORA, J			SENSITIVITY AND SPECIFICITY OF PHOTOGRAPHY AND DIRECT OPHTHALMOSCOPY IN SCREENING FOR SIGHT THREATENING EYE DISEASE - THE LIVERPOOL DIABETIC EYE STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYDRIATIC RETINAL PHOTOGRAPHY; PRIMARY CARE PHYSICIANS; FUNDUS PHOTOGRAPHY; RETINOPATHY; PREVENTION; BLINDNESS; DIAGNOSIS; CAMERA	Objective-To evaluate different methods for community based screening for sight threatening diabetic eye disease. Design-Prospective study. Setting-Mobile screening unit visiting inner city community clinics; hospital assessment clinic (tertiary centre). Subjects Subjects-395 diabetic patients registered with four general practices in an inner city location. Interventions-Community based photography with mydriasis and direct ophthalmoscopy through dilated pupils by an experienced ophthalmologist, both compared with reference standard of slit lamp biomicroscopy by a consultant specialist in medical retinal disease. Main outcome measures-Sensitivity and specificity of screening method and prevalence of sight threatening diabetic eye disease (moderate preproliferative retinopathy, circinate maculopathy, exudate within 1 disc diameter of fixation, other diabetes related eye disease). Results-358 subjects underwent photography, 326 attended hospital clinic for ophthalmoscopy, and six were ungradable on photographs and biomicroscopy, leaving 320 for analysis. Of these 295 (91%) attended clinic within four months of photography. Sensitivity of detection of eye disease by photography was 89% (95% confidence interval 80% to 98%), significantly better than for direct ophthalmoscopy (65% (51% to 79%)). Analysis of patients with false negative results indicated possible improvement of photographic sensitivity to 93% by addition of stereoscopic macular pair photographs. Specificity of detection of sight threatening eye disease was 86% (82% to 90%) for photography and 97% (95% to 99%) for direct ophthalmoscopy. Conclusions-Since high sensitivity is essential for an effective screening programme, a photographic method should be considered as preferred option in national, community based screening programmes. Even in the hands of an experienced ophthalmologist, direct ophthalmoscopy is limited by weaknesses inherent to the instrument.	ROYAL LIVERPOOL UNIV HOSP, DEPT ENDOCRINOL & DIABET, LIVERPOOL L7 8XP, MERSEYSIDE, ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	HARDING, SP (corresponding author), ROYAL LIVERPOOL UNIV HOSP, ST PAULS EYE UNIT, LIVERPOOL L7 8XP, MERSEYSIDE, ENGLAND.			Harding, Simon/0000-0003-4676-1158				ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552; [Anonymous], 1987, Int Ophthalmol Clin, V27, P265; [Anonymous], 1991, Ophthalmology, V98, P786; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; AWH CC, 1993, INVEST OPHTH VIS SCI, V34, P713; BURNSCOX CJ, 1985, BMJ-BRIT MED J, V290, P1052, DOI 10.1136/bmj.290.6474.1052; BUXTON MJ, 1991, DIABETIC MED, V8, P371, DOI 10.1111/j.1464-5491.1991.tb01612.x; DCCT Res Grp, 1987, ARCH OPHTHALMOL-CHIC, V105, P1344; ELLINGFORD A, 1992, Journal of Audiovisual Media in Medicine, V15, P104, DOI 10.3109/17453059209018361; FINLAY R, 1991, HLTH TRENDS, V23, P104; FORREST RD, 1987, DIABETES RES CLIN EX, V5, P39; Foulds W S, 1983, Health Bull (Edinb), V41, P318; GEHRS KM, 1993, INVEST OPHTH VIS SCI, V34, P1182; JACOB J, 1995, DIABETIC MED, V12, P419, DOI 10.1111/j.1464-5491.1995.tb00506.x; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; JONES D, 1988, BRIT MED J, V296, P1029, DOI 10.1136/bmj.296.6628.1029; KINYOUN JL, 1992, INVEST OPHTH VIS SCI, V33, P1888; KLEIN R, 1985, OPHTHALMOLOGY, V92, P485; Kleinstein R N, 1987, J Am Optom Assoc, V58, P879; KOHNER EM, 1984, DIABETOLOGIA, V26, P173; KOHNER EM, 1991, BRIT MED J, V302, P176, DOI 10.1136/bmj.302.6769.176; LEE CM, 1991, OPHTHALMOLOGY, V98, P1594; LEESE GP, 1993, BRIT MED J, V306, P187, DOI 10.1136/bmj.306.6871.187; MOHAN R, 1988, BRIT J OPHTHALMOL, V72, P841, DOI 10.1136/bjo.72.11.841; MOSS SE, 1985, OPHTHALMOLOGY, V92, P62; ROGERS D, 1990, DIABETIC MED, V7, P165, DOI 10.1111/j.1464-5491.1990.tb01353.x; ROHAN TE, 1989, BMJ-BRIT MED J, V299, P1198, DOI 10.1136/bmj.299.6709.1198; RYDER REJ, 1985, BRIT MED J, V291, P1256, DOI 10.1136/bmj.291.6504.1256; RYDER REJ, 1985, PRACTICAL DIABETES, V2, P34; RYDER REJ, 1995, BRIT MED J, V311, P207; SAVOLAINEN EA, 1982, DIABETOLOGIA, V23, P138, DOI 10.1007/BF01271176; SCHACHAT AP, 1993, ARCH OPHTHALMOL-CHIC, V111, P1064, DOI 10.1001/archopht.1993.01090080060019; SPARROW JM, 1993, EYE, V7, P158, DOI 10.1038/eye.1993.34; SUSSMAN EJ, 1982, JAMA-J AM MED ASSOC, V247, P3231, DOI 10.1001/jama.247.23.3231; TAYLOR R, 1990, BRIT MED J, V301, P1243, DOI 10.1136/bmj.301.6763.1243; WAREHAM N, 1991, DIABETIC MED, V8, P607, DOI 10.1111/j.1464-5491.1991.tb01665.x; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; WILLIAMS R, 1986, BRIT MED J, V293, P1140, DOI 10.1136/bmj.293.6555.1140; 1991, BRIT MED J, V302, P174; 1991, DIABETIC MED, V8, P263; 1988, CAUSES BLINDNESS PAR	41	197	202	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	1995	311	7013					1131	1135		10.1136/bmj.311.7013.1131	http://dx.doi.org/10.1136/bmj.311.7013.1131			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580708	Green Published			2022-12-28	WOS:A1995TC46600017
J	KUMAR, M; QIU, D; SPIRO, TG; RAGSDALE, SW				KUMAR, M; QIU, D; SPIRO, TG; RAGSDALE, SW			A METHYLNICKEL INTERMEDIATE IN A BIMETALLIC MECHANISM OF ACETYL-COENZYME-A SYNTHESIS BY ANAEROBIC-BACTERIA	SCIENCE			English	Article							CARBON-MONOXIDE DEHYDROGENASE; IRON-SULFUR PROTEIN; TRANSFORM RAMAN-SPECTROSCOPY; CO-C BOND; CLOSTRIDIUM-THERMOACETICUM; A SYNTHESIS; PHOTOLABILE ORGANOCOBALT-B12; MODEL COMPOUNDS; BINDING-SITE; M REDUCTASE	Resonance Raman (RR) spectroscopy was used to identify a methylnickel adduct (nu(Ni-C) = 422 wave numbers) of carbon monoxide dehydrogenase (CODH) from Clostridium thermoaceticum. Formed at a nickel/iron-sulfur cluster on CODH called center A, the methylnickel species is the precursor of the methyl group of acetyl-coenzyme A in an anaerobic pathway of carbon monoxide or carbon dioxide fixation. Rapid kinetic and RR studies demonstrated that methylation of nickel occurs by heterolysis of the methyl-cobalt bond (nu(Co-C) = 429 wave numbers) of a methylated corrinoid/iron-sulfur protein. In combination with the earlier finding of an iron-carbonyl adduct at center A, defection of the methylnickel intermediate establishes a bimetallic mechanism for acetyl-coenzyme A synthesis.	UNIV NEBRASKA,BEADLE CTR,DEPT BIOCHEM,LINCOLN,NE 68588; PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544	University of Nebraska System; University of Nebraska Lincoln; Princeton University					NIGMS NIH HHS [GM39451, GM 13498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM039451, R01GM013498, R29GM039451, R37GM013498, R01GM039451] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABIOR B M, 1988, Biofactors, V1, P21; BABIOR BM, 1990, MOL MECHANISMS BIOOR, P244; BERKESSEL A, 1991, BIOORG CHEM, V19, P101, DOI 10.1016/0045-2068(91)90047-S; DIEKERT G, 1980, FEMS MICROBIOL LETT, V7, P187, DOI 10.1111/j.1574-6941.1980.tb01622.x; DIEKERT GB, 1979, ARCH MICROBIOL, V122, P117, DOI 10.1007/BF00408054; ERVIN AM, 1984, SPECTROSC LETT, V17, P603, DOI 10.1080/00387018408072642; FAN CL, 1991, BIOCHEMISTRY-US, V30, P431, DOI 10.1021/bi00216a018; FORSTER D, 1976, J AM CHEM SOC, V98, P846, DOI 10.1021/ja00419a041; FORSTER D, 1979, ADV ORGANOMET CHEM, V17, P255; FRIEDMANN HC, 1990, FEMS MICROBIOL LETT, V87, P339; GORST CM, 1991, J BIOL CHEM, V266, P20687; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; HEGEDUS LS, 1985, CHEM METAL CARBON BO, V2, P401, DOI DOI 10.1002/9780470771747.CH6; KUMAR M, 1993, J AM CHEM SOC, V115, P11646, DOI 10.1021/ja00077a093; KUMAR M, 1992, J AM CHEM SOC, V114, P8713, DOI 10.1021/ja00048a062; LINDAHL PA, 1990, J BIOL CHEM, V265, P3880; LINDAHL PA, 1990, J BIOL CHEM, V265, P3873; LJUNGDAHL LG, 1986, ANNU REV MICROBIOL, V40, P415, DOI 10.1146/annurev.mi.40.100186.002215; LU WP, 1990, J BIOL CHEM, V265, P3124; MARTIN BD, 1990, J AM CHEM SOC, V112, P2419, DOI 10.1021/ja00162a053; MARTIN BD, 1985, J AM CHEM SOC, V107, P7952, DOI 10.1021/ja00312a025; MATTHEWS R G, 1990, Biofactors, V2, P147; NIE SM, 1990, J AM CHEM SOC, V112, P6084, DOI 10.1021/ja00172a026; NIE SM, 1990, J CHEM SOC CHEM COMM, P770, DOI 10.1039/c39900000770; PEZACKA E, 1988, J BIOL CHEM, V263, P16000; PRATT JM, 1982, VITAMIN B12, P325; QIU D, 1994, SCIENCE, V264, P817, DOI 10.1126/science.8171334; QIU D, 1995, J AM CHEM SOC, V117, P2653, DOI 10.1021/ja00114a032; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; RAGSDALE SW, 1991, CRIT REV BIOCHEM MOL, V26, P261, DOI 10.3109/10409239109114070; RAGSDALE SW, 1985, P NATL ACAD SCI USA, V82, P6811, DOI 10.1073/pnas.82.20.6811; RAGSDALE SW, 1983, J BIOL CHEM, V258, P2364; RAM MS, 1995, J AM CHEM SOC, V117, P2365, DOI 10.1021/ja00113a032; RAYBUCK SA, 1988, BIOCHEMISTRY-US, V27, P7698, DOI 10.1021/bi00420a019; ROBERTS JR, 1992, J BACTERIOL, V174, P4667, DOI 10.1128/JB.174.14.4667-4676.1992; ROSEN RP, 1984, ORGANOMETALLICS, V3, P846, DOI 10.1021/om00084a004; SHIN WS, 1992, BIOCHEMISTRY-US, V31, P12870, DOI 10.1021/bi00166a023; Sunderman FW, 1985, NICKEL HUMAN ENV; TTUCCI GC, 1995, J AM CHEM SOC, V117, P6489; WIRT MD, 1995, BIOCHEMISTRY-US, V34, P5269, DOI 10.1021/bi00015a042; WIRT MD, 1992, BIOPHYS J, V63, P412, DOI 10.1016/S0006-3495(92)81605-3; WIRT MD, 1993, J AM CHEM SOC, V115, P2146, DOI 10.1021/ja00059a007	42	59	60	3	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					628	630		10.1126/science.270.5236.628	http://dx.doi.org/10.1126/science.270.5236.628			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570019				2022-12-28	WOS:A1995TB55700038
J	BLAESE, RM; CULVER, KW; MILLER, AD; CARTER, CS; FLEISHER, T; CLERICI, M; SHEARER, G; CHANG, L; CHIANG, YW; TOLSTOSHEV, P; GREENBLATT, JJ; ROSENBERG, SA; KLEIN, H; BERGER, M; MULLEN, CA; RAMSEY, WJ; MUUL, L; MORGAN, RA; ANDERSON, WF				BLAESE, RM; CULVER, KW; MILLER, AD; CARTER, CS; FLEISHER, T; CLERICI, M; SHEARER, G; CHANG, L; CHIANG, YW; TOLSTOSHEV, P; GREENBLATT, JJ; ROSENBERG, SA; KLEIN, H; BERGER, M; MULLEN, CA; RAMSEY, WJ; MUUL, L; MORGAN, RA; ANDERSON, WF			T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS	SCIENCE			English	Article							ADENOSINE-DEAMINASE DEFICIENCY; SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW TRANSPLANTATION; ENZYME REPLACEMENT THERAPY; CELL-LINES; RETROVIRAL VECTORS; AVIAN RETROVIRUS; VIRUS; EXPRESSION; SEQUENCES	In 1990, a clinical trial was started using retroviral-mediated transfer of the adenosine deaminase (ADA) gene into the T cells of two children with severe combined immunodeficiency (ADA(-) SCID). The number of blood T cells normalized as did many cellular and humoral immune responses. Gene treatment ended after 2 years, but integrated vector and ADA gene expression in T cells persisted. Although many components remain to be perfected, it is concluded here that gene therapy can be a safe and effective addition to treatment for some patients with this severe immunodeficiency disease.	NCI,BETHESDA,MD 20892; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; NIH,CTR CLIN,BETHESDA,MD 20892; NHLBI,BETHESDA,MD 20892; GENET THERAPY,GAITHERSBURG,MD 20878; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PEDIAT,CLEVELAND,OH 44106	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Case Western Reserve University	BLAESE, RM (corresponding author), NIH,NATL CTR HUMAN GENOME RES,BLDG 49,ROOM 2A03,BETHESDA,MD 20892, USA.			Clerici, Mario/0000-0001-5920-6191; Miller, Dusty/0000-0002-3736-3660				AKESON AL, 1989, J CELL BIOCHEM, V39, P217, DOI 10.1002/jcb.240390302; ARMENTANO D, 1987, J VIROL, V61, P1647, DOI 10.1128/JVI.61.5.1647-1650.1987; BIDDISON WE, 1980, J IMMUNOL, V124, P548; BLAESE RM, 1990, HUM GENE THER, V1, P327; BLAESE RM, 1993, PEDIATR RES, pS49; BLAESE RM, UNPUB; BUCKLEY RH, 1986, J IMMUNOL, V136, P398; BUNNELL BA, 1995, P NATL ACAD SCI USA, V92, P7739, DOI 10.1073/pnas.92.17.7739; CARSON DA, 1981, J IMMUNOL, V126, P348; CARSON DA, 1979, P NATL ACAD SCI USA, V76, P2430, DOI 10.1073/pnas.76.5.2430; CHUN JD, 1993, ANN ALLERGY, V70, P462; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CLERICI M, 1991, J IMMUNOL, V146, P2214; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; COLEMAN MS, 1978, J BIOL CHEM, V253, P1619; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; CULVER KW, 1990, HUM GENE THER, V1, P399, DOI 10.1089/hum.1990.1.4-399; CULVER KW, 1991, HUM GENE THER, V2, P107, DOI 10.1089/hum.1991.2.2-107; DADDONA PE, 1985, J BIOL CHEM, V260, P3875; DADDONA PE, 1983, J CLIN INVEST, V72, P483, DOI 10.1172/JCI110996; DAVIES EG, 1982, CLIN EXP IMMUNOL, V50, P303; DONOFRIO J, 1978, J CLIN INVEST, V62, P884, DOI 10.1172/JCI109201; FERRARI G, 1991, SCIENCE, V251, P1363, DOI 10.1126/science.1848369; FONG SW, 1974, TRANSFUSION, V14, P551, DOI 10.1111/j.1537-2995.1974.tb04576.x; FRIEDRICH W, 1984, LANCET, V1, P761; FRIEDRICH W, 1985, EUR J PEDIATR, V144, P125, DOI 10.1007/BF00451897; GIBLETT ER, 1972, LANCET, V2, P1067; GILBOA E, 1986, BIOTECHNIQUES, V4, P504; HERSHFIELD MS, 1993, PEDIATR RES, V33, pS42; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; Hershfield MS, 1991, TREATMENT GENETIC DI, P169; Hirschhorn R, 1983, Birth Defects Orig Artic Ser, V19, P73; HIRSCHHORN R, 1980, NEW ENGL J MED, V303, P377, DOI 10.1056/NEJM198008143030706; HIRSCHHORN R, 1979, J CLIN INVEST, V64, P1130, DOI 10.1172/JCI109552; HIRSCHHORN R, 1983, J CLIN INVEST, V71, P1887, DOI 10.1172/JCI110944; HOCK RA, 1989, BLOOD, V74, P876; HUTTON JJ, 1981, J CLIN INVEST, V68, P413, DOI 10.1172/JCI110270; KANTOFF PW, 1986, P NATL ACAD SCI USA, V83, P6563, DOI 10.1073/pnas.83.17.6563; KEEVER CA, 1988, CLIN IMMUNOL IMMUNOP, V48, P261, DOI 10.1016/0090-1229(88)90020-7; KIRCHNER H, 1979, J IMMUNOL, V122, P1310; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; KOHN DB, 1987, BLOOD CELLS, V13, P285; KOHN DB, 1989, J IMMUNOL, V142, P3971; KOHN DB, 1989, CANCER INVEST, V7, P179, DOI 10.3109/07357908909038283; KOHN DB, 1987, PEDIATR RES, V21, pA313; LEVY Y, 1988, J PEDIATR-US, V113, P312, DOI 10.1016/S0022-3476(88)80271-3; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARKERT ML, 1987, J CLIN IMMUNOL, V7, P389, DOI 10.1007/BF00917017; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER AD, 1983, P NATL ACAD SCI-BIOL, V80, P4709, DOI 10.1073/pnas.80.15.4709; MORGAN RA, 1990, HUM GENE THER, V1, P135, DOI 10.1089/hum.1990.1.2-135; MULLEN CA, UNPUB; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; OCHS HD, 1992, BLOOD, V80, P1163; ORKIN SH, 1983, J BIOL CHEM, V258, P2753; POLMAR SH, 1976, NEW ENGL J MED, V295, P1337, DOI 10.1056/NEJM197612092952402; POLMAR SH, 1980, SEMIN HEMATOL, V17, P30; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; RUBINSTEIN A, 1979, NEW ENGL J MED, V300, P387, DOI 10.1056/NEJM197902223000802; SANTISTEBAN I, 1993, J CLIN INVEST, V92, P2291, DOI 10.1172/JCI116833; SCHMALSTIEG FC, 1978, J PEDIATR-US, V93, P597, DOI 10.1016/S0022-3476(78)80894-4; SHIMOTOHNO K, 1981, CELL, V26, P67, DOI 10.1016/0092-8674(81)90034-9; SILBER GM, 1987, CLIN IMMUNOL IMMUNOP, V44, P317, DOI 10.1016/0090-1229(87)90075-4; SORENSEN RU, 1990, PEDIATR RES, V27, pA162; VALERIO D, 1983, GENE, V25, P231, DOI 10.1016/0378-1119(83)90227-5; WALDMANN TA, 1974, LANCET, V2, P609; WALKER RH, 1993, AABB TECHNICAL MANUA, P622; WATANABE S, 1982, P NATL ACAD SCI-BIOL, V79, P5986, DOI 10.1073/pnas.79.19.5986; WEINBERG K, 1993, J CLIN INVEST, V92, P596, DOI 10.1172/JCI116626; WIGINTON DA, 1983, P NATL ACAD SCI-BIOL, V80, P7481, DOI 10.1073/pnas.80.24.7481; WIJNAENDTS L, 1989, BLOOD, V74, P2212; WORTMANN RL, 1979, P NATL ACAD SCI USA, V76, P2434, DOI 10.1073/pnas.76.5.2434; YEAGER AM, 1988, PEDIATR ANN, V17, P694; ZIEGLER JB, 1980, ARCH DIS CHILD, V55, P452, DOI 10.1136/adc.55.6.452	75	981	1113	2	144	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					475	480		10.1126/science.270.5235.475	http://dx.doi.org/10.1126/science.270.5235.475			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7570001	Green Submitted			2022-12-28	WOS:A1995TA37400043
J	BOERRIGTER, METI; DOLLE, MET; MARTUS, HJ; GOSSEN, JA; VIJG, J				BOERRIGTER, METI; DOLLE, MET; MARTUS, HJ; GOSSEN, JA; VIJG, J			PLASMID-BASED TRANSGENIC MOUSE MODEL FOR STUDYING IN-VIVO MUTATIONS	NATURE			English	Article							MICE; INVIVO; RESCUE; GENE; DNA	A new transgenic mouse model for studying in vivo somatic mutations is based on the efficient recovery of chromosomally integrated lacZ-containing plasmids, using magnetic beads.	HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Harvard Medical School	BOERRIGTER, METI (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV GERONTOL,MOLEC GENET SECT,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							ADHYA SL, 1969, GENETICS, V62, P231; ALBERTINI RJ, 1994, ENVIRON MOL MUTAGEN, V23, P18, DOI 10.1002/em.2850230607; ASHBY J, 1993, MUTAT RES, V292, P25, DOI 10.1016/0165-1161(93)90005-K; DOLLE MET, IN PRESS MUTAGENESIS; DOUGLAS GR, 1994, MUTAGENESIS, V9, P451, DOI 10.1093/mutage/9.5.451; GOSSEN J, 1993, TRENDS GENET, V9, P27, DOI 10.1016/0168-9525(93)90069-T; GOSSEN JA, 1993, BIOTECHNIQUES, V14, P624; GOSSEN JA, 1995, MUTAT RES-FUND MOL M, V331, P89, DOI 10.1016/0027-5107(95)00055-N; GOSSEN JA, 1992, NUCLEIC ACIDS RES, V20, P3254, DOI 10.1093/nar/20.12.3254; GOSSEN JA, 1988, NUCLEIC ACIDS RES, V16, P9343, DOI 10.1093/nar/16.19.9343; GOSSEN JA, 1989, P NATL ACAD SCI USA, V86, P7971, DOI 10.1073/pnas.86.20.7971; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; MORRISON V, 1994, MUTAGENESIS, V9, P367, DOI 10.1093/mutage/9.4.367; PROVOST GS, MUTAT RES, V288, P133; SUZUKI T, 1993, MUTAT RES, V285, P219, DOI 10.1016/0027-5107(93)90109-S; TAO KS, 1993, P NATL ACAD SCI USA, V90, P10681, DOI 10.1073/pnas.90.22.10681	16	120	121	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					657	659		10.1038/377657a0	http://dx.doi.org/10.1038/377657a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566182				2022-12-28	WOS:A1995TA27500060
J	FRANK, SA				FRANK, SA			MUTUAL POLICING AND REPRESSION OF COMPETITION IN THE EVOLUTION OF COOPERATIVE GROUPS	NATURE			English	Article							DICTYOSTELIUM	EVOLUTIONARY theory has not explained how competition among lower level units is suppressed in the formation of higher-level evolutionary units(1,2). For example, the key problem of early evolution is how small, individual replicators formed cooperative groups of sufficient complexity to allow accurate copying of the genetic material(3). The puzzle is why parasites did not subvert the formation of cells by obtaining benefits from the group without contributing to shared traits that enhance reproduction(4). These parasites would outcompete other replicators within the cell, disrupting reproductive fairness among subunits and destroying the functional coherence of the group. A similar problem arose at a later evolutionary stage with the orderly mendelian segregation of subunits (chromosomes) within cells, and reproductive fairness continued to be a problem in the evolution of insect(5) and human societies(6). Here I present a simple model to show how reproductive fairness evolves among subunits to create functional coherence and higher-level units. Self-restraint, which evolves according to the kin-selection coefficient of relatedness, is not sufficient: mutual policing and enforcement of reproductive fairness are also required for the evolution of increasing social complexity.			FRANK, SA (corresponding author), UNIV CALIF IRVINE, DEPT ECOL & EVOLUTIONARY BIOL, IRVINE, CA 92717 USA.			Frank, Steven/0000-0001-7348-7794				Alexander R., 1987, BIOL MORAL SYSTEMS; BONNER JT, 1967, CELLULAR SLIME MOLDS; BREMERMANN HJ, 1983, J THEOR BIOL, V100, P411, DOI 10.1016/0022-5193(83)90438-1; Eigen M, 1979, THE HYPERCYCLE, P60; FRANK SA, 1994, P ROY SOC B-BIOL SCI, V258, P153, DOI 10.1098/rspb.1994.0156; HAMILTON WD, 1970, NATURE, V228, P1218, DOI 10.1038/2281218a0; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Hardin G., 1993, LIVING LIMITS ECOLOG; HURST LD, 1994, P ROY SOC B-BIOL SCI, V258, P287, DOI 10.1098/rspb.1994.0175; LLOYD WF, 1833, 2 LECTURES CHECKS PO; Maynard Smith J., 1982, pi; Morrissey J, 1982, DEV DICTYOSTELIUM DI, P411; OZAKI T, 1993, DEVELOPMENT, V117, P1299; PRICE GR, 1970, NATURE, V227, P520, DOI 10.1038/227520a0; RATNIEKS FLW, 1992, J THEOR BIOL, V158, P33, DOI 10.1016/S0022-5193(05)80647-2; RATNIEKS FLW, 1989, NATURE, V342, P796, DOI 10.1038/342796a0; SMITH JM, 1979, NATURE, V280, P445, DOI 10.1038/280445a0; Szathmary E, 1995, MAJOR TRANSITIONS EV; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILSON DS, 1994, BEHAV BRAIN SCI, V17, P585, DOI 10.1017/S0140525X00036104; WILSON DS, 1989, J THEOR BIOL, V136, P337, DOI 10.1016/S0022-5193(89)80169-9	21	276	283	1	48	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 12	1995	377	6549					520	522		10.1038/377520a0	http://dx.doi.org/10.1038/377520a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566147	Green Submitted			2022-12-28	WOS:A1995RZ33600059
J	BRAUTIGAM, M; NOLTING, S; SCHOPF, RE; WEIDINGER, G				BRAUTIGAM, M; NOLTING, S; SCHOPF, RE; WEIDINGER, G			RANDOMIZED DOUBLE-BLIND COMPARISON OF TERBINAFINE AND ITRACONAZOLE FOR TREATMENT OF TOENAIL TINEA INFECTION	BRITISH MEDICAL JOURNAL			English	Article							PHARMACOKINETIC PROPERTIES; THERAPEUTIC USE; ONYCHOMYCOSIS; ULTRAMICROSIZE; KETOCONAZOLE; MYCOSES; NAIL	Objective-To compare the efficacy and tolerability of terbinafine and itraconazole in the treatment of toenail tinea unguium. Design-Multicentre, double blind, parallel group study. Setting-17 university hospitals, one army hospital, and five dermatology practices. Patients-195 patients with clinically suspected toenail tinea and growth of dermatophytes in baseline culture; data on 86 patients in the terbinafine group and 84 patients in the itraconazole group were fully evaluated for efficacy. Interventions-Daily dose of 250 mg terbinafine or 200 mg itraconazole for 12 weeks, with follow up for a further 40 weeks. Main outcome measures-Mycological cure (negative results on microscopy and culture) and clinical improvement (length and area of unaffected nail) at week 52 or at discontinuation of treatment. Results-At the end of the study mycological cure rates were 81% (70 out of 86) for terbinafine and 63% (53 out of 84) for itraconazole (2P<0.01). Negative culture was achieved in 92% (79 out of 86) in the terbinafine group and 67% (56 out of 84) in the itraconazole group (2P<0 0001). Length of unaffected nail was 9.44 mm in the terbinafine group and 7.85 mm in the itraconazole group (2P<0.05). Conclusion-Terbinafine is more effective than itraconazole in the treatment of toenail tinea infection.	UNIV MUNSTER,DEPT DERMATOL,D-48149 MUNSTER,GERMANY; UNIV MAINZ,DEPT DERMATOL,D-55131 MAINZ,GERMANY	University of Munster; Johannes Gutenberg University of Mainz	BRAUTIGAM, M (corresponding author), SANDOZ PHARMA AG,DEPT CLIN RES,D-90429 NURNBERG,GERMANY.			Braeutigam, Matthias/0000-0002-1961-6396				ANDERSON DW, 1965, ANN ALLERGY, V23, P103; ARENAS R, 1995, INT J DERMATOL, V34, P138, DOI 10.1111/j.1365-4362.1995.tb03600.x; BALFOUR JA, 1992, DRUGS, V43, P259, DOI 10.2165/00003495-199243020-00010; BAUDRAZROSSELET F, 1992, BRIT J DERMATOL, V126, P40, DOI 10.1111/j.1365-2133.1992.tb00009.x; BEUTLER M, 1993, BRIT MED J, V307, P26, DOI 10.1136/bmj.307.6895.26-b; CLAYTON YM, 1994, BRIT J DERMATOL, V130, P7, DOI 10.1111/j.1365-2133.1994.tb06084.x; DEKEYSER P, 1994, BRIT J DERMATOL, V130, P22, DOI 10.1111/j.1365-2133.1994.tb06089.x; EFFENDY I, 1991, Z HAUTKRANKHEITEN, V66, P620; FAERGEMANN J, 1994, CLIN EXP DERMATOL, V19, P121, DOI 10.1111/j.1365-2230.1994.tb01138.x; GOODFIELD MJD, 1992, BRIT J DERMATOL, V126, P33, DOI 10.1111/j.1365-2133.1992.tb00007.x; GOODFIELD MJD, 1990, J DERMATOL TREAT S2, V1, P55; GRANT SM, 1989, DRUGS, V37, P310, DOI 10.2165/00003495-198937030-00003; Greer D. L., 1990, Antifungal drug therapy. A complete guide for the practitioner., P5; HOFMANN H, 1995, ARCH DERMATOL, V131, P919, DOI 10.1001/archderm.131.8.919; KORTING HC, 1993, ANTIMICROB AGENTS CH, V37, P2064, DOI 10.1128/AAC.37.10.2064; LEWIS JH, 1984, GASTROENTEROLOGY, V86, P503; MONK JP, 1987, DRUGS, V33, P539, DOI 10.2165/00003495-198733060-00002; REINEL D, 1992, CLIN EXP DERMATOL, V17, P44, DOI 10.1111/j.1365-2230.1992.tb00278.x; ROBERTS DT, 1992, BRIT J DERMATOL, V126, P23, DOI 10.1111/j.1365-2133.1992.tb00005.x; ROSEEUW D, 1993, J AM ACAD DERMATOL, V29, pS45, DOI 10.1016/S0190-9622(08)81837-3; SCHATZ F, IN PRESS CLIN EXP DE; VANDERSCHROEFF JG, 1992, BRIT J DERMATOL, V126, P36, DOI 10.1111/j.1365-2133.1992.tb00008.x; WILLEMSEN M, 1992, J AM ACAD DERMATOL, V26, P731, DOI 10.1016/0190-9622(92)70102-L; ZAIAS N, 1983, J AM ACAD DERMATOL, V9, P912, DOI 10.1016/S0190-9622(83)70208-2; ZALAS N, 1980, NAIL HLTH DISEASE, P91; 1979, J INVEST DERMATOL, V73, P395	26	104	110	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					919	922						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580551	Green Published			2022-12-28	WOS:A1995RZ23700022
J	HORLEIN, AJ; NAAR, AM; HEINZEL, T; TORCHIA, J; GLOSS, B; KUROKAWA, R; RYAN, A; KAMEL, Y; SODERSTROM, M; GLASS, CK; ROSENFELD, MG				HORLEIN, AJ; NAAR, AM; HEINZEL, T; TORCHIA, J; GLOSS, B; KUROKAWA, R; RYAN, A; KAMEL, Y; SODERSTROM, M; GLASS, CK; ROSENFELD, MG			LIGAND-INDEPENDENT REPRESSION BY THE THYROID-HORMONE RECEPTOR-MEDIATED BY A NUCLEAR RECEPTOR CO-REPRESSOR	NATURE			English	Article							RETINOID X-RECEPTOR; V-ERBA; TRANSCRIPTION FACTOR; RXR-BETA; PROTEIN; ACID; BINDING; ACTIVATION; INHIBITION; SILENCER	Thyroid-hormone and retinoic-acid receptors exert their regulatory functions by acting as both activators and repressors of gene expression. A nuclear receptor co-repressor (N-CoR) of relative molecular mass 270K has been identified which mediates ligand-independent inhibition of gene transcription by these receptors, suggesting that the molecular mechanisms of repression by thyroid-hormone and retinoic-acid receptors are analogous to the co-repressor-dependent transcriptional inhibitory mechanisms of yeast and Drosophila.	UNIV CALIF SAN DIEGO, DEPT MED, GRAD PROGRAM MOLEC PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	HORLEIN, AJ (corresponding author), UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA.		Glass, Christopher/AAI-3933-2021; Heinzel, Thorsten/B-1013-2015; Söderström, Mats/C-4005-2009	Glass, Christopher/0000-0003-4344-3592; Söderström, Mats/0000-0003-3927-4394				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BANLAHMAD A, 1992, EMBO J, V11, P1015; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BRENT G A, 1989, New Biologist, V1, P329; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; ING NH, 1992, J BIOL CHEM, V267, P17617; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; MADDEN SL, 1993, ONCOGENE, V8, P1713; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MARTIN B, 1994, NUCLEIC ACIDS RES, V22, P4898, DOI 10.1093/nar/22.23.4898; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; QI JS, 1995, MOL CELL BIOL, V15, P1817; RENKAWITZ R, 1993, ANN NY ACAD SCI, V684, P1, DOI 10.1111/j.1749-6632.1993.tb32266.x; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	52	1670	1690	2	49	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 5	1995	377	6548					397	404		10.1038/377397a0	http://dx.doi.org/10.1038/377397a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566114				2022-12-28	WOS:A1995RY19000039
J	DEPEE, S; WEST, CE; MUHILAL; KARYADI, D; HAUTVAST, JGAJ				DEPEE, S; WEST, CE; MUHILAL; KARYADI, D; HAUTVAST, JGAJ			LACK OF IMPROVEMENT IN VITAMIN-A STATUS WITH INCREASED CONSUMPTION OF DARK-GREEN LEAFY VEGETABLES	LANCET			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; BETA-CAROTENE; CARBONYL IRON; BIOAVAILABILITY; SINGLE	There is little evidence to support the general assumption that dietary carotenoids can improve vitamin A status. We investigated in Bogor District, West Java, Indonesia, the effect of an additional daily portion of dark-green leafy vegetables on vitamin A and iron status in women with low haemoglobin concentrations (<130 g/L) who were breastfeeding a child of 3-17 months. Every day for 12 weeks one group (n=57) received stir-fried vegetables, a second (n=62) received a wafer enriched with beta-carotene, iron, vitamin C, and folic acid, and a third (n=56) received a non-enriched wafer to control for additional energy intake. The vegetable supplement and the enriched wafer contained 3.5 mg beta-carotene, 5.2 mg and 4.8 mg iron, and 7.8 g and 4.4 g fat, respectively. Assignment to vegetable or wafer groups was by village. Wafers were distributed double-mashed. In the enriched-wafer group there were increases in serum retinol (mean increase 0.32 [95% CI 0.23-0.40] mu mol/L), breastmilk retinol (0.59 [0.35-0.84] mu mol/L), and serum beta-carotene (0.73 [0.59-0.88] mu mol/L). These changes differed significantly from those in the other two groups, in which the only significant changes were small increases in breastmilk retinol in the control-wafer group (0.16 [0.02-0.30] mu mol/L) and in serum beta-carotene in the vegetable group (0.03 [0-0.06] mu mol/L). Changes in iron status were similar in all three groups. An additional daily portion of dark-green leafy vegetables did not improve vitamin A status, whereas a similar amount of beta-carotene from a simpler matrix produced a strong improvement. These results suggest that the approach to combating Vitamin A deficiency by increases in the consumption of provitamin A carotenoids from vegetables should be re-examined.	AGR UNIV WAGENINGEN,DEPT HUMAN NUTR,6700 EV WAGENINGEN,NETHERLANDS; NUTR RES & DEV CTR,BOGOR,INDONESIA; EMORY UNIV,ROLLINS SCH PUBL HLTH,DEPT INT HLTH,ATLANTA,GA 30322	Wageningen University & Research; Nutrition Research & Development Center - Indonesia; Emory University; Rollins School Public Health								BEATON GH, 1993, UN ACC SCN13 NUTR PO; BEGUIN Y, 1993, BLOOD, V81, P1067; BLOEM MW, 1990, AM J CLIN NUTR, V51, P76, DOI 10.1093/ajcn/51.1.76; BROWN ED, 1989, AM J CLIN NUTR, V49, P1258, DOI 10.1093/ajcn/49.6.1258; BULUX J, 1994, AM J CLIN NUTR, V59, P1369, DOI 10.1093/ajcn/59.6.1369; BUSHWAY RJ, 1982, CAN I FOOD SC TECH J, V15, P165, DOI 10.1016/S0315-5463(82)72531-3; CARLIER C, 1992, BRIT J NUTR, V68, P529, DOI 10.1079/BJN19920110; CRAFT NE, 1992, J CHROMATOGR, V589, P171, DOI 10.1016/0021-9673(92)80019-Q; DEPEE S, IN PRESS EUR J CLIN; DEVASTHALI SD, 1991, EUR J HAEMATOL, V46, P272; DEWEY KG, 1993, AM J CLIN NUTR, V58, P162, DOI 10.1093/ajcn/58.2.162; ERDMAN JW, 1993, ANN NY ACAD SCI, V691, P76, DOI 10.1111/j.1749-6632.1993.tb26159.x; HALLBERG L, 1986, AM J CLIN NUTR, V43, P59, DOI 10.1093/ajcn/43.1.59; HUME EM, 1989, 264 MED RES COUNC SP; JALAL F, 1991, THESIS CORNELL U ITH; KLEINBAUM DG, 1987, APPLIED REGRESSION A; MARMOR B, 1994, FASEB J, V8, P192; Osborne DR, 1978, ANAL NUTR FOODS; PROSKY L, 1984, J ASSOC OFF ANA CHEM, V67, P1044; SPEEK AJ, 1986, FOOD CHEM, V19, P65, DOI 10.1016/0308-8146(86)90128-7; SPEEK AJ, 1982, J AGR FOOD CHEM, V32, P342; STOLTZFUS RJ, 1993, J NUTR, V123, P666, DOI 10.1093/jn/123.4.666; SUHARNO D, 1993, LANCET, V342, P3425; TANUMIHARDJO SA, 1994, AM J CLIN NUTR, V60, P142, DOI 10.1093/ajcn/60.1.142; WAHLQVIST ML, 1994, AM J CLIN NUTR, V60, P936, DOI 10.1093/ajcn/60.6.936; West C. E., 1993, CAROTENOID CONTENT F; WHITE WS, 1993, J NUTR, V123, P1405; 1988, FAO FOOD NUTR SER, V23; 1993, LANCET, V342, P7	29	290	296	0	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					75	81		10.1016/S0140-6736(95)92111-7	http://dx.doi.org/10.1016/S0140-6736(95)92111-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603216	Green Accepted			2022-12-28	WOS:A1995RH22000009
J	SEJNOWSKI, TJ				SEJNOWSKI, TJ			PATTERN-RECOGNITION - TIME FOR A NEW NEURAL CODE	NATURE			English	Editorial Material							DELAY		UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	SEJNOWSKI, TJ (corresponding author), SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, LA JOLLA, CA 92037 USA.		Sejnowski, Terrence/AAV-5558-2021					ABELES M, 1994, PROG BRAIN RES, V102, P395; BIALEK W, 1991, SCIENCE, V252, P1854, DOI 10.1126/science.2063199; BURR DC, 1979, VISION RES, V19, P523, DOI 10.1016/0042-6989(79)90137-8; CELEBRINI S, 1993, VISUAL NEUROSCI, V10, P811, DOI 10.1017/S0952523800006052; HEILIGENBERG W, 1991, NEURAL NETS ELECTRIC; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; KONIG P, 1995, NEURAL COMPUT, V7, P469, DOI 10.1162/neco.1995.7.3.469; KUWABARA N, 1993, J NEUROPHYSIOL, V69, P1713, DOI 10.1152/jn.1993.69.5.1713; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; POGGIO T, 1990, COLD SPRING HARB SYM, V55, P899; POUGET A, 1994, CEREB CORTEX, V4, P314, DOI 10.1093/cercor/4.3.314; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SINGER W, 1994, INT REV NEUROBIOL, V37, P153; Softky W R, 1995, Curr Opin Neurobiol, V5, P239, DOI 10.1016/0959-4388(95)80032-8	15	66	71	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 6	1995	376	6535					21	22		10.1038/376021a0	http://dx.doi.org/10.1038/376021a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596425				2022-12-28	WOS:A1995RH11100038
J	ROCHON, PA; GURWITZ, JH				ROCHON, PA; GURWITZ, JH			DRUG-THERAPY	LANCET			English	Article							CLINICAL-TRIALS; ELDERLY PERSONS; NURSING-HOMES; HIP FRACTURE; RISK; AGE; OSTEOARTHRITIS; THROMBOLYSIS; KNEE; OLD	Drug therapy for individuals of any age is difficult but prescribing for older patients offers special challenges. Older people take about three times as many prescription medications as younger individuals do, mainly because of their increased prevalence of chronic medical conditions.(1) However, taking several drugs together substantially increases the risk of drug interactions, unwanted effects, and adverse reactions. Many medications need to be used with special caution because of age-related changes in pharmacokinetics and pharmacodynamics.(2) For some drugs, an increase in the volume of distribution (eg, diazepam) or a reduction in drug clearance (eg, digoxin) may lead to higher plasma concentrations in older than in younger patients.(2) Pharmacodynamic changes with ageing may result in an increased sensitivity to the effects of certain drugs (eg, opioids) for any given plasma concentration.(3) While a physician can usually do little to alter the characteristics of individual older patients to affect the kinetics or dynamics of drugs, the decision whether to prescribe anything at all, the choice of drug, and the manner in which it is to be used (eg, dose and duration of therapy) are all factors that are under control of the prescriber. Patient adherence to the regimen prescribed is important, and there should be a partnership between physician and patient in therapeutic decision making. We will discuss here mays of improving prescribing for older patients. Specifically, we will examine the scarcity of information to guide prescribing decisions, the general principles of prudent prescribing, and the opportunities to clarify and expand knowledge about drug therapy in the elderly.	UNIV TORONTO,MT SINAI HOSP,DEPT MED,DIV GERIATR MED,TORONTO,ON,CANADA; UNIV TORONTO,MT SINAI HOSP,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV GERONTOL,PROGRAM ANAL CLIN STRATEGIES,BOSTON,MA; BROCKTON W ROXBURY VET AFFAIRS MED CTR,BOSTON,MA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University	ROCHON, PA (corresponding author), BAYCREST CTR GERIATR CARE,3560 BATHURST ST,N YORK,ON M6A 2E1,CANADA.		McLaughlin, Thomas F/A-9416-2009; Rochon, Paula A/J-2918-2016	McLaughlin, Thomas F/0000-0002-2722-3066; Rochon, Paula A/0000-0002-5973-4151	NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER; NIA NIH HHS [K08 AG00510] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1994, ARCH INTERN MED, V154, P1449; AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; CHRISCHILLES EA, 1992, J GERONTOL, V47, pM137, DOI 10.1093/geronj/47.5.M137; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; DUDLEY NJ, 1992, AGE AGEING, V21, P95, DOI 10.1093/ageing/21.2.95; Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; GREENBLATT DJ, 1982, NEW ENGL J MED, V306, P1081; GREENBLATT DJ, 1991, NEW ENGL J MED, V324, P1691, DOI 10.1056/NEJM199106133242403; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GRIFFIN MR, 1988, ANN INTERN MED, V114, P359; GRUWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P781; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; GURWITZ JH, 1990, JAMA-J AM MED ASSOC, V264, P471, DOI 10.1001/jama.264.4.471; JACOX A, 1994, AHCPR940593 AG HLTH; JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003-4819-121-4-199408150-00011; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LIANG MH, 1991, NEW ENGL J MED, V325, P125, DOI 10.1056/NEJM199107113250210; MONANE M, 1993, ARCH INTERN MED, V153, P633, DOI 10.1001/archinte.153.5.633; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; RAY WA, 1993, ARCH INTERN MED, V153, P713, DOI 10.1001/archinte.153.6.713; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; ROCHON PA, 1993, ARCH INTERN MED, V153, P243, DOI 10.1001/archinte.153.2.243; SALZMAN C, 1992, CLIN GERIATRIC PSYCH, V1, P363; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SHORR RI, 1994, JAMA-J AM MED ASSOC, V271, P358; STEPHEN PJ, 1984, LANCET, V2, P1082; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TOPOL EJ, 1992, NEW ENGL J MED, V327, P45, DOI 10.1056/NEJM199207023270109; TRIMBLE EL, 1994, CANCER, V74, P2208, DOI 10.1002/1097-0142(19941001)74:7+<2208::AID-CNCR2820741737>3.0.CO;2-#; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; 1989, GUIDELINE STUDY DRUG, P16; 1991, CIRCULATION, V84, P527; 1986, BRIT MED J, V292, P614	38	87	92	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					32	36		10.1016/S0140-6736(95)92656-9	http://dx.doi.org/10.1016/S0140-6736(95)92656-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603146				2022-12-28	WOS:A1995RF98500014
J	HORN, D; CROSS, GAM				HORN, D; CROSS, GAM			A DEVELOPMENTALLY-REGULATED POSITION EFFECT AT A TELOMERIC LOCUS IN TRYPANOSOMA-BRUCEI	CELL			English	Article							GENE-EXPRESSION SITE; BLOOD-STREAM FORMS; TRANSCRIPTION UNIT; ANTIGENIC VARIATION; REPETITIVE PROTEIN; II TRANSCRIPTION; SURFACE-ANTIGEN; VSG GENE; PROMOTER; DNA	Trypanosoma brucei undergoes antigenic variation in the mammalian host. This can be achieved by activation and inactivation of telomeric variant-specific surface glycoprotein genes (vsg). In procyclic (insect midgut stage) cells, Vsg is not expressed. The mechanisms that regulate transcription of vsg expression sites (ESs) are unknown. Here we demonstrate that transcription from three different promoters was repressed when they were inserted at a transcriptionally silent telomere-proximal locus in bloodstream-form cells. This position effect was stable and heritable. Only transcription from an ES promoter was repressed in procyclic cells. The observed position effect and the promoter-specific developmental regulation suggest that these phenomena reflect the mechanisms that regulate vsg expression.			HORN, D (corresponding author), ROCKEFELLER UNIV,MOLEC PARASITOL LAB,NEW YORK,NY 10021, USA.		Cross, George A M/B-7444-2011	Cross, George A M/0000-0003-1374-6955; Horn, David/0000-0001-5173-9284	NIAID NIH HHS [AI21729] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021729, R01AI021729] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; BERNARDS A, 1984, CELL, V36, P163, DOI 10.1016/0092-8674(84)90085-0; BORST P, 1993, COLD SPRING HARB SYM, V58, P105, DOI 10.1101/SQB.1993.058.01.014; BROWN SD, 1992, MOL CELL BIOL, V12, P2644, DOI 10.1128/MCB.12.6.2644; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CARRUTHERS VB, 1993, NUCLEIC ACIDS RES, V21, P2537, DOI 10.1093/nar/21.10.2537; CHUNG HM, 1992, PARASITOL TODAY, V8, P414, DOI 10.1016/0169-4758(92)90194-7; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DROCOURT D, 1990, NUCLEIC ACIDS RES, V18, P4009, DOI 10.1093/nar/18.13.4009; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAJDUK SL, 1981, PARASITOLOGY, V83, P609, DOI 10.1017/S0031182000080574; HARTREE D, 1995, MOL BIOCHEM PARASIT, V71, P27, DOI 10.1016/0166-6851(95)00034-X; HEHL A, 1994, PARASITOL TODAY, V10, P442, DOI 10.1016/0169-4758(94)90180-5; HIRUMI H, 1994, PARASITOL TODAY, V10, P80, DOI 10.1016/0169-4758(94)90402-2; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; JANZ L, 1994, MOL CELL BIOL, V14, P5804, DOI 10.1128/MCB.14.9.5804; JEFFERIES D, 1993, NUCLEIC ACIDS RES, V21, P191, DOI 10.1093/nar/21.2.191; JOHNSON JG, 1979, BIOCHEM J, V178, P689, DOI 10.1042/bj1780689; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LEE MGS, 1995, MOL BIOCHEM PARASIT, V69, P223, DOI 10.1016/0166-6851(94)00186-Q; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; OVERATH P, 1986, EUR J BIOCHEM, V160, P175, DOI 10.1111/j.1432-1033.1986.tb09955.x; PATNAIK PK, 1993, EMBO J, V12, P2529, DOI 10.1002/j.1460-2075.1993.tb05908.x; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHLIMME W, 1993, PARASITOLOGY, V107, P237, DOI 10.1017/S003118200007921X; SHERMAN DR, 1991, EMBO J, V10, P3379, DOI 10.1002/j.1460-2075.1991.tb04902.x; URMENYI TP, 1995, NUCLEIC ACIDS RES, V23, P1010, DOI 10.1093/nar/23.6.1010; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VIJAYASARATHY S, 1990, NUCLEIC ACIDS RES, V18, P2967, DOI 10.1093/nar/18.10.2967; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1993, MOL BIOCHEM PARASIT, V57, P295, DOI 10.1016/0166-6851(93)90205-C; ZOMERDIJK JCBM, 1992, NUCLEIC ACIDS RES, V20, P2725, DOI 10.1093/nar/20.11.2725; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	43	123	123	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					555	561		10.1016/0092-8674(95)90095-0	http://dx.doi.org/10.1016/0092-8674(95)90095-0			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585958	Bronze			2022-12-28	WOS:A1995TF24800008
J	VELCULESCU, VE; ZHANG, L; VOGELSTEIN, B; KINZLER, KW				VELCULESCU, VE; ZHANG, L; VOGELSTEIN, B; KINZLER, KW			SERIAL ANALYSIS OF GENE-EXPRESSION	SCIENCE			English	Article							CDNA CLONES; SEQUENCE; DNA; IDENTIFICATION	The characteristics of an organism are determined by the genes expressed within it. A method was developed, called serial analysis of gene expression (SAGE), that allows the quantitative and simultaneous analysis of a large number of transcripts. To demonstrate this strategy, short diagnostic sequence tags were isolated from pancreas, concatenated, and cloned. Manual sequencing of 1000 tags revealed a gene expression pattern characteristic of pancreatic function. New pancreatic transcripts corresponding to novel tags were identified. SAGE should provide a broadly applicable means for the quantitative cataloging and comparison of expressed genes in a variety of normal, developmental, and disease states.	JOHNS HOPKINS UNIV,CTR ONCOL,HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,PROGRAM HUMAN GENET & MOLEC BIOL,BALTIMORE,MD 21231	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University			Velculescu, Victor/ABF-4846-2020; Zhang, Lin/A-7389-2009	Velculescu, Victor/0000-0003-1195-438X; Zhang, Lin/0000-0003-0018-3903	NATIONAL CANCER INSTITUTE [R01CA035494, R01CA057345, R37CA057345, R37CA035494] Funding Source: NIH RePORTER; NCI NIH HHS [CA35494, CA57345] Funding Source: Medline; NIGMS NIH HHS [GM07309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; HAN JH, 1986, P NATL ACAD SCI USA, V83, P110, DOI 10.1073/pnas.83.1.110; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SZYBALSKI W, 1985, GENE, V40, P169, DOI 10.1016/0378-1119(85)90039-3; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	16	3211	3836	6	188	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					484	487		10.1126/science.270.5235.484	http://dx.doi.org/10.1126/science.270.5235.484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7570003				2022-12-28	WOS:A1995TA37400045
J	ASPINALL, PJ				ASPINALL, PJ			DEPARTMENT-OF-HEALTH REQUIREMENT FOR MANDATORY COLLECTION OF DATA ON ETHNIC-GROUP OF INPATIENTS	BRITISH MEDICAL JOURNAL			English	Article							CENSUS	On 1 April the Department of Health introduced the mandatory collection of data on the ethnic group of patients admitted to hospital. Its coding was based on a national minimum standard for classifying ethnic groups, ostensibly using the categories in the 1991 census. In the census, however, one in four people from ethnic groups other than white, including many of mixed parentage, provided non-standard responses to the question on ethnic group. The Department of Health's standard does not include provision for respondents to write in a description of their ethnic group, and this has produced a flawed system out of step with current practice on collection of data on ethnic group. Different methods of analysis preclude comparison with census statistics, and the difficulties in aggregating more detailed local categories to the standard raise concerns about consistency of reporting and quality of the data.			ASPINALL, PJ (corresponding author), UNITED MED & DENT SCH,SE INST PUBL HLTH,TUNBRIDGE WELLS TN3 0XT,KENT,ENGLAND.							BOTTOMLEY V, 1993, HLTH SERVICE J  0107, P13; HEATH I, 1991, BRIT J GEN PRACT, V41, P310; LAVEIST TA, 1994, HEALTH SERV RES, V29, P1; LEE SM, 1993, ETHNIC RACIAL STUD, V16, P75, DOI 10.1080/01419870.1993.9993773; MCKENNEY NR, 1994, PUBLIC HEALTH REP, V109, P16; NICHOLLS IG, 1993, COLLECTING INFORMATI; RANGER C, 1994, HLTH SERVCE J   0407, P22; SENIOR PA, 1994, BRIT MED J, V309, P327, DOI 10.1136/bmj.309.6950.327; SILLITOE K, 1992, J ROY STAT SOC A STA, V155, P141, DOI 10.2307/2982673; Starr P, 1987, POLITICS NUMBERS; 1994, COLLECTION ETHNIC GR; 1994, OPCS CENSUS NEWSLETT, V29, P2; 1993, 1991 CENSUS ETHNIC G; 1993, HLTH QUEST SE REGION; 1994, OPCS SS942 OFF POP C; 1994, COLLECTING ETHNIC GR; 1992, 1991 CENSUS DEFINITI; 1994, ETHNIC GROUP DATA CO	18	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					1006	1009						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TA079	7580590				2022-12-28	WOS:A1995TA07900032
J	CLOSE, CF; COLLINS, A; GREGORY, W; HILL, C; JARRETT, RJ; JONES, SL; KEEN, H; SCOTT, GS; VIBERTI, G; VORA, H; YIP, J; GRENFELL, A; MACKIE, A; SAMPSON, MJ; WATKINS, PJ; FISHWICK, C; GATLING, W; HILL, RD; THOMSON, M; MARSHALL, SM; COATES, P; OWENS, DR; PETERS, JR; VORA, B; WARREN, S				CLOSE, CF; COLLINS, A; GREGORY, W; HILL, C; JARRETT, RJ; JONES, SL; KEEN, H; SCOTT, GS; VIBERTI, G; VORA, H; YIP, J; GRENFELL, A; MACKIE, A; SAMPSON, MJ; WATKINS, PJ; FISHWICK, C; GATLING, W; HILL, RD; THOMSON, M; MARSHALL, SM; COATES, P; OWENS, DR; PETERS, JR; VORA, B; WARREN, S			INTENSIVE THERAPY AND PROGRESSION TO CLINICAL ALBUMINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS AND MICROALBUMINURIA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLOMERULAR-FILTRATION RATE; MICROVASCULAR COMPLICATIONS; METABOLIC CONTROL; GLYCEMIC CONTROL; GLUCOSE CONTROL; KIDNEY-FUNCTION; BLOOD-GLUCOSE; NEPHROPATHY	Objective-To study the effect of intensive therapy of diabetes on the progression to clinical albuminuria in insulin dependent diabetic patients with microalbuminuria. Design-Randomised controlled clinical trial of intensive versus conventional therapy of diabetes for a median of 5 years (range 2-8). Setting-Nine hospital based specialist diabetes centres in England and Wales. Subjects-70 European insulin dependent diabetic patients aged 17-59 years with microalbuminuria (albumin excretion 30-199 mu g/min), but without arterial hypertension, recruited from the nine hospital based specialist diabetes centres. Interventions-Intensive diabetic therapy was allocated to 36 patients (27 men, 9 women) and conventional diabetic therapy to 34 (24 men, 10 women). Main outcome measures-Development of clinical albuminuria, defined as albumin excretion greater than 200 mu g/min on at least two consecutive occasions, and rate of change of albumin excretion. Results-Mean glycated haemoglobin concentration, similar at baseline in the two groups (intensive therapy group 10.3% (SEM 1.9%), conventional therapy group 9.8% (1.6%)), fell significantly (by 14%) in the intensive therapy group only. A significant glycaemic separation between the two groups was maintained for up to three years. Progression to clinical albuminuria occurred in six patients in each group. Blood pressure, similar at baseline, fell significantly by 1 mm Hg (95% confidence interval -4.20 to 1.43) per year in the conventional therapy group, but the difference in the rate of blood pressure change between the groups was not significant. Independent of treatment assignment, a mean blood pressure above the group mean (93.6 mm Hg), but not the glycated haemoglobin concentration, predicted progression to clinical albuminuria (relative risk 4.2, 95% confidence interval 1.3 to 13.0). Conclusions-Intensive therapy with improved glycaemic control for three years had no impact on the progression of albuminuria in insulin dependent diabetic patients with microalbuminuria. The reduction in blood pressure in the conventional therapy group may have affected outcome-in that arterial blood pressure rather than glycated haemoglobin concentration seemed to be the main predictor of progression from microalbuminuria to clinical albuminuria.	UNITED MED & DENT SCH, METAB MED UNIT, LONDON SE1 9RT, ENGLAND; UNIV LONDON KINGS COLL HOSP, LONDON, ENGLAND; POOLE GEN HOSP, POOLE, DORSET, ENGLAND; UNIV NEWCASTLE UPON TYNE, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND; UNIV WALES HOSP, CARDIFF CF4 4XW, S GLAM, WALES	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Poole Hospital; Newcastle University - UK; Cardiff University								BENDING JJ, 1986, BRIT MED J, V292, P83, DOI 10.1136/bmj.292.6513.83; CHANTLER C, 1969, CLIN SCI, V37, P169; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; DAHLJORGENSEN K, 1992, KIDNEY INT, V41, P920, DOI 10.1038/ki.1992.140; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; FAWDRY RM, 1985, EUR J NUCL MED, V11, P7, DOI 10.1007/BF00440953; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; HANSSEN KF, 1986, DIABETOLOGIA, V29, P677, DOI 10.1007/BF00870275; Jarrett R J, 1979, Diabetes Care, V2, P175, DOI 10.2337/diacare.2.2.175; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; NIELSEN HB, 1990, DIABETES RES, V15, P185; PARVING HH, 1988, BMJ-BRIT MED J, V296, P156, DOI 10.1136/bmj.296.6616.156; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; VIBERTI GC, 1979, NEW ENGL J MED, V300, P638, DOI 10.1056/NEJM197903223001202; WALKER JD, 1992, KIDNEY INT, V41, P741, DOI 10.1038/ki.1992.116; WISEMAN MJ, 1985, NEW ENGL J MED, V312, P617, DOI 10.1056/NEJM198503073121004; YIP J, 1993, LANCET, V342, P883, DOI 10.1016/0140-6736(93)91943-G; YIP J, 1993, BRIT MED J, V306, P1235; 1985, NEW ENGL J MED, V311, P365; 1992, DIABETES CARE, V4, P495	24	91	94	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 14	1995	311	7011					973	977						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580637				2022-12-28	WOS:A1995TA07900019
J	ROBERTS, J				ROBERTS, J			PLAYING POLITICS WITH THE POOR - THE CITIES	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					832	832						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RY191	7580487				2022-12-28	WOS:A1995RY19100017
J	DAVID, M; PETRICOIN, E; BENJAMIN, C; PINE, R; WEBER, MJ; LARNER, AC				DAVID, M; PETRICOIN, E; BENJAMIN, C; PINE, R; WEBER, MJ; LARNER, AC			REQUIREMENT FOR MAP KINASE (ERK2) ACTIVITY IN INTERFERON-ALPHA-STIMULATED AND INTERFERON-BETA-STIMULATED GENE-EXPRESSION THROUGH STAT PROTEINS	SCIENCE			English	Article							ACTIVATION; CELLS	Activation of early response genes by interferons (IFNs) requires tyrosine phosphorylation of STAT (signal transducers and activators of transcription) proteins. It was found that the serine-threonine kinase mitogen-activated protein kinase (MAPK) [specifically, the 42-kilodalton MAPK or extracellular signal-regulated kinase 2 (ERK2)] interacted with the alpha subunit of IFN-alpha/beta receptor in vitro and in vivo. Treatment of cells with IFN-beta induced tyrosine phosphorylation and activation of MAPK and caused MAPK and Stat1 alpha to coimmunoprecipitate. Furthermore, expression of dominant negative MAPK inhibited IFN-beta-induced transcription. Therefore, MAPK appears to regulate IFN-alpha and IFN-beta activation of early response genes by modifying the Jak-STAT signaling cascade.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892; BIOGEN INC,CAMBRIDGE,MA 02142; PUBL HLTH RES INST,NEW YORK,NY 10016; UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,CTR CANC,CHARLOTTESVILLE,VA 22908	US Food & Drug Administration (FDA); Biogen; University of Virginia; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DAVID M, UNPUB; FINBLOOM DS, UNPUB; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	16	519	536	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1721	1723		10.1126/science.7569900	http://dx.doi.org/10.1126/science.7569900			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569900				2022-12-28	WOS:A1995RV94800038
J	ANDERSON, JW; JOHNSTONE, BM; COOKNEWELL, ME				ANDERSON, JW; JOHNSTONE, BM; COOKNEWELL, ME			METAANALYSIS OF THE EFFECTS OF SOY PROTEIN-INTAKE ON SERUM-LIPIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBSTITUTING SOYBEAN PROTEIN; PLASMA-CHOLESTEROL LEVELS; HEALTHY-YOUNG-WOMEN; HYPERCHOLESTEROLEMIC PATIENTS; ANIMAL PROTEIN; DAIRY PROTEIN; LOW-FAT; FAMILIAL HYPERCHOLESTEROLEMIA; II HYPERLIPOPROTEINEMIA; NORMOLIPIDEMIC SUBJECTS	Background. In laboratory animals, the consumption of soy protein, rather than animal protein, decreases serum cholesterol concentrations, but studies in humans have been inconclusive. In this meta-analysis of 38 controlled clinical trials, we examined the relation between soy protein consumption and serum lipid concentrations in humans. Methods. We used a random-effects model to quantify the average effects of soy protein intake on serum lipids in the studies we examined and used hierarchical mixed-effects regression models to predict variation as a function of the characteristics of the studies. Results. In most of the studies, the intake of energy, fat, saturated fat, and cholesterol was similar when the subjects ingested control and soy-containing diets; soy protein intake averaged 47 g per day. Ingestion of soy protein was associated with the following net changes in serum lipid concentrations from the concentrations reached with the control diet: total cholesterol, a decrease of 23.2 mg per deciliter (0.60 mmol per liter; 95 percent confidence interval, 13.5 to 32.9 mg per deciliter [0.35 to 0.85 mmol per liter]), or 9.3 percent; low-density lipoprotein (LDL) cholesterol, a decrease of 21.7 mg per deciliter (0.56 mmol per liter; 95 percent confidence interval, 11.2 to 31.7 mg per deciliter [0.30 to 0.82 mmol per liter]), or 12.9 percent; and triglycerides, a decrease of 13.3 mg per deciliter (0.15 mmol per liter; 95 percent confidence interval, 0.3 to 25.7 mg per deciliter [0.003 to 0.29 mmol per liter]), or 10.5 percent, The changes in serum cholesterol and LDL cholesterol concentrations were directly related to the initial serum cholesterol concentration (P<0.001). The ingestion of soy protein was associated with a nonsignificant 2.4 percent increase in serum concentrations of high-density lipoprotein (HDL) cholesterol. Conclusions, We found that the consumption of soy protein rather than animal protein significantly decreased serum concentrations of total cholesterol, LDL cholesterol, and triglycerides.	UNIV KENTUCKY,COLL MED,DEPT BEHAV SCI,LEXINGTON,KY; UNIV KENTUCKY,COLL MED,DEPT MED,LEXINGTON,KY; UNIV KENTUCKY,DEPT NUTR SCI,LEXINGTON,KY	University of Kentucky; University of Kentucky; University of Kentucky	ANDERSON, JW (corresponding author), VET AFFAIRS MED CTR,MED SERV,METAB RES GRP,111C,LEESTOWN RD,LEXINGTON,KY 40511, USA.							Anthony M. S., 1995, Journal of Nutrition, V125, p803S; ANTHONY MS, 1994, CIRCULATION, V90, P235; ANTHONY MS, 1995, CIRCULATION, V91, P925; BAKHIT RM, 1994, J NUTR, V124, P213, DOI 10.1093/jn/124.2.213; Bryk A. S., 1992, HIERARCHICAL LINEAR; BRYK AS, 1994, HLM23; CARROLL KK, 1978, AM J CLIN NUTR, V31, P1312, DOI 10.1093/ajcn/31.8.1312; CARROLL KK, 1991, J AM DIET ASSOC, V91, P820; CARROLL KK, 1982, FED PROC, V41, P2792; CASSIDY A, 1994, AM J CLIN NUTR, V60, P333, DOI 10.1093/ajcn/60.3.333; CHAIT A, 1993, CIRCULATION, V88, P3008, DOI 10.1161/01.CIR.88.6.3008; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESCOVICH GC, 1980, LANCET, V2, P709; DWYER JT, 1994, J AM DIET ASSOC, V94, P739, DOI 10.1016/0002-8223(94)91939-9; FUMAGALLI R, 1982, ATHEROSCLEROSIS, V43, P341, DOI 10.1016/0021-9150(82)90034-X; GADDI A, 1987, ARCH DIS CHILD, V62, P274, DOI 10.1136/adc.62.3.274; GADDI A, 1991, AM J CLIN NUTR, V53, P1191, DOI 10.1093/ajcn/53.5.1191; GIOVANNETTI PM, 1986, NUTR RES, V6, P609, DOI 10.1016/S0271-5317(86)80002-1; GOLDBERG AP, 1982, ATHEROSCLEROSIS, V43, P355, DOI 10.1016/0021-9150(82)90035-1; GRUNDY SM, 1983, AM J CLIN NUTR, V38, P245, DOI 10.1093/ajcn/38.2.245; HILLEBOE H E, 1957, J Chronic Dis, V6, P210, DOI 10.1016/0021-9681(57)90003-6; HODGES RE, 1967, AM J CLIN NUTR, V20, P198, DOI 10.1093/ajcn/20.2.198; HOLMES WL, 1980, ATHEROSCLEROSIS, V36, P379, DOI 10.1016/0021-9150(80)90218-X; HUFF MW, 1977, ATHEROSCLEROSIS, V28, P187, DOI 10.1016/0021-9150(77)90156-3; HUFF MW, 1984, AM J CLIN NUTR, V39, P888, DOI 10.1093/ajcn/39.6.888; Ignatowski A., 1908, ARCH MED EXP ANAT PA, V20, P1; JENKINS DJA, 1989, ATHEROSCLEROSIS, V78, P99, DOI 10.1016/0021-9150(89)90213-X; KOLB S, 1984, NUTR REP INT, V30, P719; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LAURIN D, 1991, AM J CLIN NUTR, V54, P98, DOI 10.1093/ajcn/54.1.98; LOVATI MR, 1987, J CLIN INVEST, V80, P1498, DOI 10.1172/JCI113232; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MEINERTZ H, 1989, AM J CLIN NUTR, V50, P786, DOI 10.1093/ajcn/50.4.786; MEINERTZ H, 1988, ATHEROSCLEROSIS, V72, P63, DOI 10.1016/0021-9150(88)90063-9; MERCER NJH, 1987, NUTR REP INT, V35, P279; Morris CN, 1992, BAYESIAN STATISTICS, P321; POTTER SM, 1993, AM J CLIN NUTR, V58, P501, DOI 10.1093/ajcn/58.4.501; SACKS FM, 1983, J LIPID RES, V24, P1012; SANCHEZ A, 1985, NUTR REP INT, V32, P1047; SCHWANDT P, 1981, ATHEROSCLEROSIS, V40, P371, DOI 10.1016/0021-9150(81)90148-9; SETCHELL KDR, 1985, ESTROGENS ENV, V2, P69; SHOREY RL, 1981, AM J CLIN NUTR, V34, P1769, DOI 10.1093/ajcn/34.9.1769; SIRTORI CR, 1985, ANN NUTR METAB, V29, P348, DOI 10.1159/000176991; SIRTORI CR, 1977, LANCET, V1, P275; SIRTORI CR, 1979, AM J CLIN NUTR, V32, P1645, DOI 10.1093/ajcn/32.8.1645; Steele M. G., 1992, Australian Journal of Nutrition and Dietetics, V49, P24; Terpstra A H, 1983, World Rev Nutr Diet, V42, P1; VANRAAIJ JMA, 1982, AM J CLIN NUTR, V35, P925, DOI 10.1093/ajcn/35.5.925; VANRAAIJ JMA, 1981, AM J CLIN NUTR, V34, P1261, DOI 10.1093/ajcn/34.7.1261; VERRILLO A, 1985, ATHEROSCLEROSIS, V54, P321, DOI 10.1016/0021-9150(85)90125-X; VESSBY B, 1982, HUM NUTR-APPL NUTR, V36, P179; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WIDHALM K, 1993, J PEDIATR-US, V123, P30, DOI 10.1016/S0022-3476(05)81533-1; WIDHALM K, 1986, NUTRITIONAL EFFECTS, P133; WIEBE SL, 1984, AM J CLIN NUTR, V40, P982, DOI 10.1093/ajcn/40.5.982; WOLFE BM, 1981, NUTR REP INT, V24, P1187; WOLFE BM, 1985, NUTR REP INT, V32, P1057; 1986, DEP AGR HDB, V816; 1992, COMBINING INFORMATIO	60	1497	1557	4	102	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					276	282		10.1056/NEJM199508033330502	http://dx.doi.org/10.1056/NEJM199508033330502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL694	7596371	Bronze			2022-12-28	WOS:A1995RL69400002
J	MOMIN, F; CHANDRASEKAR, PH				MOMIN, F; CHANDRASEKAR, PH			ANTIMICROBIAL PROPHYLAXIS IN BONE-MARROW TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Review							CYTOMEGALO-VIRUS INFECTION; HERPES-SIMPLEX-VIRUS; COLONY-STIMULATING FACTOR; PLACEBO-CONTROLLED TRIAL; VERSUS-HOST DISEASE; SEVERELY IMMUNOCOMPROMISED PATIENTS; ACUTE NONLYMPHOCYTIC LEUKEMIA; VARICELLA-ZOSTER VIRUS; DOUBLE-BLIND TRIAL; FACTOR GM-CSF	Objective: To review the efficacy of antimicrobial prophylaxis in bone marrow Data Sources: English-language articles identified through a MEDLINE search (1975 to 1994) and through the bibliographies of selected articles. Study Selection: Articles on the use of antimicrobial agents for the prevention of infections in bone marrow transplant recipients and neutropenic patients with cancer. Data Synthesis: Use of quinolones reduces the incidence of gram-negative bacillary infections but increases the frequency of infections caused by streptococci and staphylococci before marrow engraftment. Death associated with cu-hemolytic streptococcal bacteremia is of concern and may justify the use of penicillin for prophylaxis. Conflicting data exist regarding prophylaxis with vancomycin. Although ganciclovir has diminished the incidence of infection and disease caused by cytomegalovirus in seropositive recipients, drug-induced myelotoxicity, emergence of resistant virus, and cost are major concerns. High-dose acyclovir may suppress reactivation of cytomegalovirus. Acyclovir prevents herpes simplex virus infection, but its prolonged use to prevent reactivation of varicella-zoster virus is not cost-effective and remains controversial. Fluconazole prevents colonization and infection with Candida species other than C. krusei and Torulopsis glabrata before marrow engraftment. Elevation of cyclosporine concentrations because of interaction between azoles and cyclosporine requires close monitoring of plasma drug levels. Optimal chemoprophylaxis is not available against aspergillus or fungal infections that develop after engraftment. Trimethoprim-sulfamethoxazole decreases the incidence of Pneumocystis carinii infection and ''late'' bacterial infections in recipients of allogeneic transplants who have chronic graft-versus-host disease. Conclusion: Available antimicrobial agents can prevent common bacterial, viral, and ''early'' fungal infections. However, the few studies that address antimicrobial prophylaxis in bone marrow transplantation have not always shown a survival benefit. Toxicity and cost-effectiveness of prophylactic strategies should be critically evaluated.	WAYNE STATE UNIV, SCH MED, DIV INFECT DIS, HEMATOL ONCOL INFECT DIS LIAISON UNIT, DETROIT, MI 48201 USA	Wayne State University								ADVANI R, 1992, ANN INTERN MED, V116, P183, DOI 10.7326/0003-4819-116-3-183; AKHTAR A, 1992, JUN INT S INF IMM HO; ALANGADEN G, 1994, BONE MARROW TRANSPL, V14, P919; [Anonymous], 1994, JAMA, V272, P1183; ARMSTRONG D, 1981, CLIN APPROACH INFECT, P195; ATKINSON K, 1991, BRIT J HAEMATOL, V79, P57, DOI 10.1111/j.1365-2141.1991.tb08007.x; ATKINSON K, 1990, BONE MARROW TRANSPL, V5, P69; ATTAL M, 1991, J CLIN ONCOL, V9, P865, DOI 10.1200/JCO.1991.9.5.865; AULITZKY WE, 1988, J INFECT DIS, V158, P488, DOI 10.1093/infdis/158.2.488a; BACIGALUPO A, 1994, BONE MARROW TRANSPL, V13, P783; BODEY GP, 1986, AM J MED, V81, P11, DOI 10.1016/0002-9343(86)90510-3; BODEY GP, 1988, J HOSP INFECT, V11, P411, DOI 10.1016/0195-6701(88)90220-4; BOW EJ, 1988, AM J MED, V84, P847, DOI 10.1016/0002-9343(88)90062-9; BOWDEN R, 1992, OCT INT C ANT AG CHE; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; BOWDEN RA, 1990, SEMIN HEMATOL, V27, P17; BOWDEN RA, 1987, TRANSFUSION, V27, P478, DOI 10.1046/j.1537-2995.1987.27688071699.x; BUSTAMANTE CI, 1991, J CLIN ONCOL, V9, P1903, DOI 10.1200/JCO.1991.9.10.1903; CHANDRASEKAR PH, 1991, SEP ANN M AM COLL PH; CHOU SW, 1990, REV INFECT DIS, V12, pS727; CHOU SW, 1987, J INFECT DIS, V155, P1054, DOI 10.1093/infdis/155.5.1054; CLASSEN DC, 1990, AM J MED, V89, P441, DOI 10.1016/0002-9343(90)90373-L; COLLIER AC, 1984, ANN INTERN MED, V101, P205, DOI 10.7326/0003-4819-101-2-205; CONNEALLY E, 1990, BONE MARROW TRANSPL, V5, P403; CUTTNER J, 1986, AM J MED, V81, P771, DOI 10.1016/0002-9343(86)90342-6; DANTONIO D, 1992, BONE MARROW TRANSPL, V9, P299; DEKKER AW, 1987, ANN INTERN MED, V106, P7, DOI 10.7326/0003-4819-106-1-7; DELFAVERO A, 1991, ANN INTERN MED, V115, P7, DOI 10.7326/0003-4819-115-1-7; DEPAUW BE, 1990, BONE MARROW TRANSPL, V5, P179; DEROUIN F, 1986, BONE MARROW TRANSPL, V1, P67; DEROUIN F, 1992, CLIN INFECT DIS, V15, P267, DOI 10.1093/clinids/15.2.267; DIETRICH M, 1979, EUR J CANCER, V15, P45; DONNELLY JP, 1984, J HOSP INFECT, V5, P83, DOI 10.1016/0195-6701(84)90105-1; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; DROBYSKI WR, 1991, TRANSPLANTATION, V52, P155; EINSELE H, 1991, BLOOD, V77, P1104; ELLIS ME, 1994, EUR J CLIN MICROBIOL, V13, P3, DOI 10.1007/BF02026116; ERICE A, 1989, NEW ENGL J MED, V320, P289, DOI 10.1056/NEJM198902023200505; EZDINLI EZ, 1979, JAMA-J AM MED ASSOC, V242, P258, DOI 10.1001/jama.242.3.258; FOOT ABM, 1994, BONE MARROW TRANSPL, V14, P241; GANLY PS, 1988, POSTGRAD MED J, V64, P389, DOI 10.1136/pgmj.64.751.389; GIEBINK GS, 1986, J INFECT DIS, V154, P590, DOI 10.1093/infdis/154.4.590; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; GOODRICH JM, 1991, J INFECT DIS, V164, P731, DOI 10.1093/infdis/164.4.731; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; GORIN NC, 1990, BLOOD S, V76, pA542; GRANT SM, 1990, DRUGS, V39, P877, DOI 10.2165/00003495-199039060-00006; GRANT SM, 1989, DRUGS, V37, P310, DOI 10.2165/00003495-198937030-00003; GREENE J, 1992, JUN INT S INF IMM HO; GRUNDY JE, 1986, LANCET, V1, P159; GUIOT HFL, 1983, J INFECT DIS, V147, P615, DOI 10.1093/infdis/147.4.615; GUIOT HFL, 1990, INFECTION, V18, P131, DOI 10.1007/BF01642100; GULATI SC, 1992, ANN INTERN MED, V116, P177, DOI 10.7326/0003-4819-116-3-177; HANN IM, 1982, J ANTIMICROB CHEMOTH, V10, P489, DOI 10.1093/jac/10.6.489; HANN IM, 1982, LANCET, V1, P826; HERTENSTEIN B, 1994, ANN HEMATOL, V68, P21, DOI 10.1007/BF01695915; JEFFERY GM, 1991, AM J MED, V90, P685, DOI 10.1016/S0002-9343(05)80056-7; JOHNSON JR, 1992, CLIN INFECT DIS, V14, P38, DOI 10.1093/clinids/14.1.38; KARP JE, 1987, ANN INTERN MED, V106, P1, DOI 10.7326/0003-4819-106-1-1; KERN W, 1990, INFECTION, V18, P138, DOI 10.1007/BF01642101; KRAMER MR, 1990, ANN INTERN MED, V113, P327, DOI 10.7326/0003-4819-113-4-327; KROWKA MJ, 1985, CHEST, V87, P237, DOI 10.1378/chest.87.2.237; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; LEW MA, 1991, TRANSPLANTATION, V51, P630, DOI 10.1097/00007890-199103000-00017; LINK H, 1990, BLOOD S, V76, pA152; LOCKSLEY RM, 1985, J INFECT DIS, V152, P1172, DOI 10.1093/infdis/152.6.1172; LOWENBERG B, 1983, TRANSPLANTATION, V35, P30, DOI 10.1097/00007890-198301000-00007; LUM LG, 1987, BLOOD, V69, P369; MACHADO CM, 1992, BONE MARROW TRANSPL, V10, P475; MACHIDA H, 1986, ANTIMICROB AGENTS CH, V29, P524, DOI 10.1128/AAC.29.3.524; MCDONALD GB, 1993, ANN INTERN MED, V118, P255, DOI 10.7326/0003-4819-118-4-199302150-00003; MENICHETTI F, 1989, BONE MARROW TRANSPL, V4, P489; METCALF D, 1990, CANCER, V65, P1286; MEUNIER F, 1987, REV INFECT DIS, V9, P408; MEUNIERCARPENTIER F, 1984, NEW ENGL J MED, V311, P1056; MEUNIERCARPENTIER F, 1981, AM J MED, V71, P363, DOI 10.1016/0002-9343(81)90162-5; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MEYERS JD, 1982, AM J MED, V73, P229, DOI 10.1016/0002-9343(82)90097-3; MEYERS JD, 1986, AM J MED, V81, P27, DOI 10.1016/0002-9343(86)90511-5; MEYERS JD, 1990, SEMIN ONCOL, V17, P10; MEYERS JD, 1990, J INFECT DIS, V162, P373, DOI 10.1093/infdis/162.2.373; MEYERS JD, 1986, J INFECT DIS, V153, P478, DOI 10.1093/infdis/153.3.478; MEYERS JD, 1989, EUR J CANCER CLIN ON, V25, P1369, DOI 10.1016/0277-5379(89)90089-8; MEYERS JD, 1983, CLIN HAEMATOL, V12, P791, DOI 10.1016/S0308-2261(83)80011-3; MILLER W, 1986, BLOOD, V67, P1162; MILLER WJ, 1991, BONE MARROW TRANSPL, V7, P227; MILLIKEN ST, 1990, REV INFECT DIS, V12, pS374; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; NOVAKOVA I, 1991, ANTIMICROB AGENTS CH, V35, P672, DOI 10.1128/AAC.35.4.672; OWENS NJ, 1984, ARCH INTERN MED, V144, P290, DOI 10.1001/archinte.144.2.290; PAULIN T, 1986, SCAND J INFECT DIS, V18, P199, DOI 10.3109/00365548609032328; PENDRY K, 1990, BONE MARROW TRANSPL, V5, P65; PERFECT JR, 1992, J INFECT DIS, V165, P891, DOI 10.1093/infdis/165.5.891; PERSONS DA, 1991, NEW ENGL J MED, V325, P1315; Pizzo PA, 1989, REV INFECT DIS    S7, V11, pS1551; POWLES R, 1990, LANCET, V336, P1417, DOI 10.1016/0140-6736(90)93111-2; PRENTICE HG, 1994, LANCET, V343, P749, DOI 10.1016/S0140-6736(94)91835-X; PRZEPIORKA D, 1994, BONE MARROW TRANSPL, V13, P461; RANSON MR, 1990, J HOSP INFECT, V15, P95, DOI 10.1016/0195-6701(90)90025-J; REUSSER P, 1992, J INFECT DIS, V166, P473, DOI 10.1093/infdis/166.3.473; ROUSEY SR, 1991, AM J MED, V91, P484, DOI 10.1016/0002-9343(91)90184-Y; ROZENBERGARSKA M, 1989, INFECTION, V17, P240, DOI 10.1007/BF01639528; SARAL R, 1984, CLIN HAEMATOL, V13, P645; SARAL R, 1981, NEW ENGL J MED, V305, P63, DOI 10.1056/NEJM198107093050202; SCHAFFNER A, 1985, J INFECT DIS, V151, P902, DOI 10.1093/infdis/151.5.902; SCHIMPFF SC, 1975, ANN INTERN MED, V82, P351, DOI 10.7326/0003-4819-82-3-351; SCHMEISER T, 1988, SCAND J INFECT DIS, V20, P625, DOI 10.3109/00365548809035663; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SELBY PJ, 1989, BRIT J CANCER, V59, P434, DOI 10.1038/bjc.1989.88; SHERERTZ RJ, 1987, AM J MED, V83, P709, DOI 10.1016/0002-9343(87)90902-8; SOULIERLAUPER M, 1991, AM J HEMATOL, V38, P324, DOI 10.1002/ajh.2830380413; STRAUS SE, 1984, ANN INTERN MED, V100, P522, DOI 10.7326/0003-4819-100-4-522; SUD IJ, 1983, ANTIMICROB AGENTS CH, V23, P185, DOI 10.1128/AAC.23.1.185; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; THE TH, 1990, REV INFECT DIS, V12, pS737; TRICOT G, 1987, REV INFECT DIS, V9, pS94; VANDENBERG AP, 1991, J INFECT DIS, V164, P265; VANDERMEER JWM, 1984, SEMIN HEMATOL, V21, P123; WADE JC, 1982, ANN INTERN MED, V96, P265, DOI 10.7326/0003-4819-96-3-265; WINGARD JR, 1987, AM J MED, V83, P1103, DOI 10.1016/0002-9343(87)90949-1; WINGARD JR, 1988, MEDICINE, V67, P175, DOI 10.1097/00005792-198805000-00004; WINGARD JR, 1993, ANTIMICROB AGENTS CH, V37, P1847, DOI 10.1128/AAC.37.9.1847; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; WINGARD JR, 1990, REV INFECT DIS, V12, pS793; Winston D J, 1993, Curr Clin Top Infect Dis, V13, P293; WINSTON DJ, 1990, AM J MED, V88, P36, DOI 10.1016/0002-9343(90)90125-W; WINSTON DJ, 1986, AM J MED, V80, P884, DOI 10.1016/0002-9343(86)90633-9; WINSTON DJ, 1983, ARCH INTERN MED, V143, P1735, DOI 10.1001/archinte.143.9.1735; WINSTON DJ, 1990, REV INFECT DIS, V12, pS776; WINSTON DJ, 1993, ANN INTERN MED, V118, P179, DOI 10.7326/0003-4819-118-3-199302010-00004; WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003; WINSTON DJ, 1979, ANN INTERN MED, V91, P835, DOI 10.7326/0003-4819-91-6-835; WOLFSON JS, 1988, ANN INTERN MED, V108, P238, DOI 10.7326/0003-4819-108-2-238; ZAIA JA, 1990, HEMATOL ONCOL CLIN N, V4, P603, DOI 10.1016/S0889-8588(18)30481-7	135	59	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					205	215		10.7326/0003-4819-123-3-199508010-00008	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598303				2022-12-28	WOS:A1995RL10400008
J	COCKERELL, OC; JOHNSON, AL; SANDER, JWAS; HART, YM; SHORVON, SD				COCKERELL, OC; JOHNSON, AL; SANDER, JWAS; HART, YM; SHORVON, SD			REMISSION OF EPILEPSY - RESULTS FROM THE NATIONAL GENERAL-PRACTICE STUDY OF EPILEPSY	LANCET			English	Article							1ST SEIZURE; PROGNOSIS; POPULATION; ROCHESTER; MINNESOTA; NGPSE	Remission of seizures is a crucial measure of outcome in epilepsy. The National General Practice Study of Epilepsy (NGPSE) aimed to investigate the remission of patients with epilepsy and the effect of various factors on the likelihood of remission. The NGPSE is a prospective population-based study free from major selection bias. We enrolled 1091 patients with newly diagnosed or suspected epilepsy who attended one of 275 general practices throughout the UK between 1984 and 1987, Remission was analysed in those patients who were classified after 6 months as having definite epilepsy (n=564) or possible epilepsy (n=228). After 9 years from the index seizure, 86% (95% CI 81-90) of patients with definite epilepsy had achieved a remission of 3 years and 68% (61-75) a remission of 5 years. For the complete cohort, including those with possible epilepsy, the remission rates at 9 years were 87% (83-91) for 3-year remission and 71% (65-77) for 5-year remission. The proportion of patients with definite epilepsy who were still in remission at 9 years' follow-up (terminal remission) was 68% (62-74) for 3-year and 54% (48-60) for 5-year remission. 61% (56-68) of patients with idiopathic seizures and 61% (46-75) of those with remote symptomatic epilepsy had achieved 5-year remission by 9 years. Overall, age and seizure type had little effect on the chances of achieving remission, This study confirms the good outcome for seizure control in the majority of patients.	CHALFONT CTR EPILEPSY, CHALFONT ST PETER, BUCKS, ENGLAND; INST PUBL HLTH, MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND	MRC Biostatistics Unit; University of Cambridge	COCKERELL, OC (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, EPILEPSY RES GRP, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.		Sander, Josemir W/C-1576-2008; Shorvon, Simon D/A-2019-2009	Sander, Josemir W/0000-0001-6041-9661; 				ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; BEGHI E, 1992, EPILEPSIA, V33, P45; CHADWICK D, 1991, LANCET, V337, P1175; CHADWICK D, 1993, BRIT MED J, V306, P1374; COCKERELL OC, 1994, LANCET, V344, P918, DOI 10.1016/S0140-6736(94)92270-5; COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; CROMBIE DL, 1960, BRIT MED J, V2, P416; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; GOODRIDGE DMG, 1983, BRIT MED J, V287, P645, DOI 10.1136/bmj.287.6393.645; HART YM, 1989, NEUROEPIDEMIOLOGY, V8, P221; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; JANZ D, 1990, COMPREHENSIVE EPILEP, P171; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANFORD M, 1992, NEUROLOGY, V42, P1911; RAMSAY RE, 1983, NEUROLOGY, V33, P904, DOI 10.1212/WNL.33.7.904; RODIN EA, 1968, PROGNOSIS PATIENTS E; SANDER JWAS, 1993, LANCET, V342, P874, DOI 10.1016/0140-6736(93)92737-E; SANDER JWAS, 1993, EPILEPSIA, V34, P1007, DOI 10.1111/j.1528-1157.1993.tb02126.x; SHAFER SQ, 1988, EPILEPSIA, V29, P590, DOI 10.1111/j.1528-1157.1988.tb03767.x; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; VANDONSELAAR CA, 1989, NEUROLOGY, V39, P267, DOI 10.1212/WNL.39.2.267	23	291	295	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 15	1995	346	8968					140	144		10.1016/S0140-6736(95)91208-8	http://dx.doi.org/10.1016/S0140-6736(95)91208-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603228				2022-12-28	WOS:A1995RJ03100008
J	ZHENG, XF; FIORENTINO, D; CHEN, J; CRABTREE, GR; SCHREIBER, SL				ZHENG, XF; FIORENTINO, D; CHEN, J; CRABTREE, GR; SCHREIBER, SL			TOR KINASE DOMAINS ARE REQUIRED FOR 2 DISTINCT FUNCTIONS, ONLY ONE OF WHICH IS INHIBITED BY RAPAMYCIN	CELL			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN PHOSPHATASE; YEAST; MUTATIONS; VECTORS; TARGET	The rapamycin-sensitive signaling pathway is required to transduce specific mitogenic signals to the cell cycle machinery responsible for G1 progression. Genetic studies in yeast identified two related genes on this pathway, TOR1 and TOR2, thought to encode novel phosphatidylinositol kinases. We now show that an intact kinase domain is required for the G1 cell cycle functions of both proteins, for the ability of a mutation in a neighboring FKBP12-rapamycin-binding domain of the TOR1 protein to inhibit the growth of yeast cells when overexpressed, and for the essential function of the TOR2 protein. The G1 function of both TOR proteins is sensitive to rapamycin, but the essential function of TOR2 is not. Thus, FKBP12-rapamycin does not appear to inhibit the kinase activity of TOR proteins in a general way; instead, it may interfere selectively with TOR protein binding to or phosphorylation of G1 effecters.	HARVARD UNIV, DEPT CHEM, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT DEV BIOL, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA	Harvard University; Harvard University; Howard Hughes Medical Institute; Stanford University; Stanford University	ZHENG, XF (corresponding author), HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA.			Chen, Jie/0000-0002-7887-3747; Fiorentino, David/0000-0001-7951-3674	NATIONAL CANCER INSTITUTE [R37CA039612, R01CA039612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39612] Funding Source: Medline; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRIZUELA L, 1991, MOL CELL BIOL, V11, P4616, DOI 10.1128/MCB.11.9.4616; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11149; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; GUTHRIE C, 1991, METH ENZYMOL, V194; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARLOW E, 1988, ANTIBODIES; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SIKORSKI RS, 1989, GENETICS, V122, P19; STACK JH, 1994, J BIOL CHEM, V269, P31552; STAN R, 1994, J BIOL CHEM, V269, P32027	22	244	254	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					121	130		10.1016/0092-8674(95)90058-6	http://dx.doi.org/10.1016/0092-8674(95)90058-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606777	Bronze			2022-12-28	WOS:A1995RK42400015
J	BEG, AA; SHA, WC; BRONSON, RT; GHOSH, S; BALTIMORE, D				BEG, AA; SHA, WC; BRONSON, RT; GHOSH, S; BALTIMORE, D			EMBRYONIC LETHALITY AND LIVER DEGENERATION IN MICE LACKING THE RELA COMPONENT OF NF-KAPPA-B	NATURE			English	Article								NF-kappa B, which consists of two polypeptides, p50 (M, 50K) and p65/RelA (M(r) 65K), is thought to be a key regulator of genes involved in responses to infection, inflammation and stress(1). Indeed, although developmentally normal, mice deficient in p50 display functional defects in immune responses(2). Here we describe the generation of mice deficient in the RelA subunit of NF-kappa B. Disruption of the relA locus leads to embryonic lethality at 15-16 days of gestation, concomitant with a massive degeneration of the liver by programmed cell death or apoptosis. Embryonic fibroblasts from RelA-deficient mice are defective in the tumour necrosis factor (TNF)-mediated induction of messenger RNAs for I kappa B alpha and granulocyte/macrophage colony stimulating factor (GM-CSF), although basal levels of these transcripts are unaltered. These results indicate that RelA controls inducible, but not basal, transcription in NF-kappa B-regulated pathways.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; TUFTS UNIV,SCH MED & VET MED,DEPT PATHOL,BOSTON,MA 02111; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520	Massachusetts Institute of Technology (MIT); Tufts University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University								ABBADIE C, 1993, CELL, V75, P889; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CRESSMANDE, 1994, J BIOL CHEM, V269, P30429; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRILLI M, 1991, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; STEIN B, 1993, EMBO J, V10, P3879; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEIH F, 1994, CELL, V80, P331; WYLLIE AH, 1994, J PATHOL, V142, P67	23	1585	1645	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					167	170		10.1038/376167a0	http://dx.doi.org/10.1038/376167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603567				2022-12-28	WOS:A1995RJ02800059
J	FONG, GH; ROSSANT, J; GERTSENSTEIN, M; BREITMAN, ML				FONG, GH; ROSSANT, J; GERTSENSTEIN, M; BREITMAN, ML			ROLE OF THE FLT-1 RECEPTOR TYROSINE KINASE IN REGULATING THE ASSEMBLY OF VASCULAR ENDOTHELIUM	NATURE			English	Article							GROWTH-FACTOR; MOLECULAR-CLONING; STEM-CELLS; EXPRESSION; VASCULOGENESIS; ANGIOGENESIS; FLK-1; MICE; TEK	THE vascular endothelial growth factor (VEGF) and its high-affinity binding receptors, the tyrosine kinases Flt-1 and Flk-1, are thought to be important for the development of embryonic vasculature(1-8). Here we report that Flt-1 is essential for the organization of embryonic vasculature, but is not essential for endothelial cell differentiation. Mouse embryos homozygous for a targeted mutation in the flt-1 locus, flt-1(lcz), formed endothelial cells in both embryonic and extra-embryonic regions, but assembled these cells into abnormal vascular channels and died in utero at mid-somite stages. At earlier stages, the blood islands of flt-1(lcz) homozygotes were abnormal, with angioblasts in the interior as well as on the periphery. We suggest that the Flt-1 signalling pathway may regulate normal endothelial cell-cell or cell-matrix interactions during vascular development.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BRELER G, 1992, DEVELOPMENT, V114, P521; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FINNERTY H, 1993, ONCOGENE, V8, P2293; Hogan B, 1994, MANIPULATING MOUSE E; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KORHNONEN J, 1994, ONCOGENE, V9, P995; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NODEN DM, 1989, AM REV RESPIR DIS, V149, P1097; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PARK JE, 1994, J BIOL CHEM, V269, P25646; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PATAN S, 1993, ANAT EMBRYOL, V187, P121; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; RISAU W, 1988, DEVELOPMENT, V102, P471; Risau W., 1991, DEV VASCULAR SYSTEM, P58; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P622; SHIBUYA M, 1990, ONCOGENE, V5, P519; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	27	2055	2159	2	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					66	70		10.1038/376066a0	http://dx.doi.org/10.1038/376066a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596436				2022-12-28	WOS:A1995RH11100063
J	BELL, SP; MITCHELL, J; LEBER, J; KOBAYASHI, R; STILLMAN, B				BELL, SP; MITCHELL, J; LEBER, J; KOBAYASHI, R; STILLMAN, B			THE MULTIDOMAIN STRUCTURE OF ORC1P REVEALS SIMILARITY TO REGULATORS OF DNA-REPLICATION AND TRANSCRIPTIONAL SILENCING	CELL			English	Article							ORIGIN RECOGNITION COMPLEX; SACCHAROMYCES-CEREVISIAE; YEAST; LOCI; REPRESSION; DIVISION; MUTANTS; MITOSIS; CDC6	The origin recognition complex (ORC) is a six protein assembly that binds S. cerevisiae origins of replication and directs DNA replication throughout the genome and transcriptional silencing at the yeast mating-type loci. Here we report the cloning of the genes encoding the 120 kDa (ORC1), 62 kDa (ORC3), and 56 kDa (ORC4) subunits of ORC and the reconstitution of the complete complex after expression of all six subunits in insect cells. Orc1p is related to Cdc6p and Cdc18p, which regulate DNA replication and mitosis, and to Sir3p, a regulator of transcriptional silencing. The N-terminal region of Orc1p is highly related to Sir3p, and studies of Orc1p/Sir3p chimeric proteins indicate that this domain is dedicated to the transcriptional silencing function of ORC.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	BELL, SP (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Bell, Stephen/0000-0002-2876-610X; Stillman, Bruce/0000-0002-9453-4091	PHS HHS [A120460] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NEWTON CS, 1993, CURR OPIN GENE DEV, V3, P752; PLATTI S, 1995, EMBO J, V14, P3788; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	28	216	221	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					563	568		10.1016/0092-8674(95)90096-9	http://dx.doi.org/10.1016/0092-8674(95)90096-9			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585959	Bronze			2022-12-28	WOS:A1995TF24800009
J	SUBRAMANIAN, V; MEYER, BI; GRUSS, P				SUBRAMANIAN, V; MEYER, BI; GRUSS, P			DISRUPTION OF THE MURINE HOMEOBOX GENE CDX1 AFFECTS AXIAL SKELETAL IDENTITIES BY ALTERING THE MESODERMAL EXPRESSION DOMAINS OF HOX GENES	CELL			English	Article							EMBRYONIC STEM-CELLS; CAUDAL GENE; C-ELEGANS; HOMEOTIC TRANSFORMATION; CERVICAL-VERTEBRAE; ECTOPIC EXPRESSION; DROSOPHILA; MOUSE; MICE; GRADIENT	Cdx1 is expressed along the embryonic axis from day 7.5 postcoitum until day 12, by which time the anterior limit of expression has regressed from the hindbrain level to the forelimb bud region. To assign a functional role for Cdx1 in murine embryonic development, we have inactivated the gene via homologous recombination. Viable fertile homozygous mutant mice were obtained that show anterior homeotic transformations of vertebrae. These abnormalities were concomitant with posterior shifts of Hox gene expression domains in the semitic mesoderm. The presence of putative Cdx1-binding sites in Hox gene control regions as well as in vitro transactivation of Hoxa-7 indicates a direct regulation.	UNIV BATH,SCH BIOL & BIOCHEM,BATH BA2 7AY,AVON,ENGLAND	University of Bath	SUBRAMANIAN, V (corresponding author), MAX PLANCK INST BIOPHYS CHEM,DEPT MOLEC CELL BIOL,D-37077 GOTTINGEN,GERMANY.							BELLAIRS R, 1986, ANAT EMBRYOL, V174, P1, DOI 10.1007/BF00318331; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BREIER G, 1986, EMBO J, V5, P2209, DOI 10.1002/j.1460-2075.1986.tb04486.x; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CAPECCHI MR, 1974, P NATL ACAD SCI USA, V71, P4732, DOI 10.1073/pnas.71.12.4732; CONDIE BG, 1993, DEVELOPMENT, V119, P579; CONDIE BG, 1994, NATURE, V370, P304, DOI 10.1038/370304a0; DAWES B, 1930, PHILOS T ROY SOC B, V218, P155; DEAROLF CR, 1989, NATURE, V341, P340, DOI 10.1038/341340a0; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; FLINT OP, 1977, CELL INTERACTIONS DE; FRUMKIN A, 1991, DEVELOPMENT, V112, P207; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HOGAN B, 1986, MANIPULATING MOUSE E; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; JAMES R, 1991, J BIOL CHEM, V266, P3246; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; JOLY JS, 1992, DIFFERENTIATION, V50, P75, DOI 10.1111/j.1432-0436.1992.tb00488.x; Joyner AL, 1993, GENE TARGETING PRACT; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIENY M, 1972, DEV BIOL, V28, P142, DOI 10.1016/0012-1606(72)90133-9; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARGALIT Y, 1993, NUCLEIC ACIDS RES, V21, P4915, DOI 10.1093/nar/21.21.4915; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MAVILIO F, 1993, EUR J BIOCHEM, V212, P273, DOI 10.1111/j.1432-1033.1993.tb17660.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEYER BI, 1993, DEVELOPMENT, V117, P191; Miller J.H., 1972, EXPT MOL GENETICS; MLODZIK M, 1990, DEVELOPMENT, V109, P271; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NORTHROP JL, 1994, DEV BIOL, V161, P490, DOI 10.1006/dbio.1994.1047; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; PUSCHEL AW, 1990, DEVELOPMENT, V106, P435; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; SERRANO J, 1993, BIOCHEM BIOPH RES CO, V190, P270, DOI 10.1006/bbrc.1993.1041; SHARPE PT, 1988, DEVELOPMENT, V102, P397; SUH E, 1995, MOL CELL BIOL, V14, P7340; TAM PPL, 1986, SOMITES DEV EMBRYOS, P17; TREMBLAY P, 1995, IN PRESS DEV BIOL; VANDERLUGT N, 1994, THESIS U AMSTERDAM A; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; WARING DA, 1991, NATURE, V350, P712, DOI 10.1038/350712a0; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; XU X, 1994, DEVELOPMENT, V120, P277	61	289	295	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					641	653		10.1016/0092-8674(95)90104-3	http://dx.doi.org/10.1016/0092-8674(95)90104-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585967	Bronze			2022-12-28	WOS:A1995TF24800017
J	JANSEN, ASP; NGUYEN, XV; KARPITSKIY, V; METTENLEITER, TC; LOEWY, AD				JANSEN, ASP; NGUYEN, XV; KARPITSKIY, V; METTENLEITER, TC; LOEWY, AD			CENTRAL COMMAND NEURONS OF THE SYMPATHETIC NERVOUS-SYSTEM - BASIS OF THE FIGHT-OR-FLIGHT RESPONSE	SCIENCE			English	Article							PSEUDORABIES VIRUS; PREGANGLIONIC NEURONS; CHEMICAL-STIMULATION; RAT; MARKER; CATECHOLAMINES; INNERVATION; HEART	During stress, the activity of the sympathetic nervous system is changed in a global fashion, leading to an increase in cardiovascular function and a release of adrenal catecholamines. This response is thought to be regulated by a common set of brain neurons that provide a dual input to the sympathetic preganglionic neurons regulating cardiac and adrenal medullary functions. By using a double-virus transneuronal labeling technique, the existence of such a set of central autonomic neurons in the hypothalamus and brainstem was demonstrated. These neurons innervate both of the sympathetic outflow systems and likely function in circumstances where parallel sympathetic processing occurs, such as in the fight-or-flight response.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; FED RES CTR VIRUS DIS ANIM,FRIEDRICH LOEFFLER INST,INST MOLEC & CELLULAR VIROL,D-17498 INSEL RIEMS,GERMANY	Washington University (WUSTL); Friedrich Loeffler Institute			Mettenleiter, h. c. Thomas C./U-1016-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025449, R37HL025449] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-25449] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEREITER DA, 1990, PAIN, V42, P81, DOI 10.1016/0304-3959(90)91094-Y; Cannon WB, 1930, LANCET, V1, P1109; Cannon WB., BODILY CHANGES PAIN, DOI [10.1037/10013-000, DOI 10.1037/10013-000]; CARD JP, 1993, J NEUROSCI, V13, P2515, DOI 10.1523/JNEUROSCI.13-06-02515.1993; DIAMANT M, 1992, NEUROENDOCRINOLOGY, V56, P750, DOI 10.1159/000126303; JANSEN ASP, 1995, BRAIN RES, V683, P1, DOI 10.1016/0006-8993(95)00276-V; JANSEN ASP, 1993, BRAIN RES, V617, P103, DOI 10.1016/0006-8993(93)90619-X; KATAFUCHI T, 1988, NEUROSCI LETT, V86, P195, DOI 10.1016/0304-3940(88)90570-8; METTENLEITER TC, 1990, J VIROL METHODS, V30, P55, DOI 10.1016/0166-0934(90)90043-F; METTENLEITER TC, 1988, J VIROL, V62, P2712, DOI 10.1128/JVI.62.8.2712-2717.1988; MINSON JB, 1987, J AUTONOM NERV SYST, V13, P39; PARDINI BJ, 1989, J AUTONOM NERV SYST, V28, P193, DOI 10.1016/0165-1838(89)90146-X; PARDINI BJ, 1990, NEUROSCI LETT, V117, P300, DOI 10.1016/0304-3940(90)90681-X; RINAMAN L, 1993, J NEUROSCI, V13, P684; ROSS CA, 1984, J NEUROSCI, V4, P474; SAMS JM, 1995, BRAIN RES, V687, P182, DOI 10.1016/0006-8993(95)00484-8; STANEK KA, 1984, AM J PHYSIOL, V246, pH44, DOI 10.1152/ajpheart.1984.246.1.H44; STRACK AM, 1990, J NEUROSCI, V10, P2139; STRACK AM, 1989, BRAIN RES, V491, P274, DOI 10.1016/0006-8993(89)90063-2; STRACK AM, 1988, BRAIN RES, V455, P187, DOI 10.1016/0006-8993(88)90132-1; SWANSON LW, 1992, BRAINMAPS	21	493	503	4	113	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					644	646		10.1126/science.270.5236.644	http://dx.doi.org/10.1126/science.270.5236.644			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570024				2022-12-28	WOS:A1995TB55700043
J	HUDSON, KL; ROTHENBERG, KH; ANDREWS, LB; KAHN, MJE; COLLINS, FS				HUDSON, KL; ROTHENBERG, KH; ANDREWS, LB; KAHN, MJE; COLLINS, FS			GENETIC DISCRIMINATION AND HEALTH-INSURANCE - AN URGENT NEED FOR REFORM	SCIENCE			English	Editorial Material									UNIV MARYLAND, SCH LAW, LAW & HLTH CARE PROGRAM, BALTIMORE, MD 21201 USA; NIH US DOE, WORKING GRP ETH LEGAL & SOCIAL IMPLICAT, BETHESDA, MD USA; CHICAGO KENT COLL LAW, CHICAGO, IL USA; NATL ACT PLAN BREAST CANC, HEREDITARY SUSCEPTIBIL WORKING GRP, BETHESDA, MD USA	University System of Maryland; University of Maryland Baltimore; United States Department of Energy (DOE)	HUDSON, KL (corresponding author), NIH, NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA.							ANDREWS L, 1987, MED GENETICS LEGAL F; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; EASTON DF, 1993, AM J HUM GENET, V52, P678; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; LAPHAM EV, ALLIANCE GENETIC SUP; ROTHENBERG KH, IN PRESS J LAW MED E; 1995, SR28 EMPL BEN RES I; 1993, GENETIC INFORMATION	8	182	183	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 20	1995	270	5235					391	393		10.1126/science.270.5235.391	http://dx.doi.org/10.1126/science.270.5235.391			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569991	Green Submitted			2022-12-28	WOS:A1995TA37400028
J	SUNDARESAN, M; YU, ZX; FERRANS, VJ; IRANI, K; FINKEL, T				SUNDARESAN, M; YU, ZX; FERRANS, VJ; IRANI, K; FINKEL, T			REQUIREMENT FOR GENERATION OF H2O2 FOR PLATELET-DERIVED GROWTH-FACTOR SIGNAL-TRANSDUCTION	SCIENCE			English	Article							VITAMIN-E CONSUMPTION; CELLS; PROTEIN; DISEASE; PHOSPHORYLATION; INHIBITION; EXPRESSION; APOPTOSIS; RECEPTOR; RISK	Stimulation of rat vascular smooth muscle cells (VSMCs) by platelet-derived growth factor (PDGF) transiently increased the intracellular concentration of hydrogen peroxide (H2O2). This increase could be blunted by increasing the intracellular concentration of the scavenging enzyme catalase or by the chemical antioxidant N-acetylcysteine. The response of VSMCs to PDGF, which includes tyrosine phosphorylation, mitogen-activated protein kinase stimulation, DNA synthesis, and chemotaxis, was inhibited when the growth factor-stimulated rise in H2O2 concentration was blocked. These results suggest that H2O2 may act as a signal-transducing molecule, and they suggest a potential mechanism for the cardioprotective effects of antioxidants.	NHLBI, CARDIOL BRANCH, BETHESDA, MD 20892 USA; NHLBI, PATHOL SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Irani, Kaikobad/0000-0001-9194-7387				ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Aebi H, 1994, METHOD ENZYMOL, V105, P121; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; CAMPBELL JH, 1987, VASCULAR SMOOTH MUSC, P15; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; ERZURUM SC, 1993, NUCLEIC ACIDS RES, V21, P1607, DOI 10.1093/nar/21.7.1607; GAZIANO JM, 1992, ANN NY ACAD SCI, V669, P249; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; LEFF JA, 1992, FREE RADICAL BIO MED, V13, P143, DOI 10.1016/0891-5849(92)90076-S; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; RANKIN S, 1994, J BIOL CHEM, V269, P704; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; SUNDARESAN M, UNPUB; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	31	2224	2298	2	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 13	1995	270	5234					296	299		10.1126/science.270.5234.296	http://dx.doi.org/10.1126/science.270.5234.296			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569979	Green Submitted			2022-12-28	WOS:A1995RZ34200038
J	MILLMAN, A; LEE, N; SHARMA, R				MILLMAN, A; LEE, N; SHARMA, R			ABC OF MEDICAL COMPUTING - COMPUTERS IN GENERAL-PRACTICE .3.	BRITISH MEDICAL JOURNAL			English	Article									WESTERN EYE HOSP,LONDON,ENGLAND; HILLINGDON HOSP,LONDON,ENGLAND	Brunel University; Imperial College London	MILLMAN, A (corresponding author), GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					938	941						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580558				2022-12-28	WOS:A1995RZ23700030
J	LEWIS, C; NEIDHART, S; HOLY, C; NORTH, RA; BUELL, G; SURPRENANT, A				LEWIS, C; NEIDHART, S; HOLY, C; NORTH, RA; BUELL, G; SURPRENANT, A			COEXPRESSION OF P2X(2) AND P2X(3) RECEPTOR SUBUNITS CAN ACCOUNT FOR ATP-GATED CURRENTS IN SENSORY NEURONS	NATURE			English	Article							RAT	Cation-selective P2X receptor channels were first described in sensory neurons(1-4) where they are important for primary afferent neurotransmission and nociception(5,6). Here we report the cloning of a complementary DNA (P2X(3)) from rat dorsal root ganglia that had properties dissimilar to those of sensory neurons. We also found RNA for (P2X(1)) (ref. 7), (P2X(2)) (ref. 8) and P2X(4) (ref. 9) in sensory neurons; channels expressed from individual cDNAs did not reproduce those of sensory ganglia. Coexpression of P2X(3) with P2X(2), but not other combinations, yielded ATP-activated currents that closely resembled those in sensory neurons. These properties could not be accounted for by addition of the two sets of channels, indicating that a new channel had formed by subunit heteropolymerization. Although in some tissues responses to ATP can be accounted for by homomeric channels(1,7-10), our results indicate that ATP-gated channels of sensory neurons may form by a specific heteropolymerization of P2X receptor subunits.			LEWIS, C (corresponding author), GLAXO INST MOLEC BIOL SA,CH-1228 GENEVA,SWITZERLAND.		North, Richard/GQA-6156-2022					ABBRACCHIO MP, 1995, PHARMACOL THERAPEUT, V64, P445; BEAN BP, 1990, J NEUROSCI, V10, P1; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BUELL G, IN PRESS SOC NEUR AB; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; FRIEL DD, 1988, J PHYSIOL-LONDON, V401, P361, DOI 10.1113/jphysiol.1988.sp017167; FYFFE REW, 1984, P NATL ACAD SCI-BIOL, V81, P6890, DOI 10.1073/pnas.81.21.6890; HOLTON FA, 1954, J PHYSIOL-LONDON, V126, P124, DOI 10.1113/jphysiol.1954.sp005198; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; KHAKH BS, 1995, J PHYSIOL-LONDON, V484, P385, DOI 10.1113/jphysiol.1995.sp020672; KHAKH BS, 1995, J PHARM, V115, P117; KRISHTAL OA, 1988, BRIT J PHARMACOL, V95, P1057, DOI 10.1111/j.1476-5381.1988.tb11739.x; KRISHTAL OA, NEUROSCI LETT, V35, P41; LEWIS C, IN PRESS SOC NEUR AB; LINDSTROM JM, 1995, LIGAND VOLTAGE GATED, P153; SPRENGEL R, 1995, LIGAND VOLTAGE GATED, P213; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VULCANOVA L, IN PRESS SOC NEUR AB	20	881	906	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					432	435		10.1038/377432a0	http://dx.doi.org/10.1038/377432a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566120				2022-12-28	WOS:A1995RY19000050
J	TAYLOR, W; RODESCH, G				TAYLOR, W; RODESCH, G			RECENT ADVANCES - INTERVENTIONAL NEURORADIOLOGY	BRITISH MEDICAL JOURNAL			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; INTRAARTERIAL FIBRINOLYTIC THERAPY; CAROTID-ARTERY; ACUTE STROKE; MALFORMATIONS; ANEURYSMS; TERRITORY; UROKINASE; OCCLUSION; VEIN		UNIV PARIS 11, HOP BICETRE, SERV RADIOL, F-94275 PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	TAYLOR, W (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, LYSHOLM DEPT RADIOL, LONDON WC1N 3BG, ENGLAND.							BUCKENHAM T, 1994, CRITICAL ISCHAEMIA, V4, P93; CAMERLINGO M, 1995, STROKE, V26, P160; CASTO L, 1992, ACTA NEUROL SCAND, V86, P308, DOI 10.1111/j.1600-0404.1992.tb05091.x; CLIFTON AG, 1995, NEURORADIOLOGY S, V37, P445; DELZOPPO GJ, 1994, AM J NEURORADIOL, V15, P217; DEZOPPO GJ, 1988, STROKE, V19, P307; ECKERT B, 1994, CEREBROVASC DIS, V4, P259; FERGUSON RDG, 1994, AM J NEURORADIOL, V15, P1201; GARCIAMONACO R, 1991, CHILD NERV SYST, V7, P44; GEREMIA G, 1994, AM J NEURORADIOL, V15, P1223; GIRARD N, 1994, CHILD NERV SYST, V10, P141, DOI 10.1007/BF00301078; Guglielmi G, 1993, INTERV NEURORADIOL, P111; Guglielmi G, 1992, INTERV NEURORADIOL, P63; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; Higashida R, 1992, INTERV NEURORADIOL, P51; JANE JA, 1985, J NEUROSURG, V62, P321, DOI 10.3171/jns.1985.62.3.0321; KACHEL R, 1991, NEURORADIOLOGY, V33, P191, DOI 10.1007/BF00588215; KASSELL NF, 1983, NEUROSURGERY, V12, P291, DOI 10.1227/00006123-198303000-00007; LASJAUNIAS P, 1991, NEURORADIOLOGY, V33, P234, DOI 10.1007/BF00588224; LASJAUNIAS P, 1995, CHILD NERV SYST, V11, P66, DOI 10.1007/BF00303807; LASJAUNIAS P, 1987, NEUROCHIRURGIE, V33, P315; LASJAUNIAS P, 1994, RIV NEURORADIOL, V7, P35; LASJAUNIAS P, IN PRESS ARCH PEDIAT; Maiza D, 1988, Ann Vasc Surg, V2, P205, DOI 10.1016/S0890-5096(07)60002-8; MARKUS HS, 1994, STROKE, V25, P2403, DOI 10.1161/01.STR.25.12.2403; MARTIN D, IN PRESS NEURORADIOL; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; MORI E, 1988, STROKE, V19, P802, DOI 10.1161/01.STR.19.7.802; SCHUMACHER M, 1993, NEURORADIOLOGY, V35, P600, DOI 10.1007/BF00588405; SENGUPTA RP, 1986, SUBARACHNOID HAEMORR, P237; SOLOMON RA, 1994, J NEUROSURG, V80, P440, DOI 10.3171/jns.1994.80.3.0440; STEVENS JM, 1994, POSTGRAD MED J, V70, P604, DOI 10.1136/pgmj.70.827.604; SZIKORA I, 1994, AM J NEURORADIOL, V15, P1091; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; THERON J, 1989, AM J NEURORADIOL, V10, P753; TURJMAN F, 1994, AM J NEURORADIOL, V15, P1087; WOLPERT SM, 1981, AM J NEURORADIOL, V2, P535; WOLPERT SM, 1993, AM J NEURORADIOL, V14, P3; ZERAH M, 1992, CHILD NERV SYST, V8, P1; ZEUMER H, 1993, NEURORADIOLOGY, V35, P159, DOI 10.1007/BF00593977; ZEUMER H, 1989, NEURORADIOLOGY, V31, P36; 1991, LANCET, V337, P135; 1992, HLTH NATION, P11	43	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					789	792		10.1136/bmj.311.7008.789	http://dx.doi.org/10.1136/bmj.311.7008.789			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580443	Green Published			2022-12-28	WOS:A1995RX10700024
J	METZ, T; HARRIS, AW; ADAMS, JM				METZ, T; HARRIS, AW; ADAMS, JM			ABSENCE OF P53 ALLOWS DIRECT IMMORTALIZATION OF HEMATOPOIETIC-CELLS BY THE MYC AND RAF ONCOGENES	CELL			English	Article							WILD-TYPE P53; RECOMBINANT MURINE RETROVIRUS; EMBRYO FIBROBLASTS; P53-DEFICIENT MICE; GENE AMPLIFICATION; BONE-MARROW; ERB-B; V-RAF; TRANSFORMATION; INVITRO	The p53 tumor suppressor is implicated here as a crucial barrier to unlimited cell proliferation. Its role in transformation of hematopoietic cells was studied by infecting fetal liver cells from wild-type or p53(-/-) mice with oncogenic retroviruses. Transformed colonies arose with a raf and a myc-raf virus. Absence of p53 did not affect their frequency but proved critical for their continued propagation. Colonies of p53(-/-) cells bearing both myc and raf readily yielded continuous cell lines without apparent requirement for genetic alteration. The lines, mainly of erythroid or myelomonocytic origin, were diploid but highly tumorigenic from their inception. These findings imply that p53 loss contributes directly to immortalization and tumorigenesis, probably by abrogating an intrinsic senescence program.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628	NATIONAL CANCER INSTITUTE [R01CA012421] Funding Source: NIH RePORTER; NCI NIH HHS [CA12421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; BEUG H, 1977, EXP CELL RES, V107, P417, DOI 10.1016/0014-4827(77)90363-9; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BOND JA, 1994, ONCOGENE, V9, P1885; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1991, CELL GROWTH DIFFER, V2, P165; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANDREA AD, 1994, CURR OPIN CELL BIOL, V6, P804, DOI 10.1016/0955-0674(94)90048-5; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINKEN SP, 1988, ONCOGENE RES, V3, P187; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1989, J VIROL, V63, P1489, DOI 10.1128/JVI.63.3.1489-1492.1989; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; METCALF D, 1984, CLONAL CULTURES HAEM; METZ T, 1994, SEMIN CANCER BIOL, V5, P125; MILLER M, 1990, ONCOGENE, V5, P1125; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RITTLING SR, 1992, ONCOGENE, V7, P935; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; ROVINSKI B, 1988, ONCOGENE, V2, P445; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSUKADA T, 1993, ONCOGENE, V8, P3313; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; WANECK GL, 1981, CELL, V26, P79, DOI 10.1016/0092-8674(81)90035-0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	51	114	115	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					29	36		10.1016/0092-8674(95)90049-7	http://dx.doi.org/10.1016/0092-8674(95)90049-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606782	Bronze			2022-12-28	WOS:A1995RK42400006
J	POPPERL, H; BIENZ, M; STUDER, M; CHAN, SK; APARICIO, S; BRENNER, S; MANN, RS; KRUMLAUF, R				POPPERL, H; BIENZ, M; STUDER, M; CHAN, SK; APARICIO, S; BRENNER, S; MANN, RS; KRUMLAUF, R			SEGMENTAL EXPRESSION OF HOXB-1 IS CONTROLLED BY A HIGHLY CONSERVED AUTOREGULATORY LOOP DEPENDENT UPON EXD/PBX	CELL			English	Article							HUMAN PROTOONCOGENE PBX1; HOMEOTIC DROSOPHILA GENE; VISCERAL MESODERM; HOMEOBOX GENES; PRE-B; HINDBRAIN; EMBRYOS; PROTEIN; DOMAIN; EXTRADENTICLE	Comparison of Hoxb-1 regulatory regions from different vertebrates identified three related sequence motifs critical for rhombomere 4 (r4) expression in the hindbrain. Functional analysis in transgenic mice and Drosophila embryos demonstrated that the conserved elements are involved in a positive autoregulatory loop dependent on labial (lab) family members. Binding of Hoxb-1 to these elements in vitro requires cofactors, and the motifs closely resemble the consensus binding site for pbx1, a homolog of the Drosophila extradenticle (exd) homeodomain protein. In vitro exd/pbx serves as a Hoxb-1 cofactor in cooperative binding and in Drosophila expression mediated by the r4 enhancer is dependent on both lab and exd. This provides in vivo and in vitro evidence that r4 expression involves direct autoregulation dependent on cooperative interactions of Hoxb-1 with exd/pbx proteins as cofactors.	MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND; COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; ADDENBROOKES HOSP, DEPT MED, MOLEC GENET UNIT, CAMBRIDGE CB2 2QQ, ENGLAND	MRC Laboratory Molecular Biology; Columbia University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	POPPERL, H (corresponding author), NATL INST MED RES, MRC, DEV NEUROBIOL LAB, RIDGEWAY, MILL HILL, LONDON NW7 1AA, ENGLAND.		Studer, Michele/P-4580-2016; Krumlauf, Robb/AAH-5012-2019	Studer, Michele/0000-0001-7105-2957; Krumlauf, Robb/0000-0001-9102-7927; Aparicio, Samuel/0000-0002-0487-9599	NIGMS NIH HHS [R01 GM054510] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054510] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; DIEDERICH RJ, 1989, GENE DEV, V3, P399, DOI 10.1101/gad.3.3.399; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; GODSAVE S, 1994, DEV BIOL, V166, P465, DOI 10.1006/dbio.1994.1330; HEUER JG, 1992, DEVELOPMENT, V115, P35; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOPPLER S, 1994, CELL, V76, P689, DOI 10.1016/0092-8674(94)90508-8; HUME CR, 1993, DEVELOPMENT, V119, P1147; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KEYNES R, 1994, ANNU REV NEUROSCI, V17, P109, DOI 10.1146/annurev.ne.17.030194.000545; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; PHELAN ML, 1994, MOL CELL BIOL, V14, P5066, DOI 10.1128/MCB.14.8.5066; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; REGULSKI M, 1991, GENE DEV, V5, P278, DOI 10.1101/gad.5.2.278; REUTER R, 1990, DEVELOPMENT, V110, P1031; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; SUN B, 1995, EMBO J, V14, P520, DOI 10.1002/j.1460-2075.1995.tb07028.x; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; THURINGER F, 1993, EMBO J, V12, P2419, DOI 10.1002/j.1460-2075.1993.tb05896.x; TREMML G, 1992, DEVELOPMENT, V116, P447; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; ZENG CY, 1994, EMBO J, V13, P2362, DOI 10.1002/j.1460-2075.1994.tb06520.x; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	58	443	443	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1031	1042		10.1016/S0092-8674(05)80008-X	http://dx.doi.org/10.1016/S0092-8674(05)80008-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600572	hybrid			2022-12-28	WOS:A1995RG91000008
J	RIUNITI, O; BARBUI, T; FINAZZI, G; NEGRI, M; SUD, CMN; DEGAETANO, G; MARCHIOLI, R; TOGNONI, G; PATRONO, C; LANDOLFI, R; DITORRETTE, ON; LEONI, P; RUPOLI, S; CORTELAZZO, S; VESTRI, O; TURA, S; FINELLI, C; NOCENTINI, F; ANGELI, G; DIPASQUALE, A; KRAMER, V; MARFISI, R; OLIVIERI, M; SCIULLI, L; SPOLTORE, R; CAREGGI, P; FERRINI, PR; GROSSI, A; LONGO, G; NIGUARDA, O; DECATALDO, F; GARGANTINI, L; BAUDO, F; GERARDO, S; POGLIANI, EM; MICCOLIS, IR; BIZZI, B; ROCCA, B; TARTAGLIONE, R; MANDELLI, F; MONTEFUSCO, E; SPADEA, A; GIOVANNI, S; CAROTENUTO, M; NOBILE, M; MORELLI, R; MOLINETTE, O; RESEGOTTI, L; VASINO, MAC; BARTOLO, OS; RODEGHIERO, F; RUGGERI, M; ROSSIFERRINI, P				RIUNITI, O; BARBUI, T; FINAZZI, G; NEGRI, M; SUD, CMN; DEGAETANO, G; MARCHIOLI, R; TOGNONI, G; PATRONO, C; LANDOLFI, R; DITORRETTE, ON; LEONI, P; RUPOLI, S; CORTELAZZO, S; VESTRI, O; TURA, S; FINELLI, C; NOCENTINI, F; ANGELI, G; DIPASQUALE, A; KRAMER, V; MARFISI, R; OLIVIERI, M; SCIULLI, L; SPOLTORE, R; CAREGGI, P; FERRINI, PR; GROSSI, A; LONGO, G; NIGUARDA, O; DECATALDO, F; GARGANTINI, L; BAUDO, F; GERARDO, S; POGLIANI, EM; MICCOLIS, IR; BIZZI, B; ROCCA, B; TARTAGLIONE, R; MANDELLI, F; MONTEFUSCO, E; SPADEA, A; GIOVANNI, S; CAROTENUTO, M; NOBILE, M; MORELLI, R; MOLINETTE, O; RESEGOTTI, L; VASINO, MAC; BARTOLO, OS; RODEGHIERO, F; RUGGERI, M; ROSSIFERRINI, P			POLYCYTHEMIA-VERA - THE NATURAL-HISTORY OF 1213 PATIENTS FOLLOWED FOR 20 YEARS	ANNALS OF INTERNAL MEDICINE			English	Article						POLYCYTHEMIA VERA; THROMBOSIS; MYOCARDIAL INFARCTION; CEREBROVASCULAR DISORDERS; ASPIRIN	PORTAL-VEIN THROMBOSIS; CEREBRAL BLOOD-FLOW; MYELOPROLIFERATIVE DISORDERS; PRIMARY THROMBOCYTHEMIA; VASCULAR COMPLICATIONS; VENOUS THROMBOSIS; YOUNG-PEOPLE; RISK-FACTORS; ERYTHROMELALGIA; INVITRO	Objective: To reassess the natural history of polycythemia vera and to obtain reliable estimates of both incidence of thrombosis and survival for use in defining the sample size for therapeutic clinical trials. Study Design: Retrospective cohort study of patients with polycythemia who had been followed for 20 years. Setting: 11 Italian hematology institutions. Patients: 1213 patients with polycythemia vera, which was diagnosed according to criteria established by the Polycythemia Vera Study Group and commonly used in clinical practice. Main Outcome Measures: All-cause mortality, venous and arterial thrombosis, and hematologic and nonhematologic neoplastic disease. Myocardial infarction and stroke were classified as major thrombotic events, and venous and peripheral arterial thrombosis were considered minor thrombotic events. The number of patients who died and the number of those who had major thrombotic events (combined end point) were used as a comprehensive measure of the benefit-risk ratio associated with the use of myelosuppressive agents. Results: 634 fatal and nonfatal arterial and venous thromboses were recorded in 485 patients (41%); 36% of these episodes occurred during follow-up in 230 patients (19%), and 64% occurred either at presentation or before diagnosis. Thrombotic events occurred more frequently in the 2 years preceding diagnosis, suggesting a causal relation between the latent myeloproliferative disorder and the vascular event. The incidence of thrombosis during follow-up was 3.4%/y; older patients or those with a history of thrombosis had a higher risk for thrombosis. Overall mortality was 2.9/100 patients per year; thrombotic events and hematologic or nonhematologic cancers had similar effects on mortality. Patients receiving chemotherapy died three to four times more frequently than those not receiving chemotherapy. The increased risk for cancer in patients receiving myelosuppressive agents was seen approximately 6 years after diagnosis. In addition, the combined end point, computed as the sum of the hardest available events (death, nonfatal myocardial infarction, or stroke), suggests that myelosuppressive agents have an overall unfavorable effect. Conclusions: Cytoreduction favorably affects the incidence of thrombotic events, but aggressive treatment seems to be associated with increased risk for neoplasm. These results provide a basis for reevaluating the therapeutic strategy in patients with polycythemia vera and for estimating the size of clinical trials aimed at testing new therapeutic approaches.	CONSORZIO MARIO NEGRI SUD, CLIN PHARMACOL & EPIDEMIOL LAB, I-66030 SANTA MARIA IMBARO, ITALY; OSPED RIUNITI BERGAMO, BERGAMO, ITALY; CONSORZIO MARIO NEGRI SUD, IST RIC FARMACOL MARIO NEGRI, I-66030 SANTA MARIA IMBARO, ITALY; UNIV GABRIELE DANNUNZIO, CHIETI, ITALY; UNIV CATTOLICA SACRO CUORE, ROME, ITALY; OSPED NUOVO TORRETTE, ANCONA, ITALY; UNIV BOLOGNA, BOLOGNA, ITALY; POLICLIN CAREGGI, FLORENCE, ITALY; OSPED NIGUARDA CA GRANDA, MILAN, ITALY; OSPED SAN GERARDO, MONZA, ITALY; UNIV ROMA LA SAPIENZA, ROME, ITALY; CASA SOLLIEVO SOFFERENZA, SAN GIOVANNI ROTONDO, ITALY; OSPED MOLINETTE, TURIN, ITALY; OSPED SAN BARTOLO, VICENZA, ITALY	Consorzio Mario Negri Sud; Ospedali Riuniti di Bergamo; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; G d'Annunzio University of Chieti-Pescara; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Bologna; University of Florence; Azienda Ospedaliero Universitaria Careggi; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; San Gerardo Hospital; Sapienza University Rome; IRCCS Casa Sollievo Della Sofferenza; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; ULSS 8 Berica; Ospedale San Bortolo di Vicenza			Finelli, Carlo/AAB-9686-2019; rocca, bianca/K-3922-2018; Landolfi, Raffaele/AAL-4496-2020	Finelli, Carlo/0000-0001-9372-1197; Landolfi, Raffaele/0000-0002-7913-8576; Patrono, Carlo/0000-0002-6447-2424				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1991, Lancet, V338, P1345; BARBUI T, 1983, EUR J CANCER CLIN ON, V19, P1593, DOI 10.1016/0277-5379(83)90091-3; BAROSI G, 1991, CANCER, V68, P2310, DOI 10.1002/1097-0142(19911115)68:10<2310::AID-CNCR2820681034>3.0.CO;2-2; BERK PD, 1981, NEW ENGL J MED, V304, P441, DOI 10.1056/NEJM198102193040801; BERK PD, 1986, SEMIN HEMATOL, V23, P132; CARDIN F, 1992, DIGEST DIS SCI, V37, P335, DOI 10.1007/BF01307724; CORTELAZZO S, 1990, J CLIN ONCOL, V8, P556, DOI 10.1200/JCO.1990.8.3.556; DRENOU B, 1992, NOUV REV FR HEMATOL, V34, P399; EGLI F, 1988, SCHWEIZ MED WSCHR, V118, P1969; FROHLI P, 1983, SCHWEIZ MED WSCHR, V113, P1622; HOFFMAN R, 1991, HEMATOLOGY BASIC PRI, P834; LANDOLFI R, 1992, BLOOD, V80, P1965; MCCARTHY DM, 1985, BRIT J HAEMATOL, V59, P1, DOI 10.1111/j.1365-2141.1985.tb02956.x; MICHIELS JJ, 1993, MEDIAT INFLAMM, V2, P385, DOI 10.1155/S0962935193000547; MICHIELS JJ, 1992, AM J HEMATOL, V39, P131, DOI 10.1002/ajh.2830390211; MICHIELS JJ, 1985, ANN INTERN MED, V102, P466, DOI 10.7326/0003-4819-102-4-466; MICHIELS JJ, 1993, NEUROLOGY, V43, P1107, DOI 10.1212/WNL.43.6.1107; NAJEAN Y, 1987, BRIT J HAEMATOL, V67, P285, DOI 10.1111/j.1365-2141.1987.tb02349.x; NAJEAN Y, 1994, BRIT J HAEMATOL, V86, P233, DOI 10.1111/j.1365-2141.1994.tb03289.x; NAJEAN Y, 1983, ANN MED INTERNE, V134, P390; PAGLIUCA A, 1990, Q J MED, V76, P981; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PEARCE JMS, 1983, BRIT MED J, V287, P935, DOI 10.1136/bmj.287.6397.935; PEARSON TC, 1978, LANCET, V2, P1219; Pearson TC, 1981, CLIN ASPECTS BLOOD V; PEETERMANS N, 1981, BRIT J CANCER, V44, P75; RANDI ML, 1991, J MED, V22, P213; REID CD, 1982, LANCET, V1, P14; ROZMAN C, 1991, CANCER, V67, P2658, DOI 10.1002/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C; TARTAGLIA AP, 1986, SEMIN HEMATOL, V23, P172; TEOFILI L, 1992, THROMB HAEMOSTASIS, V67, P297; THOMAS DJ, 1977, LANCET, V2, P161; THOMAS DJ, 1977, LANCET, V2, P941, DOI 10.1016/S0140-6736(77)90885-6; TOSSOU H, 1991, J CLIN GASTROENTEROL, V13, P597; VALLA D, 1985, ANN INTERN MED, V103, P329, DOI 10.7326/0003-4819-103-3-329; VALLA D, 1988, GASTROENTEROLOGY, V94, P1063, DOI 10.1016/0016-5085(88)90567-7; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WALLENTIN L, 1990, LANCET, V336, P827; WEHMEIER A, 1991, ANN HEMATOL, V63, P101, DOI 10.1007/BF01707281; WESTWOOD N, 1993, EUR J HAEMATOL, V51, P228; ZANKOVICH R, 1987, MED KLIN, V82, P889	42	378	390	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					656	+		10.7326/0003-4819-123-9-199511010-00003	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574220				2022-12-28	WOS:A1995TA69600003
J	POOLE, CJM; MILLMAN, A				POOLE, CJM; MILLMAN, A			ABC OF MEDICAL COMPUTING - ADAPTIVE COMPUTER-TECHNOLOGY	BRITISH MEDICAL JOURNAL			English	Article									GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND	Gloucestershire Royal Hospital									0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 28	1995	311	7013					1149	1151		10.1136/bmj.311.7013.1149	http://dx.doi.org/10.1136/bmj.311.7013.1149			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580714	Green Published			2022-12-28	WOS:A1995TC46600024
J	FAY, FS				FAY, FS			CALCIUM SPARKS IN VASCULAR SMOOTH-MUSCLE - RELAXATION REGULATORS	SCIENCE			English	Editorial Material							TRANSIENT OUTWARD CURRENTS; SARCOPLASMIC-RETICULUM; CELLS; CHANNELS; RELEASE; RABBIT				FAY, FS (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT PHYSIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NHLBI NIH HHS [HL47530, HL14523] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL014523, P01HL047530, R01HL014523] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON NL, 1992, SCIENCE, V258, P1812; BENHAM CD, 1986, J PHYSIOL-LONDON, V381, P385, DOI 10.1113/jphysiol.1986.sp016333; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOLTON TB, 1989, J PHYSIOL-LONDON, V409, P385, DOI 10.1113/jphysiol.1989.sp017504; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; ETTER EF, 1994, BIOPHYS J, V66, pA151; ETTER EF, 1994, J BIOL CHEM, V269, P10141; GREGOIRE G, 1993, J PHYSIOL-LONDON, V472, P483, DOI 10.1113/jphysiol.1993.sp019957; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; NELSON TE, 1990, FEBS LETT, V263, P292, DOI 10.1016/0014-5793(90)81396-6; ODONNELL ME, 1994, PHYSIOL REV, V74, P683, DOI 10.1152/physrev.1994.74.3.683; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; SINGER JJ, 1987, PFLUG ARCH EUR J PHY, V408, P98, DOI 10.1007/BF00581337; STEHNOBITTEL L, 1992, J PHYSIOL-LONDON, V451, P49, DOI 10.1113/jphysiol.1992.sp019153; WANG JX, 1992, NATURE, V359, P739, DOI 10.1038/359739a0	18	36	37	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					588	589		10.1126/science.270.5236.588	http://dx.doi.org/10.1126/science.270.5236.588			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570016				2022-12-28	WOS:A1995TB55700026
J	BORDIGNON, C; NOTARANGELO, LD; NOBILI, N; FERRARI, G; CASORATI, G; PANINA, P; MAZZOLARI, E; MAGGIONI, D; ROSSI, C; SERVIDA, P; UGAZIO, AG; MAVILIO, F				BORDIGNON, C; NOTARANGELO, LD; NOBILI, N; FERRARI, G; CASORATI, G; PANINA, P; MAZZOLARI, E; MAGGIONI, D; ROSSI, C; SERVIDA, P; UGAZIO, AG; MAVILIO, F			GENE-THERAPY IN PERIPHERAL-BLOOD LYMPHOCYTES AND BONE-MARROW FOR ADA(-) IMMUNODEFICIENT PATIENTS	SCIENCE			English	Article							ADENOSINE-DEAMINASE DEFICIENCY; ENZYME REPLACEMENT THERAPY; T-CELLS; RETROVIRAL VECTOR; TRANSPLANTATION; EXPRESSION; VEHICLES; MARKING	Adenosine deaminase (ADA) deficiency results in severe combined immunodeficiency, the first genetic disorder treated by gene therapy. Two different retroviral vectors were used to transfer ex vivo the human ADA minigene into bone marrow cells and peripheral blood lymphocytes from two patients undergoing exogenous enzyme replacement therapy. After 2 years bf treatment, long-term survival of T and B lymphocytes, marrow cells, and granulocytes expressing the transferred ADA gene was demonstrated and resulted in normalization of the immune repertoire and restoration of cellular and humoral immunity. After discontinuation of treatment, T lymphocytes, derived from transduced peripheral blood lymphocytes, were progressively replaced by marrow-derived T cells in both patients. These results indicate successful gene transfer into long-lasting progenitor cells, producing a functional multilineage progeny.	UNIV BRESCIA,SCH MED,DEPT PEDIAT,BRESCIA,ITALY; IST SCI HS RAFFAELE,DIBIT,UNITA IMMUNOCHIM,MILAN,ITALY; ROCHE MILANO RIC,MILAN,ITALY	University of Brescia; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Roche Holding	BORDIGNON, C (corresponding author), IST SCI HS RAFFAELE,DIBIT,TELETHON GENE THERAPY PROGRAM GENET DIS,MILAN,ITALY.		Ugazio, Alberto/AAA-6092-2020; Notarangelo, Luigi D/F-9718-2016; Daniela, Maggioni/AAN-6553-2020; Ferrari, Giuliana/AAB-5546-2019; Casorati, Giulia/J-7141-2018	Notarangelo, Luigi D/0000-0002-8335-0262; Daniela, Maggioni/0000-0001-9894-6387; Ferrari, Giuliana/0000-0003-0790-3133; Casorati, Giulia/0000-0002-5102-4112; Mavilio, Fulvio/0000-0003-0459-4320; Panina-Bordignon, Paola/0000-0001-9913-8568; Rossi, Claudia/0000-0002-3810-7247	Telethon [B.36] Funding Source: Medline	Telethon(Fondazione Telethon)		ABUCHOWSKI A, 1979, CANCER TREAT REP, V63, P1127; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BARNETT MJ, 1994, BLOOD, V84, P724; BENATI C, UNPUB; BORDIGNON C, 1989, P NATL ACAD SCI USA, V86, P6748, DOI 10.1073/pnas.86.17.6748; BORDIGNON C, 1993, HUM GENE THER, V4, P513, DOI 10.1089/hum.1993.4.4-513; BREGNI M, 1992, BLOOD, V80, P1418; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; CHEN RL, 1981, BIOCHIM BIOPHYS ACTA, V600, P293; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; DAVIS B, 1985, NATURE, V314, P550, DOI 10.1038/314550a0; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; FERRARI G, 1992, BLOOD, V80, P1120; FERRARI G, 1993, SCIENCE, V251, P1363; FLASSHOVE M, 1995, BLOOD, V85, P566; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GIBLETT ER, 1972, LANCET, V2, P1067; HANTZOPOULOS PA, 1989, P NATL ACAD SCI USA, V86, P3519, DOI 10.1073/pnas.86.10.3519; HERSHFIELD MS, 1993, PEDIATR RES, V33, pS42; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; HIRSCHHORN R, 1981, J CLIN INVEST, V68, P1387, DOI 10.1172/JCI110389; KASID A, 1990, P NATL ACAD SCI USA, V87, P473, DOI 10.1073/pnas.87.1.473; Kredich NM, 1983, METABOLIC BASIS INHE, P1157; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LEVY Y, 1988, J PEDIATR-US, V113, P312, DOI 10.1016/S0022-3476(88)80271-3; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MAVILIO F, 1994, BLOOD, V83, P1988; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NOTARANGELO LD, 1992, EUR J PEDIATR, V151, P811, DOI 10.1007/BF01957930; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; PARKMAN R, 1986, SCIENCE, V232, P1373, DOI 10.1126/science.3520819; POLMAR SH, 1976, NEW ENGL J MED, V295, P1337, DOI 10.1056/NEJM197612092952402; REISNER Y, 1983, BLOOD, V61, P341; Sambrook J, 1989, MOL CLONING LABORATO; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VONKALLE C, 1994, BLOOD, V84, P2890	39	583	625	1	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					470	475		10.1126/science.270.5235.470	http://dx.doi.org/10.1126/science.270.5235.470			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7570000				2022-12-28	WOS:A1995TA37400042
J	DECHIARA, TM; VEJSADA, R; POUEYMIROU, WT; ACHESON, A; SURI, C; CONOVER, JC; FRIEDMAN, B; MCCLAIN, J; PAN, L; STAHL, N; IP, NY; KATO, A; YANCOPOULOS, GD				DECHIARA, TM; VEJSADA, R; POUEYMIROU, WT; ACHESON, A; SURI, C; CONOVER, JC; FRIEDMAN, B; MCCLAIN, J; PAN, L; STAHL, N; IP, NY; KATO, A; YANCOPOULOS, GD			MICE LACKING THE CNTF RECEPTOR, UNLIKE MICE LACKING CNTF, EXHIBIT PROFOUND MOTOR-NEURON DEFICITS AT BIRTH	CELL			English	Article							CILIARY NEUROTROPHIC FACTOR; LEUKEMIA-INHIBITORY FACTOR; IL-6 SIGNAL TRANSDUCER; ONCOSTATIN-M; EMBRYONIC MOTONEURONS; NEURONOTROPHIC FACTOR; REGIONAL DISTRIBUTION; MOLECULAR-CLONING; FACTOR PREVENTS; SCIATIC-NERVE	Ciliary neurotrophic factor (CNTF) supports motor neuron survival in vitro and in mouse models of motor neuron degeneration and was considered a candidate for the muscle-derived neurotrophic activity that regulates motor neuron survival during development. However, CNTF expression is very low in the embryo, and CNTF gene mutations in mice or human do not result in notable abnormalities of the developing nervous system. We have generated and directly compared mice containing null mutations in the genes encoding CNTF or its receptor (CNTFR alpha). Unlike mice lacking CNTF, mice lacking CNTFR alpha die perinatally and display severe motor neuron deficits. Thus, CNTFR alpha is critical for the developing nervous system, most likely by serving as a receptor for a second, developmentally important, CNTF-like ligand.	UNIV GENEVA,UNIV MED CTR,DIV CLIN NEUROMUSCULAR RES,CH-1211 GENEVA,SWITZERLAND; UNIV GENEVA,UNIV MED CTR,DEPT PHARMACOL,CH-1211 GENEVA,SWITZERLAND	University of Geneva; University of Geneva	DECHIARA, TM (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.			Ip, Nancy Yuk-Yu/0000-0002-2763-8907; Conover, Joanne/0000-0003-0375-0141				ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; ASHWELL KW, 1983, J EMBRYOL EXP MORPH, V77, P117; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BLOTTNER D, 1989, NEUROSCI LETT, V105, P316, DOI 10.1016/0304-3940(89)90640-X; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1990, NATURE, V344, P78; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IP NY, 1991, J NEUROSCI, V11, P3124; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Kandel E.R., 1991, PRINC NEUROSCI, V3rd ed.; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; LANCEJONES C, 1982, DEV BRAIN RES, V4, P473, DOI 10.1016/0165-3806(82)90192-4; LEUNG DW, 1992, NEURON, V8, P1045, DOI 10.1016/0896-6273(92)90126-X; LEWIN B, 1994, CELL, V79, P935, DOI 10.1016/0092-8674(94)90025-6; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LIU X, 1995, NATURE, V375, P238, DOI 10.1038/375238a0; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOWAK R, 1989, TRENDS NEUROSCI, V12, P252; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; POVER CM, 1991, ANAT REC, V231, P573, DOI 10.1002/ar.1092310419; RENDE M, 1992, GLIA, V5, P25, DOI 10.1002/glia.440050105; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SAADAT S, 1989, J CELL BIOL, V106, P1807; SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; TTSUCHIDA T, 1994, CELL, V79, P957; VALENZUELA DM, 1995, GENOMICS, V25, P157, DOI 10.1016/0888-7543(95)80121-2; VEJSADA R, 1995, EUR J NEUROSCI, V7, P108, DOI 10.1111/j.1460-9568.1995.tb01025.x; WARE CB, IN PRESS DEVELOPMENT; Wewetzer K, 1990, Neuroreport, V1, P203, DOI 10.1097/00001756-199011000-00007	70	327	332	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					313	322		10.1016/0092-8674(95)90172-8	http://dx.doi.org/10.1016/0092-8674(95)90172-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585948	Bronze			2022-12-28	WOS:A1995TA96500017
J	SCHENA, M; SHALON, D; DAVIS, RW; BROWN, PO				SCHENA, M; SHALON, D; DAVIS, RW; BROWN, PO			QUANTITATIVE MONITORING OF GENE-EXPRESSION PATTERNS WITH A COMPLEMENTARY-DNA MICROARRAY	SCIENCE			English	Article							ARABIDOPSIS-THALIANA; HUMAN GENOME	A high-capacity system was developed to monitor the expression of many genes in parallel. Microarrays prepared by high-speed robotic printing of complementary DNAs on glass were used for quantitative expression measurements of the corresponding genes. Because of the small format and high density of the arrays, hybridization volumes of 2 microliters could be used that enabled detection of rare transcripts in probe mixtures derived from 2 micrograms of total cellular messenger RNA. Differential expression measurements of 45 Arabidopsis genes were made by means of simultaneous, two-color fluorescence hybridization.	STANFORD UNIV,MED CTR,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,MED CTR,BECKMAN CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University			Rosa, Bruce/F-6393-2010	Shalon, Tidhar Dari/0000-0003-2646-6215	NHGRI NIH HHS [R21HG00450] Funding Source: Medline; NIA NIH HHS [R37AG00198] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R21HG000450] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; COX DR, 1994, SCIENCE, V265, P2031, DOI 10.1126/science.8091223; GREEN ED, 1991, JAMA-J AM MED ASSOC, V266, P1966, DOI 10.1001/jama.266.14.1966; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; HWANG I, 1991, PLANT J, V1, P367, DOI 10.1046/j.1365-313X.1991.t01-5-00999.x; JARVIS P, 1994, PLANT MOL BIOL, V24, P685, DOI 10.1007/BF00023565; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LEGUEN L, 1994, MOL GEN GENET, V245, P390, DOI 10.1007/BF00290120; MEYEROWITZ EM, 1985, SCIENCE, V229, P1214, DOI 10.1126/science.229.4719.1214; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; SCHENA M, 1994, P NATL ACAD SCI USA, V91, P8393, DOI 10.1073/pnas.91.18.8393; SCHENA M, 1992, P NATL ACAD SCI USA, V89, P3894, DOI 10.1073/pnas.89.9.3894; SCHENA M, 1993, GENE DEV, V7, P367, DOI 10.1101/gad.7.3.367; SHALON D, 1995, THESIS STANFORD U; SHALON D, UNPUB	18	6692	7876	27	949	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					467	470		10.1126/science.270.5235.467	http://dx.doi.org/10.1126/science.270.5235.467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569999				2022-12-28	WOS:A1995TA37400041
J	PARADISO, AM; MASON, SJ; LAZAROWSKI, ER; BOUCHER, RC				PARADISO, AM; MASON, SJ; LAZAROWSKI, ER; BOUCHER, RC			MEMBRANE-RESTRICTED REGULATION OF CA2+ RELEASE AND INFLUX IN POLARIZED EPITHELIA	NATURE			English	Article							PAROTID ACINAR-CELLS; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR CALCIUM; EXTRACELLULAR ATP; AIRWAY EPITHELIUM; OSCILLATIONS; METABOLISM; TRANSPORT; MESSENGER; CULTURE	EPITHELIAL cells exist in a complex setting in which responses to mucosal or serosal environments are mediated by receptors expressed on specialized cellular domains, such as apical versus basolateral cell membranes, We investigated whether airway epithelia can react selectively through G-protein-coupled receptors to stimuli in the mucosal or serosal environments by measuring inositol phosphate and intracellular Ca2+ responses in polarized human nasal epithelial monolayers, We report here that unilateral ATP (10(-4) M) administration stimulated P-2 purinoceptors and tapped pools of intracellular Ca2+ associated with the plasma membrane ipsilateral but not contralateral to stimulated receptors. Similarly, activation of plasma membrane Ca2+ influx by ATP was confined to the membrane ipsilateral to receptor stimulation. These findings demonstrate that polarized epithelia restrict P-2 receptor-mediated responses to a single domain of the cell, reflecting membrane-specific generation and catabolism of inositol phosphates and confinement of calcium influx regulation to the membrane ipsilateral to the stimulated receptors.	UNIV N CAROLINA,CTR CYST FIBROSIS PULM RES & TREATMENT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	PARADISO, AM (corresponding author), UNIV N CAROLINA,DEPT MED,DIV PULM DIS,CHAPEL HILL,NC 27599, USA.							ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BROWN HA, 1991, MOL PHARMACOL, V40, P648; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HANSEN M, 1993, J CELL SCI, V106, P995; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; LARSEN EH, 1990, J PHYSIOL-LONDON, V424, P109, DOI 10.1113/jphysiol.1990.sp018058; LAZAROWSKI ER, 1990, J BIOL CHEM, V265, P13118; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; PARADISO AM, 1991, AM J PHYSIOL, V261, pL63, DOI 10.1152/ajplung.1991.261.2.L63; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; THORN P, 1993, CELL CALCIUM, V14, P746, DOI 10.1016/0143-4160(93)90100-K; WU R, 1985, AM REV RESPIR DIS, V132, P311	16	102	103	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					643	646		10.1038/377643a0	http://dx.doi.org/10.1038/377643a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566178				2022-12-28	WOS:A1995TA27500056
J	LI, T; STARK, MR; JOHNSON, AD; WOLBERGER, C				LI, T; STARK, MR; JOHNSON, AD; WOLBERGER, C			CRYSTAL-STRUCTURE OF THE MATA1/MAT-ALPHA-2 HOMEODOMAIN HETERODIMER BOUND TO DNA	SCIENCE			English	Article							HUMAN PROTOONCOGENE PBX1; HOMEO DOMAIN PROTEIN; SINGLE AMINO-ACID; ANTENNAPEDIA HOMEODOMAIN; BINDING SPECIFICITY; TRANSCRIPTION FACTOR; TRANSACTIVATOR VP16; ALPHA-2 REPRESSOR; NMR-SPECTROSCOPY; OPERATOR COMPLEX	The Saccharomyces cerevisiae MATa1 and MAT alpha 2 homeodomain proteins, which play a role in determining yeast cell type, form a heterodimer that binds DNA and represses transcription in a cell type-specific manner. Whereas the alpha 2 and a1 proteins on their own have only modest affinity for DNA, the a1/alpha 2 heterodimer binds DNA with high specificity and affinity. The three-dimensional crystal structure of the a1/alpha 2 homeodomain heterodimer bound to DNA was determined at a resolution of 2.5 Angstrom. The a1 and alpha 2 homeodomains bind in a head-to-tail orientation, with heterodimer contacts mediated by a 16-residue tail located carboxyl-terminal to the alpha 2 homeodomain. This tail becomes ordered in the presence of a1, part of it forming a short amphipathic helix that packs against the a1 homeodomain between helices 1 and 2. A pronounced 60 degrees bend is induced in the DNA, which makes possible protein-protein and protein-DNA contacts that could not take place in a straight DNA fragment. Complex formation mediated by flexible protein-recognition peptides attached to stably folded DNA binding domains may prove to be a general feature of the architecture of other classes of eukaryotic transcriptional regulators.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; University of California System; University of California San Francisco				Wolberger, Cynthia/0000-0001-8578-2969	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037049] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37049] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BAXTER SM, 1994, BIOCHEMISTRY-US, V33, P15309, DOI 10.1021/bi00255a012; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; FUREY W, 1990, AM CRYSTALLOGRAPHIC; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GLOVER M, UNPUB; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HO CY, 1994, EMBO J, V13, P1403, DOI 10.1002/j.1460-2075.1994.tb06394.x; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JIN YS, 1995, SCIENCE, V270, P290, DOI 10.1126/science.270.5234.290; JOHNSON A, 1992, TRANSCRIPTIONAL REGU, V2, P975; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI T, 1995, PROTEINS, V21, P161, DOI 10.1002/prot.340210210; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; PHILLIPS CL, 1994, BIOCHEMISTRY-US, V33, P9294, DOI 10.1021/bi00197a033; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHEPHERD JCW, 1984, NATURE, V310, P70, DOI 10.1038/310070a0; SMITH DL, 1995, NUCLEIC ACIDS RES, V23, P1239, DOI 10.1093/nar/23.7.1239; STARK MR, 1994, NATURE, V371, P429, DOI 10.1038/371429a0; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRATHERN J, 1988, GENETICS, V120, P75; TREISMAN J, 1989, CELL, V59, P553; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	64	234	239	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					262	269		10.1126/science.270.5234.262	http://dx.doi.org/10.1126/science.270.5234.262			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569974				2022-12-28	WOS:A1995RZ34200028
J	SCHEINMAN, RI; COGSWELL, PC; LOFQUIST, AK; BALDWIN, AS				SCHEINMAN, RI; COGSWELL, PC; LOFQUIST, AK; BALDWIN, AS			ROLE OF TRANSCRIPTIONAL ACTIVATION OF I-KAPPA-B-ALPHA IN MEDIATION OF IMMUNOSUPPRESSION BY GLUCOCORTICOIDS	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; AP-1 ACTIVITY; RECEPTOR; HORMONE; FOS; INTERLEUKIN-1; EXPRESSION; PRECURSOR; INHIBITOR; PATHWAY	Glucocorticoids are potent immunosuppressive drugs, but their mechanism is poorly understood. Nuclear factor kappa B (NF-kappa B), a regulator of immune system and inflammation genes, may be a target for glucocorticoid-mediated immunosuppression. The activation of NF-kappa B involves the targeted degradation of its cytoplasmic inhibitor, I kappa B alpha, and the translocation of NF-kappa B to the nucleus. Here it is shown that the synthetic glucocorticoid dexamethasone induces the transcription of the I kappa B alpha gene, which results in an increased rate of I kappa B alpha protein synthesis. Stimulation by tumor necrosis factor causes the release of NF-kappa B from I kappa B alpha. However, in the presence of dexamethasone this newly released NF-kappa B quickly reassociates with newly synthesized I kappa B alpha, thus markedly reducing the amount of NF-kappa B that translocates to the nucleus. This decrease in nuclear NF-kappa B is predicted to markedly decrease cytokine secretion and thus effectively block the activation of the immune system.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA052515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098, R37AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [CA52515] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARENZANASEISDED.F, 1995, MOL CELL BIOL, V15, P2689; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAYNES R C JR, 1990, P1431; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LOFQUIST AK, 1995, MOL CELL BIOL, V15, P1737; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, UNPUB; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH KA, 1980, IMMUNOL REV, V51, P337, DOI 10.1111/j.1600-065X.1980.tb00327.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; YEN HFY, 1990, CELL, V62, P1205	37	1444	1542	5	53	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					283	286		10.1126/science.270.5234.283	http://dx.doi.org/10.1126/science.270.5234.283			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569975	Green Submitted			2022-12-28	WOS:A1995RZ34200034
J	AKOULITCHEV, S; MAKELA, TP; WEINBERG, RA; REINBERG, D				AKOULITCHEV, S; MAKELA, TP; WEINBERG, RA; REINBERG, D			REQUIREMENT FOR TFIIH KINASE-ACTIVITY IN TRANSCRIPTION BY RNA-POLYMERASE-II	NATURE			English	Article							C-TERMINAL DOMAIN; LARGEST SUBUNIT; PROMOTER; REPEAT	AN array of tandem heptapeptide repeats at the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II constitute a highly conserved structure essential for viability(1-3). Studies have established that the CTD is phosphorylated at different stages of the transcription cycle(4-7), and that it may be involved in transcriptional regulation(8-12). The exact role of the CTD remains elusive, as in vitro reconstituted transcription using the adenovirus major late promoter does not require the CTD13,14. Previous studies(7,15,16) showed that transcription from the murine dihydrofolate reductase (DHFR) promoter can be only accomplished by the form of RNA polymerase II that contains the hypophosphorylated CTD (RNAPIIA), but not by the form that lacks it (RNAPIIB)(7). Here we show that the CTD, but not its phosphorylation, is required for initiation of transcription. We also show that transcription requires CTD kinase activity provided by the CDK7 subunit of TFIIH17-19.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044; Reinberg, Danny/0000-0003-4288-2016				ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, V1, P109; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; KANG ME, 1993, J BIOL CHEM, V268, P25033; KIM WY, 1989, J BIOL CHEM, V264, P3169; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	27	161	164	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					557	560		10.1038/377557a0	http://dx.doi.org/10.1038/377557a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566158				2022-12-28	WOS:A1995RZ33600070
J	KNUDSON, CM; TUNG, KSK; TOURTELLOTTE, WG; BROWN, GAJ; KORSMEYER, SJ				KNUDSON, CM; TUNG, KSK; TOURTELLOTTE, WG; BROWN, GAJ; KORSMEYER, SJ			BAX-DEFICIENT MICE WITH LYMPHOID HYPERPLASIA AND MALE GERM-CELL DEATH	SCIENCE			English	Article							APOPTOSIS; BCL-2; PROTEIN; SURVIVAL; GENE; P53	BAX, a heterodimeric partner of BCL2, counters BCL2 and promotes apoptosis in gain-of-function experiments, A Bax knockout mouse was generated that proved viable but displayed lineage-specific aberrations in cell death, Thymocytes and B cells in this mouse displayed hyperplasia, and Bax-deficient ovaries contained unusual atretic follicles with excess granulosa cells. In contrast, Bax-deficient males were infertile as a result of disordered seminiferous tubules with an accumulation of atypical premeiotic germ cells, but no mature haploid sperm, Multinucleated giant cells and dysplastic cells accompanied massive cell death. Thus, the loss of Bax results in hyperplasia or hypoplasia, depending on the cellular context.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV MOLEC ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Virginia				Knudson, Charles Michael/0000-0003-3964-5466	NCI NIH HHS [CA49712] Funding Source: Medline; NICHD NIH HHS [P30-HD28934, HD27500] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028934, R01HD027500] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARINAGA M, 1994, SCIENCE, V263, P754, DOI 10.1126/science.8303290; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOLSE LS, 1995, IMMUNITY, V3, P87; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DYM M, 1994, P NATL ACAD SCI USA, V91, P11287, DOI 10.1073/pnas.91.24.11287; ENDERS GC, 1994, DEV BIOL, V163, P331, DOI 10.1006/dbio.1994.1152; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GAURIELI Y, 1992, J CELL BIOL, V119, P493; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HINTZ M, 1977, DEV BIOL, V57, P375, DOI 10.1016/0012-1606(77)90222-6; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HUCKINS C, 1978, ANAT REC, V190, P905, DOI 10.1002/ar.1091900410; KAMADA S, 1995, CANCER RES, V55, P354; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MERRY DE, 1994, DEVELOPMENT, V120, P301; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; RUSSELL L, 1977, AM J ANAT, V148, P313, DOI 10.1002/aja.1001480303; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	40	1276	1305	0	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					96	99		10.1126/science.270.5233.96	http://dx.doi.org/10.1126/science.270.5233.96			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569956				2022-12-28	WOS:A1995RY30200041
J	KUROKAWA, R; SODERSTROM, M; HORLEIN, A; HALACHMI, S; BROWN, M; ROSENFELD, MG; GLASS, CK				KUROKAWA, R; SODERSTROM, M; HORLEIN, A; HALACHMI, S; BROWN, M; ROSENFELD, MG; GLASS, CK			POLARITY-SPECIFIC ACTIVITIES OF RETINOIC ACID RECEPTORS DETERMINED BY A CO-REPRESSOR	NATURE			English	Article							BINDING PROTEIN; DIRECT REPEAT; HORMONE; RAR	RETINOIC acid receptors (RARs) and retinoid-X receptors (RXRs) activate or repress transcription by binding as heterodimers to DNA-response elements that generally consist of two direct repeat half-sites of consensus sequence AGGTCA (reviewed in ref. 1). On response elements consisting of direct repeats spaced by five base pairs (DR + 5 elements), RAR/RXR heterodimers activate transcription in response to RAR-specific ligands, such as all-trans-retinoic acid (RA)(2). In contrast, on elements consisting of direct repeats spaced by one base pair (DR + 1 elements), RAR/RXR heterodimers exhibit little or no response to activating ligands and repress RXR-dependent transcription(3). Here we show that ligand-dependent transactivation by RAR on DR + 5 elements requires the dissociation of a new nuclear receptor co-repressor, N-CoR, and recruitment of the putative co-activators p140 and p160 (refs 4, 5). Surprisingly, on DR + 1 elements, N-CoR remains associated with RAR/RXR heterodimers even in the presence of RAR ligands, resulting in constitutive repression. These observations indicate that DNA-response elements can allosterically regulate RAR-co-repressor interactions to determine positive or negative regulation of gene expression.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; DANA FARBER CANC INST,DIV NEOPLAST DIS MECHANISMS,BOSTON,MA 02115	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Harvard University; Dana-Farber Cancer Institute			Brown, Myles/AAX-5332-2021; Brown, Myles/B-6906-2008; Söderström, Mats/C-4005-2009; Glass, Christopher/AAI-3933-2021	Brown, Myles/0000-0002-8213-1658; Söderström, Mats/0000-0003-3927-4394; Glass, Christopher/0000-0003-4344-3592; Halachmi, Shlomit/0000-0001-5921-9515				BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; CASANOVA J, 1995, MOL CELL BIOL, V14, P5756; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FOREMAN BM, 1995, CELL, V81, P541; GLASS C. K., 1994, ENDOCR REV, V15, P1503; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; TONE Y, 1994, J BIOL CHEM, V269, P31157; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x	21	475	481	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					451	454		10.1038/377451a0	http://dx.doi.org/10.1038/377451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566126				2022-12-28	WOS:A1995RY19000056
J	MARCHAND, S; LI, JX; CHAREST, J				MARCHAND, S; LI, JX; CHAREST, J			EFFECTS OF CAFFEINE ON ANALGESIA FROM TRANSCUTANEOUS ELECTRICAL NERVE-STIMULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							PAIN; TENS				MARCHAND, S (corresponding author), UNIV QUEBEC ABITIBI TEMISCARMINGUE,ROUYN,PQ J9X 5E4,CANADA.			Marchand, Serge/0000-0002-4234-5977				DALY JW, 1981, LIFE SCI, V28, P2083, DOI 10.1016/0024-3205(81)90614-7; MARCHAND S, 1993, PAIN, V54, P99, DOI 10.1016/0304-3959(93)90104-W; MARCHAND S, 1991, CLIN J PAIN, V7, P122, DOI 10.1097/00002508-199106000-00008; SALTER MW, 1987, NEUROSCIENCE, V22, P631, DOI 10.1016/0306-4522(87)90359-9; SAWYNOK J, 1993, BRAIN RES, V610, P32, DOI 10.1016/0006-8993(93)91213-C	5	50	53	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					325	326		10.1056/NEJM199508033330521	http://dx.doi.org/10.1056/NEJM199508033330521			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL694	7596392				2022-12-28	WOS:A1995RL69400034
J	RESNICK, NM				RESNICK, NM			URINARY-INCONTINENCE	LANCET			English	Article							GERIATRIC VOIDING DYSFUNCTION; STRESS-INCONTINENCE; STRUCTURAL BASIS; ELDERLY PATIENTS; DETRUSOR; OLDER; WOMEN; POPULATION		BROCKTON W ROXBURY VET AFFAIRS MED CTR,DIV UROL,BOSTON,MA; BROCKTON W ROXBURY VET AFFAIRS MED CTR,GRECC DIV,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard University; Harvard University; Harvard Medical School	RESNICK, NM (corresponding author), BRIGHAM & WOMENS HOSP,DIV GERONTOL,75 FRANCIS ST,BOSTON,MA 02115, USA.				NIA NIH HHS [AG-08812] Funding Source: Medline; NIDDK NIH HHS [R01-DK49482] Funding Source: Medline; PHS HHS [EG-04390] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG008812, P30AG008812] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAMS P, 1988, NEUROUROL URODYNAM, V7, P403, DOI 10.1002/nau.1930070502; BLACKBURN T, 1990, ARCH INTERN MED, V150, P2577, DOI 10.1001/archinte.150.12.2577; BOSCIA JA, 1986, AM J MED, V81, P979, DOI 10.1016/0002-9343(86)90391-8; BRANCH LG, 1994, J AM GERIATR SOC, V42, P1257, DOI 10.1111/j.1532-5415.1994.tb06507.x; BRANDEIS G H, 1990, Journal of Urology, V143, p223A; BURNS PA, 1993, J GERONTOL, V48, pM167; DIOKNO AC, 1991, UROLOGY, V38, P39, DOI 10.1016/0090-4295(91)80010-5; DIOKNO AC, 1988, J UROLOGY, V140, P567, DOI 10.1016/S0022-5347(17)41720-4; Dubeau Catherine, 1993, Journal of the American Geriatrics Society, V41, pSA12; DUBEAU CE, 1992, ADV INTERNAL MED, V37, P55; DUBEAU CE, 1995, J AM GERIATR SOC, V43, P310, DOI 10.1111/j.1532-5415.1995.tb07345.x; ELBADAWI A, 1993, J UROLOGY, V150, P1657, DOI 10.1016/S0022-5347(17)35867-6; ELBADAWI A, 1993, J UROLOGY, V150, P1668, DOI 10.1016/S0022-5347(17)35868-8; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; Herzog A R, 1989, Annu Rev Gerontol Geriatr, V9, P74; JENSEN JK, 1994, OBSTET GYNECOL, V83, P904; MCDOWELL BJ, 1994, J AM GERIATR SOC, V42, P501, DOI 10.1111/j.1532-5415.1994.tb04971.x; MITTENESS LS, 1990, J AM GERIATR SOC, V38, P374, DOI 10.1111/j.1532-5415.1990.tb03525.x; NIELSEN KK, 1993, BRIT J UROL, V72, P428, DOI 10.1111/j.1464-410X.1993.tb16171.x; NITTI VW, 1993, J UROLOGY, V149, P802, DOI 10.1016/S0022-5347(17)36212-2; OESTERLING JE, 1995, NEW ENGL J MED, V332, P99, DOI 10.1056/NEJM199501123320207; OUSLANDER JG, 1986, J AM GERIATR SOC, V34, P507, DOI 10.1111/j.1532-5415.1986.tb04242.x; OUSLANDER JG, 1992, NEUROUROL URODYNAM, V11, P159; RESNICK N, 1989, NEW ENGL J MED, V320, P1421; RESNICK NM, 1990, GERONTOLOGY, V36, P8, DOI 10.1159/000213236; RESNICK NM, 1987, JAMA-J AM MED ASSOC, V257, P3076, DOI 10.1001/jama.257.22.3076; RESNICK NM, 1990, J AM GERIATR SOC, V38, P263, DOI 10.1111/j.1532-5415.1990.tb03502.x; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; RESNICK NM, 1992, CAMPBELLS UROLOGY, P643; RESNICK NM, IN PRESS NEUROUROL U; RESNICK NM, IN PRESS QUALITY CAR; RESNICK NM, 1991, MINIMUM DATA SET TRA, pF24; Resnik NM, 1988, NEUROUROL URODYNAM, P303; WYMAN JF, 1990, J AM GERIATR SOC, V38, P282, DOI 10.1111/j.1532-5415.1990.tb03505.x; 1992, AHCPR920038 PHS AG H	35	111	130	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					94	99		10.1016/S0140-6736(95)92117-6	http://dx.doi.org/10.1016/S0140-6736(95)92117-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603221				2022-12-28	WOS:A1995RH22000015
J	VANNOORT, JM; VANSECHEL, AC; BAJRAMOVIC, JJ; ELOUAGMIRI, M; POLMAN, CH; LASSMANN, H; RAVID, R				VANNOORT, JM; VANSECHEL, AC; BAJRAMOVIC, JJ; ELOUAGMIRI, M; POLMAN, CH; LASSMANN, H; RAVID, R			THE SMALL HEAT-SHOCK PROTEIN ALPHA-B-CRYSTALLIN AS CANDIDATE AUTOANTIGEN IN MULTIPLE-SCLEROSIS	NATURE			English	Article							INDIRECT FLIGHT MUSCLES; T-CELL RECEPTOR; DROSOPHILA; TISSUES; DISEASE	THE identification of key antigens in human autoimmune diseases is a crucial step towards the development of specific intervention. The autoantigen(s) relevant to multiple sclerosis (MS) probably reside in myelin of the central nervous system, the target of the disease(1). Here we examine proliferative responses of human peripheral blood T cells to the complete collection of myelin proteins fractionated by reversed-phase high-performance liquid chromatography. Myelin isolated from MS-affected brain contained a single protein fraction to which T cells from MS patients and from healthy controls showed dominant responses. This highly immunogenic protein was identified as alpha B-crystallin, a small heat-shock protein. Immunohistochemical examination of MS lesions revealed the presence of oligodendrocytes and astrocytes with raised alpha B- crystallin expression, which were not found in unaffected myelin. Our findings indicate that alpha B-crystallin serves as immunodominant myelin antigen to human T cells when expressed at the elevated levels found in active MS lesions.	FREE UNIV AMSTERDAM HOSP,DEPT NEUROL,1007 MB AMSTERDAM,NETHERLANDS; AUSTRIAN ACAD SCI,EXPTL NEUROPATHOL RES UNIT,A-1090 VIENNA,AUSTRIA; NETHERLANDS INST BRAIN RES,NETHERLANDS BRAIN BANK,1105 AZ AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Austrian Academy of Sciences; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	VANNOORT, JM (corresponding author), TNO,PREVENT & HLTH,DIV INFECT DIS & IMMUNOL,POB 2215,2301 CE LEIDEN,NETHERLANDS.		Lassmann, Hans/Z-2269-2019; Bajramovic, Jeffrey/AAF-6695-2020	Lassmann, Hans/0000-0001-8617-5052; Bajramovic, Jeffrey/0000-0002-6504-3437; van Noort, Johannes/0000-0002-9060-5921				BRUCK W, 1994, ANN NEUROL, V35, P65, DOI 10.1002/ana.410350111; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; HIROMI Y, 1985, EMBO J, V4, P1681, DOI 10.1002/j.1460-2075.1985.tb03837.x; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KARLIK CC, 1984, CELL, V38, P711, DOI 10.1016/0092-8674(84)90266-6; KATO K, 1992, J BIOL CHEM, V167, P7718; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; NORTON WT, 1973, J NEUROCHEM, V31, P749; OZAWA K, 1994, BRAIN, V117, P1311, DOI 10.1093/brain/117.6.1311; PETTE M, 1990, NEUROLOGY, V40, P1770, DOI 10.1212/WNL.40.11.1770; SALVETTI M, 1992, J AUTOIMMUN, V5, P691, DOI 10.1016/0896-8411(92)90186-T; SELMAJ K, 1991, P NATL ACAD SCI USA, V88, P6452, DOI 10.1073/pnas.88.15.6452; VANNOORT JM, 1993, J NEUROIMMUNOL, V46, P67, DOI 10.1016/0165-5728(93)90234-P; VANNOORT JM, 1994, J CHROMATOGR B, V653, P155, DOI 10.1016/0378-4347(93)E0433-Q; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P4588, DOI 10.1073/pnas.89.10.4588; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	21	348	353	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					798	801		10.1038/375798a0	http://dx.doi.org/10.1038/375798a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596414				2022-12-28	WOS:A1995RF98900081
J	SCHNELL, DJ				SCHNELL, DJ			SHEDDING LIGHT ON THE CHLOROPLAST PROTEIN IMPORT MACHINERY	CELL			English	Review							BINDING				SCHNELL, DJ (corresponding author), RUTGERS STATE UNIV,DEPT BIOL SCI,NEWARK,NJ 07102, USA.							BULYCHEV A, 1994, FEBS LETT, V356, P204, DOI 10.1016/0014-5793(94)01259-8; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; KEEGSTRA K, 1995, PHYSIOL PLANTARUM, V93, P157, DOI 10.1034/j.1399-3054.1995.930122.x; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KO K, 1992, J BIOL CHEM, V267, P2986; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WU CB, 1994, J BIOL CHEM, V269, P32264	14	47	49	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					521	524		10.1016/0092-8674(95)90090-X	http://dx.doi.org/10.1016/0092-8674(95)90090-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585953	Bronze			2022-12-28	WOS:A1995TF24800003
J	MENAGE, J				MENAGE, J			FEMALE GENITAL MUTILATION - PROFESSIONALS SHOULD NOT COLLUDE WITH ABUSIVE SYSTEMS	BRITISH MEDICAL JOURNAL			English	Letter											MENAGE, J (corresponding author), HOLBROOKS MED CTR,COVENTRY,W MIDLANDS,ENGLAND.							BLACK JA, 1995, BRIT MED J, V310, P1590, DOI 10.1136/bmj.310.6994.1590; DECASTELLA H, 1994, ANN ROY COLL SURG, V76, P257; MENAGE J, 1993, J REPRODUCTIVE INFAN, V111, P221; Miller A, 1991, BANISHED KNOWLEDGE F; WRIGHT JE, 1994, AUST NZ J SURG, V64, P327, DOI 10.1111/j.1445-2197.1994.tb02220.x	5	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1088	1089		10.1136/bmj.311.7012.1088b	http://dx.doi.org/10.1136/bmj.311.7012.1088b			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB354	7580673	Green Published			2022-12-28	WOS:A1995TB35400055
J	ADAMES, N; BLUNDELL, K; ASHBY, MN; BOONE, C				ADAMES, N; BLUNDELL, K; ASHBY, MN; BOONE, C			ROLE OF YEAST INSULIN-DEGRADING ENZYME HOMOLOGS IN PROPHEROMONE PROCESSING AND BUD SITE SELECTION	SCIENCE			English	Article							FACTOR MATING PHEROMONE; STE6 GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; A-FACTOR; FARNESYL CYSTEINE; RAS PROTEINS; TERMINAL METHYLATION; SHUTTLE VECTORS; ACTIVE-SITE; METHYLTRANSFERASE	The Saccharomyces cerevisiae AXL1 gene product Axl1p shares homology with the insulin-degrading enzyme family of endoproteases. Yeast axl1 mutants showed a defect in a-factor pheromone secretion, and a probable site of processing by Axl1p was identified within the a-factor precursor. In addition, Axl1p appears to function as a morphogenetic determinant for axial bud site selection. Amino acid substitutions within the presumptive active site of Axl1p caused defects in propheromone processing but failed to perturb bud site selection. Thus, Axl1p has been shown to participate in the dual regulation of distinct signaling pathways, and a member of the insulinase family has been implicated in propeptide processing.	SIMON FRASER UNIV, INST BIOCHEM & MOLEC BIOL, BURNABY, BC V5A 1S6, CANADA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Simon Fraser University; University of California System; University of California Berkeley			Adames, Neil/AAO-7913-2020; Adames, Neil/S-1460-2017; Adames, Neil/C-8863-2012	Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348				AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; ANASTASI A, 1993, BIOCHEM J, V290, P601, DOI 10.1042/bj2900601; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; ASHBY MN, 1995, METHOD ENZYMOL, V250, P235; ASHBY MN, 1993, YEAST, V9, P907, DOI 10.1002/yea.320090810; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BECKER AB, 1993, BIOCHEM J, V292, P137, DOI 10.1042/bj2920137; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BOONE C, 1992, NUCLEIC ACIDS RES, V20, P4661, DOI 10.1093/nar/20.17.4661; CALDWELL GA, 1994, J BIOL CHEM, V269, P19817; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHEN P, 1993, THESIS J HOPKINS U S; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DUCKWORTH WC, 1989, BIOCHEMISTRY-US, V28, P2471, DOI 10.1021/bi00432a018; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; Gething M, 1985, PROTEIN TRANSPORT SE, P103; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; KUCHLER K, 1992, ENDOCR REV, V13, P499, DOI 10.1210/er.13.3.499; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LI D, 1992, J BIOL CHEM, V267, P2414; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MARR RS, 1990, J BIOL CHEM, V265, P20057; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PERLMAN RK, 1994, J BIOL CHEM, V269, P33140; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; PIEROTTI AR, 1994, P NATL ACAD SCI USA, V91, P6078, DOI 10.1073/pnas.91.13.6078; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STEINER DF, 1992, J BIOL CHEM, V267, P23435	50	113	114	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 20	1995	270	5235					464	467		10.1126/science.270.5235.464	http://dx.doi.org/10.1126/science.270.5235.464			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569998				2022-12-28	WOS:A1995TA37400040
J	RETALLACK, DM; FRIEDMAN, DI				RETALLACK, DM; FRIEDMAN, DI			A ROLE FOR A SMALL STABLE RNA IN MODULATING THE ACTIVITY OF DNA-BINDING PROTEINS	CELL			English	Article							ESCHERICHIA-COLI; 10SA RNA; PHAGE-LAMBDA; RIBONUCLEASE-P; GENE; TRANSCRIPTION; MECHANISM; ANTITERMINATION; IDENTIFICATION; EXPRESSION	The 10Sa RNA, encoded by the E. coli ssrA gene, appears to modulate action of some DNA-binding proteins. When ssrA is inactivated, lacZ expression from the lac operon, as well as galK from a gal operon fused to a phage lambda promoter, is reduced from that observed in bacteria wild-type for ssrA. These differences are not observed if the relevant repressor is inactive, suggesting that in the absence of 10Sa RNA binding of Lad and lambda cl repressors is enhanced. Gel mobility shifts show that 10Sa RNA binds these repressors and that an excess of 10Sa RNA competes for binding of lambda cl with a DNA fragment containing the O(R)2 repressor-binding sequence. Similar observations were made in studies of the E. coli LexA repressor and phage P22 C1 transcription activator proteins. These results suggest that direct interaction with 10Sa RNA may explain this modulation of protein-DNA interactions.			RETALLACK, DM (corresponding author), UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA.		Friedman, David/G-3198-2015	Friedman, David/0000-0002-2741-4671	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00042] Funding Source: Medline; NIGMS NIH HHS [5T32GM07544-14] Funding Source: Medline; PHS HHS [AL1459-10] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADHYA S, 1974, P NATL ACAD SCI USA, V71, P2534, DOI 10.1073/pnas.71.6.2534; ADHYA S, 1990, J BIOL CHEM, V265, P10797; ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Beckwith J.R., 1987, ESCHERICHIA COLI SAL, V2, P1444; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN JW, 1990, NUCLEIC ACIDS RES, V18, P2820, DOI 10.1093/nar/18.9.2820; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHAUHAN AK, 1989, MOL MICROBIOL, V3, P1481, DOI 10.1111/j.1365-2958.1989.tb00133.x; COURT D, 1993, CONTROL MRNA STABILI, V3, P71; DAMBLY-CHAUDIERE C, 1983, Journal of Molecular and Applied Genetics, V2, P45; DARR SC, 1992, BIOCHEMISTRY-US, V31, P328, DOI 10.1021/bi00117a003; DECROMBR.B, 1973, NATURE-NEW BIOL, V241, P260, DOI 10.1038/newbio241260a0; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FRIEDMAN DI, 1990, GENE DEV, V4, P2210, DOI 10.1101/gad.4.12a.2210; FRIEDMAN DI, 1973, VIROLOGY, V51, P216, DOI 10.1016/0042-6822(73)90381-4; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; HARRISON SC, 1992, TRANSCRIPTIONAL REGU, P449; HUISMAN O, 1981, NATURE, V290, P797, DOI 10.1038/290797a0; INOUYE M, 1988, CELL, V53, P5, DOI 10.1016/0092-8674(88)90480-1; JENSEN CG, 1994, J BACTERIOL, V176, P2502, DOI 10.1128/JB.176.9.2502-2506.1994; KAMBEROV ES, 1994, PHOSPHATE IN MICROORGANISMS, P302; KAOHUANG Y, 1977, P NATL ACAD SCI USA, V74, P4228, DOI 10.1073/pnas.74.10.4228; KIRBY JE, 1994, J BACTERIOL, V176, P2068, DOI 10.1128/jb.176.7.2068-2081.1994; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LIN LL, 1988, J BACTERIOL, V170, P2163, DOI 10.1128/jb.170.5.2163-2173.1988; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; OH BK, 1991, MOL GEN GENET, V229, P52, DOI 10.1007/BF00264212; PIELER T, 1993, TRENDS BIOCHEM SCI, V18, P226, DOI 10.1016/0968-0004(93)90194-R; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; RETALLACK DM, 1993, P NATL ACAD SCI USA, V90, P9562, DOI 10.1073/pnas.90.20.9562; REYES O, 1979, VIROLOGY, V94, P400, DOI 10.1016/0042-6822(79)90470-7; Sambrook J, 1989, MOL CLONING LABORATO; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; STRAUCH MA, 1986, J BACTERIOL, V167, P191, DOI 10.1128/jb.167.1.191-200.1986; SUBBARAO MN, 1989, MOL GEN GENET, V217, P499, DOI 10.1007/BF02464923; SUSSKIND MM, 1975, J MOL BIOL, V98, P413, DOI 10.1016/S0022-2836(75)80127-6; SUSSMAN R, 1962, CR HEBD ACAD SCI, V254, P1517; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TYAGI JS, 1992, NUCLEIC ACIDS RES, V20, P138, DOI 10.1093/nar/20.1.138; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	51	46	48	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 20	1995	83	2					227	235		10.1016/0092-8674(95)90164-7	http://dx.doi.org/10.1016/0092-8674(95)90164-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585940	Bronze			2022-12-28	WOS:A1995TA96500009
J	BORIES, JC; WILLERFORD, DM; GREVIN, D; DAVIDSON, L; CAMUS, A; MARTIN, P; STEHELIN, D; ALT, FW				BORIES, JC; WILLERFORD, DM; GREVIN, D; DAVIDSON, L; CAMUS, A; MARTIN, P; STEHELIN, D; ALT, FW			INCREASED T-CELL APOPTOSIS AND TERMINAL B-CELL DIFFERENTIATION-INDUCED BY INACTIVATION OF THE ETS-1 PROTOONCOGENE	NATURE			English	Article							DNA-BINDING; TRANSCRIPTION FACTORS; GENE ENHANCER; MICE; ACTIVATION; THYMOCYTES; SEQUENCE	THE Ets-1 proto-oncogene is a member of a transcription factor family characterized by homology to the v-ets oncogene(1-4). In adult mice, Ets-1 is expressed predominantly in lymphoid cells where it has been implicated in regulating transcription of lymphocyte-specific genes(5-7). Following T-cell activation, the specific DNA binding activity of Ets-1 is inactivated by transient phosphorylation, suggesting a function in the transition from the resting to activated state(8,9). Ets-1 has also been suggested to cooperate with the AP-1 transcription factor complex to mediate cellular growth factor responses(4). Here we show, by using RAG-2-deficient blastocyst complementation(10), that Ets-1 deficiency has dramatic, but different, effects on development and function of T- and B-lineage cells, Ets-1-deficient T cells were present in reduced numbers and were highly susceptible to cell death in vitro. In contrast, Ets-1-deficient B cells were present in normal numbers but a large proportion were IgM plasma cells, Our data demonstrate that Ets-1 is essential for maintenance of the normal pool of resting T- and B-lineage cells.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115; HOP ST LOUIS,INSERM,U93,F-75475 PARIS,FRANCE; INST PASTEUR,MOLEC ONCOL LAB,CNRS,URA 1160,F-59019 LILLE,FRANCE; INST PASTEUR,UNITE BIOL DEV,CNRS,URA 1960,F-75724 PARIS,FRANCE	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	BORIES, JC (corresponding author), CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.		Bories, Jean-Christophe/L-6952-2017; Camus, Anne/P-1515-2014	Camus, Anne/0000-0002-8820-0407				BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; CHEN J, 1992, P NATL ACAD SCI USA, V90, P4528; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HARDY RR, 1983, NATURE, V306, P270, DOI 10.1038/306270a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; JORCYK CL, 1991, ONCOGENE, V6, P523; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0	24	269	276	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					635	638		10.1038/377635a0	http://dx.doi.org/10.1038/377635a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566176				2022-12-28	WOS:A1995TA27500054
J	GRANDEA, AG; ANDROLEWICZ, MJ; ATHWAL, RS; GERAGHTY, DE; SPIES, T				GRANDEA, AG; ANDROLEWICZ, MJ; ATHWAL, RS; GERAGHTY, DE; SPIES, T			DEPENDENCE OF PEPTIDE BINDING BY MHC CLASS-I MOLECULES ON THEIR INTERACTION WITH TAP	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ENDOPLASMIC-RETICULUM; CELL BIOLOGY; HLA-A; ANTIGEN; TRANSPORTER; TRANSLOCATION; PROTEIN; GENE; EXPRESSION	Major histocompatibility complex (MHC) class I molecules bind peptides that are delivered from the cytosol into the endoplasmic reticulum by the MHC-encoded transporter associated with antigen processing (TAP). Peptide capture by immature heterodimers of class I heavy chains and beta(2)-microglobulin may be facilitated by their physical association with TAP. A genetic defect in a human mutant cell line causes the complete failure of diverse class I heterodimers to associate with TAP. This deficiency impairs the ability of the class I heterodimers to efficiently capture peptides and results from loss of function of an unidentified gene or genes linked to the MHC.	FRED HUTCHINSON CANC RES CTR,DIV CLIN RES,SEATTLE,WA 98104; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,H LEE MOFFITT CANC CTR,PROGRAM IMMUNOL,TAMPA,FL 33612; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19104	Fred Hutchinson Cancer Center; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NIAID NIH HHS [AI38508, AI30581] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030581, R01AI038508, R01AI030581] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BARBER LD, 1993, ANNU REV CELL BIOL, V9, P163; BURROWS SR, 1992, EUR J IMMUNOL, V22, P191, DOI 10.1002/eji.1830220128; CEMAN S, 1994, J IMMUNOL, V152, P2865; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; HAYNES BF, 1982, HUM IMMUNOL, V4, P273, DOI 10.1016/0198-8859(82)90001-5; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Nelson K, 1989, IMMUNOBIOLOGY HLA, P292; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; STUBBLEFIELD E, 1992, SOMAT CELL MOLEC GEN, V18, P485, DOI 10.1007/BF01232645; SUGITA M, 1994, J EXP MED, V180, P2163, DOI 10.1084/jem.180.6.2163; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WILLIAMS DB, 1995, CURR OPIN IMMUNOL, V7, P77, DOI 10.1016/0952-7915(95)80032-8; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	38	177	177	1	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					105	108		10.1126/science.270.5233.105	http://dx.doi.org/10.1126/science.270.5233.105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569935				2022-12-28	WOS:A1995RY30200044
J	YAN, H; NEWPORT, J				YAN, H; NEWPORT, J			FFA-1, A PROTEIN THAT PROMOTES THE FORMATION OF REPLICATION CENTERS WITHIN NUCLEI	SCIENCE			English	Article							DNA-REPLICATION; EGG EXTRACTS; INVITRO; OCCURS; SITES	In the nuclei of eukaryotic cells, initiation of DNA replication occurs at a discrete number of foci. One component of these foci is the DNA replication factor RP-A. Here, the process leading to the association of RP-A with foci was reconstituted with cytosolic fractions derived from Xenopus eggs. With the use of this fractionated system, a 170-kilodalton protein required for the assembly of RP-A into foci was identified and purified. The protein appears to be an integral component of the foci at which replication of DNA is initiated in eukaryotic nuclei.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523, R37GM033523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BENEDETTI P, 1983, EMBO J, V2, P1303, DOI 10.1002/j.1460-2075.1983.tb01585.x; COX LS, 1991, CELL, V66, P271, DOI 10.1016/0092-8674(91)90617-8; FANG F, 1993, J CELL SCI, V106, P983; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SHIODA M, 1982, P NATL ACAD SCI-BIOL, V79, P7209, DOI 10.1073/pnas.79.23.7209; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; YAN H, UNPUB	18	36	37	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1883	1885		10.1126/science.7569932	http://dx.doi.org/10.1126/science.7569932			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569932				2022-12-28	WOS:A1995RX19400042
J	WALLEY, T; BARTON, S				WALLEY, T; BARTON, S			A PURCHASER PERSPECTIVE OF MANAGING NEW DRUGS - INTERFERON-BETA AS A CASE-STUDY	BRITISH MEDICAL JOURNAL			English	Article								Many new drugs in the future will be very expensive and have major resource implications. Given current structures and legislation covering the prescribing of drugs, there are no clear means of controlling the use of these drugs to avoid diverting money away from other health care services and into drug treatment. This paper considers what mechanisms might be used by a purchaser to manage the introduction of an expensive new drug and uses interferon beta-1b for treating multiple sclerosis as an example. The most likely mechanism is the prescribing of the drug by a general practitioner on the advice of a neurologist. This would achieve a good benefit for the resources invested but would not control total expenditure. Devolving a limited budget for the drug to a specialist centre so that neurologists may prescribe it directly would be preferable, as this would link clinical, prescribing, and budgetary responsibility. These issues need to be addressed urgently by purchasers if major disruptions of services are to be avoided.			WALLEY, T (corresponding author), UNIV LIVERPOOL,DEPT PHARMACOL & THERAPEUT,POB 147,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							[Anonymous], 1994, KEY ISSUES HLTH EC; BOCHNER F, 1994, BRIT MED J, V308, P901, DOI 10.1136/bmj.308.6933.901; CRUMP BJ, 1995, BRIT MED J, V310, P509, DOI 10.1136/bmj.310.6978.509; GOODKIN DE, 1994, LANCET, V344, P1702, DOI 10.1016/S0140-6736(94)90484-7; GOODKIN DE, 1994, LANCET, V344, P1057, DOI 10.1016/S0140-6736(94)91713-2; GOULD J, 1994, BRIT MED J, V309, P1657, DOI 10.1136/bmj.309.6969.1657b; HAYCOX A, 1995, PURCHASER DECISION M; JONES R, 1992, BRIT MED J, V304, P4, DOI 10.1136/bmj.304.6818.4; LEUFKENS H, 1994, BRIT MED J, V309, P1137, DOI 10.1136/bmj.309.6962.1137; NISHIMURA LY, 1994, PHARMACOECONOMICS, V6, P498, DOI 10.2165/00019053-199406060-00003; ORME M, 1991, BRIT MED J, V303, P593, DOI 10.1136/bmj.303.6803.593; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; The IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; WALLEY T, 1994, PHARMACOECONOMICS, V5, P93, DOI 10.2165/00019053-199405020-00003; 1994, GUIDELLINES CONDUCT; 1994, BETA INTERFERON 1B P; 1995, EL955 NHS EX DEP HLT; 1994, PRIORITY SETTING NHS, V1; 1994, NEW TREATMENTS MULTI; 1991, EL91127 NHS MAN EX D; 1994, EL9472 NHS EX DEP HL; 1994, NEUROLOGY, V44, P1537; 1944, GUIDELINES TREATMENT	23	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					796	799		10.1136/bmj.311.7008.796	http://dx.doi.org/10.1136/bmj.311.7008.796			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580445	Green Published			2022-12-28	WOS:A1995RX10700027
J	WARRELL, MJ				WARRELL, MJ			HUMAN DEATHS FROM CRYPTIC BAT RABIES IN THE USA	LANCET			English	Editorial Material							VIRUS				WARRELL, MJ (corresponding author), CTR TROP MED, OXFORD, ENGLAND.							BOURHY H, 1993, VIROLOGY, V194, P70, DOI 10.1006/viro.1993.1236; BRASS DA, 1994, RABIES BATS NATURAL; Campbell J B, 1994, Curr Top Microbiol Immunol, V187, P245; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P455; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P93; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P132; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P765; CHILDS JE, 1994, EPIDEMIOL INFECT, V113, P501, DOI 10.1017/S0950268800068515; COE CL, 1995, MMWR-MORBID MORTAL W, V44, P269; Constantine DG, 1970, BIOLOGY BATS, VII, P319; Debbie J. G., 1993, Morbidity and Mortality Weekly Report, V42, P799; DEBBIE JG, 1993, MMWR-MORBID MORTAL W, V42, P805; HARDMAN MS, 1995, MMWR-MORBID MORTAL W, V44, P93; HARDMAN MS, 1995, MMWR-MORBID MORTAL W, V44, P86; HOUFF SA, 1979, NEW ENGL J MED, V300, P603, DOI 10.1056/NEJM197903153001105; LUMIO J, 1986, LANCET, V1, P378; SELIMOV MA, 1989, ACTA VIROL, V33, P542; Smith J.S., 1988, P267; SMITH JS, 1992, J INFECT DIS, V166, P296, DOI 10.1093/infdis/166.2.296; WINKLER WG, 1975, NATURAL HIST RABIES, V2, P115	20	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 8	1995	346	8967					65	66		10.1016/S0140-6736(95)92106-0	http://dx.doi.org/10.1016/S0140-6736(95)92106-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603211	Bronze			2022-12-28	WOS:A1995RH22000004
J	SATO, TN; TOZAWA, Y; DEUTSCH, U; WOLBURGBUCHHOLZ, K; FUJIWARA, Y; GENDRONMAGUIRE, M; GRIDLEY, T; WOLBURG, H; RISAU, W; QIN, Y				SATO, TN; TOZAWA, Y; DEUTSCH, U; WOLBURGBUCHHOLZ, K; FUJIWARA, Y; GENDRONMAGUIRE, M; GRIDLEY, T; WOLBURG, H; RISAU, W; QIN, Y			DISTINCT ROLES OF THE RECEPTOR TYROSINE KINASES TIE-1 AND TIE-2 IN BLOOD-VESSEL FORMATION	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MOLECULAR-CLONING; ANGIOGENESIS; EXPRESSION; GENES; CELLS; VASCULOGENESIS; MEMBER; DEFINE; FAMILY	TIE-1 and Tie-2 define a new class of receptor tyrosine kinases that are specifically expressed in developing vascular endothelial cells. To study the functions of Tie-1 and Tie-2 during vascular endothelial cell growth and differentiation in vivo, targeted mutations of the genes in mice were introduced by homologous recombination. Embryos deficient in Tie-1 failed to establish structural integrity of vascular endothelial cells, resulting in oedema and subsequently localized haemorrhage. However, analyses of embryos deficient in Tie-2 showed that it is important in angiogenesis, particularly for vascular network formation in endothelial cells. This result contrasts with previous reports on Tie-2 function in vasculogenesis and/or endothelial cen survival. Our in vivo analyses indicate that the structurally related receptor tyrosine kinases Tie-1 and Tie-2 have important hut distinct roles in the formation of blood vessels.	MAX PLANCK INST PHYSIOL & CLIN RES,WG KERCHOFF INST,MOLEK ZELLBIOL ABT,D-61231 BAD NAUHEIM,GERMANY; UNIV TUBINGEN,INST PATHOL,D-72076 TUBINGEN,GERMANY	Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	SATO, TN (corresponding author), ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110, USA.		Tozawa, Yuzuru/AAM-9620-2020; Tozawa, Yuzuru/G-2657-2013	Tozawa, Yuzuru/0000-0002-3885-1105; Deutsch, Urban/0000-0003-4265-6262				DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KALPAINEN A, 1994, CANCER RES, V54, P6571; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; OELRICHS RB, 1993, ONCOGENE, V8, P11; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; QIN Y, 1995, DEV DYNAM, V202, P172, DOI 10.1002/aja.1002020209; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RISAU W, 1988, DEVELOPMENT, V102, P471; Risau W., 1991, DEV VASCULAR SYSTEM, P58; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SUCOV HM, 1994, GENE DEV, V3, P1007; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; VIRAGH S, 1981, ANAT REC, V201, P157, DOI 10.1002/ar.1092010117; WAGNER EF, 1994, SEMIN CANCER BIOL, V5, P137; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; ZIEGLER SF, 1993, ONCOGENE, V8, P663	30	1408	1500	2	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					70	74		10.1038/376070a0	http://dx.doi.org/10.1038/376070a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596437				2022-12-28	WOS:A1995RH11100064
J	VERRIJZER, CP; CHEN, JL; YOKOMORI, K; TJIAN, R				VERRIJZER, CP; CHEN, JL; YOKOMORI, K; TJIAN, R			BINDING OF TAFS TO CORE ELEMENTS DIRECTS PROMOTER SELECTIVITY BY RNA-POLYMERASE-II	CELL			English	Article							TRANSCRIPTION FACTOR; TATA BOX; DNA-SEQUENCES; MINIMAL SET; INITIATION; GENE; COMPLEXES; PROTEIN; DOWNSTREAM	The mechanisms that govern core promoter recognition and basal transcription efficiency remain poorly understood. Here, we have assessed the potential role of TAFs and the TFIID complex in directing basal promoter function. Reconstituted transcription reactions revealed the ability of TFIID versus TBP to discriminate between distinct core promoters. A comparison of different partial TBP-TAF assemblages established that a trimeric TBP-TAF(II)250-TAF(II)150 complex is minimally required for efficient utilization of the initiator and downstream promoter elements. Depending on the promoter structure, TAFs can increase or decrease the stability of TFIID-promoter interactions. These findings suggest that TAFs play a critical role in promoter selectivity and transcription regulation through direct contacts with core promoter elements.			VERRIJZER, CP (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DYNLACHT BD, 1991, CELL, V55, P563; EMANUEL PA, 1993, P NATL ACAD SCI USA, V90, P8449, DOI 10.1073/pnas.90.18.8449; GILMOUR DS, 1990, MOL CELL BIOL, V10, P4233, DOI 10.1128/MCB.10.8.4233; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLUG A, 1993, NATURE, V365, P486, DOI 10.1038/365486a0; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; MALDONADO E, 1990, MOL CELL BIOL, V10, P653; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PARVIN JD, 1992, CELL, V68, P1153; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; SMALE ST, 1990, P NATL ACAD SCI USA, V81, P4509; SYPES MA, 1994, NUCLEIC ACIDS RES, V22, P807, DOI 10.1093/nar/22.5.807; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WANG JC, 1993, BIOCHIM BIOPHYS ACTA, V1216, P73, DOI 10.1016/0167-4781(93)90039-G; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	45	258	259	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1115	1125		10.1016/S0092-8674(05)80016-9	http://dx.doi.org/10.1016/S0092-8674(05)80016-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600579	Bronze			2022-12-28	WOS:A1995RG91000016
J	CASTLEBERRY, RP; EMANUEL, PD; ZUCKERMAN, KS; COHN, S; STRAUSS, L; BYRD, RL; HOMANS, A; CHAFFEE, S; NITSCHKE, R; GUALTIERI, RJ				CASTLEBERRY, RP; EMANUEL, PD; ZUCKERMAN, KS; COHN, S; STRAUSS, L; BYRD, RL; HOMANS, A; CHAFFEE, S; NITSCHKE, R; GUALTIERI, RJ			A PILOT-STUDY OF ISOTRETINOIN IN THE TREATMENT OF JUVENILE CHRONIC MYELOGENOUS LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOMONOCYTIC LEUKEMIA; COLONY-STIMULATING FACTOR; CHRONIC MYELOID-LEUKEMIA; NON-LYMPHOCYTIC LEUKEMIA; CELL-LINE HL-60; RETINOIC ACID; PROMYELOCYTIC LEUKEMIA; PRIMARY CULTURE; DIFFERENTIATION; INDUCTION	Background. Juvenile chronic myelogenous leukemia (CML) is a rare myeloproliferative disease of infants and young children for which there is no effective therapy other than allogeneic bone marrow transplantation. In vitro, isotretinoin (13-cis-retinoic acid) attenuates both the spontaneous proliferation of leukemic peripheral-blood progenitor cells (granulocyte-macrophage colony-forming units) and their selective hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF). We conducted a pilot study to evaluate the clinical efficacy of isotretinoin in juvenile CML. Methods. To be eligible the patients had to have newly diagnosed untreated disease, leukocytosis with monocytosis, marrow with less than 25 percent blasts, hepatosplenomegaly, no chromosomal abnormalities, and negative viral cultures and antibody titers. Isotretinoin was administered orally in single daily doses of 100 mg per square meter of body-surface area. When possible, patients subsequently underwent bone marrow transplantation. Results. Ten children (median age, 10 months) were enrolled in the study. In all 10 there was spontaneous colony formation of leukemic progenitor cells in vitro. In the eight patients tested there was hypersensitivity to GMCSF. The only toxic effect of isotretinoin therapy was cheilitis in two patients. Four children had disease progression. Two children had complete responses to isotretinoin (normalization of the white-cell count and disappearance of organomegaly), three had partial responses (more than a 50 percent reduction in the white-cell count and degree of organomegaly), and one had a minimal response (more than a 50 percent reduction in the white-cell count, but a 26 to 50 percent reduction in the degree of organomegaly). The median duration of response was 37 months (range, 6 to 83). Three of the four children who had a complete or partial response and who did not undergo bone marrow transplantation were alive 36 to 83 months after the diagnosis of juvenile CML. The spontaneous colony formation in vitro was reduced in samples from the five patients in whom this factor was reassessed during treatment. There was also a reduction in the hypersensitivity of leukemic progenitor cells to GM-CSF in the two patients retested. Conclusions. Isotretinoin can induce durable clinical and laboratory responses in patients with juvenile CML.	UNIV ALABAMA,BIRMINGHAM,AL; HL MOFFIT CANC CTR,TAMPA,FL; NORTHWESTERN UNIV,CHICAGO,IL 60611; EASTERN VIRGINIA MED SCH,NORFOLK,VA 23501; UNIV VERMONT,SCH MED,BURLINGTON,VT 05405; DARTMOUTH HITCHCOCK MED CTR,LEBANON,NH; UNIV OKLAHOMA,OKLAHOMA CITY,OK	University of Alabama System; University of Alabama Birmingham; Northwestern University; Eastern Virginia Medical School; University of Vermont; Dartmouth College; University of Oklahoma System; University of Oklahoma Health Sciences Center			Cohn, Susan/AAB-6010-2021	Emanuel, Peter/0000-0002-9764-2434; Cohn, Susan/0000-0001-5749-7650	NATIONAL CANCER INSTITUTE [U10CA029139, U10CA011233, U10CA025408] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29139, CA-25408, CA-11233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTMAN AJ, 1974, BLOOD, V43, P341, DOI 10.1182/blood.V43.3.341.341; Altman AJ, 1993, PRINCIPLES PRACTICE, P501; BREITMAN TR, 1981, BLOOD, V57, P1000; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASTLEBERRY RP, 1991, BLOOD S, V78, pA170; CASTROMALASPINA H, 1984, CANCER, V54, P675, DOI 10.1002/1097-0142(1984)54:4<675::AID-CNCR2820540415>3.0.CO;2-Q; CHAN HSL, 1987, J CLIN ONCOL, V5, P1960, DOI 10.1200/JCO.1987.5.12.1960; EMANUEL PD, 1991, BLOOD, V77, P925; EMANUEL PD, 1991, EXP HEMATOL, V19, P1017; Emanuel PD, 1991, BLOOD S, V78, p170a; ESTROV Z, 1986, BLOOD, V67, P1382; FREEDMAN MH, 1992, BRIT J HAEMATOL, V80, P40, DOI 10.1111/j.1365-2141.1992.tb06398.x; GOLD EJ, 1983, CANCER TREAT REP, V67, P981; GUALTIERI RJ, 1988, EXP HEMATOL, V16, P613; GUALTIERI RJ, 1989, BLOOD, V74, P2360; HARISIADIS L, 1978, NATURE, V274, P486, DOI 10.1038/274486a0; HOFFMAN SJ, 1988, AM J HEMATOL, V28, P124, DOI 10.1002/ajh.2830280214; HONMA Y, 1983, EUR J CANCER CLIN ON, V19, P251, DOI 10.1016/0277-5379(83)90424-8; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KOEFFLER HP, 1988, BLOOD, V71, P703; LILLEYMAN JS, 1977, BLOOD, V49, P559; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MOON RC, 1977, NATURE, V267, P620, DOI 10.1038/267620a0; SANDERS JE, 1988, BLOOD, V71, P1144; THOMAS WJ, 1981, AM J HEMATOL, V10, P181, DOI 10.1002/ajh.2830100210	25	87	90	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1680	1684		10.1056/NEJM199412223312503	http://dx.doi.org/10.1056/NEJM199412223312503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7605422				2022-12-28	WOS:A1994PX38200003
J	BARNETT, HJM; MELDRUM, HE; ELIASZIW, M				BARNETT, HJM; MELDRUM, HE; ELIASZIW, M			THE DILEMMA OF SURGICAL-TREATMENT FOR PATIENTS WITH ASYMPTOMATIC CAROTID DISEASE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ENDARTERECTOMY; STENOSIS; COMPLICATIONS; SURGERY; BRUITS	Several case series have suggested that endarterectomy is beneficial in asymptomatic carotid artery disease. Four randomized trials have been done in this area, the most recent of which is the Asymptomatic Carotid Atherosclerosis Study (ACAS). Results of the first three trials were negative, and ACAS produced a tantalizing, statistically significant finding that does not translate into clinical importance. Disabling strokes have not been reduced by surgical therapy, and the benefit for women has not been shown. It is unclear from this study whether persons with the greatest stenosis and the highest vascular risk profiles are appropriate candidates for endarterectomy. In patients in whom carotid artery disease is incidentally discovered, the benefits of the prophylactic addition of carotid endarterectomy to coronary bypass grafting or other major surgical procedure in patients are still unknown. Excellent surgical skill is of paramount importance for the future use of this procedure. Mass population screening to detect asymptomatic carotid disease will only be justified when and if future studies identify patients in whom the risk for disabling stroke after the procedure is clearly reduced.			BARNETT, HJM (corresponding author), JOHN P ROBARTS RES INST, 100 PERTH DR, LONDON, ON N6A 5K8, CANADA.							[Anonymous], 1992, Mayo Clin Proc, V67, P513; BEEBE HG, 1989, CIRCULATION, V79, P472, DOI 10.1161/01.CIR.79.2.472; BROTT T, 1995, ANN INTERN MED, V123, P720, DOI 10.7326/0003-4819-123-9-199511010-00011; CALLOW AD, 1989, ANN SURG, V210, P308, DOI 10.1097/00000658-198909000-00006; CHAMBERS BR, 1984, STROKE, V15, P964, DOI 10.1161/01.STR.15.6.964; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; DIENER HC, 1991, STROKE, V22, P1229; FODE NC, 1986, STROKE, V17, P370, DOI 10.1161/01.STR.17.3.370; GROTTA JC, 1984, NEUROLOGY, V34, P437, DOI 10.1212/WNL.34.4.437; HALLIDAY AW, 1994, EUR J VASCULAR SURG, V8, P703; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; MATTOS MA, 1995, J VASC SURG, V21, P719, DOI 10.1016/S0741-5214(05)80003-5; MCCRORY DC, 1993, STROKE, V24, P1285, DOI 10.1161/01.STR.24.9.1285; PLUM F, 1995, NEUROLOGY ALERT, V13, P81; RILES TS, 1981, ARCH SURG-CHICAGO, V116, P218; ROEDERER GO, 1984, STROKE, V15, P605, DOI 10.1161/01.STR.15.4.605; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; THOMPSON JE, 1986, SURG CLIN N AM, V66, P233; THOMPSON JE, 1978, ANN SURG, V188, P308, DOI 10.1097/00000658-197809000-00005; TOOLE JF, 1989, STROKE, V20, P844; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1995, LANCET, V345, P1254, DOI 10.1016/S0140-6736(95)90920-6	22	60	60	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					723	725		10.7326/0003-4819-123-9-199511010-00012	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574229				2022-12-28	WOS:A1995TA69600012
J	ZHANG, SM; FOLSOM, AR; FLACK, JM; LIU, K				ZHANG, SM; FOLSOM, AR; FLACK, JM; LIU, K			BODY-FAT DISTRIBUTION BEFORE PREGNANCY AND GESTATIONAL DIABETES - FINDINGS FROM CORONARY-ARTERY RISK DEVELOPMENT IN YOUNG-ADULTS (CARDIA) STUDY	BRITISH MEDICAL JOURNAL			English	Article							INSULIN-RESISTANCE		UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55454; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR HYPERTENS,WINSTON SALEM,NC 27157; NORTHWESTERN UNIV,SCH MED,DEPT COMMUNITY HLTH & PREVENT MED,CHICAGO,IL 60611	University of Minnesota System; University of Minnesota Twin Cities; Wake Forest University; Wake Forest Baptist Medical Center; Northwestern University					NHLBI NIH HHS [N01-HC-48048, N01-HC-48049, N01-HC-48047] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC048047, N01HC048049, N01HC048048] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		FOLSOM AR, 1989, AM J EPIDEMIOL, V130, P911, DOI 10.1093/oxfordjournals.aje.a115424; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; MIDTHJELL K, 1992, J EPIDEMIOL COMMUN H, V46, P537, DOI 10.1136/jech.46.5.537; WARD WK, 1985, DIABETES, V34, P861, DOI 10.2337/diabetes.34.9.861	5	27	27	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 28	1995	311	7013					1139	1140		10.1136/bmj.311.7013.1139	http://dx.doi.org/10.1136/bmj.311.7013.1139			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580711	Green Published			2022-12-28	WOS:A1995TC46600021
J	KEYNES, R; COOK, GMW				KEYNES, R; COOK, GMW			AXON GUIDANCE MOLECULES	CELL			English	Review							CENTRAL-NERVOUS-SYSTEM; C-ELEGANS; NEURITE OUTGROWTH; GROWTH CONES; EXPRESSION; MIGRATIONS; COLLAPSE; PROTEIN; INHIBITION; NEURONS				KEYNES, R (corresponding author), UNIV CAMBRIDGE,DEPT ANAT,DOWNING ST,CAMBRIDGE CB2 3DY,ENGLAND.							AMONYCAJAL S, 1892, CELLULE, V9, P119; BAIER H, 1994, SCIENCE, V265, P1541, DOI 10.1126/science.8079167; BAIRD JL, 1995, IN PRESS J NEUROSCI; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; CULOTTI JG, 1994, CURR OPIN GENET DEV, V4, P587, DOI 10.1016/0959-437X(94)90077-G; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; DEFELIPE C, 1995, SCIENCE, V269, P899; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FRADKIN LG, 1995, DEV BIOL, V168, P202, DOI 10.1006/dbio.1995.1072; GARRITY PA, 1995, CELL, V83; GINIGER E, 1994, DEVELOPMENT, V120, P1385; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GUTHRIE S, 1995, NEURON, V14, P1117, DOI 10.1016/0896-6273(95)90260-0; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; HONIG MG, 1995, DEV BIOL, V167, P563, DOI 10.1006/dbio.1995.1049; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kennedy Timothy E., 1995, Current Opinion in Neurobiology, V5, P83, DOI 10.1016/0959-4388(95)80091-3; Keynes Roger J., 1995, Current Opinion in Neurobiology, V5, P75, DOI 10.1016/0959-4388(95)80090-5; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kuwada John Y., 1995, Current Opinion in Neurobiology, V5, P50, DOI 10.1016/0959-4388(95)80086-7; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; LUNDGREN SE, 1995, DEVELOPMENT, V121, P1769; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MAHANTHAPPA NK, 1994, DEVELOPMENT, V120, P1373; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; OTSUKA AJ, 1995, J CELL BIOL, V129, P1081, DOI 10.1083/jcb.129.4.1081; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; SANCHEZ D, 1995, DEVELOPMENT, V121, P135; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHIRASAKI R, 1995, NEURON, V14, P961, DOI 10.1016/0896-6273(95)90334-8; SONG J, 1995, NEURON, V14, P537, DOI 10.1016/0896-6273(95)90310-0; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STAHL B, 1990, NEURON, V5, P733; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; TAMADA A, 1995, NEURON, V14, P1083, DOI 10.1016/0896-6273(95)90347-X; TANAKA E, 1995, CELL, V83; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; TOSNEY KW, 1987, DEV BIOL, V122, P540, DOI 10.1016/0012-1606(87)90318-6; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	63	167	173	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					161	169		10.1016/0092-8674(95)90157-4	http://dx.doi.org/10.1016/0092-8674(95)90157-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585933	Bronze			2022-12-28	WOS:A1995TA96500002
J	BELLGRAU, D; GOLD, D; SELAWRY, H; MOORE, J; FRANZUSOFF, A; DUKE, RC				BELLGRAU, D; GOLD, D; SELAWRY, H; MOORE, J; FRANZUSOFF, A; DUKE, RC			A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION	NATURE			English	Article							FAS ANTIGEN; TRANSPLANTATION; SURVIVAL; AUTOIMMUNITY; EXPRESSION; APOPTOSIS; TESTIS; DEATH; CELLS; MICE	TESTIS is a remarkable immune-privileged site, long known for its ability to support allogeneic and xenogeneic tissue transplants(1-4). Here we have investigated the molecular basis for testis immune privilege. Testis grafts derived from mice that can express functional CD95 (Fas or Ape-1) ligand(5-8) survived indefinitely when transplanted under the kidney capsule of allogeneic animals, whereas testis grafts derived from mutant gld mice, which express non-functional ligands(8,9), were rejected. Further analysis of testis showed that CD95 ligand messenger RNA is constitutively expressed by testicular Sertoli cells, and that Sertoli cells from normal mice, but not gld mice, were accepted when transplanted into allogeneic recipients. CD95 ligand expression in the testis probably acts by inducing apoptotic cell death of CD95-expressing, recipient T cells activated in response to graft antigens. These findings indicate that CD95 ligand could be used to create immune-privileged tissue for a variety of transplant uses.	UNIV COLORADO,SCH MED,DEPT IMMUNOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,BARBARA DAVIS CTR CHILDHOOD DIABET,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT CELLULAR & STRUCT BIOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT MED,DIV MED ONCOL,DENVER,CO 80262; SIDNEY KIMMEL CANC CTR,SAN DIEGO,CA 92121; VET ADM MED CTR,MEMPHIS,TN 38104	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center								BARKER CF, 1977, ADV IMMUNOL, V25, P1; BOBZIEN B, 1983, DIABETES, V32, P213, DOI 10.2337/diabetes.32.3.213; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CAMERON DF, 1990, TRANSPLANTATION, V50, P649, DOI 10.1097/00007890-199010000-00024; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; HAO LM, 1990, TRANSPLANTATION, V49, P609, DOI 10.1097/00007890-199003000-00025; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; LUCIANI MF, 1994, PHILOS T R SOC B, V345, P303, DOI 10.1098/rstb.1994.0110; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SELAWRY HP, 1984, DIABETES, V33, P405, DOI 10.2337/diabetes.33.4.405; SELAWRY HP, 1991, TRANSPLANTATION, V52, P846, DOI 10.1097/00007890-199111000-00018; SELAWRY HP, 1993, CELL TRANSPLANT, V2, P123, DOI 10.1177/096368979300200206; SELAWRY HP, 1989, DIABETES, V38, P220, DOI 10.2337/diab.38.1.S220; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SOBEL ES, 1993, INT IMMUNOL, V5, P1275, DOI 10.1093/intimm/5.10.1275; STALDER T, 1994, J IMMUNOL, V152, P1127; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WHITMORE WF, 1985, J UROLOGY, V134, P782, DOI 10.1016/S0022-5347(17)47438-6	30	1056	1111	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					630	632		10.1038/377630a0	http://dx.doi.org/10.1038/377630a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566174				2022-12-28	WOS:A1995TA27500052
J	AUSTIN, D; SLEIGH, J				AUSTIN, D; SLEIGH, J			PREDICTION OF ACUTE MOUNTAIN-SICKNESS	BRITISH MEDICAL JOURNAL			English	Article											AUSTIN, D (corresponding author), WAIKATO HOSP,DEPT ANAESTHESIA,HAMILTON,NEW ZEALAND.		Austin, David/A-5703-2012	Austin, David/0000-0001-6829-7937				GUZ A, 1957, CLIN SCI, V30, P161; Houston C. S., 1985, AM ALPINE J, V27, P162; SAMPSON JB, 1983, AVIAT SPACE ENVIR MD, V54, P1063; WRIGHT AD, 1985, AVIAT SPACE ENVIR MD, V56, P572; 1981, LANCET, V1, P180	5	14	16	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					989	990						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580641				2022-12-28	WOS:A1995TA07900024
J	HACKNEY, DD				HACKNEY, DD			HIGHLY PROCESSIVE MICROTUBULE-STIMULATED ATP HYDROLYSIS BY DIMERIC KINESIN HEAD DOMAINS	NATURE			English	Article							MOLECULES; MOVEMENT	STUDIES of immobilized kinesin have shown that a single dimeric molecule can maintain contact with and drive sliding of a microtubule(1,2). In solution, however, native kinesin binds microtubules too weakly(3) and hydrolyses ATP too slowly to produce the high sliding velocities seen in motility assays(4). This apparent inhibition in solution appears to be caused by the binding of kinesin's tail domains to its motor (head) domains in a folded conformation(5). DKH392, a construct containing two heads but no tails, has been shown to display both tight binding to microtubules and high ATPase rates(6). Furthermore, it retains one molecule of ADP per dimer when bound to microtubules(7), which could facilitate a 'hand-over-hand' mechanism for processive motion. Here we show that DKH392 hydrolyses more than 100 ATP molecules per diffusional encounter with a microtubule, even in the high-salt conditions encountered physiologically. This provides direct evidence that kinesin's activity is highly processive, with the motor remaining attached to a microtubule through many cycles of ATP hydrolysis.			HACKNEY, DD (corresponding author), CARNEGIE MELLON UNIV,DEPT BIOL SCI,4400 5TH AVE,PITTSBURGH,PA 15213, USA.							BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Hackney D. D., 1995, Biophysical Journal, V68, pA286; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1995, BIOPHYS J, V68, pS267; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; SADHU A, 1992, J BIOL CHEM, V267, P11352; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4	15	159	159	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					448	450		10.1038/377448a0	http://dx.doi.org/10.1038/377448a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566125				2022-12-28	WOS:A1995RY19000055
J	SIMONICH, SL; HITES, RA				SIMONICH, SL; HITES, RA			GLOBAL DISTRIBUTION OF PERSISTENT ORGANOCHLORINE COMPOUNDS	SCIENCE			English	Article							AIR	The global distribution of 22 potentially harmful organochlorine compounds was investigated in more than 200 tree bark samples from 90 sites worldwide. High concentrations of organochlorines were found not only in some developing countries but also in industrialized countries, which continue to be highly contaminated even though the use of many of these compounds is restricted. The distribution of relatively volatile organochlorine compounds (such as hexachlorobenzene) is dependent on latitude and demonstrates the global distillation effect, whereas less volatile organochlorine compounds (such as endosulfan) are not as effectively distilled and tend to remain in the region of use.	INDIANA UNIV,SCH PUBL & ENVIRONM AFFAIRS,BLOOMINGTON,IN 47405; INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington								ANDERSON DJ, 1989, ATMOS ENVIRON, V23, P2063, DOI 10.1016/0004-6981(89)90532-5; BUSER HR, 1993, ENVIRON SCI TECHNOL, V27, P1211, DOI 10.1021/es00043a023; CALAMARI D, 1991, ENVIRON SCI TECHNOL, V25, P1489, DOI 10.1021/es00020a020; CALAMARI D, 1994, ENVIRON SCI TECHNOL, V28, P429, DOI 10.1021/es00052a014; CHERNYAK SM, 1995, SCI TOTAL ENVIRON, V160-61, P75, DOI 10.1016/0048-9697(95)04346-3; HERMANSON MH, 1990, ENVIRON SCI TECHNOL, V24, P666, DOI 10.1021/es00075a008; HILEMAN B, 1994, CHEM ENG NEWS, V72, P19, DOI 10.1021/cen-v072n005.p019; HINCKLEY DA, 1990, J CHEM ENG DATA, V35, P232, DOI 10.1021/je00061a003; IWATA H, 1993, ENVIRON SCI TECHNOL, V27, P1080, DOI 10.1021/es00043a007; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; MACKAY D, 1995, SCI TOTAL ENVIRON, V160-61, P25, DOI 10.1016/0048-9697(95)04342-X; MACKAY D, 1995, SCI TOTAL ENVIRON, V160, P211; MUIR DCG, 1995, SCI TOTAL ENVIRON, V160-61, P447, DOI 10.1016/0048-9697(95)04378-E; SIMONICH SL, 1994, NATURE, V370, P49, DOI 10.1038/370049a0; SIMONICH SL, 1994, ENVIRON SCI TECHNOL, V28, P939, DOI 10.1021/es00054a028; SIMONICH SL, 1995, THESIS INDIANA U; TREMOLADA P, 1993, CHEMOSPHERE, V27, P2235, DOI 10.1016/0045-6535(93)90135-R; VOLDNER EC, 1995, SCI TOTAL ENVIRON, V160-61, P201, DOI 10.1016/0048-9697(95)04357-7; WANIA F, 1993, AMBIO, V22, P10; 1990, PUBLIC HLTH IMPACT P, P24; 1995, INSECT CONTROL GUIDE	21	527	551	6	188	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1851	1854		10.1126/science.7569923	http://dx.doi.org/10.1126/science.7569923			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569923				2022-12-28	WOS:A1995RX19400031
J	VALLANCE, P; PATTON, S; BHAGAT, K; MACALLISTER, R; RADOMSKI, M; MONCADA, S; MALINSKI, T				VALLANCE, P; PATTON, S; BHAGAT, K; MACALLISTER, R; RADOMSKI, M; MONCADA, S; MALINSKI, T			DIRECT MEASUREMENT OF NITRIC-OXIDE IN HUMAN-BEINGS	LANCET			English	Note							HUMAN VEINS INVIVO; ENDOTHELIUM; ACETYLCHOLINE; RELEASE	Nitric oxide is a short-lived radical involved in various biological processes. We have used an electrochemical microsensor to detect nitric oxide signals in blood vessels of healthy volunteers. The sensor was inserted into a hand vein, and the vessel was stimulated with acetylcholine or bradykinin. Dose-dependent signals were detected and were attenuated by an inhibitor of nitric oxide synthase. The results provide further evidence that endothelium-derived relaxing factor is nitric oxide and demonstrate a method for monitoring the L-arginjne/nitric-oxide pathway in human beings.	OAKLAND UNIV, DEPT PHARMACOL, ROCHESTER, MI 48309 USA; UNIV LONDON ST GEORGES HOSP, SCH MED, DEPT PHARMACOL & CLIN PHARMACOL, LONDON SW17 0RE, ENGLAND; WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND	Oakland University; St Georges University London; GlaxoSmithKline; Wellcome Research Laboratories			Radomski, Marek W/C-5195-2014					COLLIER J, 1990, CLIN SCI, V78, P101, DOI 10.1042/cs0780101; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; KIECHLE FL, 1993, AM J CLIN PATHOL, V100, P567, DOI 10.1093/ajcp/100.5.567; MALINSKI T, 1994, INT CONGR SER, V1058, P207; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; SHIBUKI K, 1990, NEUROSCI RES, V9, P69, DOI 10.1016/0168-0102(90)90048-J; VALLANCE P, 1989, CARDIOVASC RES, V23, P1053, DOI 10.1093/cvr/23.12.1053; VALLANCE P, 1994, J ROY COLL PHYS LOND, V28, P209; VALLANCE P, 1989, LANCET, V2, P997	9	131	137	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 15	1995	346	8968					153	154		10.1016/S0140-6736(95)91211-8	http://dx.doi.org/10.1016/S0140-6736(95)91211-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603231				2022-12-28	WOS:A1995RJ03100011
J	DENZIN, LK; CRESSWELL, P				DENZIN, LK; CRESSWELL, P			HLA-DM INDUCES CLIP DISSOCIATION FROM MHC CLASS-II ALPHA-BETA DIMERS AND FACILITATES PEPTIDE LOADING	CELL			English	Article							ANTIGEN-PROCESSING MUTANT; INVARIANT CHAIN PEPTIDES; DR MOLECULES; CELL LINE; BINDING; COMPLEX; EXPRESSION; TRANSPORT; GENES; COMPARTMENTS	Human leukocyte antigen DM (HLA-DM) molecules are structurally related to classical MHC class II molecules and reside in the lysosome-like compartment where class II-restricted antigen processing is thought to occur. Mutant cell lines lacking HLA-DM are defective in antigen processing and accumulate class II molecules associated with a nested set of invariant chain-derived peptides (class II-associated invariant chain peptides, CLIP). Here we show that HLA-DM catalyzes the dissociation of CLIP from MHC class II-CLIP complexes in vitro and facilitates the binding of antigenic peptides. The reaction has an acidic pH optimum, consistent with its occurrence in a lysosome-like compartment in vivo. Antibody blocking experiments suggest that a transient interaction between HLA-DM and the MHC class II-CLIP complex is required.			DENZIN, LK (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510, USA.				NIAID NIH HHS [AI 23081] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023081, R01AI023081] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; CEMAN S, 1992, J IMMUNOL, V149, P754; CHERVONSKY AV, 1994, INT IMMUNOL, V6, P1973; CRESSWELL P, 1994, CURR BIOL, V4, P541, DOI 10.1016/S0960-9822(00)00119-6; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GELUK A, 1992, EUR J IMMUNOL, V22, P107, DOI 10.1002/eji.1830220117; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; LAMPSON LA, 1980, J IMMUNOL, V125, P293; MACHAMER CE, 1984, P NATL ACAD SCI-BIOL, V81, P1287, DOI 10.1073/pnas.81.5.1287; MALCHEREK G, 1995, J EXP MED, V181, P527, DOI 10.1084/jem.181.2.527; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NEWCOMB JR, 1993, J IMMUNOL, V151, P4153; NEWCOMB JR, 1993, J IMMUNOL, V151, P499; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; RIBERDY JM, 1994, J CELL BIOL, V1125, P1225; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677	39	612	616	0	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					155	165		10.1016/0092-8674(95)90061-6	http://dx.doi.org/10.1016/0092-8674(95)90061-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606781	Bronze			2022-12-28	WOS:A1995RK42400018
J	SU, XZ; HEATWOLE, VM; WERTHEIMER, SP; GUINET, F; HERRFELDT, JA; PETERSON, DS; RAVETCH, JA; WELLEMS, TE				SU, XZ; HEATWOLE, VM; WERTHEIMER, SP; GUINET, F; HERRFELDT, JA; PETERSON, DS; RAVETCH, JA; WELLEMS, TE			THE LARGE DIVERSE GENE FAMILY VAR ENCODES PROTEINS INVOLVED IN CYTOADHERENCE AND ANTIGENIC VARIATION OF PLASMODIUM-FALCIPARUM-INFECTED ERYTHROCYTES	CELL			English	Article							HISTIDINE-RICH PROTEIN; PARASITIZED ERYTHROCYTES; MALARIA PARASITES; HOMOLOGOUS RECOMBINATION; ADHESION MOLECULE-1; MELANOMA-CELLS; P-FALCIPARUM; EXPRESSION; SEQUESTRATION; MEMBRANE	The human malaria parasite Plasmodium falciparum evades host immunity by varying the antigenic and adhesive character of infected erythrocytes. We describe a large and extremely diverse family of P. falciparum genes (var) that encode 200-350 kDa proteins having the expected properties of antigenically variant adhesion molecules. Predicted amino acid sequences of var genes show a variable extracellular segment with domains having receptor-binding features, a transmembrane sequence, and a terminal segment that is a probable submembrane anchor. There are 50-150 var genes on multiple parasite chromosomes, and some are in clustered arrangements. var probes detect two classes of transcripts in steady-state RNA: 7-9 kb var transcripts, and an unusual family of 1.8-2.4 kb transcripts that may be involved in expression or rearrangements of var genes.	SLOAN KETTERING INST, DEWITT WALLACE RES LAB, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	SU, XZ (corresponding author), NIAID, PARASIT DIS LAB, BETHESDA, MD 20892 USA.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041; Su, Xinzhuan/0000-0003-3246-3248				ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARDESHIR F, 1987, EMBO J, V6, P1421, DOI 10.1002/j.1460-2075.1987.tb02383.x; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARNWELL JW, 1983, INFECT IMMUN, V40, P985, DOI 10.1128/IAI.40.3.985-994.1983; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BLOOM BR, 1979, NATURE, V279, P21, DOI 10.1038/279021a0; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; BROWN KN, 1973, NATURE, V242, P49, DOI 10.1038/242049a0; CARCY B, 1994, MOL BIOCHEM PARASIT, V68, P221, DOI 10.1016/0166-6851(94)90167-8; CHAIYAROJ SC, 1994, MOL BIOCHEM PARASIT, V67, P21, DOI 10.1016/0166-6851(94)90092-2; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; CORCORAN LM, 1988, CELL, V53, P807, DOI 10.1016/0092-8674(88)90097-9; CREEDON KA, 1994, J BIOL CHEM, V269, P16364; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; DEBRUIN D, 1992, GENOMICS, V14, P332, DOI 10.1016/S0888-7543(05)80223-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLAN SA, 1993, MOL BIOCHEM PARASIT, V61, P137, DOI 10.1016/0166-6851(93)90166-U; DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753; ELLIS J, 1987, MOL BIOCHEM PARASIT, V26, P203, DOI 10.1016/0166-6851(87)90144-7; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; HANDUNNETTI SM, 1987, J EXP MED, V165, P1269, DOI 10.1084/jem.165.5.1269; HAYNES RO, 1992, CELL, V69, P11; HOMMEL M, 1983, J EXP MED, V157, P1137, DOI 10.1084/jem.157.4.1137; HOMMEL M, 1985, IMMUNOL TODAY, V6, P28, DOI 10.1016/0167-5699(85)90165-3; HOWARD RJ, 1988, MOL BIOCHEM PARASIT, V27, P207, DOI 10.1016/0166-6851(88)90040-0; HYNES RO, 1994, BIOESSAYS, V16, P663, DOI 10.1002/bies.950160912; LANGRETH SG, 1979, J EXP MED, V150, P1241, DOI 10.1084/jem.150.5.1241; LANZER M, 1993, NATURE, V361, P654, DOI 10.1038/361654a0; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; LUSE SA, 1971, AM J TROP MED HYG, V20, P655, DOI 10.4269/ajtmh.1971.20.655; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; NICKOLOFF JA, 1990, MOL CELL BIOL, V10, P4837, DOI 10.1128/MCB.10.9.4837; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; Okada A, 1994, Semin Immunol, V6, P185, DOI 10.1006/smim.1994.1024; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; PETERSON DS, 1995, IN PRESS P NATL ACAD, V92; POLOGE LG, 1987, P NATL ACAD SCI USA, V84, P7139, DOI 10.1073/pnas.84.20.7139; PONGPONRATN E, 1991, AM J TROP MED HYG, V44, P168, DOI 10.4269/ajtmh.1991.44.168; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; SAUL A, 1988, MOL BIOCHEM PARASIT, V27, P35, DOI 10.1016/0166-6851(88)90022-9; SEIFERT HS, 1988, MICROBIOL REV, V52, P327, DOI 10.1128/MMBR.52.3.327-336.1988; SHAPIRO MB, 1986, NUCLEIC ACIDS RES, V14, P65, DOI 10.1093/nar/14.1.65; SHARMA YD, 1987, MOL BIOCHEM PARASIT, V26, P11, DOI 10.1016/0166-6851(87)90124-1; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; SINNIS P, 1988, GENOMICS, V3, P287, DOI 10.1016/0888-7543(88)90117-6; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1994, GENE, V151, P225, DOI 10.1016/0378-1119(94)90661-0; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRIGLIA T, 1987, EMBO J, V6, P1413, DOI 10.1002/j.1460-2075.1987.tb02382.x; UDEINYA IJ, 1983, NATURE, V303, P429, DOI 10.1038/303429a0; WEBER JL, 1988, MOL BIOCHEM PARASIT, V29, P117, DOI 10.1016/0166-6851(88)90066-7; WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382	71	957	977	0	32	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					89	100		10.1016/0092-8674(95)90055-1	http://dx.doi.org/10.1016/0092-8674(95)90055-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606788	Bronze			2022-12-28	WOS:A1995RK42400012
J	CALLAHAN, CA; MURALIDHAR, MG; LUNDGREN, SE; SCULLY, AL; THOMAS, JB				CALLAHAN, CA; MURALIDHAR, MG; LUNDGREN, SE; SCULLY, AL; THOMAS, JB			CONTROL OF NEURONAL PATHWAY SELECTION BY A DROSOPHILA RECEPTOR PROTEIN-TYROSINE KINASE FAMILY MEMBER	NATURE			English	Article							CELL-ADHESION MOLECULE; GENE; DOMAIN; ELEGANS; EMBRYOS; MUSCLES; ENCODES; HOMOLOG; SUBSET; RYK	DURING development, neurons are capable of selecting specific pathways that lead them to their appropriate target areas. A variety of molecular mechanisms are thought to be involved in pathway recognition, including cell adhesion(1), repulsion(2,3) and chemotropism(4). However, apart from a few genes whose involvement has been shown genetically(5-8), the mechanisms underlying neuronal pathway selection are largely unknown. Here we report the isolation of the Drosophila derailed (drl) gene, which encodes a novel member of the receptor protein-tyrosine kinase family. Using a newly developed axon-targeted reporter gene(9) we find that drl is expressed by a small subset of embryonic interneurons whose growth cones choose common pathways during development. In drl mutant embryos these neurons fail to make the correct pathway choices. Our results provide evidence for receptor protein-tyrosine kinase involvement in key aspects of neuronal pathway recognition.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093	Salk Institute; University of California System; University of California San Diego								AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DOE CQ, 1993, DEV DROSOPHILA MELAN, P1131; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GAY P, 1993, MOL GEN GENET, V239, P361, DOI 10.1007/BF00276934; GILBERT D, 1984, GENETICS, V106, P679; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MAMINTA MLD, 1992, BIOCHEM BIOPH RES CO, V189, P1077; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; Rutishauser U, 1993, Curr Opin Neurobiol, V3, P709, DOI 10.1016/0959-4388(93)90142-L; SMITH HK, 1991, ROUX ARCH DEV BIOL, V200, P306, DOI 10.1007/BF00665525; STACKER SA, 1993, ONCOGENE, V8, P1347; THOMAS JB, 1982, NATURE, V298, P650, DOI 10.1038/298650a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANVACTOR D, 1993, CELL, V73, P1155; WRIGHT TRF, 1981, CHROMOSOMA, V83, P45, DOI 10.1007/BF00286015	30	153	158	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					171	174		10.1038/376171a0	http://dx.doi.org/10.1038/376171a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603568				2022-12-28	WOS:A1995RJ02800060
J	GODSLAND, IF; STEVENSON, JC				GODSLAND, IF; STEVENSON, JC			INSULIN-RESISTANCE - SYNDROME OR TENDENCY	LANCET			English	Review							CORONARY HEART-DISEASE; METABOLIC SYNDROME; DIABETES-MELLITUS; GLUCOSE-TOLERANCE; RISK-FACTORS; HYPERINSULINEMIA; POPULATION; OBESITY; MEN				GODSLAND, IF (corresponding author), NATL HEART & LUNG INST,WYNN DEPT METAB MED,21 WELLINGTON RD,LONDON NW8 9SQ,ENGLAND.							ADER M, 1994, AM J PHYSIOL, V266, pE17, DOI 10.1152/ajpendo.1994.266.1.E17; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARON AD, 1994, AM J PHYSIOL, V267, pE187, DOI 10.1152/ajpendo.1994.267.2.E187; BEARD JC, 1986, DIABETES, V35, P362, DOI 10.2337/diabetes.35.3.362; BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45; COATES PA, IN PRESS DIABETES; Despres Jean-Pierre, 1994, Current Opinion in Lipidology, V5, P274, DOI 10.1097/00041433-199408000-00006; EDWARDS KL, 1994, ARTERIOSCLER THROMB, V14, P1940, DOI 10.1161/01.ATV.14.12.1940; ELLIOTT TG, 1993, BAILLIERE CLIN ENDOC, V7, P1079, DOI 10.1016/S0950-351X(05)80246-0; FERRANNINI E, 1991, DIABETOLOGIA, V34, P416, DOI 10.1007/BF00403180; FERRARA A, 1994, AM J EPIDEMIOL, V10, P857; Frayn Keith N., 1993, Current Opinion in Lipidology, V4, P197, DOI 10.1097/00041433-199306000-00004; GANROT PO, 1993, DIABETOLOGIA, V36, P876, DOI 10.1007/BF00400365; GODSLAND IF, 1994, CIRCULATION, V90, P554; GODSLAND IF, IN PRESS BR HEART J; HARGREAVES AD, 1992, ATHEROSCLEROSIS, V94, P61, DOI 10.1016/0021-9150(92)90188-M; HOLLENBECK C, 1987, J CLIN ENDOCR METAB, V64, P1169, DOI 10.1210/jcem-64-6-1169; JARRETT RJ, 1994, DIABETOLOGIA, V37, P945, DOI 10.1007/BF00400952; LEY CJ, 1994, J AM COLL CARDIOL, V23, P377, DOI 10.1016/0735-1097(94)90423-5; LINDAHL B, 1993, J INTERN MED, V234, P263, DOI 10.1111/j.1365-2796.1993.tb00742.x; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Orchard Trevor J., 1994, Annals of Epidemiology, V4, P40; Proudler A. J., 1994, European Heart Journal, V15, P7; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REWERS M, 1992, CIRCULATION, V85, P865; SAAD MF, 1994, DIABETES, V43, P1114, DOI 10.2337/diabetes.43.9.1114; SCHEEN AJ, 1994, DIABETES METAB REV, V10, P151, DOI 10.1002/dmr.5610100206; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; STERN MP, 1994, DIABETOLOGIA, V37, P956, DOI 10.1007/s001250050204; STOUT RW, 1969, LANCET, V1, P1078; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; SWAN JW, 1994, EUR HEART J, V15, P1528, DOI 10.1093/oxfordjournals.eurheartj.a060425; SWAN JW, 1994, CLIN SCI, V86, P317, DOI 10.1042/cs0860317; Taskinen Marja-Riitta, 1993, Current Opinion in Lipidology, V4, P434, DOI 10.1097/00041433-199312000-00004; WALTON C, 1992, AM J PHYSIOL, V262, pE755, DOI 10.1152/ajpendo.1992.262.5.E755; WELIN L, 1992, DIABETOLOGIA, V35, P766; YARNELL JWG, 1994, BRIT HEART J, V71, P293	38	87	89	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					100	103		10.1016/S0140-6736(95)92118-4	http://dx.doi.org/10.1016/S0140-6736(95)92118-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603181				2022-12-28	WOS:A1995RH22000016
J	PROUDLER, AJ; AHMED, AIH; CROOK, D; FOGELMAN, I; RYMER, JM; STEVENSON, JC				PROUDLER, AJ; AHMED, AIH; CROOK, D; FOGELMAN, I; RYMER, JM; STEVENSON, JC			HORMONE REPLACEMENT THERAPY AND SERUM ANGIOTENSIN CONVERTING-ENZYME ACTIVITY IN POSTMENOPAUSAL WOMEN	LANCET			English	Note							DELETION POLYMORPHISM; HYPERTENSION; PLASMA; GENE	The mechanisms by which hormone replacement therapy (HRT) reduces the risk of coronary heart disease (CHD) are incompletely understood, but may include direct arterial effects. We examined the effect of oestrogen/progestagen HRT on serum angiotensin-converting-enzyme (ACE) activity in postmenopausal women. After 6 months, ACE activity was reduced by 20% (p<0.001) on average in 28 treated women but remained unchanged in 16 controls. Serum ACE activity is modifiable by gonadal steroids and changes in serum ACE may represent a novel mechanism by which HRT reduces CHD risk in women.	GUYS HOSP,DEPT NUCL MED,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	PROUDLER, AJ (corresponding author), NATL HEART & LUNG INST,WYNN DEPT METAB MED,LONDON NW8 9SQ,ENGLAND.			Crook, David/0000-0002-9587-3730				ALHENCGELAS F, 1991, J LAB CLIN MED, V117, P33; BUTTERY JE, 1993, CLIN CHEM, V39, P312; CAMBIEN F, 1994, CIRCULATION, V90, P669, DOI 10.1161/01.CIR.90.2.669; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; DUX S, 1984, ISRAEL J MED SCI, V20, P1138; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SASSANO P, 1987, AM J MED, V83, P227, DOI 10.1016/0002-9343(87)90690-5; STAMPFER MJ, 1991, PREV MED, V28, P47; STEVENSON JC, 1994, DRUGS, V47, P35, DOI 10.2165/00003495-199400472-00007	9	166	168	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					89	90		10.1016/S0140-6736(95)92114-1	http://dx.doi.org/10.1016/S0140-6736(95)92114-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603219				2022-12-28	WOS:A1995RH22000012
J	WANG, Y; PRIVES, C				WANG, Y; PRIVES, C			INCREASED AND ALTERED DNA-BINDING OF HUMAN P53 BY S AND G2/M BUT NOT G1 CYCLIN-DEPENDENT KINASES	NATURE			English	Article							PHOSPHORYLATION; PROTEIN; MUTANT; PROLIFERATION; REPLICATION; INHIBIT; ANTIGEN; GENES	CENTRAL to the role of p53 in cell regulation are its sequence-specific interactions with genes that control the cell cycle and apoptosis(1,2). p53 response elements contain two or more copies of a somewhat promiscuous consensus sequence: 5'-XXXC(A,T)(T, A)GYYY-3' (where X is a purine and Y is a pyrimidine) (ref, 3), The sequence-specific DNA-binding region of p53 resides in its central conserved region(4). Although this region itself is not known to he phosphorylated, the amino and carboxy termini of human p53 contain sites for phosphorylation by several protein kinases.			WANG, Y (corresponding author), COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA.							BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1994, ONCOGENE, V9, P3249; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEWART N, 1995, ONCOGENE, V10, P109; STURZBECHER HW, 1990, ONCOGENE, V5, P795; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	30	326	331	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	1995	376	6535					88	91		10.1038/376088a0	http://dx.doi.org/10.1038/376088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596441				2022-12-28	WOS:A1995RH11100068
J	CROSTHWAITE, SK; LOROS, JJ; DUNLAP, JC				CROSTHWAITE, SK; LOROS, JJ; DUNLAP, JC			LIGHT-INDUCED RESETTING OF A CIRCADIAN CLOCK IS MEDIATED BY A RAPID INCREASE IN FREQUENCY TRANSCRIPT	CELL			English	Article							NEUROSPORA-CRASSA; DROSOPHILA; EXPRESSION; GENES	To understand how light entrains circadian clocks, we examined the effects of light on a gene known to encode a state variable of a circadian oscillator, the frequency (frq) gene, fro is rapidly induced by short pulses of visible light; clock resetting is correlated with fro induction and is blocked by drugs that block the synthesis of protein or translatable RNA. The speed and magnitude of fro induction suggest that this may be the initial clock-specific event in light resetting. Light induction overcomes fro negative autoregulation so that frq expression can remain high in constant light. These data explain how a simple unidirectional signal (light and the induction of frq) may be turned into a bidirectional clock response (time of day-specific advances and delays). This light entrainment model is easily generalized and may be the common mechanism by which the intracellular feedback cycles that comprise circadian clacks are brought into synchrony with external cycles in the real world.			CROSTHWAITE, SK (corresponding author), DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755, USA.		Loros, Jennifer/B-6293-2014; Dunlap, Jay/L-6232-2013	Dunlap, Jay/0000-0003-1577-0457	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034985, R37GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34985] Funding Source: Medline; NIMH NIH HHS [MH01186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; ARPAIA G, 1993, PLANT PHYSIOL, V102, P1299, DOI 10.1104/pp.102.4.1299; ARPAIA G, 1995, IN PRES MOL GEN GENE, V243; DAVIS RL, 1970, METH ENZYMOL A, V27, P19; DHARMANANDA S, 1980, THESIS U CALIFORNIA; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Edmunds LN, 1988, CELLULAR MOL BASES B; ESKIN A, 1979, FED PROC, V38, P2570; FELDMAN J F, 1973, Genetics, V75, P605; HALL JC, 1995, IN PRES TRENDS NEURO; HARDIN PE, 1993, MOL GENETICS BIOL RH, P155; HASTINGS M, 1994, CURR BIOL, V4, P720, DOI 10.1016/S0960-9822(00)00159-7; HOTZVITATERNA M, 1994, SCIENCE, V264, P719; Johnson C.H., 1990, ATLAS PHASE RESPONSE; KAY SA, 1993, MOL GENETICS BIOL RH, P73; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KYRIACOU CP, 1994, TRENDS GENET, V10, P69, DOI 10.1016/0168-9525(94)90218-6; Loros J J, 1986, J Biol Rhythms, V1, P187, DOI 10.1177/074873048600100302; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; LOROS JJ, 1991, MOL CELL BIOL, V11, P558, DOI 10.1128/MCB.11.1.558; LOROS JJ, 1995, IN PRESS SEM NEUROSC; MEAD S, 1992, J NEUROSCI, V12, P2516; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; NAKASHIMA H, 1981, PLANT CELL PHYSIOL, V22, P231; PETERSON EL, 1980, J THEOR BIOL, V84, P281, DOI 10.1016/S0022-5193(80)80008-7; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; PITTENDRIGH CS, 1960, COLD SPRING HARB SYM, V25, P159, DOI 10.1101/SQB.1960.025.01.015; PITTENDRIGH CS, 1976, MOL BASIS CIRCADIAN, P11; SADAKANE Y, 1995, IN PRESS PLANT CELL; SARGENT ML, 1967, PLANT PHYSIOL, V42, P1504, DOI 10.1104/pp.42.11.1504; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; SHUTT RH, 1972, J IMMUNOL, V108, P819; TAKAHASHI JS, 1993, CURR OPIN GENET DEV, V3, P301, DOI 10.1016/0959-437X(93)90038-Q; TYSON J, 1976, MOL BASIS CIRCADIAN, P85; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247	41	292	297	0	15	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1003	1012		10.1016/S0092-8674(05)80005-4	http://dx.doi.org/10.1016/S0092-8674(05)80005-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600569	hybrid			2022-12-28	WOS:A1995RG91000005
J	HEBERLEIN, U; MOSES, K				HEBERLEIN, U; MOSES, K			MECHANISMS OF DROSOPHILA RETINAL MORPHOGENESIS - THE VIRTUES OF BEING PROGRESSIVE	CELL			English	Review							POLARITY GENE HEDGEHOG; EYE; SYSTEM		UNIV CALIF SAN FRANCISCO,DEPT NEUROL,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94110; SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110; UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089	University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of Southern California	HEBERLEIN, U (corresponding author), UNIV CALIF SAN FRANCISCO,ERNEST GALLO CLIN & RES CTR,SAN FRANCISCO,CA 94110, USA.							BAKER NE, 1995, MECH DEVELOP, V49, P173, DOI 10.1016/0925-4773(94)00314-D; BROWN NL, 1995, CELL, V80, P879, DOI 10.1016/0092-8674(95)90291-0; BROWN NL, 1991, DEVELOPMENT, V113, P1245; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; HADLER G, 1995, SCIENCE, V267, P1788; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; JARMAN AP, 1995, IN PRESS DEVELOPMENT; KALDERON D, 1995, CURR BIOL, V5, P580, DOI 10.1016/S0960-9822(95)00114-X; Kunes Samuel, 1993, Current Opinion in Neurobiology, V3, P53, DOI 10.1016/0959-4388(93)90035-W; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; MA C, 1995, IN PRESS DEVELOPMENT; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; NOHNO T, 1995, BIOCHEM BIOPH RES CO, V206, P33, DOI 10.1006/bbrc.1995.1005; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; WEHRLI M, 1995, IN PRESS DEVELOPMENT; WIKLER KC, 1994, P NATL ACAD SCI USA, V91, P6534, DOI 10.1073/pnas.91.14.6534	25	141	142	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					987	990		10.1016/S0092-8674(05)80003-0	http://dx.doi.org/10.1016/S0092-8674(05)80003-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600585	Bronze			2022-12-28	WOS:A1995RG91000003
J	KARRAN, P				KARRAN, P			APPROPRIATE PARTNERS MAKE GOOD MATCHES	SCIENCE			English	Editorial Material							HOMOLOG; CANCER				KARRAN, P (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,BLANCHE LANE,POTTERS BAR EN6 3LD,HERTS,ENGLAND.							DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J	11	18	19	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1857	1858		10.1126/science.7604258	http://dx.doi.org/10.1126/science.7604258			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604258				2022-12-28	WOS:A1995RF99000026
J	SCHIMMEL, P; DEPOUPLANA, LR				SCHIMMEL, P; DEPOUPLANA, LR			TRANSFER-RNA - FROM MINIHELIX TO GENETIC-CODE	CELL			English	Review							SYNTHETASE; RECOGNITION				SCHIMMEL, P (corresponding author), MIT, DEPT BIOL, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.		de Pouplana, Lluis Ribas/AAA-4738-2019	de Pouplana, Lluis Ribas/0000-0002-2087-0359				AULD DS, 1995, SCIENCE, V267, P1994, DOI 10.1126/science.7701322; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; DELARUE M, 1994, EMBO J, V13, P3219, DOI 10.1002/j.1460-2075.1994.tb06623.x; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; ERLANI G, 1990, NATURE, V347, P203; FRUGIER M, 1994, EMBO J, V13, P2218, DOI 10.1002/j.1460-2075.1994.tb06499.x; GLEGE R, 1993, PROG NUCL ACIDS RES, V45, P129; ILLANGASEKARE M, 1995, SCIENCE, V267, P643, DOI 10.1126/science.7530860; MAIZELS N, 1993, RNA WORLD, P577; Martinis Susan A., 1995, P349; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; McClain William H., 1995, P335; MEINNEL T, 1991, P NATL ACAD SCI USA, V88, P291, DOI 10.1073/pnas.88.1.291; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; Noller H.F., 1993, RNA WORLD, P137; NUREKI O, 1995, SCIENCE, V267, P1958, DOI 10.1126/science.7701318; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; PUGLISI EV, 1994, P NATL ACAD SCI USA, V91, P11467, DOI 10.1073/pnas.91.24.11467; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUDINGER J, 1994, BIOCHEMISTRY-US, V33, P5682, DOI 10.1021/bi00185a003; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; STROBEL SA, 1995, SCIENCE, V267, P675, DOI 10.1126/science.7839142; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J	29	146	148	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					983	986		10.1016/S0092-8674(05)80002-9	http://dx.doi.org/10.1016/S0092-8674(05)80002-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600584	Bronze			2022-12-28	WOS:A1995RG91000002
J	VARTIOVAARA, I				VARTIOVAARA, I			LIVING WITH LYME	LANCET			English	Editorial Material																			0	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					842	844		10.1016/S0140-6736(95)92970-3	http://dx.doi.org/10.1016/S0140-6736(95)92970-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7605437				2022-12-28	WOS:A1995QQ19500015
J	DEY, P; COLLINS, S; WILL, S; WOODMAN, CBJ				DEY, P; COLLINS, S; WILL, S; WOODMAN, CBJ			RANDOMIZED CONTROLLED TRIAL ASSESSING EFFECTIVENESS OF HEALTH-EDUCATION LEAFLETS IN REDUCING INCIDENCE OF SUNBURN	BRITISH MEDICAL JOURNAL			English	Article							CLUSTER		BURY & ROCHDALE HLTH AUTHOR,ROCHDALE OL12 9QB,LANCS,ENGLAND		DEY, P (corresponding author), CTR CANC EPIDEMIOL,MANCHESTER M20 4QL,LANCS,ENGLAND.							BRIER SS, 1980, BIOMETRIKA, V67, P591; DONNER A, 1993, J CLIN EPIDEMIOL, V46, P123, DOI 10.1016/0895-4356(93)90050-B; MCAVOY BR, 1991, BMJ-BRIT MED J, V302, P833, DOI 10.1136/bmj.302.6780.833; OSTERLIND A, 1992, REV ONCOL, V5, P903; PLCMO936	5	25	25	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1062	1063		10.1136/bmj.311.7012.1062	http://dx.doi.org/10.1136/bmj.311.7012.1062			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580663	Green Published			2022-12-28	WOS:A1995TB35400022
J	AIGNER, L; ARBER, S; KAPFHAMMER, JP; LAUX, T; SCHNEIDER, C; BOTTERI, F; BRENNER, HR; CARONI, P				AIGNER, L; ARBER, S; KAPFHAMMER, JP; LAUX, T; SCHNEIDER, C; BOTTERI, F; BRENNER, HR; CARONI, P			OVEREXPRESSION OF THE NEURAL GROWTH-ASSOCIATED PROTEIN GAP-43 INDUCES NERVE SPROUTING IN THE ADULT NERVOUS-SYSTEM OF TRANSGENIC MICE	CELL			English	Article							RETINAL GANGLION-CELLS; NEUROMUSCULAR-JUNCTIONS; TRANSPORTED PROTEINS; NEURITE OUTGROWTH; AXON REGENERATION; PC12 CELLS; EXPRESSION; INJURY; NEURONS; MUSCLE	Regulation of neurite outgrowth and structural plasticity may involve the expression of intrinsic determinants controlling growth competence. We have tested this concept by targeting constitutive expression of the growth-associated protein GAP-43 to the neurons of adult transgenic mice. Such mice showed striking spontaneous nerve sprouting at the neuromuscular junction and in the terminal field of hippocampal messy fibers. In control mice, these nerve fibers did not express GAP-43, and did not sprout spontaneously. Lesion-induced nerve sprouting and terminal arborization during reinnervation were greatly potentiated in GAP-43-overexpressing mice. A mutant GAP-43 that cannot be phosphorylated by PKC had reduced sprout-promoting activity. The results establish GAP-43 as an intrinsic presynaptic determinant for neurite outgrowth and plasticity.	UNIV ZURICH,BRAIN RES INST,CH-8029 ZURICH,SWITZERLAND; UNIV BASEL,DEPT PHYSIOL,CH-4000 BASEL,SWITZERLAND	University of Zurich; University of Basel	AIGNER, L (corresponding author), FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND.			Aigner, Ludwig/0000-0002-1653-8046; Arber, Silvia/0000-0002-6261-250X				AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; AIGNER L, 1995, J CELL BIOL, V128, P647, DOI 10.1083/jcb.128.4.647; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BISBY MA, 1992, MOL NEUROBIOL, V6, P107, DOI 10.1007/BF02780547; BISBY MA, 1993, SOC NEUROSCI, V23; BROWN MC, 1984, TRENDS NEUROSCI, V7, P10, DOI 10.1016/S0166-2236(84)80180-0; CARONI P, 1994, J CELL BIOL, V125, P893, DOI 10.1083/jcb.125.4.893; CARONI P, 1992, J NEUROSCI, V12, P3849; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHONG MS, 1994, J NEUROSCI, V14, P4375; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MCKERRACHER L, 1993, J NEUROSCI, V13, P5294, DOI 10.1523/JNEUROSCI.13-12-05294.1993; MEIRI KF, 1990, J NEUROSCI, V10, P256; MOYA KL, 1988, J NEUROSCI, V8, P4445; PESTRONK A, 1978, MUSCLE NERVE, V1, P70, DOI 10.1002/mus.880010110; REYNOLDS ML, 1991, NEUROSCIENCE, V41, P201, DOI 10.1016/0306-4522(91)90210-F; REYNOLDS ML, 1992, J NEUROCYTOL, V21, P50, DOI 10.1007/BF01206897; ROBBINS N, 1988, J NEUROCYTOL, V17, P545, DOI 10.1007/BF01189809; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SCHREYER DJ, 1991, J NEUROSCI, V11, P3738; SHEA TB, 1991, J NEUROSCI, V11, P1685; SHWEGLER G, 1995, J NEUROSCI, V15, P2756; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1981, J CELL BIOL, V89, P86, DOI 10.1083/jcb.89.1.86; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; SON YJ, 1995, NEURON, V114, P133; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; TETZLAFF W, 1991, J NEUROSCI, V11, P2528; THESLEFF S, 1989, Q J EXP PHYSIOL CMS, V74, P1003, DOI 10.1113/expphysiol.1989.sp003329; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503; WIDMER F, 1990, J CELL BIOL, V111, P3035, DOI 10.1083/jcb.111.6.3035; WOOLF CJ, 1992, NATURE, V355, P75, DOI 10.1038/355075a0; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K	41	527	550	0	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					269	278		10.1016/0092-8674(95)90168-X	http://dx.doi.org/10.1016/0092-8674(95)90168-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585944	Bronze			2022-12-28	WOS:A1995TA96500013
J	MANJUNATH, N; CORREA, M; ARDMAN, M; ARDMAN, B				MANJUNATH, N; CORREA, M; ARDMAN, M; ARDMAN, B			NEGATIVE REGULATION OF T-CELL ADHESION AND ACTIVATION BY CD43	NATURE			English	Article							WISKOTT-ALDRICH SYNDROME; LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODY; EXPRESSION; DIFFERENTIATION; MOLECULE; IDENTIFICATION; LEUKOSIALIN; SIALOPHORIN; ENHANCEMENT	CD43 is a cell-surface sialoglycoprotein expressed by a variety of haematopoietically derived cells, including T lymphocytes(1-9). Earlier observations of defective CD43 expression by T lymphocytes from boys with the X-chromosome-linked Wiskott-Aldrich syndrome suggested the importance of CD43 in lymphocyte function(10,11). Subsequent studies have suggested that CD43 facilitates leukocyte adhesion(12-14) and has a co-stimulatory role during T-cell activation(15). To define the physiologically relevant functions(s) of CD43, we have generated CD43-knockout mice. We report here that CD43-deficient T cells from such mice show a marked increase in their in vitro proliferative response to concanavalin A, anti-CD3, the superantigen SEB and allostimulation. Additionally, CD43-deficient T cells show a substantial enhancement in homotypic adhesion and in their ability to bind different ligands, including fibronectin and the intercellular adhesion molecule ICAM-1. Vaccinia-virus-infected CD43-knockout mice mounted an augmented anti-vaccinia, cytotoxic T-cell response compared with their wild-type littermates, yet developed an increased virus load. We conclude that CD43 negatively regulates T-cell activation and adhesion and is important for viral clearance.			MANJUNATH, N (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR HOSP,DEPT MED,DIV HAEMATOL ONCOL,750 WASHINGTON ST,BOSTON,MA 02111, USA.		Correa, Mariangela/K-8700-2019; Correa, Mariangela/A-6666-2010; Correa, Mariangela/B-3426-2019	Correa, Mariangela/0000-0003-4856-7578				ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; AXELSSON B, 1985, EUR J IMMUNOL, V15, P427, DOI 10.1002/eji.1830150503; AXELSSON B, 1988, J IMMUNOL, V141, P2912; BETTAIEB A, 1988, BLOOD, V71, P1226; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BORCHE L, 1987, EUR J IMMUNOL, V17, P1623; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CYSTER JG, 1991, EMBO J, V4, P893; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; GAHMBERG CG, 1976, J CELL BIOL, V68, P642, DOI 10.1083/jcb.68.3.642; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; GULLEY ML, 1988, J IMMUNOL, V140, P3751; GUNJI Y, 1992, BLOOD, V80, P429; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; MANJUNATH N, 1994, J IMMUNOL, V151, P1528; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MENTZER SJ, 1987, J EXP MED, V165, P1382; MOORE T, 1994, J IMMUNOL, V153, P4978; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PARKMAN R, 1981, LANCET, V2, P1387; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; REMOLDODONNELL E, 1987, BLOOD, V70, P104; REMOLDODONNELL E, 1986, J BIOL CHEM, V261, P7526; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; WIKEN M, 1988, SCAND J IMMUNOL, V28, P457, DOI 10.1111/j.1365-3083.1988.tb01476.x	30	187	190	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					535	538		10.1038/377535a0	http://dx.doi.org/10.1038/377535a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566153				2022-12-28	WOS:A1995RZ33600065
J	VANDERWIJDEN, CL; OVERBEKE, JA				VANDERWIJDEN, CL; OVERBEKE, JA			AUDIT OF REPORTS OF RANDOMIZED CLINICAL-TRIALS PUBLISHED IN ONE JOURNAL OVER 45 YEARS	BMJ-BRITISH MEDICAL JOURNAL			English	Article											VANDERWIJDEN, CL (corresponding author), NEDERLANDS TIJDSCHRIFT VOOR GENEESKUNDE, POB 75971, 1070 AZ AMSTERDAM, NETHERLANDS.							CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; Chalmers I, 1989, EFFECTIVE CARE PREGN; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; KLOPPER S., 1948, NEDERLANDSCH TIJDSCHR GENEESK, V92, P3922; Tuberculosis Trials Committee iMRCS, 1948, BMJ, V2, P769	5	14	14	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 7	1995	311	7010					918	918						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580550				2022-12-28	WOS:A1995RZ23700021
J	MASISON, DC; WICKNER, RB				MASISON, DC; WICKNER, RB			PRION-INDUCING DOMAIN OF YEAST URE2P AND PROTEASE RESISTANCE OF URE2P PRION-CONTAINING CELLS	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PSI	The genetic properties of the [URE3] non-Mendelian element of Saccharomyces cerevisiae suggest that it is a prion (infectious protein) form of Ure2p, a regulator of nitrogen catabolism. In extracts from [URE3] strains, Ure2p was partially resistant to proteinase K compared with Ure2p from wild-type extracts. Overexpression of Ure2p in wild-type strains induced a 20- to 200-fold increase in the frequency with which [URE3] arose, Overexpression of just the amino-terminal 65 residues of Ure2p increased the frequency of [URE3] induction 6000-fold. Without this ''prion-inducing domain'' the carboxyl-terminal domain performed the nitrogen regulation function of Ure2p, but could not be changed to the [URE3] prion state. Thus, this domain induced the prion state in trans, whereas in cis it conferred susceptibility of the adjoining nitrogen regulatory domain to prion infections.	NIDDKD, BIOCHEM PHARMACOL LAB, GENET SIMPLE EUKARYOTES SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COX B, 1994, CURR BIOL, V4, P744, DOI 10.1016/S0960-9822(00)00167-6; Cox Brian, 1993, P219; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; DOEL SM, 1994, GENETICS, V137, P659; GAJDUSEK DC, 1991, EUR J EPIDEMIOL, V7, P567, DOI 10.1007/BF00143141; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH A, 1979, P NATL ACAD SCI USA, V76, P1952, DOI 10.1073/pnas.76.4.1952; STANSFIELD I, 1994, CURR GENET, V25, P385, DOI 10.1007/BF00351776; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TUITE MF, 1994, NATURE, V370, P327, DOI 10.1038/370327a0; TUITE MF, 1981, GENETICS, V98, P691; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	26	319	324	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 6	1995	270	5233					93	95		10.1126/science.270.5233.93	http://dx.doi.org/10.1126/science.270.5233.93			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569955	Green Submitted			2022-12-28	WOS:A1995RY30200040
J	OHNO, H; STEWART, J; FOURNIER, MC; BOSSHART, H; RHEE, I; MIYATAKE, S; SAITO, T; GALLUSSER, A; KIRCHHAUSEN, T; BONIFACINO, JS				OHNO, H; STEWART, J; FOURNIER, MC; BOSSHART, H; RHEE, I; MIYATAKE, S; SAITO, T; GALLUSSER, A; KIRCHHAUSEN, T; BONIFACINO, JS			INTERACTION OF TYROSINE-BASED SORTING SIGNALS WITH CLATHRIN-ASSOCIATED PROTEINS	SCIENCE			English	Article							TRANS-GOLGI NETWORK; PLASMA-MEMBRANE; COATED VESICLES; CYTOPLASMIC DOMAIN; INVITRO BINDING; RECEPTOR; SEQUENCE; CLONING; TGN38; MOTIF	Tyrosine-based signals within the cytoplasmic domain of integral membrane proteins mediate clathrin-dependent protein sorting in the endocytic and secretory pathways. A yeast two-hybrid system was used to identify proteins that bind to tyrosine-based signals. The medium chains (mu(1) and mu(2)) of two clathrin-associated protein complexes (AP-1 and AP-2, respectively) specifically interacted with tyrosine-based signals of several integral membrane proteins. The interaction was confirmed by in vitro binding assays. Thus, it is likely that the medium chains serve as signal-binding components of the clathrin-dependent sorting machinery.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOLEC GENET,CHIBA 260,JAPAN	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Chiba University			Ohno, Hiroshi/L-7899-2014; Yang, Chen/G-1379-2010; Saito, Takashi/C-9684-2009; Bosshart, Herbert/N-1367-2016	Ohno, Hiroshi/0000-0001-8776-9661; Saito, Takashi/0000-0001-9495-3547; Bonifacino, Juan S./0000-0002-5673-6370; Bosshart, Herbert/0000-0002-9315-9592				BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MARKS MS, IN PRESS J CELL BIOL; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; NAKAYAMA Y, 1991, EUR J BIOCHEM, V202, P569, DOI 10.1111/j.1432-1033.1991.tb16409.x; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OHNO H, UNPUB; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WONG SH, 1993, J BIOL CHEM, V2368, P22853	35	812	822	2	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1872	1875		10.1126/science.7569928	http://dx.doi.org/10.1126/science.7569928			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569928				2022-12-28	WOS:A1995RX19400038
J	EHLERS, MD; TINGLEY, WG; HUGANIR, RL				EHLERS, MD; TINGLEY, WG; HUGANIR, RL			REGULATED SUBCELLULAR-DISTRIBUTION OF THE NR1 SUBUNIT OF THE NMDA RECEPTOR	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; CULTURED HIPPOCAMPAL-NEURONS; GLUTAMATE RECEPTORS; RAT-BRAIN; PROTEIN-KINASE; CHANNEL; SYNAPSES; PHOSPHORYLATION; LOCALIZATION; POLYAMINES	NMDA (N-methyl-D-aspartate) receptors are selectively localized at the postsynaptic membrane of excitatory synapses in the mammalian brain. The molecular mechanisms underlying this localization were investigated by expressing the NR1 subunit of the NMDA receptor in fibroblasts. NR1 splice variants containing the first COOH-terminal exon cassette (NR1A and NR1D) were located in discrete, receptor-rich domains associated with the plasma membrane. NR1 splice variants lacking this exon cassette (NR1C and NR1E) were distributed throughout the cell, with large amounts of NR1 protein present in the cell interior. Insertion of this exon cassette into the COOH-terminus of the GluR1 AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptor was sufficient to cause GluR1 to be localized to discrete, receptor-rich domains. Furthermore, protein kinase C phosphorylation of specific serines within this exon disrupted the receptor-rich domains. These results demonstrate that amino acid sequences contained within the NR1 molecule serve to localize this receptor subunit to discrete membrane domains in a manner that is regulated by alternative splicing and protein phosphorylation.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University								BENVENISTE M, 1993, J PHYSIOL-LONDON, V464, P131, DOI 10.1113/jphysiol.1993.sp019627; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CONSTANTINEPATO.M, 1990, ANN REV NEUROSCI, V13, P129; CRAIG AM, 1993, NEURON, V10, P1055, DOI 10.1016/0896-6273(93)90054-U; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; ESHHAR N, 1993, NEUROSCIENCE, V57, P943, DOI 10.1016/0306-4522(93)90040-M; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; HUNTLEY GW, 1994, J NEUROSCI, V14, P3603; JONES KA, 1991, NEURON, V7, P593, DOI 10.1016/0896-6273(91)90372-7; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PETRALIA RS, 1994, J NEUROSCI, V14, P667; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROCK DM, 1992, MOL PHARMACOL, V42, P157; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; ZHANG L, 1994, P NATL ACAD SCI USA, V91, P10883, DOI 10.1073/pnas.91.23.10883	36	250	254	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1734	1737		10.1126/science.7569904	http://dx.doi.org/10.1126/science.7569904			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569904				2022-12-28	WOS:A1995RV94800042
J	KOLLEF, MH; SHAPIRO, SD; FRASER, VJ; SILVER, P; MURPHY, DM; TROVILLION, E; HEARNS, ML; RICHARDS, RD; CRACCHILO, L; HOSSIN, L				KOLLEF, MH; SHAPIRO, SD; FRASER, VJ; SILVER, P; MURPHY, DM; TROVILLION, E; HEARNS, ML; RICHARDS, RD; CRACCHILO, L; HOSSIN, L			MECHANICAL VENTILATION WITH OR WITHOUT 7-DAY CIRCUIT CHANGES - A RANDOMIZED CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						RESPIRATION, MECHANICAL; CROSS INFECTION; PNEUMONIA; COST SAVINGS	PROSPECTIVE PAYMENT SYSTEM; PROTECTED SPECIMEN BRUSH; CARE UNIT PATIENTS; NOSOCOMIAL PNEUMONIA; MULTIVARIATE-ANALYSIS; RESPIRATORY-FAILURE; RISK; INFECTIONS; PROGNOSIS; DIAGNOSIS	Objective: To determine whether a practice of not routinely changing ventilator circuits in patients who require prolonged mechanical ventilation is associated with an increased incidence of nosocomial pneumonia. Design: Randomized controlled trial. Setting: Intensive care units in two university-affiliated teaching hospitals. Patients: 300 patients admitted to an intensive care unit who required mechanical ventilation for more than 5 days. Intervention: Patients were randomly assigned to receive either no routine ventilator circuit changes or circuit changes every 7 days. Measurements: The primary outcome measure was the incidence of ventilator-associated pneumonia. Other outcome measures included duration of mechanical ventilation, length of hospital stay, and hospital mortality. Results: 147 patients were randomly assigned to receive no routine ventilator circuit changes, and 153 patients were randomly assigned to receive circuit changes every 7 days. The two groups were similar at the time of randomization with regard to demographic characteristics, intensive care unit admission diagnoses, and severity of illness, Ventilator-associated pneumonia was seen in 36 patients (24.5%) receiving no routine changes and in 44 patients (28.8%) receiving changes every 7 days (relative risk, 0.85 [95% CI, 0.55 to 1.17]). No statistically significant differences for hospital mortality, intensive care unit mortality, death during mechanical ventilation, death in patients with ventilator-associated pneumonia, or mortality directly attributed to ventitator-associated pneumonia were found between the two treatment groups (P greater than or equal to 0.11). Patients receiving changes every 7 days had 247 circuit changes costing a total of $7410; patients receiving no routine changes had a total of 11 circuit changes costing $330. Conclusion: The elimination of routine ventilator circuit changes can reduce medical care costs without increasing the incidence of nosocomial pneumonia in patients who require prolonged mechanical ventilation.	JEWISH HOSP ST LOUIS, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA; BARNES HOSP, DEPT RESP THERAPY, ST LOUIS, MO 63110 USA; BARNES HOSP, DEPT INFECT CONTROL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital	KOLLEF, MH (corresponding author), WASHINGTON UNIV, SCH MED, DIV PULM & CRIT CARE, BOX 8052, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.			Fraser, Victoria/0000-0001-6251-0733				ALFREDSON T, 1994, RESPIR CARE, V39, P1108; BOYCE JM, 1991, ARCH INTERN MED, V151, P1109, DOI 10.1001/archinte.151.6.1109; BOYCE JM, 1985, AM J INFECT CONTROL, V13, P228, DOI 10.1016/0196-6553(85)90063-X; Campbell R S, 1994, Respir Care, V39, P227; CANTRAL DE, 1993, AM J MED, V95, P601, DOI 10.1016/0002-9343(93)90356-T; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CHASTRE J, 1984, AM REV RESPIR DIS, V130, P924; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; CRAVEN DE, 1982, NEW ENGL J MED, V306, P1505, DOI 10.1056/NEJM198206243062501; CRAVEN DE, 1991, AM J MED, V91, pS44, DOI 10.1016/0002-9343(91)90343-V; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; CRAVEN DE, 1995, ANN INTERN MED, V122, P229, DOI 10.7326/0003-4819-122-3-199502010-00013; CRAVEN DE, 1984, AM REV RESPIR DIS, V129, P625; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DREYFUSS D, 1991, AM REV RESPIR DIS, V143, P738, DOI 10.1164/ajrccm/143.4_Pt_1.738; ELNAGGAR M, 1976, ANESTH ANALG, V55, P195; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; GREENE R, 1994, AM J ROENTGENOL, V163, P1036, DOI 10.2214/ajr.163.5.7976872; HALEY RW, 1987, JAMA-J AM MED ASSOC, V257, P1611, DOI 10.1001/jama.257.12.1611; HESS D, 1994, RESPIR CARE, V94, P1149; Hess Dean, 1994, Chest, V106, p79S; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOLLEF MH, 1994, AM J ROENTGENOL, V163, P1031, DOI 10.2214/ajr.163.5.7976871; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; KOLLEF MH, 1995, CHEST, V107, P1395, DOI 10.1378/chest.107.5.1395; LAREAU SC, 1978, AM REV RESPIR DIS, V118, P493; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MEDURI GU, 1990, CHEST, V97, P1208, DOI 10.1378/chest.97.5.1208; MEDURI GU, 1992, CHEST, V102, pS551, DOI 10.1016/S0012-3692(16)34868-1; MEINERT CL, 1986, CLIN TRIALS DESIGN C, P194; MEUZIES R, 1989, CHEST, V95, P398; ORENS D, 1994, RESP CARE, V39, P1108; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153; ROUBY JJ, 1992, AM REV RESPIR DIS, V146, P1059, DOI 10.1164/ajrccm/146.4.1059; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; SALATA RA, 1987, AM REV RESPIR DIS, V135, P426; TABLAN OC, 1994, INFECT CONT HOSP EP, V15, P588, DOI 10.1086/646989; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TYRA JA, 1994, RESPIR CARE, V39, P1107; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004; 1994, RESPIR CARE, V39, P797; 1990, SAS STAT USERS GUIDE, V2, P1071	44	134	142	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					168	174		10.7326/0003-4819-123-3-199508010-00002	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598297				2022-12-28	WOS:A1995RL10400002
J	SCHWARTZ, TB				SCHWARTZ, TB			HOW TO LEARN FROM PATIENTS - ALBRIGHT,FULLER EXPLORATION OF ADRENAL-FUNCTION	ANNALS OF INTERNAL MEDICINE			English	Article								Fuller Albright (1900-1969) was acknowledged as the preeminent clinical and investigative endocrinologist of his day by many of his contemporaries, but his many achievements are all but unknown to the present generation of physicians. This article describes how he used his clinical knowledge and a few tools-the measurement of urinary 17-ketosteroid excretion and the administration of methyltestosterone-to elucidate the major hormonal functions of the adrenal cortex and to clarify the pathophysiology of the Cushing syndrome. In addition, in a tour de force of clinical reasoning, he predicted, 5 years before the event, the discovery of a hormone that would reverse the endocrinologic abnormalities of congenital adrenal hyperplasia. Fittingly, he and pioneer pediatric endocrinologist Lawson Wilkins were the first to treat this disease successfully with cortisone.										Albright F, 1941, J CLIN ENDOCRINOL, V1, P375, DOI 10.1210/jcem-1-5-375; ALBRIGHT F, 1947, RECENT PROG HORM RES, V1, P293; ALBRIGHT F, PAPERS COUNTWAY MED; ALBRIGHT F, 1942, HARVEY LECTURES SERI, V38, P23; Albright HL, 1941, NEW ENGL J MED, V225, P760; BARTTER FC, 1951, J CLIN INVEST, V30, P237, DOI 10.1172/JCI102438; BARTTER FC, 1950, J CLIN INVEST, V29, P797; BEST CH, 1939, PHYSL BASIS MED PRAC, P1385; BLACKMAN SS, 1946, B JOHNS HOPKINS HOSP, V78, P180; Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137; FISHBERG AM, 1939, HYPERTENSION NEPHRIT, P682; Fraser R, 1941, J CLIN ENDOCRINOL, V1, P297, DOI 10.1210/jcem-1-4-297; Fraser RW, 1941, J CLIN ENDOCRINOL, V1, P234, DOI 10.1210/jcem-1-3-234; Heinbecker P, 1944, MEDICINE, V23, P225, DOI 10.1097/00005792-194409000-00002; LEWIS RA, 1950, J CLIN ENDOCRINOL, V10, P703, DOI 10.1210/jcem-10-7-703; Long CNH, 1940, ENDOCRINOLOGY, V26, P309, DOI 10.1210/endo-26-2-309; LOUARD RJ, 1994, J CLIN ENDOCR METAB, V79, P278, DOI 10.1210/jc.79.1.278; MACCALLUM WG, 1940, TXB PATHOLOGY, P943; MILLER WL, 1994, J CLIN ENDOCR METAB, V78, P241, DOI 10.1210/jc.78.2.241; MONEY J, 1965, DIAGNOSIS TREATMENT; OPPENHEIMER BS, 1935, T ASSOC AM PHYSICIAN, V50, P371; Park EA, 1960, J PEDIATR, V57, P317; Parker L, 1993, ENDOCR J, V1, P441; PARKER LN, 1989, ADRENAL ANDROGENS CL; REIFENSTEIN EC, 1945, J CLIN INVEST, V24, P416, DOI 10.1172/JCI101620; SCHWARTZ TB, 1991, PERSPECT BIOL MED, V34, P327; SCHWARTZ TB, 1995, ENDOCR PRACT, V1, P142; WILKINS L, 1950, B JOHNS HOPKINS HOSP, V86, P249; Wilkins L, 1940, ENDOCRINOLOGY, V26, P385, DOI 10.1210/endo-26-3-385; WILKINS L, 1949, Pediatrics, V3, P533; WILKINS L, 1948, J CLIN ENDOCRINOL, V8, P111, DOI 10.1210/jcem-8-2-111; Young Hugh, 1937, GENITAL ABNORMALITIE	32	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					225	229		10.7326/0003-4819-123-3-199508010-00010	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598305				2022-12-28	WOS:A1995RL10400010
J	FLAHAULT, A; GARNERIN, P; CHAUVIN, P; FARRAN, N; SAIDI, Y; DIAZ, C; TOUBIANA, L; DRUCKER, J; VALLERON, AJ				FLAHAULT, A; GARNERIN, P; CHAUVIN, P; FARRAN, N; SAIDI, Y; DIAZ, C; TOUBIANA, L; DRUCKER, J; VALLERON, AJ			SENTINELLE TRACES OF AN EPIDEMIC OF ACUTE GASTROENTERITIS IN FRANCE	LANCET			English	Article									HOP NATL ST MAURICE,RESEAU NATL SANTE PUBL,F-75571 PARIS 12,FRANCE		FLAHAULT, A (corresponding author), INSERM,U263,F-75571 PARIS 12,FRANCE.		Chauvin, Pierre/G-1095-2015; Toubiana, Laurent/L-6840-2017; Chauvin, Pierre/S-2981-2019	Chauvin, Pierre/0000-0002-9183-6406; Toubiana, Laurent/0000-0002-1849-9829; Chauvin, Pierre/0000-0002-9183-6406				COSTAGLIOLA D, 1994, EUR J EPIDEMIOL, V10, P475, DOI 10.1007/BF01719680; Valleron A.-J., 1992, Morbidity and Mortality Weekly Report, V41, P101	2	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					162	163		10.1016/S0140-6736(95)91214-2	http://dx.doi.org/10.1016/S0140-6736(95)91214-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603234				2022-12-28	WOS:A1995RJ03100014
J	ROSENBERG, J				ROSENBERG, J			METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS (MRSA) IN THE COMMUNITY - WHOS WATCHING	LANCET			English	Editorial Material							MICROBIOLOGY; INFECTIONS				ROSENBERG, J (corresponding author), CALIF DEPT HLTH SERV,DIV COMMUNICABLE DIS CONTROL,INFECT CONTROL PROGRAM,BERKELEY,CA 94704, USA.							BERMAN DS, 1994, NEW ENGL J MED, V330, P1247; DECKER MD, 1992, HOSP INFECT, P221; EMBIL J, 1994, INFECT CONT HOSP EP, V15, P646; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; LAYTON MC, 1995, INFECT CONT HOSP EP, V16, P12; LINNEMANN CC, 1991, AM J MED, V91, pS238, DOI 10.1016/0002-9343(91)90375-8; MCGOWAN JE, 1995, INFECT CONT HOSP EP, V16, P67, DOI 10.1086/647058; MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; NETTLEMAN MD, 1991, AM J MED S3B, V1, pS228; SARAVOLATZ LD, 1982, ANN INTERN MED, V97, P325, DOI 10.7326/0003-4819-97-3-325; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725	12	54	55	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					132	133		10.1016/S0140-6736(95)91203-7	http://dx.doi.org/10.1016/S0140-6736(95)91203-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603224				2022-12-28	WOS:A1995RJ03100002
J	TEDDER, RS; ZUCKERMAN, MA; GOLDSTONE, AH; HAWKINS, AE; FIELDING, A; BRIGGS, EM; IRWIN, D; BLAIR, S; GORMAN, AM; PATTERSON, KG; LINCH, DC; HEPTONSTALL, J; BRINK, NS				TEDDER, RS; ZUCKERMAN, MA; GOLDSTONE, AH; HAWKINS, AE; FIELDING, A; BRIGGS, EM; IRWIN, D; BLAIR, S; GORMAN, AM; PATTERSON, KG; LINCH, DC; HEPTONSTALL, J; BRINK, NS			HEPATITIS-B TRANSMISSION FROM CONTAMINATED CRYOPRESERVATION TANK	LANCET			English	Article								Over a 25-month period, six multiply transfused patients undergoing cytotoxic treatment for haematological or other malignant disorders developed icteric acute hepatitis B virus (HBV) infection. Bone marrow or peripheral-blood stem cells had been harvested from all six patients and stored in the same cryopreservation tank for possible future transplantation. Human DNA, HBsAg, and HBV DNA with sequences identical to those from four patients with related infections were subsequently found in the liquid nitrogen. Leakage of the cryopreservation bags used to store bone marrow harvested from the first patient when acutely infected with HBV led to contamination of the tank and its contents with HBV and subsequent transmission to patients after transplantation. This incident emphasises the continuing need to screen donors of tissue to be cryopreserved for bloodborne virus infections. It also reinforces the requirement for primary containers used to cryopreserve human tissue to be sealed in a way which prevents exchange of material between the specimen and the liquid nitrogen.	UCL HOSP, DEPT HAEMATOL, LONDON, ENGLAND; ACAD DEPT GENITOURINARY MED, LONDON, ENGLAND; NE THAMES REG TRANSFUS CTR, BRENTWOOD, ESSEX, ENGLAND; PUBL HLTH LAB SERV, LONDON, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London; Public Health England	TEDDER, RS (corresponding author), UCL, SCH MED, DIV VIROL, WINDEYER BLDG, 46 CLEVELAND ST, LONDON W1P 6DB, ENGLAND.			Tedder, Richard/0000-0002-9672-5721				ALLANDER T, 1995, LANCET, V345, P603, DOI 10.1016/S0140-6736(95)90518-9; HAWKINS AE, 1994, J MED VIROL, V44, P13, DOI 10.1002/jmv.1890440105; KOIKE K, 1992, UNPUB PCR CLIN DIAGN; TEDDER RS, 1980, J MED VIROL, V6, P323, DOI 10.1002/jmv.1890060407; VOAK D, 1994, TRANSFUSION MED, V4, P165; ZUCKERMAN MA, 1994, OCT MO LBIOL HEP B V	6	327	338	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 15	1995	346	8968					137	140		10.1016/S0140-6736(95)91207-X	http://dx.doi.org/10.1016/S0140-6736(95)91207-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603227				2022-12-28	WOS:A1995RJ03100007
J	RAO, Z; HANDFORD, P; MAYHEW, M; KNOTT, V; BROWNLEE, GG; STUART, D				RAO, Z; HANDFORD, P; MAYHEW, M; KNOTT, V; BROWNLEE, GG; STUART, D			THE STRUCTURE OF A CA2+-BINDING EPIDERMAL GROWTH FACTOR-LIKE DOMAIN - ITS ROLE IN PROTEIN-PROTEIN INTERACTIONS	CELL			English	Article							HUMAN FACTOR-IX; FACTOR HOMOLOGY REGION; COAGULATION FACTOR-X; FACTOR-LIKE MODULE; EGF-LIKE DOMAINS; CALCIUM-BINDING; CRYSTAL-STRUCTURE; DROSOPHILA-NOTCH; SECONDARY STRUCTURE; MARFAN-SYNDROME	Various diverse extracellular proteins possess Ca2+-binding epidermal growth factor (EGF)-like domains, the function of which remains uncertain. We have determined, at high resolution (1.5 Angstrom), the crystal structure of such a domain, from human clotting factor IX, as a complex with Ca2+. The Ca2+ ligands form a classic pentagonal bipyramid with six ligands contributed by one polypeptide chain and the seventh supplied by a neighboring EGF-like domain. The crystal structure identifies the role of Ca2+ in maintaining the conformation of the N-terminal region of the domain, but more importantly demonstrates that Ca2+ can directly mediate protein-protein contacts. The observed crystal packing of the domains provides a plausible model for the association of multiple tandemly linked EGF-like domains in proteins such as fibrillin-1, Notch, and protein S. This model is consistent with the known functional data and suggests a general biological role for these domains.	UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, NEW CHEM LAB, OXFORD OX1 3QT, ENGLAND	University of Oxford; University of Oxford	RAO, Z (corresponding author), UNIV OXFORD, MOLEC BIOPHYS LAB, REX RICHARDS BLDG, OXFORD OX1 3QU, ENGLAND.		Rao, Zihe/HCH-6944-2022					ACHARYA KR, 1991, J MOL BIOL, V221, P571; ARLAUD GJ, 1989, BEHRING I MITT, V84, P56; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARON M, 1992, PROTEIN SCI, V1, P81; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BRUNGER AT, 1992, XPLOR VERSION 31 SYS; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DAY AJ, 1993, BEHRING I MITT, V93, P31; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GIANNELLI F, 1994, NUCLEIC ACIDS RES, V22, P3534, DOI 10.1093/nar/22.17.3534; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HASE S, 1988, J BIOCHEM-TOKYO, V104, P867, DOI 10.1093/oxfordjournals.jbchem.a122571; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; HUANG LH, 1989, BIOCHEM BIOPH RES CO, V160, P133, DOI 10.1016/0006-291X(89)91631-8; HUGHES PE, 1993, J BIOL CHEM, V268, P17727; JONES EY, 1991, ACTA CRYSTALLOGR A, V47, P753, DOI 10.1107/S0108767391006839; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PERSSON E, 1989, J BIOL CHEM, V264, P16897; RAO Z, 1995, ACTA CRYSTALLOGR D, V51, P402, DOI 10.1107/S0907444994009881; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SELANDER M, 1990, BIOCHEMISTRY-US, V29, P8111, DOI 10.1021/bi00487a018; SELANDERSUNNERH.M, 1994, THESIS U LUND SWEDEN; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1991, BLOOD, V78, P1637; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THIELENS NM, 1990, BIOCHEMISTRY-US, V29, P3570, DOI 10.1021/bi00466a021; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	64	309	316	1	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					131	141		10.1016/0092-8674(95)90059-4	http://dx.doi.org/10.1016/0092-8674(95)90059-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606779	Bronze			2022-12-28	WOS:A1995RK42400016
J	DURING, MJ; RYDER, KM; SPENCER, DD				DURING, MJ; RYDER, KM; SPENCER, DD			HIPPOCAMPAL GABA TRANSPORTER FUNCTION IN TEMPORAL-LOBE EPILEPSY	NATURE			English	Article							GAMMA-AMINOBUTYRIC ACID; EXCITATORY AMINO-ACIDS; PRIMARY CULTURE; RELEASE; NEURONS; RECEPTORS; BRAIN; GLUTAMATE; INVITRO; SEIZURE	ELECTROPHYSIOLOGICAL studies of human temporal-lobe epilepsy suggest that a loss of hippocampal GABA-mediated inhibition may underlie the neuronal hyperexcitability(1-3). However, GABA (gamma-aminobutyric acid)-containing cells are preserved(4) and GABA receptors are maintained in the surviving hippocampal neurons(5). Diminished GABA release may therefore mediate the loss of inhibition. Here we show that, in the human brain, potassium-stimulated release of GABA was increased, and glutamate-induced, calcium-independent release of GABA was markedly decreased, in epileptogenic hippocampi, in contrast with contralateral, non-epileptogenic hippocampi. The glutamate-induced GABA release in vivo was transporter-mediated in rats. Furthermore, in amygdala-kindled rats, a model for human epilepsy, a decease in glutamate-induced GABA release was associated with a 48% decrease in tbe number of GABA transporters. These data suggest that temporal-lobe epilepsy is characterized in part by a loss of glutamate-stimulated GABA release that is secondary to a reduction in the number of GABA transporters.	YALE UNIV,SCH MED,DEPT SURG,ENDOCRINOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510	Yale University; Yale University	DURING, MJ (corresponding author), YALE UNIV,SCH MED,DEPT SURG,NEUROSURG SECT,MOLEC PHARMACOL & NEUROGENET LAB,333 CEDAR ST,NEW HAVEN,CT 06510, USA.		During, Matthew/AAC-1388-2020					ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; BABB TL, 1989, J NEUROSCI, V9, P2562; BRAESTRUP C, 1990, J NEUROCHEM, V54, P639, DOI 10.1111/j.1471-4159.1990.tb01919.x; DELANEROLLE NC, 1991, DENTATE GYRUS ITS RO, P235; DREJER J, 1987, J NEUROSCI, V7, P2910; During M., 1992, Epilepsia, V33, P83; DURING MJ, 1993, LANCET, V341, P1607; DURING MJ, 1992, BRAIN RES, V584, P36, DOI 10.1016/0006-8993(92)90875-A; GALLO V, 1991, GLIA, V4, P245, DOI 10.1002/glia.440040302; GEDDES JW, 1990, EXP NEUROL, V108, P214, DOI 10.1016/0014-4886(90)90125-C; GONSALVES SF, 1989, EPILEPSY RES, V4, P34, DOI 10.1016/0920-1211(89)90056-9; HARRIS KM, 1989, BRAIN RES, V482, P23, DOI 10.1016/0006-8993(89)90538-6; HORTON RW, 1979, EUR J PHARMACOL, V59, P75, DOI 10.1016/0014-2999(79)90026-8; ISOKAWA M, 1991, EPILEPSY RES, V9, P242, DOI 10.1016/0920-1211(91)90058-N; JOHNSON EW, 1992, NEUROLOGY, V42, P811, DOI 10.1212/WNL.42.4.811; KNOWLES WD, 1992, EPILEPSIA, V33, P601, DOI 10.1111/j.1528-1157.1992.tb02335.x; MANGANO RM, 1983, BRAIN RES BULL, V10, P47, DOI 10.1016/0361-9230(83)90073-4; MCDONALD JW, 1991, ANN NEUROL, V29, P325; MCNAMARA JO, 1980, PROG NEUROBIOL, V15, P139, DOI 10.1016/0301-0082(80)90006-4; MORRISON PF, 1991, MONITORING MOLECULES IN NEUROSCIENCE, P47; PIN JP, 1989, J NEUROSCI, V9, P648; RADIAN R, 1990, J NEUROSCI, V10, P1319; SIMPSON MD, 1988, NEUROSCI LETT, V107, P211; SZERB JC, 1982, J NEUROCHEM, V39, P850, DOI 10.1111/j.1471-4159.1982.tb07970.x; WILLIAMSON A, 1994, CLIN NEUROSCI, V2, P47; WILLIAMSON A, IN PRESS J NEUROPHYS	26	298	304	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					174	177		10.1038/376174a0	http://dx.doi.org/10.1038/376174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603569				2022-12-28	WOS:A1995RJ02800061
J	GOLDIE, AS; FEARON, KCH; ROSS, JA; BARCLAY, GR; JACKSON, RE; GRANT, IS; RAMSAY, G; BLYTH, AS; HOWIE, JC				GOLDIE, AS; FEARON, KCH; ROSS, JA; BARCLAY, GR; JACKSON, RE; GRANT, IS; RAMSAY, G; BLYTH, AS; HOWIE, JC			NATURAL CYTOKINE ANTAGONISTS AND ENDOGENOUS ANTIENDOTOXIN CORE ANTIBODIES IN SEPSIS SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUMOR-NECROSIS-FACTOR; CONTROLLED CLINICAL-TRIAL; NEGATIVE SEPTIC SHOCK; ORGAN FAILURE; FACTOR TNF; ENDOTOXIN; RECEPTORS; SERUM; INTERLEUKIN-6; SURVIVAL	Objective.-To assess the value of measuring circulating concentrations of mediators (endotoxin, tumor necrosis factor-alpha [TNF-alpha], interleukin-1 beta [IL-1 beta], and interleukin-6 [IL-6]) and their endogenous antagonists (antiendotoxin core antibody [EndoCAb], interleukin-1 receptor antagonist [lL-1ra], and soluble TNF receptors [sTNF-R]) in predicting mortality and organ failure in sepsis syndrome. Design.-Cohort study with a follow-up period of 30 days. Setting.-Intensive therapy units of five tertiary referral centers in Scotland. Subjects.-A total of 146 intensive therapy unit patients with sepsis syndrome underwent repeated sampling during a 10-day period following admission to an intensive therapy unit. Main Outcome Measures.-Circulating concentrations of mediators and antagonists were compared in survivors and nonsurvivors. Results.-Median Acute Physiology and Chronic Health Evaluation II score was 23 (range, 8 to 40). Mortality at 30 days was 49%. On entry to the study, circulating endotoxin was detected in 66% of patients, TNF-alpha in 14%, and IL-1 beta in 29%. Levels did not predict mortality or organ failure. Patients with IL-6 concentrations in excess of 3000 pg/mL had an increased mortality rate (64% vs 40%, P=.02). The incidence of IgG EndoCAb depletion on entry to the study was 26% in nonsurvivors and 10% in survivors (P=.02). Initial concentrations of both type I and type II sTNF-R were significantly higher in nonsurvivors (P<.01). Initial circulating IL-1ra concentrations were not of value in predicting mortality, Cytokine antagonists were present in concentrations 30- to 100 000-fold greater than their corresponding cytokine. Conclusion.-The observed high circulating levels of the cytokine antagonists IL-1ra and sTNF-R and the relatively small proportion of patients developing EndoCAb depletion may contribute to the limitations of therapies that aim to augment natural defenses against endotoxin or the proinflammatory cytokines.	UNIV EDINBURGH, ROYAL INFIRM, DEPT SURG, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; SCOTTISH NATL BLOOD TRANSFUS SERV, EDINBURGH, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, INTENS THERAPY UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; WESTERN INFIRM & ASSOCIATED HOSP, DEPT ANAESTHET, GLASGOW, LANARK, SCOTLAND; VICTORIA INFIRM, DEPT ANAESTHET, GLASGOW G42 9TY, LANARK, SCOTLAND; ACAD ZEIKENHUIS, MAASTRICHT, NETHERLANDS	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; Maastricht University; Maastricht University Medical Centre (MUMC)								BARCLAY GR, 1989, CIRC SHOCK, V29, P93; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A; CALANDRA T, 1990, J INFECT DIS, V161, P982, DOI 10.1093/infdis/161.5.982; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CERRA FB, 1987, SURGERY, V101, P1; COYLE SM, 1993, CLIN NUTR S2, V12, P29; DAMAS P, 1989, CRIT CARE MED, V17, P975, DOI 10.1097/00003246-198910000-00001; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; DEGROOTE MA, 1989, JAMA-J AM MED ASSOC, V262, P249, DOI 10.1001/jama.262.2.249; DHAINAUT JF, 1993, AUG INT C END AMST; DING AH, 1989, J BIOL CHEM, V264, P3924; DOFFERHOFF ASM, 1992, CRIT CARE MED, V20, P185, DOI 10.1097/00003246-199202000-00007; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FROON AHM, IN PRESS CRIT CARE M; GILBERT ROBERT P., 1960, PHYSIOL REVS, V40, P245; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GRANOWITZ EV, 1991, LANCET, V338, P1423, DOI 10.1016/0140-6736(91)92725-H; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HACK CE, 1989, BLOOD, V74, P1704; HURLEY JC, 1992, CLIN INFECT DIS, V15, P840, DOI 10.1093/clind/15.5.840; ISPAHANI P, 1987, Q J MED, V63, P427; KISHIMOTO T, 1993, 8TH P INT C IMM BUD, P887; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MOHLER KM, 1993, J IMMUNOL, V151, P1548; NYS M, 1993, ANN SURG, V217, P300, DOI 10.1097/00000658-199303000-00013; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; POLLACK M, 1983, J CLIN INVEST, V72, P1874, DOI 10.1172/JCI111150; SCHEDEL I, 1991, CRIT CARE MED, V19, P1104, DOI 10.1097/00003246-199109000-00003; SPINAS GA, 1992, J CLIN INVEST, V90, P533, DOI 10.1172/JCI115891; WAAGE A, 1987, LANCET, V1, P355; WHICHER JT, 1978, ANN CLIN BIOCHEM, V15, P77, DOI 10.1177/000456327801500117; WORTEL CH, 1992, J INFECT DIS, V166, P1367, DOI 10.1093/infdis/166.6.1367; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	37	224	229	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					172	177		10.1001/jama.274.2.172	http://dx.doi.org/10.1001/jama.274.2.172			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596007				2022-12-28	WOS:A1995RH22200032
J	NUYTS, GD; VANVLEM, E; THYS, J; DELEERSNIJDER, D; DHAESE, PC; ELSEVIERS, MM; DEBROE, ME				NUYTS, GD; VANVLEM, E; THYS, J; DELEERSNIJDER, D; DHAESE, PC; ELSEVIERS, MM; DEBROE, ME			NEW OCCUPATIONAL RISK-FACTORS FOR CHRONIC-RENAL-FAILURE	LANCET			English	Article							LEAD WORKERS; BODY BURDEN; CADMIUM; DISEASE; EXPOSURE; BLOOD; GLOMERULONEPHRITIS; DYSFUNCTION; POPULATION; CREATININE	Occupational pollutants may have a role in development of chronic renal failure (CRF). Most epidemiological studies have been cross-sectional, limited to certain renal diagnoses, or concentrated on early transient renal effects. In a case-control study, we examined the association between CRF and occupational exposure. Occupational histories of 272 men and women with CRF (of all types) were compared with those of 272 controls matched for age, sex, and region of residence. Exposures were assessed and degree and frequency were scored independently by three industrial hygienists unaware of case/control status, Significantly increased risk of CRF were found for exposure to lead (odds ratio 2.11 [95% CI 1.23-4.36]), copper (2.54 [1.16-5.53]), chromium (2.77 [1.21-6.33]), tin (3.72 [1.22-11.3]), mercury (5.13 [1.02-25.7]), welding fumes (2.06 [1.05-4.04]), silicon-containing compounds (2.51 [1.37-4.60]), grain dust (2.96 [1.24-7.04]), and oxygenated hydrocarbons (5.45 [1.84-16.2]). The frequencies of various occupational exposures were high among patients with diabetic nephropathy. This epidemiological study confirms previously identified risk factors and suggests that additional occupational exposures, for which there is some other experimental evidence, may be important in the development of CRF. The role of grain dust and the association between occupational exposure and diabetic nephropathy merit further investigation.	UNIV ANTWERP HOSP,DEPT NEPHROL HYPERTENS,B-2650 EDEGEM,BELGIUM; OPEL BELGIUM NV,ANTWERP,BELGIUM; APRIM,ANTWERP,BELGIUM; BRUSSELS NATL AIRPORT,SABENA SAFETY,BRUSSELS,BELGIUM	University of Antwerp			D'Haese, Patrick C/C-9599-2019	Elseviers, Monique/0000-0001-9415-6900				BOMBASSEI GJ, 1992, AM J IND MED, V21, P141, DOI 10.1002/ajim.4700210204; BROCKHAUS A, 1983, INT ARCH OCC ENV HEA, V52, P167, DOI 10.1007/BF00405420; BROWN WD, 1987, J OCCUP ENVIRON MED, V29, P877; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; DECASTO M, 1994, SCHWEIZ ARCH TIERH, V136, P111; DHAESE PC, 1991, CLIN CHEM, V37, P1583; DIEPERINK HH, 1991, TOXICOL LETT, V46, P257; DIEPERINK HH, 1991, TOXICOL LETT, V46, P1; ELSEVIERS MM, 1987, LANCET, V1, P457; EPSTEIN E, 1994, P NATL ACAD SCI USA, V96, P11; GEERLINGS W, 1991, NEPHROL DIAL TRANSPL, V6, P5; GOLDSMITH JR, 1993, AM J IND MED, V23, P873, DOI 10.1002/ajim.4700230605; HEBERT CD, 1993, FUND APPL TOXICOL, V21, P461, DOI 10.1006/faat.1993.1122; KIDO T, 1990, ARCH ENVIRON HEALTH, V45, P35, DOI 10.1080/00039896.1990.9935922; LINDER MC, 1985, NUTRITIONAL BIOCH ME, P246; NELSON NA, 1990, AM J NEPHROL, V10, P10, DOI 10.1159/000168048; NUYTS GD, 1991, NEPHROL DIAL TRANSPL, V6, P307, DOI 10.1093/ndt/6.5.307; NUYTS GD, 1993, J OCCUP ENVIRON MED, V35, P387; NUYTS GD, IN PRESS NEPHROL DIA; NYE L. J. J., 1929, Medical Journal of Australia, V2, P145; OSORIO AM, 1987, AM J KIDNEY DIS, V9, P224, DOI 10.1016/S0272-6386(87)80059-8; PORRO A, 1992, BRIT J IND MED, V49, P738; ROELS H, 1993, BRIT J IND MED, V50, P37; ROELS HA, 1989, BRIT J IND MED, V46, P755; SCHUTZ A, 1987, ARCH ENVIRON HEALTH, V42, P340, DOI 10.1080/00039896.1987.9934356; SPEIZER FE, HARRISONS PRINCIPLES, P1167; STEENLAND NK, 1990, AM J PUBLIC HEALTH, V80, P153, DOI 10.2105/AJPH.80.2.153; STENGEL B, 1992, DEC INT S PATH PATH, P24; VANDEVYVER FL, 1988, KIDNEY INT, V33, P601, DOI 10.1038/ki.1988.39; WANG XR, 1994, TOXICOLOGY, V90, P93, DOI 10.1016/0300-483X(94)90208-9; YAQOOB M, IN PRESS DIABETIC ME	31	73	76	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					7	11		10.1016/S0140-6736(95)92648-8	http://dx.doi.org/10.1016/S0140-6736(95)92648-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603180				2022-12-28	WOS:A1995RF98500006
J	WRIGHT, CJ; MUELLER, CB				WRIGHT, CJ; MUELLER, CB			SCREENING MAMMOGRAPHY AND PUBLIC-HEALTH POLICY - THE NEED FOR PERSPECTIVE	LANCET			English	Article							BREAST-CANCER DETECTION; CARCINOMA INSITU; DEATH RATES; FOLLOW-UP; MORTALITY; TRIAL; WOMEN; DURATION; GROWTH	The early trials of screening mammography, reporting 30% relative reduction in mortality from breast cancer in women over 50 years of age, led to strong professional and public demand for screening programmes. There has been little publicity about the subsequent trials showing no Significant benefit in any age group, or about the harm and costs associated with screening mammography, For women under 50, there is a reluctant consensus that screening is not beneficial, but there is increasing pressure for publicly funded programmes for older women. When analysed in terms of population benefit, the randomised controlled prospective trials showed that the numbers of women screened to achieve one less death per year ranged from 7086 (Health Insurance Plan of New York), to 63 264 (Malmo), to infinity (Canadian National Breast Screening Study). About 5% of screening mammograms are positive or suspicious, and of these 80-93% are false positives that cause much unnecessary anxiety and further procedures including surgery. False reassurance by negative mammography occurs in 10-15% of women with breast cancer that will manifest clinically within a year. Our calculations confirm others that the mean annual cost per life ''saved'' is around $1.2 million (pound 558 000). In the allocation of limited resources, public health policy on a proposed mass population intervention must be based on a critical analysis of benefits, harm, and cost. Since the benefit achieved is marginal, the harm caused is substantial, and the costs incurred are enormous, we suggest that public funding for breast cancer screening in any age group is not justifiable.	UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER,BC V6T 1W5,CANADA; MCMASTER UNIV,DEPT SURG,HAMILTON,ON L8S 4L8,CANADA	University of British Columbia; McMaster University								ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAINES CJ, 1988, J CAN ASSOC RADIOL, V39, P273; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; ELWOOD JM, 1993, ONLINE J CURR C 0225; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MUELLER CB, 1994, AM J CLIN ONCOL-CANC, V17, P86; MUELLER CB, 1975, ANN SURG, V182, P334, DOI 10.1097/00000658-197509000-00016; NORTON LW, 1988, ARCH SURG-CHICAGO, V123, P947; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; ROBERTS MM, 1990, LANCET, V335, P241; ROSEN PP, 1978, AM J SURG PATHOL, V2, P225, DOI 10.1097/00000478-197809000-00001; SCHMIDT JG, 1990, J CLIN EPIDEMIOL, V43, P215, DOI 10.1016/0895-4356(90)90002-7; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SHAPIRO S, 1989, CANCER, V63, P1873, DOI 10.1002/1097-0142(19890515)63:10<1873::AID-CNCR2820631002>3.0.CO;2-6; SKRABANEK P, 1985, LANCET, V2, P316; SPRATT JA, 1993, CANCER-AM CANCER SOC, V71, P2020, DOI 10.1002/1097-0142(19930315)71:6<2020::AID-CNCR2820710616>3.0.CO;2-#; SPRATT JS, 1986, CANCER RES, V46, P970; STRAX P, 1989, CANCER, V63, P1881, DOI 10.1002/1097-0142(19890515)63:10<1881::AID-CNCR2820631003>3.0.CO;2-8; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; WRIGHT CJ, 1986, SURGERY, V100, P594; 1986, PAMPHLET 86 30 MM NO	27	71	72	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					29	32		10.1016/S0140-6736(95)92655-0	http://dx.doi.org/10.1016/S0140-6736(95)92655-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603143				2022-12-28	WOS:A1995RF98500013
J	PALOMBO, F; GALLINARI, P; IACCARINO, I; LETTIERI, T; HUGHES, M; DARRIGO, A; TRUONG, O; HSUAN, JJ; JIRICNY, J				PALOMBO, F; GALLINARI, P; IACCARINO, I; LETTIERI, T; HUGHES, M; DARRIGO, A; TRUONG, O; HSUAN, JJ; JIRICNY, J			GTBP, A 160-KILODALTON PROTEIN ESSENTIAL FOR MISMATCH-BINDING ACTIVITY IN HUMAN-CELLS	SCIENCE			English	Article							COLORECTAL-CANCER; GENE; MUTATIONS; CLONING; HOMOLOG; COLON	DNA mismatch recognition and binding in human cells has been thought to be mediated by the hMSH2 protein. Here it is shown that the mismatch-binding factor consists of two distinct proteins, the 100-kilodalton hMSH2 and a 160-kilodalton polypeptide, GTBP (for G/T binding protein). Sequence analysis identified GTBP as a new member of the MutS homolog family. Both proteins are required for mismatch-specific binding, a result consistent with the finding that tumor-derived cell lines devoid of either protein are also devoid of mismatch-binding activity.	IST RIC BIOL MOLEC P ANGELETTI, I-00040 POMEZIA, ITALY; UCL, SCH MED, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School			Hsuan, Justin/C-8825-2009; Iaccarino, Ingram/B-9086-2015; Gallinari, Paola/ABE-8238-2021	Hsuan, Justin/0000-0001-6083-7564; Iaccarino, Ingram/0000-0001-7324-993X; Palombo, Fabio/0000-0003-0473-4901; Lettieri, Teresa/0000-0002-3363-9666				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; AQUILINA G, 1994, P NATL ACAD SCI USA, V91, P8905, DOI 10.1073/pnas.91.19.8905; CHI NW, 1994, J BIOL CHEM, V269, P29984; COSTA LT, 1995, NAT GENET, V9, P10; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUJII H, 1989, J BIOL CHEM, V264, P10057; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; KAWASAKI H, 1990, ANAL BIOCHEM, V186, P264, DOI 10.1016/0003-2697(90)90077-M; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOUS N, SCIENCE, V268, P1915; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; UMAR A, 1994, J BIOL CHEM, V269, P14367; VOGELSTEIN B, COMMUNICATION; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	30	481	489	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1912	1914		10.1126/science.7604265	http://dx.doi.org/10.1126/science.7604265			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604265				2022-12-28	WOS:A1995RF99000042
J	TAUBES, G				TAUBES, G			MCGILL - ANALYZING THE DATA	SCIENCE			English	Note																			0	2	2	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1714	1714		10.1126/science.7605516	http://dx.doi.org/10.1126/science.7605516			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7605516				2022-12-28	WOS:A1995RE66800029
J	VANDERVLEUTEN, CPM; NEWBLE, DI				VANDERVLEUTEN, CPM; NEWBLE, DI			HOW CAN WE TEST CLINICAL REASONING	LANCET			English	Article									UNIV ADELAIDE,DEPT MED,ADELAIDE,SA 5001,AUSTRALIA	University of Adelaide	VANDERVLEUTEN, CPM (corresponding author), UNIV LIMBURG,DEPT EDUC DEV & RES,POB 616,6200 MD MAASTRICHT,NETHERLANDS.							Bordage G., 1987, FURTHER DEV ASSESSIN, P59; Council GM, 1993, TOMORROWS DOCTORS RE; Elstein AS, 1978, MED PROBLEM SOLVING; FELETTI GI, 1983, LANCET, V2, P34; Hodgkin K, 1975, PROBLEM CTR LEARNING; MCGUIRE C, 1987, FURTHER DEV ASSESSIN, P46; MCGUIRE CH, 1967, J EDUC MEAS, V4, P1, DOI 10.1111/j.1745-3984.1967.tb00562.x; Newble D, 1994, TEACH LEARN MED, V6, P213; NEWBLE DI, 1983, MED EDUC, V17, P165, DOI 10.1111/j.1365-2923.1983.tb00657.x; NEWBLE DI, IN PRESS CLIN REASON; NORCINI JJ, 1986, EVAL HEALTH PROF, V9, P286, DOI 10.1177/016327878600900302; NORMAN G, 1994, IN PRESS 6TH P OTT C; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; SWANSON D, 1987, ASSESS EVAL HIGH EDU, V12, P220, DOI DOI 10.1080/0260293870120307; Van der Vleuten C, 1994, CERTIFICATION RECERT, P105; 1984, REPORT PANEL GENERAL	16	64	64	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1032	1034		10.1016/S0140-6736(95)90763-7	http://dx.doi.org/10.1016/S0140-6736(95)90763-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7605439				2022-12-28	WOS:A1995QU57300015
J	DEVORE, DL; HORVITZ, HR; STERN, MJ				DEVORE, DL; HORVITZ, HR; STERN, MJ			AN FGF RECEPTOR SIGNALING PATHWAY IS REQUIRED FOR THE NORMAL-CELL MIGRATIONS OF THE SEX MYOBLASTS IN C-ELEGANS HERMAPHRODITES	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; CAENORHABDITIS-ELEGANS; VULVAR INDUCTION; POINT MUTATION; GENE SEM-5; MESODERM; PROTEIN; MITOGENESIS; NEMATODE; ENCODES	The sex myoblasts (SMs) in C. elegans hermaphrodites undergo anteriorly directed cell migrations that allow for the proper localization of the egg-laying muscles. These migrations are controlled in part by a signal emanating from gonadal cells that allows the SMs to be attracted to their precise final positions flanking the center of the go nad. Mutations in egl-15 alter the nature of the interaction between the gonad and the SMs, resulting in the posterior displacement of the SMs. Here we show that egl-15 encodes a receptor tyrosine kinase of the fibroblast growth factor receptor (FGFR) subfamily with multiple roles in development. Three genes were identified that behave genetically as activators or mediators of egl-15 activity. One of these genes, sem-5, encodes an adaptor molecule that transduces signals from a variety of receptor tyrosine kinases. Like egl-15 and sem-5, the other two genes may similarly act in FGFR signaling pathways in C, elegans.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	DEVORE, DL (corresponding author), YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06520, USA.							ADNANE J, 1991, ONCOGENE, V6, P659; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AROIAN RV, 1991, GENETICS, V128, P251; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLIFFORD RJ, 1989, GENETICS, V123, P771; CORNELL RA, 1994, DEVELOPMENT, V120, P453; CORNELL RA, 1995, DEVELOPMENT, V121, P2429; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Fodor A., 1985, Journal of Genetics, V64, P143, DOI 10.1007/BF02931143; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERMAN RK, 1988, NEMATODE CAENORHABDI, P17; HODGKIN J, 1979, GENETICS, V91, P67; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LABONNE C, 1994, DEVELOPMENT, V120, P463; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSBAUM C, 1989, GENETICS, V122, P579; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J, 1989, MOL CLONING LABORATO; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; STERN MJ, 1991, DEVELOPMENT, V113, P797; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Wood WB, 1988, NEMATODE CAENORHABDI	43	147	156	3	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					611	620		10.1016/0092-8674(95)90101-9	http://dx.doi.org/10.1016/0092-8674(95)90101-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585964	hybrid			2022-12-28	WOS:A1995TF24800014
J	RYAN, KR; JENSEN, RE				RYAN, KR; JENSEN, RE			PROTEIN TRANSLOCATION ACROSS MITOCHONDRIAL-MEMBRANES - WHAT A LONG, STRANGE TRIP IT IS	CELL			English	Review											RYAN, KR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.							ALAM R, 1994, J BIOCHEM-TOKYO, V116, P416, DOI 10.1093/oxfordjournals.jbchem.a124541; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LOHRET TA, 1995, J BIOL CHEM, V270, P15950, DOI 10.1074/jbc.270.27.15950; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1993, J BIOL CHEM, V268, P23743; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708	15	118	119	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					517	519		10.1016/0092-8674(95)90089-6	http://dx.doi.org/10.1016/0092-8674(95)90089-6			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585952	Bronze			2022-12-28	WOS:A1995TF24800002
J	DROSSMAN, DA; TALLEY, NJ; LESERMAN, J; OLDEN, KW; BARREIRO, MA				DROSSMAN, DA; TALLEY, NJ; LESERMAN, J; OLDEN, KW; BARREIRO, MA			SEXUAL AND PHYSICAL ABUSE AND GASTROINTESTINAL ILLNESS - REVIEW AND RECOMMENDATIONS	ANNALS OF INTERNAL MEDICINE			English	Review							IRRITABLE-BOWEL-SYNDROME; CHRONIC PELVIC PAIN; MEDICAL PROBLEMS; PSYCHIATRIC DIAGNOSES; ANOREXIA-NERVOSA; NATIONAL SAMPLE; HEALTH RISK; LIFE EVENTS; CHILDHOOD; WOMEN	Objectives: To summarize the existing data on abuse history and gastrointestinal illness, suggest a conceptual scheme to explain these associations, suggest ways to identify patients at risk, and provide information about mental health referral. Data Sources: Review of the pertinent literature by clinicians and investigators at referral centers who are involved in the care of patients with complex gastrointestinal illness and who have experience in the diagnosis and care of patients with abuse history in these settings. Study Selection: All research articles and observational data that addressed abuse history in gastroenterologic settings. Articles were identified through a MEDLINE search. Data Extraction: independent extraction by multiple observers. Data Synthesis: On the basis of literature review and consensus, it was determined that abuse history is associated with gastrointestinal illness and psychological disturbance; appears more often among women, patients with functional gastrointestinaI disorders, and patients seen in referral settings; is not usually known by the physician; and is associated with poorer adjustment to illness and adverse health outcome. Although the mechanisms for this association are unknown, psychological factors (somatization, response bias, reinforcement of abnormal illness behavior) and physiologic factors (psychophysiologic response, enhanced visceral sensitivity) probably contribute. On the basis of these data, recommendations are made on how to identify patients at risk, how to obtain this information, and, if needed, how to make appropriate referrals. Conclusions: The authors agree with existing data on the association between abuse history and gastrointestinal illness. Physicians should ask patients with severe or refractory illness about abuse history. Appropriate referral to a mental health professional may improve the clinical outcome.	UNITED MED ASSOCIATES, BINGHAMTON, NY 13903 USA; UNIV SYDNEY, SYDNEY, NSW 2006, AUSTRALIA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of Sydney; University of California System; University of California San Francisco	DROSSMAN, DA (corresponding author), UNIV N CAROLINA, DIV DIGEST DIS, 420 BURNETT WOMACK BLDG, CB 7080, CHAPEL HILL, NC 27599 USA.		Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092				ALMY TP, 1949, GASTROENTEROLOGY, V12, P425, DOI 10.1016/S0016-5085(49)80125-9; ALMY TP, 1951, AM J MED, V10, P60, DOI 10.1016/0002-9343(51)90219-7; ARNOLD RP, 1990, BRIT MED J, V300, P705, DOI 10.1136/bmj.300.6726.705; BACHMANN GA, 1988, OBSTET GYNECOL, V71, P631; BADGLEY R, 1984, SEXUAL OFFENCES CHIL, V1, P175; BAGLEY C, 1985, SOCIAL WORK PRACTICE, V4, P33; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Berkman L. F., 1985, SOCIAL SUPPORT HLTH, P241; BHARUCHA AE, 1993, GUT, V34, P397, DOI 10.1136/gut.34.3.397; BRAUN BG, 1990, AM J OCCUP THER, V44, P971, DOI 10.5014/ajot.44.11.971; BRIERE J, 1988, CHILD ABUSE NEGLECT, V12, P51, DOI 10.1016/0145-2134(88)90007-5; BRIERE J, 1988, CHILD ABUSE NEGLECT, V12, P331, DOI 10.1016/0145-2134(88)90046-4; BRIERE J, 1992, MAYO CLIN PROC, V67, P603, DOI 10.1016/S0025-6196(12)60471-6; BROWN HN, 1982, AM J PSYCHIAT, V139, P1576; BRYER JB, 1987, AM J PSYCHIAT, V144, P1426; CERVERO F, 1992, TRENDS NEUROSCI, V15, P374, DOI 10.1016/0166-2236(92)90182-8; CREED F, 1985, J PSYCHOSOM RES, V29, P113, DOI 10.1016/0022-3999(85)90032-7; DAHLSTROM WG, 1972, MMPI HDB REVISES; DARKE LL, 1988, AM PAIN SOC M, P149; Derogatis LR, 1983, ADM SCORING PROCEDUR; DEVROEDE G, 1990, MED ASPECTS HUMAN SE, V24, P40; DOMINO JV, 1987, HEADACHE, V27, P310, DOI 10.1111/j.1526-4610.1987.hed2706310.x; Drossman D A, 1994, Gastroenterologist, V2, P315; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DROSSMAN DA, 1994, AM J MED, V97, P105, DOI 10.1016/0002-9343(94)90019-1; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; DROSSMAN DA, 1978, ANN INTERN MED, V88, P366, DOI 10.7326/0003-4819-88-3-366; DROSSMAN DA, 1995, SCAND J GASTROENTERO, V30, P90, DOI 10.3109/00365529509107768; DROSSMAN DA, 1994, AM J GASTROENTEROL, V89, P1441; DROSSMAN DA, 1982, GASTROENTEROLOGY, V83, P529; DROSSMAN DA, 1991, GASTROENTEROLOGY INT, V4, P77; DROSSMAN DA, 1995, TXB GASTROENTEROLOGY; ENGEL GL, 1959, AM J MED, V26, P899, DOI 10.1016/0002-9343(59)90212-8; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; FELICE M, 1978, CLIN PEDIATR, V17, P311, DOI 10.1177/000992287801700401; FELITTI VJ, 1991, SOUTHERN MED J, V84, P328, DOI 10.1097/00007611-199103000-00008; FRY R, 1993, J PSYCHOSOM RES, V37, P89, DOI 10.1016/0022-3999(93)90075-Q; GARNER DM, 1979, PSYCHOL MED, V9, P273, DOI 10.1017/S0033291700030762; GELINAS DJ, 1983, PSYCHIATRY, V46, P312, DOI 10.1080/00332747.1983.11024207; GEORGE LK, 1992, J SOC ISSUES, V48, P105, DOI 10.1111/j.1540-4560.1992.tb01160.x; GROVES JE, 1978, NEW ENGL J MED, V298, P883, DOI 10.1056/NEJM197804202981605; HALL RCW, 1989, PSYCHOSOMATICS, V30, P73, DOI 10.1016/S0033-3182(89)72320-3; HARROPGRIFFITHS J, 1988, OBSTET GYNECOL, V71, P589; HUTCHINGS PS, 1993, COMMUNITY MENT HLT J, V29, P59, DOI 10.1007/BF00760631; JACOBSON A, 1987, AM J PSYCHIAT, V144, P908; JOACHIM G, 1987, J ADV NURS, V12, P483, DOI 10.1111/j.1365-2648.1987.tb01357.x; KOSS MP, 1985, J CONSULT CLIN PSYCH, V53, P422, DOI 10.1037/0022-006X.53.3.422; KOSS MP, 1987, J CONSULT CLIN PSYCH, V55, P162, DOI 10.1037/0022-006X.55.2.162; KOSS MP, 1990, J CONSULT CLIN PSYCH, V58, P147, DOI 10.1037/0022-006X.58.2.147; KOSS MP, 1989, J CONSULT CLIN PSYCH, V57, P242, DOI 10.1037/0022-006X.57.2.242; LAWS A, 1993, J GEN INTERN MED, V8, P441, DOI 10.1007/BF02599622; LAWS A, 1993, J WOMENS HEALTH, V2, P165; Lazarus R. S., 1984, STRESS APPRAISAL COP, DOI 10.1007/978-1-4419-1005-9_215; LECHNER ME, 1993, J FAM PRACTICE, V36, P633; LEROI AM, 1993, GASTROENTEROLOGY, V104, pA1047; LESERMAN J, 1995, IN PRESS BEHAVIORAL; LEVENTHAL JM, 1988, PEDIATRICS, V82, P766; LEVINSON W, 1993, MED CARE, V31, P285, DOI 10.1097/00005650-199304000-00001; LINDBERG FH, 1985, CHILD ABUSE NEGLECT, V9, P329, DOI 10.1016/0145-2134(85)90028-6; LOEWENSTEIN RJ, 1990, INCEST RELATED SYNDR, P75; LONGSTRETH GF, 1993, DIGEST DIS SCI, V38, P1581, DOI 10.1007/BF01303163; LOWMAN BC, 1987, J CLIN GASTROENTEROL, V9, P324, DOI 10.1097/00004836-198706000-00017; LYDIARD RB, 1993, PSYCHOSOMATICS, V34, P229, DOI 10.1016/S0033-3182(93)71884-8; MAYER EA, 1994, GASTROENTEROLOGY, V107, P271, DOI 10.1016/0016-5085(94)90086-8; Miller B A, 1987, Violence Vict, V2, P157; MORRISON J, 1989, AM J PSYCHIAT, V146, P239; NESS TJ, 1990, PAIN, V43, P377, DOI 10.1016/0304-3959(90)90035-C; Peters S.D., 1986, SOURCEBOOK CHILD SEX, P15; PILOWSKY I, 1978, BRIT J MED PSYCHOL, V51, P131, DOI 10.1111/j.2044-8341.1978.tb02457.x; PILOWSKY I, 1990, PAIN, V40, P3, DOI 10.1016/0304-3959(90)91045-K; REITER RC, 1991, AM J OBSTET GYNECOL, V165, P104, DOI 10.1016/0002-9378(91)90235-J; RESNICK HS, 1993, J CONSULT CLIN PSYCH, V61, P984, DOI 10.1037/0022-006X.61.6.984; RIMSZA ME, 1988, CHILD ABUSE NEGLECT, V12, P201, DOI 10.1016/0145-2134(88)90028-2; ROHSENOW DJ, 1988, J SUBST ABUSE TREAT, V5, P13, DOI 10.1016/0740-5472(88)90032-3; Russell D E, 1983, Child Abuse Negl, V7, P133, DOI 10.1016/0145-2134(83)90065-0; SCARINCI IC, 1994, AM J MED, V97, P108, DOI 10.1016/0002-9343(94)90020-5; SHEEHAN DV, 1989, DIAGNOSIS TREATMENT, P98; SHELDON H, 1988, BRIT J PSYCHIAT, V152, P107, DOI 10.1192/bjp.152.1.107; SIEGEL JM, 1987, AM J EPIDEMIOL, V126, P1141, DOI 10.1093/oxfordjournals.aje.a114752; Spielberger C. D., 1973, MANUAL STATE TRAIT I; SPRINGS FE, 1992, MAYO CLIN PROC, V67, P527, DOI 10.1016/S0025-6196(12)60458-3; STEIN JA, 1988, LASTING EFFECTS CHIL, P135; TALLEY NJ, 1994, GASTROENTEROLOGY, V107, P1040, DOI 10.1016/0016-5085(94)90228-3; TALLEY NJ, 1992, GASTROENTEROLOGY, V102, pA52; TONER BB, 1992, INT J PSYCHIAT MED, V22, P99, DOI 10.2190/ENP4-2PDW-A83P-PPA3; WALKER E, 1988, AM J PSYCHIAT, V145, P75; WALKER EA, 1992, AM J MED, V92, pS26, DOI 10.1016/0002-9343(92)90133-V; WALKER EA, 1993, AM J PSYCHIAT, V150, P1502; WALKER EA, 1992, PSYCHOSOM MED, V54, P658, DOI 10.1097/00006842-199211000-00005; WELGAN P, 1988, GASTROENTEROLOGY, V94, P1150, DOI 10.1016/0016-5085(88)90006-6; WHITEHEAD WE, 1982, DIGEST DIS SCI, V27, P202, DOI 10.1007/BF01296915; WHITEHEAD WE, 1992, GUT, V33, P825, DOI 10.1136/gut.33.6.825; WILLIS WD, 1993, APS J, V2, P23; WURTELE SK, 1990, CLIN J PAIN, V6, P110; WYATT GE, 1986, CHILD ABUSE NEGLECT, V10, P241, DOI 10.1016/0145-2134(86)90085-2; 1994, DIAGNOSTIC STATISTIC, P1	96	319	323	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1995	123	10					782	794		10.7326/0003-4819-123-10-199511150-00007	http://dx.doi.org/10.7326/0003-4819-123-10-199511150-00007			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TE172	7574197				2022-12-28	WOS:A1995TE17200007
J	BUTLER, VP; ODEL, JG; RATH, E; WOLIN, MJ; BEHRENS, MM; MARTIN, TJ; KARDON, RH; GOURAS, P				BUTLER, VP; ODEL, JG; RATH, E; WOLIN, MJ; BEHRENS, MM; MARTIN, TJ; KARDON, RH; GOURAS, P			DIGITALIS-INDUCED VISUAL DISTURBANCES WITH THERAPEUTIC SERUM DIGITALIS CONCENTRATIONS	ANNALS OF INTERNAL MEDICINE			English	Note							RAT RETINA; DIGOXIN; INTOXICATION; LOCALIZATION; DEGENERATION; CELLS	Objective: To assess the role of digitalis in the development of visual symptoms severe enough to warrant ophthalmologic consultation in patients who received digitalis and who had no other clinical or laboratory evidence of digitalis toxicity. Design: Clinical case study. Setting: Neuro-ophthalmology referral practice. Patients: Six elderly patients (aged 66 to 85 years) who received digitalis were referred to ophthalmologists for evaluation of photopsia (five patients) or decreased visual acuity (one patient). No patient had chromatopsia or nonvisual clinical manifestations of digitalis intoxication at the time of examination. Measurements: All patients had serum digitalis concentrations within or below the therapeutic range. In most patients, the electroretinographic cone b-wave implicit time was longer than normal. Results: Discontinuation of digitalis therapy, which was possible in five patients, was followed by resolution of visual symptoms and by shortening of the b-wave implicit time. Characteristic features of digitalis-induced photopsia were its dependence on illumination and its tendency to be localized in peripheral visual fields. Conclusions: In an elderly patient receiving digitalis, the development of photopsia characterized by innumerable points of light in the peripheral visual fields or a decrease in visual acuity raises the possibility that the patient's visual disturbance may have been digitalis induced. Digitalis-induced visual disturbances other than chromatopsia or disturbances of color vision may occur in elderly patients who have no other clinical manifestations of digitalis intoxication and who have a serum digitalis concentration within or below the therapeutic range.	UNIV IOWA, DEPT OPHTHALMOL, IOWA CITY, IA 52242 USA; COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA; VET AFFAIRS HOSP, IOWA CITY, IA USA	University of Iowa; Columbia University; NewYork-Presbyterian Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System				Kardon, Randy/0000-0002-3173-7123	NEI NIH HHS [R01 EY 04138-10] Funding Source: Medline; NHLBI NIH HHS [R01 HL 10608-27] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004138] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL010608] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURKE JM, 1993, EXP EYE RES, V57, P51, DOI 10.1006/exer.1993.1098; BUTLER V P JR, 1972, Progress in Cardiovascular Diseases, V14, P571, DOI 10.1016/0033-0620(72)90009-6; CARROLL FD, 1945, AM J OPHTHALMOL, V28, P373, DOI 10.1016/0002-9394(45)90940-8; DENDEN A, 1962, GRAEFE ARCH OPHTHAL, V165, P185; DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691; FISHER CM, 1981, NEUROLOGY, V31, P1569, DOI 10.1212/WNL.31.12.1569; GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23; GIBSON HC, 1965, ARCH OPHTHALMOL-CHIC, V74, P154, DOI 10.1001/archopht.1965.00970040156004; GILLETTE DF, 1946, T AM OPHTHAL SOC, V44, P156; GOURAS P, 1989, INVEST OPHTH VIS SCI, V30, P619; HOFFMAN B F, 1990, P814; LEAHEY EB, 1978, JAMA-J AM MED ASSOC, V240, P533, DOI 10.1001/jama.240.6.533; LELY AH, 1970, BRIT MED J, V3, P737, DOI 10.1136/bmj.3.5725.737; MADREPERLA SA, 1994, ARCH OPHTHALMOL-CHIC, V112, P807, DOI 10.1001/archopht.1994.01090180105044; MASSARO FJ, 1983, DRUG INTEL CLIN PHAR, V17, P368, DOI 10.1177/106002808301700509; MCGRAIL KM, 1986, J NEUROSCI, V6, P1272; MCGRAIL KM, 1990, EUR J NEUROSCI, V2, P170, DOI 10.1111/j.1460-9568.1990.tb00409.x; Moore C E, 1973, Aust J Ophthalmol, V1, P76, DOI 10.1111/j.1442-9071.1973.tb01413.x; OAKLEY B, 1992, EXP EYE RES, V55, P539, DOI 10.1016/S0014-4835(05)80166-6; REICHENBACH A, 1992, CAN J PHYSIOL PHARM, V70, pS239, DOI 10.1139/y92-267; ROBERTSON DM, 1966, ARCH OPHTHALMOL-CHIC, V76, P640, DOI 10.1001/archopht.1966.03850010642004; ROBERTSON DM, 1966, ARCH OPHTHALMOL-CHIC, V76, P852; SMITH TW, 1972, CIRCULATION, V46, P188; SMITH TW, 1970, J CLIN INVEST, V49, P2377, DOI 10.1172/JCI106457; Sprague HB, 1925, J AMER MED ASSOC, V85, P716, DOI 10.1001/jama.1925.02670100004002; STAHL WL, 1984, J HISTOCHEM CYTOCHEM, V32, P248, DOI 10.1177/32.2.6319483; WAGENER HP, 1946, ARCH OPHTHALMOL-CHIC, V36, P478, DOI 10.1001/archopht.1946.00890210486003; WELEBER RG, 1981, ARCH OPHTHALMOL-CHIC, V99, P1568, DOI 10.1001/archopht.1981.03930020442007; WHITE PD, 1965, NEW ENGL J MED, V272, P904, DOI 10.1056/NEJM196504292721709; Withering W, 1785, ACCOUNT FOXGLOVE SOM	30	21	21	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					676	680		10.7326/0003-4819-123-9-199511010-00006	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574223				2022-12-28	WOS:A1995TA69600006
J	SAKSELA, K; STEVENS, CE; RUBINSTEIN, P; TAYLOR, PE; BALTIMORE, D				SAKSELA, K; STEVENS, CE; RUBINSTEIN, P; TAYLOR, PE; BALTIMORE, D			HIV-1 MESSENGER-RNA IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS AS AN EARLY MARKER OF RISK FOR PROGRESSION TO AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; RNA, MESSENGER; LEUKOCYTES, MONONUCLEAR; BIOLOGICAL MARKER	HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 LYMPHOCYTE COUNTS; ANTIGEN CAPTURE ASSAY; NEW-YORK-CITY; HOMOSEXUAL MEN; TYPE-1 INFECTION; VIRAL BURDEN; SERUM BETA-2-MICROGLOBULIN; DISEASE PROGRESSION; PROGNOSTIC VALUE	Objective: To establish human immunodeficiency virus type 1 (HIV-1) messenger RNA (mRNA) expression in peripheral blood mononuclear cells as a marker of risk for progression to the acquired immunodeficiency syndrome (AIDS) in a large cohort of HIV-infected persons followed for a prolonged period. Design: Retrospective testing of cryopreserved, coded specimens. Setting: Research laboratories at the New York Blood Center and the Rockefeller University. Patients: 150 homosexual men infected with HIV-I who did not have an AIDS diagnosis at the time of testing. Measurements: Multiply spliced and unspliced HIV-I mRNAs in total peripheral blood mononuclear cell RNA were quantitated using reverse transcriptase-initiated polymerase chain reaction (PCR) and compared with other laboratory data and clinical outcome during the subsequent 8 years. Results: Although HIV-1 mRNA expression generally correlated with immunologic status, it was associated with future disease progression independently of CD4(+) cell counts or their rate of decrease at the time of sampling. The association of HIV-1 mRNA with disease progression in persons with CD4(+) cell counts higher than the median (>624 cells/mm(3)) was particularly noteworthy; further variation in the CD4(+) cell counts within this group was not prognostically significant. Conclusions: The expression of HIV-1 mRNA in peripheral blood mononuclear cells is a strong independent marker for future HIV disease progression, even in persons with normal T-cell subsets.	NEW YORK BLOOD CTR, NEW YORK, NY 10021 USA; MIT, CAMBRIDGE, MA 02139 USA	New York Blood Center; Massachusetts Institute of Technology (MIT)	SAKSELA, K (corresponding author), ROCKEFELLER UNIV, BOX 285, 1230 YORK AVE, NEW YORK, NY 10021 USA.				PHS HHS [A122346] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLAIN JP, 1987, NEW ENGL J MED, V317, P1114, DOI 10.1056/NEJM198710293171804; ASCHER DP, 1992, J ACQ IMMUN DEF SYND, V5, P1080; ASJO B, 1986, LANCET, V2, P660; BAGNARELLI P, 1994, J VIROL, V68, P2495, DOI 10.1128/JVI.68.4.2495-2502.1994; BAGNARELLI P, 1992, J VIROL, V66, P7328, DOI 10.1128/JVI.66.12.7328-7335.1992; BRIGGS NC, 1993, AIDS RES HUM RETROV, V9, P811, DOI 10.1089/aid.1993.9.811; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; Cox D. R., 1984, ANAL SURVIVAL DATA; DAILEY PJ, 1994, 34TH INT C ANT AG CH; DETELS R, 1988, J ACQ IMMUN DEF SYND, V1, P390; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FERRE F, 1992, AIDS RES HUM RETROV, V8, P269, DOI 10.1089/aid.1992.8.269; FURTADO MR, 1995, J VIROL, V69, P2092, DOI 10.1128/JVI.69.4.2092-2100.1995; GODFRIED MH, 1994, J INFECT DIS, V169, P739, DOI 10.1093/infdis/169.4.739; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GUPTA P, 1993, VIROLOGY, V196, P586, DOI 10.1006/viro.1993.1514; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOFMANN B, 1990, AIDS, V4, P207, DOI 10.1097/00002030-199003000-00005; HOGERVORST E, 1995, J INFECT DIS, V171, P811, DOI 10.1093/infdis/171.4.811; HOLODNIY M, 1991, J INFECT DIS, V163, P862, DOI 10.1093/infdis/163.4.862; HOOVER DR, 1992, J ACQ IMMUN DEF SYND, V5, P794; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOBLIN BA, 1992, AM J EPIDEMIOL, V136, P646, DOI 10.1093/oxfordjournals.aje.a116544; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KRAMER A, 1990, NEW ENGL J MED, V322, P1886; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LEFRERE JJ, 1992, BRIT J HAEMATOL, V82, P467, DOI 10.1111/j.1365-2141.1992.tb06446.x; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LIFSON AR, 1992, LANCET, V339, P1436, DOI 10.1016/0140-6736(92)92030-J; LU W, 1993, J INFECT DIS, V168, P1165, DOI 10.1093/infdis/168.5.1165; MACDONELL KB, 1990, AM J MED, V89, P706, DOI 10.1016/0002-9343(90)90210-5; MATHEZ D, 1990, P NATL ACAD SCI USA, V87, P7438, DOI 10.1073/pnas.87.19.7438; MCNEARNEY T, 1992, P NATL ACAD SCI USA, V89, P10247, DOI 10.1073/pnas.89.21.10247; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MELMED RN, 1989, J ACQ IMMUN DEF SYND, V2, P70; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MICHAEL NL, 1995, J VIROL, V69, P1868, DOI 10.1128/JVI.69.3.1868-1877.1995; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MULDER JW, 1992, J INFECT DIS, V165, P413, DOI 10.1093/infdis/165.3.413; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PHILLIPS AN, 1991, LANCET, V337, P389; PHILLIPS AN, 1993, AIDS, V7, P975, DOI 10.1097/00002030-199307000-00011; PHILLIPS AN, 1991, AIDS, V5, P1217, DOI 10.1097/00002030-199110000-00010; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; SABIN CA, 1994, BRIT J HAEMATOL, V86, P366, DOI 10.1111/j.1365-2141.1994.tb04741.x; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SAKSELA K, 1993, J VIROL, V67, P7423, DOI 10.1128/JVI.67.12.7423-7427.1993; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; SEMPLE M, 1991, J MED VIROL, V35, P38, DOI 10.1002/jmv.1890350109; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; STEVENS CE, 1986, JAMA-J AM MED ASSOC, V255, P2167, DOI 10.1001/jama.255.16.2167; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; TERSMETTE M, 1989, LANCET, V1, P983; VASUDEVACHARI MB, 1993, J CLIN IMMUNOL, V13, P185, DOI 10.1007/BF00919971; VENET A, 1991, AIDS, V5, P283, DOI 10.1097/00002030-199103000-00006; WOOD R, 1993, J ACQ IMMUN DEF SYND, V6, P237; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; 1989, MMWR MORB MORTAL S7, V38, P1; 1987, MMWR MORB MORTAL S1, V36, pS1	70	73	73	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					641	+		10.7326/0003-4819-123-9-199511010-00001	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574218				2022-12-28	WOS:A1995TA69600001
J	BUCKBINDER, L; TALBOTT, R; VELASCOMIGUEL, S; TAKENAKA, I; FAHA, B; SEIZINGER, BR; KLEY, N				BUCKBINDER, L; TALBOTT, R; VELASCOMIGUEL, S; TAKENAKA, I; FAHA, B; SEIZINGER, BR; KLEY, N			INDUCTION OF THE GROWTH INHIBITOR IGF-BINDING PROTEIN-3 BY P53	NATURE			English	Article							KINASES; P21	TRANSCRIPTIONAL activation of target genes represents an important component of the tumour-suppressor function of p53 and provides a functional link between p53 and various growth-regulatory processes, including cell cycle progression (p21/WAF1)(1-3), DNA repair (GADD45)(4) and apoptosis (bax)(5). Here we use a differential cloning approach to identify the gene encoding insulin-like growth factor binding protein 3 (IGF-BP3) as a novel p53-regulated target gene. Induction of IGF-BP3 gene expression by wild-type but not mutant p53 is associated with enhanced secretion of an active form of IGF-BP3 capable of inhibiting mitogenic signalling by the insulin-like growth factor IGF-1, Our results indicate that ICF-BP3 may link p53 to potential novel autocrine/paracrine signalling pathways and to processes regulated by or dependent on IGF(s), such as cellular growth, transformation and survival.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC GENET,PRINCETON,NJ 08543	Bristol-Myers Squibb								BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; COHEN P, 1994, J ENDOCRINOL, V142, P407, DOI 10.1677/joe.0.1420407; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRIGORIEV VG, 1994, J CELL PHYSIOL, V160, P203, DOI 10.1002/jcp.1041600123; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; MIYASHITA T, 1994, ONCOGENE, V9, P1799; RESNICOFF M, 1995, CANCER RES, V55, P2463; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIMASAKI S, 1992, PROG GROWTH FACTOR R, V3, P243; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YU H, 1995, CANCER RES, V55, P1603; YU H, 1995, CANCER RES, V55, P2104	21	736	759	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					646	649		10.1038/377646a0	http://dx.doi.org/10.1038/377646a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566179				2022-12-28	WOS:A1995TA27500057
J	MULDER, D; NUNN, A; KAMALI, A; KENGEYAKAYONDO, J				MULDER, D; NUNN, A; KAMALI, A; KENGEYAKAYONDO, J			DECREASING HIV-1 SEROPREVALENCE IN YOUNG-ADULTS IN A RURAL UGANDAN COHORT	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PREGNANT-WOMEN; INFECTION; ZAIRE	Objective-To assess the trend in HIV-1 seroprevalence in an adult population in Uganda. Design-An observational cohort study with four year follow up. Setting-A cluster of 15 villages in rural Uganda. Subjects-All residents of the 15 villages-about 10 000 people. Main outcome measure-Prevalence of HIV-1 infection as assessed by enzyme immunoassay. Results-During the five year period the overall standardised seroprevalence of HIV-1 showed little change; 8.2% in 1990, 7.6% in 1994. Among males aged 13-24 years the prevalence decreased from 3.4% to 1.0% (P for trend < 0.001); among females of the same age the corresponding values were 9.9% and 7.3%. The decrease was greatest in males aged 20-24 years and females aged 13-19 years. Conclusion-This is the first report of a decline in HIV-1 prevalence among young adults in a general population in sub-Saharan Africa with high overall HIV-1 prevalence. It is too early to conclude that the epidemic in this population is in decline, but the results of this study should be reason for some cautious optimism and encourage the vigorous pursuit of AIDS control measures.	MRC PROGRAMME AIDS UGANDA,ENTEBBE,UGANDA; UGANDA VIRUS RES INST,ENTEBBE,UGANDA	Uganda Virus Research Institute				Nunn, Andrew/0000-0002-9158-4595				ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; BATTER V, 1994, AIDS, V8, P811, DOI 10.1097/00002030-199406000-00014; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HEYWARD WL, 1994, AIDS, V8, P1285, DOI 10.1097/00002030-199409000-00011; KARITA E, 1993, INT J STD AIDS, V4, P211, DOI 10.1177/095646249300400406; KENGEYAKAYONDO JF, 1995, ANN TROP PAEDIATR, V15, P115, DOI 10.1080/02724936.1995.11747758; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; MAGAZANI K, 1993, J ACQ IMMUN DEF SYND, V6, P419; MALAMBA SS, 1994, AIDS, V8, P253, DOI 10.1097/00002030-199402000-00014; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; NUNN AJ, 1994, AIDS, V8, P81, DOI 10.1097/00002030-199401000-00012; NUNN AJ, 1994, METHOD INFORM MED, V33, P170; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; NUNN AJ, 1995, AIDS, V9, P503, DOI 10.1097/00002030-199509050-00013; NZILAMBI N, 1988, NEW ENGL J MED, V318, P276, DOI 10.1056/NEJM198802043180503; SEELEY J, 1991, AIDS Care, V3, P207, DOI 10.1080/09540129108253064; SOKAL DC, 1993, AIDS, V7, P1481, DOI 10.1097/00002030-199311000-00012; WAGNER HU, 1994, INT J STD AIDS, V5, P332, DOI 10.1177/095646249400500509; WAGNER HU, 1993, AIDS, V7, P1461, DOI 10.1097/00002030-199311000-00009; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414; 1994, WHOGPATCOSEF944; 1995, 1995 MIN HLTH SURV R	23	93	93	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					833	836		10.1136/bmj.311.7009.833	http://dx.doi.org/10.1136/bmj.311.7009.833			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580488	Green Published			2022-12-28	WOS:A1995RY19100018
J	DANIAL, NN; PERNIS, A; ROTHMAN, PB				DANIAL, NN; PERNIS, A; ROTHMAN, PB			JAK-STAT SIGNALING INDUCED BY THE V-ABL ONCOGENE	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; MURINE LEUKEMIA-VIRUS; ABELSON VIRUS; BONE-MARROW; CELL-LINE; MYELOID CELLS; TRANSFORMATION; GROWTH; DEPENDENCE; MECHANISM	The effect of the v-abl oncogene of the Abelson murine leukemia virus (A-MuLV) on the Jak-STAT pathway of cytokine signal transduction was investigated. In murine pre-B lymphocytes transformed with A-MuLV, the Janus kinases (Jaks) Jak1 and Jak3 exhibited constitutive tyrosine kinase activity, acid the STAT proteins (signal transducers and activators of transcription) normally activated by interleukin-4, and interleukin-7 were tyrosine-phosphorylated in the absence of these cytokines. Coimmunoprecipitation experiments revealed that in these cells v-Abl was physically associated with Jak1 and Jak3. Inactivation of v-Abl tyrosine kinase in a pre-B cell line transformed with a temperature-sensitive mutant of v-abl resulted in abrogation of constitutive Jak-STAT signaling. A direct link may exist between transformation by v-abl and cytokine signal transduction.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,INTEGRATED PROGRAM MOLEC CELLULAR & BIOPHYS STUD,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032	Columbia University; Columbia University					NIAID NIH HHS [AI 33540-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033540] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DANIAL NN, UNPUB; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; ENGELMAN A, 1990, MOL CELL BIOL, V10, P4365, DOI 10.1128/MCB.10.8.4365; Hariharan I K, 1988, Oncogene Res, V3, P387; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUNT P, 1987, CELL, V48, P997, DOI 10.1016/0092-8674(87)90708-2; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PERNIS A, 1995, J BIOL CHEM, V270, P14517, DOI 10.1074/jbc.270.24.14517; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PRYWES R, 1985, J VIROL, V54, P114, DOI 10.1128/JVI.54.1.114-122.1985; QUELLE FW, 1995, MOL CELL BIOL, V15, P336; ROSENBERG N, 1994, SEMIN CANCER BIOL, V5, P95; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; WHITLOCK CA, 1983, CELL, V32, P903, DOI 10.1016/0092-8674(83)90075-2; WHITLOCK CA, 1987, CELL, V48, P1009, DOI 10.1016/0092-8674(87)90709-4; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854	36	314	319	1	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1875	1877		10.1126/science.7569929	http://dx.doi.org/10.1126/science.7569929			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569929				2022-12-28	WOS:A1995RX19400039
J	DESCOTEAUX, A; LUO, Y; TURCO, SJ; BEVERLEY, SM				DESCOTEAUX, A; LUO, Y; TURCO, SJ; BEVERLEY, SM			A SPECIALIZED PATHWAY AFFECTING VIRULENCE GLYCOCONJUGATES OF LEISHMANIA	SCIENCE			English	Article							SECRETED ACID-PHOSPHATASE; MONOCLONAL-ANTIBODIES; DONOVANI PROMASTIGOTES; LIPOPHOSPHOGLYCAN; BIOSYNTHESIS; PROTEINS; EXPRESSION; EPITOPES; MUTANT	For virulence and transmission, the protozoan Leishmania must assemble a complex glycolipid on the cell surface, the lipophosphoglycan (LPG). Functional complementation identified the gene LPG2, which encodes an integral Golgi membrane protein implicated in intracellular compartmentalization of LPG biosynthesis. Ipg2(-) mutants lack only characteristic disaccharide-phosphate repeats, normally present on both LPG and other surface or secreted molecules considered critical for infectivity. In contrast, a related yeast gene, VAN2/VRG4, is essential and required for general Golgi function. These results suggest that LPG2 participates in a specialized virulence pathway, which may offer an attractive target for chemotherapy.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40546	Harvard University; Harvard Medical School; University of Kentucky				Beverley, Stephen/0000-0001-5319-0811	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BATES PA, 1989, EXP PARASITOL, V68, P335, DOI 10.1016/0014-4894(89)90115-X; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CAPPAI R, 1994, PARASITOLOGY, V108, P397, DOI 10.1017/S0031182000075946; CARVER MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P309, DOI 10.1016/0003-9861(92)90523-Y; CARVER MA, 1991, J BIOL CHEM, V266, P10974; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; DESCOTEAUX A, 1993, METHODS MOL GENETICS, V1, P22; DESCOTEAUX A, UNPUB; ELHAY M, 1990, MOL BIOCHEM PARASIT, V40, P255, DOI 10.1016/0166-6851(90)90047-P; FLINN HM, 1994, MOL BIOCHEM PARASIT, V65, P259, DOI 10.1016/0166-6851(94)90077-9; GUEIROSFILHO FJ, UNPUB; HANDMAN E, 1986, J IMMUNOL, V137, P3608; HUANG CC, 1993, J BIOL CHEM, V268, P24060; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1991, J CELL SCI, V99, P175; ILG T, 1994, PARASITOLOGY, V108, pS63, DOI 10.1017/S0031182000075739; JAFFE CL, 1990, J IMMUNOL, V144, P699; JARDIM A, 1991, J IMMUNOL, V147, P3538; JARDIM A, 1995, BIOCHEM J, V305, P305; KANIKENNULAT C, 1995, GENETICS, V140, P933; KATAKURA K, 1988, INFECT IMMUN, V56, P2856, DOI 10.1128/IAI.56.11.2856-2860.1988; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVELACE JK, 1987, MOL BIOCHEM PARASIT, V22, P19, DOI 10.1016/0166-6851(87)90065-X; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCNEELY T B, 1990, Glycobiology, V1, P63, DOI 10.1093/glycob/1.1.63; MCNEELY TB, 1990, J IMMUNOL, V144, P2475; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; POSTER JB, UNPUB; REEVES P, 1994, BACTERIAL CELL WALL, P281; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; SACKS DL, 1994, PARASITOLOGY, V108, pS55, DOI 10.1017/S0031182000075727; SMITH DF, 1995, GLYCOBIOLOGY, V5, P161, DOI 10.1093/glycob/5.2.161; TOLSON DL, 1989, MOL BIOCHEM PARASIT, V35, P109, DOI 10.1016/0166-6851(89)90113-8; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5	43	138	143	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1869	1872		10.1126/science.7569927	http://dx.doi.org/10.1126/science.7569927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569927				2022-12-28	WOS:A1995RX19400037
J	DOGGETT, NA; GOODWIN, LA; TESMER, JG; MEINCKE, LJ; BRUCE, DC; CLARK, LM; ALTHERR, MR; FORD, AA; CHI, HC; MARRONE, BL; LONGMIRE, JL; LANE, SA; WHITMORE, SA; LOWENSTEIN, MG; SUTHERLAND, RD; MUNDT, MO; KNILL, EH; BRUNO, WJ; MACKEN, CA; TORNEY, DC; WU, JR; GRIFFITH, J; SUTHERLAND, GR; DEAVEN, LL; CALLEN, DF; MOYZIS, RK				DOGGETT, NA; GOODWIN, LA; TESMER, JG; MEINCKE, LJ; BRUCE, DC; CLARK, LM; ALTHERR, MR; FORD, AA; CHI, HC; MARRONE, BL; LONGMIRE, JL; LANE, SA; WHITMORE, SA; LOWENSTEIN, MG; SUTHERLAND, RD; MUNDT, MO; KNILL, EH; BRUNO, WJ; MACKEN, CA; TORNEY, DC; WU, JR; GRIFFITH, J; SUTHERLAND, GR; DEAVEN, LL; CALLEN, DF; MOYZIS, RK			AN INTEGRATED PHYSICAL MAP OF HUMAN-CHROMOSOME-16	NATURE			English	Article							DINUCLEOTIDE REPEAT POLYMORPHISMS; REPETITIVE DNA-SEQUENCES; HUMAN GENOME; CLONES; CLONING; FRAGMENTS; REGIONS; VECTOR	We describe an integrated physical, genetic and cytogenetic map of human chromosome 16 comprising both a low-resolution megaYAC map and a high-resolution cosmid contig/miniYAC map, which provides nearly complete coverage of the euchromatic arms of the chromosome. The physical map is anchored to a high-resolution cytogenetic breakpoint map and is integrated with genetic and gene transcript maps of the chromosome by sequence-tagged sites and clone hybridizations.	LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,THEORET BIOL & BIOPHYS GRP,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,APPLICAT PROGRAMMING GRP,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,COMP RES & APPLICAT GRP,LOS ALAMOS,NM 87545; ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA; UNIV NEW MEXICO,DEPT CELL BIOL,ALBUQUERQUE,NM 87131	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; University of New Mexico	DOGGETT, NA (corresponding author), LOS ALAMOS NATL LAB,CTR HUMAN GENOME STUDIES,LOS ALAMOS,NM 87545, USA.		Callen, David F/G-1975-2012; Sutherland, Grant Robert/D-2606-2012					ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ASLANIDIS C, 1991, P NATL ACAD SCI USA, V88, P6765, DOI 10.1073/pnas.88.15.6765; AUFFRAY C, 1995, CR ACAD SCI III-VIE, V318, P263; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BOTSTEIN D, 1990, DOEER0452P; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; CALLEN DF, 1990, ANN GENET-PARIS, V33, P190; CALLEN DF, IN PRESS GENOMICS, V29; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CINKOSKY MJ, 1992, LOS ALAMOS SCI, V20, P267; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DOGGETT NA, 1995, CYTOGENET CELL GENET, V68, P165; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; Green E D, 1991, PCR Methods Appl, V1, P77; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; HARRIS PC, 1994, GENOMICS, V23, P321, DOI 10.1006/geno.1994.1507; JURKA J, 1992, J MOL EVOL, V35, P286, DOI 10.1007/BF00161166; KAHN AS, 1992, NAT GENET, V2, P180; KOZMAN HM, 1995, GENOMICS, V25, P44, DOI 10.1016/0888-7543(95)80108-X; LIU P, 1993, CANCER GENET CYTOGEN, V65, P92; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MARRONE BL, 1994, GENOMICS, V21, P202, DOI 10.1006/geno.1994.1243; MCCORMICK MK, 1993, P NATL ACAD SCI USA, V90, P1063, DOI 10.1073/pnas.90.3.1063; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; MOYZIS RK, 1987, CHROMOSOMA, V95, P375, DOI 10.1007/BF00333988; OKUMURA K, 1994, CYTOGENET CELL GENET, V67, P61, DOI 10.1159/000133799; OLSON MV, 1993, COLD SPRING HARB SYM, V57, P349; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAPPAPORT B, 1994, AUTOMATED DNA SEQUEN, P289; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; SELLERI L, 1992, GENOMICS, V14, P536, DOI 10.1016/S0888-7543(05)80263-0; SHEN Y, 1993, HUM MOL GENET, V2, P1745, DOI 10.1093/hmg/2.10.1745; SHEN Y, 1994, GENOMICS, V22, P68, DOI 10.1006/geno.1994.1346; SHEN Y, 1994, HUM MOL GENET, V3, P210, DOI 10.1093/hmg/3.1.210; SHEN Y, 1993, HUM MOL GENET, V2, P1505, DOI 10.1093/hmg/2.9.1505; SHEN Y, 1993, HUM MOL GENET, V2, P1504, DOI 10.1093/hmg/2.9.1504; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; STALLINGS RL, 1993, CYTOGENET CELL GENET, V63, P97, DOI 10.1159/000133509; STALLINGS RL, 1992, GENOMICS, V13, P332, DOI 10.1016/0888-7543(92)90249-R; STALLINGS RL, 1992, GENOMICS, V13, P1031, DOI 10.1016/0888-7543(92)90016-L; WHITMORE SA, 1994, GENOMICS, V20, P169, DOI 10.1006/geno.1994.1150; 1995, HUM MOL GENET, V4, P575	46	99	100	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			335	365						31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566100				2022-12-28	WOS:A1995TA34300006
J	KRONTIRIS, TG				KRONTIRIS, TG			MOLECULAR MEDICINE - ONCOGENES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											KRONTIRIS, TG (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,DEPT MED,750 WASHINGTON ST,BOSTON,MA 02111, USA.							GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0	3	53	54	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					303	306		10.1056/NEJM199508033330508	http://dx.doi.org/10.1056/NEJM199508033330508			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL694	7596376				2022-12-28	WOS:A1995RL69400008
J	EATON, S; SIMONS, K				EATON, S; SIMONS, K			APICAL, BASAL, AND LATERAL CUES FOR EPITHELIAL POLARIZATION	CELL			English	Review							CELL-ADHESION; POLARITY; NA+,K+-ATPASE; CYTOSKELETON; DROSOPHILA; REVERSAL				EATON, S (corresponding author), EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.			Simons, Kai/0000-0002-9231-9996				FESSLER JH, 1989, ANNU REV CELL BIOL, V5, P309, DOI 10.1146/annurev.cb.05.110189.001521; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HU RJ, 1995, J CELL BIOL, V128, P1069, DOI 10.1083/jcb.128.6.1069; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; OJAKIAN GK, 1994, J CELL SCI, V107, P561; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SCHOENENBERGER CA, 1994, J CELL SCI, V107, P527; SHIEL MJ, 1995, HARVEY LECT, V89, P125; SOROKIN L, 1990, J CELL BIOL, V111, P1265, DOI 10.1083/jcb.111.3.1265; TEPASS U, 1994, DEV BIOL, V161, P563, DOI 10.1006/dbio.1994.1054; TEPASS U, 1994, DEVELOPMENT, V120, P579; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; VANADELSBERG J, 1994, CELL, V76, P1053, DOI 10.1016/0092-8674(94)90382-4; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; WANG AZ, 1990, J CELL SCI, V95, P153; Warn Richard M., 1992, P137; WATSON AJ, 1990, DEV BIOL, V141, P104, DOI 10.1016/0012-1606(90)90105-R; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4	26	165	165	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					5	8		10.1016/0092-8674(95)90045-4	http://dx.doi.org/10.1016/0092-8674(95)90045-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606785	Bronze			2022-12-28	WOS:A1995RK42400002
J	SALINAS, F; KODADEK, T				SALINAS, F; KODADEK, T			PHAGE-T4 HOMOLOGOUS STRAND EXCHANGE - A DNA HELICASE, NOT THE STRAND TRANSFERASE, DRIVES POLAR BRANCH MIGRATION	CELL			English	Article							ESCHERICHIA-COLI RECA; PROTEIN-PROTEIN INTERACTIONS; BINDING-PROTEIN; RUVB PROTEINS; BACTERIOPHAGE-T4 UVSX; HOLLIDAY JUNCTIONS; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; GENE-32 PROTEINS; PURIFICATION	Homologous strand exchange is a central step in general genetic recombination. A multiprotein complex composed of five purified bacteriophage T4 proteins (the products of the uvsX, uvsY, 32, 41, and 59 genes) that mediates strand exchange under physiologically relevant conditions has been reconstituted. One of these proteins, the product of the uvsY gene, is required for homologous pairing but strongly inhibits branch migration catalyzed by UvsX protein, the phage RecA analog. Branch migration is completely dependent on the gene 41 protein, a DNA helicase that also functions in phage replication. The helicase is delivered to the strand exchange complex by the gene 59 accessory protein in a strand-specific fashion through direct interactions between the gene 59 and gene 32 proteins. These data suggest that strand transferases such as UvsX protein are essential for homologous pairing in vivo, but that a DNA helicase drives polar branch migration.	UNIV TEXAS, INST MOLEC BIOL, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin	SALINAS, F (corresponding author), UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA.				NIGMS NIH HHS [GM-39393] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; BARRY J, 1994, J BIOL CHEM, V269, P33063; BARRY J, 1994, J BIOL CHEM, V269, P33049; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Challberg M D, 1980, Methods Enzymol, V65, P39; CONKLING MA, 1984, GENETICS, V107, P505; COX MM, 1983, J BIOL CHEM, V258, P2577; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; EGGLESTON AK, 1991, BIOCHIMIE, V73, P163, DOI 10.1016/0300-9084(91)90199-B; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; FORMOSA T, 1985, THESIS SAN FRANCISCO; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HASHIMOTO K, 1991, J BIOL CHEM, V266, P4883; HINTON DM, 1986, J BIOL CHEM, V261, P5663; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JIANG H, 1993, J BIOL CHEM, V268, P7904; KODADEK T, 1989, J BIOL CHEM, V264, P16451; KODADEK T, 1991, J BIOL CHEM, V266, P9712; KODADEK T, 1990, BIOCHEM BIOPH RES CO, V172, P804, DOI 10.1016/0006-291X(90)90746-A; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; KODADEK T, 1988, J BIOL CHEM, V263, P9427; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LIU CC, 1981, J BIOL CHEM, V256, P2813; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; Mosig G, 1983, BACTERIOPHAGE, V4, P120; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1994, EXPERIENTIA, V50, P216; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; SHINAGAWA H, 1991, BIOCHIMIE, V73, P505, DOI 10.1016/0300-9084(91)90120-P; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; SPICER EK, 1979, J BIOL CHEM, V254, P6433; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WU R, 1975, J VIROL, V16, P5, DOI 10.1128/JVI.16.1.5-16.1975; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YONESAKI T, 1994, GENETICS, V138, P247; YONESAKI T, 1985, EUR J BIOCHEM, V148, P127, DOI 10.1111/j.1432-1033.1985.tb08816.x; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	63	57	57	2	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					111	119		10.1016/0092-8674(95)90057-8	http://dx.doi.org/10.1016/0092-8674(95)90057-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606776	Bronze			2022-12-28	WOS:A1995RK42400014
J	FRIEDRICH, M; TAUTZ, D				FRIEDRICH, M; TAUTZ, D			RIBOSOMAL DNA PHYLOGENY OF THE MAJOR EXTANT ARTHROPOD CLASSES AND THE EVOLUTION OF MYRIAPODS	NATURE			English	Article								THE evolutionary relationships among arthropods are of particular interest because the best-studied model system for ontogenetic pattern formation, the insect Drosophila, is a member of this phylum. Evolutionary inferences about the developmental mechanisms that have led to the various designs of the arthropod body plan depend on a knowledge of the phylogenetic framework of arthropod evolution, Based on morphological evidence(1-3), but also on palaeontological considerations(4), the sister group of the insects is believed to be found among the myriapods. Using nuclear ribosomal gene sequences for constructing a molecular phylogeny, we provide strong evidence that the crustaceans and not the myriapods should be considered to be the sister group of the insects. Moreover, the degree of sequence divergence suggests that the diversification of the myriapods occurred during the Cambrian. Our findings have general implications for the course of land colonization by the different arthropod groups, as well as for the interpretation of primitive and derived features of arthropod morphology.			FRIEDRICH, M (corresponding author), UNIV MUNICH,INST ZOOL,LUISENSTR 14,D-80333 MUNICH,GERMANY.		Tautz, Diethard/D-4304-2011; Tautz, Diethard/H-8436-2014	Tautz, Diethard/0000-0002-0460-5344				Anderson D. T., 1973, EMBRYOLOGY PHYLOGENY; AVEROF M, 1995, PHILOS T R SOC B, V347, P293, DOI 10.1098/rstb.1995.0028; Boudreaux H.B., 1979, P551; Brusca C.R., 1990, INVERTEBRATES; Dohle W, 1980, ABHANDLUNGEN NATURWI, V23, P45; FELSENSTEIN J, 1985, EVOLUTION, V39, P791; FELSENSTEIN J, 1989, PHYLOGENETIC INFEREN; GAUT BS, 1995, MOL BIOL EVOL, V12, P152, DOI 10.1093/oxfordjournals.molbev.a040183; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HILLIS DM, 1994, NATURE, V369, P363, DOI 10.1038/369363a0; HUELSENBECK JP, 1993, SYST BIOL, V42, P247, DOI 10.2307/2992463; JERAM AJ, 1990, SCIENCE, V250, P685; Kristensen N.P., 1991, P125; Kukalova-Peck J., 1991, P141; Kumar S., 1993, MEGA MOL EVOLUTIONAR; Lauterbach K.-E., 1980, Abhandlungen des Naturwissenschaftlichen Vereins Wuerzburg, V23, P105; MANTON SM, 1964, PHILOS T ROY SOC B, V247, P1, DOI 10.1098/rstb.1964.0001; PANGANIBAN G, 1994, CURR BIOL, V4, P671, DOI 10.1016/S0960-9822(00)00151-2; Paulus H.F., 1979, P299; ROBISON R, 1987, FOSSIL INVERTEBRATES, P206; ROBISON RA, 1990, NATURE, V343, P163, DOI 10.1038/343163a0; STYS P, 1994, EUR J ENTOMOL, V91, P257; Swofford D.L., 1993, PHYLOGENETIC ANAL US; TAUTZ D, 1988, MOL BIOL EVOL, V5, P366; Weir BS, 1990, GENETIC DATA ANAL; WEYGOLDT P, 1986, Z ZOOL SYST EVOL, V24, P19; Weygoldt P., 1985, P20; WHITINGTON PM, 1993, DEVELOPMENT, V118, P449; WHITINGTON PM, 1991, ROUX ARCH DEV BIOL, V199, P349, DOI 10.1007/BF01705928; WU CI, 1985, P NATL ACAD SCI USA, V82, P1741, DOI 10.1073/pnas.82.6.1741	30	297	320	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					165	167		10.1038/376165a0	http://dx.doi.org/10.1038/376165a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603566				2022-12-28	WOS:A1995RJ02800058
J	MATSUMOTO, S				MATSUMOTO, S			CIMETIDINE AND SURVIVAL WITH COLORECTAL-CANCER	LANCET			English	Letter											MATSUMOTO, S (corresponding author), FUJITA HLTH UNIV,TEACHING HOSP 2,DEPT SURG,NAGOYA,AICHI 454,JAPAN.							ADAMS WJ, 1994, LANCET, V344, P1768, DOI 10.1016/S0140-6736(94)92907-6; ADAMS WJ, 1994, GUT, V35, P1632, DOI 10.1136/gut.35.11.1632; KUMAR A, 1990, DICP ANN PHARMAC, V24, P289, DOI 10.1177/106002809002400316	3	77	83	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					115	115		10.1016/S0140-6736(95)92136-2	http://dx.doi.org/10.1016/S0140-6736(95)92136-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603185				2022-12-28	WOS:A1995RH22000032
J	OKADA, F; KINOSHITA, S				OKADA, F; KINOSHITA, S			SHINSHINSHO - CLINICAL ENTITY OR PSEUDOSCIENCE	LANCET			English	Editorial Material											OKADA, F (corresponding author), HOKKAIDO UNIV,CTR HLTH ADM,SAPPORO,HOKKAIDO 060,JAPAN.							Alexander F, 1950, PSYCHOSOMATIC MED IT; IKEMI Y, 1975, SEISHIN IGAKU JITEN, P331; IKEMI Y, 1962, THEORY PRACTICE PSYC; Okada F, 1994, Clin Auton Res, V4, P189, DOI 10.1007/BF01826185; SIMOSAKA K, 1979, SERIES MODERN PSYC A, V7, P3	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					66	67		10.1016/S0140-6736(95)92107-9	http://dx.doi.org/10.1016/S0140-6736(95)92107-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603212				2022-12-28	WOS:A1995RH22000005
J	RUIZAVILA, L; MCLAUGHLIN, SK; WILDMAN, D; MCKINNON, PJ; ROBICHON, A; SPICKOFSKY, N; MARGOLSKEE, RF				RUIZAVILA, L; MCLAUGHLIN, SK; WILDMAN, D; MCKINNON, PJ; ROBICHON, A; SPICKOFSKY, N; MARGOLSKEE, RF			COUPLING OF BITTER RECEPTOR TO PHOSPHODIESTERASE THROUGH TRANSDUCIN IN TASTE RECEPTOR-CELLS	NATURE			English	Article							AMINO-ACID SEQUENCE; GTP-BINDING PROTEIN; ROD OUTER SEGMENTS; ALPHA-SUBUNIT; CONFORMATIONAL-CHANGES; ADENOSINE RECEPTOR; CDNA SEQUENCE; RHODOPSIN; PROTEOLYSIS; ACTIVATION	THE rod and cone transducins rue specific G proteins originally thought to be present only in photoreceptor cells of the vertebrate retina(1-4). Transducins convert light stimulation of photoreceptor opsins into activation of cyclic GMP phosphodiesterase (reviewed in refs. 5-7). A transducin-like G protein, gustducin, has been identified and cloned from rat taste cells(8). We report here that rod transducin is also present in vertebrate taste cells, where it specifically activates a phosphodiesterase isolated from taste tissue. Furthermore, the bitter compound denatonium in the presence of taste-ceh membranes activates transducin but not G(i). A peptide that competitively inhibits rhodopsin activation of transducing also blocks taste-cell membrane activation of transducin, arguing for the involvement of a seven-transmembrane-helix G-protein-coupled receptor. These results suggest that rod transducin tranduces bitter taste by coupling taste receptor(s) to taste-cell phosphodiesterase. Phosphodiesterase-mediated degradation of cyclic nucleotides may lead to taste-cell depolarization through the recently identified cyclic-nucleotide-suppressible conductance(10).	HOFFMANN LA ROCHE INC, ROCHE RES CTR, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA	Roche Holding				Margolskee, Robert/0000-0002-9572-2887; Ruiz-Avila, Luis/0000-0001-8777-1083; robichon, alain/0000-0003-1075-9646				ABE K, 1993, FEBS LETT, V316, P253, DOI 10.1016/0014-5793(93)81302-G; ABE K, 1993, J BIOL CHEM, V268, P12033; ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HALLIDAY KR, 1984, J BIOL CHEM, V259, P516; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HWANG PM, 1990, P NATL ACAD SCI USA, V87, P7395, DOI 10.1073/pnas.87.19.7395; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; KOPF GS, 1991, METHOD ENZYMOL, V195, P257; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; MATSUOKA I, 1993, BIOCHEM BIOPH RES CO, V194, P504, DOI 10.1006/bbrc.1993.1848; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; NAIM M, 1991, COMP BIOCHEM PHYS B, V100, P455, DOI 10.1016/0305-0491(91)90203-P; PRICE S, 1973, NATURE, V241, P54, DOI 10.1038/241054a0; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SCHIFFMAN SS, 1985, PHARMACOL BIOCHEM BE, V22, P195, DOI 10.1016/0091-3057(85)90377-6; SCHIFFMAN SS, 1986, PHARMACOL BIOCHEM BE, V24, P429, DOI 10.1016/0091-3057(86)90536-8; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; Spickofsky Nancy, 1992, Chemical Senses, V17, P701; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; STRYER L, 1991, J BIOL CHEM, V266, P10711; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; Whiteside B, 1926, J COMP NEUROL, V40, P33, DOI 10.1002/cne.900400105; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	30	176	189	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	1995	376	6535					80	85		10.1038/376080a0	http://dx.doi.org/10.1038/376080a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596440				2022-12-28	WOS:A1995RH11100066
J	DUPAS, B; ELKOURI, D; CURTET, C; PELTIER, P; DEFAUCAL, P; PLANCHON, B; LEJEUNE, JJ				DUPAS, B; ELKOURI, D; CURTET, C; PELTIER, P; DEFAUCAL, P; PLANCHON, B; LEJEUNE, JJ			ANGIOMAGNETIC RESONANCE IMAGING OF ILIOFEMOROCAVAL VENOUS THROMBOSIS	LANCET			English	Article							CONTRAST VENOGRAPHY; MR-ANGIOGRAPHY; DIAGNOSIS; ULTRASONOGRAPHY; EXPERIENCE; DISEASE; ECHO	Although magnetic resonance imaging has been proposed for the diagnosis of deep venous thrombosis (DVT), its role in diagnostic strategy remains to be defined. We compared prospectively magnetic resonance angiography (MRA) with two-dimensional time-of-flight with contrast venography (CV) and colour duplex sonography (CDS) in 25 patients with DVT of the pelvis confirmed by CV. All patients were examined by CV (gold standard) and MRA and 17 by CDS. These studies were compared for DVT diagnosis in the pelvis and inferior vena cava and analysis of thrombotic spread. MRA was positive in 25 patients whose DVT was diagnosed by CV (100% sensitivity). MRA sensitivity and negative predictive value were 100%, specificity 98.5% and positive predictive value 97.5% for the diagnosis of thrombosis at each anatomic level. There were discrepancies between MRA and CV (2 false-positive results for 2 venous segments) and between CDS and CV (2 false-positive and 3 false-negative results). CV was uninterpretable for 8.8% of segments and CDS was often technically limited to the pelvic level, whereas all venous segments explored were analysable in MRA. MRA gave excellent results for positive diagnosis and DVT spread. MRA is a potentially valuable technique for assessing iliofemorocaval venous thrombosis.	HOP HOTEL DIEU,CHU,SERV MED INTERNE,F-44035 NANTES,FRANCE; INST BIOL,INSERM,U211,F-44035 NANTES,FRANCE; CHU ANGERS,SERV BIOPHYS,F-49000 ANGERS,FRANCE	Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers	DUPAS, B (corresponding author), HOP HOTEL DIEU,CHU,SERV RADIOL,F-44035 NANTES,FRANCE.							ANDERSON CM, 1990, AM J ROENTGENOL, V154, P623, DOI 10.2214/ajr.154.3.2106232; ARRIVE L, 1991, RADIOLOGY, V181, P661, DOI 10.1148/radiology.181.3.1947078; CARPENTER JP, 1993, J VASC SURG, V18, P734, DOI 10.1016/0741-5214(93)90325-G; CHIEN D, 1992, SEMIN ROENTGENOL, V27, P53, DOI 10.1016/0037-198X(92)90046-5; COHAN RH, 1987, AM J ROENTGENOL, V149, P665, DOI 10.2214/ajr.149.4.665; CRONAN JJ, 1993, RADIOLOGY, V186, P619, DOI 10.1148/radiology.186.3.8430164; DUMOULIN CL, 1990, J COMPUT ASSIST TOMO, V14, P779, DOI 10.1097/00004728-199009000-00020; EDELMAN RR, 1993, AM J ROENTGENOL, V161, P1, DOI 10.2214/ajr.161.1.8517285; ERDMAN WA, 1990, RADIOLOGY, V174, P425, DOI 10.1148/radiology.174.2.2404315; EVANS AJ, 1993, AM J ROENTGENOL, V161, P131, DOI 10.2214/ajr.161.1.8517292; FINN JP, 1992, CARDIOVASC INTER RAD, V15, P51, DOI 10.1007/BF02733899; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; NAIDICH JB, 1988, RADIOLOGY, V168, P97, DOI 10.1148/radiology.168.1.3289098; OWEN RS, 1992, NEW ENGL J MED, V326, P1577, DOI 10.1056/NEJM199206113262428; PEDERSEN OM, 1991, ARCH INTERN MED, V151, P2217, DOI 10.1001/archinte.151.11.2217; REDMAN HC, 1988, RADIOLOGY, V168, P277, DOI 10.1148/radiology.168.1.3289092; SPRITZER CE, 1990, RADIOLOGY, V176, P255, DOI 10.1148/radiology.176.1.2353099; SPRITZER CE, 1990, RADIOLOGY, V177, P235, DOI 10.1148/radiology.177.1.2399324; TAVARES NJ, 1989, AM J ROENTGENOL, V153, P173, DOI 10.2214/ajr.153.1.173; TOTTERMAN S, 1990, AM J ROENTGENOL, V154, P175, DOI 10.2214/ajr.154.1.2104705	20	52	54	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					17	19		10.1016/S0140-6736(95)92650-X	http://dx.doi.org/10.1016/S0140-6736(95)92650-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603138				2022-12-28	WOS:A1995RF98500008
J	DRUMMOND, JT; LI, GM; LONGLEY, MJ; MODRICH, P				DRUMMOND, JT; LI, GM; LONGLEY, MJ; MODRICH, P			ISOLATION OF AN HMSH2-P160 HETERODIMER THAT RESTORES DNA MISMATCH REPAIR TO TUMOR-CELLS	SCIENCE			English	Article							EXTRACTS; HOMOLOG; CANCER	A mismatch-binding heterodimer of hMSH2 and a 160-kilodalton polypeptide has been isolated from Hela cells by virtue of its ability to restore mismatch repair to nuclear extracts of hMSH2-deficient LoVo colorectal tumor cells. This heterodimer, designated hMutS alpha; also restores mismatch repair to extracts of alkylation-tolerant MT1 lymphoblastoid cells and HCT-15 colorectal tumor cells, which are selectively defective in the repair of base-base and single-nucleotide insertion-deletion mismatches. Because HCT-15 cells appear to be free of hMSH2 mutations, this selective repair defect is likely a result of a deficiency of the hMutS alpha 160-kilodalton subunit, and mutations in the corresponding gene may confer hypermutability and cancer predisposition.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University			Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578; Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHI NW, 1994, J BIOL CHEM, V269, P29984; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; ESHLEMAN JR, 1994, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Li G., UNPUB; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LOEB LA, 1994, CANCER RES, V54, P5059; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637	33	534	555	0	38	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1909	1912		10.1126/science.7604264	http://dx.doi.org/10.1126/science.7604264			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604264				2022-12-28	WOS:A1995RF99000041
J	BARRY, M; JENNER, JR				BARRY, M; JENNER, JR			ABC OF RHEUMATOLOGY - PAIN IN NECK, SHOULDER, AND ARM	BRITISH MEDICAL JOURNAL			English	Article									ADDENBROOKES NHS TRUST,DEPT RHEUMATOL,CAMBRIDGE,ENGLAND	Addenbrooke's Hospital	BARRY, M (corresponding author), JAMES CONNOLLY MEM HOSP,DEPT RHEUMATOL,DUBLIN,IRELAND.								0	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					183	186		10.1136/bmj.310.6973.183	http://dx.doi.org/10.1136/bmj.310.6973.183			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7605431	Green Published			2022-12-28	WOS:A1995QD20100033
J	MCCAULEY, J; KERN, DE; KOLODNER, K; DILL, L; SCHROEDER, AF; DECHANT, HK; RYDEN, J; BASS, EB; DEROGATIS, LR				MCCAULEY, J; KERN, DE; KOLODNER, K; DILL, L; SCHROEDER, AF; DECHANT, HK; RYDEN, J; BASS, EB; DEROGATIS, LR			THE BATTERING SYNDROME - PREVALENCE AND CLINICAL CHARACTERISTICS OF DOMESTIC VIOLENCE IN PRIMARY-CARE INTERNAL-MEDICINE PRACTICES	ANNALS OF INTERNAL MEDICINE			English	Article						DOMESTIC VIOLENCE; BATTERED WOMEN; AGE FACTORS; SUBSTANCE ABUSE; MARITAL STATUS	CHILDHOOD SEXUAL ABUSE; CHRONIC PELVIC PAIN; PHYSICAL ABUSE; WOMEN; VICTIMIZATION; HEALTH; HISTORIES; SPOUSE; SAMPLE; IMPACT	Objectives: To determine the prevalence of domestic violence among female patients and to identify clinical characteristics that are associated with current domestic violence. Design: Cross-sectional, self-administered, anonymous survey. Setting: 4 community-based, primary care internal medicine practices. Patients: 1952 female patients of varied age and marital, educational, and economic status who were seen from February to July 1993. Measurements: The survey instrument included previously validated questions on physical and sexual abuse, alcohol abuse, and emotional status and questions on demographic characteristics, physical symptoms, use of street drugs and prescribed medications, and medical and psychiatric history. Results: 108 of the 1952 respondents (5.5%) had experienced domestic violence in the year before presentation. Four hundred eighteen (21.4%) had experienced domestic violence sometime in their adult lives, 429 (22.0%) before age 18 years, and 639 (32.7%) as either an adult or child. Compared with women who had not recently experienced domestic violence, currently abused patients were more likely to be younger than 35 years of age (prevalence ratio [PR], 4.1 [95% Cl, 2.8 to 6.0]); were more likely to be single, separated, or divorced (PR, 2.5 [Cl, 1.7 to 3.6]); were more likely to be receiving medical assistance or to have no insurance (PR, 4.3 [Cl, 2.8 to 6.6]); had more physical symptoms (mean, 7.3 +/- 0.38 compared with 4.6 +/- 0.08; P < 0.001); had higher scores on instruments for depression, anxiety, somatization, and interpersonal sensitivity (low self-esteem) (P < 0.001); were more likely to have a partner abusing drugs or alcohol (PR, 6.3 [Cl, 4.4 to 9.2]); were more likely to be abusing drugs (PR, 4.4 [Cl, 1.9 to 10.4]) or alcohol (PR, 3.1 [Cl, 1.5 to 6.5]); and were more likely to have attempted suicide (PR, 4.3 [CI, 2.8 to 6.5]). They visited the emergency department more frequently (PR, 1.7 [Cl, 1.2 to 2.5]) but did not have more hospitalizations for psychiatric disorders. In a logistic regression model into which 9 risk factors were the number of risk factors, from 1.2% when O to 1 risk factors were present to 70.4% when 6 to 7 risk factors were present. Conclusions: In a large, diverse, community-based population of primary care patients, 1 of every 20 women had experienced domestic violence in the previous year; 1 of every 5 had experienced violence in their adult life; and 1 of every 3 had experienced violence as either a child or an adult. Current domestic violence is associated with single or separated status, socioeconomic status, substance abuse, specific psychological symptoms, specific physical symptoms, and the total number of physical symptoms.	MONTGOMERY CTY HLTH DEPT, MONTGOMERY, AL 36104 USA; HAHNEMANN UNIV, PHILADELPHIA, PA 19102 USA	Drexel University	MCCAULEY, J (corresponding author), JOHNS HOPKINS UNIV, BAYVIEW MED CTR, DIV GEN INTERNAL MED, 4940 EASTERN AVE, BALTIMORE, MD 21224 USA.			Bass, Eric/0000-0001-9106-527X				[Anonymous], 1992, Arch Fam Med, V1, P39; APPLETON W, 1980, ANN EMERG MED, V9, P84, DOI 10.1016/S0196-0644(80)80336-2; BERESFORD TP, 1990, LANCET, V336, P482, DOI 10.1016/0140-6736(90)92022-A; BERGMAN B, 1991, AM J PUBLIC HEALTH, V81, P1486, DOI 10.2105/AJPH.81.11.1486; Breslow N. E., 1987, STATISTICAL METHODS, VII; BRIERE J, 1989, AM J PSYCHIAT, V146, P1602; BRIERE J, 1988, CHILD ABUSE NEGLECT, V12, P51, DOI 10.1016/0145-2134(88)90007-5; BROWN R, 1992, JAMA-J AM MED ASSOC, V267, P3184; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; Checkoway H., 1989, RES METHODS OCCUPATI; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; DOMINO JV, 1987, HEADACHE, V27, P310, DOI 10.1111/j.1526-4610.1987.hed2706310.x; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; FELITTI VJ, 1991, SOUTHERN MED J, V84, P328, DOI 10.1097/00007611-199103000-00008; FRIEDMAN LS, 1992, ARCH INTERN MED, V152, P1186, DOI 10.1001/archinte.152.6.1186; GAYFORD JJ, 1975, BRIT MED J, V1, P194, DOI 10.1136/bmj.1.5951.194; GIN NE, 1991, J GEN INTERN MED, V6, P317, DOI 10.1007/BF02597429; HABER JD, 1985, ADV PAIN RES THER, V9, P889; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUDSON WW, 1981, J MARRIAGE FAM, V43, P873, DOI 10.2307/351344; JAFFE P, 1986, CAN J PSYCHIAT, V31, P625, DOI 10.1177/070674378603100705; KOSS MP, 1991, ARCH INTERN MED, V151, P342, DOI 10.1001/archinte.151.2.342; MCFARLANE J, 1991, PUBLIC HEALTH NURS, V8, P245, DOI 10.1111/j.1525-1446.1991.tb00664.x; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; MULLEN PE, 1988, LANCET, V1, P841; NOVELLO AC, 1992, JAMA-J AM MED ASSOC, V267, P3132, DOI 10.1001/jama.267.23.3132; PRIBOR EF, 1993, AM J PSYCHIAT, V150, P1507; REITER RC, 1991, AM J OBSTET GYNECOL, V165, P104, DOI 10.1016/0002-9378(91)90235-J; SCHEI B, 1989, BRIT J OBSTET GYNAEC, V96, P1379, DOI 10.1111/j.1471-0528.1989.tb06298.x; SEARINEI IC, 1994, AM J MED, V97, P108; STARK E, 1991, WIFE ABUSE MED SETTI; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; WALKER E, 1988, AM J PSYCHIAT, V145, P75; WALKER EA, 1993, AM J PSYCHIAT, V150, P1502; WALKER EA, 1992, PSYCHOSOM MED, V54, P658, DOI 10.1097/00006842-199211000-00005; 1992, STATISTICAL ABSTRACT	36	502	518	4	62	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1995	123	10					737	+		10.7326/0003-4819-123-10-199511150-00001	http://dx.doi.org/10.7326/0003-4819-123-10-199511150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TE172	7574191				2022-12-28	WOS:A1995TE17200001
J	BROTT, T; TOOLE, JF				BROTT, T; TOOLE, JF			MEDICAL COMPARED WITH SURGICAL-TREATMENT OF ASYMPTOMATIC CAROTID-ARTERY STENOSIS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ENDARTERECTOMY	The Asymptomatic Carotid Atherosclerosis Study (ACAS) results suggest that carotid endarterectomy combined with aspirin and risk factor reduction is superior to aspirin and risk factor reduction alone in preventing ipsilateral stroke in asymptomatic patients with diameter stenosis of the carotid artery of 60% or more. The absolute risk reduction over 5 years conferred by surgical therapy is modest (5.9%) compared with the risk reduction conferred by surgical therapy for symptomatic carotid disease but compares favorably with the degree of stroke prevention shown for antihypertensive therapy in the elderly. For prevention of stroke in women and for prevention of major stroke, the ACAS results favoring surgery did not reach statistical significance. The combined arteriographic and perioperative surgery-related mortality and stroke rates achieved by the carefully selected surgical teams was low (2.3%). Accordingly, carotid endarterectomy can be recommended for preventing stroke in the setting of hemodynamically significant stenosis when the arteriographic and surgical complication rates can be kept low.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC 27103 USA; UNIV CINCINNATI, MED CTR, CINCINNATI, OH 45267 USA	Wake Forest University; Wake Forest Baptist Medical Center; University of Cincinnati	BROTT, T (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, ACAS EDITORIAL OFF, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022611] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22611] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1989, Stroke, V20, P844; [Anonymous], 1995, Lancet, V345, P209; BLAKELEY DD, 1995, ANN INTERN MED, V122, P360, DOI 10.7326/0003-4819-122-5-199503010-00007; BROTT T, 1984, STROKE, V15, P950, DOI 10.1161/01.STR.15.6.950; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; DIENER HC, 1991, STROKE, V22, P1229; GABRIELSEN TO, 1994, AM J NEURORADIOL, V15, P1408; HEISERMAN JE, 1994, AM J NEURORADIOL, V15, P1401; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; Howard G, 1991, J Stroke Cerebrovasc Dis, V1, P166, DOI 10.1016/S1052-3057(10)80013-8; KEMPCZINSKI RF, 1986, J VASC SURG, V3, P911, DOI 10.1067/mva.1986.avs0030911; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MOORE WS, 1995, CIRCULATION, V91, P566, DOI 10.1161/01.CIR.91.2.566; MOORE WS, 1991, STROKE, V22, P1353, DOI 10.1161/01.STR.22.11.1353; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WIEBERS DO, 1992, MAYO CLIN PROC, V67, P513; YOUNG GR, 1994, J NEUROL NEUROSUR PS, V57, P1466, DOI 10.1136/jnnp.57.12.1466	21	33	33	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					720	722		10.7326/0003-4819-123-9-199511010-00011	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574228				2022-12-28	WOS:A1995TA69600011
J	LIU, SH; WONG, ML; CRAIK, CS; BRODSKY, FM				LIU, SH; WONG, ML; CRAIK, CS; BRODSKY, FM			REGULATION OF CLATHRIN ASSEMBLY AND TRIMERIZATION DEFINED USING RECOMBINANT TRISKELION HUBS	CELL			English	Article							HEAVY-CHAIN; LIGHT-CHAINS; MOLECULAR-CLONING; SECONDARY-STRUCTURE; COATED VESICLES; PROTEINS; SEQUENCE; GENE; BINDING; TRIMERS	Clathrin polymerization into a polyhedral vesicle coat drives receptor sorting at cellular membranes during endocytosis and organelle biogenesis. To study clathrin self-assembly, we expressed the C-terminal third of the clathrin heavy chain in bacteria. The recombinant fragment trimerized, bound clathrin light chains, and morphologically resembled the hub domain of the triskelion-shaped clathrin molecule. Self-assembly of recombinant hubs demonstrated a regulatory role for clathrin light chains and for the distal portions of triskelion legs in clathrin coat formation. Deletion mutagenesis of the hub localized a domain mediating light chain binding and clathrin self-assembly and mapped a transferable trimerization domain. These studies define molecular interactions controlling clathrin self-assembly and establish a recombinant system for future analysis.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MICROBIOL & IMMUNOL,GW HOOPER FDN,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Brodsky, Frances/0000-0002-1334-9258	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM026691, R01GM038093] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26691, GM38093] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACTON SL, 1990, J CELL BIOL, V111, P1419, DOI 10.1083/jcb.111.4.1419; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; BAZINET C, 1993, GENETICS, V134, P1119; BLANK GS, 1986, EMBO J, V5, P2087, DOI 10.1002/j.1460-2075.1986.tb04470.x; BLANK GS, 1987, J CELL BIOL, V105, P2011, DOI 10.1083/jcb.105.5.2011; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BRODSKY FM, 1983, J CELL BIOL, V96, P911, DOI 10.1083/jcb.96.3.911; BRODSKY FM, 1987, NATURE, V326, P203, DOI 10.1038/326203a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DODGE GR, 1991, GENOMICS, V11, P174, DOI 10.1016/0888-7543(91)90115-U; ENNIS PD, 1988, J IMMUNOL, V141, P642; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1991, J BIOL CHEM, V266, P7950; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1993, J BIOL CHEM, V268, P10268; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON SK, 1991, J CELL BIOL, V112, P65, DOI 10.1083/jcb.112.1.65; LISANTI MP, 1982, EUR J BIOCHEM, V125, P463, DOI 10.1111/j.1432-1033.1982.tb06706.x; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MOOLBROEK MJ, 1987, J BIOL CHEM, V262, P25; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; OHALLORAN TJ, 1992, DNA CELL BIOL, V11, P321, DOI 10.1089/dna.1992.11.321; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; PONNAMBALAM S, 1994, GENOMICS, V24, P440, DOI 10.1006/geno.1994.1650; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAMM S, 1992, NUCLEIC ACIDS RES, V20, P5097, DOI 10.1093/nar/20.19.5097; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; UNGEWICKELL E, 1991, J BIOL CHEM, V266, P12710; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x; WONG DH, 1990, J NEUROSCI, V10, P3025	45	130	134	0	15	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					257	267		10.1016/0092-8674(95)90167-1	http://dx.doi.org/10.1016/0092-8674(95)90167-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585943	Bronze			2022-12-28	WOS:A1995TA96500012
J	LEE, N; MILLMAN, A				LEE, N; MILLMAN, A			ABC OF MEDICAL COMPUTING - HOSPITAL-BASED COMPUTER-SYSTEMS	BRITISH MEDICAL JOURNAL			English	Article									HILLINGDON HOSP,LONDON,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND	Brunel University; Imperial College London; Gloucestershire Royal Hospital	LEE, N (corresponding author), WESTERN EYE HOSP,LONDON,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					1013	1016						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580592				2022-12-28	WOS:A1995TA07900034
J	ELBERT, T; PANTEV, C; WIENBRUCH, C; ROCKSTROH, B; TAUB, E				ELBERT, T; PANTEV, C; WIENBRUCH, C; ROCKSTROH, B; TAUB, E			INCREASED CORTICAL REPRESENTATION OF THE FINGERS OF THE LEFT HAND IN STRING PLAYERS	SCIENCE			English	Article							ADULT OWL MONKEYS; TOPOGRAPHIC REORGANIZATION; FUNCTIONAL REORGANIZATION; SOMATOSENSORY CORTEX; DISCRIMINATION TASK; AUDITORY-CORTEX; PLASTICITY; DEAFFERENTATION; STIMULATION; AMPUTATION	Magnetic source imaging revealed that the cortical representation of the digits of the left hand of string players was larger than that in controls. The effect was smallest for the left thumb, and no such differences were observed for the representations of the right hand digits. The amount of cortical reorganization in the representation of the fingering digits was correlated with the age at which the person had begun to play. These results suggest that the representation of different parts of the body in the primary somatosensory cortex of humans depends on use and changes to conform to the current needs and experiences of the individual.	UNIV MUNSTER,CTR BIOMAGNETISM,D-48129 MUNSTER,GERMANY; UNIV ALABAMA,DEPT PSYCHOL,BIRMINGHAM,AL 35294	University of Munster; University of Alabama System; University of Alabama Birmingham	ELBERT, T (corresponding author), UNIV KONSTANZ,DEPT PSYCHOL,D-78434 CONSTANCE,GERMANY.		Elbert, Thomas/C-8556-2009	Elbert, Thomas/0000-0003-1332-4939				CLARK SA, 1988, NATURE, V332, P444, DOI 10.1038/332444a0; COHEN LG, 1991, BRAIN, V114, P615, DOI 10.1093/brain/114.1.615; DARLANSMITH C, 1994, NATURE, V368, P737; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; IRVINE D R F, 1991, Society for Neuroscience Abstracts, V17, P1485; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; KALASKA J, 1979, J NEUROPHYSIOL, V42, P618, DOI 10.1152/jn.1979.42.2.618; KELLOHAN AM, 1984, SOMATOSENS RES, V2, P49; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; MOGILNER A, 1993, P NATL ACAD SCI USA, V90, P3593, DOI 10.1073/pnas.90.8.3593; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PASCUALLEONE A, 1993, BRAIN, V116, P39, DOI 10.1093/brain/116.1.39; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RASMUSSON DD, 1982, J COMP NEUROL, V205, P313, DOI 10.1002/cne.902050402; RECANZONE GH, 1993, J NEUROSCI, V13, P87; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; ROBERTSON D, 1989, J COMP NEUROL, V282, P456, DOI 10.1002/cne.902820311; ROSLER F, 1993, COGNITIVE BRAIN RES, V1, P145, DOI 10.1016/0926-6410(93)90022-W; SANES JN, 1988, P NATL ACAD SCI USA, V85, P2003, DOI 10.1073/pnas.85.6.2003; WALL JT, 1986, J NEUROSCI, V6, P218; WALL JT, 1984, J NEUROSCI, V4, P1499; WEINBERGER NM, 1990, CONCEPTS NEUROSCIENC, V1, P91; WILLIAMSON SJ, 1990, AUDITORY EVOKED MAGN, P1; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010; YANG TT, 1993, P NATL ACAD SCI USA, V90, P3089	30	1257	1278	4	129	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					305	307		10.1126/science.270.5234.305	http://dx.doi.org/10.1126/science.270.5234.305			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569982	Green Submitted			2022-12-28	WOS:A1995RZ34200041
J	KYVIK, KO; GREEN, A; BECKNIELSEN, H				KYVIK, KO; GREEN, A; BECKNIELSEN, H			CONCORDANCE RATES OF INSULIN-DEPENDENT DIABETES-MELLITUS - A POPULATION-BASED STUDY OF YOUNG DANISH TWINS	BRITISH MEDICAL JOURNAL			English	Article							IDENTICAL-TWINS; ZYGOSITY; PAIRS	Objective-To study the genetic contribution to the aetiology of insulin dependent diabetes mellitus. Design-Historical cohort study of twins, with information on diabetes being gathered by questionnaire, verification of the diagnosis by the subject's diabetologist or general practitioner, and clinical examination in available twins. Setting-Danish twin register and diabetic clinics and general practices throughout Denmark. Subjects-20 888 twin pairs born during 1953-82, included in a population based nationwide register. Main outcome measures-Crude and cumulative concordance rates and heritability in monozygotic and dizygotic twins. Results-The crude probandwise concordance rate was 0.53 (95% confidence interval 0.33 to 0.73) for monozygotic twin pairs and 0.11 (0.05 to 0.21) for dizygotic twin pairs. When adjusted for age at onset of diabetes and age at last observation among unaffected twin partners the cumulative probandwise risk from birth to age 35 was estimated as 0.70 (0.45 to 0.95) for monozygotic twins and 0.13 (0.05 to 0.20) for dizygotic twins. The correlations of liability for monozygotic and dizygotic twin pairs were estimated as 0.96 (SE 0.09) and 0.58 (0.07), with a heritability estimate of 0.72 (0.21). Conclusions-The risk of insulin dependent diabetes in monozygotic twins is higher than previously thought and for dizygotic twins is higher than in ordinary first degree relatives. Based on the findings of this study the genetic component to the disease seems more important than hitherto believed.	ODENSE UNIV HOSP,CLIN RES INST,DEPT ENDOCRINOL M,ODENSE,DENMARK	University of Southern Denmark; Odense University Hospital	KYVIK, KO (corresponding author), ODENSE UNIV,INST COMMUNITY HLTH,GENET EPIDEMIOL RES UNIT,DK-5000 ODENSE,DENMARK.		Kyvik, Kirsten Ohm/K-5680-2016	Kyvik, Kirsten Ohm/0000-0003-2981-0245				ALLEN G, 1967, ACTA GENET STAT MED, V17, P475; Armitage P., 1994, STAT METHODS MED RES, V3; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; Bergh HT, 1939, Z GESAMTE NEUROL PSY, V165, P278, DOI 10.1007/BF02871508; GEDDA L, 1966, ACTA GENET MED GEMEL, V15, P109; GJESSING HJ, 1989, DIABETOLOGIA, V32, P305, DOI 10.1007/BF00265547; GOTTLIEB MS, 1968, DIABETES, V17, P693, DOI 10.2337/diab.17.11.693; GREEN A, 1981, DIABETOLOGIA, V20, P468; GREEN A, 1990, CURR TOP MICROBIOL, V164, P3; HARVALD B, 1965, DHEW PUBLICATION, V1163, P61; Hauge M, 1981, PROSPECTIVE LONGITUD, P217; HOLM NV, 1983, ACTA GENET MED GEMEL, V32, P37, DOI 10.1017/S000156600000814X; HOTHERNIELSEN O, 1988, DIABETES CARE, V11, P531, DOI 10.2337/diacare.11.7.531; Joslin EP, 1959, TREATMENT DIABETES M; KAPRIO J, 1992, DIABETOLOGIA, V35, P1060, DOI 10.1007/BF02221682; Khoury M, 1993, FUNDAMENTALS GENETIC; KUMAR D, 1993, DIABETES, V42, P1351, DOI 10.2337/diabetes.42.9.1351; KYVIK KO, 1995, INT J EPIDEMIOL, V24, P589, DOI 10.1093/ije/24.3.589; LORENZEN T, 1994, DIABETOLOGIA, V37, P321, DOI 10.1007/BF00398061; MAGNUS P, 1983, CLIN GENET, V24, P103; MCGUE M, 1992, SCHIZOPHRENIA BULL, V18, P171, DOI 10.1093/schbul/18.2.171; Neale M. C., 1990, NATO ASI SERIES; OLMOS P, 1988, DIABETOLOGIA, V31, P747, DOI 10.1007/BF00274777; SMITH C, 1974, AM J HUM GENET, V26, P454; TATTERSALL RB, 1972, LANCET, V2, P1120; 1994, WHO TECH REP SER, V844; [No title captured]	27	253	255	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					913	917						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580548				2022-12-28	WOS:A1995RZ23700019
J	KUH, D; STIRLING, S				KUH, D; STIRLING, S			SOCIOECONOMIC VARIATION IN ADMISSION FOR DISEASES OF FEMALE GENITAL SYSTEM AND BREAST IN A NATIONAL COHORT AGED 15-43	BRITISH MEDICAL JOURNAL			English	Article							HYSTERECTOMY; WOMEN; EPIDEMIOLOGY; MENORRHAGIA	Objective-To investigate socioeconomic variation among young women in the risk of hospital admission for diseases (including neoplasms) of the female genital system and breast and for the common surgical procedures of dilatation and curettage and hysterectomy. Design-Large nationally representative cohort study with individual records of confirmed admissions to NHS and private hospitals since birth and data on occupational and educational experience. Setting-England, Scotland, and Wales. Patients-General population sample of 1628 women, 1549 of whom had a complete admissions record for the ages of 15-43 years. Main outcome measures-The percentage of women admitted for neoplasms or other diseases of the female genital system and breast or who had dilatation and curettage or hysterectomy between the ages of 15 and 43 years. Results-By the age of 43, 35% of women had been admitted, 17% had undergone dilatation and curettage at least once, and 10% had had a hysterectomy. There were significant inverse educational gradients, the risk of admission increasing more than twofold between the most and least educated women. The differential risk was most striking for disorders of menstruation, in which only 1% of those with the highest educational qualifications and 19% of those with minimal qualifications had been admitted to hospital. There was a significant educational gradient in the hysterectomy rate (from 1% to 15%) and a twofold difference in the risk of dilatation and curettage. There were also significant gradients in risk of admission and of hysterectomy according to partner's social class. Conclusions-Socioeconomic variations in the risk of dilatation and curettage and of hysterectomy were large. Lessening the socioeconomic gradient in risks of admissions and surgery for diseases of the female genital system. and breast, particularly for menstrual disorders, could have important resource implications.			KUH, D (corresponding author), UNIV LONDON UNIV COLL,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,MED RES COUNCIL NATL SURVEY HLTH DEV,LONDON WC1E 6BT,ENGLAND.		Kuh, Diana/L-6019-2014	Kuh, Diana/0000-0001-7386-2857				BAYER LM, 1981, PRESENT PAST MIDDLE, P55, DOI DOI 10.1016/B978-0-12-233680-5.50009-5; BLAXTER M, 1987, LANCET, V2, P30; BLAXTER N, 1987, HLTH LIFESTYLE SURVE, P5; BOTO TCA, 1990, BRIT J HOSP MED, V44, P93; BRINTON LA, 1986, J CHRON DIS, V39, P1051, DOI 10.1016/0021-9681(86)90139-6; Buchan IC, 1973, TIME STUDY CONSULTAT; CARTWRIGHT A, 1976, SOCIOL REV MONOGR, V22, P77; CENTERWALL BS, 1981, AM J OBSTET GYNECOL, V139, P58, DOI 10.1016/0002-9378(81)90412-9; COLE SK, 1971, J OBSTET GYN BR COMM, V78, P933; COULTER A, 1993, BRIT MED J, V306, P236, DOI 10.1136/bmj.306.6872.236; COULTER A, 1994, FAM PRACT, V11, P67, DOI 10.1093/fampra/11.1.67; COULTER A, 1986, Q J SOC AFF, V2, P379; COULTER A, 1985, BRIT MED J, V291, P183, DOI 10.1136/bmj.291.6489.183; COULTER A, 1995, EUROPEAN J PUBLIC HL, V5, P123; GATH D, 1987, BMJ-BRIT MED J, V294, P213, DOI 10.1136/bmj.294.6566.213; GOLDBLATT P, 1990, 1971 1981 LONGITUDIN, P163; KJERULFF K, 1993, AM J PUBLIC HEALTH, V83, P106, DOI 10.2105/AJPH.83.1.106; MAGOS AL, 1991, LANCET, V337, P1074, DOI 10.1016/0140-6736(91)91718-A; MEILAHN EN, 1989, MATURITAS, V11, P319, DOI 10.1016/0378-5122(89)90028-5; Moser K., 1990, LONGITUDINAL STUDY M, P145; PENDLETON DA, 1980, SOC SCI MED, V36, P669; SIDDLE N, 1987, FERTIL STERIL, V47, P94; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x; Wadsworth M E, 1987, Paediatr Perinat Epidemiol, V1, P95, DOI 10.1111/j.1365-3016.1987.tb00093.x; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300; 1977, MB4 DEP HLTH SOC SEC; 1972, 1968 1972 DEP HLTH S; 1986, MB5 OFF POP CENS SUR; 1994, INPATIENT TREATMENT; 1982, MB1 OFF POP CENS SUR; 1964, 1961 1966 MIN HLTH G; 1972, BURNHAM FURTHER ED C; 1977, 1973 DEP HLTH SOC SE; 1983, MB4 OFF POP CENS SUR	35	32	33	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					840	843		10.1136/bmj.311.7009.840	http://dx.doi.org/10.1136/bmj.311.7009.840			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580490	Green Published			2022-12-28	WOS:A1995RY19100021
J	SHEPHERD, RM; DENT, THS; ALEXANDER, GJM; LONDON, M				SHEPHERD, RM; DENT, THS; ALEXANDER, GJM; LONDON, M			PREVALENCE OF ALCOHOL HISTORIES IN MEDICAL AND NURSING NOTES OF PATIENTS ADMITTED WITH SELF-POISONING	BRITISH MEDICAL JOURNAL			English	Article									FULBOURNE HOSP,CAMBRIDGE & HUNTINGDON HLTH COMMISS,DEPT HLTH POLICY & PUBL HLTH,CAMBRIDGE CB1 5EF,ENGLAND; DRINKING PROBLEMS SERV,CAMBRIDGE CB1 3DF,ENGLAND; ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge								DALY M, 1988, CURRENT RES SUICIDE; FREEMANTLE N, 1993, BRIEF INTERVENTIONS; GROOTENHUIS M, 1994, BRIT J PSYCHIAT, V165, P73, DOI 10.1192/bjp.165.1.73; PATEL AR, 1975, BRIT MED J, V2, P426, DOI 10.1136/bmj.2.5968.426; 1992, HLTH NATION STRATEGY	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					847	847		10.1136/bmj.311.7009.847	http://dx.doi.org/10.1136/bmj.311.7009.847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580493	Green Published			2022-12-28	WOS:A1995RY19100024
J	POWER, EJ				POWER, EJ			IDENTIFYING HEALTH TECHNOLOGIES THAT WORK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											POWER, EJ (corresponding author), US CONGRESS,OFF TECHNOL ASSESSMENT,HLTH PROGRAM,WASHINGTON,DC 20510, USA.							1994, IDENTIFYING HLTH TEC	1	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					205	205						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609216				2022-12-28	WOS:A1995RH93700005
J	SMITH, WC; MCKENDRY, R; RIBISI, S; HARLAND, RM				SMITH, WC; MCKENDRY, R; RIBISI, S; HARLAND, RM			A NODAL-RELATED GENE DEFINES A PHYSICAL AND FUNCTIONAL DOMAIN WITHIN THE SPEMANN ORGANIZER	CELL			English	Article							XENOPUS-LAEVIS; NEURAL INDUCTION; MESODERM INDUCTION; DORSAL MESODERM; INJECTED XWNT-8; EARLY RESPONSE; CELL MOTILITY; ACTIVIN; EMBRYOS; EXPRESSION	A functional screen for gene products that rescue dorsal development in ventralized Xenopus embryos has yielded Xenopus nodal-related 3 (Xnr3), a diverged member of the TGF beta superfamily. Xnr3 is specifically expressed in the Spemann organizer and is only expressed in the epithelial layer of the organizer immediately preceding and extending through gastrulation, Like noggin, Xnr3 can induce muscle in ventral mesoderm explants, consistent with a role in patterning the gastrula, In other ways, the activity of Xnr3 is different from noggin. Embryos receiving injections of Xnr3, particularly in the animal pole, send out tube-like extensions of tissue from the site of injection. These protrusions usually contain no axial mesoderm and only occasionally are positive for neural markers. It has previously been proposed that the epithelial layer of the organizer initiates and coordinates the morphogenetic movements at gastrulation. The protrusions observed may reflect an activity of Xnr3 in promoting morphogenesis.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley								AMAYA E, 1993, DEVELOPMENT, V118, P477; BOLCE ME, 1992, DEVELOPMENT, V115, P681; BOLCE ME, 1993, DEV BIOL, V160, P413, DOI 10.1006/dbio.1993.1317; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CONLON FL, 1994, DEVELOPMENT, V120, P1919; CONLON FL, 1991, DEVELOPMENT, V118, P969; Faber J., 1994, NORMAL TABLE XENOPUS, P2; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; HARLAND R, 1988, DEVELOPMENT, V102, P837; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; JOHNSON AD, 1994, GENE, V147, P233; JONES EA, 1989, DEVELOPMENT, V107, P785; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER R, 1991, METHOD CELL BIOL, V36, P61; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KNECHT AK, 1995, DEVELOPMENT, V121, P1911; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; LETTICE LA, 1993, DEVELOPMENT, V117, P263; PIERCE SB, 1995, DEVELOPMENT, V121, P755; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SHIH J, 1992, DEVELOPMENT, V116, P887; SHIH J, 1992, DEVELOPMENT, V116, P901; SHIH J, 1992, DEVELOPMENT, V116, P915; SLACK JMW, 1988, DEVELOPMENT, V103, P581; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; WILSON P, 1991, DEVELOPMENT, V112, P289; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	46	290	295	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					37	46		10.1016/0092-8674(95)90050-0	http://dx.doi.org/10.1016/0092-8674(95)90050-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606783	Bronze			2022-12-28	WOS:A1995RK42400007
J	BERTEAUXLECELLIER, V; PICARD, M; THOMPSONCOFFE, C; ZICKLER, D; PANVIERADOUTTE, A; SIMONET, JM				BERTEAUXLECELLIER, V; PICARD, M; THOMPSONCOFFE, C; ZICKLER, D; PANVIERADOUTTE, A; SIMONET, JM			A NONMAMMALIAN HOMOLOG OF THE PAF1 GENE (ZELLWEGER-SYNDROME) DISCOVERED AS A GENE INVOLVED IN CARYOGAMY IN THE FUNGUS PODOSPORA-ANSERINA	CELL			English	Article							ASSEMBLY FACTOR-I; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; NUCLEAR GENES; PEROXISOME; CLONING; COMPLEMENTATION; LOCALIZATION; BIOGENESIS; MUTANTS	The car1 gene of the filamentous fungus Podospora anserina was cloned by complementation of a mutant defective for caryogamy (nuclear fusion), a process required for sexual sporulation. This gene encodes a protein that shows similarity to the mammalian PAF1 protein (Zellweger syndrome). Besides sequence similarity, the two proteins share a transmembrane domain and the same type of zinc finger motif. A combination of molecular, physiological, genetical, and ultrastructural approaches gave evidence that the P. anserina car1 protein is actually a peroxisomal protein. This study shows that peroxisomes are required at a specific stage of sexual development, at least in P. anserina, and that a functional homolog of the PAF1 gene is present in a lower eucaryote.			BERTEAUXLECELLIER, V (corresponding author), UNIV PARIS 11,INST GENET & MICROBIOL,CNRS,URA 1354,F-91405 ORSAY,FRANCE.		BERTEAUX-LECELLIER, Veronique/P-6456-2019	BERTEAUX-LECELLIER, Veronique/0000-0003-2152-6231				AKINS RA, 1985, MOL CELL BIOL, V5, P2272, DOI 10.1128/MCB.5.9.2272; AUBOURG P, 1994, CURR OPIN GENET DEV, V4, P407, DOI 10.1016/0959-437X(94)90029-9; BELCOUR L, 1991, P NATL ACAD SCI USA, V88, P3579, DOI 10.1073/pnas.88.9.3579; BOSSIER P, 1994, YEAST, V10, P681, DOI 10.1002/yea.320100512; CAMONIS JH, 1990, GENE, V86, P263, DOI 10.1016/0378-1119(90)90288-3; DEBUCHY R, 1985, EMBO J, V4, P3553, DOI 10.1002/j.1460-2075.1985.tb04116.x; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; Esser K, 1974, HDB GENETICS, V1, P531; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HII V, 1982, J BACTERIOL, V150, P981, DOI 10.1128/JB.150.2.981-983.1982; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIONKA C, 1985, J BACTERIOL, V161, P153, DOI 10.1128/JB.161.1.153-157.1985; Kunau W.-H., 1987, PEROXISOMES BIOL MED, P128; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; KYTE J, 1982, J MOL BIOL, V157, P106; Lazarow Paul B., 1993, Trends in Cell Biology, V3, P89, DOI 10.1016/0962-8924(93)90079-G; LECELLIER G, 1994, CURR GENET, V25, P122, DOI 10.1007/BF00309536; MULLER WH, 1991, EMBO J, V10, P489, DOI 10.1002/j.1460-2075.1991.tb07971.x; ORACH MJ, 1991, FUNGAL GENET NEWSL, V38, P16; PATARCA R, 1992, FEBS LETT, V312, P1, DOI 10.1016/0014-5793(92)81397-5; PICARD M, 1991, GENETICS, V128, P539; PICARDBENNOUN M, 1976, MOL GEN GENET, V147, P299, DOI 10.1007/BF00582881; Reisener H.J., 1976, FUNGAL SPORE FORM FU, P165; RIZET GEORGES, 1949, REV CYTOL ET BIOL VEG, V11, P201; Rose MD, 1993, CURR OPIN CELL BIOL, V5, P105, DOI 10.1016/S0955-0674(05)80015-8; ROSE MD, 1991, ANNU REV MICROBIOL, V45, P539; ROSENTHAL A, 1993, NUCLEIC ACIDS RES, V21, P173, DOI 10.1093/nar/21.1.173; ROSSEN JM, 1967, C R A TRAV LAB CARLS, V35, P247; SHIMOZAWA N, 1993, AM J HUM GENET, V52, P843; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SIMONET JM, 1978, MOL GEN GENET, V162, P237, DOI 10.1007/BF00268848; SIMONET JM, 1972, CHROMOSOMA, V37, P327, DOI 10.1007/BF00319874; SLONIMSKI PP, 1993, YEAST, V9, P941, DOI 10.1002/yea.320090902; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; THIERINGER R, 1993, J BIOL CHEM, V17, P2631; THOMPSONCOFFE C, 1994, DEV BIOL, V165, P257, DOI 10.1006/dbio.1994.1251; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; TURCQ B, 1990, CURR GENET, V17, P297, DOI 10.1007/BF00314876; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDIJKEN JP, 1975, ARCH MICROBIOL, V105, P261, DOI 10.1007/BF00447145; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	45	92	94	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1043	1051		10.1016/S0092-8674(05)80009-1	http://dx.doi.org/10.1016/S0092-8674(05)80009-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600573	Bronze			2022-12-28	WOS:A1995RG91000009
J	BARRY, MA; LAI, WC; JOHNSTON, SA				BARRY, MA; LAI, WC; JOHNSTON, SA			PROTECTION AGAINST MYCOPLASMA-INFECTION USING EXPRESSION-LIBRARY IMMUNIZATION	NATURE			English	Article							IMMUNE-RESPONSES; GENETIC IMMUNIZATION; DNA; TRYPTOPHAN; UBIQUITIN; PULMONIS; ANTIGEN; CELLS; READ; UGA	As is evident from the human immunodeficiency virus epidemic, there is no systematic method for producing a vaccine, Genetic immunization(1) is a new approach to vaccine production that has many of the advantages of live/attenuated pathogens but no risk of infection. It involves introducing DNA encoding a pathogen protein into host cells and has shown promise in several disease models(2-13) Here we describe a new method for vaccine development, expression-library immunization, which makes use of the technique of genetic immunization and the fact that all the antigens of a pathogen are encoded in its DNA. An expression library of pathogen DNA is used to immunize a host thereby producing the effects of antigen presentation of a live vaccine without the risk. We show that even partial expression libraries made from the DNA of Mycoplasma pulmonis, a natural pathogen in rodents, provide protection against challenge from the pathogen. Expression library immunization may prove to be a general method for vaccination against any pathogen.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DIV COMPARAT MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARRY MA, 1994, BIOTECHNIQUES, V16, P616; CASSELL GH, 1982, REV INFECT DIS, V4, P518; CONEY L, 1994, VACCINE, V12, P1545, DOI 10.1016/0264-410X(94)90082-5; CONRY RM, 1994, CANCER RES, V54, P1164; COX GJM, 1993, J VIROL, V67, P5664, DOI 10.1128/JVI.67.9.5664-5667.1993; DAVIDSON MK, 1982, REV INFECT DIS, V4, pS243; DAVIS HL, 1993, HUM MOL GENET, V2, P1847, DOI 10.1093/hmg/2.11.1847; ECKER DJ, 1989, J BIOL CHEM, V264, P7715; EISENBRAUN MD, 1993, DNA CELL BIOL, V12, P791, DOI 10.1089/dna.1993.12.791; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; INAMINE JM, 1990, J BACTERIOL, V172, P504, DOI 10.1128/JB.172.1.504-506.1990; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KATSUMI A, 1994, HUM GENE THER, V5, P1335, DOI 10.1089/hum.1994.5.11-1335; Lai Wayne C., 1995, P469, DOI 10.1016/B978-012583805-4/50050-9; LAI WC, 1991, INFECT IMMUN, V59, P346, DOI 10.1128/IAI.59.1.346-350.1991; LAI WC, 1990, J INFECT DIS, V161, P1269, DOI 10.1093/infdis/161.6.1269; LINDSEY JR, 1978, PATHOLOGY LABORATORY, P1482; NEIMARK HC, 1990, NUCLEIC ACIDS RES, V18, P5443, DOI 10.1093/nar/18.18.5443; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; TAYLOR G, 1976, IMMUNOLOGY, V30, P611; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105; XU D, 1994, VACCINE, V12, P1534, DOI 10.1016/0264-410X(94)90079-5; YAMAO F, 1985, P NATL ACAD SCI USA, V82, P2306, DOI 10.1073/pnas.82.8.2306	29	255	297	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					632	635		10.1038/377632a0	http://dx.doi.org/10.1038/377632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566175				2022-12-28	WOS:A1995TA27500053
J	GELLERT, GA				GELLERT, GA			HUMANITARIAN RESPONSES TO MASS VIOLENCE PERPETRATED AGAINST VULNERABLE POPULATIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH	This multidisciplinary review links three areas of legitimate inquiry for practitioners of medicine and public health. The first is occurrences of mass violence or genocide perpetrated against vulnerable populations, with a focus on the failure of national and international mechanisms to prevent or predict such violence. The second is evolving concepts of national sovereignty and an emerging framework in which the imperative to assist vulnerable populations supersedes a state's right to self determination. The last is how medical, public health, and other systems of surveillance and rapid assessment of mass violence can accelerate public awareness and facilitate structured, consistent political decision making to prevent mass violence and to provide international humanitarian assistance.			GELLERT, GA (corresponding author), PROJECT HOPE SCI EDUC CTR, MILLWOOD, VA 22646 USA.							BAZYLER MJ, 1987, STANFORD J INT LAW, V23, P547; BIGELOW KR, 1992, GENOCIDE WATCH, P189; Boutros-Ghali B., 1992, INT RELAT, V11, P201; BROWN LR, 1972, WORLD BORDERS INTERD; de Cuellar J.P., 1991, REPORT SECRETARY GEN; Deng F. M., 1993, PROTECTING DISPOSSES; EZELL WK, 1992, GENOCIDE WATCH, P87; FEIN H, 1992, GENOCIDE WATCH, P1; FRELICK B, 1992, GENOCIDE WATCH, P45; FRELICK B, 1989, WORLD REFUGEE SURVEY, P13; GELLERT GA, 1990, JAMA-J AM MED ASSOC, V264, P610; GURR TR, 1989, HUM RIGHTS QUART, V11, P375; HARFF B, 1992, GENOCIDE WATCH, P27; Harff Barbara, 1989, INT REV VICTIMOLOGY, V1, P23, DOI DOI 10.1177/026975808900100103; HEMRET G, 1992, MED FRONTIERES POPUL; Keohane RobertO., 1997, POWER INTERDEPENDENC; KOESTLER A, 1987, SOCIAL SCI RECORD, V24, P63; KUPER L, 1992, GENOCIDE WATCH, P135; LEMKIN A, 1944, AXIS RLE OCCUPIED EU; Minear Larry, 1992, CHALLENGES FAMINE RE; PECHOTA V, 1992, GENOCIDE WATCH, P197; SHEARS P, 1987, BMJ-BRIT MED J, V295, P314, DOI 10.1136/bmj.295.6593.314; SHEARS P, 1987, INT MIGR REV, V21, P783, DOI 10.2307/2546622; SIVARD R, 1993, WORLD MILITARY SOCIA; STANLEY W, 1985, REFUGEE REPORTS 0816, P1; Staub Ervin, 1989, ROOTS EVIL ORIGINS G; THOMPSON M, 1994, TIME           1212, P46; 1986, MMWR-MORBID MORTAL W, V35, P384; 1990, FOOD POLICY, V1, P6; 1984, MMWR-MORBID MORTAL W, V33, P565; 1991, MMWR-MORBID MORTAL W, V40, P222; 1989, US EC ASSISTANCE 21S; 1992, MOBMORTAL WKLY REP, V41, pRR13; 1989, CRIME GENOCIDE BILL; 1991, MMWR-MORBID MORTAL W, V40, P443; 1985, MMWR-MORBID MORTAL W, V43, P665; 1989, MMWR-MORBID MORTAL W, V38, P848; 1986, MMWR-MORBID MORTAL W, V35, P5; 1946, UN GENOCIDE CONVENTI; 1987, MMWR-MORBID MORTAL W, V37, P104	40	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 14	1995	311	7011					995	1001						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580643				2022-12-28	WOS:A1995TA07900029
J	HEITMANN, BL; LISSNER, L				HEITMANN, BL; LISSNER, L			DIETARY UNDERREPORTING BY OBESE INDIVIDUALS - IS IT SPECIFIC OR NONSPECIFIC	BRITISH MEDICAL JOURNAL			English	Article							AGED 35-65 YEARS; ENERGY-EXPENDITURE; BODY-COMPOSITION; DANISH POPULATION; URINE NITROGEN; WOMEN; PREDICTION; FAT; MEN	Objective-To examine the distribution of patterns of macronutrient density in relation to obesity. Design-Cross sectional. Setting-Denmark. Subjects-323 men and women aged 35-65 years, selected randomly from a larger population sample of Danish adults. Main outcome measure-Bias in dietary reporting of energy and protein intake in relation to percentage body fat, assessed by comparison of data from an interview on dietary intake with data estimated from 24 hour nitrogen output, validated by administering p-aminobenzoic acid, and estimated 24 hour energy expenditure. Results-Degree of obesity was positively associated with underreporting of total energy and protein, whereas compared with total energy reported, protein was overreported by the obese subjects. Conclusion-Errors in dietary reporting of protein seem to occur disproportionately with respect to total energy, suggesting a differential reporting pattern of different foods. Although, on average, all subjects showed a greater underreporting of energy than of protein, this was most common in the obese subjects. Snack-type foods may be preferentially forgotten when obese people omit food items in dietary reporting. These results seem to agree with the general assumption that obese people tend to underreport fatty foods and foods rich in carbohydrates rather than underreport their total dietary intake. These results may have implications for the interpretation of studies of diet and comorbidities related to obesity.	DANISH EPIDEMIOL SCI CTR,INST PREVENT MED,COPENHAGEN,DENMARK; GLOSTRUP CTY HOSP,DEPT MED C,GLOSTRUP,DENMARK; GOTHENBURG UNIV,DEPT INTERNAL MED & PRIMARY HLTH CARE,GOTHENBURG,SWEDEN	Aarhus University; University of Copenhagen; University of Gothenburg				Heitmann, Berit Lilienthal/0000-0002-6809-4504				ASTRUP A, 1990, AM J CLIN NUTR, V52, P777, DOI 10.1093/ajcn/52.5.777; BINGHAM S, 1983, CLIN SCI, V64, P629, DOI 10.1042/cs0640629; BINGHAM SA, 1985, AM J CLIN NUTR, V42, P1276, DOI 10.1093/ajcn/42.6.1276; BINGHAM SA, 1991, BIOMARKERS DIETARY E, P41; BLACK AE, 1991, EUR J CLIN NUTR, V45, P583; BLACK AE, 1991, P NUTR SOC, V50, pA108; CUNNINGHAM JJ, 1991, AM J CLIN NUTR, V54, P963, DOI 10.1093/ajcn/54.6.963; DREWNOWSKI A, 1992, APPETITE, V18, P207, DOI 10.1016/0195-6663(92)90198-F; GARBY L, 1988, EUR J CLIN NUTR, V42, P301; HEITMANN BL, 1992, J CLIN EPIDEMIOL, V45, P693, DOI 10.1016/0895-4356(92)90046-P; HEITMANN BL, 1993, INT J OBESITY, V17, P329; HEITMANN BL, 1991, INT J OBESITY, V15, P535; HEITMANN BL, 1990, INT J OBESITY, V14, P789; HULTEN B, 1990, EUR J CLIN NUTR, V44, P169; ISAKSSON B, 1980, AM J CLIN NUTR, V33, P4, DOI 10.1093/ajcn/33.1.4; JENSEN KH, 1991, GASTROENTEROLOGY, V100, P790, DOI 10.1016/0016-5085(91)80027-7; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; LISSNER L, 1994, EUR J CLIN NUTR, V48, P453; LISSNER L, 1989, AM J CLIN NUTR, V49, P320, DOI 10.1093/ajcn/49.2.320; LIVINGSTONE MBE, 1990, BRIT MED J, V300, P708, DOI 10.1136/bmj.300.6726.708; MOLLER A, 1986, PUBLICATION MINISTRY, V75; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; RUTISHAUSER IHE, 1995, EUR J CLIN NUTR, V49, P219; SCHOELLER DA, 1990, NUTR REV, V48, P373, DOI 10.1111/j.1753-4887.1990.tb02882.x; SUMMERBELL CD, 1995, EUR J CLIN NUTR, V49, P33; 1989, WHO EUR ICP NUT125 N	26	510	512	1	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					986	989						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580640				2022-12-28	WOS:A1995TA07900023
J	KEITH, CT; SCHREIBER, SL				KEITH, CT; SCHREIBER, SL			PIK-RELATED KINASES - DNA-REPAIR, RECOMBINATION, AND CELL-CYCLE CHECKPOINTS	SCIENCE			English	Editorial Material							ATAXIA-TELANGIECTASIA; PROTEIN-KINASE; SCID MUTATION; MUTANTS; YEAST; ENDS				KEITH, CT (corresponding author), HARVARD UNIV, HOWARD HUGHES MED INST, DEPT CHEM, CAMBRIDGE, MA 02138 USA.							ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CANMAN CE, 1994, CANCER RES, V54, P5054; CIMPJRICH K, COMMUNICATION; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GOTTLIEB TM, 1994, TRENDS BIOCHEM SCI, V19, P500, DOI 10.1016/0968-0004(94)90138-4; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HITTELMAN WN, 1994, INT J RADIAT BIOL, V66, pS109; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KIRSCH IR, 1994, INT J RADIAT BIOL, V66, pS97, DOI 10.1080/09553009414551921; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	32	435	461	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 6	1995	270	5233					50	51		10.1126/science.270.5233.50	http://dx.doi.org/10.1126/science.270.5233.50			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569949				2022-12-28	WOS:A1995RY30200027
J	BROWN, EJ; BEAL, PA; KEITH, CT; CHEN, J; SHIN, TB; SCHREIBER, SL				BROWN, EJ; BEAL, PA; KEITH, CT; CHEN, J; SHIN, TB; SCHREIBER, SL			CONTROL OF P70 S6 KINASE BY KINASE-ACTIVITY OF FRAP IN-VIVO	NATURE			English	Article							RAPAMYCIN-INDUCED INHIBITION; PROTEIN-KINASE; LYMPHOCYTES-T; RAT-LIVER; ACTIVATION; IDENTIFICATION; ENZYME; VPS34	WHEN complexed with the inh acellular protein FKBP12, rapamycin is a potent immunosuppressant(1,2) and an inhibitor of a mitogen-stimulated signalling pathway that leads to activation of p70 S6 kinase(3-6) (p70(S6k)) and cyclin-dependent kinases(7-10) (CDKs). A recently cloned FKBP12-rapamycin-associated protein (FRAP/RAFT) is the likely mediator of these effects(11,12). Using FRAP variants that do not bind FKBP12-rapamycin, we demonstrate here that FRAP is a rapamycin-sensitive regulator of p70(S6k) in vivo and that the kinase activity of FRAP is required for this regulation. In addition, we show that FRAP autophosphorylates in vitro. Consistent with an essential role for FRAP kinase activity in vivo, autophosphorylation of FRAP is inhibited by FKBP12-rapamycin. Deletion studies indicate that the kinase activity of FRAP alone is not sufficient for control of p70(S6k) and that an amino-terminal domain in FRAP is also required.	HARVARD UNIV, HOWARD HUGHES MED INST, DEPT CHEM, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, PROGRAM IMMUNOL, CAMBRIDGE, MA 02138 USA	Harvard University; Howard Hughes Medical Institute; Harvard University				Chen, Jie/0000-0002-7887-3747				ALBERS MW, 1993, J BIOL CHEM, V268, P22825; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORICE WG, 1993, J BIOL CHEM, V268, P3734; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	26	604	614	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 5	1995	377	6548					441	446		10.1038/377441a0	http://dx.doi.org/10.1038/377441a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566123				2022-12-28	WOS:A1995RY19000053
J	MCGEHEE, DS; HEATH, MJS; GELBER, S; DEVAY, P; ROLE, LW				MCGEHEE, DS; HEATH, MJS; GELBER, S; DEVAY, P; ROLE, LW			NICOTINE ENHANCEMENT OF FAST EXCITATORY SYNAPTIC TRANSMISSION IN CNS BY PRESYNAPTIC RECEPTORS	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT INTERPEDUNCULAR NUCLEUS; ACETYLCHOLINE-RECEPTORS; SYMPATHETIC NEURONS; CHICK RETINA; H-3 NICOTINE; SUBUNIT; CALCIUM; SENSITIVITY; MODULATION	The behavioral and cognitive effects of nicotine suggest that nicotinic acetylcholine receptors (nAChRs) participate in central nervous system (CNS) function. Although nAChR subunit messenger RNA (mRNA) and nicotine binding sites are common in the brain, there is little evidence for synapses mediated by nAChRs in the CNS. To test whether CNS nAChRs might modify rather than mediate transmission, the regulation of excitatory synaptic transmission by these receptors was examined. Nanomolar concentrations of nicotine enhanced both glutamatergic and cholinergic synaptic transmission by activation of presynaptic nAChRs that increased presynaptic [Ca2+](i). Pharmacological and subunit deletion experiments reveal that these presynaptic nAChRs include the alpha 7 subunit. These findings reveal that CNS nAChRs enhance fast excitatory transmission, providing a likely mechanism for the complex behavioral effects of nicotine.	COLUMBIA UNIV, COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, DEPT CELL BIOL & ANAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT ANESTHESIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University			Role, LW/Q-7371-2018	Role, LW/0000-0001-5851-212X	NINDS NIH HHS [NS09395, NS22061] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022061] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANAND R, 1993, MOL PHARMACOL, V44, P1046; ANAND R, 1993, FEBS LETT, V327, P241, DOI 10.1016/0014-5793(93)80177-V; Benowitz N. L, 1990, NICOTINE PSYCHOPHARM, P112; BROWN DA, 1983, J PHYSIOL-LONDON, V341, P655, DOI 10.1113/jphysiol.1983.sp014831; BRUSSAARD AB, 1994, PFLUG ARCH EUR J PHY, V429, P27, DOI 10.1007/BF02584027; CLARKE PBS, 1986, J COMP NEUROL, V251, P407, DOI 10.1002/cne.902510311; CLARKE PBS, 1985, BRAIN RES, V348, P355, DOI 10.1016/0006-8993(85)90456-1; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DINELEYMILLER K, 1992, MOL BRAIN RES, V16, P339, DOI 10.1016/0169-328X(92)90244-6; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; ELBIZRI H, 1994, BRIT J PHARMACOL, V111, P414, DOI 10.1111/j.1476-5381.1994.tb14750.x; FAZELI MS, 1992, TRENDS NEUROSCI, V15, P115, DOI 10.1016/0166-2236(92)90350-H; GARDETTE R, 1991, DEV BIOL, V147, P83, DOI 10.1016/S0012-1606(05)80009-0; GRADY S, 1992, J NEUROCHEM, V59, P848, DOI 10.1111/j.1471-4159.1992.tb08322.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL GS, 1986, J COMP NEUROL, V251, P398, DOI 10.1002/cne.902510310; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEATH MJS, 1995, J PHYSL, P139; HEINEMANN S, 1990, PROG BRAIN RES, V86, P195; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IWAMOTO ET, 1991, J PHARMACOL EXP THER, V257, P120; KEYSER KT, 1993, J NEUROSCI, V13, P442; LENA C, 1993, J NEUROSCI, V13, P2680, DOI 10.1523/JNEUROSCI.13-06-02680.1993; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MCMAHON LL, 1994, NEUROSCIENCE, V59, P689, DOI 10.1016/0306-4522(94)90187-2; Press WP, 1986, NUMERICAL RECIPES, P472; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RATHOUZ MM, 1994, J NEUROSCI, V14, P6935; ROLE LW, 1988, P NATL ACAD SCI USA, V85, P2825, DOI 10.1073/pnas.85.8.2825; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHOEPFER R, 1994, MOL PHARMACOL, V45, P212; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; SEGUELA P, 1993, J NEUROSCI, V13, P596; Siegelbaum S A, 1991, Curr Opin Neurobiol, V1, P113, DOI 10.1016/0959-4388(91)90018-3; SORENSON EM, 1989, J COMP NEUROL, V281, P641, DOI 10.1002/cne.902810412; STOLERMAN IP, 1990, NICOTINE PSYCHOPHARM, P278; VERNINO S, 1994, J NEUROSCI, V14, P5514; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; VIDAL C, 1989, NEUROSCIENCE, V29, P261, DOI 10.1016/0306-4522(89)90056-0; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WARBURTON DM, 1992, PROG NEURO-PSYCHOPH, V16, P181, DOI 10.1016/0278-5846(92)90069-Q; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; WILSON JR, 1972, J COMP PHYSIOL PSYCH, V78, P442, DOI 10.1037/h0032371; WIRTSHAFTER D, 1981, PHYSIOL BEHAV, V26, P985, DOI 10.1016/0031-9384(81)90197-9; WONNACOTT S, 1990, CIBA F SYMP, V152, P87; Yang X., UNPUB; YU ZJ, 1994, J NEUROCHEM, V63, P186; ZHANG M, 1993, EXP BRAIN RES, V96, P83, DOI 10.1007/BF00230441	49	885	901	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 22	1995	269	5231					1692	1696		10.1126/science.7569895	http://dx.doi.org/10.1126/science.7569895			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569895				2022-12-28	WOS:A1995RV94800028
J	TSUGORKA, A; RIOS, E; BLATTER, LA				TSUGORKA, A; RIOS, E; BLATTER, LA			IMAGING ELEMENTARY EVENTS OF CALCIUM-RELEASE IN SKELETAL-MUSCLE CELLS	SCIENCE			English	Article							SARCOPLASMIC-RETICULUM; CARDIAC-MUSCLE; RYANODINE; FIBERS; CHANNEL; RECEPTORS; CHARGE; BRAIN	In skeletal muscle cells, calcium release to trigger contraction occurs at triads, specialized junctions where sarcoplasmic reticulum channels are opened by voltage sensors in the transverse tubule. Scanning confocal microscopy was used in cells under voltage clamp to measure the concentration of intracellular calcium, [Ca2+](i), at individual triads and [Ca2+](i) gradients that were proportional to calcium release. In cells stimulated with small depolarizations, the [Ca2+](i) gradients broke down into elementary events, corresponding to sing le-chan net currents of about 0.1 picoampere. Because these events were one-tenth to one-fifth the size of calcium sparks (elementary release events of cardiac muscle), skeletal muscle control mechanisms appear to be fundamentally different.	RUSH UNIV,DEPT MOLEC BIOPHYS & PHYSIOL,CHICAGO,IL 60612; LOYOLA UNIV,DEPT PHYSIOL,MAYWOOD,IL 60153; AA BOGOMOLETS PHYSIOL INST,KIEV 252601,UKRAINE	Rush University; Loyola University Chicago; National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of Physiology			Blatter, Lothar/AAC-8431-2020					ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BERS DM, 1993, AM J PHYSIOL, V264, pC1587, DOI 10.1152/ajpcell.1993.264.6.C1587; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRUM G, 1988, J PHYSIOL-LONDON, V398, P441, DOI 10.1113/jphysiol.1988.sp017052; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; ESCOBAR AL, 1994, NATURE, V367, P739, DOI 10.1038/367739a0; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GONZALEZ A, 1993, J GEN PHYSIOL, V102, P272; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARKINS AB, 1993, BIOPHYS J, V65, P865, DOI 10.1016/S0006-3495(93)81112-3; KOVACS L, 1979, NATURE, V279, P391, DOI 10.1038/279391a0; LESH RE, 1993, CIRC RES, V72, P481, DOI 10.1161/01.RES.72.2.481; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; LOPEZLOPEZ JR, 1994, J PHYSIOL-LONDON, V480, P21, DOI 10.1113/jphysiol.1994.sp020337; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MEISSNER G, 1994, ANN REV PHYSL, V76, P485; MELZER W, 1984, BIOPHYS J, V45, P637, DOI 10.1016/S0006-3495(84)84203-4; MELZER W, 1987, BIOPHYS J, V51, P849, DOI 10.1016/S0006-3495(87)83413-6; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; SATOH H, UNPUB; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SHIROKOVA N, IN PRESS J GEN PHYSL; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; SUN XH, 1995, J CELL BIOL, V129, P979; TINKER A, 1992, J GEN PHYSIOL, V100, P495, DOI 10.1085/jgp.100.3.495	34	251	257	1	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1723	1726		10.1126/science.7569901	http://dx.doi.org/10.1126/science.7569901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569901				2022-12-28	WOS:A1995RV94800039
J	NAKAO, S; TAKENAKA, T; MAEDA, M; KODAMA, C; TANAKA, A; TAHARA, M; YOSHIDA, A; KURIYAMA, M; HAYASHIBE, H; SAKURABA, H; TANAKA, H				NAKAO, S; TAKENAKA, T; MAEDA, M; KODAMA, C; TANAKA, A; TAHARA, M; YOSHIDA, A; KURIYAMA, M; HAYASHIBE, H; SAKURABA, H; TANAKA, H			AN ATYPICAL VARIANT OF FABRYS-DISEASE IN MEN WITH LEFT-VENTRICULAR HYPERTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-GALACTOSIDASE-A; POINT MUTATIONS; CARDIOMYOPATHY; GENE; MANIFESTATIONS; HEMIZYGOTES; IDENTIFICATION; HETEROZYGOTES; REGION	Background. Fabry's disease is an x-linked recessive disorder that results from a deficiency of alpha-galactosidase. Left ventricular hypertrophy is one of the common manifestations in men with classic hemizygous disease. Recently, several cases of an atypical variant of hemizygous Fabry's disease, with manifestations limited to the heart, have been reported. Therefore, we assessed the incidence of hemizygosity for Fabry's disease among male patients with left ventricular hypertrophy. Methods. We measured plasma alpha-galactosidase activity in 230 consecutive male patients with left ventricular hypertrophy. Clinical manifestations were assessed, endomyocardial biopsies were performed, and the patients were screened for mutations in the alpha-galactosidase gene. Results. Seven of the 230 patients with left ventricular hypertrophy (3 percent) had low plasma alpha-galactosidase activity (4 to 14 percent of the mean value in normal controls). These seven unrelated patients, ranging in age from 55 to 72 years, did not have angiokeratoma, acroparesthesias, hypohidrosis, or corneal opacities, which are typical manifestations of Fabry's disease. Endomyocardial biopsy was performed in five patients and revealed marked sarcoplasmic vacuolization in all five. Samples from four patients were examined by electron microscopy and revealed typical lysosomal inclusions with a concentric lamellar configuration in all four. Two patients had novel missense mutations in exon 1 and exon 6. The remaining five had no mutations in the coding region of the alpha-galactosidase gene, but the amounts of the alpha-galactosidase messenger RNA were markedly lower than normal. Conclusions. Seven unrelated patients with atypical variants of hemizygous Fabry's disease were found among 230 men with left ventricular hypertrophy. Fabry's disease should be considered as a cause of unexplained left ventricular hypertrophy.	KAGOSHIMA UNIV, FAC MED, DEPT INTERNAL MED 1, KAGOSHIMA 890, JAPAN; KAGOSHIMA UNIV, FAC MED, DEPT PATHOL 1, KAGOSHIMA 890, JAPAN; KAGOSHIMA UNIV, FAC MED, DEPT INTERNAL MED 3, KAGOSHIMA 890, JAPAN; TOKYO METROPOLITAN INST MED SCI, DEPT CLIN GENET, TOKYO 113, JAPAN	Kagoshima University; Kagoshima University; Kagoshima University; Tokyo Metropolitan Institute of Medical Science								ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; BASS JL, 1980, AM HEART J, V100, P807, DOI 10.1016/0002-8703(80)90060-5; BECKER AE, 1975, AM J CARDIOL, V36, P829, DOI 10.1016/0002-9149(75)90468-3; BISHOP DF, 1988, P NATL ACAD SCI USA, V85, P3903, DOI 10.1073/pnas.85.11.3903; BRADY RO, 1967, NEW ENGL J MED, V276, P1163, DOI 10.1056/NEJM196705252762101; COLUCCI WS, 1982, NEW ENGL J MED, V307, P926, DOI 10.1056/NEJM198210073071505; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DESNICK RJ, 1973, J LAB CLIN MED, V81, P157; DESNICK RJ, 1976, CIRCULATION, V54, P818, DOI 10.1161/01.CIR.54.5.818; DESNICK RJ, 1995, METABOLIC MOL BASIS, V2, P2741; ELLEDER M, 1990, VIRCHOWS ARCH A, V417, P449, DOI 10.1007/BF01606034; ENG CM, 1993, AM J HUM GENET, V53, P1186; FELNER JM, 1990, HEART, P1990; FERRANS VJ, 1969, AM J CARDIOL, V24, P95, DOI 10.1016/0002-9149(69)90055-1; FISHER EA, 1992, ANN INTERN MED, V117, P221, DOI 10.7326/0003-4819-117-3-221; GOLDMAN ME, 1986, J AM COLL CARDIOL, V7, P1157, DOI 10.1016/S0735-1097(86)80238-8; HENRY WL, 1973, CIRCULATION, V47, P225, DOI 10.1161/01.CIR.47.2.225; IKARI Y, 1992, BRIT HEART J, V68, P323; ISHII S, 1992, HUM GENET, V89, P29, DOI 10.1007/BF00207037; ISHII S, 1994, BBA-PROTEIN STRUCT M, V1204, P265, DOI 10.1016/0167-4838(94)90017-5; KOIDE T, 1990, FEBS LETT, V259, P353, DOI 10.1016/0014-5793(90)80046-L; KUHN H, 1982, CIRCULATION, V66, P117; MATSUI S, 1977, JPN CIRC J, V41, P1023, DOI 10.1253/jcj.41.1023; MAYES JS, 1981, CLIN CHIM ACTA, V112, P247, DOI 10.1016/0009-8981(81)90384-3; MEHTA J, 1977, AM HEART J, V93, P699, DOI 10.1016/S0002-8703(77)80064-1; NAGAO Y, 1991, CLIN GENET, V39, P233; OGAWA K, 1990, HUM PATHOL, V21, P1067, DOI 10.1016/0046-8177(90)90258-7; ROUDEBUSH CP, 1973, NEW ENGL J MED, V289, P357, DOI 10.1056/NEJM197308162890709; SAKURABA H, 1986, CLIN GENET, V29, P276; SAKURABA H, 1990, AM J HUM GENET, V47, P784; Sambrook J, 1989, MOL CLONING LABORATO; VONSCHEIDT W, 1991, NEW ENGL J MED, V324, P395, DOI 10.1056/NEJM199102073240607; WEBB JG, 1990, J AM COLL CARDIOL, V15, P83, DOI 10.1016/0735-1097(90)90180-W; YANAGAWA Y, 1988, Acta Paediatrica Japonica, V30, P38	34	571	612	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					288	293		10.1056/NEJM199508033330504	http://dx.doi.org/10.1056/NEJM199508033330504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL694	7596372	Bronze			2022-12-28	WOS:A1995RL69400004
J	PECKHAM, C; GIBB, D				PECKHAM, C; GIBB, D			CURRENT CONCEPTS - MOTHER-TO-CHILD TRANSMISSION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PNEUMOCYSTIS-CARINII PNEUMONIA; HIV-1 INFECTION; ANTIBODIES; TYPE-1; SURVIVAL; INFANTS; RISK		GREAT ORMOND ST HOSP CHILDREN,LONDON,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	PECKHAM, C (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,30 GUILFORD ST,LONDON WC1,ENGLAND.							BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; BORKOWSKY W, 1994, J PEDIATR-US, V125, P345, DOI 10.1016/S0022-3476(05)83274-3; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; BRYSON Y, 1993, 9TH INT C AIDS 4TH S, V1, P91; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; BURGARD M, 1992, NEW ENGL J MED, V327, P1192, DOI 10.1056/NEJM199210223271702; BURNS DN, 1994, J ACQ IMMUN DEF SYND, V7, P718; CHU SY, 1991, PEDIATRICS, V87, P806; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CONNOR EM, 1994, PEDIATR INFECT DIS J, V13, P719; CONNOR EM, 1994, PEDIATR INFECT DIS J, V13, P608; CONNOR EM, 1994, PEDIATR INFECT DIS J, V13, P440, DOI 10.1097/00006454-199405000-00036; Dabis F, 1995, AIDS, V9 Suppl A, pS67; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; DUNN DT, 1994, J ACQ IMMUN DEF SYND, V7, P1064; GIBB DM, 1994, ARCH DIS CHILD, V70, P241, DOI 10.1136/adc.70.3.241; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; KATZ BZ, 1992, J PEDIATR-US, V120, P228, DOI 10.1016/S0022-3476(05)80432-9; KIND C, 1992, EUR J PEDIATR, V151, P442, DOI 10.1007/BF01959360; KLIKS SC, 1994, JAMA-J AM MED ASSOC, V272, P467, DOI 10.1001/jama.272.6.467; MCINTOSH K, 1994, J INFECT DIS, V170, P996, DOI 10.1093/infdis/170.4.996; MILES SA, 1993, NEW ENGL J MED, V328, P297, DOI 10.1056/NEJM199302043280501; NAIR P, 1993, J ACQ IMMUN DEF SYND, V6, P298; NEWELL ML, 1993, AIDS, V7, pS91, DOI 10.1097/00002030-199301001-00012; NEWELL ML, IN PRESS J MED VIROL; NEWELL ML, 1994, PEDIATR AIDS HIV INF, P21; NICOLL A, 1994, AIDS, V8, P995, DOI 10.1097/00002030-199407000-00019; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; QUINN TC, 1991, JAMA-J AM MED ASSOC, V266, P3439, DOI 10.1001/jama.266.24.3439; ROGERS MF, 1994, NEW ENGL J MED, V331, P1223; ROQUES P, 1993, AIDS, V7, pS39, DOI 10.1097/00002030-199311002-00009; SCARLATTI G, 1993, J INFECT DIS, V168, P207, DOI 10.1093/infdis/168.1.207; STAVOLA JJ, 1993, PEDIATR INFECT DIS J, V12, P644, DOI 10.1097/00006454-199308000-00004; The European Collaborative Study, 1994, PEDIATRICS, V94, P815; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; TURNER BJ, 1993, PEDIATR INFECT DIS J, V12, P310, DOI 10.1097/00006454-199304000-00010; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; WEISER B, 1994, P NATL ACAD SCI USA, V91, P8037, DOI 10.1073/pnas.91.17.8037; WILFERT CM, 1994, J INFECT DIS, V170, P286, DOI 10.1093/infdis/170.2.286; 1992, CONSENSUS STATEMENT; 1994, PEDIATR INFECT DIS J, V13, P502; 1995, MMWR-MORBID MORTAL W, V44, P1; 1994, MMWR-MORBID MORTAL W, V43, P1; 1993, PEDIATR INFECT DIS J, V12, P513; 1995, MMWR-MORBID MORTAL W, V44, P135; 1992, J ACQ IMMUN DEF SYND, V5, P1019; 1992, PEDIATR INFECT DIS J, V11, P1018; 1991, JAMA-J AM MED ASSOC, V265, P1637; 1991, LANCET, V337, P253; 1995, J AIDS HUM VIROL, V8, P161; 1992, J ACQ IMMUN DEF SYND, V5, P1169; 1994, BRIT MED J, V308, P437; 1994, LANCET, V343, P191; 1992, LANCET, V339, P1007; 1995, J ACQ IMMUN DEF SYND, V8, P1495; 1994, LANCET, V343, P1464	59	147	150	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					298	302		10.1056/NEJM199508033330507	http://dx.doi.org/10.1056/NEJM199508033330507			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL694	7596375				2022-12-28	WOS:A1995RL69400007
J	FOREYT, J; GOODRICK, K				FOREYT, J; GOODRICK, K			THE ULTIMATE TRIUMPH OF OBESITY	LANCET			English	Editorial Material											FOREYT, J (corresponding author), BAYLOR COLL MED,DEPT MED,NUTR RES CLIN,HOUSTON,TX 77030, USA.							BENNETT WI, 1995, NEW ENGL J MED, V332, P673, DOI 10.1056/NEJM199503093321009; Foreyt J P, 1994, Obes Res, V2, P378; FOREYT JP, 1994, LIVING DIETING; KIRSCHENBAUM DS, 1995, BEHAV THER, V26, P43, DOI 10.1016/S0005-7894(05)80082-6; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LISSNER L, 1994, PHARMACOECONOMICS, V5, P8, DOI 10.2165/00019053-199400051-00004; Logue A. W., 2014, PSYCHOL EATING DRINK; POWELL KE, 1994, MED SCI SPORT EXER, V26, P851; RESNICOW K, 1993, ANN NY ACAD SCI, V699, P154, DOI 10.1111/j.1749-6632.1993.tb18847.x; Seligman, 1994, WHAT YOU CAN CHANGE; THOMAS PR, 1995, WEIGHTING OPTIONS CR; VANITALLIE TB, 1994, PHARMACOECONOMICS, V5, P1, DOI 10.2165/00019053-199400051-00003; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; WOLF AM, 1994, PHARMACOECONOMICS, V5, P34, DOI 10.2165/00019053-199400051-00007; 1994, MMWR-MORBID MORTAL W, V43, P116; 1994, SHAPE UP AM EXECUTIV	16	58	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					134	135		10.1016/S0140-6736(95)91205-3	http://dx.doi.org/10.1016/S0140-6736(95)91205-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603226				2022-12-28	WOS:A1995RJ03100005
J	YOKOYAMA, N; HAYASHI, N; SEKI, T; PANTE, N; OHBA, T; NISHII, K; KUMA, K; HAYASHIDA, T; MIYATA, T; AEBI, U; FUKUI, M; NISHIMOTO, T				YOKOYAMA, N; HAYASHI, N; SEKI, T; PANTE, N; OHBA, T; NISHII, K; KUMA, K; HAYASHIDA, T; MIYATA, T; AEBI, U; FUKUI, M; NISHIMOTO, T			A GIANT NUCLEOPORE PROTEIN THAT BINDS RAN/TC4	NATURE			English	Article							NUCLEAR-PORE COMPLEX; CELL-CYCLE; CHROMOSOME CONDENSATION; MESSENGER-RNA; RCC1; IMPORT; GENES; DNA	RAN/TC4 is a small nuclear G protein(1) that forms a complex with the chromatin-bound guanine nucleotide release factor RCC1 (ref. 2). Loss of RCC1 causes defects in cell-cycle progression(3,4), RNA export(5-7) and nuclear protein import(8). Some of these can be suppressed by overexpression of Ran/TC4 (ref. 1), suggesting that Ran/TC4 functions downstream of RCC1. We have searched for proteins that bind Ran/TC4 by using a two-hybrid screen, and here we report the identification of RanBP2, a novel protein of 3,224 residues. This giant protein comprises an amino-terminal 700-residue leucine-rich region, four RanBP1-homologous (refs 9, 10) domains, eight zinc-finger motifs similar to those of NUP153 (refs 11, 12), and a carboxy terminus with high homology to cyclophilin(13). The molecule contains the XFXFG pentapeptide motif characteristic of nuclear pore complex (NPC) proteins(14), and immunolocalization suggests that RanBP2 is a constituent of the NPC. The fact that NLS-mediated nuclear import can be inhibited by an antibody directed against RanBP2 supports a functional role in protein import through the NPC.	KYUSHU UNIV,GRAD SCH MED SCI,DEPT NEUROSURG,HIGASHI KU,FUKUOKA 81282,JAPAN; KYUSHU UNIV,GRAD SCH MED SCI,DEPT ANAT,HIGASHI KU,FUKUOKA 81282,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN; UNIV BASEL,BIOZENTRUM,ME MULLER INST MICROSCOPY,CH-4056 BASEL,SWITZERLAND; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	Kyushu University; Kyushu University; Kyoto University; University of Basel; Johns Hopkins University	YOKOYAMA, N (corresponding author), KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,HIGASHI KU,MAIDASHI 3-1-1,FUKUOKA 81282,JAPAN.		Oba, Tomoyuki/ABT-2152-2022; Pante, Nelly/GVR-8478-2022	Oba, Tomoyuki/0000-0002-6715-7892; Hayashi, Naoyuki/0000-0001-9626-3689				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GERACE L, 1984, J CELL SCI S, V1, P137; HARPER JW, 1993, CELL, V75, P805; HAYASHI N, IN PRESS MOL GEN GEN; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MCMORROW I, 1994, BBA-GENE STRUCT EXPR, V1217, P219, DOI 10.1016/0167-4781(94)90040-X; MELCHIOR F, 1993, J CELL BIOL 2, V123, P1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OHTSUBO M, 1991, EMBO J, V10, P1265, DOI 10.1002/j.1460-2075.1991.tb08068.x; PANTE N, 1994, J STRUCT BIOL, V113, P179, DOI 10.1006/jsbi.1994.1052; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1994, J BIOL CHEM, V269, P17600; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TOH H, 1983, NATURE, V305, P827, DOI 10.1038/305827a0; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687	32	425	431	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					184	188		10.1038/376184a0	http://dx.doi.org/10.1038/376184a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603572				2022-12-28	WOS:A1995RJ02800064
J	BOYD, JW; HIMMELSTEIN, DU; WOOLHANDLER, S				BOYD, JW; HIMMELSTEIN, DU; WOOLHANDLER, S			THE TOBACCO HEALTH-INSURANCE CONNECTION	LANCET			English	Editorial Material									HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,DEPT MED,CAMBRIDGE,MA; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,CAMBRIDGE,MA 02138	Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University	BOYD, JW (corresponding author), HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,DEPT PSYCHIAT,CAMBRIDGE,MA 02138, USA.							ANDERS G, 1994, WALL STREET J   1221, P1; DAVIS RM, 1991, JAMA-J AM MED ASSOC, V266, P3186, DOI 10.1001/jama.266.22.3186; Friedman M, 1962, CAPITALISM FREEDOM, DOI DOI 10.2307/825316; MACKAY J, 1992, NATL CANCER I MONOGR, V12, P25; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; SALMON J, 1994, CORPORATE TRANSFORMA; Taylor Peter, 1984, SMOKE RING TOBACCO M; Tudor Hart J, 1994, FEASIBLE SOCIALISM N; 1995, COMPACT DISCLOSURE D	9	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					64	64		10.1016/S0140-6736(95)92104-4	http://dx.doi.org/10.1016/S0140-6736(95)92104-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603209				2022-12-28	WOS:A1995RH22000002
J	NICHOLSON, DW; ALI, A; THORNBERRY, NA; VAILLANCOURT, JP; DING, CK; GALLANT, M; GAREAU, Y; GRIFFIN, PR; LABELLE, M; LAZEBNIK, YA; MUNDAY, NA; RAJU, SM; SMULSON, ME; YAMIN, TT; YU, VL; MILLER, DK				NICHOLSON, DW; ALI, A; THORNBERRY, NA; VAILLANCOURT, JP; DING, CK; GALLANT, M; GAREAU, Y; GRIFFIN, PR; LABELLE, M; LAZEBNIK, YA; MUNDAY, NA; RAJU, SM; SMULSON, ME; YAMIN, TT; YU, VL; MILLER, DK			IDENTIFICATION AND INHIBITION OF THE ICE/CED-3 PROTEASE NECESSARY FOR MAMMALIAN APOPTOSIS	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; ENDONUCLEASE; CELLS; RIBOSYLATION; SEQUENCE; ENCODES; VIRUS; GENE	The protease responsible for the cleavage of poly(ADP-ribose) polymerase and necessary for apoptosis has been purified and characterized. This enzyme, named apopain, is composed of two subunits of relative molecular mass (M(r)) 17K and 12K that are derived from a common proenzyme identified as CPP32. This proenzyme is related to interleukin-1 beta-converting enzyme (ICE) and CED-3, the product of a gene required for programmed cell death in Caenorhabditis elegans. A potent peptide aldehyde inhibitor has been developed and shown to prevent apoptotic events In vitro, suggesting that apopain/CPP32 is important for the initiation of apoptotic cell death.	MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT MED CHEM,POINTE CLAIRE,PQ H9R 4P8,CANADA; MERCK & CO INC,RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065; MERCK & CO INC,RES LABS,DEPT INFLAMMAT RES,RAHWAY,NJ 07065; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; GEORGETOWN UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC	Merck & Company; Merck & Company; Merck & Company; Cold Spring Harbor Laboratory; Georgetown University	NICHOLSON, DW (corresponding author), MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POB 1005,POINTE CLAIRE,PQ H9R 4P8,CANADA.							AYALA JM, 1994, J IMMUNOL, V153, P2592; BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; BERGER NA, 1980, BIOCHEMISTRY-US, V19, P289, DOI 10.1021/bi00543a006; BURKLE A, 1992, EXP CLIN IMMUNOGENET, V9, P230; CARSON DA, 1994, LANCET, V341, P1251; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHAPMAN KT, 1992, BIOORG MED CHEM LETT, V2, P613, DOI 10.1016/S0960-894X(01)81209-9; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; ELLIS RE, 1991, REV CELL BIOL, V7, P663; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOWARD AD, 1995, J IMMUNOL, V154, P2321; JUAREZSALINAS H, 1979, NATURE, V282, P740, DOI 10.1038/282740a0; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LANGLOIS AJ, 1974, CANCER RES, V34, P1457; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MIURA M, 1993, CELL, V76, P653; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; SOLARY E, 1993, BLOOD, V81, P1359; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WESTERIK JO, 1972, J BIOL CHEM, V247, P8195; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YOSHIHAR.K, 1974, BIOCHEM BIOPH RES CO, V59, P658, DOI 10.1016/S0006-291X(74)80030-6; YOSHIHARA K, 1975, P NATL ACAD SCI USA, V72, P289, DOI 10.1073/pnas.72.1.289; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	48	3712	3862	1	91	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					37	43		10.1038/376037a0	http://dx.doi.org/10.1038/376037a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596430				2022-12-28	WOS:A1995RH11100055
J	WEATHERALL, DJ; LEDINGHAM, JGG; WARRELL, DA				WEATHERALL, DJ; LEDINGHAM, JGG; WARRELL, DA			ON DINOSAURS AND MEDICAL TEXTBOOKS	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; FIBRINOLYTIC THERAPY		JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, OXFORD OX3 9DU, ENGLAND	University of Oxford	WEATHERALL, DJ (corresponding author), JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; CHALMERS I, 1994, BMJ-BRIT MED J, V309, P862, DOI 10.1136/bmj.309.6958.862; CHARLTON BG, 1995, J ROY COLL PHYS LOND, V29, P96; COLLINS R, 1995, LANCET, V345, P669; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; KENNEDY JW, 1985, NEW ENGL J MED, V312, P1073, DOI 10.1056/NEJM198504253121701; MITCHELL JRA, 1986, BRIT MED J, V292, P973, DOI 10.1136/bmj.292.6526.973; PENTECOST BL, 1987, OXFORD TXB MED, V13, P167; RAUP DM, 1991, EXTINCTIONS BAD GENE; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1993, CIRCULATION, V87, P2043, DOI 10.1161/01.CIR.87.6.2043; 1995, MED RES NHS REFORMS; 1986, LANCET, V1, P421	14	18	18	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 1	1995	346	8966					4	5		10.1016/S0140-6736(95)92646-1	http://dx.doi.org/10.1016/S0140-6736(95)92646-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603148				2022-12-28	WOS:A1995RF98500004
J	ELLIS, NA; GRODEN, J; YE, TZ; STRAUGHEN, J; LENNON, DJ; CIOCCI, S; PROYTCHEVA, M; GERMAN, J				ELLIS, NA; GRODEN, J; YE, TZ; STRAUGHEN, J; LENNON, DJ; CIOCCI, S; PROYTCHEVA, M; GERMAN, J			THE BLOOMS-SYNDROME GENE-PRODUCT IS HOMOLOGOUS TO RECQ HELICASES	CELL			English	Article							SYNDROME FIBROBLASTS; SYNDROME CELLS; ADENOMATOUS POLYPOSIS; PUTATIVE HELICASES; DNA GLYCOSYLASE; RECOMBINATION; REPAIR; IDENTIFICATION; REPLICATION; SENSITIVITY	The Bloom's syndrome (BS) gene, BLM, plays an important role in the maintenance of genomic stability in somatic cells. A candidate for BLM was identified by direct selection of a cDNA derived from a 250 kb segment of the genome to which BLM had been assigned by somatic crossover point mapping. In this novel mapping method, cells were used from persons with BS that had undergone intragenic recombination within BLM. cDNA analysis of the candidate gene identified a 4437 bp cDNA that encodes a 1417 amino acid peptide with homology to the RecQ helicases, a subfamily of DExH box-containing DNA and RNA helicases. The presence of chain-terminating mutations in the candidate gene in persons with BS proved that it was BLM.	UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati	ELLIS, NA (corresponding author), NEW YORK BLOOD CTR, HUMAN GENET LAB, NEW YORK, NY 10021 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD004134] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA050897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NCI NIH HHS [CA-50897] Funding Source: Medline; NICHD NIH HHS [HD-04134] Funding Source: Medline; NIEHS NIH HHS [ES-06096] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKMANN JS, 1993, HUM MOL GENET, V2, P2019, DOI 10.1093/hmg/2.12.2019; CHAN JYH, 1987, NATURE, V325, P357, DOI 10.1038/325357a0; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; DEHAZYA P, 1986, CANCER RES, V46, P3756; ELLIS NA, 1994, AM J HUM GENET, V55, P453; ELLIS NA, 1994, NAT GENET, V6, P394, DOI 10.1038/ng0494-394; ELLIS NA, 1995, AM J HUM GENET, V57, P1019; FREJTER WL, 1992, P NATL ACAD SCI USA, V89, P261; FRIEDBERG EC, 1979, ADV RADIAT BIOL, V8, P85; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1989, CLIN GENET, V35, P57; GERMAN J, 1994, P NATL ACAD SCI USA, V91, P6669, DOI 10.1073/pnas.91.14.6669; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GERMAN J, IN PRESS CLIN GENET; GERMAN J, 1980, GENETIC ENV FACTORS, P175; GLANNELLI F, 1977, NATURE, V265, P466; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAND R, 1975, P NATL ACAD SCI USA, V72, P758, DOI 10.1073/pnas.72.2.758; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEARTLEIN MW, 1987, EXP CELL RES, V169, P245; Heddle J.A., 1983, CHROMOSOME MUTATION, P203; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; ISHIZAKI K, 1981, MUTAT RES, V80, P213, DOI 10.1016/0027-5107(81)90189-5; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIM S, 1986, MUTAT RES, V173, P141, DOI 10.1016/0165-7992(86)90092-8; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; KREPINSKY AB, 1980, MUTAT RES, V69, P357, DOI 10.1016/0027-5107(80)90100-1; KURIHARA T, 1987, MUTAT RES, V184, P147, DOI 10.1016/0167-8817(87)90071-X; KUSANO K, 1994, P NATL ACAD SCI USA, V91, P1173, DOI 10.1073/pnas.91.3.1173; LEHESJOKI AE, 1993, HUM MOL GENET, V2, P1229, DOI 10.1093/hmg/2.8.1229; LONN U, 1990, CANCER RES, V50, P3141; LUISIDELUCA C, 1989, GENETICS, V122, P269; MA LB, 1994, MOL CELL BIOL, V14, P4126, DOI 10.1128/MCB.14.6.4126; MATHEW S, 1993, CYTOGENET CELL GENET, V63, P33, DOI 10.1159/000133496; MCDANIEL LD, 1992, P NATL ACAD SCI USA, V89, P7968, DOI 10.1073/pnas.89.17.7968; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NICOTERA TM, 1989, CANCER RES, V49, P5239; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEAL G, 1988, P NATL ACAD SCI USA, V85, P2339, DOI 10.1073/pnas.85.7.2339; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SHIRAISHI Y, 1989, MUTAT RES, V211, P273, DOI 10.1016/0027-5107(89)90010-9; SIRUGO G, 1992, AM J HUM GENET, V50, P559; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SURDEJ P, 1994, ANNU REV GENET, V28, P263; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TSENG YC, 1994, MUTAT RES, V315, P1; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; WARBURTON D, 1990, GENOMICS, V6, P358, DOI 10.1016/0888-7543(90)90577-H; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0	61	1153	1186	1	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 17	1995	83	4					655	666		10.1016/0092-8674(95)90105-1	http://dx.doi.org/10.1016/0092-8674(95)90105-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585968	Bronze			2022-12-28	WOS:A1995TF24800018
J	HEALE, SM; PETES, TD				HEALE, SM; PETES, TD			THE STABILIZATION OF REPETITIVE TRACTS OF DNA BY VARIANT REPEATS REQUIRES A FUNCTIONAL DNA MISMATCH REPAIR SYSTEM	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CAG REPEAT; YEAST; INSTABILITY; GENE; SEQUENCE; MUTANTS; RECOMBINATION; MUTATIONS	Simple repetitive tracts of DNA are unstable in all organisms thus far examined. In the yeast S. cerevisiae, we show that a 51 bp poly(GT) tract alters length at a rate of about 10(-5) per cell division. Insertion of a single variant repeat (either AT or CT) into the middle of the poly(GT) tract results in 100-fold stabilization. This stabilization requires the DNA mismatch repair system. Alterations within tracts with variant repeats occur more frequently on one side of the interruption than on the other. The stabilizing effects of variant repeats and polarity of repeat alterations have also been observed in trinucleotide repeats associated with certain human diseases.			HEALE, SM (corresponding author), UNIV N CAROLINA,DEPT BIOL,CB 3280,CHAPEL HILL,NC 27599, USA.				NIGMS NIH HHS [GM50892] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1994, GENETICS, V137, P19; ALANI E, 1987, GENETICS, V117, P5; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BICHARA M, 1992, GENETICS, V140, P897; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DETLOFF P, 1992, MOL CELL BIOL, V12, P1805, DOI 10.1128/MCB.12.4.1805; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FARBER RA, 1994, HUM MOL GENET, V3, P253, DOI 10.1093/hmg/3.2.253; FREUND AM, 1989, P NATL ACAD SCI USA, V86, P7465, DOI 10.1073/pnas.86.19.7465; GACY AM, 1995, CELL, V81, P533; GORDENIN DA, 1992, P NATL ACAD SCI USA, V89, P3785, DOI 10.1073/pnas.89.9.3785; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; HIRST MC, 1994, HUM MOL GENET, V3, P1553, DOI 10.1093/hmg/3.9.1553; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; NANCARROW JK, 1995, HUM MOL GENET, V4, P367, DOI 10.1093/hmg/4.3.367; NELSON DL, 1993, NAT GENET, V4, P107, DOI 10.1038/ng0693-107; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; Sambrook J, 1989, MOL CLONING LABORATO; SELVA EM, 1995, GENETICS, V139, P1175; Sherman F., 1983, METHODS YEAST GENETI; SMITH GP, 1973, COLD SPRING HARB SYM, V38, P507, DOI 10.1101/SQB.1974.038.01.055; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STRAND MK, 1995, IN PRESS P NATL ACAD; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; WALMSLEY RM, 1983, NATURE, V302, P84, DOI 10.1038/302084a0; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5345; WILLIAMSON MS, 1985, GENETICS, V110, P609; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	47	59	74	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					539	545		10.1016/0092-8674(95)90093-4	http://dx.doi.org/10.1016/0092-8674(95)90093-4			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585956	Bronze, Green Submitted			2022-12-28	WOS:A1995TF24800006
J	TROEMEL, ER; CHOU, JH; DWYER, ND; COLBERT, HA; BARGMANN, CI				TROEMEL, ER; CHOU, JH; DWYER, ND; COLBERT, HA; BARGMANN, CI			DIVERGENT 7 TRANSMEMBRANE RECEPTORS ARE CANDIDATE CHEMOSENSORY RECEPTORS IN C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; OLFACTORY EPITHELIUM; NEURONS; CHEMOTAXIS; EXPRESSION; ALIGNMENT; MUTANTS; PROTEIN; GENES; OPSIN	Using their senses of taste and smell, animals recognize a wide variety of chemicals, The nematode C. elegans has only fourteen types of chemosensory neurons, but it responds to dozens of chemicals, because each chemosensory neuron detects several stimuli. Here we describe over 40 highly divergent members of the G protein-coupled receptor family that could contribute to this functional diversity. Most of these candidate receptor genes are in clusters of two to nine similar genes. Eleven of fourteen tested genes appear to be expressed in small subsets of chemosensory neurons. A single type of chemosensory neuron can potentially express at least four different receptor genes. Some of these genes might encode receptors for water-soluble attractants, repellents, and pheromones.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, PROGRAM NEUROSCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, GENET PROGRAM, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	TROEMEL, ER (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA.			Chou, Joseph/0000-0002-3138-0777; Bargmann, Cornelia/0000-0002-8484-0618; Dwyer, Noelle/0000-0002-1995-7203	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001393] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC01393] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1990, COLD SPRING HARB SYM, V55, P529; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BOEKHOFF I, 1994, J NEUROSCI, V14, P3304; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BRENNER S, 1974, GENETICS, V77, P71; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CARULLI JP, 1992, GENETICS, V132, P193; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; CULOTTI JG, 1978, GENETICS, V90, P243; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; DUSENBER.DB, 1974, J EXP ZOOL, V188, P41, DOI 10.1002/jez.1401880105; GOLDEN JW, 1984, J CHEM ECOL, V10, P1265, DOI 10.1007/BF00988553; HODGKIN J, 1983, GENETICS, V103, P43; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; HUBER A, 1990, J BIOL CHEM, V265, P17906; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lawless H. T, 1987, NEUROBIOLOGY TASTE S, P401; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; LYNCH AS, 1995, IN PRESS NATURE GENE; MCBURNEY DH, 1972, PERCEPT PSYCHOPHYS, V11, P228, DOI 10.3758/BF03206255; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Sambrook J, 1989, MOL CLONING LABORATO; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; THOMAS DD, 1982, J MOL BIOL, V154, P145, DOI 10.1016/0022-2836(82)90422-3; THOMAS JH, 1990, GENETICS, V124, P855; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	48	530	595	1	64	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 20	1995	83	2					207	218		10.1016/0092-8674(95)90162-0	http://dx.doi.org/10.1016/0092-8674(95)90162-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585938	Bronze			2022-12-28	WOS:A1995TA96500007
J	JIN, YS; MEAD, J; LI, T; WOLBERGER, C; VERSHON, AK				JIN, YS; MEAD, J; LI, T; WOLBERGER, C; VERSHON, AK			ALTERED DNA RECOGNITION AND BENDING BY INSERTIONS IN THE ALPHA-2 TAIL OF THE YEAST A1/ALPHA-2 HOMEODOMAIN HETERODIMER	SCIENCE			English	Article							PROTEIN; BINDING; SPECIFICITY; DROSOPHILA; REPRESSOR; ORIENTATION; RECEPTORS; GENE; MCM1; A1	The yeast MAT alpha 2 and MATa1 homeodomain proteins bind cooperatively as a heterodimer to sites upstream of haploid-specific genes, repressing their transcription. In the crystal structure of alpha 2 and a1 bound to DNA, each homeodomain makes independent base-specific contacts with the DNA and the two proteins contact each other through an extended tail region of alpha 2 that tethers the two homeodomains to one another. Because this extended region may be flexible, the ability of the heterodimer to discriminate among DNA sites with altered spacing between alpha 2 and a1 binding sites was examined. Spacing between the half sites was critical for specific DNA binding and transcriptional repression by the complex. However, amino acid insertions in the tail region of alpha 2 suppressed the effect of altering an a1/alpha 2 site by increasing the spacing between the half sites. Insertions in the tail also decreased DNA bending by a1/alpha 2. Thus tethering the two homeodomains contributes to DNA bending by a1/alpha 2, but the precise nature of the resulting bend is not essential for repression.	RUTGERS STATE UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08855; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University				Wolberger, Cynthia/0000-0001-8578-2969	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JIN Y, UNPUB; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MEAD J, UNPUB; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PHILLIPS CL, 1994, BIOCHEMISTRY-US, V33, P9294, DOI 10.1021/bi00197a033; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH DL, 1995, NUCLEIC ACIDS RES, V23, P1239, DOI 10.1093/nar/23.7.1239; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERSHON AK, 1992, MOL CELL BIOL, V12, P3706, DOI 10.1128/MCB.12.9.3706; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	31	20	21	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					290	293		10.1126/science.270.5234.290	http://dx.doi.org/10.1126/science.270.5234.290			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569977				2022-12-28	WOS:A1995RZ34200036
J	SIZEMORE, DR; BRANSTROM, AA; SADOFF, JC				SIZEMORE, DR; BRANSTROM, AA; SADOFF, JC			ATTENUATED SHIGELLA AS A DNA DELIVERY VEHICLE FOR DNA-MEDIATED IMMUNIZATION	SCIENCE			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; FLEXNERI; CONSTRUCTION; SELECTION; PLASMID; VECTOR; CELLS; GENES	Direct inoculation of DNA, in the form of purified bacterial plasmids that are unable to replicate in mammalian cells but are able to direct cell synthesis of foreign proteins, is being explored as an approach to vaccine development. Here, a highly attenuated Shigella vector invaded mammalian cells and delivered such plasmids into the cytoplasm of cells, and subsequent production of functional foreign protein was measured. Because this Shigella vector was designed to deliver DNA to colonic mucosa, the method is a potential basis for oral and other mucosal DNA immunization and gene therapy strategies.			SIZEMORE, DR (corresponding author), WALTER REED ARMY INST RES,DEPT BACTERIAL DIS,DIV COMMUNICABLE DIS & IMMUNOL,WASHINGTON,DC 20307, USA.							Bethesda MD, 1985, NIH PUBLICATION, V86-23; DONNELLY JJ, 1994, J IMMUNOL METHODS, V176, P145, DOI 10.1016/0022-1759(94)90308-5; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; HARTMAN AB, 1991, INFECT IMMUN, V59, P4075, DOI 10.1128/IAI.59.11.4075-4083.1991; HAZIZA C, 1982, EMBO J, V1, P379, DOI 10.1002/j.1460-2075.1982.tb01178.x; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MILLS JA, 1988, INFECT IMMUN, V56, P2933, DOI 10.1128/IAI.56.11.2933-2941.1988; NAKAYAMA K, 1988, BIO-TECHNOL, V6, P693, DOI 10.1038/nbt0688-693; OAKS EV, 1985, INFECT IMMUN, V48, P124, DOI 10.1128/IAI.48.1.124-129.1985; PORTNOY DA, 1994, ANN NY ACAD SCI, V730, P15, DOI 10.1111/j.1749-6632.1994.tb44235.x; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; SANDER B, 1993, J IMMUNOL METHODS, V166, P201, DOI 10.1016/0022-1759(93)90361-A; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SANSONETTI PJ, 1983, INFECT IMMUN, V39, P1392, DOI 10.1128/IAI.39.3.1392-1402.1983; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SIZEMORE DR, UNPUB; SUN JB, 1994, P NATL ACAD SCI USA, V91, P10795, DOI 10.1073/pnas.91.23.10795; VANDEVERG LL, 1995, INFECT IMMUN, V63, P1947, DOI 10.1128/IAI.63.5.1947-1954.1995; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	22	237	308	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					299	302		10.1126/science.270.5234.299	http://dx.doi.org/10.1126/science.270.5234.299			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569980	Green Submitted			2022-12-28	WOS:A1995RZ34200039
J	OHASHI, M; DEVRIES, KJ; FRANK, R; SNOEK, G; BANKAITIS, V; WIRTZ, K; HUTTNER, WB				OHASHI, M; DEVRIES, KJ; FRANK, R; SNOEK, G; BANKAITIS, V; WIRTZ, K; HUTTNER, WB			A ROLE FOR PHOSPHATIDYLINOSITOL TRANSFER PROTEIN IN SECRETORY VESICLE FORMATION	NATURE			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; SACCHAROMYCES-CEREVISIAE; REQUIREMENT	VESICULAR traffic in eukaryotic cells is characterized by two steps of membrane rearrangement: the formation of vesicles from donor membranes and their fusion with acceptor membranes. With respect to vesicle formation, several of the cytosolic proteins implicated in budding and fission have been identified. A feature common to all these proteins is that their targets, when known, are other proteins rather than lipids. Here we report, using a previously established cell-free system(1,2) derived from a neuroendocrine cell line, the purification of cytosolic factors that stimulate the formation of constitutive secretory vesicles and immature secretory granules from the trans-Golgi network. One such factor, referred to as CAST1, was identified as the alpha and beta isoforms of the mammalian phosphatidylinositol transfer protein (PtdIns-TP) (refs 3-5). The yeast PtdIns-TP, SEC14p (ref. 6), which has no sequence homology to mammalian PtdIns-TP (refs 7,8), was able to substitute for the mammalian PtdIns-TP in secretory vesicle formation. Our results suggest a highly conserved role for phosphoinositides in vesicle formation.	UNIV HEIDELBERG,DEPT NEUROBIOL,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,CTR BIOL MOLEC,D-69120 HEIDELBERG,GERMANY; UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,3584 CH UTRECHT,NETHERLANDS; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Utrecht University; University of Alabama System; University of Alabama Birmingham			Huttner, Wieland B./P-4080-2018					BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BECK KA, 1991, J BIOL CHEM, V266, P4442; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; DEVRIES KJ, 1995, BIOCHEM J, V310, P643, DOI 10.1042/bj3100643; DICKESON SK, 1989, J BIOL CHEM, V294, P16557; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GEITENBEEK TB, 1994, BIOCHIM BIOPHYS ACTA, V1213, P309; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; OHASHI M, 1994, J BIOL CHEM, V269, P24897; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; SNOEK GT, 1992, J CELL BIOCHEM, V49, P339, DOI 10.1002/jcb.240490404; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; VANDENAKKER WMR, 1990, FEBS LETT, V276, P123, DOI 10.1016/0014-5793(90)80523-L; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	30	166	173	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					544	547		10.1038/377544a0	http://dx.doi.org/10.1038/377544a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566155				2022-12-28	WOS:A1995RZ33600067
J	LABINGER, JA				LABINGER, JA			TUNING INTO BETTER CATALYSTS	SCIENCE			English	Editorial Material											LABINGER, JA (corresponding author), CALTECH,BECKMAN INST,PASADENA,CA 91125, USA.							Centi G., 1990, NEW DEV SELECTIVE OX; DEMONTELLANO PRO, 1985, CYTOCHROME P450 STRU; GARDNER KA, 1995, SCIENCE, V269, P1849, DOI 10.1126/science.7569922; GROVES JT, 1983, J AM CHEM SOC, V105, P6243, DOI 10.1021/ja00358a009; ROSENZWEIG AC, 1994, ACCOUNTS CHEM RES, V27, P229, DOI 10.1021/ar00044a003; Wolf E. E., 1992, METHANE CONVERSION O	6	5	5	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1833	1833		10.1126/science.7569918	http://dx.doi.org/10.1126/science.7569918			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569918				2022-12-28	WOS:A1995RX19400026
J	BOLSHAKOV, VY; SIEGELBAUM, SA				BOLSHAKOV, VY; SIEGELBAUM, SA			REGULATION OF HIPPOCAMPAL TRANSMITTER RELEASE DURING DEVELOPMENT AND LONG-TERM POTENTIATION	SCIENCE			English	Article							MINIATURE SYNAPTIC CURRENTS; QUANTAL ANALYSIS; PYRAMIDAL CELLS; NEURONS; PROBABILITY; AMPLITUDE; SLICES; TRANSMISSION; SYNAPSES; PAIRS	Developmental changes in rat hippocampal transmitter release and synaptic plasticity were investigated. Recordings from pairs of pyramidal neurons in slices showed that an action potential in a CA3 neuron released only a single quantum of transmitter onto a CAI neuron. Failures of synaptic transmission reflected probabilistic transmitter release. The probability of release (P-r) was 0.9 in 4- to 8-day-old rats and decreased to less than 0.5 at 2 to 3 weeks. Long-term potentiation (LTP) in 2- to 3-week-old rats was associated with an increase in P-r from a single synaptic site. The high initial P-r in 4- to 8-day-old rats normally occludes the expression of LTP at this stage.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	BOLSHAKOV, VY (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT PHARMACOL,722 W 168TH ST,NEW YORK,NY 10032, USA.							ARANCIO O, 1994, J PHYSIOL-LONDON, V481, P395, DOI 10.1113/jphysiol.1994.sp020448; BAUDRY M, 1981, DEV BRAIN RES, V1, P37, DOI 10.1016/0165-3806(81)90092-4; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; CONSTANTINEPATO.M, 1990, ANN REV NEUROSCI, V13, P1229; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUDEK SM, 1993, J NEUROSCI, V13, P2910; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; JESSELL TM, 1993, NEURON S, V10, P1; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; Katz B., 1969, RELEASE NEURAL TRANS; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; MALENKA RC, 1993, P NATL ACAD SCI USA, V90, P3121, DOI 10.1073/pnas.90.8.3121; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1994, SCIENCE, V266, P1195, DOI 10.1126/science.7973700; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULLER D, 1989, DEV BRAIN RES, V49, P105, DOI 10.1016/0165-3806(89)90063-1; PURVES D, 1985, PRINCIPLES NEURAL DE; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SAYER RJ, 1990, J NEUROSCI, V10, P826; SORRA KE, 1993, J NEUROSCI, V13, P3736; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P175, DOI 10.1085/jgp.76.2.175; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	43	300	303	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1730	1734		10.1126/science.7569903	http://dx.doi.org/10.1126/science.7569903			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569903				2022-12-28	WOS:A1995RV94800041
J	GUILLOT, T				GUILLOT, T			CONDENSATION OF METHANE, AMMONIA, AND WATER AND THE INHIBITION OF CONVECTION IN GIANT PLANETS	SCIENCE			English	Article							RADIO OCCULTATION MEASUREMENTS; MOIST CONVECTION; JUPITERS ATMOSPHERE; VERTICAL STRUCTURE; PARA-HYDROGEN; TROPOSPHERE; ABUNDANCE; NEPTUNE; URANUS; VOYAGER-2	The condensation of chemical species of high molecular mass such as methane, ammonia, and water can inhibit convection in the hydrogen-helium atmospheres of the giant planets. Convection is inhibited in Uranus and Neptune when methane reaches an abundance of about 15 times the solar value and in Jupiter and Saturn if the abundance of water is more than about five times the solar value. The temperature gradient consequently becomes superadiabatic, which is observed in temperature profiles inferred from radio-occultation measurements. The planetary heat flux is then likely to be transported by another mechanism, possibly radiation in Uranus, or diffusive convection.			GUILLOT, T (corresponding author), UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.			Guillot, Tristan/0000-0002-7188-8428				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BAINES KH, 1995, ICARUS, V114, P328, DOI 10.1006/icar.1995.1065; BAINES KH, 1994, ICARUS, V109, P20, DOI 10.1006/icar.1994.1075; BJORAKER GL, 1986, ICARUS, V66, P579, DOI 10.1016/0019-1035(86)90093-X; CARLSON BE, 1992, ASTROPHYS J, V388, P648, DOI 10.1086/171182; CARLSON BE, 1988, J ATMOS RES, V45, P2067; CONRATH BJ, 1984, ICARUS, V57, P184, DOI 10.1016/0019-1035(84)90065-4; DELGENIO AD, 1990, ICARUS, V84, P29, DOI 10.1016/0019-1035(90)90156-4; FLASAR FM, 1988, JUN UR C PAS; FLASAR FM, COMMUNICATION; GAUTIER D, IN PRESS NEPTUNE; GIERASCH PJ, 1987, J GEOPHYS RES, V92, P15019, DOI 10.1029/JA092iA13p15019; GUILLOT T, 1994, ICARUS, V112, P37; GUILLOT T, 1994, ICARUS, V112, P57; GUILLOTEAU S, 1993, ASTRON ASTROPHYS, V279, P661; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; INGERSOLL AP, 1995, NATURE, V374, P706, DOI 10.1038/374706a0; Kippenhahn R., 1990, STELLAR STRUCTURE EV; LEDOUX P, 1947, ASTROPHYS J, V125, P242; LEWIS JS, 1969, ICARUS, V10, P365, DOI 10.1016/0019-1035(69)90091-8; LINDAL GF, 1992, ASTRON J, V103, P967, DOI 10.1086/116119; LINDAL GF, 1985, ASTRON J, V90, P1136, DOI 10.1086/113820; LINDAL GF, 1987, J GEOPHYS RES, V92, P14987, DOI 10.1029/JA092iA13p14987; LODDERS K, 1994, ICARUS, V112, P368, DOI 10.1006/icar.1994.1190; LUNINE JI, 1989, PLANET SPACE SCI, V37, P151, DOI 10.1016/0032-0633(89)90003-2; LUNINE JI, 1987, ICARUS, V69, P566, DOI 10.1016/0019-1035(87)90025-X; MARTEN A, 1981, ICARUS, V46, P233, DOI 10.1016/0019-1035(81)90211-6; MARTEN A, 1993, ASTROPHYS J, V406, P285, DOI 10.1086/172440; MASSIE ST, 1982, ICARUS, V49, P213, DOI 10.1016/0019-1035(82)90073-2; NEAL VT, 1969, SCIENCE, V166, P373, DOI 10.1126/science.166.3903.373; RAGES K, 1991, ICARUS, V89, P359, DOI 10.1016/0019-1035(91)90183-T; ROSSOW WB, 1978, ICARUS, V36, P1, DOI 10.1016/0019-1035(78)90072-6; SCHMITT RW, 1994, ANNU REV FLUID MECH, V26, P255, DOI 10.1146/annurev.fl.26.010194.001351; SHIRTCLIFFE TG, 1967, NATURE, V213, P489, DOI 10.1038/213489a0; STEVENSON DJ, 1979, MON NOT R ASTRON SOC, V187, P129, DOI 10.1093/mnras/187.2.129; STOKER CR, 1989, GEOPHYS RES LETT, V16, P929, DOI 10.1029/GL016i008p00929; STOKER CR, 1986, ICARUS, V67, P106, DOI 10.1016/0019-1035(86)90179-X; Turner J. S., 1973, BUOYANCY EFFECTS FLU; VERONIS G, 1968, J FLUID MECH, V34, P315, DOI 10.1017/S0022112068001916; YAIR Y, 1992, ICARUS, V98, P72, DOI 10.1016/0019-1035(92)90208-O; [No title captured]	42	61	61	1	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1697	1699		10.1126/science.7569896	http://dx.doi.org/10.1126/science.7569896			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569896				2022-12-28	WOS:A1995RV94800029
J	BERGASA, NV; ALLING, DW; TALBOT, TL; SWAIN, MG; YURDAYDIN, C; TURNER, ML; SCHMITT, JM; WALKER, EC; JONES, EA				BERGASA, NV; ALLING, DW; TALBOT, TL; SWAIN, MG; YURDAYDIN, C; TURNER, ML; SCHMITT, JM; WALKER, EC; JONES, EA			EFFECTS OF NALOXONE INFUSIONS IN PATIENTS WITH THE PRURITUS OF CHOLESTASIS - A DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						NALOXONE; PRURITUS; CHOLESTASIS; NARCOTIC ANTAGONISTS	PRIMARY BILIARY-CIRRHOSIS; NALMEFENE THERAPY; RAT MODEL; OPIATES; OPIOIDS; STRESS; PLASMA; RELIEF	Objective: To determine whether endogenous opioids contribute to the pruritus of cholestasis by studying the effect of the opiate antagonist naloxone on the perception of pruritus and on scratching activity in patients with this form of pruritus. Design: Double-blind, placebo-controlled, crossover trial with four periods. Setting: Clinical research referral center. Patients: 29 pruritic patients with liver diseases of various causes. Intervention: Each patient received as many as two naloxone and two placebo solution infusions consecutively in random order. Each infusion lasted 24 hours. Measurements: During the infusions, visual analog scores of pruritus were recorded every 4 hours while patients were awake; scratching activity independent of limb movements was recorded continuously. Results: One patient had a mild reaction consistent with a naloxone-precipitated syndrome similar to opiate withdrawal. A significant 24-hour rhythm of scratching activity was seen in 7 of 11 patients for whom complete 96-hour data were collected. The mean of a visual analog score of the perception of pruritus (maximum, 10.0) recorded during naloxone infusions was 0.582 lower than that recorded during placebo infusions (95% CI, 0.176 to 0.988; P < 0.01). Furthermore, the ratio of the geometric mean hourly scratching activity during naloxone infusions to that during placebo infusions was 0.727 (CI, 0.612 to 0.842; P < 0.001) and was greater than 1.0 in only five patients. Conclusions: Naloxone administration is associated with amelioration of the perception of pruritus and reduction of scratching activity in cholestatic patients. Because of the opioid receptor specificity of the action of naloxone, these findings support the hypothesis that a mechanism underlying the pruritus of cholestasis is modulated by endogenous opioids and suggest that opiate antagonists may have a role in the management of this complication of cholestasis.	NIH, BETHESDA, MD 20892 USA; NCI, DERMATOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BALLANTYNE JC, 1988, PAIN, V33, P149, DOI 10.1016/0304-3959(88)90085-1; BERGASA NV, 1994, J HEPATOL, V20, P85; BERGASA NV, 1992, J HEPATOL, V15, P220, DOI 10.1016/0168-8278(92)90040-V; BERGASA NV, 1992, GASTROENTEROLOGY, V102, P544, DOI 10.1016/0016-5085(92)90102-5; BERGASA NV, 1995, AM J PHYSIOL-GASTR L, V268, pG346, DOI 10.1152/ajpgi.1995.268.2.G346; BERGASA NV, 1991, AM J GASTROENTEROL, V86, P1404; BERGASA NV, 1993, HEPATOLOGY, V18, pA177, DOI 10.1016/0270-9139(93)92233-P; BERGASA NV, 1991, HEPATOLOGY, V14, pA154; BERNSTEIN JE, 1979, ARCH DERMATOL, V115, P360, DOI 10.1001/archderm.115.3.360; Colton T., 1974, STAT MED, V1; DIXON R, 1987, J CLIN PHARMACOL, V27, P233, DOI 10.1002/j.1552-4604.1987.tb02191.x; EDWARDS AE, 1976, ARCH DERMATOL, V112, P339, DOI 10.1001/archderm.112.3.339; FREZZA M, 1990, GASTROENTEROLOGY, V99, P211, DOI 10.1016/0016-5085(90)91250-A; GAL TJ, 1986, ANESTHESIOLOGY, V64, P175, DOI 10.1097/00000542-198602000-00008; Jaffe JH., 1985, GOODMAN GILMANS PHAR, P491; JOHNSTONE RE, 1974, ANESTHESIOLOGY, V41, P361, DOI 10.1097/00000542-197410000-00010; JONES EA, 1992, JAMA-J AM MED ASSOC, V268, P3359, DOI 10.1001/jama.268.23.3359; JONES EA, 1990, HEPATOLOGY, V11, P884, DOI 10.1002/hep.1840110526; KOENIGSTEIN H, 1948, ARCH DERMATOL SYPH, V57, P828, DOI 10.1001/archderm.1948.01520180045006; KUMAR D, 1986, GASTROENTEROLOGY, V91, P926, DOI 10.1016/0016-5085(86)90696-7; MCCORMACK HM, 1988, PSYCHOL MED, V18, P1007, DOI 10.1017/S0033291700009934; MORLEY JE, 1980, SCIENCE, V209, P1259, DOI 10.1126/science.6250222; OLIVERAS JL, 1986, J NEUROSCI, V6, P3086; SCHEFF H, 1959, ANAL VARIANCE, P119; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; SHERLOCK S, 1991, DIS LIVER BILIARY SY, P236; SIEGEL S, 1956, NONPARAMETRIC STAT, P202; SUMMERFIELD JA, 1980, BRIT J CLIN PHARMACO, V10, P180, DOI 10.1111/j.1365-2125.1980.tb01742.x; SWAIN MG, 1992, GASTROENTEROLOGY, V103, P630, DOI 10.1016/0016-5085(92)90857-U; TALBOT T L, 1991, Biomedical Instrumentation and Technology, V25, P400; THOMAS DA, 1992, BRAIN RES, V585, P315, DOI 10.1016/0006-8993(92)91227-6; THORNTON JR, 1988, BRIT MED J, V297, P1501, DOI 10.1136/bmj.297.6662.1501; THORNTON JR, 1988, BRIT MED J, V297, P1241, DOI 10.1136/bmj.297.6658.1241; WEI WWS, 1990, TIME SERIES ANAL UNI, P256; YATES F, 1948, BIOMETRIKA, V35, P176, DOI 10.1093/biomet/35.1-2.176; 1989, SAS STAT USERS GUIDE	36	286	294	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					161	167		10.7326/0003-4819-123-3-199508010-00001	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598296				2022-12-28	WOS:A1995RL10400001
J	WINSTON, DJ; WIRIN, D; SHAKED, A; BUSUTTIL, RW				WINSTON, DJ; WIRIN, D; SHAKED, A; BUSUTTIL, RW			RANDOMIZED COMPARISON OF GANCICLOVIR AND HIGH-DOSE ACYCLOVIR FOR LONG-TERM CYTOMEGALOVIRUS PROPHYLAXIS IN LIVER-TRANSPLANT RECIPIENTS	LANCET			English	Article							POLYMERASE CHAIN-REACTION; PLACEBO-CONTROLLED TRIAL; MARROW TRANSPLANT; ORAL ACYCLOVIR; VIRUS DISEASE; DOUBLE-BLIND; INFECTION; ORGAN; PREVENTION; DIAGNOSIS	Despite current approaches to prophylaxis, cytomegalovirus (CMV) continues to be a common cause of infection and disease in solid-organ-transplant patients. Thus, we conducted a controlled trial comparing long-term administration of ganciclovir with high-dose acyclovir for prevention of CMV infection and disease in liver transplant recipients. At the time of transplant, patients were randomised to receive either ganciclovir (6 mg/kg body weight per day intravenously from postoperative day 1 to day 30, then 6 mg/kg per day Monday through Friday until day 100) or acyclovir (10 mg/kg intravenously every 8 h from postoperative day 1 to day of discharge, then 800 mg orally four times a day until day 100). Patients were followed for development of CMV infection, CMV disease, and drug-related toxicity by frequent cultures, serological tests, laboratory measurements, and tissue biopsies. During the first 120 days after transplant, CMV infection occurred in 48 of 126 (38%) acyclovir patients but in only 6 of 124 (5%) ganciclovir patients (p<0.0001). Similarly, symptomatic CMV disease developed in 12 of 126 (10%) acyclovir patients but in only 1 of 124 (0.8%) ganciclovir patients (p=0.002). Ganciclovir reduced the incidence of CMV infection in both CMV antibody positive (37 vs 4%, p=0.001) and negative patients (42 vs 11%, p=0.06). In a multivariate analysis of donor-recipient CMV antibody status and other risk factors, prophylactic ganciclovir was the most significant factor protecting against CMV infection (p<0.0001) and disease (p=0.001). Ganciclovir and acyclovir were generally well-tolerated. Incidences of leukopenia, thrombocytopenia, renal failure, and other adverse events were similar in the two groups. CMV can be eliminated almost completely as significant pathogen in liver transplant recipients by the long-term administration of prophylactic ganciclovir. In addition, the treatment is safe.	UNIV CALIF LOS ANGELES,MED CTR,DEPT SURG,DUMONT UCLA TRANSPLANT CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	WINSTON, DJ (corresponding author), UNIV CALIF LOS ANGELES,MED CTR,DEPT MED,LOS ANGELES,CA 90024, USA.							BALFOUR HH, 1989, NEW ENGL J MED, V320, P1381, DOI 10.1056/NEJM198905253202105; BOIVIN G, 1993, J INFECT DIS, V168, P332, DOI 10.1093/infdis/168.2.332; BUHLES WC, 1988, REV INFECT DIS, V10, pS495; BUSUTTIL RW, 1994, ANN SURG, V219, P490, DOI 10.1097/00000658-199405000-00007; COLE NL, 1987, DIAGN MICR INFEC DIS, V6, P255, DOI 10.1016/0732-8893(87)90020-4; DAVIS CL, 1990, AM J KIDNEY DIS, V16, P175, DOI 10.1016/S0272-6386(12)81016-X; DELGADO R, 1992, J CLIN MICROBIOL, V30, P1876, DOI 10.1128/JCM.30.7.1876-1878.1992; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; DUMMER JS, 1990, REV INFECT DIS, V12, pS767; DUNN DL, 1994, TRANSPLANTATION, V57, P876, DOI 10.1097/00007890-199403270-00019; EMMANOUILIDES C, IN PRESS LIVER TRANS; FLETCHER C, 1985, DRUG INTEL CLIN PHAR, V19, P518, DOI 10.1177/106002808501900703; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; HIBBERD PL, 1992, TRANSPLANTATION, V53, P68, DOI 10.1097/00007890-199201000-00013; JAOUR AJ, 1994, AIDS CLIN CARE, V6, P23; MARTIN M, 1994, TRANSPLANTATION, V58, P779; MCCARTHY JM, 1993, TRANSPLANTATION, V55, P1277, DOI 10.1097/00007890-199306000-00013; MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803; RAND KH, 1978, NEW ENGL J MED, V298, P951, DOI 10.1056/NEJM197804272981705; RUBIN RH, 1989, JAMA-J AM MED ASSOC, V261, P3607; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SINGH N, 1988, J INFECT DIS, V158, P124, DOI 10.1093/infdis/158.1.124; SINGH N, 1994, ANN INTERN MED, V120, P375, DOI 10.7326/0003-4819-120-5-199403010-00004; SNYDMAN DR, 1993, ANN INTERN MED, V119, P984, DOI 10.7326/0003-4819-119-10-199311150-00004; SOMMADOSSI JP, 1988, REV INFECT DIS, V10, pS507; STRATTA RJ, 1989, ARCH SURG-CHICAGO, V124, P1443; VANDENBERG AP, 1991, J INFECT DIS, V164, P265; WINSTON DJ, 1993, ANN INTERN MED, V118, P179, DOI 10.7326/0003-4819-118-3-199302010-00004; WOLFF MA, 1993, TRANSPLANTATION, V56, P572, DOI 10.1097/00007890-199309000-00015	30	215	221	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					69	74		10.1016/S0140-6736(95)92110-9	http://dx.doi.org/10.1016/S0140-6736(95)92110-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603215	Bronze			2022-12-28	WOS:A1995RH22000008
J	VISWANATHAN, R; MADSEN, LL; ZASADZINSKI, JA; SCHWARTZ, DK				VISWANATHAN, R; MADSEN, LL; ZASADZINSKI, JA; SCHWARTZ, DK			LIQUID TO HEXATIC TO CRYSTALLINE ORDER IN LANGMUIR-BLODGETT-FILMS	SCIENCE			English	Article							ATOMIC-FORCE MICROSCOPY; BOND-ORIENTATIONAL ORDER; NORMAL-ALKANES; ELECTRON-DIFFRACTION; ROTATOR PHASES; VORTEX GLASS; MONOLAYERS; RESOLUTION; LATTICE; SUPERSTRUCTURES	Atomic force microscope images of zinc arachidate (ZnA(2)) Langmuir-Blodgett films show that three- and five-layer films are ''hexatic,'' with long-range bond-orientational order and short-range positional correlations of three to five lattice repeats. The monolayer in contact with the substrate is disordered. Films of seven or more layers of ZnA(2) are crystalline. A population of dislocations, most likely originating at the substrate, disrupts the positional but not the orientational order of the lattice, leading to hexatic layers intermediate between crystal and liquid. The influence of the substrate propagates farther into ZnA(2) films than into cadmium arachidate films because the molecular cohesion is much weaker in ZnA(2) than in cadmium arachidate, as evidenced by a less dense molecular packing.	UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106; TULANE UNIV,DEPT CHEM,NEW ORLEANS,LA 70118	University of California System; University of California Santa Barbara; Tulane University			Schwartz, Daniel K/H-5153-2012	Schwartz, Daniel K/0000-0001-5397-7200	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51177] Funding Source: Medline; NIGMS NIH HHS [GM47334] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BIRGENEAU RJ, 1978, J PHYS LETT-PARIS, V39, pL399; BISHOP DJ, 1992, SCIENCE, V255, P165, DOI 10.1126/science.255.5041.165; BONNEROT A, 1985, CHEM PHYS, V97, P365, DOI 10.1016/0301-0104(85)87045-2; BOURDIEU L, 1991, PHYS REV LETT, V67, P2029, DOI 10.1103/PhysRevLett.67.2029; BROCK JD, 1986, PHYS REV LETT, V57, P98, DOI 10.1103/PhysRevLett.57.98; CHENG M, 1987, PHYS REV LETT, V59, P1112, DOI 10.1103/PhysRevLett.59.1112; CHUDNOVSKY EM, 1989, PHYS REV B, V40, P11355, DOI 10.1103/PhysRevB.40.11355; DAI HJ, 1992, PHYS REV LETT, V69, P1576, DOI 10.1103/PhysRevLett.69.1576; DAI HJ, 1991, PHYS REV LETT, V66, P3183, DOI 10.1103/PhysRevLett.66.3183; DAI HJ, 1993, J PHYS CHEM-US, V97, P2362, DOI 10.1021/j100112a042; ECKHARDT CJ, 1993, NATURE, V362, P614, DOI 10.1038/362614a0; EGGER M, 1990, J STRUCT BIOL, V103, P89, DOI 10.1016/1047-8477(90)90089-U; FROMMER J, 1992, ANGEW CHEM INT EDIT, V31, P1298, DOI 10.1002/anie.199212981; GARNAES J, 1992, NATURE, V357, P54, DOI 10.1038/357054a0; HALPERIN BI, 1978, PHYS REV LETT, V41, P121, DOI 10.1103/PhysRevLett.41.121; HALPERIN BI, 1978, PHYS REV LETT, V41, P519, DOI 10.1103/PhysRevLett.41.519; HELM CA, 1987, BIOPHYS J, V52, P381, DOI 10.1016/S0006-3495(87)83226-5; JOSEFOWICZ JY, 1993, SCIENCE, V260, P323, DOI 10.1126/science.260.5106.323; KIMURA F, 1986, LANGMUIR, V2, P96, DOI 10.1021/la00067a017; Kitaigorodskii A.I., 1961, ORGANIC CHEM CRYSTAL; KJAER K, 1987, PHYS REV LETT, V58, P2224, DOI 10.1103/PhysRevLett.58.2224; KOSTERLI.JM, 1972, J PHYS PART C SOLID, V5, pL124, DOI 10.1088/0022-3719/5/11/002; Kosterlitz JM, 1973, J PHYS C SOLID STATE, V6, P1181, DOI 10.1088/0022-3719/6/7/010; MACLENNAN J, 1992, PHYS REV LETT, V69, P2082, DOI 10.1103/PhysRevLett.69.2082; MARCHETTI MC, 1990, PHYS REV B, V41, P1910, DOI 10.1103/PhysRevB.41.1910; MARTI O, 1988, SCIENCE, V239, P50, DOI 10.1126/science.3336773; MEYER E, 1991, NATURE, V349, P398, DOI 10.1038/349398a0; MURRAY CA, 1987, PHYS REV LETT, V58, P1200, DOI 10.1103/PhysRevLett.58.1200; MURRAY CA, 1989, PHYS REV LETT, V62, P1643, DOI 10.1103/PhysRevLett.62.1643; MURRAY CA, 1990, PHYS REV LETT, V64, P2312, DOI 10.1103/PhysRevLett.64.2312; NELSON DR, 1979, PHYS REV B, V19, P2457, DOI 10.1103/PhysRevB.19.2457; NELSON DR, 1982, PHILOS MAG A, V46, P105, DOI 10.1080/01418618208236211; OHNESORGE F, 1993, SCIENCE, V260, P1451, DOI 10.1126/science.260.5113.1451; PINDAK R, 1981, PHYS REV LETT, V46, P1135, DOI 10.1103/PhysRevLett.46.1135; PRAKASH M, 1986, CHEM PHYS LETT, V128, P354, DOI 10.1016/0009-2614(86)80376-1; QIU X, 1991, PHYS REV LETT, V67, P703, DOI 10.1103/PhysRevLett.67.703; SCHWARTZ DK, 1993, J AM CHEM SOC, V115, P7374, DOI 10.1021/ja00069a040; SCHWARTZ DK, 1993, LANGMUIR, V9, P1384, DOI 10.1021/la00029a036; SCHWARTZ DK, 1993, PHYS REV E, V47, P452, DOI 10.1103/PhysRevE.47.452; SCHWARTZ DK, 1992, SCIENCE, V257, P508, DOI 10.1126/science.257.5069.508; SCHWARTZ DK, 1993, PHYS REV LETT, V70, P1267, DOI 10.1103/PhysRevLett.70.1267; SELINGER JV, 1993, PHYS REV LETT, V70, P1139, DOI 10.1103/PhysRevLett.70.1139; SIROTA EB, 1993, J CHEM PHYS, V98, P5809, DOI 10.1063/1.464874; SIROTA EB, 1992, PHYS REV LETT, V68, P492, DOI 10.1103/PhysRevLett.68.492; Strandburg KJ., 1992, BOND ORIENTATIONAL O, DOI 10.1007/978-1-4612-2812-7; UNGAR G, 1983, J PHYS CHEM-US, V87, P689, DOI 10.1021/j100227a032; VISWANATHAN R, 1994, NATURE, V368, P440, DOI 10.1038/368440a0; VISWANATHAN R, 1993, SCIENCE, V261, P449, DOI 10.1126/science.8392751; ZASADZINSKI JA, 1994, SCIENCE, V263, P1726, DOI 10.1126/science.8134836	50	53	54	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					51	54		10.1126/science.7604278	http://dx.doi.org/10.1126/science.7604278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604278				2022-12-28	WOS:A1995RG98000027
J	ARANCIO, O; KANDEL, ER; HAWKINS, RD				ARANCIO, O; KANDEL, ER; HAWKINS, RD			ACTIVITY-DEPENDENT LONG-TERM ENHANCEMENT OF TRANSMITTER RELEASE BY PRESYNAPTIC 3',5'-CYCLIC GMP IN CULTURED HIPPOCAMPAL-NEURONS	NATURE			English	Article							NITRIC-OXIDE; RAT HIPPOCAMPUS; SYNAPTIC TRANSMISSION; POTENTIATION; MESSENGER; PLASTICITY; INDUCTION; CURRENTS; PATHWAY; AREA	LONG-TERM potentiation (LTP) in hippocampus is a type of synaptic plasticity that is thought to be involved in learning and memory(1). Several lines of evidence suggest that LTP involves 3',5'-cyclic GMP (cGMP), perhaps as an activity-dependent presynaptic effector of one or more retrograde messengers (refs 2-12, but see ref, 13). However, previous results are also consistent with postsynaptic effects of cGMP. This is difficult to test in hippocampal slices, but more rigorous tests are possible in dissociated cell culture(14-17). We have therefore developed a reliable method for producing N-methyl-D-aspartate (NMDA) receptor-dependent LTP at synapses between individual hippocampal pyramidal neurons in culture, We report that inhibitors of guanylyl cyclase or of cGMP-dependent protein kinase block potentiation by either tetanic stimulation or low-frequency stimulation paired with postsynaptic depolarization. Conversely, application of 8-Br-cGMP to the bath or injection of cGMP into the presynaptic neuron produces activity-dependent long-lasting potentiation, The potentiation by cGMP involves an increase in transmitter release that is in part independent of changes in the presynaptic action potential. These results support a presynaptic role for cGMP in LTP.	HOWARD HUGHES MED INST,NEW YORK,NY 10032	Howard Hughes Medical Institute	ARANCIO, O (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,NEW YORK STATE PSYCHIAT INST,CTR NEUROBIOL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032, USA.		arancio, ottavio/AAB-7959-2019	arancio, ottavio/0000-0001-6335-164X				Arancio O., 1994, Society for Neuroscience Abstracts, V20, P1713; Arancio O., 1993, Society for Neuroscience Abstracts, V19, P241; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DEVENTE J, 1988, BRAIN RES, V446, P387, DOI 10.1016/0006-8993(88)90900-6; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; FABER DS, 1991, BIOPHYS J, V60, P1288, DOI 10.1016/S0006-3495(91)82162-2; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAWKINS RD, 1994, J NEUROBIOL, V25, P652, DOI 10.1002/neu.480250607; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MATSUOKA I, 1992, J NEUROSCI, V12, P3350; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; NEHER E, 1988, CALCIUM ION CHANNEL, P371; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; SCHWARTZKROIN PA, 1975, BRAIN RES, V89, P107, DOI 10.1016/0006-8993(75)90138-9; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0; ZHUO M, 1994, NEUROREPORT, V5, P1033, DOI 10.1097/00001756-199405000-00004	28	264	275	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					74	80		10.1038/376074a0	http://dx.doi.org/10.1038/376074a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596438				2022-12-28	WOS:A1995RH11100065
J	LEE, S; ELENBAAS, B; LEVINE, A; GRIFFITH, J				LEE, S; ELENBAAS, B; LEVINE, A; GRIFFITH, J			P53 AND ITS 14 KDA C-TERMINAL DOMAIN RECOGNIZE PRIMARY DNA-DAMAGE IN THE FORM OF INSERTION DELETION MISMATCHES	CELL			English	Article							WILD-TYPE P53; SACCHAROMYCES-CEREVISIAE; SV40-TRANSFORMED CELLS; ESCHERICHIA-COLI; TUMOR-ANTIGEN; PROTEIN; BINDING; REPAIR; VISUALIZATION; ASSOCIATION	Insertion/deletion (IDL) mismatches in DNA are lesions consisting of extra bases on one strand. Here, the binding of p53 and its 14 kDa C-terminal domain to DNAs containing one or three 3-cytosine IDL mismatches was examined. Electron microscopy showed that both p53 forms bound predominantly as tetramers at the lesions while single-stranded binding proteins did not bind. Gel retardation assays showed that p53 formed highly stable complexes when the DNA contained the IDL mismatches, but only unstable complexes when the DNA lacked lesions (but did contain free ends). The highly stable complexes had a half-life of >2 hr, suggesting that upon encountering lesions, p53 may recruit other proteins to the site, providing a signal for DNA damage.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University	LEE, S (corresponding author), UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599, USA.				NCI NIH HHS [CA41086] Funding Source: Medline; NIGMS NIH HHS [GM31819, GM42342] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA041086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; ALANI E, 1994, GENETICS, V137, P19; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAYLE JH, 1995, IN PRESS P NATL ACAD, V92; BISHOP DK, 1986, MOL CELL BIOL, V6, P3401, DOI 10.1128/MCB.6.10.3401; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; CHI NW, 1994, J BIOL CHEM, V269, P29984; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDIERY WS, 1993, CELL, V75, P817; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GRIFFITH JD, 1995, J MOL BIOL, V246, P576, DOI 10.1016/S0022-2836(05)80107-X; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MUSTERNASSAL C, 1986, P NATL ACAD SCI USA, V83, P7618, DOI 10.1073/pnas.83.20.7618; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PRICE BD, 1993, ONCOGENE, V8, P3055; REENAN RAG, 1992, GENETICS, V132, P975; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SPIVAK G, 1992, BIOCHEMISTRY-US, V31, P6794, DOI 10.1021/bi00144a021; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TISHLER RB, 1993, CANCER RES, V53, P2212; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG YH, 1993, J BIOL CHEM, V268, P17571; WANG YH, 1992, J BIOL CHEM, V267, P4911; WAU L, 1995, MOL CELL BIOL, V15, P497; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	55	414	421	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1013	1020		10.1016/S0092-8674(05)80006-6	http://dx.doi.org/10.1016/S0092-8674(05)80006-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600570	Bronze			2022-12-28	WOS:A1995RG91000006
J	FARTHING, MJG				FARTHING, MJG			FORTNIGHTLY REVIEW - IRRITABLE BOWEL, IRRITABLE BODY, OR IRRITABLE BRAIN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SYMPTOMS; COMMUNITY; DISEASE; TOLERANCE; MOTILITY; PAIN				FARTHING, MJG (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, DIGEST DIS RES CTR, LONDON EC1M 6BQ, ENGLAND.							[Anonymous], 1992, GASTROENTEROL INT; COOK IJ, 1987, GASTROENTEROLOGY, V93, P727, DOI 10.1016/0016-5085(87)90434-3; GOMBORONE JE, 1993, GASTROENTEROLOGY, V104, pA513; GOMBORONE JE, 1993, GUT, V34, P1230, DOI 10.1136/gut.34.9.1230; GOMBORONE JE, IN PRESS J PSYCHOSOM; GORARD DA, 1994, GUT, V35, P496, DOI 10.1136/gut.35.4.496; GORARD DA, 1994, DIGEST DIS, V12, P72, DOI 10.1159/000171440; GORARD DA, IN PRESS DIG DIS SCI; GUTHRIE E, 1994, EUR J GASTROEN HEPAT, V6, P489, DOI 10.1097/00042737-199406000-00007; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; HEATON KW, 1992, GASTROENTEROLOGY, V102, P1962, DOI 10.1016/0016-5085(92)90320-X; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; KELLOW JE, 1990, GASTROENTEROLOGY, V98, P1208, DOI 10.1016/0016-5085(90)90335-X; KENDALL GPN, 1990, GUT, V31, P1062, DOI 10.1136/gut.31.9.1062; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; KRUIS W, 1984, GASTROENTEROLOGY, V87, P1; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MAYER EA, 1990, GASTROENTEROLOGY, V99, P1688, DOI 10.1016/0016-5085(90)90475-G; MORIARTY KJ, 1982, BRIT MED J, V284, P1670, DOI 10.1136/bmj.284.6330.1670; POYNARD T, 1994, ALIMENT PHARM THERAP, V8, P499; PRIOR A, 1990, GUT, V31, P458, DOI 10.1136/gut.31.4.458; TALLEY NJ, 1991, EUR J GASTROEN HEPAT, V3, P71; THOMPSON WG, 1984, GUT, V25, P1089, DOI 10.1136/gut.25.10.1089; THOMPSON WG, 1993, LANCET, V341, P1569, DOI 10.1016/0140-6736(93)90705-L; TROTMAN IF, 1988, GUT, V29, P218, DOI 10.1136/gut.29.2.218; WHITE AM, 1991, GASTROENTEROLOGY, V100, P68, DOI 10.1016/0016-5085(91)90584-8; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P1187, DOI 10.1016/0016-5085(90)90332-U; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0; WHITEHEAD WE, 1992, GUT, V33, P825, DOI 10.1136/gut.33.6.825; WHORWELL PJ, 1987, GUT, V28, P423, DOI 10.1136/gut.28.4.423; WHORWELL PJ, 1986, GUT, V27, P37, DOI 10.1136/gut.27.1.37	31	96	100	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 21	1995	310	6973					171	175		10.1136/bmj.310.6973.171	http://dx.doi.org/10.1136/bmj.310.6973.171			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7605430	Green Published			2022-12-28	WOS:A1995QD20100027
J	CONIBEAR, E; STEVENS, TH				CONIBEAR, E; STEVENS, TH			VACUOLAR BIOGENESIS IN YEAST - SORTING OUT THE SORTING PROTEINS	CELL			English	Review							ENDOCYTOSIS; DYNAMIN; MUTANT				CONIBEAR, E (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.		Conibear, Elizabeth/G-5297-2010	Conibear, Elizabeth/0000-0001-5129-0499; Stevens, Tom/0000-0001-6427-6848				BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; NOTHWEHR SF, 1994, J BIOL CHEM, V269, P10185; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x	17	56	57	1	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					513	516		10.1016/0092-8674(95)90088-8	http://dx.doi.org/10.1016/0092-8674(95)90088-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585951	Bronze			2022-12-28	WOS:A1995TF24800001
J	RACHUBINSKI, RA; SUBRAMANI, S				RACHUBINSKI, RA; SUBRAMANI, S			HOW PROTEINS PENETRATE PEROXISOMES	CELL			English	Review									UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	RACHUBINSKI, RA (corresponding author), UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON,AB T6G 2H7,CANADA.							DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; MOTLEY A, 1994, J CELL BIOL, V125, P755, DOI 10.1083/jcb.125.4.755; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; SZILARD RK, IN PRESS J CELL BIOL; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65	14	178	182	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					525	528		10.1016/0092-8674(95)90091-8	http://dx.doi.org/10.1016/0092-8674(95)90091-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585954	Bronze			2022-12-28	WOS:A1995TF24800004
J	GIANAKOS, D				GIANAKOS, D			UMANA	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											GIANAKOS, D (corresponding author), LYNCHBURG FAMILY PRACTICE RESIDENCY, 2097 LANGHORNE RD, LYNCHBURG, VA 24501 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					730	730		10.7326/0003-4819-123-9-199511010-00016	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00016			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574233				2022-12-28	WOS:A1995TA69600016
J	MORLEY, CA; LIM, BA				MORLEY, CA; LIM, BA			LESSON OF THE WEEK - THE RISKS OF DELAY IN DIAGNOSIS OF BREATHLESSNESS IN PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							DISEASE				MORLEY, CA (corresponding author), ST LUKES HOSP,DEPT CARDIOL,BRADFORD BD5 0NA,W YORKSHIRE,ENGLAND.							Bernal J M, 1986, Obstet Gynecol Surv, V41, P1, DOI 10.1097/00006254-198601000-00001; MCFAUL PB, 1988, BRIT J OBSTET GYNAEC, V95, P861, DOI 10.1111/j.1471-0528.1988.tb06570.x; OAKLEY CM, 1990, CAN J CARDIOL, V6, pB3; SAFIAN RD, 1988, CATHETER CARDIO DIAG, V15, P103, DOI 10.1002/ccd.1810150209	4	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1083	1084		10.1136/bmj.311.7012.1083	http://dx.doi.org/10.1136/bmj.311.7012.1083			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580671	Green Published			2022-12-28	WOS:A1995TB35400032
J	STRACHAN, DP; CAREY, IM				STRACHAN, DP; CAREY, IM			HOME-ENVIRONMENT AND SEVERE ASTHMA IN ADOLESCENCE - A POPULATION-BASED CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; RISK-FACTORS; CHILDREN; PETS; SENSITIZATION; ALLERGY	Objective-To investigate the effects of the home environment on the risk of severe asthma during adolescence. Design-A questionnaire based case-control study drawn from a cross sectional survey of allergic diseases among secondary school pupils in Sheffield in 1991. Subjects-763 children whose parents had reported that over the previous 12 months they had suffered either 12 or more wheezing attacks or a speech limiting attack of wheeze. A further 763 children were frequency matched for age and school class to act as controls. Analysis was restricted to 486 affected children and 475 others born between 1975 and 1980 who had lived at their present address for more than three years. Results-Independent associations with severe wheeze were seen for non-feather bedding, especially foam pillows (odds ratio 2.78; 95% confidence interval 1.89 to 4.17), and the ownership of furry pets now (1.51; 1.04 to 2.20) and at birth (1.70; 1.20 to 2.40). These estimates were derived from subjects whose parents denied making changes in the bedroom or avoiding having a pet because of allergy. Parental smoking, use of gas for cooking, age of mattress, and mould growth in the child's bedroom were not significantly associated with wheezing. Conclusions-Either our study questionnaire failed to detect the avoidance or removal of feather bedding by allergic families or there is some undetermined hazard related to foam pillows. Synthetic bedding and furry pets were both widespread in this population and may represent remediable causes of childhood asthma.			STRACHAN, DP (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Carey, Iain/O-6973-2014	Carey, Iain/0000-0003-1099-8460				ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; Francis B., 1993, GLIM SYSTEM RELEASE; HONG CY, 1994, Q J MED, V87, P639; HOSEIN HR, 1989, INT J EPIDEMIOL, V18, P390, DOI 10.1093/ije/18.2.390; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834, DOI 10.1093/oxfordjournals.aje.a116745; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; LINNA O, 1983, ALLERGY, V38, P513, DOI 10.1111/j.1398-9995.1983.tb02360.x; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; PEARCE N, 1993, EUR RESPIR J, V6, P1455; POPP W, 1990, ALLERGY, V45, P75, DOI 10.1111/j.1398-9995.1990.tb01087.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SHATZ G, 1982, ANN ALLERGY, V48, P59; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174; WARDLAW AJ, 1992, J ALLERGY CLIN IMMUN, V90, P358	17	137	142	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1053	1056		10.1136/bmj.311.7012.1053	http://dx.doi.org/10.1136/bmj.311.7012.1053			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580660	Green Published			2022-12-28	WOS:A1995TB35400018
J	DULAC, C; AXEL, R				DULAC, C; AXEL, R			A NOVEL FAMILY OF GENES ENCODING PUTATIVE PHEROMONE RECEPTORS IN MAMMALS	CELL			English	Article							RABBIT OLFACTORY-BULB; MITRAL TUFTED CELLS; VOMERONASAL ORGAN; ODOR MOLECULES; MALE-MICE; EXPRESSION; SYSTEM; EPITHELIUM; RAT; ORGANIZATION	In mammals, olfactory sensory perception is mediated by two anatomically and functionally distinct sensory organs: the main olfactory epithelium (MOE) and the vomeronasal organ (VNO). Pheromones activate the VNO and elicit a characteristic array of innate reproductive and social behaviors, along with dramatic neuroendocrine responses. Differential screening of cDNA libraries constructed from single sensory neurons from the rat VNO has led to the isolation of a family of about 30 putative receptor genes. Sequence analysis indicates that these genes comprise a novel family of seven transmembrane domain proteins unrelated to the receptors expressed in the MOE. Moreover, the expression of each member of the gene family is restricted to a small subpopulation of VNO neurons. These genes are likely to encode mammalian pheromone receptors.			DULAC, C (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.			Dulac, Catherine/0000-0001-5024-5418; Axel, Richard/0000-0002-3141-4076	NINDS NIH HHS [NS 29832-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029832] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BEAN NJ, 1982, PHYSIOL BEHAV, V29, P433, DOI 10.1016/0031-9384(82)90262-1; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BERTMAR G, 1981, EVOLUTION, V35, P359, DOI 10.1111/j.1558-5646.1981.tb04893.x; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; BROADWELL RD, 1975, J COMP NEUROL, V163, P329, DOI 10.1002/cne.901630306; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CLANCY AN, 1984, J NEUROSCI, V4, P2222; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; EISTHEN HL, 1992, MICROSC RES TECHNIQ, V23, P1, DOI 10.1002/jemt.1070230102; FARBMAN AI, 1992, CELL BIOL OLFACTION; GARCIAVELASCO J, 1991, J STEROID BIOCHEM, V39, P561, DOI 10.1016/0960-0760(91)90253-2; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; HENZEL WJ, 1988, J BIOL CHEM, V263, P16682; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; JACOBSON L, 1811, ANN MUS HIST NAT PAR, V18, P412; JOHNS MA, 1978, NATURE, V272, P446, DOI 10.1038/272446a0; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; KEVETTER GA, 1981, J COMP NEUROL, V197, P81, DOI 10.1002/cne.901970107; KRETTEK JE, 1978, J COMP NEUROL, V178, P225, DOI 10.1002/cne.901780204; KRETTEK JE, 1977, J COMP NEUROL, V172, P687, DOI 10.1002/cne.901720408; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LOMAS DE, 1982, J REPROD FERTIL, V66, P101, DOI 10.1530/jrf.0.0660101; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MACRIDES F, 1985, CHEM SENSES, V10, P175, DOI 10.1093/chemse/10.2.175; MELROSE DR, 1971, BRIT VET J, V127, P497, DOI 10.1016/S0007-1935(17)37337-2; MEREDITH M, 1986, PHYSIOL BEHAV, V36, P737, DOI 10.1016/0031-9384(86)90362-8; MEREDITH M, 1994, PSYCHONEUROENDOCRINO, V19, P657, DOI 10.1016/0306-4530(94)90048-5; MICHAEL RP, 1968, NATURE, V218, P746, DOI 10.1038/218746a0; MONTIBLOCH L, 1994, PSYCHONEUROENDOCRINO, V19, P673, DOI 10.1016/0306-4530(94)90049-3; MORAN DT, 1991, J STEROID BIOCHEM, V39, P545, DOI 10.1016/0960-0760(91)90251-Y; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; Potiquet M, 1891, REV LARYNGOL, V2, P737; PROBST WC, 1992, DNA CELL BIOL, V2, P1; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; REYNOLDS J, 1979, J REPROD FERTIL, V57, P31; ROGERS KE, 1987, P NATL ACAD SCI USA, V84, P1704, DOI 10.1073/pnas.84.6.1704; Sambrook J, 1989, MOL CLONING LABORATO; SCALIA F, 1975, J COMP NEUROL, V161, P31, DOI 10.1002/cne.901610105; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SINGER AG, 1991, J STEROID BIOCHEM, V39, P627, DOI 10.1016/0960-0760(91)90261-3; SORENSEN PW, 1988, BIOL REPROD, V39, P1039, DOI 10.1095/biolreprod39.5.1039; STACEY NE, 1986, CAN J ZOOL, V64, P2412, DOI 10.1139/z86-360; STENSAAS LJ, 1991, J STEROID BIOCHEM, V39, P553, DOI 10.1016/0960-0760(91)90252-Z; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TAKAMI S, 1991, J COMP NEUROL, V311, P65, DOI 10.1002/cne.903110106; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WINANS SS, 1970, SCIENCE, V170, P325; WYSOCKI CJ, 1991, J STEROID BIOCHEM, V39, P661, DOI 10.1016/0960-0760(91)90265-7; WYSOCKI CJ, 1989, NEURAL CONTROL REPRO, P545	62	770	809	2	39	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					195	206		10.1016/0092-8674(95)90161-2	http://dx.doi.org/10.1016/0092-8674(95)90161-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585937	hybrid			2022-12-28	WOS:A1995TA96500006
J	WAKEFORD, R; SOUTHGATE, L; WASS, V				WAKEFORD, R; SOUTHGATE, L; WASS, V			IMPROVING ORAL EXAMINATIONS - SELECTING, TRAINING, AND MONITORING EXAMINERS FOR THE MRCGP	BRITISH MEDICAL JOURNAL			English	Article								Unless examiners are carefully selected, trained, and monitored, examinations may become haphazard. This is perhaps most true of oral or viva voce (''viva)'') examinations, which can generate marks unrelated to competence. To help other bodies to short circuit some years of experiment in connection with the oral component of the Royal College of General Practitioners' membership examination (MRCGP), this paper describes the selection, training, guidance, and monitoring arrangements that have been developed.	ST BARTHOLOMEWS HOSP,COLL MED,LONDON EC1M 6BQ,ENGLAND; ROYAL LONDON HOSP,COLL MED,LONDON EC1M 6BQ,ENGLAND	University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital	WAKEFORD, R (corresponding author), UNIV CAMBRIDGE,OLD SCH,CAMBRIDGE CB2 1TT,ENGLAND.							Anderson J., 1965, NEW LOOK MED ED; COOK M, 1988, PERSONNEL SELECTION, P45; Des Marchais JE, 1989, ANN R COLL PHYS SURG, V22, P213; Des Marchais JE, 1993, TEACH LEARN MED, V5, P24; EVANS LR, 1966, J MED EDUC, V41, P651; Guilford J.P., 1954, J EDUC PSYCHOL, V2nd ed.; LOCKIE C, 1990, EXAMINATION MEMBERSH; NEWBLE D, 1994, CERTIFICATION RECERT, P233; NEWBLE DI, 1980, MED EDUC, V14, P345, DOI 10.1111/j.1365-2923.1980.tb02379.x; Norman GR, 1985, J INSTRUCTIONAL DEV, V8, P11; PENDLETON D, 1988, J ROY COLL GEN PRACT, V38, P147; RAYMOND MR, 1991, EVAL HEALTH PROF, V14, P100, DOI 10.1177/016327879101400107; THOMAS CS, 1993, MED EDUC, V27, P433, DOI 10.1111/j.1365-2923.1993.tb00297.x; WAKEFORD R, 1992, TEACH LEARN MED, V4, P210; WAKEFORD R, 1992, REPORT SURVEY UNDERG, V1, P53; WAKEFORD RE, 1984, MED EDUC, V18, P168, DOI 10.1111/j.1365-2923.1984.tb00999.x	16	55	55	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					931	935						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580556				2022-12-28	WOS:A1995RZ23700027
J	NEWTON, JN; HENDERSON, J; GOLDACRE, MJ				NEWTON, JN; HENDERSON, J; GOLDACRE, MJ			WAITING LIST DYNAMICS AND THE IMPACT OF EARMARKED FUNDING	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	Objective-To determine how changes in the number of admissions from waiting lists and changes in the number of additions to the lists are related to list size and waiting times, in the context of local waiting list initiatives. Design-Review of national and Korner statistics. Setting-England (1987-94) and districts of the former Oxford region (1987-91). Main outcome measures-Correlation of quarterly changes in the number of admissions from waiting Lists in England with changes in total list size, numbers of patients waiting one to two, or over two years, and number of additions to the lists; examination of changes in waiting list statistics for individual district specialties in one region in relation to funding for waiting list initiatives. Results-Nationally, changes in the number of admissions to hospital from lists closely correlated with changes in the number of additions to lists (r=0.84; P<0.01). After adjusting for changes in the number of additions to lists, changes in the number of admissions correlated inversely with changes in List size (r=-0.62; P<0.001), Decreases in the number of patients waiting from one to two years were significantly associated with increases in the number of admissions (r=-0.52; P<0.01); locally, only six of 44 waiting list initiatives were followed by an increase in admissions and a fall in list size, although a further 11 were followed by a fall in list size without a corresponding increase in admissions. Conclusions-An increase in admissions improved waiting times but did not reduce list size because additions to the list tended to increase at the same time. The appropriateness of waiting list initiatives as a method of funding elective surgery should be reviewed.			NEWTON, JN (corresponding author), UNIV OXFORD,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND.		Newton, John/HCH-8693-2022	Newton, John/0000-0002-5641-6457; Henderson, Jane/0000-0001-7527-694X				Arnstein P M, 1991, Br J Plast Surg, V44, P553, DOI 10.1016/0007-1226(91)90029-J; Frankel S, 1989, Health Trends, V21, P56; GOLDACRE MJ, 1987, BRIT MED J, V295, P1105, DOI 10.1136/bmj.295.6606.1105; HEMINGWAY H, 1995, BRIT MED J, V310, P818, DOI 10.1136/bmj.310.6983.818; MILLS RP, 1991, J ROY SOC MED, V84, P405, DOI 10.1177/014107689108400709; Naylor C D, 1994, Qual Health Care, V3, P221, DOI 10.1136/qshc.3.4.221; PARMAR JR, 1993, ANN ROY COLL SURG, V75, P4; POPE C, 1991, SOCIOL HEALTH ILL, V13, P193, DOI 10.1111/1467-9566.ep11340798; POPE C, 1992, BRIT MED J, V305, P577, DOI 10.1136/bmj.305.6853.577; Umeh H N, 1994, Ann R Coll Surg Engl, V76, P4; WILLIAMS M, 1992, EPIDEMIOLOGICALLY BA; 1992, HLTH SERVICE CHARTER; 1994, EL9490 NHS EX; 1992, 4TH REPORT PROGR NHS; 1987, HOSPITAL WAITING STA; 1909, REVISED EXPANDED PAT; 1995, BRIT MED J, V310, P1045	17	27	27	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					783	785		10.1136/bmj.311.7008.783	http://dx.doi.org/10.1136/bmj.311.7008.783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580440	Green Published			2022-12-28	WOS:A1995RX10700021
J	BAKER, LRI				BAKER, LRI			SALT, WATER, AND THE KIDNEY	LANCET			English	Editorial Material							NEPHROTIC SYNDROME; SODIUM RETENTION; RENIN; ALDOSTERONE; EDEMA; RAT				BAKER, LRI (corresponding author), ST BARTHOLOMEWS HOSP,DEPT NEPHROL,LONDON,ENGLAND.							BROWN EA, 1985, NEPHRON, V39, P290, DOI 10.1159/000183392; BROWN EA, 1982, NEPHRON, V32, P102, DOI 10.1159/000182827; BROWN EA, 1984, NEPHRON, V37, P43, DOI 10.1159/000183206; CHANDRA M, 1981, PEDIATR RES, V15, P340, DOI 10.1203/00006450-198104000-00010; CHONKO AM, 1977, AM J MED, V63, P881, DOI 10.1016/0002-9343(77)90541-1; DUSING R, 1980, NEPHRON, V25, P187, DOI 10.1159/000181779; FIRTH JD, 1989, CLIN SCI, V76, P335, DOI 10.1042/cs0760335; FIRTH JD, 1990, CLIN SCI, V79, P559, DOI 10.1042/cs0790559; FIRTH JD, 1992, ADV RENAL MED, P341; ICHIKAWA I, 1983, J CLIN INVEST, V71, P91, DOI 10.1172/JCI110756; MEES EJD, 1979, AM J MED, V67, P378, DOI 10.1016/0002-9343(79)90782-4; MEES EJD, 1995, NEPHRON, V70, P1; MELTZER JI, 1979, ANN INTERN MED, V91, P688, DOI 10.7326/0003-4819-91-5-688	13	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					133	134		10.1016/S0140-6736(95)91204-5	http://dx.doi.org/10.1016/S0140-6736(95)91204-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603225				2022-12-28	WOS:A1995RJ03100004
J	JONES, C; PENNY, L; MATTINA, T; YU, S; BAKER, E; VOULLAIRE, L; LANGDON, WY; SUTHERLAND, GR; RICHARDS, RI; TUNNACLIFFE, A				JONES, C; PENNY, L; MATTINA, T; YU, S; BAKER, E; VOULLAIRE, L; LANGDON, WY; SUTHERLAND, GR; RICHARDS, RI; TUNNACLIFFE, A			ASSOCIATION OF A CHROMOSOME DELETION SYNDROME WITH A FRAGILE SITE WITHIN THE PROTOONCOGENE CBL2	NATURE			English	Article							LINKED MENTAL-RETARDATION; SOMATIC-CELL HYBRIDS; X-SYNDROME; MICROSATELLITE INSTABILITY; CGG REPEAT; DNA; REGION; CANCER; FMR-1; 11Q23	The fragile site FRA11B has been localized to the p(CCG)(n) repeat of the CBL2 proto-oncogene. A proportion of Jacobsen (11q(-)) syndrome patients inherited a chromosome carrying a CBL2 p(CCG)(n) expansion, which was truncated close to FRA11B. These results have broad implications for the role of p(CCG)(n) repeat expansion in the aetiology of genetic disease involving chromosome rearrangements.	UNIV CALIF SAN DIEGO,DEPT MED,DIV MED GENET,LA JOLLA,CA 92093; UNIV CATANIA 1,PEDIAT CLIN,CATANIA,ITALY; ADELAIDE WOMENS & CHILDRENS HOSP,CTR MED GENET,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA; ROYAL CHILDRENS HOSP,MURDOCH INST,MELBOURNE,VIC 3052,AUSTRALIA; UNIV WESTERN AUSTRALIA,DEPT BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA; QUADRANT RES FDN,CAMBRIDGE CB2 2SY,ENGLAND	University of California System; University of California San Diego; University of Catania; Womens & Childrens Hospital Australia; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Western Australia	JONES, C (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		Richards, Robert/ABE-6423-2020; Sutherland, Grant Robert/D-2606-2012; Mattina, Teresa/AGB-4604-2022	Tunnacliffe, Alan/0000-0001-8570-125X; Mattina, Teresa/0000-0001-6143-6682; Richards, Robert Ian/0000-0002-5978-6453				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BLAKE TJ, 1991, ONCOGENE, V6, P653; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Brown W T, 1992, Mol Genet Med, V2, P39; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLYNN GA, 1993, J MED GENET, V30, P97, DOI 10.1136/jmg.30.2.97; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GIRAUD F, 1976, HUM GENET, V34, P125, DOI 10.1007/BF00278880; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARVEY J, 1977, J MED GENET, V14, P46, DOI 10.1136/jmg.14.1.46; HUMMERICH H, 1994, HUM MOL GENET, V3, P73, DOI 10.1093/hmg/3.1.73; JACOBSEN P, 1973, HUM HERED, V23, P568, DOI 10.1159/000152624; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; Knudson A. G., 1973, ADV CANCER RES, V17, P317; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MULLEY JC, 1995, J MED GENET, V32, P162, DOI 10.1136/jmg.32.3.162; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PENNY LA, 1995, AM J HUM GENET, V56, P676; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; Sambrook J, 1989, MOL CLONING LABORATO; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHINZEL A, 1977, J MED GENET, V14, P438, DOI 10.1136/jmg.14.6.438; Sutherland G, 1985, FRAGILE SITES HUMAN; SUTHERLAND GR, 1983, AM J HUM GENET, V35, P432; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TUNNACLIFFE A, 1990, GENOMICS, V8, P447, DOI 10.1016/0888-7543(90)90030-X; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; VOULLAIRE LE, 1987, HUM GENET, V76, P202, DOI 10.1007/BF00284923; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WARREN ST, 1987, SCIENCE, V237, P420, DOI 10.1126/science.3603029; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	46	130	131	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					145	149		10.1038/376145a0	http://dx.doi.org/10.1038/376145a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603564				2022-12-28	WOS:A1995RJ02800052
J	JANG, JK; MESSINA, L; ERDMAN, MB; ARBEL, T; HAWLEY, RS				JANG, JK; MESSINA, L; ERDMAN, MB; ARBEL, T; HAWLEY, RS			INDUCTION OF METAPHASE ARREST IN DROSOPHILA OOCYTES BY CHIASMA-BASED KINETOCHORE TENSION	SCIENCE			English	Article							CHROMOSOMES	In normal Drosophila melanogaster oocytes, meiosis arrests at metaphase I and resumes after oocyte passage through the oviduct. Thus, metaphase arrest defines a control point in the meiotic cell cycle. Metaphase arrest only occurs in oocytes that have undergone at least one meiotic exchange. Here it Is shown that crossovers between homologs attached to the same centromere do not induce metaphase arrest. Hence, exchanges induce metaphase arrest only when they physically conjoin two separate kinetochores. Thus, the signal that mediates metaphase arrest is not the exchange event per se but the resulting tension on homologous kinetochores.	UNIV CALIF DAVIS,DEPT GENET,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis				Hawley, R. Scott/0000-0002-6478-0494	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD023144] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-2-3144] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		COURTOT C, 1992, DEVELOPMENT, V116, P405; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; HAWLEY RS, 1993, DEV GENET, V13, P440; HOLM DG, 1976, GENET BIOL DROSOPHIL, P529; JANG J, UNPUB; King R. C., 1970, OVARIAN DEV DROSOPHI; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MCKIM KS, 1993, NATURE, V362, P364, DOI 10.1038/362364a0; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; REIDER CL, 1994, J CELL BIOL, V127, P1301; Sonnenblick BP, 1965, BIOLOGY DROSOPHILA, P62; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; WHITECOOPER H, 1993, J CELL SCI, V106, P1035	16	48	48	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1917	1919		10.1126/science.7604267	http://dx.doi.org/10.1126/science.7604267			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604267				2022-12-28	WOS:A1995RF99000044
J	LIN, JJ; ZAKIAN, VA				LIN, JJ; ZAKIAN, VA			AN IN-VITRO ASSAY FOR SACCHAROMYCES TELOMERASE REQUIRES EST1	CELL			English	Article							TERMINAL TRANSFERASE-ACTIVITY; YEAST TELOMERES; PHOSPHOGLYCERATE KINASE; BINDING-PROTEIN; DNA; IDENTIFICATION; CLONING; RNA; TETRAHYMENA; CEREVISIAE	Telomerase activity was demonstrated in cell-free extracts from S. cerevisiae through the use of a PCR-based assay. As expected, this activity was eliminated by RNase or phenol treatment of the extract and was dependent on dGTP and dTTP. Telomerase was not detected in extracts prepared from cells grown far similar to 30 or more cell divisions in the absence of the EST1 product, Est1p. TLC1 RNA, which determines the sequence of telomeric DNA in vivo, was present in normal amounts in est1 Delta cells. Moreover, TLC1 RNA specifically precipitated with epitope-tagged Est1p. These data indicate that Est1p is either a subunit of yeast telomerase or an accessory protein associated with telomerase that is essential in vitro for its activity.	UNIV WASHINGTON, DEPT GENET, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	LIN, JJ (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Lin, Jing-Jer/G-8068-2015	LIN, JING-JER/0000-0001-8250-7398	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM026938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BROWN WRA, 1989, NATURE, V338, P774, DOI 10.1038/338774a0; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CROSS SH, 1989, NATURE, V338, P771, DOI 10.1038/338771a0; DANI GM, 1983, P NATL ACAD SCI-BIOL, V80, P3406, DOI 10.1073/pnas.80.11.3406; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HOLLAND MJ, 1978, BIOCHEMISTRY-US, V17, P4900, DOI 10.1021/bi00616a007; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1990, CELL, V60, P529; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MELEK M, 1994, MOL CELL BIOL, V14, P7827, DOI 10.1128/MCB.14.12.7827; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PERKINS RE, 1983, BIOCHEM J, V211, P199, DOI 10.1042/bj2110199; PLUTA AF, 1984, P NATL ACAD SCI-BIOL, V81, P1475, DOI 10.1073/pnas.81.5.1475; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; SAKAKIBARA Y, 1974, P NATL ACAD SCI USA, V71, P802, DOI 10.1073/pnas.71.3.802; Sambrook J, 1989, MOL CLONING LABORATO; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SINGER MS, 1994, SCIENCE, V266, P387; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT JH, 1995, NUCLEIC ACIDS RES, V23, P1454, DOI 10.1093/nar/23.9.1454; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	52	96	99	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1127	1135		10.1016/S0092-8674(05)80017-0	http://dx.doi.org/10.1016/S0092-8674(05)80017-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600580	Bronze			2022-12-28	WOS:A1995RG91000017
J	OTTERBACH, B; STOFFEL, W				OTTERBACH, B; STOFFEL, W			ACID SPHINGOMYELINASE-DEFICIENT MICE MIMIC THE NEUROVISCERAL FORM OF HUMAN LYSOSOMAL STORAGE DISEASE (NIEMANN-PICK DISEASE)	CELL			English	Article							ACTIVATED PROTEIN-KINASE; NUCLEOTIDE-SEQUENCE; CERAMIDE; CELLS; GENE	We have generated an acid sphingomyelinase (aSMase)-deficient mouse line by gene targeting. This novel strain of mutant mouse mimics the lethal, neurovisceral form of the human sphingomyelin storage disease, known as Niemann-Pick disease. Homozygous mice accumulate sphingomyelin extensively in the reticuloendothelial system of liver, spleen, bone marrow, and lung, and in the brain. Most strikingly, the ganglionic cell layer of Purkinje cells of the cerebellum degenerates completely, leading to severe impairment of neuromotor coordination. The Niemann-Pick mouse might facilitate studies on the function of aSMase in the generation of ceramide as proposed second messenger in the intracellular signaling pathways and across the plasma membrane. Furthermore, it provides a suitable model for the development of strategies for somatic gene therapy.			OTTERBACH, B (corresponding author), UNIV COLOGNE,FAC MED,INST BIOCHEM,D-50931 COLOGNE,GERMANY.							AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRADY R, 1987, METABOLIC BASIS INHE, P831; BUNDZA A, 1979, VET PATHOL, V16, P530, DOI 10.1177/030098587901600504; CALLAHAN JW, 1976, CURRENT TRENDS SPHIN, P367; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONZELMANN E, 1991, DEV NEUROSCI-BASEL, V13, P197, DOI 10.1159/000112160; CROCKER AC, 1961, J NEUROCHEM, V7, P69, DOI 10.1111/j.1471-4159.1961.tb13499.x; DITTMER JC, 1964, J LIPID RES, V5, P126; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FREDRICKSON DS, 1969, J LIPID RES, V10, P288; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Klenk E, 1935, H-S Z PHYSIOL CHEM, V235, P24, DOI 10.1515/bchm2.1935.235.1-2.24; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; NEWRZELLA D, 1992, BIOL CHEM H-S, V373, P1233, DOI 10.1515/bchm3.1992.373.2.1233; Niemann A., 1914, JB KINDERHEILKD, V79, P1; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; PEREIRA LD, 1991, GENOMICS, V9, P229, DOI 10.1016/0888-7543(91)90246-B; Pick L., 1927, MED KLIN, V23, P1483; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SNYDER SP, 1982, AM J PATHOL, V108, P252; SPENCE MW, 1993, ADV LIPID RES, V26, P3; STOFFEL W, 1971, H-S Z PHYSIOL CHEM, V352, P1058, DOI 10.1515/bchm2.1971.352.2.1058; VANIER MT, 1991, DEV NEUROSCI-BASEL, V13, P307, DOI 10.1159/000112178; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	32	179	192	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1053	1061		10.1016/S0092-8674(05)80010-8	http://dx.doi.org/10.1016/S0092-8674(05)80010-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600574	Bronze			2022-12-28	WOS:A1995RG91000010
J	RIDDLE, RD; ENSINI, M; NELSON, C; TSUCHIDA, T; JESSELL, TM; TABIN, C				RIDDLE, RD; ENSINI, M; NELSON, C; TSUCHIDA, T; JESSELL, TM; TABIN, C			INDUCTION OF THE LIM HOMEOBOX GENE LMX1 BY WNT7A ESTABLISHES DORSOVENTRAL PATTERN IN THE VERTEBRATE LIMB	CELL			English	Article							ECTODERMAL CONTROL; WINGLESS PROTEIN; IMAGINAL DISKS; INSULIN GENE; CHICK-EMBRYO; DROSOPHILA; EXPRESSION; BUD; DIFFERENTIATION; HOMEODOMAIN	During vertebrate limb development, the ectoderm directs the dorsoventral patterning of the underlying mesoderm. To define the molecular events involved in this process, we have analyzed the function of WNT7a, a secreted factor expressed in the dorsal ectoderm, and LMX1, a LIM homeodomain transcription factor expressed in the dorsal mesenchyme. Ectopic expression of Wnt7a is sufficient to induce and maintain Lmx1 expression in limb mesenchyme, both in vivo and in vitro. Ectopic expression of Lmx1 in the ventral mesenchyme is sufficient to generate double-dorsal limbs. Thus, the dorsalization of limb mesoderm appears to involve the WNT7a-mediated induction of Lmx1 in limb mesenchymal cells.	COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	RIDDLE, RD (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.							BAKER NE, 1988, DEVELOPMENT, V102, P489; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; CHUONG CM, 1993, BIOESSAYS, V15, P513, DOI 10.1002/bies.950150804; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DENT JA, 1989, DEVELOPMENT, V105, P61; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FEKETE DM, 1993, P NATL ACAD SCI USA, V90, P2350, DOI 10.1073/pnas.90.6.2350; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GAVIN BJ, 1991, GENE DEV, V4, P2319; GEDUSPAN JS, 1987, DEV BIOL, V124, P398, DOI 10.1016/0012-1606(87)90492-1; GEDUSPAN JS, 1989, ANAT REC, V224, P79, DOI 10.1002/ar.1092240110; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUMASON GL, 1972, ANIMAL TISSUE TECHNI, P173; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LUNDGREN FE, 1995, DEVELOPMENT, V121, P1769; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSSE R, 1992, CELL, V75, P1073; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; PAUTOU MP, 1977, J EMBRYOL EXP MORPH, V42, P177; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZAKANY J, 1993, NATURE, V362, P546, DOI 10.1038/362546a0	49	386	397	1	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					631	640		10.1016/0092-8674(95)90103-5	http://dx.doi.org/10.1016/0092-8674(95)90103-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585966	Bronze			2022-12-28	WOS:A1995TF24800016
J	BURNS, ME; AUGUSTINE, GJ				BURNS, ME; AUGUSTINE, GJ			SYNAPTIC STRUCTURE AND FUNCTION - DYNAMIC ORGANIZATION YIELDS ARCHITECTURAL PRECISION	CELL			English	Review							FROG NEUROMUSCULAR-JUNCTION; TRANSMITTER RELEASE; CALCIUM CHANNELS; PURKINJE-CELLS; PLASTICITY; NEURONS; NEUROTRANSMITTER; TRANSMISSION; EXOCYTOSIS; MUSCLE				BURNS, ME (corresponding author), DUKE UNIV, MED CTR, DEPT NEUROBIOL, DURHAM, NC 27710 USA.		Augustine, George James/J-9228-2013		NIGMS NIH HHS [GM07184] Funding Source: Medline; NINDS NIH HHS [NS-21624, NS-34045] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021624, R01NS034045] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKERT K, 1973, BRAIN RES, V49, P511; ANDREWS SB, 1986, ANN NY ACAD SCI, V483, P284, DOI 10.1111/j.1749-6632.1986.tb34534.x; ASTRAND P, 1989, J PHYSIOL-LONDON, V409, P207, DOI 10.1113/jphysiol.1989.sp017493; ASTRAND P, 1988, J PHYSIOL-LONDON, V401, P657, DOI 10.1113/jphysiol.1988.sp017185; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; BAILEY CH, 1994, ADV SEC MESS PHOSPH, V29, P529; BARBOUR B, 1993, NEURON, V11, P759, DOI 10.1016/0896-6273(93)90085-6; BASBAUM CB, 1979, J CELL BIOL, V80, P310, DOI 10.1083/jcb.80.2.310; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BERNSTEIN BW, 1989, NEURON, V3, P257, DOI 10.1016/0896-6273(89)90039-1; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BURNSTOCK G, 1979, NEUROSCI RES PROG B, V17, P383; COUTEAUX R, 1970, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences Serie D Sciences Naturelles, V271, P2346; EDWARDS FA, 1995, TRENDS NEUROSCI, V18, P250, DOI 10.1016/0166-2236(95)80003-K; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; GARRITY PA, 1995, CELL, V83, P177, DOI 10.1016/0092-8674(95)90159-0; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HALL ZW, 1992, INTRO MOL NEUROBIOLO; HARRIS KM, 1988, J NEUROSCI, V8, P4455; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HENKART M, 1976, J CELL BIOL, V70, P338, DOI 10.1083/jcb.70.2.338; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Heuser JE, 1977, HDB PHYSL, VI, P261; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; KATZ B, 1979, PROC R SOC SER B-BIO, V205, P369, DOI 10.1098/rspb.1979.0070; Katz B., 1966, NERVE MUSCLE SYNAPSE; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KELLY RB, 1993, J CELL SCI, P81; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; KORNAU HC, 1995, IN PRESS SCIENCE; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MARTIN AR, 1994, P ROY SOC B-BIOL SCI, V258, P321, DOI 10.1098/rspb.1994.0180; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; MOCHIDA S, 1994, NEURON, V13, P1131, DOI 10.1016/0896-6273(94)90051-5; NUSSER Z, 1994, NEUROSCIENCE, V61, P421, DOI 10.1016/0306-4522(94)90421-9; PARSONS TD, 1994, NEURON, V13, P875, DOI 10.1016/0896-6273(94)90253-4; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; RAOMIROTZNIK R, 1995, NEURON, V14, P561, DOI 10.1016/0896-6273(95)90312-7; ROBERTS WM, 1990, J NEUROSCI, V10, P3664; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; SCHELLER RH, 1995, NEURON, V14, P893; SCHWEIZER FE, 1995, NEURON, V14, P689, DOI 10.1016/0896-6273(95)90213-9; SEALOCK R, 1994, CELL, V77, P617, DOI 10.1016/0092-8674(94)90045-0; STEVENS CF, 1994, CURR BIOL, V4, P268, DOI 10.1016/S0960-9822(00)00062-2; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; WAGNER HJ, 1980, J NEUROCYTOL, V9, P573, DOI 10.1007/BF01205026; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; YOSHIKAMI D, 1989, ANN NY ACAD SCI, V560, P230, DOI 10.1111/j.1749-6632.1989.tb24100.x; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	64	116	118	2	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 20	1995	83	2					187	194		10.1016/0092-8674(95)90160-4	http://dx.doi.org/10.1016/0092-8674(95)90160-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585936	Bronze			2022-12-28	WOS:A1995TA96500005
J	GARRITY, PA; ZIPURSKY, SL				GARRITY, PA; ZIPURSKY, SL			NEURONAL TARGET RECOGNITION	CELL			English	Review							OCULAR DOMINANCE COLUMNS; MOUSE OLFACTORY-BULB; CATS VISUAL-CORTEX; CAENORHABDITIS-ELEGANS; ADHESION MOLECULE; NERVOUS-SYSTEM; SYNAPTIC INPUT; MOTOR NEURONS; FASCICLIN-III; C-ELEGANS		UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	GARRITY, PA (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095, USA.			Zipursky, Stephen/0000-0001-5630-7181; Garrity, Paul/0000-0002-8274-6564				ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; CHIBA A, 1993, J NEUROSCI, V13, P714; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Frank E, 1993, Curr Opin Neurobiol, V3, P82, DOI 10.1016/0959-4388(93)90039-2; FRASER SE, 1990, J NEUROBIOL, V21, P51, DOI 10.1002/neu.480210105; GOODMAN CS, 1990, CELL NEURON S, V72, P77; HEBB DO, 1949, ORG BEHAVIOR; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KAHN P, 1994, SCIENCE, V264, P904, DOI 10.1126/science.8178149; Kandler Karl, 1995, Current Opinion in Neurobiology, V5, P98, DOI 10.1016/0959-4388(95)80093-X; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KOBAYASHI T, 1990, DEV BRAIN RES, V57, P29, DOI 10.1016/0165-3806(90)90181-W; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; KRISHNAN SN, 1993, CELL, V73, P967, DOI 10.1016/0092-8674(93)90274-T; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LUMSDEN AGS, 1986, NATURE, V323, P538, DOI 10.1038/323538a0; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MARTIN KA, 1995, NEURON, V14, P229, DOI 10.1016/0896-6273(95)90281-3; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MELSTER M, 1991, SCIENCE, V252, P939; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; MOONEY R, 1993, NEURON, V10, P815, DOI 10.1016/0896-6273(93)90198-Z; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; OLEARY DDM, 1990, COLD SH Q B, V55, P453; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; POMEROY SL, 1990, J NEUROSCI, V10, P1952; RAMONYCAJAL S, 1892, CELLULE, V9, P119; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; SAJJADI FG, 1991, NEW BIOL, V3, P769; SATO M, 1994, NEURON, V13, P791, DOI 10.1016/0896-6273(94)90246-1; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHATZ CJ, 1994, INT J DEV NEUROSCI, V12, P531, DOI 10.1016/0736-5748(94)90061-2; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; SIMON DK, 1992, NEURON, V9, P977, DOI 10.1016/0896-6273(92)90249-D; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STAHL B, 1990, NEURON, V5, P733; STARICH TA, 1993, GENETICS, V133, P527; STRYKER MP, 1986, J NEUROSCI, V6, P2117; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; THOMPSON WJ, 1986, TRENDS NEUROSCI, V9, P25, DOI 10.1016/0166-2236(86)90010-X; TOSNEY KW, 1987, DEV BIOL, V122, P540, DOI 10.1016/0012-1606(87)90318-6; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WALTER J, 1987, DEVELOPMENT, V101, P685; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1992, NATURE, V355, P838, DOI 10.1038/355838a0; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; WONG ROL, 1995, NATURE, V374, P716, DOI 10.1038/374716a0; YOON MG, 1973, J PHYSIOL-LONDON, V233, P575, DOI 10.1113/jphysiol.1973.sp010324	78	54	54	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					177	185		10.1016/0092-8674(95)90159-0	http://dx.doi.org/10.1016/0092-8674(95)90159-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585935	Bronze			2022-12-28	WOS:A1995TA96500004
J	HOFMEISTER, AEM; LONDONOVALLEJO, A; HARRY, E; STRAGIER, P; LOSICK, R				HOFMEISTER, AEM; LONDONOVALLEJO, A; HARRY, E; STRAGIER, P; LOSICK, R			EXTRACELLULAR SIGNAL PROTEIN TRIGGERING THE PROTEOLYTIC ACTIVATION OF A DEVELOPMENTAL TRANSCRIPTION FACTOR IN BACILLUS-SUBTILIS	CELL			English	Article							CONTROL GENE-EXPRESSION; ENCODING SIGMA-FACTORS; BACILLUS-SUBTILIS; RNA-POLYMERASE; ESCHERICHIA-COLI; ENDOSPORE FORMATION; CELL-TYPE; SPORULATION; DNA; FORESPORE	We present biochemical evidence for an intercellular signal transduction pathway in B. subtilis. This pathway governs the conversion of the proprotein pro-sigma(E) to the mature transcription factor rho(E). Proteolytic processing is mediated by the membrane protein SpoIIGA and is triggered by the inferred extracellular signal protein SpoIIR. A factor in conditioned medium from B. subtilis cells engineered to produce SpoIIR during growth triggered processing in protoplasts of B. subtilis cells that had been engineered to produce SpoIIGA and pro-sigma(E). The factor was also detected in, and partially purified from, extracts of SpoIIR-producing cells of E. coli. We speculate that SpoIIGA is both a receptor and a protease and that SpoIIR interacts with SpoIIGA on the outside of the cytoplasmic membrane, activating the intracellular protease domain of SpoIIGA.	INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE		HOFMEISTER, AEM (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,BIOL LABS,CAMBRIDGE,MA 02138, USA.		Harry, Elizabeth/G-8123-2017; Londono-Vallejo, Arturo/ABH-5555-2020; Harry, Liz/AAT-9396-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563; STRAGIER, Patrick/0000-0003-0849-3025; Harry, Elizabeth/0000-0003-0858-9473	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018568, R01GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS LF, 1991, J BACTERIOL, V173, P3846, DOI 10.1128/JB.173.12.3846-3854.1991; BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CUTTING S, 1991, GENE DEV, V5, P456, DOI 10.1101/gad.5.3.456; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; Cutting SM, 1990, MOL BIOL METHODS BAC, P65; DRIKS A, 1991, P NATL ACAD SCI USA, V88, P9934, DOI 10.1073/pnas.88.22.9934; DUBNAU D, 1971, J MOL BIOL, V56, P209, DOI 10.1016/0022-2836(71)90460-8; ERRLNGTON J, 1993, MICROBIOL REV, V57, P1; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; JONAS RM, 1988, J BACTERIOL, V170, P507, DOI 10.1128/jb.170.2.507-511.1988; KARMAZYNCAMPELL.C, 1989, GENES DEV, V3, P150, DOI 10.1101/gad.3.2.150; KAROW LM, 1995, P NATL ACAD SCI USA, V92, P2012; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; LONDONOVALLEJO JA, 1995, GENE DEV, V9, P503, DOI 10.1101/gad.9.4.503; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MASUDA ES, 1988, P NATL ACAD SCI USA, V85, P7637, DOI 10.1073/pnas.85.20.7637; MIYAO A, 1993, J BACTERIOL, V175, P4081, DOI 10.1128/JB.175.13.4081-4086.1993; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS HK, 1991, J BACTERIOL, V173, P7821, DOI 10.1128/jb.173.24.7821-7827.1991; PETERS HK, 1994, J BACTERIOL, V176, P7763, DOI 10.1128/JB.176.24.7763-7766.1994; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; RICCA E, 1992, J BACTERIOL, V174, P3177, DOI 10.1128/jb.174.10.3177-3184.1992; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SHAZAND K, 1995, EMBO J, V14, P1439, DOI 10.1002/j.1460-2075.1995.tb07130.x; STRAGIER P, 1984, NATURE, V312, P376, DOI 10.1038/312376a0; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TREMPY JE, 1985, P NATL ACAD SCI USA, V82, P4189, DOI 10.1073/pnas.82.12.4189; TREMPY JE, 1985, J BACTERIOL, V161, P340, DOI 10.1128/JB.161.1.340-346.1985; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANSURA DG, 1984, P NATL ACAD SCI-BIOL, V81, P439, DOI 10.1073/pnas.81.2.439; YOUNGMAN P, 1984, MOL GEN GENET, V195, P424, DOI 10.1007/BF00341443	39	93	94	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					219	226		10.1016/0092-8674(95)90163-9	http://dx.doi.org/10.1016/0092-8674(95)90163-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585939	Bronze			2022-12-28	WOS:A1995TA96500008
J	OLSON, MV				OLSON, MV			A TIME TO SEQUENCE	SCIENCE			English	Editorial Material							HUMAN GENOME PROJECT; PHYSICAL MAP; CHROMOSOMES; YEAST; DNA; STRATEGY; REGION				OLSON, MV (corresponding author), UNIV WASHINGTON,DEPT MOLEC BIOTECHNOL,SEATTLE,WA 98195, USA.							[Anonymous], 1988, MAPPING SEQUENCING H; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; Green E D, 1991, PCR Methods Appl, V1, P77; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; HUNKAPILLER T, 1991, SCIENCE, V254, P59, DOI 10.1126/science.1925562; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOSHLAND DE, 1994, SCIENCE, V266, P199, DOI 10.1126/science.7939646; LEWIN R, 1987, SCIENCE, V235, P747, DOI 10.1126/science.3468626; MARSHALL E, 1995, SCIENCE, V268, P1270, DOI 10.1126/science.7761844; MARSHALL E, 1995, SCIENCE, V267, P783, DOI 10.1126/science.7846520; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; OLSON MV, 1993, P NATL ACAD SCI USA, V90, P4338, DOI 10.1073/pnas.90.10.4338; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P87794; SMITHIES O, 1995, GENETICS, V139, P1; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	25	48	53	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					394	396		10.1126/science.270.5235.394	http://dx.doi.org/10.1126/science.270.5235.394			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569992				2022-12-28	WOS:A1995TA37400029
J	ANDREWS, BJ; DONOVIEL, MS				ANDREWS, BJ; DONOVIEL, MS			A HETERODIMERIC TRANSCRIPTIONAL REPRESSOR BECOMES CRYSTAL CLEAR	SCIENCE			English	Article							ALPHA-2 REPRESSOR; HOMEO DOMAIN; YEAST; PROTEIN; OPERATOR; BINDS; DNA; HOMEODOMAIN; EUKARYOTES; GENES				ANDREWS, BJ (corresponding author), UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA.							BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HERSKOWITZ I, 1992, MOL CELLULAR BIOL YE, V2, P583; JIN YS, 1995, SCIENCE, V270, P290, DOI 10.1126/science.270.5234.290; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PHILLIPS CL, 1994, BIOCHEMISTRY-US, V33, P9294, DOI 10.1021/bi00197a033; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SMITH DL, 1995, NUCLEIC ACIDS RES, V23, P1239, DOI 10.1093/nar/23.7.1239; STARK MR, 1994, NATURE, V371, P429, DOI 10.1038/371429a0; STRATHERN J, 1988, GENETICS, V120, P75; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	26	1	1	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					251	253		10.1126/science.270.5234.251	http://dx.doi.org/10.1126/science.270.5234.251			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569972				2022-12-28	WOS:A1995RZ34200025
J	TURNER, GM; COULTHARD, MG				TURNER, GM; COULTHARD, MG			FEVER CAN CAUSE PYURIA IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTION		ROYAL VICTORIA INFIRM,PAEDIAT NEPHROL UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Newcastle University - UK								BUYS H, 1994, BRIT MED J, V308, P690, DOI 10.1136/bmj.308.6930.690; DOGUNRO AS, 1991, TROP DOCT, V21, P26, DOI 10.1177/004947559102100111; HOGG RJ, 1987, PEDIATR INFECT DIS J, V6, P233, DOI 10.1097/00006454-198703000-00002; VICKERS D, 1991, LANCET, V338, P767, DOI 10.1016/0140-6736(91)90662-9	4	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					924	924						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580553				2022-12-28	WOS:A1995RZ23700024
J	CHEN, JD; EVANS, RM				CHEN, JD; EVANS, RM			A TRANSCRIPTIONAL CO-REPRESSOR THAT INTERACTS WITH NUCLEAR HORMONE RECEPTORS	NATURE			English	Article							RETINOIC ACID RECEPTOR; A ONCOGENE PRODUCT; THYROID-HORMONE; V-ERBA; PROTEIN; BINDING; SILENCER; ALPHA; BETA	TRANSCRIPTIONAL silencing mediated by nuclear receptors is important in development, differentiation and oncogenesis(1-3). The mechanism underlying this effect is unknown but is one key to understanding the molecular basis of hormone action. Here we identify a receptor-interacting factor, SMRT, as a silencing mediator (co-repressor) for retinoid and thyroid-hormone receptors. SMRT is a previously undiscovered protein whose association with receptors both in solution and bound to DNA-response elements is destabilized by ligand. The interaction with mutant receptors correlates with their transcriptional silencing activities. In vivo, SMRT functions as a potent co-repressor, and a GAL4 DNA-binding domain fusion of SMRT behaves as a frank repressor of a GALA-dependent reporter. Together, our results identify a new class of cofactors which may be important mediators of hormone action.			CHEN, JD (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	31	1637	1675	0	36	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					454	457		10.1038/377454a0	http://dx.doi.org/10.1038/377454a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566127				2022-12-28	WOS:A1995RY19000057
J	LOCKWOOD, DNJ; SAUNDERSON, PR				LOCKWOOD, DNJ; SAUNDERSON, PR			HARNESSING THE STRENGTHS OF THE LEPROSY PROGRAM TO CONTROL TUBERCULOSIS	BRITISH MEDICAL JOURNAL			English	Article								Tuberculosis remains a leading cause of death in Ethiopia but there is no effective national tuberculosis control programme, By contrast, the leprosy control programme has been very successful, with a 10-fold reduction in the number of leprosy cases requiring antibacterial treatment, though patients with nerve damage require continuing care. The paradox of rising numbers of tuberculosis cases and declining numbers of leprosy cases may be solved by joint leprosy-tuberculosis clinics. The strengths of leprosy fieldworkers in control management, case holding, and compliance can be harnessed in developing an effective tuberculosis control programme. Implementing a joint programme in Ethiopia may be beneficial not only for tuberculosis patients but also for leprosy patients, who are thus brought closer to general medical services.	ALERT,LEPROSY & TB CONTROL PROGRAMME,ADDIS ABABA,ETHIOPIA				Saunderson, Paul/AAH-8770-2021					1994, HLTH INDICATORS 1994	1	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					862	863		10.1136/bmj.311.7009.862	http://dx.doi.org/10.1136/bmj.311.7009.862			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580498	Green Published			2022-12-28	WOS:A1995RY19100031
J	GARDNER, KA; MAYER, JM				GARDNER, KA; MAYER, JM			UNDERSTANDING C-H BOND OXIDATIONS - H-CENTER-DOT AND H- TRANSFER IN THE OXIDATION OF TOLUENE BY PERMANGANATE	SCIENCE			English	Article							AQUEOUS-SOLUTION; RATE CONSTANTS; METAL-OXIDES; RADICALS; HYDROXYLASE; MECHANISM; REDUCTION; ACID	The oxidation of toluene by permanganate has been studied as a model for the oxidation of C-H bonds by metal reagents, metalloenzymes, and metal oxide surfaces. In water, the reaction proceeds by hydride (H-) transfer from toluene to a permanganate oxygen, whereas in toluene solution, permanganate abstracts a hydrogen atom (H-.). The ability of permanganate to abstract a hydrogen atom is rationalized on the basis of the strong O-H bond formed on H addition to permanganate. This approach allows understanding and prediction of the rates of hydrogen atom transfer from substrates to metal active sites.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								AVILA DV, 1993, J AM CHEM SOC, V115, P466, DOI 10.1021/ja00055a015; BERKOWITZ J, 1994, J PHYS CHEM-US, V98, P2744, DOI 10.1021/j100062a009; BORDWELL FG, 1994, J AM CHEM SOC, V116, P6605, DOI 10.1021/ja00094a015; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRAUMAN JI, 1970, J AM CHEM SOC, V92, P329, DOI 10.1021/ja00705a642; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; CENTI G, 1988, CHEM REV, V88, P55, DOI 10.1021/cr00083a003; COLUSSI AJ, 1988, CHEM KINETICS SMALL, P33; COOK GK, 1994, J AM CHEM SOC, V116, P8859, DOI 10.1021/ja00098a077; COOK GK, 1994, J AM CHEM SOC, V116, P1855, DOI 10.1021/ja00084a029; CULLIS CF, 1955, J CHEM SOC, P555, DOI 10.1039/jr9550000555; DEMONTELLANO PRO, 1985, CYTOCHROME P450 STRU; Exner O., 1978, CORRELATION ANAL CHE, P439; GARDNER KA, UNPUB; HOWARD JA, 1984, LANDOLTBORNSTEIN D, V13; INGOLD KU, 1973, FREE RADICALS, V1, P67; JONSSON M, 1994, J AM CHEM SOC, V116, P1423, DOI 10.1021/ja00083a030; KARAMAN H, 1984, J ORG CHEM, V49, P4509, DOI 10.1021/jo00197a037; Knox J. H., 1968, OXIDATION ORGANIC CO, P1; Kochi J.K., 1973, FREE RADICALS; Latimer W. M., 1952, OXIDATION STATES ELE, V2nd; LEE DG, 1993, J AM CHEM SOC, V115, P11231, DOI 10.1021/ja00077a023; LIND J, 1990, J AM CHEM SOC, V112, P479, DOI 10.1021/ja00158a002; MAILLARD B, 1983, J AM CHEM SOC, V105, P5095, DOI 10.1021/ja00353a039; PEREZBENITO JF, 1992, J COLLOID INTERF SCI, V152, P70, DOI 10.1016/0021-9797(92)90009-B; PEREZBENITO JF, 1985, CAN J CHEM, V63, P1275; PEREZBENITO JF, 1979, J CHEM SOC CHEM COMM, V18, P69; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSS SD, 1975, ANODIC OXYDATION, P83; RUCHARDT C, 1992, ANGEW CHEM INT EDIT, V31, P1523, DOI 10.1002/anie.199215231; RUSSELL GA, 1973, FREE RADICALS, V1, P275; SCHMIDT HJ, 1979, ANGEW CHEM INT EDIT, V18, P68, DOI 10.1002/anie.197900681; STEENKEN S, 1982, J AM CHEM SOC, V104, P1244, DOI 10.1021/ja00369a017; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; STEWART R, 1964, OXIDATION MECHANISMS; THOMPSON MS, 1982, J AM CHEM SOC, V104, P5070, DOI 10.1021/ja00383a013; TONG YD, 1991, J AM CHEM SOC, V113, P4741, DOI 10.1021/ja00013a005; WATANABE Y, 1992, ENZYMES, V20, P405; WIBERG KB, 1963, J AM CHEM SOC, V85, P3487, DOI 10.1021/ja00904a040	39	218	221	2	104	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1849	1851		10.1126/science.7569922	http://dx.doi.org/10.1126/science.7569922			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569922				2022-12-28	WOS:A1995RX19400030
J	VERSCHUREN, WMM; KROMHOUT, D				VERSCHUREN, WMM; KROMHOUT, D			TOTAL CHOLESTEROL CONCENTRATION AND MORTALITY AT A RELATIVELY YOUNG AGE - DO MEN AND WOMEN DIFFER	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; FOLLOW-UP; PLASMA-CHOLESTEROL; PAISLEY SURVEY; CANCER; POPULATION; RENFREW; COHORT; RISK	Objective-To investigate the relation between total cholesterol concentration and mortality from coronary heart disease, cardiovascular diseases, non-cardiovascular causes, and all causes. Design-Population based cohort study. Subjects-23000 men and 26000 women aged 30-51 years examined between 1974 and 1980. Main outcome measures-Mortality for the above mentioned end points for fifths of cholesterol distribution, and relative risks estimated by using Cox's proportional hazard (survival) analysis. Adjustment was made for age, smoking, systolic blood pressure, and body mass index. Results-Mortality from coronary heart disease in men was five times higher than that in women. A strong positive association between total cholesterol concentration and mortality from coronary heart disease and cardiovascular diseases was observed in both men and women, The relative risk for the highest compared with the lowest fifth of the cholesterol distribution was for mortality from coronary heart disease (3.0 (95% confidence interval 1.8 to 5.1) in men and 3.8 (1.1 to 13.1) in women) and for mortality from cardiovascular disease (2.8 (1.8 to 4.2) in men and 2.9 (1.4 to 6.0) in women). No increase of non-cardiovascular mortality at low cholesterol concentration was observed. All cause mortality was significantly higher in the highest compared with the lowest fifth of the cholesterol distribution: relative risk 1.6 (1.3 to 2.0) in men and 1.5 (1.1 to 1.9) in women. Conclusion-Total cholesterol concentration is a strong predictor of mortality from coronary heart disease, cardiovascular diseases, and all causes in women as well as in men. Low cholesterol concentrations are not associated with increased mortality from non-cardiovascular causes,			VERSCHUREN, WMM (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,POB 1,3720 BA BILTHOVEN,NETHERLANDS.		Kromhout, Daan/A-8566-2014					ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; [Anonymous], 1993, NETH J CARDIOL; [Anonymous], 1989, SAS STAT USERS GUIDE, V2; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; HUANG TC, 1961, ANAL CHEM, V33, P1405, DOI 10.1021/ac60178a040; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; KARK JD, 1980, J CHRON DIS, V33, P311, DOI 10.1016/0021-9681(80)90026-0; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MEIJER J, 1976, HART B, V7, P42; NEATON JD, 1992, ARCH INTERN MED, V152, P1480; PERSSON B, 1984, ACTA MED SCAND, V216, P485; RUWAARD D, 1993, PUBLIC HLTH STATUS F, P377; SCHATZKIN A, 1988, CANCER RES, V48, P452; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; VERSCHUREN WMM, 1991, AM J EPIDEMIOL, V134, P1290, DOI 10.1093/oxfordjournals.aje.a116032; 1989, SAS STAT USERS GUIDE, V1; 1994, WOMEN CARDIOVASCULAR; 1982, JAMA-J AM MED ASSOC, V248, P2853; 1990, HART B S, V23, P9	28	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					779	783		10.1136/bmj.311.7008.779	http://dx.doi.org/10.1136/bmj.311.7008.779			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580439	Green Published, Green Accepted			2022-12-28	WOS:A1995RX10700020
J	GALLIN, JI; FARBER, JM; HOLLAND, SM; NUTMAN, TB				GALLIN, JI; FARBER, JM; HOLLAND, SM; NUTMAN, TB			INTERFERON-GAMMA IN THE MANAGEMENT OF INFECTIOUS-DISEASES	ANNALS OF INTERNAL MEDICINE			English	Article							MYCOBACTERIUM-AVIUM-INTRACELLULARE; SEVERE ATOPIC-DERMATITIS; CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; PENTAVALENT ANTIMONY; IGE LEVELS; T-CELLS; RECEPTOR; AIDS; RESPONSES	Interferon-gamma has pleiotropic adjuvant effects on host defenses. These effects have made interferon-gamma particularly useful for enhancing host defenses in patients with chronic granulomatous disease of childhood and thus for reducing the incidence of life-threatening infections in these patients. Increasingly, data suggest that interferon-gamma will be useful for treating infections characterized by intracellular persistence in macrophages, such as toxoplasmosis, leishmaniasis, and mycobacteriosis. Interferon-gamma is emerging as an important cytokine for use in the treatment of infectious diseases.	NIAID, CLIN INVEST LAB, BETHESDA, MD 20892 USA; NIAID, HOST DEF LAB, BETHESDA, MD 20892 USA; NIAID, PARASIT DIS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	GALLIN, JI (corresponding author), NIH, WARREN G MAGNUSON CLIN CTR, BLDG 10, ROOM 2C146, 10 CTR DR, BETHESDA, MD 20892 USA.							AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ARANA BA, 1994, CLIN INFECT DIS, V18, P381, DOI 10.1093/clinids/18.3.381; BADARO R, 1993, J INFECT DIS, V167, pS13, DOI 10.1093/infdis/167.Supplement_1.S13; BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BENSON CA, 1994, CLIN INFECT DIS, V18, pS218, DOI 10.1093/clinids/18.Supplement_3.S218; BERMUDEZ LE, 1991, ANTIMICROB AGENTS CH, V35, P2625, DOI 10.1128/AAC.35.12.2625; BOGUNIEWICZ M, 1990, AM J MED, V88, P365, DOI 10.1016/0002-9343(90)90490-5; BOTTASSO O, 1992, ARCH DERMATOL, V128, P996, DOI 10.1001/archderm.128.7.996; CURNETTE JT, 1994, 6TH INT C INF DIS PR, P42; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DEGORGOLAS M, 1993, CLIN INFECT DIS, V17, P56, DOI 10.1093/clinids/17.1.56; DELEMARRE FGA, 1993, J INFECT DIS, V168, P516, DOI 10.1093/infdis/168.2.516; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; GALLIN JI, 1990, JAMA-J AM MED ASSOC, V263, P1533, DOI 10.1001/jama.263.11.1533; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; HARMS G, 1991, T ROY SOC TROP MED H, V85, P214, DOI 10.1016/0035-9203(91)90026-U; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; HORSBURGH CR, 1985, MEDICINE, V64, P36, DOI 10.1097/00005792-198501000-00003; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; KAPLAN G, 1993, J INFECT DIS, V167, pS18, DOI 10.1093/infdis/167.Supplement_1.S18; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; KLEBANOFF SJ, 1992, BLOOD, V80, P225; KURKCUOGLU N, 1990, ARCH DERMATOL, V126, P831, DOI 10.1001/archderm.126.6.831; LOCKSLEY RM, 1992, CURR OPIN IMMUNOL, V4, P413, DOI 10.1016/S0952-7915(06)80032-4; MALECH HL, 1993, CURR OPIN HEMATOL, P123; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURRAY HW, 1994, AM J MED, V97, P459, DOI 10.1016/0002-9343(94)90326-3; MURRAY HW, 1988, J INFECT DIS, V157, P973, DOI 10.1093/infdis/157.5.973; MURRAY HW, 1992, AM J MED, V93, P234, DOI 10.1016/0002-9343(92)90059-K; NAGANO Y, 1954, CR SOC BIOL, V148, P1700; NATHAN C, 1992, INFLAMMATION BASIC P, P265; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PUNG YH, 1993, ANN ALLERGY, V71, P234; REED SG, 1993, CURR OPIN IMMUNOL, V5, P524, DOI 10.1016/0952-7915(93)90033-O; REINHOLD U, 1990, LANCET, V335, P1282, DOI 10.1016/0140-6736(90)91347-D; REINHOLD U, 1988, INT ARCH ALLER A IMM, V87, P120, DOI 10.1159/000234661; REINHOLD U, 1993, J AM ACAD DERMATOL, V29, P58, DOI 10.1016/0190-9622(93)70152-J; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; SAMPAIO EP, 1992, J EXP MED, V175, P1729, DOI 10.1084/jem.175.6.1729; SECHLER JMG, 1988, P NATL ACAD SCI USA, V85, P4874, DOI 10.1073/pnas.85.13.4874; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SQUIRES KE, 1993, AM J TROP MED HYG, V48, P666, DOI 10.4269/ajtmh.1993.48.666; SQUIRES KE, 1992, J INFECT DIS, V166, P686, DOI 10.1093/infdis/166.3.686; SQUIRES KE, 1989, J INFECT DIS, V159, P599, DOI 10.1093/infdis/159.3.599; SUNDAR S, 1994, J INFECT DIS, V170, P659, DOI 10.1093/infdis/170.3.659; SUZUKI Y, 1988, SCIENCE, V240, P516, DOI 10.1126/science.3128869; WHEELOCK EF, 1965, SCIENCE, V149, P310, DOI 10.1126/science.149.3681.310; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	63	109	111	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					216	224		10.7326/0003-4819-123-3-199508010-00009	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598304				2022-12-28	WOS:A1995RL10400009
J	GLANTZ, SA; BARNES, DE; BERO, L; HANAUER, P; SLADE, J				GLANTZ, SA; BARNES, DE; BERO, L; HANAUER, P; SLADE, J			LOOKING THROUGH A KEYHOLE AT THE TOBACCO INDUSTRY - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To introduce a series of papers discussing previously undocumented tobacco industry activities regarding strategies to avoid products liability litigation, understand nicotine addiction, and manipulate both internal and external scientific research on the effects of both active and passive smoking. Data Sources.-Documents from Brown and Williamson Tobacco Corporation (B&W), the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-These documents provide our first look at the inner workings of the tobacco industry during the crucial period in which the scientific case that smoking is addictive and kills smokers solidified. The documents show a sophisticated legal and public relations strategy to avoid liability for the diseases induced by tobacco use. The documents show that lawyers steered scientists away from particular research avenues, which is inconsistent with the company's purported disbelief in the causation and addiction claims; if the company had been genuinely unconvinced by the causation and addiction hypotheses, then it should have had no concern that new research would provide ammunition for the enemy. Quite the contrary, the documents show that B&W and BAT recognized more than 30 years ago that nicotine is addictive and that tobacco smoke is ''biologically active'' (leg, carcinogenic).	UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ 08903	University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center	GLANTZ, SA (corresponding author), UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,DIV CARDIOL,BOX 0124,SAN FRANCISCO,CA 94143, USA.				NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES DE, 1995, JAMA-J AM MED ASSOC, V274, P248, DOI 10.1001/jama.274.3.248; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P241, DOI 10.1001/jama.274.3.241; HANAUER P, 1995, JAMA-J AM MED ASSOC, V274, P234; HILTS P, 1994, NY TIMES        0310, pA10; HILTS PJ, 1994, NY TIMES        0507, pA1; KING W, 1976, NY TIMES        1030, pA8; MAXWELL JJ, 1993, HIST SALES TRENDS CI; MAXWELL JJ, 1993, MAXWELL CONSUMER REP; MILLHISER RR, 1978, NY TIMES        0112, pA19; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; WEISZ P, 1995, BRANDWEEK       0606, P20; WOLINSKY H, 1985, NEW YORK STATE J MED, V85, P451; 1964, US DHEW PHS1103 PUBL; 1988, PHS CDC888406 US DEP; 1989, PHS DHHS CDC898411 U; 1981, DHHS PHS8150156 US D; 1982, DHHS PHS8550179 US D; 1979, NY TIMES        0922, pA6; 1972, PHS DHEW HSM727516 H; 1979, DHEW PHS7950066 OFF; 1985, ORG POLICY STATEMENT; 1986, PHS DHHS CDC878398 U; 1986, TOBACCO SMOKE NONSMO	23	91	92	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					219	224		10.1001/jama.274.3.219	http://dx.doi.org/10.1001/jama.274.3.219			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609230				2022-12-28	WOS:A1995RH93700027
J	DONZELLI, GP; PRATESI, S; RAPISARDI, G; AGATI, G; FUSI, F; PRATESI, R				DONZELLI, GP; PRATESI, S; RAPISARDI, G; AGATI, G; FUSI, F; PRATESI, R			1-DAY PHOTOTHERAPY OF NEONATAL JAUNDICE WITH BLUE-GREEN LAMP	LANCET			English	Letter									UNIV FLORENCE,DEPT PHYS,FLORENCE,ITALY; CNR,INST QUANTUM ELECTR,FLORENCE,ITALY	University of Florence; Consiglio Nazionale delle Ricerche (CNR)	DONZELLI, GP (corresponding author), UNIV FLORENCE,OSPED MEYER,DEPT PEDIAT,I-50132 FLORENCE,ITALY.		Pratesi, Simone/M-6697-2016; Agati, Giovanni/F-5572-2013; fusi, franco/K-4637-2013	Pratesi, Simone/0000-0002-8943-7246; fusi, franco/0000-0002-4349-0842; AGATI, GIOVANNI/0000-0003-0855-9389				AGATI G, 1993, J PHOTOCH PHOTOBIO B, V18, P197, DOI 10.1016/1011-1344(93)80063-F; DONZELLI GP, 1994, SPIE, V2084, P332; PRATESI R, 1983, LANCET, V2, P859; SISSON T R C, 1970, Birth Defects Original Article Series, V6, P100; VECCHI C, 1982, LANCET, V2, P390	5	16	18	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					184	185						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603251				2022-12-28	WOS:A1995RJ03100045
J	JAYARAMAN, L; PRIVES, C				JAYARAMAN, L; PRIVES, C			ACTIVATION OF P53 SEQUENCE-SPECIFIC DNA-BINDING BY SHORT SINGLE STRANDS OF DNA REQUIRES THE P53 C-TERMINUS	CELL			English	Article							SERUM RESPONSE FACTOR; TRANSCRIPTIONAL ACTIVATION; WILD-TYPE; REPLICATION; MUTANT; ANTIGEN; DOMAINS	Upon cellular DNA damage, the p53 tumor suppressor protein transmits a signal to genes that control the cell cycle and apoptosis. One function of p53 that is important for its role in this pathway is its ability to function as a sequence-specific transcriptional activator. We demonstrate here that short single DNA strands can markedly stimulate the ability of human and murine p53 proteins to bind specifically to a p53 response element in supercoiled DNA. We also show that single-stranded DNA does not stimulate binding by a truncated p53 that lacks the C-terminal domain. Finally, we establish that a peptide spanning the p53 C-terminus has the ability in trans to stimulate sequence-specific DNA binding by p53 dramatically. These data taken together suggest a model in which the p53 C-terminus can recognize DNA structures resulting from damage-induced lesions, and this interaction can be propagated to regulate positively p53 sequence-specific DNA binding.			JAYARAMAN, L (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.				NCI NIH HHS [CA58316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058316, R37CA058316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BRAIN R, 1994, ONCOGENE, V9, P1775; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DLIC V, 1994, CELL, V76, P1013; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V78, P817; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11653; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, COLD SPRING HARB SYM, V59, P207, DOI 10.1101/SQB.1994.059.01.025; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZHU H, 1994, J BIOL CHEM, V236, P3489	45	359	363	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1021	1029		10.1016/S0092-8674(05)80007-8	http://dx.doi.org/10.1016/S0092-8674(05)80007-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600571	Bronze			2022-12-28	WOS:A1995RG91000007
J	SHERRINGTON, R; ROGAEV, EI; LIANG, Y; ROGAEVA, EA; LEVESQUE, G; IKEDA, M; CHI, H; LIN, C; LI, G; HOLMAN, K; TSUDA, T; MAR, L; FONCIN, JF; BRUNI, AC; MONTESI, MP; SORBI, S; RAINERO, I; PINESSI, L; NEE, L; CHUMAKOV, I; POLLEN, D; BROOKES, A; SANSEAU, P; POLINSKY, RJ; WASCO, W; DASILVA, HAR; HAINES, JL; PERICAKVANCE, MA; TANZI, RE; ROSES, AD; FRASER, PE; ROMMENS, JM; STGEORGEHYSLOP, PH				SHERRINGTON, R; ROGAEV, EI; LIANG, Y; ROGAEVA, EA; LEVESQUE, G; IKEDA, M; CHI, H; LIN, C; LI, G; HOLMAN, K; TSUDA, T; MAR, L; FONCIN, JF; BRUNI, AC; MONTESI, MP; SORBI, S; RAINERO, I; PINESSI, L; NEE, L; CHUMAKOV, I; POLLEN, D; BROOKES, A; SANSEAU, P; POLINSKY, RJ; WASCO, W; DASILVA, HAR; HAINES, JL; PERICAKVANCE, MA; TANZI, RE; ROSES, AD; FRASER, PE; ROMMENS, JM; STGEORGEHYSLOP, PH			CLONING OF A GENE BEARING MISSENSE MUTATIONS IN EARLY-ONSET FAMILIAL ALZHEIMERS-DISEASE	NATURE			English	Article							PRECURSOR PROTEIN GENE; CAENORHABDITIS-ELEGANS; HUMAN GENOME; APOLIPOPROTEIN-E; CHROMOSOME-14; IDENTIFICATION; LINKAGE; LIBRARY; ALLELE; CLONES	Some cases of Alzheimer's disease are inherited as an autosomal dominant trait. Genetic linkage studies have mapped a locus (AD3) associated with susceptibility to a very aggressive form of Alzheimer's disease to chromosome 14q24.3. We have defined a minimal cosegregating region containing the AD3 gene, and isolated at least 19 different transcripts encoded within this region. One of these transcripts (S182) corresponds to a novel gene whose product is predicted to contain multiple transmembrane domains and resembles an integral membrane protein. Five different missense mutations have been found that cosegregate with early-onset familial Alzheimer's disease. Because these changes occurred In conserved domains of this gene, and are not present in normal controls, they are likely to be causative of AD3.	UNIV TORONTO,DEPT MED NEUROL,CTR RES NEURODEGENERAT DIS,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED,DIV NEUROL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED & MOLEC GENET,TORONTO,ON M5S 1A8,CANADA; ECOLE PRAT HAUTES ETUD,NEUROHIST LAB,F-75651 PARIS 13,FRANCE; INSERM LA SALPETRIERE,U106,F-75651 PARIS 13,FRANCE; USL 6,I-88046 LAMEZIA TERME,ITALY; CNR,UO,I-88046 LAMEZIA TERME,ITALY; UNIV FLORENCE,DEPT NEUROL & PSYCHIAT,FLORENCE,ITALY; UNIV TURIN,DEPT NEUROL,I-10126 TURIN,ITALY; NINCDS,CLIN NEUROPHARMACOL SECT,BETHESDA,MD 20892; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; UNIV MASSACHUSETTS,MED CTR,DEPT NEUROL,WORCESTER,MA 01655; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,MOLEC NEUROGENET LAB,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,GENET & AGING LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; DUKE UNIV,MED CTR,BRYAN ALZHEIMERS DIS RES CTR,DURHAM,NC 27710; GLAXO GRP RES LTD,RES & DEV,MOLEC PATHOL,GREENFORD UB6 0HE,MIDDX,ENGLAND; SANDOZ PHARMACEUT CORP,SANDOZ RES INST,E HANOVER,NJ 07936; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut National de la Sante et de la Recherche Medicale (Inserm); Consiglio Nazionale delle Ricerche (CNR); University of Florence; University of Turin; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Duke University; GlaxoSmithKline; Novartis; Sandoz; University of Edinburgh			Rogaev, Evgeny/AAN-7662-2020; de Silva, Rohan/C-1734-2008; Tanzi, Rudolph/AAE-9622-2019; Haines, Jonathan/C-3374-2012; Bruni, Amalia/K-5038-2016	de Silva, Rohan/0000-0002-5052-5775; Tanzi, Rudolph/0000-0002-7032-1454; Haines, Jonathan/0000-0002-4351-4728; Bruni, Amalia/0000-0003-3471-3343; sorbi, sandro/0000-0002-0380-6670	CIHR [64309] Funding Source: Medline; Telethon [E.0010] Funding Source: Medline	CIHR(Canadian Institutes of Health Research (CIHR)); Telethon(Fondazione Telethon)		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bergamini L, 1991, Acta Neurol (Napoli), V13, P534; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; CRUTS M, 1994, NEUROBIOL AGING, V15, pS129; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; ETCHEBERRIGARAY R, 1994, P NATL ACAD SCI USA, V90, P8209; FONCIN JF, 1985, REV NEUROL, V141, P194; FROMMELT P, 1991, ALZ DIS ASSOC DIS, V5, P36, DOI 10.1097/00002093-199100510-00005; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOUDSMIT J, 1981, J NEUROL SCI, V49, P78; GUSELLA JF, 1993, CELL, V72, P971; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kosik Kenneth S., 1994, P335; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; LIU Q, 1995, BIOTECHNIQUES, V18, P470; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NEE LE, 1983, ARCH NEUROL-CHICAGO, V40, P203, DOI 10.1001/archneur.1983.04050040033004; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; Pollen D. A., 1993, HANNAHS HEIRS QUEST; PTACEK LJ, 1991, CELL, V67, P1021; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROGAEV EI, 1993, NEUROLOGY, V43, P2275, DOI 10.1212/WNL.43.11.2275; ROMMENS JM, 1993, HUM MOL GENET, V2, P901, DOI 10.1093/hmg/2.7.901; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SALEEBA JA, 1993, METHOD ENZYMOL, V217, P285; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1993, AM J HUM GENET, V53, P619; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STGEORGEHYSLOP PH, 1994, SCIENCE, V263, P536; STGEORGEHYSLOP PH, 1991, NATURE, V347, P194; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VAN BROECKHOVEN C, 1992, NAT GENET, V2, P335, DOI 10.1038/ng1292-335; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WONG L, 1993, NEUROSCI LETT, V152, P96, DOI 10.1016/0304-3940(93)90492-4	50	3365	3527	1	179	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					754	760		10.1038/375754a0	http://dx.doi.org/10.1038/375754a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596406				2022-12-28	WOS:A1995RF98900069
J	WEINBERG, RB				WEINBERG, RB			COMMUNION	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											WEINBERG, RB (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.								0	13	13	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1995	123	10					804	805		10.7326/0003-4819-123-10-199511150-00011	http://dx.doi.org/10.7326/0003-4819-123-10-199511150-00011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE172	7574201				2022-12-28	WOS:A1995TE17200011
J	FOULDS, J; GODFREY, C				FOULDS, J; GODFREY, C			COUNTING THE COSTS OF CHILDRENS SMOKING	BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE	The recent publication of the 1994 OPCS survey of smoking among secondary school children confirmed that the Health of the Nation target for children's smoking (a reduction in regular smoking from 8% in 1988 to less than 6% in 1994) has not been achieved. In 1994, 12% of English schoolchildren aged 11-15 were regular smokers (as were 12% in Scotland, 9% in Wales, and 12.5% in Northern Ireland). In 1994 the government spent around pound 10 million on initiatives to prevent smoking, but received around, pound 8643 million in tax receipts from tobacco sales, about pound 108 million of which was tax receipts from the illegal sale of cigarettes to children under 16 years old. The tobacco industry spent an estimated; pound 100 million on promotional activities. Improving current trends in children's smoking by the year 2000 will require decisive action by the government. The government should legislate to ban tobacco advertising and should use the pound 108 million taken each year in taxes from smoking children to fund smoking cessation and prevention initiatives.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; DEPT HLTH SCI & CLIN EVALUAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK; University of York - UK	FOULDS, J (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT ADDICT BEHAV,LONDON SW17 0RE,ENGLAND.		Foulds, Jonathan/AAM-6750-2021	Foulds, Jonathan/0000-0003-2296-0726				ADRIAANSE H, 1992, TOBACCO CONTROL, V1, P57; AITKEN PP, 1990, BRIT J ADDICT, V85, P399; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; BUCK D, 1994, HELPING SMOKERS GIVE; Department of Health, 1992, POL REQ AV COMP SPEC; DIAMOND A, 1995, SMOKING SECONDARY SC; DiFranza J.R., 1992, TOB CONTROL, V1, P58, DOI [10.1136/tc.1.1.58a, DOI 10.1136/TC.1.1.58A]; Glantz S., 1993, TOB CONTROL, V2, P311, DOI DOI 10.1136/TC.2.4.311; GODDARD E, 1990, WHY CHILDREN START S; GODFREY C, 1992, SMOKING EPIDEMIC PRE; HASTINGS GB, 1994, BRIT MED J, V309, P933, DOI 10.1136/bmj.309.6959.933; JASON LA, 1991, JAMA-J AM MED ASSOC, V266, P3159, DOI 10.1001/jama.266.22.3159; PETO R, 1994, MORTALITY SMOKING; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; WEST R, 1995, NICOTINE TRAP REPORT; 1995, TEENAGE SMOKING TRAC; 1994, TOBACCO HLTH EUROPEA; 1992, HLTH NATION; 1992, SMOKING YOUNG; 1995, HLTH BEHAVIOUR SCH C; 1995, ILLEGAL SALES TOBACC; 1995, UK NATIONAL ACCOUNT	22	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 28	1995	311	7013					1152	1154		10.1136/bmj.311.7013.1152	http://dx.doi.org/10.1136/bmj.311.7013.1152			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580715	Green Published			2022-12-28	WOS:A1995TC46600025
J	THOENEN, H				THOENEN, H			NEUROTROPHINS AND NEURONAL PLASTICITY	SCIENCE			English	Review							NERVE GROWTH-FACTOR; FACTOR MESSENGER-RNA; LONG-TERM POTENTIATION; FACTOR GENE-EXPRESSION; VISUAL CORTICAL-CELLS; HIPPOCAMPAL-NEURONS; OCULAR DOMINANCE; RAT HIPPOCAMPUS; FACTOR NGF; LIMBIC SEIZURES	There is increasing evidence that neurotrophins (NTs) are involved in processes of neuronal plasticity besides their well-established actions in regulating the survival, differentiation, and maintenance of functions of specific populations of neurons. Nerve growth factor, brain-derived neurotrophic factor, NT-4/5, and corresponding antibodies dramatically modify the development of the visual cortex. Although the neuronal Elements involved have not yet been identified, complementary studies of other systems have demonstrated that NT synthesis is rapidly regulated by neuronal activity and that NTs are released in an activity-dependent manner from neuronal dendrites. These data, together with the observation that NTs enhance transmitter release from neurons that express the corresponding signal-transducing Trk receptors, suggest a role for NTs as selective retrograde messengers that regulate synaptic efficacy.			THOENEN, H (corresponding author), MAX PLANCK INST PSYCHIAT, DEPT NEUROCHEM, AM KLOPFERSPITZ 18A, D-82152 MARTINSRIED, GERMANY.							ALOE L, 1989, P NATL ACAD SCI USA, V86, P5636, DOI 10.1073/pnas.86.14.5636; APPLEYARD ME, 1988, NEUROSCIENCE, V25, P133, DOI 10.1016/0306-4522(88)90012-7; AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; BANDTLOW CE, 1987, EMBO J, V6, P891, DOI 10.1002/j.1460-2075.1987.tb04835.x; BANNERMAN DM, 1994, J NEUROSCI, V14, P7415; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARBANY G, 1992, EUR J NEUROSCI, V4, P396, DOI 10.1111/j.1460-9568.1992.tb00888.x; BARBANY G, 1993, NEUROSCIENCE, V54, P909, DOI 10.1016/0306-4522(93)90584-3; BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BARTH EM, 1984, J CELL BIOL, V99, P839, DOI 10.1083/jcb.99.3.839; BEAR MF, 1990, J NEUROSCI, V10, P909; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; BERARDI N, 1994, P NATL ACAD SCI USA, V91, P684, DOI 10.1073/pnas.91.2.684; BERNINGER B, 1995, DEVELOPMENT, V121, P2327; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; BERNINGER B, UNPUB; Berzaghi M. P., 1995, Society for Neuroscience Abstracts, V21, P545; BERZAGHI MD, 1993, J NEUROSCI, V13, P3818; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; BLOCHL A, IN PRESS LIFE DEATH; BLOCHL A, UNPUB; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CABELLI RJ, UNPUB; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CASTREN E, 1995, NEUROSCIENCE, V64, P71, DOI 10.1016/0306-4522(94)00386-J; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CASTREN E, 1993, NEUROREPORT, V4, P895, DOI 10.1097/00001756-199307000-00014; CELLERINO A, 1995, THESIS PISA; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHAO MV, 1994, NEUROBIOLOGY, V25, P1373; COSI C, 1993, NEUROREPORT, V4, P527, DOI 10.1097/00001756-199305000-00016; CROLL SD, 1994, EUR J NEUROSCI, V6, P1343, DOI 10.1111/j.1460-9568.1994.tb00325.x; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DOMENICI L, 1994, VISUAL NEUROSCI, V11, P1093, DOI 10.1017/S095252380000691X; DOMENICI L, 1991, P NATL ACAD SCI USA, V88, P8811, DOI 10.1073/pnas.88.19.8811; DOMENICI L, 1994, NEUROREPORT, V5, P2041, DOI 10.1097/00001756-199410270-00013; DRAGUNOW M, 1993, NEUROSCI LETT, V160, P232, DOI 10.1016/0304-3940(93)90420-P; DUGICHDJORDJEVIC MM, 1992, NEUROSCIENCE, V47, P303, DOI 10.1016/0306-4522(92)90246-X; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; FIORENTINI A, 1995, VISUAL NEUROSCI, V12, P51, DOI 10.1017/S0952523800007306; FREGNAC Y, 1978, J PHYSIOL-LONDON, V278, P27, DOI 10.1113/jphysiol.1978.sp012290; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; Galuske R. A. W., 1994, Society for Neuroscience Abstracts, V20, P312; GREENFIELD SA, 1985, NEUROCHEM INT, V7, P887, DOI 10.1016/0197-0186(85)90136-6; Griesbeck O., 1995, Society for Neuroscience Abstracts, V21, P1046; GU Q, 1995, EUR J NEUROSCI, V7, P1146, DOI 10.1111/j.1460-9568.1995.tb01104.x; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUTTNER W, UNPUB; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KASAMATSU T, 1976, SCIENCE, V194, P206, DOI 10.1126/science.959850; KNIPPER M, 1994, NEUROREPORT, V5, P2433, DOI 10.1097/00001756-199412000-00007; KNIPPER M, 1994, EUR J NEUROSCI, V6, P668, DOI 10.1111/j.1460-9568.1994.tb00312.x; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; KORTE M, UNPUB; KOZARSKY KF, 1993, CURR OPIN GENET DEV, V3, P499, DOI 10.1016/0959-437X(93)90126-A; LAUTERBORN J, 1995, NEUROSCIENCE, V68, P363, DOI 10.1016/0306-4522(95)00150-H; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEWIN G, IN PRESS ANN REV NEU; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; LINDHOLM D, 1993, J CELL BIOL, V122, P443, DOI 10.1083/jcb.122.2.443; LINDHOLM D, 1992, EUR J NEUROSCI, V4, P404, DOI 10.1111/j.1460-9568.1992.tb00889.x; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LONNERBERG P, 1995, P NATL ACAD SCI USA, V92, P4046, DOI 10.1073/pnas.92.9.4046; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; MAFFEI L, 1992, J NEUROSCI, V12, P4651; Matteoli M, 1991, Curr Opin Neurobiol, V1, P91, DOI 10.1016/0959-4388(91)90015-Y; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; MCMAHON SB, 1995, NAT MED, V1, P774, DOI 10.1038/nm0895-774; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEFFERT MK, 1994, NEURON, V13, P1225, DOI 10.1016/0896-6273(94)90060-4; MISAWA H, 1992, J BIOL CHEM, V267, P20392; MURPHY KPSJ, 1994, NEUROPHARMACOLOGY, V33, P1375, DOI 10.1016/0028-3908(94)90039-6; NAWA H, 1994, J NEUROSCI, V14, P3751; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; ROHRER H, 1988, DEV BIOL, V128, P240, DOI 10.1016/0012-1606(88)90286-2; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHELTON DL, 1986, J CELL BIOL, V102, P1940, DOI 10.1083/jcb.102.5.1940; SINGER W, 1977, BRAIN RES, V134, P568, DOI 10.1016/0006-8993(77)90832-0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; STOCKEL K, 1978, NEUROSCI LETT, V10, P61, DOI 10.1016/0304-3940(78)90012-5; SUDHOF TC, 1993, CELL, V75, P1; THOENEN H, 1987, REV PHYSIOL BIOCH P, V109, P145, DOI 10.1007/BFb0031026; THOENEN H, 1993, EXP NEUROL, V124, P47, DOI 10.1006/exnr.1993.1173; Thureson-Klein A K, 1990, Int Rev Cytol, V121, P67, DOI 10.1016/S0074-7696(08)60659-2; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; WESTON J, 1986, NEUROSCIENCE, V17, P1079, DOI 10.1016/0306-4522(86)90078-3; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037; ZAFRA F, 1992, J NEUROSCI, V12, P4793; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	114	1670	1692	4	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 27	1995	270	5236					593	598		10.1126/science.270.5236.593	http://dx.doi.org/10.1126/science.270.5236.593			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570017				2022-12-28	WOS:A1995TB55700028
J	HUGHES, CH; BAUMER, JH				HUGHES, CH; BAUMER, JH			MOVING HOUSE - A RISK FACTOR FOR THE DEVELOPMENT OF CHILDHOOD ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							SMOKING; ILLNESS		DERRIFORD HOSP,DEPT CHILD HLTH,PLYMOUTH PL6 8DH,DEVON,ENGLAND	Derriford Hospital	HUGHES, CH (corresponding author), CTR HLTH,ESTOVER,PLYMOUTH PL6 8UE,DEVON,ENGLAND.							ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; KAPLAN BA, 1985, J EPIDEMIOL COMMUN H, V39, P152, DOI 10.1136/jech.39.2.152; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786, DOI 10.1136/adc.62.8.786; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692	5	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1069	1070		10.1136/bmj.311.7012.1069	http://dx.doi.org/10.1136/bmj.311.7012.1069			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580667	Green Published			2022-12-28	WOS:A1995TB35400026
J	JONES, R; LAMONT, T; HAINES, A				JONES, R; LAMONT, T; HAINES, A			SETTING PRIORITIES FOR RESEARCH-AND-DEVELOPMENT IN THE NHS - A CASE-STUDY ON THE INTERFACE BETWEEN PRIMARY AND SECONDARY CARE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS	Since 1991 the NHS has attempted to identify and prioritise its needs for research and development in a systematic manner. This has not been done before and there is little evidence on which to draw. Multidisciplinary expert groups have identified priorities in different topics using explicit criteria and after widespread consultation within the NHS and research community to identify pressing problems and opportunities for research. This paper focuses on a review completed in 1993 to identify research and development priorities for the NHS in relation to the interface between primary and secondary care. The review covered several recent developments which require evaluation. The authors describe the process used to identify research and development priorities in this complex subject and examine the strengths and weaknesses of the approach. This case study should help to stimulate a wider debate on methods of identifying priorities, particularly those using participatory approaches, in research and non-research contexts.	NATL HLTH SERV EXECUT,RES & DEV DIRECTORATE,LEEDS,W YORKSHIRE,ENGLAND; NATL HLTH SERV EXECUT,RES & DEV DIRECTORATE,N THAMES,ENGLAND		JONES, R (corresponding author), UNITED MED & DENT SCH,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND.			Haines, Andy/0000-0002-8053-4605				BLACK DAJ, 1975, BRIT J PREVENTIVE SO, V29, P2222; Coote A., 1993, CRITICAL PUBLIC HLTH, V4, P37; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; Delbecq AL, 1975, J HUMAN SCI; DRUMMOND MF, 1992, SOC SCI MED, V34, P973, DOI 10.1016/0277-9536(92)90128-D; FEACHEM RG, 1989, J TROP MED HYG, V92, P133; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; KNOTTNERUS JA, 1990, BRIT J GEN PRACT, V40, P178; Pateman C., 1970, PARTICIPATION DEMOCR; SMITH R, 1987, BRIT MED J, V295, P1248, DOI 10.1136/bmj.295.6608.1248; Tomlinson B., 1992, REPORT INQUIRY LONDO; 1995, NHS4TH HOUS LORDS SE; 1992, HLTH NATION STRATEGY; 1991, PATIENTS CHARTER; 1992, PROGRAM OECD HLTH DA; 1992, RES HLTH; 1994, RES DEV PRIORITIES R	17	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1076	1080		10.1136/bmj.311.7012.1076	http://dx.doi.org/10.1136/bmj.311.7012.1076			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580669	Green Published			2022-12-28	WOS:A1995TB35400030
J	GOFFEAU, A				GOFFEAU, A			LIFE WITH 482-GENES	SCIENCE			English	Editorial Material											GOFFEAU, A (corresponding author), UNIV CATHOLIQUE LOUVAIN,UNITE BIOCHIM PHYSIOL,PL CROIX SUD 2-20,B-1348 LOUVAIN,BELGIUM.							ADAMS MD, 1995, NATURE S3, V377; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; WILLIAMS N, 1995, SCIENCE, V268, P1560, DOI 10.1126/science.7777850	4	13	16	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					445	446		10.1126/science.270.5235.445	http://dx.doi.org/10.1126/science.270.5235.445			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569997				2022-12-28	WOS:A1995TA37400034
J	MANDEL, MA; YANOFSKY, MF				MANDEL, MA; YANOFSKY, MF			A GENE TRIGGERING FLOWER FORMATION IN ARABIDOPSIS	NATURE			English	Article							INFLORESCENCE DEVELOPMENT; FLORAL DEVELOPMENT; THALIANA; LEAFY	IN Arabidopsis, the apical shoot meristem produces lateral meristems that develop into either shoots or flowers. The decision to form flowers instead of shoots is mediated by the action of floral-meristem-identity genes, such as APETALA1 (API) and LEAFY (LFY), which specify meristem fate(1-7). Here we show that transgenic plants which constitutively express the AP1 gene show transformations of apical and lateral shoots into flowers, and that these plants flower much earlier than wild-type plants. These results indicate that AP1 alone can convert infloresence shoot meristems into floral meristems, and that ectopic AP1 expression can dramatically reduce the time to flowering.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; CHUNG YY, PL MOL BIOL, V26, P657; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KEMPIN SA, 1995, SCIENCE, V267, P522, DOI 10.1126/science.7824951; LEVIN J, 1995, CELL, V7, P529; MANDEL MA, 1992, NATURE, V380, P273; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; Weigel D, 1995, ANNU REV GENET, V29, P19, DOI 10.1146/annurev.ge.29.120195.000315; WEIGEL D, 1992, CELL, V89, P843; WEIGEL D, IN PRESS NATURE; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	20	409	475	3	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					522	524		10.1038/377522a0	http://dx.doi.org/10.1038/377522a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566148				2022-12-28	WOS:A1995RZ33600060
J	SALADIN, R; DEVOS, P; GUERREMILLO, M; LETURQUE, A; GIRARD, J; STAELS, B; AUWERX, J				SALADIN, R; DEVOS, P; GUERREMILLO, M; LETURQUE, A; GIRARD, J; STAELS, B; AUWERX, J			TRANSIENT INCREASE IN OBESE GENE-EXPRESSION AFTER FOOD-INTAKE OR INSULIN ADMINISTRATION	NATURE			English	Article							PROTEIN	OBESITY is a disorder of energy balance, indicating a chronic disequilibrium between energy intake and expenditure(1). Recently, the mouse ob gene(2), and subsequently its human and rat homologues(2-6), have been cloned. The ob gene product, leptin(7), is expressed exclusively in adipose tissue, and appears to be a signalling factor regulating body-weight homeostasis and energy balance(2,7-9). Because the level of ob gene expression might indicate the size of the adipose depot, we suggest that it is regulated by factors modulating adipose tissue size. Here we show that ob gene exhibits diurnal variation, increasing during the night, after rats start eating. This variation was linked to changes in food intake, as fasting prevented the cyclic variation and decreased ob messenger RNA. Furthermore, refeeding fasted rats restored ob mRNA within 4 hours to levels of fed animals. A single insulin injection in fasted animals increased ob mRNA to levels of fed controls. Experiments to control glucose and insulin independently in animals, and studies in primary adipocytes, showed that insulin regulates ob gene expression directly in rats, regardless of its glucose-lowering effects. Whereas the ob gene product, leptin, has been shown to reduce food intake and increase energy expenditure(7-9) our data demonstrate that ob gene expression is increased after food ingestion in rats, perhaps through a direct action of insulin on the adipocyte.	INST BIOMED CORDELIERS,INSERM,U177,F-75006 PARIS,FRANCE; CNRS,UPR 1511,CEREMOD,F-92190 MEUDON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	SALADIN, R (corresponding author), INST PASTEUR,BIOL REGULAT CHEZ EUCARYOTES LAB,INSERM,U325,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		Auwerx, Johan/ABE-9307-2021; Staels, Bart/N-9497-2016; Leturque, Armelle/Q-9437-2017	Staels, Bart/0000-0002-3784-1503; Leturque, Armelle/0000-0001-6570-6387; Auwerx, Johan/0000-0002-5065-5393				CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; GAZDAR AF, 1990, CANCER RES, V50, P5488; GEFFROY S, 1995, GENOMICS, V28, P603, DOI 10.1006/geno.1995.1201; GRUNDY SM, 1990, DM-DIS MON, V36, P641; HAJDUCH EJ, 1992, J CELL BIOCHEM, V49, P251, DOI 10.1002/jcb.240490307; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PERET J, 1973, J NUTR, V103, P866, DOI 10.1093/jn/103.6.866; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; [No title captured]	17	1037	1064	0	39	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					527	529		10.1038/377527a0	http://dx.doi.org/10.1038/377527a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566150				2022-12-28	WOS:A1995RZ33600062
J	IWASA, Y; POMIANKOWSKI, A				IWASA, Y; POMIANKOWSKI, A			CONTINUAL CHANGE IN MATE PREFERENCES	NATURE			English	Article							SEXUAL SELECTION; EVOLUTION; FISHER; SPECIATION; PRINCIPLE; MUTATION	SECONDARY sexual characters are highly variable both within(1) and between species(2-6). Closely related species often differ markedly in sexual morphology but hardly at all In non-sexual traits(2-5). Here we show that Fisher's runaway process of sexual selection is intrinsically unstable and naturally leads to continual change in sexual traits. Runaway leads to semi-stable exaggeration of female preference for a malt sexual character, followed by a slow decay of both traits until runaway is triggered again In a different direction. The process then repeats itself resulting in continual change in male sexual traits through time. Allopatric populations are thus expected to diverge without drift or substantial changes in selective pressures. If there is significant mutation bias acting on the male trait, continual change stops and a stable equilibrium appears. Such an outcome is more likely when exaggeration of the male sexual trait signals good genes.	UNIV LONDON UNIV COLL, DEPT GENET & BIOMETRY, LONDON NW1 2HE, ENGLAND; KYUSHU UNIV, FAC SCI, DEPT BIOL, FUKUOKA 81281, JAPAN	University of London; University College London; Kyushu University			Iwasa, Yoh/G-5368-2010; Pomiankowski, Andrew/X-3888-2019	Iwasa, Yoh/0000-0003-0691-1852; Pomiankowski, Andrew/0000-0002-5171-8755				Andersson Malte, 1994; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; Darwin C., 1871, P475; Eberhard W.G., 1985, SEXUAL SELECTION ANI; Fisher R.A., 1930, GENETICAL THEORY NAT; FRYER G, 1980, CICHLID FISHES GREAT; Hirsch M., 1974, DIFFERENTIAL EQUATIO; IWASA Y, 1994, EVOLUTION, V48, P853, DOI 10.1111/j.1558-5646.1994.tb01367.x; IWASA Y, 1991, EVOLUTION, V45, P1431, DOI [10.1111/j.1558-5646.1991.tb02646.x, 10.2307/2409890]; KARLIN S, 1990, THEOR POPUL BIOL, V38, P306, DOI 10.1016/0040-5809(90)90017-P; KIRKPATRICK M, 1990, EVOLUTION, V44, P180, DOI 10.1111/j.1558-5646.1990.tb04288.x; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; LANDE R, 1982, EVOLUTION, V36, P213, DOI 10.1111/j.1558-5646.1982.tb05034.x; MUKAI T, 1977, P NATL ACAD SCI USA, V74, P2514, DOI 10.1073/pnas.74.6.2514; POMIANKOWSKI A, 1995, P ROY SOC B-BIOL SCI, V260, P21, DOI 10.1098/rspb.1995.0054; POMIANKOWSKI A, 1991, EVOLUTION, V45, P1422, DOI 10.1111/j.1558-5646.1991.tb02645.x; POMIANKOWSKI A, 1993, P ROY SOC B-BIOL SCI, V253, P173, DOI 10.1098/rspb.1993.0099; TEMPLETON AR, 1980, GENETICS, V94, P1011; YOUNG JR, 1994, ANIM BEHAV, V47, P1353, DOI 10.1006/anbe.1994.1183	19	169	171	2	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 5	1995	377	6548					420	422		10.1038/377420a0	http://dx.doi.org/10.1038/377420a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566117				2022-12-28	WOS:A1995RY19000046
J	MILLMAN, A; LEE, N; BROOKE, A				MILLMAN, A; LEE, N; BROOKE, A			ABC OF MEDICAL COMPUTING - COMPUTERS IN GENERAL-PRACTICE .2.	BRITISH MEDICAL JOURNAL			English	Article									WESTERN EYE HOSP,LONDON,ENGLAND; HILLINGDON HOSP,LONDON,ENGLAND	Brunel University; Imperial College London	MILLMAN, A (corresponding author), GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					864	867		10.1136/bmj.311.7009.864	http://dx.doi.org/10.1136/bmj.311.7009.864			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580499	Green Published			2022-12-28	WOS:A1995RY19100032
J	SCHULTZ, PG; LERNER, RA				SCHULTZ, PG; LERNER, RA			FROM MOLECULAR DIVERSITY TO CATALYSIS - LESSONS FROM THE IMMUNE-SYSTEM	SCIENCE			English	Review							DIELS-ALDER REACTION; ANTIBODY CATALYSIS; CLAISEN REARRANGEMENT; CHORISMATE MUTASE; TRANSITION-STATE; PEPTIDE; GENERATION; LIGANDS; HYDROLYSIS; PREPHENATE	By combining the enormous molecular diversity of the immune system with basic mechanistic principles of chemistry, one can produce catalytic antibodies that allow control of reactions in ways heretofore not possible. Mechanistic and structural studies of these antibodies are also providing insights into important aspects of enzymatic catalysis and the evolution of catalytic function, Moreover, the ability to rationally direct the immune response to generate selective catalysts for reactions ranging from pericyclic and redox reactions to cationic rearrangement reactions underscores the chemical potential of this and other large combinatorial libraries.			SCHULTZ, PG (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT CHEM,BERKELEY,CA 94720, USA.							ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; [Anonymous], 1975, ORG REACT; ASHLEY JA, 1992, J ORG CHEM, V57, P6691, DOI 10.1021/jo00051a003; BALDWIN E, 1989, SCIENCE, V245, P1104, DOI 10.1126/science.2672338; BALDWIN JE, 1976, J CHEM SOC CHEM COMM, P734, DOI 10.1039/c39760000734; BALDWIN JE, 1977, J CHEM SOC CHEM COMM, P233, DOI 10.1039/c39770000233; BALDWIN JE, 1982, TETRAHEDRON, V19, P2939; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, UNPUB; BARTSCH RA, 1980, CHEM REV, V80, P453, DOI 10.1021/cr60328a001; BORCHARD.JK, 1974, J AM CHEM SOC, V96, P3918, DOI 10.1021/ja00819a032; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; BRAISTED AC, 1994, J AM CHEM SOC, V116, P221; BRANCHAUD BP, 1985, J AM CHEM SOC, V107, P2153, DOI 10.1021/ja00293a054; BRAY AM, 1990, TETRAHEDRON LETT, V31, P5811, DOI 10.1016/S0040-4039(00)97966-8; BUNIN BA, 1994, P NATL ACAD SCI USA, V91, P4708, DOI 10.1073/pnas.91.11.4708; CAMPBELL DA, 1994, J AM CHEM SOC, V116, P2165, DOI 10.1021/ja00084a075; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; COCHRAN AG, 1990, SCIENCE, V249, P781, DOI 10.1126/science.2389144; COCHRAN AG, 1990, J AM CHEM SOC, V112, P9414, DOI 10.1021/ja00181a065; COPLEY SD, 1985, J AM CHEM SOC, V107, P5306, DOI 10.1021/ja00304a064; COPLEY SD, 1987, J AM CHEM SOC, V109, P5008, DOI 10.1021/ja00250a040; CRAVATT BF, 1994, J AM CHEM SOC, V116, P6013, DOI 10.1021/ja00092a080; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DAILEY HA, 1983, J BIOL CHEM, V11, P453; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Doering E., 1963, ANGEW CHEM INT EDIT, V2, P115; DURFOR CN, 1988, J AM CHEM SOC, V110, P8713, DOI 10.1021/ja00234a032; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FLETTERICK RJ, UNPUB; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GALLACHER G, 1992, BIOCHEM J, V284, P675, DOI 10.1042/bj2840675; GOLINELLIPIMPAN.B, 1994, STRUCTURE, V0002; GOLOLOBOV GV, 1995, P NATL ACAD SCI USA, V92, P254, DOI 10.1073/pnas.92.1.254; GONG B, 1992, J AM CHEM SOC, V114, P1486, DOI 10.1021/ja00030a056; GOODMAN JW, 1985, ANTIGEN, V3; GORISCH H, 1979, BIOCHEMISTRY-US, V17, P3700; GOUVERNEUR VE, 1993, SCIENCE, V262, P204, DOI 10.1126/science.8211138; GRAY JV, 1990, BIOCHEMISTRY-US, V29, P8872, DOI 10.1021/bi00489a051; GUILFORD WJ, 1987, J AM CHEM SOC, V109, P5013, DOI 10.1021/ja00250a041; HALDANE JBS, 1930, ENZYMES, P182; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HILVERT D, 1988, J AM CHEM SOC, V110, P5593, DOI 10.1021/ja00224a066; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; HIRSCHMANN R, 1994, SCIENCE, V265, P234, DOI 10.1126/science.8023141; HONJO T, 1985, ANNU REV BIOCHEM, V54, P803, DOI 10.1146/annurev.bi.54.070185.004103; HSIEH LC, 1994, J AM CHEM SOC, V116, P2167, DOI 10.1021/ja00084a076; HSIEH LC, 1993, SCIENCE, V260, P337, DOI 10.1126/science.10049109; IKEDA S, 1991, J AM CHEM SOC, V113, P7764; IVERSON BL, 1989, SCIENCE, V243, P1184, DOI 10.1126/science.2922606; IWABUCHI Y, 1994, J AM CHEM SOC, V116, P771, DOI 10.1021/ja00081a049; IZADYAR L, 1993, P NATL ACAD SCI USA, V90, P8876, DOI 10.1073/pnas.90.19.8876; JACKSON DY, 1992, ANGEW CHEM INT EDIT, V31, P182, DOI 10.1002/anie.199201821; JACKSON DY, 1991, P NATL ACAD SCI USA, V88, P58, DOI 10.1073/pnas.88.1.58; JACKSON DY, 1988, J AM CHEM SOC, V110, P4841, DOI 10.1021/ja00222a060; JACOBSEN JR, 1994, P NATL ACAD SCI USA, V91, P5888, DOI 10.1073/pnas.91.13.5888; JACOBSEN JR, 1992, SCIENCE, V256, P365, DOI 10.1126/science.256.5055.365; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JANDA KD, 1990, J AM CHEM SOC, V112, P8886, DOI 10.1021/ja00180a035; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P2532, DOI 10.1073/pnas.91.7.2532; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; JANDA KD, 1988, SCIENCE, V241, P1188, DOI 10.1126/science.3413482; JANDA KD, IN PRESS J AM CHEM S; KITAZUME T, 1991, J AM CHEM SOC, V113, P8573, DOI 10.1021/ja00022a083; KOCH A, 1994, J AM CHEM SOC, V116, P803, DOI 10.1021/ja00081a065; KU J, 1995, P NATL ACAD SCI USA, V92, P6552, DOI 10.1073/pnas.92.14.6552; LANDRY DW, 1993, SCIENCE, V259, P1899, DOI 10.1126/science.8456315; Lavallee D. K., 1988, MOL STRUCT ENERG, V9, P279; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LESLEY SA, 1993, P NATL ACAD SCI USA, V90, P1160, DOI 10.1073/pnas.90.4.1160; LI TY, 1994, SCIENCE, V264, P1289, DOI 10.1126/science.8191282; LIGHT DR, 1982, BIOCHEMISTRY-US, V21, P2490, DOI 10.1021/bi00539a031; MARCH J, 1985, ADV ORG CHEM, P874; Marchand AP, 1977, PERICYCLIC REACTIONS; MARKS JD, 1991, J MOL BIOL, V222, P481; MIYASHITA H, 1993, P NATL ACAD SCI USA, V90, P5337, DOI 10.1073/pnas.90.11.5337; NAKAYAMA GR, 1992, J AM CHEM SOC, V114, P780, DOI 10.1021/ja00028a066; NAPPER AD, 1987, SCIENCE, V237, P1041, DOI 10.1126/science.3616626; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; Nisonoff A, 1975, ANTIBODY MOL; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; PATTEN PA, UNPUB; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; Pressman D, 1968, STRUCTURAL BASIS ANT; PRUDENT JR, 1994, SCIENCE, V264, P1924; REYMOND JL, 1994, ANGEW CHEM INT EDIT, V33, P475, DOI 10.1002/anie.199404751; REYMOND JL, 1992, J AM CHEM SOC, V114, P2257, DOI 10.1021/ja00032a050; SARVETNICK N, 1993, P NATL ACAD SCI USA, V90, P4008, DOI 10.1073/pnas.90.9.4008; SASTRY L, 1989, P NATL ACAD SCI USA, V86, P5728, DOI 10.1073/pnas.86.15.5728; SAUER J, 1980, ANGEW CHEM INT EDIT, V19, P779, DOI 10.1002/anie.198007791; SCHULTZ PG, 1993, ACCOUNTS CHEM RES, V26, P391, DOI 10.1021/ar00032a001; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHABAT D, 1995, NATURE, V374, P143, DOI 10.1038/374143a0; SHOKAT K, 1994, J AM CHEM SOC, V116, P2261, DOI 10.1021/ja00085a004; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; SINHA SC, 1995, J AM CHEM SOC, V117, P3653, DOI 10.1021/ja00117a051; SMILEY JA, 1994, P NATL ACAD SCI USA, V91, P8319, DOI 10.1073/pnas.91.18.8319; SOGO SG, 1984, J AM CHEM SOC, V106, P2701, DOI 10.1021/ja00321a039; STEPHENS DB, 1993, BIOCHEM BIOPH RES CO, V192, P1439, DOI 10.1006/bbrc.1993.1577; SUH JH, 1991, B KOR CHEM SOC, V12, P352; TANG Y, 1991, P NATL ACAD SCI USA, V88, P8784, DOI 10.1073/pnas.88.19.8784; TAWFIK DS, 1993, P NATL ACAD SCI USA, V90, P373, DOI 10.1073/pnas.90.2.373; THORN SN, 1995, NATURE, V373, P288; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; UNO T, 1994, J AM CHEM SOC, V116, P1145, DOI 10.1021/ja00082a052; WAXMAN DJ, 1982, BIOCHEMISTRY-US, V21, P2499, DOI 10.1021/bi00539a032; WIRSCHING P, 1991, SCIENCE, V252, P680, DOI 10.1126/science.2024120; Woodward R. B., 1972, CONSERVATION ORBITAL; XIANG XD, 1995, SCIENCE, V268, P1738, DOI 10.1126/science.268.5218.1738; YU JH, 1994, ANGEW CHEM INT EDIT, V33, P339, DOI 10.1002/anie.199403391; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	117	402	416	1	40	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1835	1842		10.1126/science.7569920	http://dx.doi.org/10.1126/science.7569920			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569920				2022-12-28	WOS:A1995RX19400028
J	CHUMAKOV, IM; RIGAULT, P; LEGALL, I; BELLANNECHANTELOT, C; BILLAULT, A; GUILLOU, S; SOULARUE, P; GUASCONI, G; POULLIER, E; GROS, I; BELOVA, M; SAMBUCY, JL; SUSINI, L; GERVY, P; GLIBERT, F; BEAUFILS, S; BUI, H; MASSART, C; DETAND, MF; DUKASZ, F; LECOULANT, S; OUGEN, P; PERROT, V; SAUMLER, M; SORAVITO, C; BAHOUAYILA, R; COHENAKENINE, A; BARILLOT, E; BERTRAND, S; CODANI, JJ; CATERINA, D; GEORGES, I; LACROIX, B; LUCOTTE, G; SAHBATOU, M; SCHMIT, C; SANGOUARD, M; TUBACHER, E; DIB, C; FAURE, S; FIZAMES, C; GYAPAY, G; MILLASSEAU, P; NGUYEN, S; MUSELET, D; VIGNAL, A; MORISSETTE, J; MENNINGER, J; LIEMAN, J; DESAI, T; BANKS, A; BRAYWARD, P; WARD, D; HUDSON, T; GERETY, S; FOOTE, S; STEIN, L; PAGE, DC; LANDER, ES; WEISSENBACH, J; LEPASLIER, D; COHEN, D				CHUMAKOV, IM; RIGAULT, P; LEGALL, I; BELLANNECHANTELOT, C; BILLAULT, A; GUILLOU, S; SOULARUE, P; GUASCONI, G; POULLIER, E; GROS, I; BELOVA, M; SAMBUCY, JL; SUSINI, L; GERVY, P; GLIBERT, F; BEAUFILS, S; BUI, H; MASSART, C; DETAND, MF; DUKASZ, F; LECOULANT, S; OUGEN, P; PERROT, V; SAUMLER, M; SORAVITO, C; BAHOUAYILA, R; COHENAKENINE, A; BARILLOT, E; BERTRAND, S; CODANI, JJ; CATERINA, D; GEORGES, I; LACROIX, B; LUCOTTE, G; SAHBATOU, M; SCHMIT, C; SANGOUARD, M; TUBACHER, E; DIB, C; FAURE, S; FIZAMES, C; GYAPAY, G; MILLASSEAU, P; NGUYEN, S; MUSELET, D; VIGNAL, A; MORISSETTE, J; MENNINGER, J; LIEMAN, J; DESAI, T; BANKS, A; BRAYWARD, P; WARD, D; HUDSON, T; GERETY, S; FOOTE, S; STEIN, L; PAGE, DC; LANDER, ES; WEISSENBACH, J; LEPASLIER, D; COHEN, D			A YAC CONTIG MAP OF THE HUMAN GENOME	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; POLYMERASE CHAIN-REACTION; DNA; CLONES; SEQUENCES; CLONING; VECTORS; LIBRARY; REPEATS; GENES	A yeast artificial chromosome library containing 33,000 clones with an average insert size of one megabase of human genomic DNA was extensively analysed by several different procedures for detecting overlaps and positional information. We developed an analysis strategy that resulted, after confirmatory tests, in a YAC contig map reliably covering about 75% of the human genome in 225 contigs having an average size of about ten megabases.	GENETHON SA,F-91000 EVRY,FRANCE; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; MIT,WHITEHEAD INST BIOMED RES,CTR GENOME RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV LAVAL,CTR HOSP,CTR RECH,QUEBEC CITY,PQ G1V 4G2,CANADA	Yale University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Laval University	CHUMAKOV, IM (corresponding author), FDN JEAN DAUSSET,CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.		Vignal, Alain/I-6253-2017; susini, laurent/N-7913-2019; Susini, Laurent/O-4227-2016; Foote, Simon J/F-2802-2013	Vignal, Alain/0000-0002-6797-2125; Susini, Laurent/0000-0002-5164-2770; Fizames, Cecile/0000-0002-0551-8250; BARILLOT, Emmanuel/0000-0003-2724-2002; Le Paslier, Denis/0000-0003-4335-9956; Hudson, Thomas/0000-0002-1376-4849; Foote, Simon/0000-0002-9142-2107				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ARATIA R, 1991, GENOMICS, V11, P806; BELL CJ, 1995, HUM MOL GENET, V4, P59; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; FIELDS CA, 1992, GENOMICS, V13, P431, DOI 10.1016/0888-7543(92)90264-S; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAIDI M, 1994, GENOMICS, V24, P478; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KAPLAN DJ, 1991, NUCLEIC ACIDS RES, V19, P4731, DOI 10.1093/nar/19.17.4731; LITT M, 1989, AM J HUM GENET, V44, P397; MATERA AG, 1990, NUCLEIC ACIDS RES, V18, P6019, DOI 10.1093/nar/18.20.6019; McKusick V.A., 1978, MENDELIAN INHERITANC; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MULLIVOR RA, 1991, AM J HUM GENET S, V49, P370; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; SHAFITZAGARDO B, 1982, NUCLEIC ACIDS RES, V10, P3175, DOI 10.1093/nar/10.10.3175; WEBER JL, 1989, AM J HUM GENET, V44, P388; YANG SY, 1989, IMMUNOBIOLOGY HLA, V1; 1993, HUNTINGTON DISEASE C, V72, P971	31	320	325	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			175	&						0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566096				2022-12-28	WOS:A1995TA34300003
J	MCDANIEL, DO; ALARCON, GS; PRATT, PW; REVEILLE, JD				MCDANIEL, DO; ALARCON, GS; PRATT, PW; REVEILLE, JD			MOST AFRICAN-AMERICAN PATIENTS WITH RHEUMATOID-ARTHRITIS DO NOT HAVE THE RHEUMATOID ANTIGENIC DETERMINANT (EPITOPE)	ANNALS OF INTERNAL MEDICINE			English	Article						ARTHRITIS, RHEUMATOID; BLACKS; HLA-DR ANTIGENS; ANTIGENIC DETERMINANTS	HLA-DR ANTIGENS; DISEASE SEVERITY; D REGION; ASSOCIATION; SUSCEPTIBILITY; GENES; BLACKS; HYPOTHESIS; POPULATION; SEQUENCE	Objective: To evaluate the relation between the presence of the ''rheumatoid epitope,'' defined by a sequence motif in the HLA-DRB1 alleles, and disease severity in African-American patients with rheumatoid arthritis. Design: Cross-sectional study. Setting: Rheumatology outpatient clinics at two university medical centers. Patients: 86 African-American patients with rheumatoid arthritis (66 seropositive and 20 seronegative for the rheumatoid factor) attending the clinics and 88 healthy African-American persons. Measurements: HLA-DRB1 alleles were determined by restriction fragment length polymorphism and by allele-specific oligonucleotide typing of polymerase chain reaction-amplified HLA-DRB1 second exons. Results: With the exception of an increased frequency of HLA-DRB1*04 alleles in seropositive patients with rheumatoid arthritis (27.3%) compared with controls (13.1%) (P = 0.02), the frequencies of HLA-DRB1 alleles were similar in patients and controls. Most seropositive (48 of 66) and seronegative (15 of 20) patients were HLA-DR4 negative, but some (7 of 48 seropositive patients and 3 of 15 seronegative persons) inherited the rheumatoid epitope on a non-DR4 allele. Disease features, including severity, were similar for patients without the epitope and for those with either a single or a double dose of an epitope-positive allele. Positivity for rheumatoid factor, but not for the rheumatoid epitope, was weakly associated with severity in these patients. Conclusion: Most African-American patients with rheumatoid arthritis did not express the rheumatoid epitope. The predisposition to and severity of rheumatoid arthritis in African-Americans appears to be independent of the presence and dose of the shared rheumatoid epitope.	UNIV TEXAS, HLTH SCI CTR, DIV RHEUMATOL & CLIN IMMUNOGENET, HOUSTON, TX 77225 USA; UNIV ALABAMA, DIV CLIN IMMUNOL & RHEUMATOL, BIRMINGHAM, AL 35294 USA	University of Texas System; University of Texas Health Science Center Houston; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039325, P60AR020614] Funding Source: NIH RePORTER; NIAMS NIH HHS [P0-AR 20614, AR39325] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALARCON GS, 1983, J RHEUMATOL, V10, P579; ALARCON GS, 1982, ARTHRITIS RHEUM, V25, P502, DOI 10.1002/art.1780250503; ALARIF LI, 1983, J RHEUMATOL, V10, P297; ANGELINI G, 1992, HUM IMMUNOL, V34, P135, DOI 10.1016/0198-8859(92)90039-P; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BOKI KA, 1992, ARTHRITIS RHEUM, V35, P749, DOI 10.1002/art.1780350706; CASTRO F, 1994, B ASS PERUAN RHEUM, V13, P14; DEJUAN MD, 1994, TISSUE ANTIGENS, V43, P320; DEVRIES N, 1993, TISSUE ANTIGENS, V41, P26; GAO XJ, 1991, ARTHRITIS RHEUM, V34, P1310, DOI 10.1002/art.1780341016; GAO XJ, 1990, ARTHRITIS RHEUM, V33, P939, DOI 10.1002/art.1780330704; GORONZY J, 1986, J CLIN INVEST, V77, P1042, DOI 10.1172/JCI112358; GOUGH A, 1994, ARTHRITIS RHEUM, V37, P1166, DOI 10.1002/art.1780370809; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; KARR RW, 1980, ARTHRITIS RHEUM-US, V23, P1241, DOI 10.1002/art.1780231102; LONG EO, 1983, EMBO J, V2, P389, DOI 10.1002/j.1460-2075.1983.tb01435.x; LOPEZMENDEZ A, 1989, J RHEUMATOL, V16, P1197; MARSAL S, 1994, ARTHRITIS RHEUM, V37, P504, DOI 10.1002/art.1780370410; MARTELL RW, 1989, TISSUE ANTIGENS, V36, P1326; MCDANIEL DO, 1989, TISSUE ANTIGENS, V34, P299, DOI 10.1111/j.1399-0039.1989.tb01746.x; MCDANIEL DO, 1993, BIOTECHNIQUES, V15, P140; MODY GM, 1989, J RHEUMATOL, V16, P1326; NELSON JL, 1991, TISSUE ANTIGENS, V38, P145, DOI 10.1111/j.1399-0039.1991.tb01888.x; NELSON JL, 1994, ARTHRITIS RHEUM, V37, P673; NEPOM GT, 1986, LANCET, V2, P1002; OHTA N, 1982, HUM IMMUNOL, V5, P123, DOI 10.1016/0198-8859(82)90057-X; PERDRIGER A, 1992, TISSUE ANTIGENS, V39, P14, DOI 10.1111/j.1399-0039.1992.tb02149.x; PILE KD, 1992, TISSUE ANTIGENS, V39, P138, DOI 10.1111/j.1399-0039.1992.tb01924.x; RENNINGEN KS, 1990, TISSUE ANTIGENS, V36, P235, DOI 10.1111/j.1399-0039.1990.tb01834.x; Reveille J. D., 1994, Arthritis and Rheumatism, V37, pS359; SILMAN AJ, 1993, J RHEUMATOL, V20, P618; SINGAL DP, 1994, CLIN EXP RHEUMATOL, V12, P29; SINGAL DP, 1987, LANCET, V2, P1118; STASTNY P, 1976, J CLIN INVEST, V57, P1148, DOI 10.1172/JCI108382; STEPHENS HAF, 1989, IMMUNOGENETICS, V30, P119, DOI 10.1007/BF02421540; TAN PLJ, 1993, ARTHRITIS RHEUM, V36, P15, DOI 10.1002/art.1780360104; TANEJA V, 1993, ARTHRITIS RHEUM, V36, P1380, DOI 10.1002/art.1780361009; VANDERHEIJDE DMFM, 1992, BRIT J RHEUMATOL, V31, P519; WATANABE Y, 1989, J EXP MED, V169, P2263, DOI 10.1084/jem.169.6.2263; WEYAND CM, 1994, B RHEUM DIS, V43, P5; WEYAND CM, 1992, J CLIN INVEST, V89, P2033, DOI 10.1172/JCI115814; WEYAND CM, 1992, ANN INTERN MED, V117, P801, DOI 10.7326/0003-4819-117-10-801; WEYAND CM, 1989, IMMUNOBIOLOGY HLA IM, P422; WILLKENS RF, 1991, ARTHRITIS RHEUM, V34, P43, DOI 10.1002/art.1780340107; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049; YELAMOS J, 1993, ARTHRITIS RHEUM-US, V36, P811, DOI 10.1002/art.1780360611; ZOSCHKE D, 1986, HUM IMMUNOL, V15, P118, DOI 10.1016/0198-8859(86)90322-8; [No title captured]	48	72	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					181	187		10.7326/0003-4819-123-3-199508010-00004	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598299				2022-12-28	WOS:A1995RL10400004
J	SHEEAN, GL; MURRAY, NMF; MARSDEN, CD				SHEEAN, GL; MURRAY, NMF; MARSDEN, CD			PAIN AND REMOTE WEAKNESS IN LIMBS INJECTED WITH BOTULINUM TOXIN A FOR WRITERS CRAMP	LANCET			English	Note							BRACHIAL-PLEXUS NEUROPATHY; NEURALGIC AMYOTROPHY; PLEXOPATHY	We describe two cases of a syndrome resembling neuralgic amyotrophy that occurred in limbs injected with botulinum toxin for writer's cramp. In both cases, one of the injections was followed by pain and the next, 7-10 weeks later, by weakness. We believe that unexplained pain in the shoulder region after an injection of botulinum toxin contraindicates a second injection.			SHEEAN, GL (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND.							BEGHI E, 1985, ANN NEUROL, V18, P320, DOI 10.1002/ana.410180308; CATHALA J, 1934, PRESSE MED, V42, P65; ENGLAND JD, 1987, MUSCLE NERVE, V10, P60, DOI 10.1002/mus.880100112; GLANZMAN RL, 1990, NEUROLOGY, V40, P1143, DOI 10.1212/WNL.40.7.1143; HAMBLETON P, 1992, BRIT MED J, V304, P959, DOI 10.1136/bmj.304.6832.959-a; SAMPAIO C, 1993, J NEUROL NEUROSUR PS, V56, P220, DOI 10.1136/jnnp.56.2.220; SCHOTT GD, 1983, J NEUROL NEUROSUR PS, V46, P555, DOI 10.1136/jnnp.46.6.555; SIEGEL LS, 1989, J CLIN MICROBIOL, V27, P1906, DOI 10.1128/JCM.27.8.1906-1908.1989; SUBRAMONY SH, 1988, MUSCLE NERVE, V11, P39, DOI 10.1002/mus.880110108; Thomas P.K., 1993, PERIPHERAL NEUROPATH, V3rd ed., P1219	10	38	39	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 15	1995	346	8968					154	156		10.1016/S0140-6736(95)91212-6	http://dx.doi.org/10.1016/S0140-6736(95)91212-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603232				2022-12-28	WOS:A1995RJ03100012
J	MALES, MA				MALES, MA			ADULT INVOLVEMENT IN TEENAGE CHILDBEARING AND STD	LANCET			English	Editorial Material							PREGNANCY				MALES, MA (corresponding author), UNIV CALIF IRVINE,SCH SOCIAL ECOL,IRVINE,CA 92717, USA.							BOYER D, 1992, FAM PLANN PERSPECT, V24, P4, DOI 10.2307/2135718; BOYER D, 1992, FAMILY PLANNING PERS, V24, P19; DEAN M, 1994, LANCET, V343, P1149, DOI 10.1016/S0140-6736(94)90243-7; GERSHENSON H, 1989, J INTERPERS VIOLENCE, V4, P204; JONES EF, 1985, FAM PLANN PERSPECT, V17, P53, DOI 10.2307/2135261; MALES M, 1994, APR ANN M POP ASS AM; 1994, SEX AM TEENAGERS; 1994, IV AIDS SURVEILLANCE; 1994, LANCET, V344, P899; 1994, CALIFORNIA RESIDENT; 1994, BRITHS TEEN MOMS AGE	11	19	19	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					64	65		10.1016/S0140-6736(95)92105-2	http://dx.doi.org/10.1016/S0140-6736(95)92105-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603210				2022-12-28	WOS:A1995RH22000003
J	SASAKI, J; BROWN, LS; CHON, YS; KANDORI, H; MAEDA, A; NEEDLEMAN, R; LANYI, JK				SASAKI, J; BROWN, LS; CHON, YS; KANDORI, H; MAEDA, A; NEEDLEMAN, R; LANYI, JK			CONVERSION OF BACTERIORHODOPSIN INTO A CHLORIDE-ION PUMP	SCIENCE			English	Article							X-RAY-DIFFRACTION; NATRONOBACTERIUM-PHARAONIS; BACTERIAL RHODOPSINS; PROTON TRANSLOCATION; STRUCTURAL-CHANGES; HALORHODOPSIN; PHOTOCYCLE; IDENTIFICATION; INTERMEDIATE; TRANSPORT	In the light-driven proton pump bacteriorhodopsin, proton transfer from the retinal Schiff base to aspartate-85 is the crucial reaction of the transport cycle. In halorhodopsin, a light-driven chloride ion pump, the equivalent of residue 85 is threonine. When aspartate-85 was replaced with threonine, the mutated bacteriorhodopsin became a chloride ion pump when expressed in Halobacterium salinarium and, like halorhodopsin, actively transported chloride ions in the direction opposite from the proton pump. Chloride was bound to it, as revealed by large shifts of the absorption maximum of the chromophore, and its photointermediates included a red-shifted state in the millisecond time domain, with its amplitude and decay rate dependent on chloride concentration. Bacteriorhodopsin and halorhodopsin thus share a common transport mechanism, and the interaction of residue 85 with the retinal Schiff base determines the ionic specificity.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN; WAYNE STATE UNIV,DEPT BIOCHEM,DETROIT,MI 48201	University of California System; University of California Irvine; Kyoto University; Wayne State University			Lanyi, Janos/C-3808-2011; Brown, Leonid/X-7445-2019; Brown, Leonid/A-1050-2008	Brown, Leonid/0000-0002-5614-8317; Brown, Leonid/0000-0002-5614-8317	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029498, R37GM029498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCK A, 1987, EMBO J, V6, P265, DOI 10.1002/j.1460-2075.1987.tb04749.x; BROWN LO, UNPUB; DUSCHL A, 1990, J BIOL CHEM, V265, P1261; KATAOKA M, 1994, J MOL BIOL, V243, P621, DOI 10.1016/0022-2836(94)90037-X; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; KOUYAMA T, 1988, BIOCHEMISTRY-US, V27, P5855, DOI 10.1021/bi00416a006; Lanyi J K, 1979, Methods Enzymol, V56, P398; LANYI JK, 1982, J BIOL CHEM, V257, P2674; LANYI JK, 1990, J BIOL CHEM, V265, P1253; LANYI JK, 1990, PHYSIOL REV, V70, P319, DOI 10.1152/physrev.1990.70.2.319; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LANYI JK, 1986, BIOCHEMISTRY-US, V25, P1465, DOI 10.1021/bi00354a042; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MATSUNOYAGI A, 1977, BIOCHEM BIOPH RES CO, V78, P237, DOI 10.1016/0006-291X(77)91245-1; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; NAKASAKO M, 1991, FEBS LETT, V292, P73, DOI 10.1016/0014-5793(91)80837-S; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; OESTERHELT D, 1989, TRENDS BIOCHEM SCI, V14, P57, DOI 10.1016/0968-0004(89)90044-3; OGURUSU T, 1984, J BIOCHEM-TOKYO, V95, P1073, DOI 10.1093/oxfordjournals.jbchem.a134695; OTOMO J, 1992, BIOCHIM BIOPHYS ACTA, V1112, P7, DOI 10.1016/0005-2736(92)90246-I; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; SASAKI J, UNPUB; SCHARF B, 1994, BIOCHEMISTRY-US, V33, P6387, DOI 10.1021/bi00187a002; SCHOBERT B, 1986, J BIOL CHEM, V261, P2690; SCHOBERT B, 1982, J BIOL CHEM, V257, P306; SOPPA J, 1993, J BACTERIOL, V175, P2720, DOI 10.1128/JB.175.9.2720-2726.1993; SPUDICH JL, 1994, CELL, V79, P747, DOI 10.1016/0092-8674(94)90064-7; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; SUBRAMANIAM S, 1993, EMBO J, V12, P1; SUNDBERG SA, 1990, J BACTERIOL, V172, P2328, DOI 10.1128/jb.172.5.2328-2335.1990; TITTOR J, 1994, BIOPHYS J, V67, P1682, DOI 10.1016/S0006-3495(94)80642-3; TITTOR J, 1987, BIOPHYS J, V52, P999, DOI 10.1016/S0006-3495(87)83292-7; VARO G, 1995, BIOPHYS J, V68, P2062, DOI 10.1016/S0006-3495(95)80385-1; VARO G, UNPUB; ZIMANYI L, 1989, BIOCHEMISTRY-US, V28, P5165, DOI 10.1021/bi00438a038; ZIMANYI L, 1993, BIOCHEMISTRY-US, V32, P7669, DOI 10.1021/bi00081a010	37	211	216	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					73	75		10.1126/science.7604281	http://dx.doi.org/10.1126/science.7604281			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604281				2022-12-28	WOS:A1995RG98000035
J	SAVILLE, MW; LIETZAU, J; PLUDA, JM; FEUERSTEIN, I; ODOM, J; WILSON, WH; HUMPHREY, RW; FEIGAL, E; STEINBERG, SM; BRODER, S; YARCHOAN, R				SAVILLE, MW; LIETZAU, J; PLUDA, JM; FEUERSTEIN, I; ODOM, J; WILSON, WH; HUMPHREY, RW; FEIGAL, E; STEINBERG, SM; BRODER, S; YARCHOAN, R			TREATMENT OF HIV-ASSOCIATED KAPOSIS-SARCOMA WITH PACLITAXEL	LANCET			English	Note							ACQUIRED-IMMUNODEFICIENCY-SYNDROME	We investigated whether paclitaxel was active in AIDS-associated Kaposi's sarcoma. We gave 135 mg/m(2) intravenously over 3 hours every 21 days. Follow-up is available on the first 20 patients, mast of whom had advanced Kaposi's sarcoma and severe immunocompromise. Neutropenia was the most frequent dose-limiting toxic effect; novel toxic effects included late fevers, rash, and eosinophilia. Creatinine increased in 2 patients and 1 patient had cardiomyopathy. There were 13 partial responses (65%, 95% CI 41-85%). All 5 patients with pulmonary involvement responded. Paclitaxel appeals to be active against Kaposi's sarcoma as a single agent. Further studies, including a randomised trial, are warranted.	NCI,BETHESDA,MD 20892; NIH,WARREN MAGNUSON CLIN CTR,BETHESDA,MD; HENRY M JACKSON FDN ADVANCEMENT MIL MED,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc								ARBUCK SG, 1994, HEMATOL ONCOL CLIN N, V8, P121, DOI 10.1016/S0889-8588(18)30191-6; CANTOR ES, 1991, ARCH INTERN MED, V151, P125, DOI 10.1001/archinte.151.1.125; GELMON K, 1994, LANCET, V344, P1267, DOI 10.1016/S0140-6736(94)90754-4; HRYNIUK WM, 1990, J CLIN ONCOL, V8, P1935, DOI 10.1200/JCO.1990.8.12.1935; KROWN SE, 1989, J CLIN ONCOL, V7, P1201, DOI 10.1200/JCO.1989.7.9.1201; KUPPERMANN BD, 1993, AM J OPHTHALMOL, V115, P575, DOI 10.1016/S0002-9394(14)71453-9; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SAFAI B, 1994, TXB AIDS MED, P401; VADHANRAJ S, 1986, CANCER RES, V46, P417	9	160	163	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					26	28		10.1016/S0140-6736(95)92654-2	http://dx.doi.org/10.1016/S0140-6736(95)92654-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603142	Green Submitted			2022-12-28	WOS:A1995RF98500012
J	STEINBERG, D				STEINBERG, D			CLINICAL-TRIALS OF ANTIOXIDANTS IN ATHEROSCLEROSIS - ARE WE DOING THE RIGHT THING	LANCET			English	Editorial Material							LOW-DENSITY-LIPOPROTEIN; VITAMIN-E; CORONARY-DISEASE; HEART-DISEASE; PROGRESSION; PREVENTION; CAROTENE; ANGINA; RISK	The hypothesis that oxidative modification of low density lipoprotein contributes to the progression of atherosclerosis is supported by an impressive body of in-vitro findings and by persuasive results in animal models of atherosclerosis. The hypothesis was originally proposed specifically to account for foam cell formation but oxidation of LDL has now been shown to confer on it a long list of new biological properties any one of which could in principle enhance its atherogenicity.(1,2) The relative importance of these altered biological properties in vivo remains uncertain. Whatever the precise mechanisms, we know that antioxidants can slow the atherogenic process in several experimental models, including LDL-receptor-deficient rabbits, cholesterol-fed rabbits, and cholesterol-fed non-human primates. Of 18 published studies, 13 have given strongly positive results, the rate of progression of lesions being reduced by 50-80%; 2 have yielded marginally positive results; and 3 have been negative (see ref 3 for references). Furthermore, the fact that four different antioxidant compounds have been used-probucol, butylated hydroxytoluene, N,N'-diphenyl-phenylenediamine, and vitamin E-supports the conclusion that they are working via the property they all share, namely, their antioxidant potential.			STEINBERG, D (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED, DEPT 0682, 9500 GILMAN DR, LA JOLLA, CA 92093 USA.							BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; FRUEBIS J, 1994, J CLIN INVEST, V94, P392, DOI 10.1172/JCI117334; GAZIANO JM, 1990, CIRCULATION, V82, P201; GEY KF, 1989, ANN NY ACAD SCI, V570, P268; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; REGNSTROM J, 1990, ATHEROSCLEROSIS, V82, P43, DOI 10.1016/0021-9150(90)90142-6; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; SALONEN JT, 1993, CIRCULATION, V87, P56; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; STEINBERG D, 1993, NEW ENGL J MED, V328, P1487, DOI 10.1056/NEJM199305203282012; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WALLDIUS G, 1994, AM J CARDIOL, V74, P875, DOI 10.1016/0002-9149(94)90579-7; WATERS D, 1990, CIRCULATION, V82, P1940, DOI 10.1161/01.CIR.82.6.1940; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9	16	162	169	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 1	1995	346	8966					36	38		10.1016/S0140-6736(95)92657-7	http://dx.doi.org/10.1016/S0140-6736(95)92657-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603147				2022-12-28	WOS:A1995RF98500015
J	FEHLING, HJ; KROTKOVA, A; SAINTRUF, C; VONBOEHMER, H				FEHLING, HJ; KROTKOVA, A; SAINTRUF, C; VONBOEHMER, H			CRUCIAL ROLE OF THE PRE-T-CELL RECEPTOR-ALPHA GENE IN DEVELOPMENT OF ALPHA-BETA BUT NOT GAMMA-DELTA T-CELLS	NATURE			English	Article							DEFICIENT MICE; EXPRESSION; SURFACE; CHAIN; TCR; GENERATION; THYMOCYTES; IMMATURE; ANTIGENS	T-cell precursors, the T-cell-receptor B chain is expressed before the T-cell-receptor alpha chain(1,2) and is sufficient to advance T-cell development in the absence of T-cell receptor a chains(3-7). In immature T cells, the T-cell-receptor beta protein can form disulphide-linked heterodimers with the pre-T-cell-receptor alpha chain(8,9) and associate with signal-transducing CD3 molecules(5). The recently cloned pre-T-cell-receptor alpha gene encodes a transmembrane protein that is expressed in immature but not mature T cells(9,10). Here we show that alpha beta, but not gamma delta, cell development is severely hampered in pre-T-cell-receptor alpha-gene-deficient mice, which establishes a crucial role for the pre-T-cell receptor in early thymocyte development.	INST NECKER,INSERM,U373,F-75730 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	FEHLING, HJ (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.			Fehling, Hans Joerg/0000-0002-4580-1990				ALLISON JP, 1987, UCLA S MOL CELLULAR; BRUNO LEA, IN PRESS EUR J IMMUN; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; FEHLING HJ, IN PRESS IMMUNOGENET; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LYNCH F, 1993, INT IMMUNOL, V5, P991, DOI 10.1093/intimm/5.8.991; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHORES EW, 1990, EUR J IMMUNOL, V20, P69, DOI 10.1002/eji.1830200111; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; VONBOEHMER H, 1993, J EXP MED, V177, P891, DOI 10.1084/jem.177.4.891; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	22	455	458	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					795	798		10.1038/375795a0	http://dx.doi.org/10.1038/375795a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596413	Green Submitted			2022-12-28	WOS:A1995RF98900080
